

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 17:38:23 ; Search time 693 Seconds

(without alignments)
3.951 Million cell updates/sec

Title: us-10-664-775-5

Perfect score: 2267

Sequence: 1 gatactctctagtgaag.....ttgtaattctagtggtgat 2267

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rgedb.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	44.2	1.9	289	1	ACCESSION:AR162089
C 2	44.2	1.9	289	1	ACCESSION:AR166614
C 3	44.2	1.9	2422	1	ACCESSION:AR030786
C 4	44.2	1.9	2422	1	ACCESSION:AR045090
C 5	44.2	1.9	2422	1	ACCESSION:AR052946
C 6	44.2	1.9	2422	1	ACCESSION:AR122899
C 7	44.2	1.9	2422	1	ACCESSION:AR127821
C 8	44.2	1.9	2462	1	ACCESSION:AR095304
C 9	44.2	1.9	2462	1	ACCESSION:AR103988
C 10	44.2	1.9	2462	1	ACCESSION:AR335083
C 11	44.2	1.9	2462	1	ACCESSION:AR409604
C 12	44.2	1.9	2462	1	ACCESSION:MT1322
C 13	44.2	1.9	2483	1	ACCESSION:E01076
C 14	44.2	1.9	2483	1	ACCESSION:I07990
C 15	44	1.9	2177	1	ACCESSION:E01075
C 16	44	1.9	2438	1	ACCESSION:I07991
C 17	37.4	1.6	1573	1	ACCESSION:BC040125
C 18	32.4	1.4	300	1	ACCESSION:BD211952
C 19	28	1.2	1403	1	ACCESSION:BC009726
C 20	27.2	1.2	1792	1	ACCESSION:BC034377
C 21	25.2	1.1	1843	1	ACCESSION:AR390799
C 22	25.2	1.1	1843	1	ACCESSION:AX411026
C 23	25.2	1.1	1843	1	ACCESSION:X02750
C 24	24.4	1.1	251	1	ACCESSION:AY083553
C 25	24	1.1	1499	1	ACCESSION:DI0445
C 26	24	1.1	1580	1	ACCESSION:AF318182
C 27	24	1.1	1603	1	ACCESSION:BC013896
C 28	23.8	1.0	364	1	ACCESSION:AR425705
C 29	23.8	1.0	364	1	ACCESSION:BD121258
C 30	23.8	1.0	868	1	ACCESSION:BD124660
C 31	23.8	1.0	868	1	ACCESSION:BD126609
C 32	23.6	1.0	1671	1	ACCESSION:AY040345
C 33	23	1.0	364	1	ACCESSION:AR425705

C 34	23	1.0	364	1	BD121258
C 35	23	1.0	394	1	AX839180
C 36	23	1.0	1329	1	AF465274
C 37	23	1.0	1507	1	AX774765
C 38	23	1.0	1507	1	HUMFACX
C 39	22.8	1.0	200	1	AX395271
C 40	22.8	1.0	210	1	AB06245853
C 41	22.8	1.0	210	1	AB06245853
C 42	22.2	1.0	223	1	AX908508
C 43	22.2	1.0	223	1	BD044041
C 44	22	1.0	121	1	AX265077
C 45	22	1.0	121	1	AX265078
C 46	22	1.0	121	1	AX265081
C 47	22	1.0	121	1	AX265082
C 48	22	1.0	121	1	AX265085
C 49	22	1.0	121	1	AX265086
C 50	22	1.0	121	1	AX265089
C 51	22	1.0	121	1	AX265090
C 52	22	1.0	121	1	AX265093
C 53	22	1.0	121	1	AX265094
C 54	22	1.0	121	1	AX265073
C 55	22	1.0	121	1	AX265074
C 56	22	1.0	193	1	HUMKALR4
C 57	22	1.0	240	1	HUMFIXG3
C 58	22	1.0	385	1	AX892787
C 59	22	1.0	385	1	BD028320
C 60	22	1.0	409	1	AX839163
C 61	21.6	1.0	860	1	AF011898
C 62	21.6	1.0	861	1	AF011352
C 63	21.6	1.0	1869	1	BC061149
C 64	21.4	0.9	328	1	AX839181
C 65	21.4	0.9	1129	1	AX464088
C 66	21.4	0.9	1129	1	AY359106
C 67	21.4	0.9	6098	1	AX565990
C 68	21.2	0.9	121	1	AX265101
C 69	21.2	0.9	121	1	AX265102
C 70	21.2	0.9	121	1	AX265097
C 71	21.2	0.9	121	1	AX265098
C 72	21.2	0.9	1541	1	BC046125
C 73	21	0.9	267	1	BD060364
C 74	21	0.9	280	1	AF306917
C 75	21	0.9	280	1	AF306913
C 76	21	0.9	280	1	AF306914
C 77	21	0.9	280	1	AF306915
C 78	21	0.9	280	1	AF306919
C 79	21	0.9	1722	1	AF515269
C 80	20.8	0.9	484	1	RATCFX
C 81	20.6	0.9	341	1	AX524243
C 82	20.6	0.9	341	1	AX552981
C 83	20.6	0.9	1206	1	E63001
C 84	20.6	0.9	1206	1	E63002
C 85	20.6	0.9	1221	1	E62997
C 86	20.6	0.9	1221	1	E62998
C 87	20.6	0.9	1221	1	E62999
C 88	20.6	0.9	1221	1	E63000
C 89	20.6	0.9	1440	1	AR112953
C 90	20.6	0.9	1440	1	AR112969
C 91	20.6	0.9	1440	1	I19358
C 92	20.6	0.9	1440	1	I19360
C 93	20.6	0.9	1440	1	BD194674
C 94	20.6	0.9	6098	1	AX565990
C 95	20.4	0.9	394	1	AX839180
C 96	20.4	0.9	1416	1	AF465269
C 97	20.4	0.9	2072	1	AF272774
C 98	20.4	0.9	2078	1	AF272773
C 99	20.2	0.9	183	1	AY155152
C 100	20.2	0.9	214	1	AB083386
C 101	20.2	0.9	214	1	AB084901
C 102	20.2	0.9	227	1	AY022473
C 103	20.2	0.9	227	1	AY023221
C 104	20.2	0.9	272	1	HUMPROS01
C 105	20.2	0.9	274	1	AF306920
C 106	20.2	0.9	352	1	HUMPS02

ACCESSION:BD121258
ACCESSION:AX839180
ACCESSION:AF465274
ACCESSION:AX774765
ACCESSION:M57285
ACCESSION:AX395271
ACCESSION:AB062462
ACCESSION:AB062463
ACCESSION:AX908508
ACCESSION:BD044041
ACCESSION:AX265077
ACCESSION:AX265078
ACCESSION:AX265081
ACCESSION:AX265082
ACCESSION:AX265085
ACCESSION:AX265086
ACCESSION:AX265089
ACCESSION:AX265090
ACCESSION:AX265093
ACCESSION:AX265094
ACCESSION:AX265073
ACCESSION:AX265074
ACCESSION:M33108
ACCESSION:K02050
ACCESSION:AX892787
ACCESSION:BD028320
ACCESSION:AX839163
ACCESSION:AF011898
ACCESSION:AF011352
ACCESSION:BC061149
ACCESSION:AX839181
ACCESSION:AX464088
ACCESSION:AX359106
ACCESSION:AX565990
ACCESSION:AX265101
ACCESSION:AX265102
ACCESSION:AX265097
ACCESSION:AX265098
ACCESSION:BC046125
ACCESSION:BD060364
ACCESSION:AF306917
ACCESSION:AF306913
ACCESSION:AF306914
ACCESSION:AF306915
ACCESSION:AF306919
ACCESSION:AF515269
ACCESSION:D21215
ACCESSION:AX524243
ACCESSION:AX552981
ACCESSION:E63001
ACCESSION:E63002
ACCESSION:E62997
ACCESSION:E62998
ACCESSION:E62999
ACCESSION:E63000
ACCESSION:AR112953
ACCESSION:AR112969
ACCESSION:I19358
ACCESSION:I19360
ACCESSION:BD194674
ACCESSION:AX565990
ACCESSION:AX839180
ACCESSION:AF465269
ACCESSION:AF272774
ACCESSION:AF272773
ACCESSION:AY155152
ACCESSION:AB083386
ACCESSION:AB084901
ACCESSION:AY022473
ACCESSION:AY023221
ACCESSION:M36551 J
ACCESSION:AF306920
ACCESSION:M57841 J

C 107	20.2	0.9	985	1	AR108139	ACCESSION:AR108139	C 180	18.6	0.8	168	1	AR151537	ACCESSION:AR151537
C 108	20.2	0.9	1543	1	AX401899	ACCESSION:AX401899	C 181	18.6	0.8	168	1	I82435	ACCESSION:I82435
C 109	20.2	0.9	1543	1	RNPROC	ACCESSION:X64336 S	C 182	18.6	0.8	174	1	HUMPRBS01	ACCESSION:M36565 J
C 110	20	0.9	855	1	AF011899	ACCESSION:AF011899	C 183	18.6	0.8	189	1	AY135778S1	ACCESSION:AY135778S1
C 111	20	0.9	1130	1	AR234337	ACCESSION:AR234337	C 184	18.6	0.8	189	1	AY135796S1	ACCESSION:AY135796S1
C 112	20	0.9	1142	1	AR219285	ACCESSION:AR219285	C 185	18.6	0.8	200	1	AR047835	ACCESSION:AR047835
C 113	20	0.9	1166	1	AR221273	ACCESSION:AR221273	C 186	18.6	0.8	222	1	AX260845	ACCESSION:AX260845
C 114	20	0.9	1169	1	AR219284	ACCESSION:AR219284	C 187	18.6	0.8	241	1	HS98A12P	ACCESSION:263614
C 115	20	0.9	1722	1	AF515269	ACCESSION:AF515269	C 188	18.6	0.8	289	1	AR162089	ACCESSION:AR162089
C 116	19.8	0.9	254	1	AX587861	ACCESSION:AX587861	C 189	18.6	0.8	289	1	AR166614	ACCESSION:AR166614
C 117	19.8	0.9	268	1	HSUKB1PJ7	ACCESSION:AF055326	C 190	18.6	0.8	427	1	AX524284	ACCESSION:AX524284
C 118	19.8	0.9	384	1	BD095271	ACCESSION:BD095271	C 191	18.6	0.8	427	1	AX553022	ACCESSION:AX553022
C 119	19.8	0.9	394	1	AX814618	ACCESSION:AX814618	C 192	18.6	0.8	439	1	AX277349	ACCESSION:AX277349
C 120	19.8	0.9	535	1	DLA6882	ACCESSION:AJ006882	C 193	18.6	0.8	439	1	AX277375	ACCESSION:AX277375
C 121	19.8	0.9	556	1	BV036036	ACCESSION:BV036036	C 194	18.6	0.8	484	1	MACCFX	ACCESSION:D21214
C 122	19.8	0.9	813	1	PIGFIAX	ACCESSION:M26235	C 195	18.6	0.8	546	1	AX775014	ACCESSION:AX775014
C 123	19.8	0.9	873	1	HUMCFIX	ACCESSION:M35672	C 196	18.6	0.8	624	1	AX335885	ACCESSION:AX335885
C 124	19.8	0.9	1850	1	MMU44795	ACCESSION:U44795	C 197	18.6	0.8	624	1	HUMFX8	ACCESSION:L29433 M
C 125	19.6	0.9	484	1	HAMCFX	ACCESSION:D21216	C 198	18.6	0.8	711	1	BD173590	ACCESSION:BD173590
C 126	19.6	0.9	596	1	AX193364	ACCESSION:AX193364	C 199	18.6	0.8	773	1	AX827818	ACCESSION:AX827818
C 127	19.6	0.9	609	1	AX763043	ACCESSION:AX763043	C 200	18.6	0.8	773	1	RNTRY2	ACCESSION:V01274
C 128	19.6	0.9	882	1	AX675583	ACCESSION:AX675583	C 201	18.6	0.8	819	1	DOGRYPA	ACCESSION:M11589
C 129	19.6	0.9	1442	1	AR219285	ACCESSION:AR219285	C 202	18.6	0.8	854	1	PVTRYP8IN	ACCESSION:X86369
C 130	19.6	0.9	1161	1	AX675581	ACCESSION:AX675581	C 203	18.6	0.8	1278	1	AF465268	ACCESSION:AF465268
C 131	19.6	0.9	1169	1	AR219284	ACCESSION:AR219284	C 204	18.6	0.8	1443	1	HUMFXM	ACCESSION:X03194
C 132	19.6	0.9	1373	1	BOVPBC	ACCESSION:X02435	C 205	18.6	0.8	1467	1	A86859	ACCESSION:A86859
C 133	19.4	0.9	177	1	AR109618	ACCESSION:AR109618	C 206	18.6	0.8	1467	1	A86886	ACCESSION:A86886
C 134	19.4	0.9	177	1	AR150638	ACCESSION:AR150638	C 207	18.6	0.8	1467	1	AR316969	ACCESSION:AR316969
C 135	19.4	0.9	177	1	E16187	ACCESSION:E16187	C 208	18.6	0.8	1467	1	AR340866	ACCESSION:AR340866
C 136	19.4	0.9	177	1	E27213	ACCESSION:E27213	C 209	18.6	0.8	1467	1	AX082959	ACCESSION:AX082959
C 137	19.4	0.9	177	1	E28271	ACCESSION:E28271	C 210	18.6	0.8	1467	1	BD070392	ACCESSION:BD070392
C 138	19.4	0.9	177	1	AR300928	ACCESSION:AR300928	C 211	18.6	0.8	1467	1	BD070435	ACCESSION:BD070435
C 139	19.4	0.9	204	1	AR109885	ACCESSION:AR109885	C 212	18.6	0.8	1514	1	AF191307	ACCESSION:AF191307
C 140	19.4	0.9	204	1	AR150703	ACCESSION:AR150703	C 213	18.4	0.8	193	1	HUMKALR4	ACCESSION:X33108
C 141	19.4	0.9	249	1	AJ586104	ACCESSION:AJ586104	C 214	18.4	0.8	249	1	HUMDPBIA	ACCESSION:N77674
C 142	19.4	0.9	290	1	AX839191	ACCESSION:AX839191	C 215	18.4	0.8	249	1	HUMDPBA	ACCESSION:D10478
C 143	19.4	0.9	352	1	HUMPS02	ACCESSION:M57841 J	C 216	18.4	0.8	249	1	HUMDPBB	ACCESSION:D10479
C 144	19.4	0.9	471	1	DOGA2	ACCESSION:D43751	C 217	18.4	0.8	249	1	HUMMDPBH	ACCESSION:M23680
C 145	19.4	0.9	823	1	SHPFIXA	ACCESSION:M26233	C 218	18.4	0.8	256	1	HUMMDP1H	ACCESSION:M23333
C 146	19.4	0.9	829	1	BC061135	ACCESSION:BC061135	C 219	18.4	0.8	257	1	AF180970	ACCESSION:AF180970
C 147	19.4	0.9	1126	1	AR095306	ACCESSION:AR095306	C 220	18.4	0.8	264	1	HUMDPB1KT	ACCESSION:D10882
C 148	19.4	0.9	1126	1	AR103990	ACCESSION:AR103990	C 221	18.4	0.8	283	1	AF336224	ACCESSION:AF336224
C 149	19.4	0.9	1126	1	HUMFX	ACCESSION:R01886	C 222	18.4	0.8	285	1	AF492638	ACCESSION:AF492638
C 150	19.4	0.9	1404	1	A93124	ACCESSION:A93124	C 223	18.4	0.8	285	1	HUMMDPBZ	ACCESSION:M83912
C 151	19.4	0.9	1414	1	HUMCFX	ACCESSION:M2613	C 224	18.4	0.8	804	1	AF312826	ACCESSION:AF312826
C 152	19.4	0.9	1551	1	AX147505	ACCESSION:AX147505	C 225	18.4	0.8	823	1	SHPFIXA	ACCESSION:M26233
C 153	19.4	0.9	1850	1	MMU44795	ACCESSION:U44795	C 226	18.4	0.8	832	1	AF011900	ACCESSION:AF011900
C 154	19.4	0.9	1869	1	BC061149	ACCESSION:BC061149	C 227	18.4	0.8	1293	1	AF465275	ACCESSION:AF465275
C 155	19.2	0.8	281	1	MUSACROS02	ACCESSION:M96427 M	C 228	18.4	0.8	1505	1	AX523898	ACCESSION:AX523898
C 156	19.2	0.8	471	1	GOTA3	ACCESSION:D43752	C 229	18.2	0.8	171	1	S78934	ACCESSION:S78934
C 157	19.2	0.8	596	1	BV094002	ACCESSION:BV094002	C 230	18.2	0.8	240	1	AX318568	ACCESSION:AX318568
C 158	19.2	0.8	826	1	RABTHRO	ACCESSION:M81396	C 231	18.2	0.8	251	1	AY083553	ACCESSION:AY083553
C 159	19.2	0.8	1302	1	AF465270	ACCESSION:AF465270	C 232	18.2	0.8	265	1	HSTCRB9	ACCESSION:X74849
C 160	19.2	0.8	1341	1	AF532184	ACCESSION:AF532184	C 233	18.2	0.8	836	1	AF011901	ACCESSION:AF011901
C 161	19.2	0.8	1619	1	OCU77477	ACCESSION:U77477 S	C 234	18.2	0.8	987	1	AF542056	ACCESSION:AF542056
C 162	19.1	0.8	279	1	AF306907	ACCESSION:AF306907	C 235	18.2	0.8	1558	1	OCU49933	ACCESSION:U49933
C 163	19.1	0.8	279	1	AF306908	ACCESSION:AF306908	C 236	18	0.8	199	1	S68634	ACCESSION:S68634
C 164	19.1	0.8	279	1	AF306912	ACCESSION:AF306912	C 237	18	0.8	276	1	I14646	ACCESSION:I14646
C 165	19	0.8	244	1	HSRCYB2S3	ACCESSION:U72402	C 238	18	0.8	276	1	AY267909S2	ACCESSION:AY267910
C 166	18.8	0.8	340	1	AR263850	ACCESSION:AR263850	C 239	18	0.8	276	1	HSJA507648	ACCESSION:AJ507648
C 167	18.8	0.8	340	1	AR263851	ACCESSION:AR263851	C 240	18	0.8	276	1	HSJLAAGN2	ACCESSION:UJ0243
C 168	18.8	0.8	352	1	DMU58868	ACCESSION:U58868	C 241	18	0.8	290	1	AR249144	ACCESSION:AR249144
C 169	18.8	0.8	596	1	AX193364	ACCESSION:AX193364	C 242	18	0.8	299	1	AX312474	ACCESSION:AX312474
C 170	18.8	0.8	882	1	AX675583	ACCESSION:AX675583	C 243	18	0.8	302	1	BT271156	ACCESSION:AJ271156
C 171	18.8	0.8	1161	1	AX675581	ACCESSION:AX675581	C 244	18	0.8	335	1	FRSPLEX2	ACCESSION:X95338
C 172	18.8	0.8	1505	1	AX523898	ACCESSION:AX523898	C 245	18	0.8	383	1	AF266240	ACCESSION:AF266240
C 173	18.8	0.8	1671	1	AY040345	ACCESSION:AY040345	C 246	18	0.8	815	1	AX921761	ACCESSION:AX921761
C 174	18.6	0.8	168	1	AR081819	ACCESSION:AR081819	C 247	18	0.8	873	1	HUMCFIX	ACCESSION:M35672
C 175	18.6	0.8	168	1	AR081819	ACCESSION:AR081819	C 248	18	0.8	1329	1	AF465274	ACCESSION:AF465274
C 176	18.6	0.8	168	1	AR098999	ACCESSION:AR098999	C 249	18	0.8	1389	1	E02492	ACCESSION:E02492
C 177	18.6	0.8	168	1	AR116830	ACCESSION:AR116830	C 250	17.8	0.8	177	1	AX381010	ACCESSION:AX381010
C 178	18.6	0.8	168	1	AR127061	ACCESSION:AR127061							
C 179	18.6	0.8	168	1	AR141647	ACCESSION:AR141647							

ALIGNMENTS

```
RESULT 1
AR162089/c
LOCUS          AR162089          289 bp      DNA          linear      PAT 17-OCT-2001
DEFINITION     Sequence 17 from patent US 6258558.
ACCESSION      AR162089
VERSION        AR162089.1 GI:16229155
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 289)
AUTHORS        Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE          Method for selection of proteins using RNA-protein fusions
JOURNAL        Patent: US 6258558-A 17 10-JUL-2001;
FEATURES       Location/Qualifiers
source         1..289
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match          1.9%; Score 44.2; DB 1; Length 289;
Best Local Similarity 12.8%; Pred. No. 4.9e-05;
Matches 37; Conservative 105; Mismatches 147; Indels 0; Gaps 0;

Qy 1625 GGTGTTTGTATGCTTCTTGACCTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 1684
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 289 GGTGTTTGTATGCTTCTTGACCTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 230
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1685 TCTTTTGGTTTCTTGAAAATATTTTCCCTGCTTTTGACCTGCTTCTTCCCTTCTCT 1744
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 229 YAGYCYTYGYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 170
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1745 CTATTCCTTTGGTTTGTGCAATGATCTCTGGCTTCCGATGTTTATGCTGCAATPAT 1804
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 169 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 110
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1805 TTTAGACTTAACATTTCTTTGACCAAGGATATCCATTTCTTCTATCTTCTTCTCT 1864
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 109 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 50
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1865 TGAGATTCCTCTCTTCTATCTCTTCTATCTCTTCTATCTCTAGTGAGGCTTCTCT 1913
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 49 YGYTYAYATYTYGYTYAYAYAYTYAYGYTYAYAYTYTYGYTYCYCY 1
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 2
AR166614/c
LOCUS          AR166614          289 bp      DNA          linear      PAT 17-OCT-2001
DEFINITION     Sequence 17 from patent US 6281344.
ACCESSION      AR166614
VERSION        AR166614.1 GI:16242009
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 289)
AUTHORS        Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE          Nucleic acid-protein fusion molecules and libraries
JOURNAL        Patent: US 6281344-A 17 28-AUG-2001;
FEATURES       Location/Qualifiers
source         1..289
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match          1.9%; Score 44.2; DB 1; Length 289;
Best Local Similarity 12.8%; Pred. No. 4.9e-05;
Matches 37; Conservative 105; Mismatches 147; Indels 0; Gaps 0;

Qy 1625 GGTGTTTGTATGCTTCTTGACCTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 1684
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 289 GGTGTTTGTATGCTTCTTGACCTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 230
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1685 TCTTTTGGTTTCTTGAAAATATTTTCCCTGCTTTTGACCTGCTTCTTCCCTTCTCT 1744
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 229 YAGYCYTYGYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 170
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1745 CTATTCCTTTGGTTTGTGCAATGATCTCTGGCTTCCGATGTTTATGCTGCAATPAT 1804
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 169 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 110
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1805 TTTAGACTTAACATTTCTTTGACCAAGGATATCCATTTCTTCTATCTTCTTCTCT 1864
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 109 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 50
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1865 TGAGATTCCTCTCTTCTATCTCTTCTATCTCTGATGAGGCTTCTCTCT 1913
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 49 YGYTYAYATYTYGYTYAYAYAYTYAYGYTYAYAYTYTYGYTYCYCY 1
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 3
AR030786/c
LOCUS          AR030786          2422 bp      DNA          linear      PAT 29-SEP-1999
DEFINITION     Sequence 1 from patent US 5861374.
ACCESSION      AR030786
VERSION        AR030786.1 GI:5944000
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 2422)
AUTHORS        Berkner,K.L., Petersen,L.Christian. and Hart,C.E.
TITLE          Modified Factor VII
JOURNAL        Patent: US 5861374-A 1 19-JAN-1999;
FEATURES       Location/Qualifiers
source         1..2422
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match          1.9%; Score 44.2; DB 1; Length 2422;
Best Local Similarity 61.9%; Pred. No. 5.7e-05;
Matches 70; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

Qy 1104 GCACCTTGGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1163
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2167 GCACATATGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 2108
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1164 TGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTGTCTG 1216
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2107 GGTGTGTGTGCGCAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 2055
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 4
AR045090/c
LOCUS          AR045090          2422 bp      DNA          linear      PAT 29-SEP-1999
DEFINITION     Sequence 1 from patent US 5817788.
ACCESSION      AR045090
VERSION        AR045090.1 GI:5966555
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 2422)
AUTHORS        Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and
               Bregengaard,C.
TITLE          Modified factor VII
JOURNAL        Patent: US 5817788-A 1 06-OCT-1998;
FEATURES       Location/Qualifiers
source         1..2422
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match          1.9%; Score 44.2; DB 1; Length 2422;
Best Local Similarity 61.9%; Pred. No. 5.7e-05;
Matches 70; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

Qy 1625 GGTGTTTGTATGCTTCTTGACCTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 1684
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 289 GGTGTTTGTATGCTTCTTGACCTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 230
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
```


[illegible]

[illegible]

SOURCE: HUMANITARIAN/

ACCESSION

A10655553


```

VERSION          AY083553.1  GI:20146915
KEYWORDS
SOURCE           Macaca mulatta (rhesus monkey)
ORGANISM         Macaca mulatta
                 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                 Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
                 Cercopithecinae; Macaca.
REFERENCE
  1 (bases 1 to 251)
  Norgren,R.B. Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.
  Construction of a targeted rhesus macaque microarray
  Unpublished
REFERENCE
  2 (bases 1 to 251)
  Norgren,R.B. Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.
  Direct Submission
  Molecular and Cellular Biology Core, Oregon
  Submitted (11-MAR-2002)
  Regional Primate Research Center, 505 NW 185th Avenue, Beaverton,
  OR 97006, USA
FEATURES
  source         Location/Qualifiers
                  1..251
                  /organism="Macaca mulatta"
                  /mol_type="genomic DNA"
                  /db_xref="taxon:9544"
                  <1..>251
                  /gene="GAP43"
                  <1..>251
                  /gene="GAP43"
                  /product="growth associated protein 43"
                  <1..>251
                  /gene="GAP43"

  gene
  mRNA
  3'UTR

  Query Match      1.1%; Score 24.4; DB 1; Length 251;
  Best Local Similarity 82.4%; Pred. No. 6.5;
  Matches 28; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

  Qy 1681 TTTTCTTTTGTCTTCTGAAATATTTTC 1714
      |||||
  Db 99 TTTTCTTTTGTCTTCTGAAATATTTTC 66

  RESULT 25
  MUSCP/c         1499 bp      mRNA      linear      ROD 01-FEB-2000
  LOCUS           Mouse mRNA for protein C, complete cds.
  DEFINITION
  ACCESSION       D10445
  VERSION         D10445.1  GI:220385
  KEYWORDS        anti-clotting activity; anti-coagulation factor; blood coagulation
                  factor; calcium binding; mouse protein C; phospholipid binding;
                  serine protease.
  SOURCE          Mus musculus (house mouse)
  ORGANISM        Mus musculus
                  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  REFERENCE
  1 (bases 1 to 1499)
  Tada,N., Sato,M., Tsujimura,A., Iwase,R. and Hashimoto-Gotoh,T.
  Isolation and characterization of a mouse protein C cDNA
  J. Biochem. 111 (4), 491-495 (1992)
  MEDLINE         92316897
  PUBMED         1618739
  REFERENCE
  2 (bases 1 to 1499)
  Sato,M.
  Direct Submission
  TITLE           Submitted (31-JAN-1992) Masahiro Sato, Hoechst Japan Co., Ltd.,
  JOURNAL         Pharma Research Laboratories; 1-3-2 Minamidai, Kawagoe, Saitama
                  350, Japan (E-mail:rkikuno@dbj.nig.ac.jp, Tel:0492-43-6149,
                  Fax:0492-41-6475)
  SUBMITTED (31-JAN-1992) to DBJ by:
  Baboratory for Molecular Biology
  Pharma Research Laboratories
  Hoechst Japan Co., Ltd.
  1-3-2 Minamida, Kawagoe
  Saitama 350
  Japan
  Phone: 0492-43-6149

  Query Match      1.1%; Score 24; DB 1; Length 1499;
  Best Local Similarity 46.9%; Pred. No. 9.4;
  Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

  Qy 1879 CTATCTCTGATTTCTCTCAGTGAGCTTGTCTCTGAGGTTCTGTTGGGTTCTTAATTT 1938
      |||||
  Db 715 CTTCTCTTGAGTCCAGAGGATTGCTGCGAAGGACTGTCACCCCTGCTTCGTCAGCGT 656

  Qy 1939 TTTCATTTCCAGATTTCCCTTCAGTTGGGTTGTTGTTTATTAATTCATTTCCATTTTCAG 1998
      |||||
  Db 655 TCGTTCACTATCTCTGATCTGTTCCAGTTCACTCTTAAGTCTGTCTGCTGTTTGGAG 596

  Qy 1999 GTCTGAAATGTTTACTCTATTTTCCTCCAGTATTACA 2038
      |||||
  Db 595 GAUCTTCGGTTCTTCTCTATCCACCTCCAGTTCCCA 556

  RESULT 26
  AF318182/c      1580 bp      mRNA      linear      ROD 14-FEB-2001
  LOCUS           Mus musculus anticoagulant protein C mRNA, complete cds.
  DEFINITION
  ACCESSION       AF318182
  VERSION         AF318182.1  GI:12802522
  KEYWORDS
  SOURCE          Mus musculus (house mouse)
  ORGANISM        Mus musculus
                  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  REFERENCE
  1 (bases 1 to 1580)
  Korf,I.
  Complete sequence of UC72A01
  TITLE           Unpublished
  JOURNAL
  REFERENCE
  2 (bases 1 to 1580)
  Korf,I.
  Direct Submission
  TITLE           Submitted (02-NOV-2000) Genetics, Washington University, 4444
  JOURNAL         Forest Park Avenue, St. Louis, MO 63108, USA
  FEATURES
  source         Location/Qualifiers
                  1..1580
                  /organism="Mus musculus"
                  /mol_type="mRNA"
                  /strain="C57BL"
                  /db_xref="dbEST:AA986009"
                  /db_xref="taxon:10090"

```

Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgapsb-remail.nih.gov
Tissue Procurement: Jeffrey E. Green, M.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
<http://www.systemsbiology.org>
contact: amadane@systemsbiology.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettelman, Anuradha Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAC Plate: 18 Row: n Column: 8
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6679476.

Location/Qualifiers

1. 1603
/organism="Mus musculus"
/mol_type="mRNA"
/strain="FVB/N"
/db_xref="taxon:10090"
/clone="MGC:13870 IMAGE:4211329"
/tissue_type="Liver, normal. 5 month old male mouse."
/clone_lib="NCI_CGAP L19"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"

```

/!note="synonym: PC"
/db_xref="locusID:19123"
/db_xref="MGI:97771"
100..1482
/codon_start=1
/product="protein_C"
/protein_id="AAH13896.1"
/db_xref="GI:15530230"
/db_xref="locusID:19123"
/db_xref="translation="NM03RFVLLMSTMWGISSIPAHDPDPVFSSEHAHQVLRVRRANS
FLEEMRPLSRECMEEICDFEEAEIQFNVEDTIAFWIKYFDQCSCAPLDDHQDCS
PCCGHGTICDIGISPCSCDKWEGKFCQOEIRFQDFQVNGGCKHYCLEESNGRCA
CAGYELAADHMRCKSTVNFPCGKLGMRTEKKRKLTDLEDELEPPRIVNGLT
KQGDSPWAKILLDDSKKALCCGVLHTSWLTAACHVEGTKTLVGLVEDLRRDRHM
ELDDILHVPNTIRSSDDVLIHTLRRAQATLSKTIPIPLPNNGLAQELTQBAQ
ETVTWGWYQSDRIKDGRRNRTFIITRIPILVARNECVEMKNVVSSENLCAIGIIG
TRDADCGSGSGPMVVFRTGFWELVGLVSGEGCGHTNNYGIYTKVGSYLKWHISYIG
KVGVSLSQKL"
175..357
/!note="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
400..489
/!note="SGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
730..1431
/!note="Tryp SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"
11.1%; Score 24; DB 1; Length 1603;
1 Similarity 46.9%; Pred.No. 9.4; Indels 0. Gaps 0;
75; Conservative 0; Mismatches 85;

```



```
Db      217 SSKYMTCKSSKKRYSATYYSCMWWKKYCMMSATYSCMWWRYCYSCMMSRYSCT 158
Qy      780 CTGCGTGATTTT 792
       : : : : : : : :
Db      157 SYSRKGCSCTGWK 145

RESULT 34
BD121258/c
LOCUS   BD121258               364 bp      DNA      linear      PAT 18-SEP-2002
DEFINITION EST and encoded human protein.
ACCESSION BD121258
VERSION   BD121258.1 GI:23216168
KEYWORDS  JP 2002010789-A/13335.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 364)
AUTHORS   Edwards,J.B.D.M., Jobert,S. and Giordano,J.E.
TITLE     EST and encoded human protein
JOURNAL   Patent: JP 2002010789-A 13335 15-JAN-2002;
GENSET    CORP
COMMENT   OS Homo sapiens (human)
          PN JP 2002010789-A/13335
          PD 15-JAN-2002
          PF 07-AUG-2000 JP 2000280989
          PR 05-AUG-1999 US 60/147499
          PI JEAN BAPTISTE DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
          PC C12N15/09,C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19, PC
          PC C12N5/10,C12P21/02,C12P21/08,C12Q1/68,C12N15/00,C12N5/00, PC
          CC EST and encoded human protein
          FH Key Location/Qualifiers
          FT source
          FT Location/Qualifiers
             1..364
             /organism="Homo sapiens"
             /mol_type="genomic DNA"
             /db_xref="taxon:9606"

FEATURES             source
   Query Match      1.0%; Score 23; DB 1; Length 364;
   Best Local Similarity 10.5%; Pred. No. 15;
   Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;

Qy      660 TTGAAGTAGCCCACTATCTGTGTGAGGTCAATATGTGATTTAGCTGTAGCTGTGCTT 719
       :|::: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      277 WTGRSMWMSYTKRWSRAGSWMTGYRMSRWMTGSTRCSYTKRKRKKGSTSSKYASTSGK 218

Qy      720 GTTTATGAACCTGGTGACATTTGTTGTGTGCATAGACATTAAGAATTGCAATGCTCT 779
       : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      217 SSKYMTCKSSKKRYSATYYSCMWWKKYCMMSATYSCMWWRYCYSCMMSRYSCT 158

Qy      780 CTGCGTGATTTT 792
       : : : : : : : :
Db      157 SYSRKGCSCTGWK 145

RESULT 35
AX839180
LOCUS   AX839180               394 bp      DNA      linear      PAT 15-DEC-2003
DEFINITION Sequence 23 from Patent WO03076610.
ACCESSION AX839180
VERSION   AX839180.1 GI:39922629
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
```

```
AUTHORS   Bracco,L., Brinkman,B. and Coignard,F.
TITLE     Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL   Patent: WO 03076610-A 23 18-SEP-2003;
          Exonhit Therapeutics S.A. (FR)
FEATURES             Location/Qualifiers
   source          1..394
                   /organism="Homo sapiens"
                   /mol_type="unassigned DNA"
                   /db_xref="taxon:9606"

   Query Match      1.0%; Score 23; DB 1; Length 394;
   Best Local Similarity 60.3%; Pred. No. 16;
   Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

Qy      1127 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1186
       ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      270 GTGTGTCTACCCGTGTATCTCTCTGCCAGGCTCTGTCTCTGGTCTCTGTCTACCTGTG 329

Qy      1187 TCT 1189
       ||
Db      330 CCT 332

RESULT 36
AF465274
LOCUS   AF465274               1329 bp      mRNA      linear      VRT 02-FEB-2003
DEFINITION Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete cds.
ACCESSION AF465274
VERSION   AF465274.1 GI:28194019
KEYWORDS  Takifugu rubripes (Fugu rubripes)
SOURCE    Takifugu rubripes
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
           Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
           Tetraodontoidea; Tetraodontidae; Takifugu.
REFERENCE 1 (bases 1 to 1329)
AUTHORS   Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
          Tuddenham,E.G.D. and McVey,J.H.
TITLE     Comparative sequence analysis and molecular evolution of blood
          coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL   Unpublished
REFERENCE 2 (bases 1 to 1329)
AUTHORS   McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
TITLE     Direct Submission
JOURNAL   Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
          Centre, The Faculty of Medicine, Imperial College, Hammersmith
          Campus, Du Cane Road, London W12 0NN, UK
FEATURES             Location/Qualifiers
   source          1..1329
                   /organism="Takifugu rubripes"
                   /mol_type="mRNA"
                   /db_xref="taxon:31033"
                   1..1329
                   /EC_number="3.4.21.21"
                   /function="serum prothrombinconversion accelerator"
                   /note="vitamin K dependent serine protease; similar to
                   Fugu rubripes FVII; synthesized in liver; contains 2
                   EGF-like domains; member of peptidase family S1/trypsin
                   family"
                   /codon_start=1
                   /product="coagulation factor VIIb precursor"
                   /protein_id="AA033369.1"
                   /db_xref="GI:28194020"
                   /translation="MLIRICTWILFSATAAAVFERDDASTVLORRRANSFGLE
                   EMQGNLKRCEIENYEARSVFDDAQTREWTYNHDPSCWPCQNGVCVSM
                   GNTYQCHCPGFGQCEIKAEEDFLKLYNQCCQHCFCDSGASRKCFAHGTYLAD
                   GRCIAEVEFPQGLPPETGPDTQTVVGTGTRLVGTNGECPCWFLVQLHGQSHCG
                   GVLRPDWVITAACHVTGKQPHLSVAGEHNLNDNDGTEQIKIPARVFAHEGVSET
                   GKDIALLHLNASVTLNRGYPVCLPTKDLAERELLMTRYHTVSGWKRTNGNEDHG
                   VNTAPVSPFLRKFSVPIENPOCSHRSQFNTDMFCAGYLEGNOQSCRGDGSPLV
                   TLYGSHFLILGVVGWRCGCPNGYGYTNGNMFVDWANGIMMAANKKST"
```

```
CDS
Query Match 1.0%; Score 23; DB 1; Length 1329;
Best Local Similarity 74.4%; Pred. No. 17;
Matches 29; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1573 TGATTGATTATTATGCACTGTGGGAGTTCTTTCCG 1611
|||||
Db 5 TGATTAGGATTGCTGCACCTGTTGGATTCTCTTTCCG 43

RESULT 37
AX774765/c
LOCUS AX774765 1507 bp DNA linear PAT 09-JUL-2003
DEFINITION Sequence 81 from Patent WO03038129.
ACCESSION AX774765
VERSION AX774765.1 GI:32486281
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Raponi, M.
TITLE Methods for assessing and treating leukemia
JOURNAL Patent: WO 03038129-A 81 08-MAY-2003;
Ortho-Clinical Diagnostics, Inc. (US)
FEATURES
source
1..1507
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 23; DB 1; Length 1507;
Best Local Similarity 60.3%; Pred. No. 17;
Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 1622 TTGTGTTTTGATGCTTTGTACCTTGATAGGCACTCTTTCTCAAGTTAGGAAT 1681
|||||
Db 1506 TTTTGTGTTTTGATGCTTTGTACCTTGATAGGCACTCTTTCTCAAGTTAGGAAT 1681
|||||
QY 1682 TTT 1684
Db 1446 TAT 1444

RESULT 39
AX395271/c
LOCUS AX395271 200 bp DNA linear PAT 18-MAY-2002
DEFINITION Sequence 8 from Patent WO0203787.
ACCESSION AX395271
VERSION AX395271.1 GI:21066295
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Allen, K.D. and Leviten, M.W.
TITLE Transgenic mice containing targeted gene disruptions
JOURNAL Patent: WO 0203787-A 8 17-JAN-2002;
Deltagen, Inc. (US)
FEATURES
source
1..200
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Targeting Vector"

Query Match 1.0%; Score 22.8; DB 1; Length 200;
Best Local Similarity 46.8%; Pred. No. 17;
Matches 72; Conservative 0; Mismatches 82; Indels 0; Gaps 0;

QY 3 TCACCTCTCTAGTAAAGGTGGGGTCTGAGGCTCCCAATGGTTGTTGATGTGTAGAGTA 62
|||||
Db 198 TCCCTCTCTGATCCAGGTGTGATGTCGGGCATCCCTGTGGTGTGTTGTGTCGGCTG 139
|||||
QY 63 TCTCATACAGAGATAGACACTAGACTCTCTGGGCATAGGTAGCTTCCAGAGAC 122
|||||
Db 138 TCTGTCCATGCTGCTATACCCAGTGTGCTCTTTGATCCAGTCCCGAACCTACAGGAGCC 79
|||||
QY 123 TTCAATAATATATTTTCTTGAAGCCTCTGCTGGCA 156
|||||
Db 78 TTGTGTACAGCGCTGGCTTGTTCCTCTGAGCGCA 45
/|
/gene="F10"
```

[illegible]

[illegible]


```
Db 28 AATTGGCAGCTAAACTGCTTAGAATG 3
||||| ||| ||| ||| ||| |||
RESULT 47
AX265082
LOCUS AX265082 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2473 from Patent WO0173002.
ACCESSION AX265082
VERSION AX265082.1 GI:16513881
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
Patent: WO 0173002-A 2473 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGCTCGTGTGTTGTTATGTCGTGTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 34 CCATTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 93
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 94 AATTGGCAGCTAAACTGCTTAGAATG 119
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
RESULT 48
AX265085/c
LOCUS AX265085 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2476 from Patent WO0173002.
ACCESSION AX265085
VERSION AX265085.1 GI:16513884
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
Patent: WO 0173002-A 2476 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGCTCGTGTGTTGTTATGTCGTGTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 89 CCATTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 30
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
Db 29 AATTGGCAGCTAAACTGCTTAGAATG 4
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
RESULT 49
AX265086
LOCUS AX265086 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2477 from Patent WO0173002.
ACCESSION AX265086
VERSION AX265086.1 GI:16513885
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
Patent: WO 0173002-A 2477 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGCTCGTGTGTTGTTATGTCGTGTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 33 CCATTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 92
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 93 AATTGGCAGCTAAACTGCTTAGAATG 118
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
RESULT 50
AX265089/c
LOCUS AX265089 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2480 from Patent WO0173002.
ACCESSION AX265089
VERSION AX265089.1 GI:16513888
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
Patent: WO 0173002-A 2480 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGCTCGTGTGTTGTTATGTCGTGTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 86 CCATTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 27
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 26 AATTGGCAGCTAAACTGCTTAGAATG 1
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
RESULT 51
AX265090
LOCUS AX265090 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2481 from Patent WO0173002.
ACCESSION AX265090
VERSION AX265090.1 GI:16513889
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2481 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTAATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 95
QY 2216 CTTTGGCATATAGCGGCTGAGTTG 2241
DB 96 AATTGGCAGTAACTGCTTAGAATG 121
RESULT 52
AX265093/c
LOCUS AX265093 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2484 from Patent WO0173002.
ACCESSION AX265093
VERSION AX265093.1 GI:16513892
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2484 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTAATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 86 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 27
QY 2216 CTTTGGCATATAGCGGCTGAGTTG 2241
DB 26 AATTGGCAGTAACTGCTTAGAATG 1
```

```
RESULT 53
AX265094
LOCUS AX265094 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2485 from Patent WO0173002.
ACCESSION AX265094
VERSION AX265094.1 GI:16513893
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2485 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTAATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 95
QY 2216 CTTTGGCATATAGCGGCTGAGTTG 2241
DB 96 AATTGGCAGTAACTGCTTAGAATG 121
RESULT 54
AX265073/c
LOCUS AX265073 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2464 from Patent WO0173002.
ACCESSION AX265073
VERSION AX265073.1 GI:16513872
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2464 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTAATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 91 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 32
QY 2216 CTTTGGCATATAGCGGCTGAGTTG 2241
DB 31 AATTGGCAGTAACTGCTTAGAATG 6
```

```

RESULT 55
AX265074
LOCUS
DEFINITION Sequence 2465 from Patent WO0173002.
ACCESSION AX265074
VERSION AX265074.1 GI:16513873
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kniec,E.B., Gamper,H.B. and Rice,M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2465 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACAGGAGACATATTCCTGGTTGTTATGCTGTGTTTTC 2215
Db 31 CCATTAAACATGATGGACTCACATGATCTCCATCTTTGAGATAGGTTAAGAAATTG 90
QY 2216 CTTTGGCATATACGGCTCAGTTTG 2241
Db 91 AATTGGCAGCTAAACTGCTTAGAATG 116

RESULT 56
HUMKALR4/c
LOCUS
DEFINITION Human renal kallikrein, exon 4.
ACCESSION M33108
VERSION M33108.1 GI:186648
KEYWORDS kallikrein; kininogenase.
SEGMENT 4 of 5
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Evans,B.A., Yun,Z.X., Close,J.A., Tregear,G.W., Kitamura,N.,
AUTHORS Nakanishi,S., Cailien,D.F., Baker,E., Hyland,V.J., Sutherland,G.R.
and Richards,R.I.
TITLE Structure and chromosomal localization of the human renal
JOURNAL kallikrein gene
MEDLINE Biochemistry 27 (9), 3124-3129 (1988)
PUBMED 88263498
COMMENT Original source text: Human parotid gland, cDNA to mRNA.
FEATURES
source
1..193
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="19q13.3"
prim_transcript <1..>193
/gene="KLK1"
/note="kallikrein mRNA and introns"
intron <1..>29
/gene="KLK1"
/note="kallikrein intron C"
exon 30..166
/gene="KLK1"
/note="G00-120-118"

```

```

intron
/number=4
167..>193
/gene="KLK1"
/note="kallikrein intron D"
Query Match 1.0%; Score 22; DB 1; Length 193;
Best Local Similarity 67.4%; Pred. No. 27;
Matches 31; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
QY 953 GTAGGTGCTTTTTTGGATGCGAGCAGTAGGATGATCTTTGTTTC 998
Db 104 GCAGCTGGGGCTTTTTCATCATCATCATTAGGCAGGATTTTGAGGTC 59

RESULT 57
HUMFIXG3/c
LOCUS
DEFINITION Human factor IX gene, exon 4.
ACCESSION K02050
VERSION K02050.1 GI:182616
KEYWORDS Christmas factor; factor IX.
SEGMENT 3 of 6
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 240)
AUTHORS Anson,D.S., Choo,K.H., Rees,D.J., Giannelli,F., Gould,K.,
Huddleston,J.A. and Brownlee,G.G.
TITLE The gene structure of human anti-haemophilic factor IX
JOURNAL EMBO J. 3 (5), 1053-1060 (1984)
MEDLINE 84236100
PUBMED 6329734
COMMENT Original source text: Human: cDNA to liver mRNA, clones cVII, cVI,
108.1, and DB.1; 4X lymphoblastoid cell line (GM14168) DNA, clone
lambda-HIX-4; genomic DNA library of Lawn et al., clones
lambda-HIX-1,2,3.
See segment 1
FEATURES
source
1..240
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="Xq26.3-q27.1"
prim_transcript <1..>240
/gene="F9"
/note="fix mRNA"
intron <1..>64
/gene="F9"
/note="fix intron 3"
exon 65..178
/gene="F9"
/note="G00-119-900"
number=4
intron 179..>240
/gene="F9"
/note="fix intron 4"
Query Match 1.0%; Score 22; DB 1; Length 240;
Best Local Similarity 53.5%; Pred. No. 27;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACAGGAGACATATTCCTGGTTGTTATGCTGTGTTTTC 2215
Db 101 CCATTAAACATGATGGACTCACATGATCTCCATCTTTGAGATAGGTTAAGAAATTG 42
QY 2216 CTTTGGCATATACGGCTCAGTTTG 2241
Db 41 AATTGGCAGCTAAACTGCTTAGAATG 16

RESULT 58
AX892787/c

```

LOCUS AX892787 385 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 8650 from Patent EP1033401.
ACCESSION AX892787
VERSION AX892787.1 GI:40047671
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE Expressed sequence tags and encoded human proteins
JOURNAL Patent: EP 1033401-A 8650 06-SEP-2000;
Genset (FR)
FEATURES
Location/Qualifiers
source 1..385
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 385;
Best Local Similarity 57.1%; Pred. No. 28;
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 217 TCTCTCTCCCTTCTCTTAACACTTCGGGCGAGGTAGGGGCACTACCGCATTCCTC 276
DB 135 TCTCACTCCAGCTCCCAATCCGAGACTGATGAGGGGCGACCGCATGTCACC 76
QY 277 TCTCTTCCAA 286
DB 75 CCACAGACAA 66
RESULT 59
BD028320/c
LOCUS BD028320 385 bp DNA linear PAT 27-AUG-2002
DEFINITION Sequence tag and encoded human protein.
ACCESSION BD028320
VERSION BD028320.1 GI:22570062
KEYWORDS JP 2001269182-A/4566.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 385)
AUTHORS Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
TITLE Sequence tag and encoded human protein
JOURNAL Patent: JP 2001269182-A 4566 02-OCT-2001;
GENSET
COMMENT OS Homo sapiens (human)
PN JP 2001269182-A/4566
PD 02-OCT-2001
PF 24-FEB-2000 JP 2000118773
PR 26-FEB-1999 US 60/122487
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,EIMERIC DUCCLAIR,JEAN YVES
PI JORDAN
PC C12N15/09,C07K14/435,C07K16/18,C12N1/15,C12N1/19,C12N1/21,PC
C12N5/10,
PC C12P21/02,C12P21/08,C12Q1/68//G06F17/30,C12N15/00,C12N5/00,PC
CC G06F15/40
FH Key Location/Qualifiers.
FEATURES
source 1..385
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 385;
Best Local Similarity 57.1%; Pred. No. 28;
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 217 TCTCTCTCCCTTCTCTTAACACTTCGGGCGAGGTAGGGGCACTACCGCATTCCTC 276

DB 135 TCTCACTCCAGCTCCCAATCCGAGACTGATGAGGGGCGACCGCATGTCACC 76
QY 277 TCTCTTCCAA 286
DB 75 CCACAGACAA 66
RESULT 60
AX839163/c
LOCUS AX839163 409 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 6 from Patent WO03076610.
ACCESSION AX839163
VERSION AX839163.1 GI:39922612
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Bracco,L., Brinkman,B. and Coignard,F.
TITLE Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL Patent: WO 03076610-A 6 18-SEP-2003;
Exonhit Therapeutics S.A. (FR)
FEATURES
Location/Qualifiers
source 1..409
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 409;
Best Local Similarity 57.1%; Pred. No. 28;
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 217 TCTCTCTCCCTTCTCTTAACACTTCGGGCGAGGTAGGGGCACTACCGCATTCCTC 276
DB 108 TCTCACTCCAGCTCCCAATCCGAGACTGATGAGGGGCGACCGCATGTCACC 49
QY 277 TCTCTTCCAA 286
DB 48 CCACAGACAA 39
RESULT 61
AF011898/c
LOCUS AF011898 860 bp mRNA linear VRT 09-SEP-1997
DEFINITION Petromyzon marinus trypsinogen a2 (TRYP2) mRNA, complete cds.
ACCESSION AF011898
VERSION AF011898.1 GI:2367494
KEYWORDS
SOURCE Petromyzon marinus (sea lamprey)
ORGANISM Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE 1 (bases 1 to 860)
AUTHORS Roach,J.C.
TITLE The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 860)
AUTHORS Roach,J.C.
TITLE Direct Submission
JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA
FEATURES
Location/Qualifiers
source 1..860
/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="ammocoete"
/tissue_lib="anterior intestine"
gene 1..860
/gene="TRYP2"
CDS 6..749

QY	2124	CTTGTGCTTCAGCTATGTTGCAATTCCTCAGGCCCTATTGTAATAGGTTTTCAGGAGACA	2188
Db	190	CTGGTGCAACCCCGAGTGGTCTCTCACAGCTGCCACTGCATCAGGAAGTGAAGTAGGGGCC	249
QY	2184	TATTGTCTCTGGTGTGTTATTGTCCTGT	2210
Db	250	TGGGTCTGGGAGCAGGTGCTGTGT	276
RESULT 65			
AX464088/c			
LOCUS	AX464088	1129 bp	DNA linear PAT 16-JUL-2002
DEFINITION	Sequence 221 from Patent WO0140466.		
ACCESSION	AX464088		
VERSION	AX464088.1	GI:21899060	
KEYWORDS	Homo sapiens (human)		
SOURCE	Homo sapiens		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
REFERENCE	1	Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E., Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L., Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K., Wood, W.L. and Zhang, Z.,	
AUTHORS	Secreted and transmembrane polypeptides and nucleic acids encoding same		
TITLE	Patent: WO 0140466-A 221 07-JUN-2001; Genentech Inc. (US)		
JOURNAL	Location/Qualifiers		
FEATURES	1..1129		
source	/organism="Homo sapiens"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:9606"		
Query Match	0.9%; Score 21.4; DB 1; Length 1129;		
Best Local Similarity	66.0%; Pred. No. 43;		
Matches	31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;		
QY	1929	TTCTTAATTTTTCATTCAGATTCTTCAGTTTGGTTGGTTTGT	1975
Db	1129	TTTTTTTTTTTTTTTTTTTTCAGTGGCACACAGCTGGTTTATT	1083
RESULT 66			
AX359106/c			
LOCUS	AX359106	1129 bp	mRNA linear PRI 03-OCT-2003
DEFINITION	Homo sapiens clone DNA99391 MFN (UNQ1884)		
ACCESSION	AX359106		
VERSION	AX359106.1	GI:37183328	
KEYWORDS	FLI CDNA.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	1	(bases 1 to 1129)	
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
	Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J., Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B., Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E., Heldens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S., Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C., Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V., Stinson, J., Vagts, A., Vandlen, R., Watanabe, C., Wieand, D., Woods, K., Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z., Goddard, A., Wood, W.I. and Godowski, P.		
TITLE	The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment		
JOURNAL	Genome Res. 13 (10), 2265-2270		
PUBMED	12975309		
REFERENCE	2	(bases 1 to 1129)	
AUTHORS	Clark, H.F.		

/tissue_type="Liver, mouse"			
/clone_lib="NIH MGC 177"			
/lab_host="DH10B"			
/note="Vector: pDNR-LIB"			
1..1869			
/gene="F7"			
/note="synonyms: FVII, mfvII"			
/db_xref="LocusId:14068"			
/db_xref="MGI:109325"			
10..1350			
/codon_start=1			
/product="coagulation factor VII"			
/protein_id="AAH61149.1"			
/db_xref="GI:38511702"			
/db_xref="LocusId:14068"			
/translation="MVPQAGLLLLLCFLQLQGLPGLTAVITQEEAHGVHLHQRANS LLEELWPNCEERNECEFEAREIFKSPRTQFWIVSDGDCASNPQCGGTG CDHLKSYVCFLLPEGRNCKNEOLICANENGDCQYCRDHVGTKRTCSKEDYT LPDVSVCCKPVEYPCGRIPVVERKNSSSRGRIVGVNCPKGECPQWQAVLKINGLL CGAVLLDARWITAAHCFDNTYRWNTIVMGEHDFSEKDGDSQVRYTOVIMPKYI RKNHNDIALRLHRPVTFTDIYVPLCLPEKFSFENTHARIRFSVSGWQLDRGAT ALELMSIVRLMTQDCLIEHAHKSNTPKTINMPCAGYMDTKDACCKGDSGGEHATH YHGTWLTGVSVSWGEGCAIGHIVYTRVSQYIDWLVRHMDSKLQGVFRLPL"			
79..264			
/note="GLA; Region: Domain containing Gla (gamma-carboxyglutamate) residues"			
/db_xref="CDD:smart00069"			
268..378			
/note="EGF CA; Region: Calcium-binding EGF-like domain, present in a large number of membrane-bound and extracellular (mostly animal) proteins. Many of these proteins require calcium for their biological function and calcium-binding sites have been found to be located at the N-terminus of particular EGF-like domains"			
/db_xref="CDD:cd00054"			
589..1302			
/note="Tryp SPc; Region: Trypsin-like serine protease"			
/db_xref="CDD:cd00190"			
Query Match	1.0%; Score 21.6; DB 1; Length 1869;		
Best Local Similarity	68.2%; Pred. No. 39;		
Matches	30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;		
QY	1681	TTTTTTTGGTTTCTTGAAATATTTCCCTGCTTTGA	1724
Db	1860	TTTTTTTTTTTTTTTGACCATCTTCTCATTTAATGA	1817
RESULT 64			
AX839181			
LOCUS	AX839181	328 bp	DNA linear PAT 15-DEC-2003
DEFINITION	Sequence 24 from Patent WO03076610.		
ACCESSION	AX839181		
VERSION	AX839181.1	GI:39922630	
KEYWORDS	Homo sapiens (human)		
SOURCE	Homo sapiens		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
REFERENCE	1	Bracco, L., Brinkman, B. and Coignard, F.	
AUTHORS	Bracco, L., Brinkman, B. and Coignard, F.		
TITLE	Variant of human kallikrein-2 and kallikrein-3 and uses thereof		
JOURNAL	Patent: WO 03076610-A 24 18-SEP-2003;		
EXONHIT	Exonhit Therapeutics S.A. (FR)		
FEATURES	Location/Qualifiers		
source	1..328		
	/organism="Homo sapiens"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:9606"		
Query Match	0.9%; Score 21.4; DB 1; Length 328;		
Best Local Similarity	52.9%; Pred. No. 40;		
Matches	46; Conservative 0; Mismatches 41; Indels 0; Gaps 0;		

ACCESSION	AX265101
VERSION	AX265101.1 GI:16513900
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	Kniec,E.B., Gamber,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2492 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US) Location/Qualifiers 1..121 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match	0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity	53.7%; Pred.No.42;
Matches	44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY	2156 CTATTGTAATAGGGTTTTTACAGGGACAATAATGCCTCGTTGTATTGTCGTGTTTTTG 2215
Db	83 CCATTTAAACATGGATTGGACTCACACTGATCCTCATCTTTGAGTAGGTTAAGAATTG 24
QY	2216 CTTTGGCATATACCGCTGAG 2237
Db	23 AATTGGCAGTAACTGCTTAG 2
RESULT 69	
AX265102	
LOCUS	AX265102 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	Sequence 2493 from Patent W00173002.
ACCESSION	AX265102
VERSION	AX265102.1 GI:16513901
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	Kniec,E.B., Gamber,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2493 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US) Location/Qualifiers 1..121 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match	0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity	53.7%; Pred.No.42;
Matches	44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY	2156 CTATTGTAATAGGGTTTTTACAGGGACAATAATGCCTCGTTGTATTGTCGTGTTTTTG 2215
Db	39 CCATTTAAACATGGATTGGACTCACACTGATCCTCATCTTTGAGTAGGTTAAGAATTG 98
QY	2216 CTTTGGCATATACCGCTGAG 2237
Db	99 AATTGGCAGTAACTGCTTAG 120
RESULT 70	
AX265097/c	
LOCUS	AX265097 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	Sequence 2488 from Patent W00173002.
ACCESSION	AX265097

```

VERSION      AX265097.1  GI:16513896
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE        Targeted chromosomal genomic alterations with modified single
              stranded oligonucleotides
JOURNAL      Patent: WO 0173002-A 2488 04-OCT-2001;
              UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 42;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTAGCAGGACATATTGCTCGTGTGTTATTGCTGTTTGG 2215
Db 84 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 25

QY 2216 CTTTGGCATATAGCGGCTGAG 2237
Db 24 AATTGGCAGCTAACTGCTTAG 3

RESULT 71
LOCUS      AX265098                      121 bp      DNA      linear      PAT 26-OCT-2001
DEFINITION Sequence 2489 from Patent WO0173002.
ACCESSION  AX265098
VERSION     AX265098.1  GI:16513897
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS      Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE        Targeted chromosomal genomic alterations with modified single
              stranded oligonucleotides
JOURNAL      Patent: WO 0173002-A 2489 04-OCT-2001;
              UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 42;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTAGCAGGACATATTGCTCGTGTGTTATTGCTGTTTGG 2215
Db 38 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 97

QY 2216 CTTTGGCATATAGCGGCTGAG 2237
Db 98 AATTGGCAGCTAACTGCTTAG 119

RESULT 72
LOCUS      BC046125/c                      1541 bp      mRNA      linear      PRI 07-OCT-2003
DEFINITION Homo sapiens coagulation factor X, mRNA (cDNA clone MGC:57588
              IMAGE:5723510), complete cds.
ACCESSION    BC046125

```

```

VERSION      BC046125.1  GI:28374355
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1 (bases 1 to 1541)
AUTHORS      Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,
              Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
              Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
              Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
              Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
              Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
              Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
              Carninci,P., Prange,C., Raha,S., Loquellano,N.A., Peters,G.J.,
              Abramson,R.D., Mullany,S.J., Bosak,S.A., McEwan,P.J.,
              McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
              Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
              Villalon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
              Fahey,J., Helton,E., Kettman,M., Madan,A., Rodriguez,S.,
              Sanchez,A., Whitting,M., Madan,A., Young,A.C., Shvchenko,Y.,
              Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
              Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
              Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalhus,D.E.,
              Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
              Generation and initial analysis of more than 15,000 full-length
              human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
12477932
2 (bases 1 to 1541)
Direct Submission
AUTHORS      Strausberg,R.
TITLE        Submitted (31-JAN-2003) National Institutes of Health, Mammalian
              Gene Collection (MGC), Cancer Genomics Office, National Cancer
              Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
              USA
REMARK       NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT      Contact: MGC help desk
              Email: cgabbs-r@mail.nih.gov
              Tissue Procurement: Invitrogen
              cDNA Library Preparation: Life Technologies, Inc.
              cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
              DNA Sequencing by: Sequencing Group at the Stanford Human Genome
              Center, Stanford University School of Medicine, Stanford, CA 94305
              Web site: http://www-shgc.stanford.edu
              Contact: (Dickson, Mark) mcdexpaxil.stanford.edu
              Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
              R. M.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAC Plate: 107 Row: h Column: 24
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 9961350.
Location/Qualifiers
1..1541
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:57588 IMAGE:5723510"
/tissue_type="Ovary, pooled from 3 adults"
/clone_lib="NIH MGC_125"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"
1..1541
/clone="F10"
/note="synonyms: FX, FXA"
/db_xref="LocusID:2159"
/db_xref="MIM:227600"
39..1505
/codon_start=1
/product="coagulation factor X precursor"

```

```

FEATURES
source
gene
CDS

```


[illegible]

[illegible]

```

RESULT 81
AX524243
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
AX524243
Sequence 273 from Patent EP1236798.
AX524243
AX524243.1 GI:25169339
Mus musculus (house mouse)
Mus musculus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1
Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and
Schlueter, T.
Gene library and method for its production
Patent: EP 1236798-A 273 04-SEP-2002;
LION Bioscience AG (DE)
Location/Qualifiers
1..341
/organism="Mus musculus"
/mol_type="unassigned DNA"
/Ab_xref="traxon.10090"

```

	Query Match	0.9%	Score 20.6	DB 1	Length 341
	Best Local Similarity	53.0%	Pred. No. 64		
	Matches 44	Conservative 0	Mismatches 39	Indels 0	Gaps 0
Qy	2121	TGCTTTGGCTTCAGCTATGTTGCATTTCTCAGGCCCTATTCCTAATAGAGTTTTAGCAGG	2180		
Db	213	TGCTTTGGCTTCACCCATCTCTCCTGCACACAGCATGACATCTGTGACTTCTGTAGGT	272		
Qy	2181	ACATATTGCTCCTGGTTGTTATTG	2203		
Db	273	AGACTTTGGCACAGTTCTCATG	295		

RESULT 82
 AX552981
 LOCUS 341 bp DNA linear PAT 27-NOV-2002
 DEFINITION Sequence 273 from Patent WO02074953.
 ACCESSION AX552981
 VERSION AX552981.1 GI:25896981
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1
 Hoefer, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and
 Schluer, T.
 Gene library and a method for producing the same
 TITLE Patent: WO 02074953-A 273 26-SEP-2002;
 JOURNAL LION Bioscience AG (DE)
 FEATURES Location/Qualifiers
 1..341
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"
 Query Match 0.9%; Score 20.6; DB 1; Length 341;
 Best Local Similarity 53.0%; Pred. No. 64;

	Matches	44;	Conservative	0;	Mismatches	39;	Indels	0;	Gaps	0;
Qy	2121	TGCTTGTGCTT	CAGCTATGCTTC	ATCTCAGGGCC	TATGTAATAGGCTTT	TAGCAGGG	2180			
Db	213	TGCTTTGGCTC	TACCCATCTC	CTCCGCA	CACAGCATG	ACATCTGTGAC	TTTCTGTAGGT	272		
Qy	2181	ACATATTGCTC	TGGTTGTTATTG	2203						
Db	273	AGACTTTGGC	ACAGTTCTCATTG	295						

RESULT	83
E63001/c	
LOCUS	linear PAT 31-JAN-2002
DEFINITION	Hemocoagulation factor VII modification.
ACCESSION	E63001
VERSION	E63001.1 GI:18633643
KEYWORDS	JP 2001061479-A/5.
SOURCE	synthetic construct
ORGANISM	artificial sequences
REFERENCE	1 (bases 1 to 1206)
AUTHORS	Fukushima,K., Mizuguchi,J., Yuguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE	Hemocoagulation factor VII modification
JOURNAL	Patent: JP 2001061479-A 5 13-MAR-2001:
COMMENT	JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE OS Artificial Sequence PN JP 2001061479-A/5 PD 13-MAR-2001. PF 24-AUG-1999 JP 1999237610 PR PI KENJI FUKUSHIMA,JUN MIZUGUCHI,MASATO YUGUCHI,TOMOHIRO

NAME	SADAAKI IWANAGA
PI	C12N15/09.A61K38/43.A61P7/04.C07K14/755.C12N9/76.C12N15/00.PC
PC	A61K37/465
CC	
EH	Key
FT	source
FT	Location/Qualifiers
	1..1206
	/organism='Artificial Sequence'.
FEATURES	
source	Location/Qualifiers
	1..1206
	/organism="synthetic construct"
	/mol_type="genomic DNA"
	/Ab_xref="nt:avon:32630"

Query Match	0.9%	Score 20.6;	DB 1;	Length 1206;
Best Local Similarity	59.3%;	Pred. No. 68;		
Matches 35;	Conservative 0;	Mismatches 24;	Indels 0;	Gaps 0;
<p>QY 440 TTCAATTGTCCTTTTATCTGTCGACACTGCTTTCTTTTGAATAATGATTCAATTTGG 498</p> <p>444 TTTCCTGCGCAATTCCTTTTCTAGCAATAGGTATTTTCCACATGGATATCAACTGTGG 386</p> <p>DB</p>				

RESULT	84
E63002/c	
LOCUS	
DEFINITION	E63002 Hemocoagulation factor VII modification.
ACCESSION	E63002
VERSION	E63002.1 GI:18633644
KEYWORDS	JP 2001061479-A/6
SOURCE	synthetic construct
ORGANISM	artificial sequences.
REFERENCE	1 (bases 1 to 1206)
AUTHORS	Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE	Hemocoagulation factor VII modification
JOURNAL	Patient: JP 2001061479-A 6 13-MAR-2001;
	JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT	OS Artificial Sequence
	PN JP 2001061479-A/6
	PD 13-MAR-2001

/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 68;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTGTTTGTTCGAATATGTAATTCATTTGG 498
|||
Db 444 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACCTGTGG 386

RESULT 88

E63000/c
LOCUS 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.

ACCESSION E63000

VERSION E63000.1 GI:18633642

KEYWORDS JP 2001061479-A/4.

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1 (bases 1 to 1221)

AUTHORS Fukushima.K., Mizuguchi.J., Yuguchi.M., Nakagaki.T. and Iwanaga.S.

TITLE Hemocoagulation factor VII modification

JOURNAL Patent: JP 2001061479-A 4 13-MAR-2001;

COMMENT JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE

OS Artificial Sequence

PN JP 2001061479-A/4

PD 13-MAR-2001

PF 24-AUG-1999 JP 1999237610

PR

PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO

NAKAGAKI,

PI SADAOKI IWANAGA

PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N15/00, PC

A61K37/465

CC

FH Key Location/Qualifiers

FT source 1..1221

FT Location/Qualifiers

/organism='Artificial Sequence'.

1..1221

/organism='synthetic construct'

/mol_type='genomic DNA'

/db_xref="taxon:32630"

Query Match 0.9%; Score 20.6; DB 1; Length 1221;

Best Local Similarity 59.3%; Pred. No. 68;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTGTTTGTTCGAATATGTAATTCATTTGG 498

|||

Db 444 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACCTGTGG 386

RESULT 89

AR112953/c
LOCUS 1440 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 13 from patent US 6132729.

ACCESSION AR112953

VERSION AR112953.1 GI:14093275

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1440)

AUTHORS Thorpe,P.E., King,S.W. and Gao,B.

TITLE Combined tissue factor and chemotherapeutic methods and

compositions for coagulation and tumor treatment

Patent: US 6132729-A 13 17-OCT-2000;

JOURNAL

FEATURES Location/Qualifiers

source 1..1440

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTGTTTGTTCGAATATGTAATTCATTTGG 498
|||
Db 659 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACCTGTGG 601

RESULT 90

AR112969/c
LOCUS 1440 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 13 from patent US 6132730.

ACCESSION AR112969

VERSION AR112969.1 GI:14093291

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 1440)

AUTHORS Thorpe,P.E., King,S.W. and Gao,B.

TITLE Combined tissue factor and factor VIIa methods and compositions for

coagulation and tumor treatment

Patent: US 6132730-A 13 17-OCT-2000;

JOURNAL

FEATURES Location/Qualifiers

source 1..1440

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;

Best Local Similarity 59.3%; Pred. No. 69;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTGTTTGTTCGAATATGTAATTCATTTGG 498

|||

Db 659 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACCTGTGG 601

RESULT 91

I19358/c
LOCUS 1440 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 3 from patent US 5504064.

ACCESSION I19358

VERSION I19358.1 GI:1599713

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 1440)

AUTHORS Morrissey,J.H. and Comp,P.C.

TITLE Treatment of bleeding with modified tissue factor in combination

with an activator of FVII

Patent: US 5504064-A 3 02-APR-1996;

JOURNAL

FEATURES Location/Qualifiers

source 1..1440

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;

Best Local Similarity 59.3%; Pred. No. 69;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTGTTTGTTCGAATATGTAATTCATTTGG 498

|||

Db 659 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACCTGTGG 601

RESULT 92

I19360/c
LOCUS 1440 bp DNA linear PAT 07-OCT-1996

```
DEFINITION Sequence 3 from patent US 5504067.
ACCESSION I19360
VERSION I19360.1 GI:1599715
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Morrissey, J.H. and Comp, P.C.
TITLE Treatment of bleeding with modified tissue factor in combination with FVII
JOURNAL Patent: US 5504067-A 3 02-APR-1996;
FEATURES Location/Qualifiers
source 1..1440
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCAATTGG 498
Db 659 TTGCTGGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGGTGG 601

RESULT 93
BD194674/c
LOCUS BD194674 1440 bp DNA linear PAT 17-JUL-2003
DEFINITION Tissue factor methods and compositions for coagulation and tumor treatment.
ACCESSION BD194674
VERSION BD194674.1 GI:33004420
KEYWORDS JP 2002514201-A/3.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe, P.E., King, S.W. and Gao, B.
TITLE Tissue factor methods and compositions for coagulation and tumor treatment
JOURNAL Patent: JP 2002514201-A 3 14-MAY-2002;
COMMENT BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
OS Mammalian
PN JP 2002514201-A/3
PD 14-MAY-2002
PF 20-JAN-1998 JP 1998534630
PR 22-JAN-1997 US 60/035920, 27-JAN-1997 US 60/036205 PR
PI PHILIP E THORPE, STEVEN W KING, BONING GAO
PC A61K47/48
CC Tissue factor methods and compositions for coagulation and CC
tumor treatment
FH Key Location/Qualifiers
FT source 1..1440
/organism="Mammalian".
FEATURES Location/Qualifiers
source 1..1440
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCAATTGG 498
Db 659 TTGCTGGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGGTGG 601

RESULT 94
AX565990/c
LOCUS AX565990 6098 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 2 from Patent WO02077218.
ACCESSION AX565990
VERSION AX565990.1 GI:26001242
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Persson, E.
TITLE Coagulation factor vii derivatives
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;
NOVO NORDISK A/S (DK)
FEATURES Location/Qualifiers
source 1..6098
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Plasmid DNA pLN174"

Query Match 0.9%; Score 20.6; DB 1; Length 6098;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCAATTGG 498
Db 728 TTGCTGGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGGTGG 670

RESULT 95
AX839180/c
LOCUS AX839180 394 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 23 from Patent WO03076610.
ACCESSION AX839180
VERSION AX839180.1 GI:39922629
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Bracco, L., Brinkman, B. and Coignard, F.
TITLE Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL Patent: WO 03076610-A 23 18-SEP-2003;
Exonhit Therapeutics S.A. (FR)
FEATURES Location/Qualifiers
source 1..394
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 20.4; DB 1; Length 394;
Best Local Similarity 52.3%; Pred. No. 73;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

Qy 38 CAATGGTTGTGATGTTGGTAGAGTATCTCATACAGAGATAGACTAGATGCTCTCTGGG 97
Db 272 CACTGGCTAGAGAGGGGACTAGAGAAGGACAGAGAGGGGGGATATGGAGATTCTCTGAT 213
Qy 98 ACATAGGTAAGCTTTTCCAGAGAGACT 123
Db 212 GCAGTGGGAGCTGTGAGGCCCACT 187

RESULT 96
AF465269/c
LOCUS AF465269 1416 bp mRNA linear VRT 02-FEB-2003
DEFINITION Gallus gallus coagulation factor IX precursor (F9) mRNA, complete cds.
ACCESSION AF465269
VERSION AF465269.1 GI:28194009
KEYWORDS
SOURCE Gallus gallus (chicken)
```

ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
REFERENCE 1 (bases 1 to 1416)
AUTHORS Davidson, C.J., Hart, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
TITLE Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1416)
AUTHORS McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
TITLE Direct Submission
JOURNAL Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK

FEATURES
source
1..1416
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
gene
1..1416
/gene="F9"
CDS
1..1416
/gene="F9"
/EC number="3.4.21.22"
/function="converts factor X to its active form in the
presence of Ca++ ions, phospholipids, and factor VIIa"
/note="vitamin K dependent serine protease; Christmas
factor; contains 2 EGF-like domains; member of peptidase
family S1/trypsin family"
/codon_start=1
/product="coagulation factor IX precursor"
/protein_id="AA033364.1"
/db_xref="GI:28194010"
/translation="MAKPLILSFLCLLEAFLEAEVTFIENKEASTVLSRTRGNSNR
LEELPGNERICEKCSFEAREVFENTKTFWKIYIDGQCNPNCKNGAVCK
DGVSSVCEPCPGYGRNCEIDSTCATKNGGCEHFCRHDTPKAVCSAGSKLHEDG
KSCPAVYPCGRIITAPMRGKVTRTENTIBRWNTAHDEGDAHDEALDITPPPPPT
TSAAPAKVPLTKNTRVGGYDSVKGLPQVHLVDSRGLFCGSGSLINEKVVVTA
HCLFQDNVTAVAGYNTKEDDHTQRQVVKLIPYPTNTRKHNDLLELDQ
LTFNSYVPTICGSRDFTNLLNSGFGVSGMSLVRGRSAIVLQVLPVPEVDRTIC
YKSTTTILHSMFCAGYTAGGDKTCGSDGSGPYTNSIGETFLTGTWGECAKPGK
YGIYTKVAKYKWIREFTRLT"

Query Match 0.9%; Score 20.4; DB 1; Length 1416;
Best Local Similarity 53.8%; Pred. No. 77;
Matches 42; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 24 GGGGTCGAGGCTCCAAATGGTTGATGTGTAGATATCTCATACAGAGGATAGCACT 83
DB 408 GTGCTCGAGGCCCCCATTTTCTGTAGCACAGTAGATCTATCTCACAGTTCTCGCTCC 349

QY 84 AGATGCTGTCTGGGACAT 101
DB 348 ATAACAGGTGGGACAT 331

RESULT 97
AF272774/c
LOCUS Homo sapiens factor VII active site mutant immunocjugate mRNA, PRI 07-FEB-2003
DEFINITION complete cds.
ACCESSION AF272774.2 GI:28269793
VERSION 1 (bases 1 to 2072)
KEYWORDS Targeting tissue factor on tumor vascular endothelial cells and
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2072)
AUTHORS Hu, Z. and Garen, A.
TITLE Targeting tumor vasculature endothelial cells and tumor cells for

ORGANISM tumor cells for immunotherapy in mouse models of prostatic cancer
Proc. Natl. Acad. Sci. U.S.A. 98 (21), 12180-12185 (2001)
MEDLINE 21477448
PUBMED 11593034
REFERENCE 2 (bases 1 to 2072)
AUTHORS Hu, Z. and Garen, A.
TITLE Direct Submission
JOURNAL Submitted (26-MAY-2000) Department of Molecular Biophysics and
Biochemistry, Yale University, 266 Whitney Ave., New Haven, CT
06520, USA
REFERENCE 3 (bases 1 to 2072)
AUTHORS Hu, Z. and Garen, A.
TITLE Direct Submission
JOURNAL Submitted (07-FEB-2003) Department of Molecular Biophysics and
Biochemistry, Yale University, 266 Whitney Ave., New Haven, CT
06520, USA
REMARK Sequence update by submitter
COMMENT On Feb 7, 2003 this sequence version replaced gi:14279677.
FEATURES
source
1..2072
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
22..2061
/note="hVIIaism"
/codon_start=1
/product="factor VII active site mutant immunocjugate"
/protein_id="AAK58686.2"
/db_xref="GI:28269794"
/translation="MVSQALRLCLLLGQCLAAVFTQBEAHGVLHRRRANAFLE
ELRPSLEREKEQCSFEAREVIFKDAERTKLFWISYSDGQCSQPCQNGSKDQ
LQSYICFLCPAPPELLGSPSVFLPPPKDLMISRTPEVTGVVDSHEDPEVKFN
WYDQVHNNAKTVPREQYNSYRWSVLTVHQDLNGKEYKCKVSNKALPAPEK
TISKAGOPRPOVYTLPSRDELTKNOVSLTCLVKGFVPSPIAVEWESNGOPENNYK
TTPVLDSDGSEFLYSKLTVDKSRWQQNVFSCVMHEALHNHYTKSLSLSPGK"

Query Match 0.9%; Score 20.4; DB 1; Length 2072;
Best Local Similarity 61.1%; Pred. No. 77;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 445 TTGCTTTTATCTCGAGACTTGTCTTTGTTTGAATATGATTCATTTGG 498
DB 574 TGGCATTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACACTGG 521

RESULT 98
AF272773/c
LOCUS Synthetic construct mutated mouse factor VII molecule
DEFINITION immunocjugate mRNA, complete cds.
ACCESSION AF272773
VERSION 1 (bases 1 to 2078)
KEYWORDS Targeting tumor vasculature endothelial cells and tumor cells for
SOURCE Synthetic construct
ORGANISM Synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 2078)
AUTHORS Hu, Z., Sun, Y. and Garen, A.
TITLE Targeting tumor vasculature endothelial cells and tumor cells for
immunotherapy of human melanoma in a mouse xenograft model
Proc. Natl. Acad. Sci. U.S.A. 96 (14), 8161-8166 (1999)
MEDLINE 99324206
PUBMED 10393965
REFERENCE 2 (bases 1 to 2078)
AUTHORS Hu, Z. and Garen, A.
TITLE Intratumoral injection of adenoviral vectors encoding
tumor-targeted immunocjugates for cancer immunotherapy

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (16), 9221-9225 (2000)
 MEDLINE 20381364
 PUBMED 10922073
 REFERENCE 3 (bases 1 to 2078)
 AUTHORS Hu, Z. and Garen, A.
 TITLE Direct Submission
 JOURNAL Submitted (26-MAY-2000) Molecular Biophysics and Biochemistry, Yale University, 266 Whitney Ave, New Haven, CT 06520, USA

FEATURES
 source Location/Qualifiers
 1..2078
 /organism="synthetic construct"
 /mol_type="mRNA"
 /db_xref="taxon:32630"
 22..2067
 /note="mfVIIasm; contains active site mutation"
 /codon_start=1
 /transl_table=11
 /product="mutated mouse factor VII molecule immunconjugate"
 /protein_id="AAG00449.1"
 /db_xref="GI:9837150"
 /translation="MVPQAHGILLCLLQLOGLTAVFITOEAAHGVHLHRRANS
 LLEELPFGSLERECNEQCSFEAREIFKSPERTKQFWIVSDGQCSNPQCNVGT
 QDLKSVYCFCLDFEGRNCEKNEOLICANENGDCDOYCRDHVGTKRTCSHEDYT
 LQPLVSKCPKVPYCGRI PVWEKRNSSRQGRIVGNCVCPKGCPCWQAVLKGILL
 CGAVLDARWVTAACHFDNLRYWGNITVWGBHDFSEKDGQDQVRVTVQVIMPKYI
 RGINHDIALRLHRPVTFDYVPLCLPEKFSSENTILARFSRVSGWGLLDRGAT
 ALEMSLEVPRLMTQDCLHAKSSNTPKITENMFCAGYMDGDKACAGDSGGPHATH
 YHGTWLTGVSVGEGCAAGIHIGVYTRVQYIDWLVRHMDSKLQVFRPLPLIGSAE
 PKSCDKTHTCPCPCAPKTELLGGPSVFLPPPKPDKTLMISRTPEVTVVVDVSHEDPEVK
 FNVVDGVEVHNATKPREQYNSYTRVSVLTVLHODWLNKGYCKKSVKNKALPAPI
 EKTISKAGQEPPOVYVTLPPSDELTKNQVSLTCLVKGYPSPIAVEWESNGQPPEN
 YKTPPVLDSGDFFLYKSLTVDKSRQQQNVFSCVMHEALHNHYTKSLSLSPGR"

Query Match 0.9%; Score 20.4; DB 1; Length 2078;
 Best Local Similarity 58.1%; Pred. No. 77;
 Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 31 GAGGCTCAATGGTTGTTGATGGTAGATATCTCATAGAGGATAGCACTAGATGCT 90
 DB 2046 GAGGCTCTTCTGCGTAGTGTGTTGTCAGAGCCTCATCAGGAGCATGAGAGAC 1987
 QY 91 GT 92
 DB 1986 GT 1985

RESULT 99
 AY155152/c
 LOCUS Drosophila straubae 183 bp DNA linear INV 16-MAR-2003
 DEFINITION Drosophila straubae isolate 5 mastermind (mast) gene, partial cds.
 ACCESSION AY155152
 VERSION AY155152.1 GI:28975316
 KEYWORDS
 SOURCE Drosophila straubae
 ORGANISM Drosophila straubae
 Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
 Ephydroidea; Drosophilidae; Drosophila; mayaguana subcluster.
 1 (bases 1 to 183)
 O'Grady, P.M. II, Durando, C.M., Heed, W.B., Wasserman, M., Etges, W.
 and DeSalle, R.
 TITLE Genetic divergence within the *Drosophila* mayaguana subcluster, a
 closely related triad of Caribbean species in the repleta species
 group
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 183)
 AUTHORS O'Grady, P.M. II, Durando, C.M., Heed, W.B., Wasserman, M., Etges, W.
 and DeSalle, R.
 TITLE Direct Submission
 JOURNAL Submitted (25-SEP-2002) Invertebrate Zoology, American Museum of
 Natural History, Central Park West at 79th Street, New York, NY
 10024, USA

FEATURES
 source Location/Qualifiers
 1..183
 /organism="Drosophila straubae"
 /mol_type="genomic DNA"
 /isolate="5"
 /db_xref="taxon:214823"
 /clone="12"
 /country="Navassa Island"
 <1..>183
 /gene="mast"
 <1..>183
 /gene="mast"
 /product="mastermind"
 <1..>183
 /gene="mast"
 /codon_start=3
 /product="mastermind"
 /protein_id="AAO61936.1"
 /db_xref="GI:28975317"
 /translation="DLKRLQQQAMQQQQQHHAAQQQQQHPNPGMVGPMGGAGNFA
 KQQQQQVVTVXXQQQQ"

Query Match 0.9%; Score 20.2; DB 1; Length 183;
 Best Local Similarity 53.1%; Pred. No. 78;
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 344 TGGTTCCATAAGTTTCTAAGTTTCTGTTGTTCTCTGTTGTTGTTGTTGTTGTTGTTGTT 403
 DB 111 TGGGTACACCAATTTTGGGACCATTTGGGATGTTGTTGTTGTTGTTGTTGTTGTTGTT 52
 QY 404 TAAGCTGTGTTGTCAGATAG 424
 DB 51 GTTGCTGTTGTTGTCATTG 31

RESULT 100
 AB083386/c
 LOCUS Homo sapiens PROS1 gene for Protein S, partial cds,
 DEFINITION isolate:patient: PS 1.
 ACCESSION AB083386
 VERSION AB083386.1 GI:27531049
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1
 Hamasaki, N., Dong Chon, K., Kinoshita, S., Iida, H., Inoue, S.,
 Watanabe, K., Kurihara, M., Wada, Y. and Ono, M.
 TITLE Gene analysis of anticoagulation factors in Japanese thrombotic
 patients. Genetic background of thrombophilia in Japan
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 214)
 AUTHORS Hamasaki, N.
 TITLE Direct Submission
 JOURNAL Submitted (10-APR-2002) Naotaka Hamasaki, Kyushu University
 Hospital, Department of clinical chemistry and laboratory medicine;
 3-1-1 maldashi, Higashi-ku Fukuokasi, Fukuoka 812-8582, Japan
 (E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,
 Fax:81-92-642-5772)

FEATURES
 source Location/Qualifiers
 1..214
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /isolate="patient: PS 1"
 /db_xref="taxon:9606"
 24
 /replace="g"
 25..182
 /gene="PROS1"
 <25..>182
 /gene="PROS1"

variation
 gene
 CDS


```
COMMENT Original source text: Human liver DNA.
FEATURES
  source      Location/Qualifiers
    1..352
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
      /map="3p11-q11.2"
      /tissue_type="liver"
      join(M57840.1:837..912,135..181)
      /gene="PS-alpha"
      order(M57840.1:913..1014,1..134)
      /gene="PROS1"
      /number=1
      135..292
      /gene="PROS1"
      /note="G00-120-721"
      /number=2

  Query Match      0.9%; Score 20.2; DB 1; Length 352;
  Best Local Similarity 51.7%; Pred. No. 81;
  Matches 46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 290 CTTCTATTCTTGATTCTATCTTGCTCATTTTAACTCAGTAGTGAGTGTGTTT 349
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 260 CTTCTCTTTATTGACAGTCTCTGATGCAATCTCTTTCAAGATTACCTGTGTTT 201
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 350 CCATAGTTTGAAGTTTCTGTGTTTC 378
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 200 CTTCAAGTAAAGATTTCGACGAGCTTC 172
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 107
AR108139/c
LOCUS AR108139 885 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 1 from patent US 6110721.
ACCESSION AR108139
VERSION AR108139.1 GI:12823626
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 885)
AUTHORS Gibbs,C.S., Leung,L.L.K. and Tsiang,M.
TITLE Polypeptides and coagulation therapy
JOURNAL Patent: US 6110721-A 1 29-AUG-2000;
FEATURES
  source      Location/Qualifiers
    1..885
      /organism="unknown"
      /mol_type="unassigned DNA"

  Query Match      0.9%; Score 20.2; DB 1; Length 885;
  Best Local Similarity 63.3%; Pred. No. 85;
  Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 167 GGCTGCTGCTTCTCCTGCTGTGATTCTAGGTCAGGTCACCACTG 215
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 489 GAGTGGCGTCTCCTGCTGGGAGACACAGGTCAGTACTG 441
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 108
AX401899/c
LOCUS AX401899 1543 bp DNA linear PAT 06-JUN-2002
DEFINITION Sequence 1575 from Patent WO0210453.
ACCESSION AX401899
VERSION AX401899.1 GI:21338079
KEYWORDS Rattus norvegicus (Norway rat)
SOURCE Rattus norvegicus
ORGANISM Rattus norvegicus
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
          Rattus.
REFERENCE 1
AUTHORS Mendrick,D., Porter,M.W., Johnson,K.R., Castle,A.L. and
```

```
Elashoff,M.R.
Molecular toxicology modeling
Patent: WO 0210453-A 1575 07-FEB-2002;
Gene Logic, Inc. (US)
FEATURES
  source      Location/Qualifiers
    1..1543
      /organism="Rattus norvegicus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:10116"
      /note="EMBL/GenBank Accession No. NM_012803"

  Query Match      0.9%; Score 20.2; DB 1; Length 1543;
  Best Local Similarity 68.3%; Pred. No. 86;
  Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCCTTTTACTCTAAGTGATGTCTATCCATCGTAGGTG 960
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1408 CATCCCTTCCCTATGTAGCTGTGATCCATTTAGGTAG 1368
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 109
RNPROC/c
LOCUS Rattus norvegicus mRNA for protein C precursor.
DEFINITION X64336 S40352
ACCESSION X64336.1 GI:56962
VERSION protein C.
KEYWORDS Rattus norvegicus (Norway rat)
SOURCE Rattus norvegicus
ORGANISM Rattus norvegicus
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
          Rattus.
REFERENCE 1 (bases 1 to 1543)
AUTHORS Okafuji,T., Maekawa,K., Nawa,K. and Marumoto,Y.
TITLE The cDNA cloning and mRNA expression of rat protein C
JOURNAL Biochim. Biophys. Acta 1131 (3), 329-332 (1992)
MEDLINE 92329550
PUBMED 1627650
REFERENCE 2 (bases 1 to 1543)
AUTHORS Okafuji,T.
TITLE Direct Submission
JOURNAL Submitted (03-FEB-1992) Okafuji T., Mol Biology Research Lab,
Daiichi Pharmaceutical Co LTD, 16-13 Kitakasai 1-Chome, Edogawa-Ku,
Tokyo 134, JAPAN
COMMENT On Nov 19, 2003 this sequence version replaced gi:251769.
FEATURES
  source      Location/Qualifiers
    1..1543
      /organism="Rattus norvegicus"
      /mol_type="mRNA"
      /strain="Wistar"
      /db_xref="taxon:10116"
      /clone="28000"
      49..1434
      /codon_start=1
      /product="protein C precursor"
      /protein_id="CAA45617.1"
      /db_xref="GI:56963"
      /db_xref="GOA:P31394"
      /db_xref="SWISS-PROT:P31394"
      /translation="MWQPRIFLLFASTWIGSVSAHPDPVFSSEGAHQVLRVRANS
      FLEVRAGSLRECEMBEICDFEAEQEIFQNVEDTLAFWKYFDGQCSTPPLDHQCD
      PCGHTCIDGLGFGSCSDGWEGRFCQEGKGFQDCRVKNGGCHYCLEETRRRCR
      CAGVELADDMHCRPTVNFPCGKLWRTDKRKNPKRDI DPDEDELELGPRTVNGTL
      TKQGPSMQAILLDSSKKLACGVLHTSWLTAHCLSESSKLTVRLGEYDLRRDP
      WELDLDIKEVLVHPNYSNSNDIALLSQPATLSKTIPTICLPNSGLAELSQAG
      QETVVTGYSQSKVDKGRNRPTFLTFRIFLAARNDQMWNVSVSEMLCAGLIG
      DTRDACDSDSGGPMVFFRGFTWFLVLSWGGEGCGHNNYITTKVGSTLKHSTIG
      ERDVSLSKSEKL"
      49..147
      169..1431
      /product="protein C"
      1514..1519
      polyA_signal

  sig_peptide
  mat_peptide
  polyA_signal
```

```
Query Match      0.9%; Score 20.2; DB 1; Length 1543;
Best Local Similarity 69.3%; Pred. No. 86;
Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCTTTTACTCTAAGGTGATGCTCTATCATGCTAGTGTG 960
||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1408 CATCCCTTTCCCTATGATGCTGTCATCATTTGAGGTAG 1368

RESULT 110
AF011899/c
LOCUS AF011899 855 bp mRNA linear VRT 09-SEP-1997
DEFINITION Petromyzon marinus trypsinogen a3 (TRYP3) mRNA, complete cds.
ACCESSION AF011899
VERSION AF011899.1 GI:2367496
SOURCE Petromyzon marinus (sea lamprey)
ORGANISM Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE Roach, J.C.
AUTHORS The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 855)
AUTHORS Roach, J.C.
TITLE Direct Submission
JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA
FEATURES
source
1..855
/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="ammocoete"
/tissue_lib="anterior intestine"
1..855
/gene="TRYP3"
1..744
/gene="TRYP3"
/codon_start=1
/product="trypsinogen a3"
/protein_id="AAB69655.1"
/db_xref="GI:2367497"
/translation="MHGLILALVGVAAAPYMYEDHIVGGSECAHSPQWVSLNIG
YHFCGSLINSQWVSAHCYQASRISVRIGEHNFVNEGTEQQIQASKAIQHPQYN
SWTIDNIMLIKSSPATLNQYAIALPSSCVNTGWCITISGNETQTSVGSPPDVLN
CVOAPVLSDTSCRNSYPGDITNNMICLGLEGKDCQGDGGPVPVNCBELQGVSWG
RGCALEPNYPGVYTKVCNNAWIAQTIAN"
sig_peptide 1..45
/gene="TRYP3"
/evidence=not_experimental
mat_peptide 46..741
/gene="TRYP3"
/product="trypsin a3"
/evidence=not_experimental

Query Match      0.9%; Score 20; DB 1; Length 855;
Best Local Similarity 65.9%; Pred. No. 95;
Matches 29; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 1540 TTTTAATATCTTCTTTGTTCTATCTTTTAGTGATTGATTA 1583
||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 855 TTTTATTTTATGATTAGTTCACATTTTATTCATTGTTGA 812

RESULT 111
AR234337
LOCUS AR234337 1130 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 8 from patent US 6458564.
ACCESSION AR234337
VERSION AR234337.1 GI:27277021
KEYWORDS
```

```
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1130)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE DNA encoding the human serine protease T
JOURNAL Patent: US 6458564-A 8 01-OCT-2002;
FEATURES Location/Qualifiers
source
1..1130
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.9%; Score 20; DB 1; Length 1130;
Best Local Similarity 58.3%; Pred. No. 96;
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 715 TGCTTGTTTTATGAACCTGGTGACATTTGTTTGGTGTCATAGACATTAAAGAAATGCAAT 774
||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1059 TGCTTATTTTGTGAATTTGTGATGCTATTGCTTTATTGTACCATATTAAGCTGCAAT 1118

RESULT 112
AR219285
LOCUS AR219285 1142 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 8 from patent US 6420157.
ACCESSION AR219285
VERSION AR219285.1 GI:23320255
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1142)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 8 16-JUL-2002;
FEATURES Location/Qualifiers
source
1..1142
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.9%; Score 20; DB 1; Length 1142;
Best Local Similarity 58.3%; Pred. No. 96;
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 715 TGCTTGTTTTATGAACCTGGTGACATTTGTTTGGTGTCATAGACATTAAAGAAATGCAAT 774
||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1071 TGCTTATTTTGTGAATTTGTGATGCTATTGCTTTATTGTACCATATTAAGCTGCAAT 1130

RESULT 113
AR221273
LOCUS AR221273 1166 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 2 from patent US 6426199.
ACCESSION AR221273
VERSION AR221273.1 GI:23328188
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1166)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE DNA
JOURNAL Patent: US 6426199-A 2 30-JUL-2002;
FEATURES Location/Qualifiers
source
1..1166
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.9%; Score 20; DB 1; Length 1166;
Best Local Similarity 58.3%; Pred. No. 96;
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 715 TGCTTGTTTTATGAACCTGGTGACATTTGTTTGGTGTCATAGACATTAAAGAAATGCAAT 774
```


Cancer Res. (1998) In press
 2 (bases 1 to 268)
 Bignell,G.R., Barfoot,R., Seal,S., Collins,N., Warren,W. and Stratton,M.R.
 TITLE
 Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer
 Cancer Res. 58 (7), 1384-1386 (1998)
 JOURNAL
 MEDLINE
 PUBMED
 98196525
 9537235
 REFERENCE
 3 (bases 1 to 268)
 Avizienyte,E., Roth,S., Loukola,A., Hemminki,A., Bignell,G.R., Warren,W., Stratton,M.R. and Aaltonen,L.A.
 DIRECT SUBMISSION
 TITLE
 Submitted (25-MAR-1998) Department of Medical Genetics, Haartman Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3), Helsinki FIN-00014, Finland
 JOURNAL
 HELSINKI
 FIN-00014, Finland
 FEATURES
 Location/Qualifiers
 source
 1. .268
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosome="19"
 /map="19p13.3"
 41. .228
 /gene="LKB1"
 /number=8
 exon
 Query Match 0.9%; Score 19.8; DB 1; Length 268;
 Best Local Similarity 60.0%; Pred. No. 1e+02;
 Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
 Qy 938 TGTGTCATCCATGCTAGGTGTCCTTTTGGATGACAGCAGTAGGATGATCTT 992
 Db 105 TGGTGCTGGCTCGGTGGATGGCAGCTGCTGCTCAGCGGAGGATGTTCTT 51
 RESULT 118
 BD095271/c
 LOCUS
 BD095271 384 bp DNA linear PAT 27-AUG-2002
 DEFINITION
 Structural coordinate and NMR chemical shift of protein and utilization thereof.
 ACCESSION
 BD095271
 VERSION
 BD095271.1 GI:22640859
 KEYWORDS
 WO 0142453-A/3.
 SOURCE
 Homo sapiens (human)
 ORGANISM
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 Koda,D., Hiroaki,H. and Sumimoto,H.
 TITLE
 Structural coordinate and NMR chemical shift of protein and utilization thereof
 Patent: WO 0142453-A 3 14-JUN-2001;
 JOURNAL
 BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE,DAISUKE KODA, HIDEKAZU HIROAKI, HIDEKI SUMIMOTO
 OS
 Homo sapiens (human)
 PN
 WO 0142453-A/3
 PD
 14-JUN-2001
 PF
 01-DEC-2000 WO 2000JP008501
 PR
 06-DEC-1999 JP 99P 346193
 PI
 DAISUKE KODA, HIDEKAZU HIROAKI, HIDEKI SUMIMOTO PC
 C12N15/09, C12N9/02, G06F17/30, G06F17/50, G01N33/68, G01N24/02 CC
 Structural coordinate and NMR chemical shift of protein and CC utilization thereof
 CC
 thereof
 FH
 Key
 FT
 source
 Location/Qualifiers
 1. .384
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 Cancer Res. (1998) In press
 2 (bases 1 to 268)
 Bignell,G.R., Barfoot,R., Seal,S., Collins,N., Warren,W. and Stratton,M.R.
 TITLE
 Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer
 Cancer Res. 58 (7), 1384-1386 (1998)
 JOURNAL
 MEDLINE
 PUBMED
 98196525
 9537235
 REFERENCE
 3 (bases 1 to 268)
 Avizienyte,E., Roth,S., Loukola,A., Hemminki,A., Bignell,G.R., Warren,W., Stratton,M.R. and Aaltonen,L.A.
 DIRECT SUBMISSION
 TITLE
 Submitted (25-MAR-1998) Department of Medical Genetics, Haartman Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3), Helsinki FIN-00014, Finland
 JOURNAL
 HELSINKI
 FIN-00014, Finland
 FEATURES
 Location/Qualifiers
 source
 1. .268
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosome="19"
 /map="19p13.3"
 41. .228
 /gene="LKB1"
 /number=8
 exon
 Query Match 0.9%; Score 19.8; DB 1; Length 268;
 Best Local Similarity 60.0%; Pred. No. 1e+02;
 Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
 Qy 938 TGTGTCATCCATGCTAGGTGTCCTTTTGGATGACAGCAGTAGGATGATCTT 992
 Db 105 TGGTGCTGGCTCGGTGGATGGCAGCTGCTGCTCAGCGGAGGATGTTCTT 51
 RESULT 118
 BD095271/c
 LOCUS
 BD095271 384 bp DNA linear PAT 27-AUG-2002
 DEFINITION
 Structural coordinate and NMR chemical shift of protein and utilization thereof.
 ACCESSION
 BD095271
 VERSION
 BD095271.1 GI:22640859
 KEYWORDS
 WO 0142453-A/3.
 SOURCE
 Homo sapiens (human)
 ORGANISM
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 Koda,D., Hiroaki,H. and Sumimoto,H.
 TITLE
 Structural coordinate and NMR chemical shift of protein and utilization thereof
 Patent: WO 0142453-A 3 14-JUN-2001;
 JOURNAL
 BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE,DAISUKE KODA, HIDEKAZU HIROAKI, HIDEKI SUMIMOTO
 OS
 Homo sapiens (human)
 PN
 WO 0142453-A/3
 PD
 14-JUN-2001
 PF
 01-DEC-2000 WO 2000JP008501
 PR
 06-DEC-1999 JP 99P 346193
 PI
 DAISUKE KODA, HIDEKAZU HIROAKI, HIDEKI SUMIMOTO PC
 C12N15/09, C12N9/02, G06F17/30, G06F17/50, G01N33/68, G01N24/02 CC
 Structural coordinate and NMR chemical shift of protein and CC utilization thereof
 CC
 thereof
 FH
 Key
 FT
 source
 Location/Qualifiers
 1. .384
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

Query Match 0.9%; Score 19.8; DB 1; Length 384;
 Best Local Similarity 77.4%; Pred. No. 1e+02;
 Matches 24; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 Qy 1674 TAGGAATTTTCTTTTGGTTTCTTTCTTGA 1704
 Db 178 TAGGAACATTTCTTTTAAAGGTTTATGAA 148
 RESULT 119
 AX814618/c
 LOCUS
 AX814618 394 bp DNA linear PAT 05-DEC-2003
 DEFINITION
 Sequence 56 from Patent WO03064641.
 ACCESSION
 AX814618
 VERSION
 AX814618.1 GI:39103831
 KEYWORDS
 SOURCE
 Homo sapiens (human)
 ORGANISM
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 Bouqueleret,L., Niknejad,A. and Saudrais,C.
 TITLE
 Gene encoding serine proteases
 JOURNAL
 Patent: WO 03064641-A 56 07-AUG-2003;
 FEATURES
 Location/Qualifiers
 source
 1. .394
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 misc_feature
 1. .394
 /note="exon 14"
 Query Match 0.9%; Score 19.8; DB 1; Length 394;
 Best Local Similarity 60.0%; Pred. No. 1e+02;
 Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
 Qy 1149 GTCTCCCT 1203
 Db 391 GTAGCTGGTCT 337
 RESULT 120
 DLA6882
 LOCUS
 DLA6882 535 bp mRNA linear VRT 12-OCT-1998
 DEFINITION
 Dicertrarchus labrax mRNA for trypsin, partial.
 ACCESSION
 AJ006882
 VERSION
 AJ006882.1 GI:3228220
 KEYWORDS
 trypsin.
 SOURCE
 Dicertrarchus labrax (European sea bass)
 ORGANISM
 Dicertrarchus labrax
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Percoidae; Moronidae; Dicertrarchus.
 Peres,A., Zambonino Infante,J.L. and Cahu,C.L.
 TITLE
 Dietary regulation of activities and mRNA levels of trypsin and amylase in sea bass (Dicertrarchus labrax) larvae
 JOURNAL
 Fish Physiol. Biochem. 19, 145-152 (1998)
 REFERENCE
 2 (bases 1 to 535)
 Zambonino Infante,J.L.
 DIRECT SUBMISSION
 TITLE
 Submitted (11-JUN-1998) Zambonino Infante J.L., Unite Mixte Inra-Iframer de Nutrition des Poissons, Ifremer, BP 70, 29280 Plouzane, FRANCE
 FEATURES
 Location/Qualifiers
 source
 1. .535
 /organism="Dicertrarchus labrax"
 /mol_type="mRNA"
 /db_xref="taxon:13489"
 /dev_stage="larvae"

AUTHORS Jagadeeswaran, P., Lavelle, D.E., Kaul, R., Mohandas, T. and Warren, S.T.
 TITLE Isolation and characterization of human factor IX cDNA: identification of Tag I polymorphism and regional assignment
 JOURNAL Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)
 MEDLINE 84300526
 PUBMED 6089357
 COMMENT Original source text: Human adult liver, cDNA to mRNA.
 FEATURES
 source
 1. .873
 /location="Qualifiers"
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /map="xq26.3-q27.1"
 1. .873
 /genes="F9"
 <1. .>873
 /genes="F9"
 /note="coagulation factor IX"
 /codon_start=1
 /protein_id="AA51991.1"
 /db_xref="GI:180288"
 /db_xref="GDB:G00-119-900"
 /translation="NANKILNRPKRYNSGKLEFVQGNLERECMEKCSPEAREVFE NTERTFEAKQYVDGQCSNPCLNGSKDDINSYECWCPFGEGKNCSELDVTCNIK NGRCEQFCNADKNVVCSTEGYRLAENQKSCPEAPVPPCGRVSVQTSKYLTRAETV FPDVYVNSTEATILDNITQSTQSDFTFRVVGDBAKPGPPQWVWLNKGVDAFCG GSIVNEKWIIVTAHCVETGVTITVAVGEHNIEETHEQKRNIRIIPHNNYNAALNK YNHDIALLLEDEPLV"
 Query Match 0.9%; Score 19.8; DB 1; Length 873;
 Best Local Similarity 45.7%; Pred. No. 1.1e+02;
 Matches 69; Conservative 0; Mismatches 82; Indels 0; Gaps 0;
 QY 1977 TTAATCTATTTCACCTTCAGCTCCTGAAATGTTTACTCATTTCTCCAGTATTTA 2036
 Db 749 TCAATATTATGTTCACTCGGCAACTGTAAATTTTAAACACCACTTTCAACACAGTGGCA 690
 QY 2037 CATTTTCATAGGTTCTTTTAATGGATTATTCATTTCTCTTCAAGACCTTTTATGAAT 2096
 Db 689 GCAGTTACATCATCATTTTTCATTAACGATAGAGCTCCAGAAATGCATCAACTTTACCA 630
 QY 2097 TCATAAATGATGTTAAGTCTCTGCTG 2127
 Db 629 TTCAAAACACCTGCCAGGGAATTGACCTG 599
 RESULT 124
 MMU44795/c
 LOCUS Mus musculus coagulation factor VII (FVII) mRNA, complete cds.
 DEFINITION
 ACCESSION U44795
 VERSION U44795.1 GI:1184738
 KEYWORDS
 SOURCE Mus musculus (house mouse)
 ORGANISM
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 Iduosogie, E., Rosen, E., Geng, J.P., Carmeliet, P., Collen, D. and Castellino, F.J.
 TITLE Characterization of a cDNA encoding murine coagulation factor VII
 JOURNAL Thromb. Haemost. 75 (3), 481-487 (1996)
 MEDLINE 96276538
 PUBMED 8701412
 REFERENCE 2 (bases 1 to 1850)
 AUTHORS Rosen, E.D., Iduosogie, E., Carmeliet, P., Collen, D. and Castellino, F.J.
 TITLE Direct Submission
 JOURNAL Submitted (05-JAN-1996) Elliot D. Rosen, Chemistry, Univ. of Notre Dame, Notre Dame, IN 46556, USA
 FEATURES
 source
 1. .1850

/organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="taxon:10090"
 /tissue_type="liver"
 1. .1850
 /gene="fVII"
 16. .1356
 /gene="fVII"
 /note="Initiation of extrinsic pathway of blood coagulation; serine protease"
 /codon_start=1
 /product="coagulation factor VII"
 /protein_id="AAC52570.1"
 /db_xref="GI:1184739"
 /translation="MVPOAGLLLLCLLQLOGLTAVFITOEAEHVLHRRRANS LLEELWPSGLERECEEQCSFEAREIFKSPERTKQWIVYSDGQCSNPQNVGTC QDHLKSVCFCLDDPGRNCKSNQOLICANENGDDOYCRDHVGTGKTCSCHEDYT LOPDEVSKPKVEYPCGRIPVVEKRNSSROGRIVGNCVKGCECPQAVLKNGLLL CGAVLLDARWIVTAHCFDNIRYWGNTVVMSEHDFSEKDGQEVQRVQVIMPDXYI RGINHDIALRLHLPVFTDYVPLCLPEKSPSENTLARIKRSVSGQGLLDRGAT ALELMSIEVPRMLTQCLFEAKHSSNTPKITENMFCAGYMGDTKACKSGGPHATH YHGTWYLTGVSWGEGCAIGHGVYTRVSQYIDVLVRHMDSKLVGVFLPLL"
 1850
 /gene="fVII"
 /note="54 A nucleotides"
 Query Match 0.9%; Score 19.8; DB 1; Length 1850;
 Best Local Similarity 69.2%; Pred. No. 1.1e+02;
 Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
 QY 1860 CTCCTCGAGATTCCTCTCTATCTCTCTGTTATTCGTCA 1898
 Db 581 CTGCTGGAGTTCTTTTCTTCTACACAGGTTATTCCTCCA 543
 polyA_site
 1850
 /gene="fVII"
 /note="54 A nucleotides"
 RESULT 125
 HAMCFX/c
 LOCUS Syrian hamster gene for coagulation factor X, partial cds.
 DEFINITION
 ACCESSION D21216
 VERSION D21216.1 GI:415304
 KEYWORDS
 SOURCE Mesocricetus auratus (golden hamster)
 ORGANISM
 Mesocricetus auratus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae; Mesocricetus.
 REFERENCE 1 (bases 1 to 484)
 AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Niho, Y.
 TITLE Analysis of the partial nucleotide sequences and deduced primary structures of the protease domains of mammalian blood coagulation factors VII and X
 JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
 MEDLINE 94222160
 PUBMED 8168596
 REFERENCE 2 (bases 1 to 484)
 AUTHORS Murakawa, M.
 TITLE Direct Submission
 JOURNAL Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
 COMMENT Submitted (18-Oct-1993) to DDBJ by:
 Masahiro Murakawa
 Division of Hematology
 Harasanshin General Hospital
 1-8 Taihaku-machi, Hakata-ku
 Fukuoka, Fukuoka 812
 Japan
 Phone: 092-291-3434
 Fax: 092-291-3266
 FEATURES
 source
 1. .484

```

/organism="Mesocricetus auratus"
/mol_type="genomic DNA"
/db_xref="taxon:10036"
<!-->484
/codon_start=2
/product="coagulation factor X"
/protein_id="BAA04757.1"
/db_xref="GI:455393"
/translation="EGNMTHEVDVVIKHNKFRVETYDFJAVLRRLKTPILFRNNVAP
ACLPKDWAEATLMTQSGIVSGFRTHGRQSHILKLEVPVVDNNTCKLSTSTPT
TQNMFCAQYDAKPEDACQDGGPHVTRFKDTYFVTGTVSGECARKGKGYIVTKV
A"

```

Query Match	0.98;	Score 19.6;	DB 1;	Length 484;
Best Local Similarity	50.0%;	Pred. No. 1.2e+02;		
Matches 49;	Conservative	0;	Mismatches 49;	Indels 0;
Gaps	0;			

QY	740	ATTGTGTTTCGGTGCATAGACATTAAAGAAATGCAATGTCCTCTTGGTGCATTTTCCCTTTGA	799
DB	114	AATATATATGGGGGTCTTCAGCCCTGAGCAGCGCATGTCGAAGTCGTAGGTCCTCCCTCACA	55
QY	800	TGCTATGTAGTATTTCTCCCAATCTCATCTGCTTAGT	837
DB	54	AACCTTGTTGTTTATGACCACTCCACCTCATGTGT	17

RESULT 126					
AX193364					
LOCUS	AX193364	596 bp	DNA	linear	PAT 15-AUG-2001
DEFINITION	Sequence 931 from Patent WO0149716.				
ACCESSION	AX193364				
VERSION	AX193364.1	GI:15211315			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
	Eukaryota; Chordata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.				
REFERENCE	1.				
AUTHORS	Xu, J., Lodes, M.J., Seerist, H., Benson, D.R., Meagher, M.J.,				
	Stolk, J.A., King, G.E., Wang, T. and Jiang, Y.				
TITLE	Compounds for immunotherapy and diagnosis of colon cancer and				
	methods for their use				
JOURNAL	Patent: WO 0149716-A 931 12-JUL-2001;				

FEATURES	CORIAX CORPORATION (US)			
source	Location/Qualifiers			
	1..596			
	/organism="Homo sapiens"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:9606"			
Query Match	0.9%;	Score 19.6;	DB 1;	Length 596;
Best Local Similarity	58.6%;	Pred. No. 1.2e+02;		
Matches	34;	Conservative	0;	Mismatches 24; Indels 0; Gaps 0;
Qy	727	GAACCTGGGTGCACATGTGGTTGGTGCATGACACATTAAGAAATTCGAATGCATTCCTCTTGG	784	
Db	122	GATCTAGCGGAGAAAGTGATGGCTGTGCTGCTGAAGTTGGAGAGAGTGCAAATGTCCCTCTGG	179	

RESULT	127
AX763043	
LOCUS	AX763043
DEFINITION	Sequence 37 from Patent WO03040393.
ACCESSION	AX763043
VERSION	AX763043.1 GI:32257659
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1
AUTHORS	Martinez,R.A. and Sigurdsson,G.T.
TITLE	Nucleic acids encoding proteases

```

JOURNAL      Patent: WO 03040393-A 37 15-MAY-2003;
FEATURES     Decode Genetics EHF. (IS)
              Location/Qualifiers
              source          1. .609
                           /organism="Homo sapiens"
                           /mol_type="unassigned DNA"
                           /db_xref="taxon:9606"

              Query Match      0.9%; Score 19.6; DB 1; Length 609;
              Best Local Similarity 54.1%; Pred. No. 1.2e+02;
              Matches 40; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

Qy           435 ATTATTCAATTCTCTTTTATCTGTGCGAGACTTGTCTTTTGAATATGTATTCAATT 494
              |||||
Db           142 ATTATTGGCATATATTAGATCATGTGTGGCCCTTTGTTTGTGCAAAATTTCTTCATT 201
              |||||

Qy           495 TTGGAGAGTTTCAT 508
              |||||
Db           202 TGGAAATGGGAACAT 215
              |||||

RESULT 128
AX675583/c
LOCUS
DEFINITION Sequence 33 from Patent WO02055704.
LOCUS      AX675583      882 bp      DNA      linear      PAT 27-MAR-2003

```

RESULT 128	AX675583	882 bp	DNA	linear	PAT 27-MAR-2003
AX675583/C	Sequence 33 from Patent WO02055704.				
LOCUS	AX675583				
DEFINITION	Sequence 33 from Patent WO02055704.				
ACCESSION	AX675583				
VERSION	AX675583.1	GI:293333568			
KEYWORDS	.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				

1
REFERENCE
AUTHORS
Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Szytek, K.A., Zhong, M., Gangoli, E.A., Burgess, C.E., Patturajan, M.,
Varbet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
Baldes, F.L., Grosse, M.M., Alsobrook, J.P., Gerlach, V.,
Eisingermark, S., Ruchenberg, M.E., Ellerman, K., Macdonald, J.,
Malyankar, U., Millet, I., Feyman, J., Smithson, G., Guntner, E., and
Stone, D.J.
TITLE
Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL
Patent: WO 02055704-A 33 18-JUL-2002;

```

JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES Location/Qualifiers
source
1..882
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.6; DB 1; Length 882;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 727 GACTTGGGTGCATCTGTTTGGTCATGACATTAAGCAATTCCTCTTGG 784

Db 369 GATCTACGGGAGAGGGTGATGGGTCTGCTGAGTTGGAGGAGTGCATATGCGCCTGG 312

```

RESULT 129					
AR219285/c					
LOCUS	AR219285	1142 bp	DNA	linear	PAT 25-SEP-2002
DEFINITION	Sequence 8 from patent US 6420157.				
ACCESSION	AR219285				
VERSION	AR219285.1	GI:23320255			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 1142)				
AUTHORS	Darrow,A., Qi,J. and Andrade-Gordon,P.				
TITLE	Zymogen activation system				
JOURNAL	Patent: US 6420157-A 8 16-JUL-2002;				

```

Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

727 GAACCTGGGTGACATCTGTTGGTGCATAGACATTAAAGAAATTCGAATGCTCTTGG 784
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 483 GATGTACGGGAGAAGGTGATGGTCTGCTGAGTTGGAGGAGTGCAATGCGCCTGG 426

RESULT 132
BOVPBC/c
LOCUS BOVPBC Bovine protein C mRNA. 1373 bp mRNA linear MAM 27-APR-1993
DEFINITION Bovine protein C mRNA.
ACCESSION K02435
VERSION K02435.1 GI:163486
KEYWORDS autoproteolysin IIA; protein C; serine protease.
SOURCE Bos taurus (cow)
ORGANISM Bos taurus
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
          Bovidae; Bovinae; Bos.
REFERENCE 1 (bases 1 to 1373)
AUTHORS Long,G.L., Belagaje,R.M. and MacGillivray,R.T.
TITLE Cloning and sequencing of liver cDNA coding for bovine protein C
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)
MEDLINE 85014826
PubMed 6091100
COMMENT Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and
pBC-7.
The sequence reported in [1] included homopolymeric tails on the 5'
and 3' ends (not shown here).
FEATURES             Location/Qualifiers
     source            1..1373
                       /organism="Bos taurus"
                       /mol_type="mRNA"
                       /db_xref="taxon:9913"
     CDS               1..1370
                       /note="protein C prepropeptide"
                       /codon_start=3
                       /protein_id="AAA30685.1"
                       /db_xref="GI:163487"
                       /translation="TSLLPVTWIGISSTPAPDSVPSSORAHQVLRIRKTRANSFLE
ELRPGNVNRCSEVECFEAREILFONTEMTAFSKYSDGDOCEPSPGCDLPCC
GRKCIDLGLGPRCDCAEGWEGFRCLEHVFNSCARNGGCAHYCWEERRHSCSAP
GYRLDDHQICVCSKVTFPCGRLGKRMKKRKLKRDITNQDKDQLDPRIVDQGEAGW
GESPGQAVLLDSKKLVCGAVLIHVSNVLTVAHCLDSRKKLIVRLGEYDMRWESVEV
DLDIKEVIHPNYTKTSDNDIALRLAKPATLSQITVPICLPDSGLSERKLTQVGGE
TWTGWSYDRETNRNFTVLSFIKVPVPYNACVHAMENKISENMLCAGILGPRDACL
EGDSGGPMVTFFRGTWFLVGLVSGEGCGRLYNYGVYTKVSRVLYLDTWITYHKAQAPFL
ESQVP"
     sig_peptide       <1..86
                       /note="protein C signal peptide"
     mat_peptide       117..581
                       /product="protein C light chain"
     mat_peptide       588..1367
                       /product="protein C inactive heavy chain"
     mat_peptide       630..1367
                       /product="protein C active heavy chain"

Query Match          0.9%; Score 19.6; DB 1; Length 1373;
Best Local Similarity 50.08; Pred. No. 1.2e+02;
Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

2069 ATTTCCTCTTCAAGACCTTTATGAATTCATAAATGTATGTAAAGTCCTTGCCTTGT 2128
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 895 ATGTCGTGTGCACTGGTGCCTTGGTATAGTAGTAGGGTGATGATGACCTCTTTGATGCC 836

2129 GCTTCAGCTATGTTGCATTTCTCAGGCGCTATTGTAATA 2166
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 835 AGGTCCACCTCCAGCTCTCCCGCGCGCATGTGTAATA 798

RESULT 133
AR109618
LOCUS AR109618 177 bp DNA linear PAT 14-FEB-2001

```

DEFINITION Sequence 30 from patent US 6114139.

ACCESSION ARI09618

VERSION ARI09618.1 GI:12825894

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 177)

AUTHORS Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.

TITLE G-protein coupled receptor protein and a DNA encoding the receptor

JOURNAL Patent: US 6114139-A 30 05-SEP-2000;

FEATURES Location/Qualifiers

1..177

source

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 177;

Best Local Similarity 57.4%; Pred. No. 1.2e+02;

Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTGACCTGCTCTTCCCTCTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774

DB 7 CTGCTGGTCACTACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 66

QY 1775 G 1775

DB 67 G 67

RESULT 134

ARI50638

LOCUS ARI50638 177 bp DNA linear PAT 08-AUG-2001

DEFINITION Sequence 25 from patent US 6228984.

ACCESSION ARI50638

VERSION ARI50638.1 GI:15115229

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 177)

AUTHORS Hinuma,S., Habata,Y., Kawamata,Y., Hosoya,M., Fujii,R., Fukusumi,S.

and Kitada,C.

TITLE Polypeptides their production and use

JOURNAL Patent: US 6228984-A 25 08-MAY-2001;

FEATURES Location/Qualifiers

1..177

source

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 177;

Best Local Similarity 57.4%; Pred. No. 1.2e+02;

Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTGACCTGCTCTTCCCTCTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774

DB 7 CTGCTGGTCACTACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 66

QY 1775 G 1775

DB 67 G 67

RESULT 135

E16187

LOCUS E16187 177 bp DNA linear PAT 28-JUL-1999

DEFINITION Partial sequence of cDNA encoding G protein-coupled receptor.

ACCESSION E16187

VERSION E16187.1 GI:5710870

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

1 (bases 1 to 177)

Hinuma,K., Habatake,Y., Kawamata,Y., Hosoya,M., Fujii,A.,

Fukuzumi,M. and Kitada,C.

NEW PHYSIOLOGICALLY ACTIVE SUBSTANCE, ITS PRODUCTION AND USE

PATENT: JP 1998146192-A 11 02-JUN-1998;

TAKEDA CHEM IND LTD

OS Homo sapiens (human)

PN JP 1998146192-A/11

PD 02-JUN-1998

PF 26-DEC-1996 JP 1996348328

PR 28-DEC-1995 JP 95P 343371, 15-MAR-1996 JP 96P 59419, PR

12-AUG-1996 JP 96P 211805, 18-SEP-1996 JP 96P 246573 PI

HINUMA KUNII, HABATAKE YUUGO, KAWAMATA YUJI, HOSoya MASAKI, PI

FUJII AKIRA,

PI FUKUZUMI MASASHI, KITADA CHIEKO

PC C12N15/09,A61K31/70,A61K31/70,A61K31/70,A61K31/70,A61K31/70,

PC A61K31/70,

PC A61K35/76,A61K38/00,A61K48/00,C07H21/00,C07K14/47,C12N5/10, PC

C12P21/02,

PC C12Q1/02,G01N33/566,(C12N5/10,C12R1:91),(C12P21/02,C12R1:91);

CC strandedness: Double;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

FH Key

FH Location/Qualifiers

FT source

FT 1..177

FT /organism="Homo sapiens"

FT /tissue_type="pituitary gland".

FT Location/Qualifiers

1..177

/organism="Homo sapiens"

/mol_type="genomic DNA"

/db_xref="taxon:9606"

Query Match 0.9%; Score 19.4; DB 1; Length 177;

Best Local Similarity 57.4%; Pred. No. 1.2e+02;

Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTGACCTGCTCTTCCCTCTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774

DB 7 CTGCTGGTCACTACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 66

QY 1775 G 1775

DB 67 G 67

RESULT 136

E27213

LOCUS E27213 177 bp DNA linear PAT 18-JUN-2001

DEFINITION Novel physiologically active substance, process for producing the

same and utilization thereof.

ACCESSION E27213

VERSION E27213.1 GI:13025230

KEYWORDS

SOURCE unidentified

ORGANISM unidentified

unclassified.

REFERENCE 1 (bases 1 to 177)

AUTHORS Shuji,H. and Shoji,F.

Novel physiologically active substance, process for producing the

same and utilization thereof

PATENT: JP 1999009286-A 4 19-JAN-1999;

TAKEDA CHEM IND LTD

OS Unidentified

PN JP 1999009286-A/4

PD 19-JAN-1999

PF 27-APR-1998 JP 1998117189

PR SHUJI HINUMA, SHOJI FUKUZUMI

PI C12N15/09,A01K67/027,A61K38/00,A61K38/00,C07K14/47,C07K16/18,

PC C12N1/21,

```
PC C12N5/10, C12P21/02, G01N33/53, G01N33/57//C12P21/08, (C12N15/09,
PC C12R1:91), (C12N1/21, C12R1:19), (C12N5/10, C12R1:91), (C12P21/02, C12R1:19),
PC C12N15/00,
PC A61K37/02, A61K37/02, C12N5/00, (C12N15/00, C12R1:91), (C12N5/00,
PC C12R1:91)
CC Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..177
   /organism="Unidentified"
FEATURES
    source
        Location/Qualifiers
            1..177
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.2e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1715 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTGCTGTCACCTACCTGCTCCCTCTGCTGTCATCCTCCTGCTTACGTCGGGTGCA 66
Qy 1775 G 1775
Db 67 G 67
Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.2e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1715 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTGCTGTCACCTACCTGCTCCCTCTGCTGTCATCCTCCTGCTTACGTCGGGTGCA 66
Qy 1775 G 1775
Db 67 G 67
RESULT 137
LOCUS E28271 177 bp DNA linear PAT 18-JUN-2001
DEFINITION Utilization of peptide.
ACCESSION E28271
VERSION E28271.1 GI:13025305
KEYWORDS JP 1999071300-A/11.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 177)
AUTHORS Shuji, H., Ryo, F., Yuji, K. and Hirokazu, M.
TITLE Utilization of peptide
JOURNAL Patent: JP 1999071300-A 11 16-MAR-1999;
TAKEDA CHEM IND LTD
OS Unidentified
PN JP 1999071300-A/11
PD 16-MAR-1999
PE 22-JUN-1998 JP 1998175007
PR SHUJI HINUMA, RYO FUJII, YUJI KAWAMATA, HIROKAZU MATSUMOTO PC
A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, PC
A61K38/00,
PC A61K38/00, A61K38/00, C07K14/705//C12N15/09, C12P21/02,
PC (C12P21/02, C12R1:91), A61K37/02, A61K37/02, A61K37/02, A61K37/02,
PC A61K37/02,
PC A61K37/02, A61K37/02, A61K37/02, A61K37/02, C12N15/00 CC
Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..177
   /organism="Unidentified"
FEATURES
    source
        Location/Qualifiers
            1..177
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.2e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1715 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774
```

```
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTGCTGTCACCTACCTGCTCCCTCTGCTGTCATCCTCCTGCTTACGTCGGGTGCA 66
Qy 1775 G 1775
Db 67 G 67
RESULT 138
LOCUS AR300928 177 bp mRNA linear PAT 12-JUN-2003
DEFINITION Sequence 30 from patent US 6538107.
ACCESSION AR300928
VERSION AR300928.1 GI:31688601
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 177)
AUTHORS Hinuma, S., Ito, Y. and Fujii, R.
TITLE G protein coupled receptor protein production, and use thereof
JOURNAL Patent: US 6538107-A 30 25-MAR-2003;
FEATURES
    source
        Location/Qualifiers
            1..177
            /organism="unknown"
            /mol_type="mRNA"
Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.2e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1715 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTGCTGTCACCTACCTGCTCCCTCTGCTGTCATCCTCCTGCTTACGTCGGGTGCA 66
Qy 1775 G 1775
Db 67 G 67
RESULT 139
LOCUS AR109885 204 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 310 from patent US 6114139.
ACCESSION AR109885
VERSION AR109885.1 GI:12826161
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 204)
AUTHORS Hinuma, S., Hosoya, M., Fujii, R., Ohtaki, T., Fukusumi, S. and Ohgi, K.
TITLE G-protein coupled receptor protein and a DNA encoding the receptor
JOURNAL Patent: US 6114139-A 310 05-SEP-2000;
FEATURES
    source
        Location/Qualifiers
            1..204
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 0.9%; Score 19.4; DB 1; Length 204;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1715 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGGTTTGGCATAGTGTCTCT 1774
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTGCTGTCACCTACCTGCTCCCTCTGCTGTCATCCTCCTGCTTACGTCGGGTGCA 66
Qy 1775 G 1775
Db 67 G 67
RESULT 140
```

AR150703
LOCUS AR150703 204 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 127 from patent US 6228984.
ACCESSION AR150703
VERSION AR150703.1 GI:15115294
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 204)
AUTHORS Hinuma,S., Habata,Y., Kawamata,Y., Hosoya,M., Fujii,R., Fukusumi,S. and Kitada,C.
TITLE Polypeptides their production and use
JOURNAL Patent: US 6228984-A 127 08-MAY-2001;
FEATURES Location/Qualifiers
source 1..204
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 204;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTGACCTGCTTCCCTCTCTATTCCTTTCCTTGGTTTTCATAGTGTCT 1774
Db 7 CTGCTGGTCACTACTGCTCTCTCTGCTGGTCACTCTCTCTTACGTCGGGTGCA 66

QY 1775 G 1775
Db 67 G 67

RESULT 141
AJ586104/c
LOCUS AJ586104 249 bp mRNA linear PLN 23-OCT-2003
DEFINITION Lolium multiflorum partial mRNA for putative 4-coumarate coA ligase (4cl gene).
ACCESSION AJ586104
VERSION AJ586104.1 GI:37805458
KEYWORDS 4-coumarate coA ligase; 4cl gene.
SOURCE Lolium multiflorum (Italian ryegrass)
ORGANISM Lolium multiflorum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooidae; Poae; Lolium.

REFERENCE 1
AUTHORS Bettany,A.J.E. and Morris,P.
TITLE cDNA and genomic clones of Festuca arundinacea and Lolium multiflorum
JOURNAL Unpublished
2 (bases 1 to 249)
AUTHORS Bettany,A.J.E.
TITLE Direct Submission
JOURNAL Submitted (13-OCT-2003) Bettany A.J.E., Plant, Animal & Microbial Science, Inst. Grassland & Environmental Research, Plas Gogerddan, Aberystwyth, Ceredigion SY23 3EB, UNITED KINGDOM
FEATURES Location/Qualifiers
source 1..249
/organism="Lolium multiflorum"
/mol_type="mRNA"
/cultivar="Trident"
/db_xref="taxon:4521"
/tissue_type="young leaves with leaf bases"
/dev_stage="seedlings"
1..249
/gene="4cl"
/EC number="6.2.1.12"
/function="activation of thioester substrates for phenylpropanoid synthesis"
/codon_start=3
/product="putative 4-coumarate coA ligase"

gene
CDS

/protein id="CAE51882.1"
/db_xref="GI:37805459"
/translation="PPKVKSGCTVVERNAELKVDPDTGASLGRNQPGEICVRGKQI
MLGYLNDPESTKNITDKGWLHTGDIGLVDDDEIFIV"

Query Match 0.9%; Score 19.4; DB 1; Length 249;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1880 TATCTCTGTATTCTGTCAGTCAGGAGCTGTCTCTCTGAGGTCTCTGTGGTTCT 1932
Db 210 TGTCTCCGCTGTCAGCCAGCCGCTCTGTCTGATGCTGTCTGTGCGACTCT 158

RESULT 142
AX839191/c
LOCUS AX839191 290 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 34 from Patent WO03076610.
ACCESSION AX839191
VERSION AX839191.1 GI:39922640
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Bracco,L., Brinkman,B. and Coignard,F.
TITLE Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL Patent: WO 03076610-A 34 18-SEP-2003;
FEATURES Exonhit Therapeutics S.A. (FR)
Location/Qualifiers
source 1..290
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.4; DB 1; Length 290;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 217 TCTCTCTCCCTTCTCTAACACTTCTGGCCAGGTCAGGGGCATCAGCATTCCTC 276
Db 113 TCTCGACTCCAGGCTCCCAATCCGAGCAGGATGAGGGTGCAGCAATCCACG 54

QY 277 TCTCTTCCA 285
Db 53 TCACGGACA 45

RESULT 143
HUMPS02
LOCUS HUMPS02 352 bp DNA linear PRI 10-JAN-1995
DEFINITION Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION M57841 J02917
VERSION M57841.1 GI:190535
KEYWORDS S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT 2 of 14
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 352)
AUTHORS Schmidt,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
TITLE Organization of the human protein S genes
JOURNAL Biochemistry 29 (34), 7845-7852 (1990)
MEDLINE 91084444
PUBMED 2148110
COMMENT Original
FEATURES Location/Qualifiers
source 1..352
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

```

/map="3p11-q11.2"
/tissue_type="liver"
Join(M57840.1:837..912,135..181)
/gene="PS-alpha"
order(M57840.1:913..1014,1..134)
/gene="PROS1"
/number=1
135..292
/gene="PROS1"
/note="G00-120-721"
/number=2

Query Match      0.9%; Score 19.4; DB 1; Length 352;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 1309 AAGATGATATCTTTACATCTGATTTTATCTTAGAATGCTCTTCTTCTTCCCACTATG 1368
      |||||
Db 80 AATATATTTACATGGAATAATGATTAATCATATAAATGATGTTTCTTCTTCTTCTTCTT 139

Qy 1369 TGACAGAAA 1377
      |||||
Db 140 TCAAAGCAA 148

RESULT 144
LOCUS DOGA2 471 bp DNA linear MAM 09-FEB-1999
DEFINITION Dog gene for protein C (precursor of vitamin K-dependent serine
            protease), partial cds (catalytic region).
ACCESSION D43751
VERSION D43751.1 GI:601886
KEYWORDS protein C; serine protease zymogen; vitamin K-dependent serine
            protease; blood coagulation-related.
SOURCE Canis familiaris (dog)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1 (bases 1 to 471)
AUTHORS Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
            Niho,Y.
TITLE A comparative study of partial primary structures of the catalytic
            region of mammalian protein C
JOURNAL Br. J. Haematol. 86 (3), 590-600 (1994)
MEDLINE 94318474
PUBMED 8043441
REFERENCE 2 (bases 1 to 471)
AUTHORS Murakawa,M.
TITLE Direct Submission
JOURNAL Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General
            Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
            Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
            Location/Qualifiers
            1..471
            /organism="Canis familiaris"
            /mol_type="genomic DNA"
            /db_xref="taxon:9615"
            <1..>471
            /function="regulation of blood coagulation"
            /note="catalytic region"
            /codon_start=1
            /product="protein C"
            /protein_id="BAA07808.1"
            /db_xref="GI:1304048"
            /translation="EKGEVDVDEKVLHPNYSKSTDDIALIHLAQAIFQSOTIVP
            ICLPDSGLARELTGVQETVTVGWVSRTEKRNRTFLNFIPIVAPHNECICQAMYN
            MISNMLCAGILGDSRDACEGSGPVTFRGTWFLVLVSGEGGRLHNYGI"

Query Match      0.9%; Score 19.4; DB 1; Length 471;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 1191 TGTCTCTCCCTCTTTTGATTTTGGCCTGGAATTATTTATTTATTTATTTCTTTGAA 1250

```

```

Db 322 TGTTCAGATATCATGTTGTACATGGCCTGGATGCACTCATTTGCGGGCCACAGGGA 263
      |||||
Qy 1251 TGTGGGTAA 1259
      |||||
Db 262 TGTGTATAA 254
      |||||

RESULT 145
LOCUS SHPFIYA/c 823 bp mRNA linear MAM 27-APR-1993
DEFINITION Sheep factor IX mRNA, partial cds.
ACCESSION M26233
VERSION M26233.1 GI:165878
KEYWORDS factor IX.
SOURCE Ovis aries (sheep)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
            Bovidae; Caprinae; Ovis.
REFERENCE 1 (bases 1 to 823)
AUTHORS Sarkar,G., Koerberl,D.D. and Sommer,S.S.
TITLE Direct sequencing of the activation peptide and the catalytic
            domain of the factor IX gene in six species
JOURNAL Genomics 6 (1), 133-143 (1990)
MEDLINE 90152675
PUBMED 2303254
COMMENT Original source text: Sheep liver, cDNA to mRNA.
            Draft entry and computer-readable sequence for [1] kindly provided
            by G.Sarkar, 18-JUL-1989.
            Location/Qualifiers
            1..823
            /organism="Ovis aries"
            /mol_type="mRNA"
            /db_xref="taxon:9940"
            <1..>823
            /note="factor IX"
            /codon_start=1
            /protein_id="AAA31520.1"
            /db_xref="GI:552419"
            /translation="RASVLHTSKLTRAETIFSNMNYENSEAEIINDNVTQNSQSP
            DFRVVGGEAARGQFFQVOLLHGEIAAFCGGSIVNEKVVTAHCHIKPGVKITVWAG
            EHNTKEPTEQRNRVIRALPIYGINASINKYSHDIALLEDEPLELNSVYTPICIAE
            REYTNIFLKFGYGVGWVFRNRSASILQYLKVLVDRATCLRTSTKFTIYNHMF
            AGYHEGKDCQGDGSGPHVTEVGEFTGLIISWGECAKMGKIYTKVSYEV"

Query Match      0.9%; Score 19.4; DB 1; Length 823;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 1663 TTTCTCAAGGTAGGAAATTTTCTTTTGGTTTCTTGTGAAATATTTCCCTGCTTTT 1722
      |||||
Db 93 TATTTCAGTTCAGAGAAATTTTCATAGTTCATATTCGAAAAATAGTCTCAGCACGGT 34
      |||||

Qy 1723 GACCTGCCT 1731
      |||||
Db 33 GAGCTTCTT 25
      |||||

RESULT 146
LOCUS BC061135/c 829 bp mRNA linear ROD 25-NOV-2003
DEFINITION Mus musculus trypsin 4, mRNA (cDNA clone MGC:74265 IMAGE:30306436),
            complete cds.
ACCESSION BC061135
VERSION BC061135.1 GI:38511692
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 829)
AUTHORS Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,

```

Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, P., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.P., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S., Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullah, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahney, J., Helton, E., Kettman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smal, D.E., Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

22388257

12477932

2 (bases 1 to 829)

Strausberg, R.

Direct Submission

Submitted (03-NOV-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 1A03, Bethesda, MD 20892-2590, USA

NIH-MGC Project URL: <http://mgc.nci.nih.gov>

Contact: MGC help desk

Email: cgabs-remail.nih.gov

Tissue Procurement: Dr. Michael Brownstein

cDNA Library Preparation: Michael Brownstein / Ted Usdin

Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Sequencing Group at the Stanford Human Genome Center, Stanford University School of Medicine, Stanford, CA 94305

Web site: <http://www.shgc.stanford.edu>

Contact: (Dickson, Mark) mcd@paxil.stanford.edu

Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

Series: IRAL Plate: 53 Row: 0 Column: 2

This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6755892.

FEATURES

source

1. .829
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="MGC:74265 IMAGE:30306436"
/tissue type="Liver, mouse"
/clone_lib="NIH MGC 177"
/lab host="DH10B"
/note="Vector: pDNR-LIB"
1. .829
/gene="Try4"
/note="synonyms: 0910001B19rik, Tc"
/db_xref="LocusID:22074"
/db_xref="MGI:102757"

CDS

14. .754
/codon_start=1
/product="trypsin 4"
/protein_id="AAH61135.1"
/db_xref="GI:38511693"
/db_xref="LocusID:22074"
/translation="MRALLFLALGAAVAPPVDDDKIVGGYTCRENSVPYQVLSNLSG
YHFCGSLNDQWVSAACHYKRIQVRLGEHNLVLEGEQFVNSAKILKHPENSR
TLNDLMLKALPVLNARVATLVPSSCAPAGTQCLISGWNLTLSFGVNNPDLIQ
LDAPLLPQADCEASYFGKLTNNMICVGFLEGGKDSQGGSGPVCNQGQIGVLSWGI

gene

misc_feature

GCALKDNPGVYTKVCNVYVDWIQNTIAAN"
83. .739
/note="Tryp SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 0.9%; Score 19.4; DB 1; Length 829;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1681 TTTTCTTTTGGTTTCTTCAAAATATTTCCCTGCTTTGACCTGCCTTC 1733
|||||
Db 817 TTTTCTTTTGGTTTCTTCAAAATATTTCCCTGCTTTGACCTGCCTTC 765
|||||

RESULT 147
AR095306/c

LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Unassigned.
Unclassified.
1 (bases 1 to 1126)
Thorpe, P.E. and Edgington, T.S.
TITLE
Methods for the specific coagulation of vasculature
JOURNAL
Patent: US 6004555-A 27 21-DEC-1999;
FEATURES
Location/Qualifiers
source
1. .1126
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGGTGAATAGTCTGTAATATCTCTAGTCCACTTGGTTTATGACATCAGTTAGCTCC 601
|||||
Db 596 TTGTGACCGGTGTGCTTGATGACCACTCCACCTCGTGACCGCTCACCGCCCTCC 537
|||||

QY 602 AGCATTTCTCTGTTGCTTTTGTGATGACATGACCTAACTGTGGAGAGATGGGT 658
|||||
Db 536 TCTGCTCGTGTTCGGTCCCTTCGAATCTCTGGCTTGGTAGAGAGATGGGT 480
|||||

RESULT 148
AR103990/c

LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Unassigned.
Unclassified.
1 (bases 1 to 1126)
Thorpe, P.E. and Edgington, T.S.
TITLE
Methods and compositions for the specific coagulation of
vasculature
JOURNAL
Patent: US 6093399-A 27 25-JUL-2000;
FEATURES
Location/Qualifiers
source
1. .1126
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGGTGAATAGTCTGTAATATCTCTAGTCCACTTGGTTTATGACATCAGTTAGCTCC 601
|||||
Db 596 TTGTGACCGGTGTGCTTGATGACCACTCCACCTCGTGACCGCTCACCGCCCTCC 537
|||||


```
QY 602 AGCATTTCTCTGTTTCGTTTTTTTGTGAGATGACCTAACTGTTGGAGAGAATGGGGT 658
Db 536 TCCTGCTCCGGTGTCCCGTCCCTTCGAACTCTCTTGGCTTGGTAGAGACAGTGGGCT 480

RESULT 149
HUMFX/c
LOCUS HUMFX Human factor X mRNA. 1126 bp mRNA linear PRI 08-NOV-1994
DEFINITION Human factor X mRNA.
ACCESSION K01886
VERSION K01886.1 GI:182820
KEYWORDS Stuart factor; factor X; serine protease.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 1126)
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Leytus, S.P., Chung, D.W., Kistiel, W., Kurachi, K. and Davie, E.W.
JOURNAL Characterization of a cDNA coding for human factor X
MEDLINE Proc. Natl. Acad. Sci. U.S.A. 81 (12), 3699-3702 (1984)
PUBMED 84222026
COMMENT Original source text: Human liver, cDNA to mRNA, clone
lambda-X-1137.
In processing, factor X (Stuart factor) is converted to Xa by
cleavage of a glycopeptide from the amino-terminal end of the heavy
chain. It then acts as a serine protease in converting prothrombin
to thrombin.
FEATURES
source Location/Qualifiers
1..1126
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="13q34"
1..1126
/gene="F10"
<1..1126
/gene="F10"
/product="factor X mRNA"
<1..1116
/gene="F10"
/notes="factor X precursor peptide"
/codon_start=1
/protein_id="AA52486.1"
/db_xref="GI:182821"
/db_xref="GDB:G00-119-890"
/translation="GEGKNCLEFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTILA
DNKACIPTPGYPGKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFD
LLDFNOTOPERGDNNTLRIVGQCKDEGCPWOALLINEEGFCGGTILSEFYILTA
AHCYQAKPEEGDNTQOEGGSAVHEVVIKHNPTKETYDFDIAVLRLKPTIFR
MNVAPACLPRDWAESTLMTQKGI VSGFGRTHEKGRQRLKMLEVFPVYDRNSCKLS
SSFLITQNMFCAGDYTKQEDACDQSGSPHVTFRFKDTYFVTGIVSWGEGCARKGKGI
YTKVTAFLKWDKSMKTRGLPKAKSHAPEVITSSPLK"
mat_peptide <1..1195
/gene="F10"
/product="factor X light chain"
mat_peptide 205..1113
/gene="F10"
/product="factor X heavy chain"
mat_peptide 361..1113
/gene="F10"
/product="factor Xa heavy chain"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGCTGAATAGTCTGTAATAATCTCTAGTCCACCTGGTTTATGACATCAGTAGCTCC 601
Db 596 TTGTGAACCGGTGTGCTTGTATGACACCTCCACCTCGTGACCGCTCACCGCCCTCC 537
QY 602 AGCATTTCTCTGTTTCGTTTTTTTGTGAGATGACCTAACTGTTGGAGAGAATGGGGT 658
```

```
Db 536 TCCTGCTCCGGTGTCCCGTCCCTTCGAACTCTCTTGGCTTGGTAGAGACAGTGGGCT 480

RESULT 150
A93124/c
LOCUS A93124 1404 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 15 from Patent WO9747737.
ACCESSION A93124
VERSION A93124.1 GI:6741514
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1404)
AUTHORS Kopetzki, E. and Hopfner, K.
TITLE RECOMBINANT BLOOD-COAGULATION PROTEASES
JOURNAL Patent: WO 9747737-A 15 18-DEC-1997;
KOPETZKI ERHARD (DE); BOEHRINGER MANNHEIM GMBH (DE)
FEATURES
source Location/Qualifiers
1..1404
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 19.4; DB 1; Length 1404;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGCTGAATAGTCTGTAATAATCTCTAGTCCACCTGGTTTATGACATCAGTAGCTCC 601
Db 884 TTGTGAACCGGTGTGCTTGTATGACACCTCCACCTCGTGACCGCTCACCGCCCTCC 825
QY 602 AGCATTTCTCTGTTTCGTTTTTTTGTGAGATGACCTAACTGTTGGAGAGAATGGGGT 658
Db 824 TCCTGCTCCGGTGTCCCGTCCCTTCGAACTCTCTTGGCTTGGTAGAGACAGTGGGCT 768

RESULT 151
HUMCFX/c
LOCUS HUMCFX 1414 bp mRNA linear PRI 01-NOV-1994
DEFINITION Human blood-coagulation factor X mRNA, complete cds.
ACCESSION M22613
VERSION M22613.1 GI:180335
KEYWORDS coagulation factor X.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Kaul, R.K., Hildebrand, B., Roberts, S. and Jagadeeswaran, P.
TITLE Isolation and characterization of human blood-coagulation factor X
cDNA
JOURNAL Gene 41 (2-3), 311-314 (1986)
MEDLINE 86221713
PUBMED 3011603
COMMENT source text: Human liver, cDNA to mRNA, clone pKT218.
FEATURES
source Location/Qualifiers
1..1414
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="13q34"
1..1414
/gene="F10"
<1..1414
/gene="F10"
/product="coagulation factor X mRNA"
<1..1404
/notes="coagulation factor X precursor"
/codon_start=1
/protein_id="AA51984.1"

gene
mRNA
CDS
```

```
/db_xref="GI:180336"
/db_xref="GDB:G00-119-890"
/translation="LLGESLIRREQANNILARVTRANSFLFEMKKHLEECMEETC
SYEARFEDSKTNEFNWKYKDGQCEPQCQKCKDGLGEYTCLEGFEGKN
CELFPRKCLSLDNGCDQFCHQNSVCSARGYTLADNGKACICTPGYPGCKQTL
RRKSVAQATSSSGAPDSITWKPYDAADLPDENPDLDFNOTQPRGDNLLTRIV
GQCEKDECPWQALLINEEGFCGGTILSEFYLLTAHCLYQAKRPEGDRNTEORE
GGEAVEVEVTKHNRFTKETYDFDIIVLRKTPITFRMNVAPACLPREDWASTLMT
KGTGIVSGFTHRGROSLKMLEVYDRNSCKLSSFLITQNMFCAGDTIKQED
ACQDGSQGHVTRFDYTFYTVGIVSWGEGCARKGYGTYTKVTFELKWDLSMKTRGL
PKAKSHAPVITSSPLK"
<1..66
/gene="F10"
/note="coagulation factor X signal peptide"
67..483
/gene="F10"
/product="coagulation factor X light chain"
493..1401
/gene="F10"
/product="coagulation factor X heavy chain"
493..648
/gene="F10"
/product="coagulation factor X activation peptide"

Query Match 0.9%; Score 19.4; DB 1; Length 1414;
Best Local Similarity 47.9%; Pred. No. 1.3e+02; Indels 0; Gaps 0;
Matches 56; Conservative 0; Mismatches 61;

QY 542 TTGTGGAATAGCTGTAAATATCTAGTGCACCTGGTTTATGACATCATGCTAGCTCC 601
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 884 TTGTGACCGGTGTGCTGTGATGACCACTCCACCTGTCGACCGCTCCCGCGCTCC 825
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 602 ACATTCTCTGTTTCGTTTTTTGTGAGATGACCTAATCTGTGGAGAAATGGGT 658
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 824 TCGTCTCGTGTTCGGTCCCTTCGAAATCTCTTGGCTTGGTAGAGACAGTGGCT 768
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 152
AX147505 1551 bp DNA linear PAT 08-JUN-2001
LOCUS
DEFINITION
Sequence 59 from Patent WO0136632.
ACCESSION AX147505
VERSION AX147505.1 GI:14346662
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.
AUTHORS
Variants of alternative splicing
TITLE
Patent: WO 0136632-A 59 25-MAY-2001;
JOURNAL
CompuGen Ltd. (IL)
FEATURES
Location/Qualifiers
source
1..1551
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.4; DB 1; Length 1551;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1136 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1188
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1448 TGCATGTGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1500
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 153
MMU44795 1850 bp mRNA linear ROD 23-MAY-1996
LOCUS
DEFINITION
Mus musculus coagulation factor VII (FVII) mRNA, complete cds.
ACCESSION
U44795

/db_xref="GI:180336"
/db_xref="GDB:G00-119-890"
/translation="LLGESLIRREQANNILARVTRANSFLFEMKKHLEECMEETC
SYEARFEDSKTNEFNWKYKDGQCEPQCQKCKDGLGEYTCLEGFEGKN
CELFPRKCLSLDNGCDQFCHQNSVCSARGYTLADNGKACICTPGYPGCKQTL
RRKSVAQATSSSGAPDSITWKPYDAADLPDENPDLDFNOTQPRGDNLLTRIV
GQCEKDECPWQALLINEEGFCGGTILSEFYLLTAHCLYQAKRPEGDRNTEORE
GGEAVEVEVTKHNRFTKETYDFDIIVLRKTPITFRMNVAPACLPREDWASTLMT
KGTGIVSGFTHRGROSLKMLEVYDRNSCKLSSFLITQNMFCAGDTIKQED
ACQDGSQGHVTRFDYTFYTVGIVSWGEGCARKGYGTYTKVTFELKWDLSMKTRGL
PKAKSHAPVITSSPLK"
<1..66
/gene="F10"
/note="coagulation factor X signal peptide"
67..483
/gene="F10"
/product="coagulation factor X light chain"
493..1401
/gene="F10"
/product="coagulation factor X heavy chain"
493..648
/gene="F10"
/product="coagulation factor X activation peptide"

Query Match 0.9%; Score 19.4; DB 1; Length 1414;
Best Local Similarity 47.9%; Pred. No. 1.3e+02; Indels 0; Gaps 0;
Matches 56; Conservative 0; Mismatches 61;

QY 542 TTGTGGAATAGCTGTAAATATCTAGTGCACCTGGTTTATGACATCATGCTAGCTCC 601
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 884 TTGTGACCGGTGTGCTGTGATGACCACTCCACCTGTCGACCGCTCCCGCGCTCC 825
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 602 ACATTCTCTGTTTCGTTTTTTGTGAGATGACCTAATCTGTGGAGAAATGGGT 658
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 824 TCGTCTCGTGTTCGGTCCCTTCGAAATCTCTTGGCTTGGTAGAGACAGTGGCT 768
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 152
AX147505 1551 bp DNA linear PAT 08-JUN-2001
LOCUS
DEFINITION
Sequence 59 from Patent WO0136632.
ACCESSION AX147505
VERSION AX147505.1 GI:14346662
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.
AUTHORS
Variants of alternative splicing
TITLE
Patent: WO 0136632-A 59 25-MAY-2001;
JOURNAL
CompuGen Ltd. (IL)
FEATURES
Location/Qualifiers
source
1..1551
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.4; DB 1; Length 1551;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1136 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1188
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1448 TGCATGTGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1500
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 153
MMU44795 1850 bp mRNA linear ROD 23-MAY-1996
LOCUS
DEFINITION
Mus musculus coagulation factor VII (FVII) mRNA, complete cds.
ACCESSION
U44795
```

```
U44795.1 GI:1184738
Mus musculus (house mouse)
Mus musculus
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 1850)
Idusogie, E., Rosen, E., Geng, J.P., Carmeliet, P., Collen, D. and
Castellino, F.J.
Characterization of a cDNA encoding murine coagulation factor VII
Thromb. Haemost. 75 (3), 481-487 (1996)
MEDLINE 96276538
PUBMED 8701412
2 (bases 1 to 1850)
Rosen, E.D., Idusogie, E., Carmeliet, P., Collen, D. and
Castellino, F.J.
Direct Submission
Submitted (05-JAN-1996) Elliot D. Rosen, Chemistry, Univ. of Notre
Dame, Notre Dame, IN 46556, USA
Location/Qualifiers
1..1850
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/tissue_type="liver"
1..1850
/gene="FVII"
16..1356
/note="initiation of extrinsic pathway of blood
coagulation; serine protease"
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAC52570.1"
/db_xref="GI:1184739"
/translation="MVPOAHGLLLCLLQGLGTAVFTQEEAHGVHLHRRRANS
LLEELPGSLERECNEQCEFEAREIFKSPERTQFQWIVSDGDCASNPQNVGTC
ODHLKSYVCFCLLDPEGCNEKNEQLICANENGDCQYCDRHVGTGRTCSCHEDYT
LQPDVSCSKPKVEYPCGRIPVVEKSSROGRIVGNVCPKGECPQWAVLKGILL
CGAVLLDARWIWTAHCFDNIHNGNITVMGEHDESKDQGVRRVTVIMEDKVI
RQKINHDLRLRHPVTFDITVYVPLCLPEKSFSENTLARIKFSRVSGWQLLDGAT
ALELMSIEVPLMTQDCEHAKHSNTPKITEMFCAGMDGDKACKGSGSGPHATH
YHGTWLTGTVSWSGCAIGHYIVYTRVSQYIDWLVRHMSKDLQGVRLPLL"
1850
/gene="FVII"
/note="54 A nucleotides"

polya_site

Query Match 0.9%; Score 19.4; DB 1; Length 1850;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1136 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1188
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1749 TGCATGTGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1801
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 154
BC061149 1869 bp mRNA linear ROD 25-NOV-2003
LOCUS
DEFINITION
Mus musculus coagulation factor VII, mRNA (cDNA clone MGC:74281
IMAGE:30305571), complete cds.
ACCESSION BC061149
VERSION BC061149.1 GI:38511701
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 1869)
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
```


DEFINITION	Goat gene for protein C (precursor of vitamin k-dependent serine protease), partial cds (catalytic region).		
ACCESSION	D43752		
VERSION	D43752.1 GI:601887		
KEYWORDS	protein C; blood coagulation-related; serine protease zymogen; vitamin K-dependent serine protease.		
SOURCE	Capra hircus (goat)		
ORGANISM	Capra hircus		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Caprinae; Capra.		
AUTHORS	1 (bases 1 to 471) Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and Nihoy.		
TITLE	A comparative study of partial primary structures of the catalytic region of mammalian protein C		
JOURNAL	Br. J. Haematol. 86 (3), 590-600 (1994)		
MEDLINE	94318474		
PubMed	8043441		
FEATURES	2 (bases 1 to 471) Murakawa,M. Direct Submission Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)		
CDs	Location/Qualifiers 1..471 /organism="Capra hircus" /mol_type="genomic DNA" /db_xref="taxon:9925" <1..>471 /function="regulation of blood coagulation" /note="catalytic region" /codon_start=1 /product="protein C" /protein_id="BAA07809.1" /db_xref="GI:1304082" /translations="ESWEVDLDIKEVIVRPNTKSTSDNDIALHLAKPATLSQTVV ICLPDGLSRKLTQVQETVVTGWYDETKKRNRSILNFIKIPVSYNACVHVMEN KVSNEMLCAGILGNRDACSGDSGGPNVTFRTGFWFLGLVSGEGGRLLNNGI"		
Query Match	0.8%; Score 19.2; DB 1; Length 471;		
Best Local Similarity	50.0%; Pred. No. 1.5e+02;		
Matches	48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;		
Qy	1826 GACCAAGTATCCATTTCTTCTATCTTGTCTTCACTGCTGAGATTCCTCTTCTATCTC 1885		
Db	246 GATGAGGCGCGGTTTTCTTGGTCTCGTCAGGTAGCCCGCCTGTACCACTTC 187		
Qy	1886 TTGTATTCTGTCACTGAGGCTTGTCTCTGAGTTCC 1921		
Db	186 CTGCCGACCTGAGTGAGCTTGCCTCAGAGAGGCC 151		
RESULT 157	BV094002/c		
LOCUS	BV094002		
DEFINITION	RPAMSEQ0005940 Roche Palo Alto Mus musculus STS genomic, sequence tagged site.		
ACCESSION	BV094002		
VERSION	BV094002.1 GI:37671481		
KEYWORDS	STS.		
SOURCE	Mus musculus (house mouse)		
ORGANISM	Mus musculus		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
AUTHORS	1 (bases 1 to 596) Usuka,J., Liao,G., Cheng,J., Nguyen,A., Bach,C., Puech,A., McPherson,J.D., Foerzler,D. and Peltz,G.		
TITLE	Mus musculus SNPs		
COMMENT	Unpublished (2003)		
CONTACT	Jonathan Usuka		

1 (bases 1 to 1619)
 Brothers,A.B., Clarke,B.J., Sheffield,W.P. and Blajchman,M.A.
 Complete nucleotide sequence of the cDNA encoding rabbit
 coagulation factor VII
 Thromb. Res. 69 (2), 231-238 (1993)
 JOURNAL 93190306
 MEDLINE 8383365
 PUBMED
 2 (bases 1 to 1619)
 Ruiz,S.R., Blajchman,M.A. and Clarke,B.J.
 Direct Submission
 Submitted (05-NOV-1996) Pathology, McMaster University, 1200 Main
 St. West, Hamilton, ONT L8N 3Z5, Canada
 On Feb 8, 2002 this sequence version replaced gi:266294.
 COMMENT Location/Qualifiers
 FEATURES
 source
 1. .1619
 /organism="Oryctolagus cuniculus"
 /mol_type="mRNA"
 /db_xref="taxon:9986"
 /tissue_type="liver"
 22..1356
 /codon_start=1
 /product="coagulation factor VII"
 /protein_id="AAB37326.1"
 /db_xref="GI:1698965"
 /translation="MAPQARGGLCSLLAQSLAAVFITQEAHSVLRQRANSGL
 EELRPSLEKECEELCSFEAREVFQSTERTKQFWITVNDGQASNPQCSGCCSG
 QISQYICFLADPEGRNCKNKDQLICMYENGCCBOYCSDDHVGSRSCRCHGYILL
 PNGSVCTPVDIYPCGVPALEKGNAPQGRIVGGKVCPEGCECPQWQAALMNGSLILCG
 GSLIDTHWVAASDFPKLSLRNLITVLGEHLSBHEGDEQVRHVAQLIMPDKYVFG
 KTDHIALRLLOPAALTNVNVFLCLPERNFSELTATIRFSVSGMQLLYRGALAR
 ELMAIDVRLMTQDQVPSHKGCSPEVTGNMFCAGYLDGSKDACKDGSGGPHATSYR
 GTWYLTGVSWGEGCAAVGVHVTVRSRYTEWLSRLMRSLKHGIGQRHFPF"
 Query Match 0.8%; Score 19.2; DB 1; Length 1619;
 Best Local Similarity 67.5%; Pred. No. 1.5e+02;
 Matches 27; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
 Qy 1096 GTTATCTTGCACTGTGAAGTGTGTGTGTGTGTGTGTG 1135
 Db 1610 GTTAAATGACACTCTCGAGAGATGTGTGTGTGTGTCG 1571
 RESULT 162
 AF306907 279 bp DNA linear VRT 23-JAN-2001
 LOCUS Brachyramphus marmoratus haplotype MMC ribosomal protein 40 gene,
 intron 5 and partial sequence.
 ACCESSION AF306907
 VERSION AF306907.1 GI:12382279
 KEYWORDS
 SOURCE Brachyramphus marmoratus
 ORGANISM Brachyramphus marmoratus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Archosauria; Aves; Neognathae; Charadriiformes; Alcidae;
 Brachyramphus.
 REFERENCE 1 (bases 1 to 279)
 AUTHORS Pacheco,N.M. and Friesen,V.L.
 TITLE A molecular investigation of hybridization in Brachyramphus
 murrelets
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 279)
 AUTHORS Pacheco,N.M. and Friesen,V.L.
 TITLE Direct Submission
 JOURNAL Submitted (21-SEP-2000) Department of Biology, Queen's University,
 Kingston, ON K7L 3N6, Canada
 FEATURES Location/Qualifiers
 source
 1. .279
 /organism="Brachyramphus marmoratus"
 /mol_type="genomic DNA"
 /db_xref="taxon:28694"
 /haplotype="MMC"
 join(<1..14,263..>279)
 /product="ribosomal protein 40"
 mRNA

```

/gene="CRYBB2"
/note="forward PCR primer"
49..181
/gene="CRYBB2"
/number=4
complement(223..244)
/note="reverse PCR primer"

primer_bind

Query Match
Best Local Similarity 0.8%; Score 19; DB 1; Length 244;
Matches 28; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 258 GGCACATACCGATTCCCTCTCTCTCCAAACACTTCTATTCT 300
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 193 GCCATCACCTACTCCCTCTCTCTGCCCATCATCCTACTTCT 235

RESULT 166
LOCUS AR263850 340 bp DNA linear PAT 29-JAN-2003
DEFINITION Sequence 28 from patent US 6331427.
ACCESSION AR263850
VERSION AR263850.1 GI:28075854
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 340)
AUTHORS Robison,K.E.
TITLE Protease homologs
JOURNAL Patent: US 6331427-A 28 18-DEC-2001;
FEATURES
source
1..340
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 18.8; DB 1; Length 340;
Matches 41; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

Qy 570 GTGCCACTTGTTATGACATCAGTAGTTCAGCTCCAGCATTTCTGTTTCGTTTTTGTGA 629
Db 156 GATACCCCTGAGTTTACACAGAAGTTAGTTTCTACAGAAATGGATTATTGATCACCTGA 97
Qy 630 GATGACCTAACTGTTGA 647
Db 96 GACAAGTTCCTGTTGA 79

RESULT 167
LOCUS AR263851 340 bp DNA linear PAT 29-JAN-2003
DEFINITION Sequence 29 from patent US 6331427.
ACCESSION AR263851
VERSION AR263851.1 GI:28075855
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 340)
AUTHORS Robison,K.E.
TITLE Protease homologs
JOURNAL Patent: US 6331427-A 29 18-DEC-2001;
FEATURES
source
1..340
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 18.8; DB 1; Length 340;
Matches 41; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

Qy 570 GTGCCACTTGTTATGACATCAGTAGTTCAGCTCCAGCATTTCTGTTTCGTTTTTGTGA 629

```


QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 175
AR081819/c
LOCUS 168 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 28 from patent US 5972645.
ACCESSION AR081819
VERSION AR081819.1 GI:10008545
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea serine protease nucleic acid molecules
JOURNAL Patent: US 5972645-A 28 26-OCT-1999;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACAGCACAAATCAATATTTGGTAATATTAGTCCTTCATTTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 176
AR098999/c
LOCUS 168 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 28 from patent US 6077687.
ACCESSION AR098999
VERSION AR098999.1 GI:12808765
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L. and Gaines,P.J.
TITLE Flea aminopeptidase nucleic acid molecules and uses thereof
JOURNAL Patent: US 6077687-A 28 20-JUN-2000;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACAGCACAAATCAATATTTGGTAATATTAGTCCTTCATTTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 177
AR116830/c

LOCUS 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6139840.
ACCESSION AR116830
VERSION AR116830.1 GI:14097736
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and Stiegler,G.L.
TITLE Methods of eliciting an antibody response using flea protease proteins and homologs thereof
JOURNAL Patent: US 6139840-A 28 31-OCT-2000;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACAGCACAAATCAATATTTGGTAATATTAGTCCTTCATTTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 178
AR127061/c
LOCUS 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6180383.
ACCESSION AR127061
VERSION AR127061.1 GI:14113654
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea leucine aminopeptidase proteins and uses thereof
JOURNAL Patent: US 6180383-A 28 30-JAN-2001;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACAGCACAAATCAATATTTGGTAATATTAGTCCTTCATTTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 179
AR141647/c
LOCUS 168 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 28 from patent US 6146870.
ACCESSION AR141647
VERSION AR141647.1 GI:15101163
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea protease proteins
JOURNAL Patent: US 6146870-A 28 14-NOV-2000;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;
QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAATTTTCTTTTGGTTTCTTGAAA 1705
DB 150 ATCAGGATAACACGACACAAATCATATTTTGGTAATTATTAGTCCTTCATTTCCATATAT 91
QY 1706 ATATTTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1758
DB 90 AGTTTGCACCTGAGTCCAGTTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38
RESULT 180
LOCUS ARL151537 168 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 28 from patent US 6232096.
ACCESSION ARL151537
VERSION ARL151537.1 GI:15117587
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L., Gaines,P.J. and Silver,G.
TITLE Flea serine protease nucleic acid molecules and uses thereof
JOURNAL Patent: US 6232096-A 28 15-MAY-2001;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;
QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAATTTTCTTTTGGTTTCTTGAAA 1705
DB 150 ATCAGGATAACACGACACAAATCATATTTTGGTAATTATTAGTCCTTCATTTCCATATAT 91
QY 1706 ATATTTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1758
DB 90 AGTTTGCACCTGAGTCCAGTTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38
RESULT 181
LOCUS I82435 168 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 28 from patent US 5712143.
ACCESSION I82435
VERSION I82435.1 GI:3210732
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea protease proteins, nucleic acid molecules, and uses thereof
JOURNAL Patent: US 5712143-A 28 27-JAN-1998;

FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;
QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAATTTTCTTTTGGTTTCTTGAAA 1705
DB 150 ATCAGGATAACACGACACAAATCATATTTTGGTAATTATTAGTCCTTCATTTCCATATAT 91
QY 1706 ATATTTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1758
DB 90 AGTTTGCACCTGAGTCCAGTTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38
RESULT 182
LOCUS HUMPRBS01/c 174 bp DNA linear PRI 08-JAN-1995
DEFINITION Human protein S pseudogene beta (PS-beta), exon 1.
ACCESSION M36565 J02918
VERSION M36565.1 GI:190309
KEYWORDS S protein.
SEGMENT 1 of 12
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 174)
AUTHORS Ploos van Amstel,H.K., Reitsma,P.H., van der Logt,C.P. and Bertina,R.M.
TITLE Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution
JOURNAL Biochemistry 29 (34), 7853-7861 (1990)
MEDLINE 91084445
PUBMED 2148111
COMMENT Original source text: Human DNA.
Draft entry and computer-readable sequence for [Biochemistry 29, 7853-4861 (1990)] kindly submitted by H.K.Ploos van Amstel, 13-JUL-1990.
FEATURES Location/Qualifiers
source 1..174
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="3p21-cen"
prim_transcript <1..>174
/notes="protein S pseudogene beta mRNA and introns"
exon 11..>168
/genes="PROS2"
/notes="protein S pseudogene beta; G00-120-757"
/number=1
/pseudo
exon 11..168
/genes="PROS2"
/notes="protein S pseudogene beta, exon 1 (AA at 11); G00-120-757; putative"
intron 169..>174
/genes="PROS2"
/notes="intron 2"
Query Match 0.8%; Score 18.6; DB 1; Length 174;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 310 TCTTGCTCATTTTAACTCAGTAGTCAGTTGTTGGTTTCCATAAGTTTGAAGTT 366
DB 116 TCTTCGATGATCTCTTTTCAAGATTACCCCTGTTGGTTTCTTCAAGTAAGAACTT 60

```
RESULT 183
AY135778S1/c
LOCUS      AY135778S14      189 bp      DNA      linear      PRI 23-SEP-2002
DEFINITION Gorilla gorilla HCR (HCR) gene, exon 14.
ACCESSION  AY135791
VERSION     AY135791.1  GI:23296123
KEYWORDS   .
SEGMENT    14 of 18
SOURCE     Gorilla gorilla (gorilla)
ORGANISM   Gorilla gorilla
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.
REFERENCE  1 (bases 1 to 189)
AUTHORS   Asumalahti,K. and Kere,J.
TITLE     HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and
            orangutan
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 189)
AUTHORS   Asumalahti,K. and Kere,J.
TITLE     Direct Submission
JOURNAL    Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum,
            University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki
            FIN-00014, Finland
FEATURES   Location/Qualifiers
            source            1..189
                                /organism="Gorilla gorilla"
                                /mol_type="genomic DNA"
                                /db_xref="taxon:9593"
            exon              1..189
                                /gene="HCR"
                                /number=14

Query Match      0.8%; Score 18.6; DB 1; Length 189;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTCTGCTGGCAATACCTCTGGGCTGTGCTTCTCCCT 185
    |||||
Db 52 TCTGTCCAGCTGCTGGCCACCTTGCTCAGCTGCTGCGCTCTGCCT 4

RESULT 184
AY135796S1/c
LOCUS      AY135796S14      189 bp      DNA      linear      PRI 23-SEP-2002
DEFINITION Pongo pygmaeus HCR (HCR) gene, exon 14.
ACCESSION  AY135809
VERSION     AY135809.1  GI:23296145
KEYWORDS   .
SEGMENT    14 of 18
SOURCE     Pongo pygmaeus (orangutan)
ORGANISM   Pongo pygmaeus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE  1 (bases 1 to 189)
AUTHORS   Asumalahti,K. and Kere,J.
TITLE     HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and
            orangutan
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 189)
AUTHORS   Asumalahti,K. and Kere,J.
TITLE     Direct Submission
JOURNAL    Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum,
            University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki
            FIN-00014, Finland
FEATURES   Location/Qualifiers
            source            1..189
                                /organism="Pongo pygmaeus"
                                /mol_type="genomic DNA"
                                /db_xref="taxon:9600"
            exon              1..189
                                /gene="HCR"
                                /number=14

Query Match      0.8%; Score 18.6; DB 1; Length 189;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTCTGCTGGCAATACCTCTGGGCTGTGCTTCTCCCT 185
    |||||
Db 52 TCTGTCCAGCTGCTGGCCACCTTGCTCAGCTGCTGCGCTCTGCCT 4

RESULT 185
AY135796S1/c
LOCUS      AY135796S14      189 bp      DNA      linear      PRI 23-SEP-2002
DEFINITION Pongo pygmaeus HCR (HCR) gene, exon 14.
ACCESSION  AY135809
VERSION     AY135809.1  GI:23296145
KEYWORDS   .
SEGMENT    14 of 18
SOURCE     Pongo pygmaeus (orangutan)
ORGANISM   Pongo pygmaeus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE  1 (bases 1 to 189)
AUTHORS   Asumalahti,K. and Kere,J.
TITLE     HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and
            orangutan
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 189)
AUTHORS   Asumalahti,K. and Kere,J.
TITLE     Direct Submission
JOURNAL    Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum,
            University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki
            FIN-00014, Finland
FEATURES   Location/Qualifiers
            source            1..189
                                /organism="Pongo pygmaeus"
                                /mol_type="genomic DNA"
                                /db_xref="taxon:9600"
            exon              1..189
                                /gene="HCR"
                                /number=14

Query Match      0.8%; Score 18.6; DB 1; Length 189;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTCTGCTGGCAATACCTCTGGGCTGTGCTTCTCCCT 185
    |||||
Db 52 TCTGTCCAGCTGCTGGCCACCTTGCTCAGCTGCTGCGCTCTGCCT 4
```

```
Query Match      0.8%; Score 18.6; DB 1; Length 189;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTCTGCTGGCAATACCTCTGGGCTGTGCTTCTCCCT 185
    |||||
Db 52 TCTGTCCAGCTGCTGGCCACCTTGCTCAGCTGCTGCGCTCTGCCT 4

RESULT 195
AR047835/c
LOCUS      AR047835      200 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5817798.
ACCESSION  AR047835
VERSION     AR047835.1  GI:5969300
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
            Unclassified.
REFERENCE  1 (bases 1 to 200)
AUTHORS   Gundling,G.J.
TITLE     Rapid RNA isolation procedure in the presence of a transition metal
            ion
JOURNAL    Patent: US 5817798-A 1 06-OCT-1998;
FEATURES   Location/Qualifiers
            source            1..200
                                /organism="unknown"
                                /mol_type="unassigned DNA"

Query Match      0.8%; Score 18.6; DB 1; Length 200;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 217 TCTCTCTCCCTTCTTACACTTCTGGGCCAGGTAGGGSCACTACCGCATTC 273
    |||||
Db 60 TCTCGACTCCAGCTCCCAATCCAGATGAGGTAGGGTGACGACCAATCC 4

RESULT 186
AX260845
LOCUS      AX260845      222 bp      DNA      linear      PAT 26-OCT-2001
DEFINITION Sequence 496 from Patent WO0173027.
ACCESSION  AX260845
VERSION     AX260845.1  GI:16509812
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Meagher,M.J., Xu,J. and King,G.E.
TITLE     Compositions and methods for therapy and diagnosis of colon cancer
JOURNAL    Patent: WO 0173027-A 496 04-OCT-2001;
            CORIXA CORPORATION (US)
FEATURES   Location/Qualifiers
            source            1..222
                                /organism="Homo sapiens"
                                /mol_type="unassigned DNA"
                                /db_xref="taxon:9606"

Query Match      0.8%; Score 18.6; DB 1; Length 222;
Best Local Similarity 53.4%; Pred. No. 2e+02;
Matches 39; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 414 TGGTCAGATAGGACATAGATATTATTTCAATTGCTTTTATCTGTCGAGACTTGT 473
    |||||
Db 138 TGGTTGGGTGCTCAGAGAGATGTTTCCGCTTTAGTCCCTGTGGGATGCCTTTG 197
    |||||
QY 474 TTTTGAATATATGT 486
    |||||
Db 198 TTATGCAGAAAGT 210
    |||||
```

```

RESULT 187
HS88A12F
LOCUS HS88A12F 241 bp DNA linear PRI 22-OCT-1995
DEFINITION H.sapiens CpG island DNA genomic MseI fragment, clone 88a12,
forward read cp388a12.ft1a.
ACCESSION Z63614
VERSION Z63614.1 GI:1035992
KEYWORDS CpG island; genomic MseI fragment.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 241)
AUTHORS MacDonald,M., Huckle,E., Wilkinson,P. and Micklem,G.
TITLE Direct Submission
JOURNAL Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire,
CB10 1RQ, England. E-mail contact: humquery@sanger.ac.uk
COMMENT Vector: pGEM-5zf(-)
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: biohelp@hgmp.mrc.ac.uk.
FEATURES
Location/Qualifiers
source 1..241
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="88a12"
/sex="male"
/tissue type="blood"
/clone.lib="CGI-1"
/dev_stage="adult"

Query Match 0.8%; Score 18.6; DB 1; Length 241;
Best Local Similarity 55.4%; Pred. No. 2e+02;
Matches 36; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1710 TTTCCTGCTTTGACCTGCTTCCCTTCCTCTATTCCTTTGTTTGCATAGTG 1769
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
175 TTTCCTGCTGTCGCGAGGCGCTTCCCGTCGAGTTGCCATTATTTTCAAGGAG 234
QY 1770 TCCTCT 1774
Db 235 GTTTT 239

RESULT 188
AR162089
LOCUS AR162089 289 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 17 from patent US 6258558.
ACCESSION AR162089
VERSION AR162089.1 GI:16229155
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 289)
AUTHORS Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE Method for selection of proteins using RNA-protein fusions
JOURNAL Patent: US 6258558-A 17 10-JUL-2001;
FEATURES Location/Qualifiers
source 1..289
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 289;
Best Local Similarity 21.4%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCAATTTTAACTCAGTAGTGAGTTGTTTCCATPAAG 356
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
115 TTCTGGCTCTTAAGGAGACACCTTTTCCCAATGTAACCTGTAATCCATTGAGGTAG 174
QY 357 TTCTGATTTTCTGTTGTTTCTGTTGTTTCTGTTGTTTCTGTTGTTTGT 393
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
175 CTTCCACATTGGTGTAGTAGTCCATAGTTGTTGTTGT 211

RESULT 191
AX553022

```

```

Matches 12; Conservative 27; Mismatches 17; Indels 0; Gaps 0;

QY 1110 GTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1165
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
4 GRGARCRARATRTTRACRTRARTRTRTRARCRARATRTTRACRARATRGRR 59

RESULT 189
AR166614
LOCUS AR166614 289 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 17 from patent US 6281344.
ACCESSION AR166614
VERSION AR166614.1 GI:16242009
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 289)
AUTHORS Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE Nucleic acid-protein fusion molecules and libraries
JOURNAL Patent: US 6281344-A 17 28-AUG-2001;
FEATURES Location/Qualifiers
source 1..289
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 289;
Best Local Similarity 21.4%; Pred. No. 2.1e+02;
Matches 12; Conservative 27; Mismatches 17; Indels 0; Gaps 0;

QY 1110 GTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1165
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
4 GRGARCRARATRTTRACRTRARTRTRTRARCRARATRTTRACRARATRGRR 59

RESULT 190
AX524284
LOCUS AX524284 427 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 314 from Patent EP1236798.
ACCESSION AX524284
VERSION AX524284.1 GI:25169380
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Hoefler,M., Hofmann,M., Kaiser,C., Kranz,H., Loebbert,R. and
Schlueter,T.
TITLE Gene library and method for its production
JOURNAL Patent: EP 1236798-A 314 04-SEP-2002;
FEATURES Location/Qualifiers
source 1..427
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 18.6; DB 1; Length 427;
Best Local Similarity 49.5%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCAATTTTAACTCAGTAGTGAGTTGTTTCCATPAAG 356
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
115 TTCTGGCTCTTAAGGAGACACCTTTTCCCAATGTAACCTGTAATCCATTGAGGTAG 174
QY 357 TTCTGATTTTCTGTTGTTTCTGTTGTTTCTGTTGTTTCTGTTGTTTGT 393
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
175 CTTCCACATTGGTGTAGTAGTCCATAGTTGTTGTTGT 211

RESULT 191
AX553022

```

LOCUS AX553022 427 bp DNA linear PAT 27-NOV-2002
 DEFINITION Sequence 314 from Patent WO02074953.
 ACCESSION AX553022
 VERSION AX553022.1 GI:25897022
 KEYWORDS Mus musculus (house mouse)
 SOURCE
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1
 REFERENCE Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and Schluerer, T.
 AUTHORS Gene library and a method for producing the same
 TITLE Patent: WO 02074953-A 314 26-SEP-2002;
 JOURNAL LION Bioscience AG (DE)
 FEATURES Location/Qualifiers
 source
 1..427
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"
 Query Match 0.8%; Score 18.6; DB 1; Length 427;
 Best Local Similarity 49.5%; Pred. No. 2.1e+02;
 Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
 QY 297 TTCTTGATTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
 |||||
 DB 115 TTCTGGCTTTAAGGAGACACCCCTTTTCCCAATGTAAGTCCATTCATTTGAGGTAG 174
 |||||
 QY 357 TTTGTAAGTTTCTGTTGTTCTTCTGTTGTTGTTGTTGT 393
 |||||
 DB 175 CTTCACACTTGTGTAGATGCCATAGTTGTTGGTGT 211
 |||||

RESULT 192
 MACFPX/c
 LOCUS AX277349/1 439 bp DNA linear PAT 29-OCT-2001
 DEFINITION Sequence 7 from Patent WO0174897.
 ACCESSION AX277349
 VERSION AX277349.1 GI:16548914
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1
 REFERENCE Vernet, C.A., Burgess, C.E., Fernandes, E., Taupier, R.J., Quinlan, K.E.,
 AUTHORS Spytek, K.A., Rastelli, L. and Herrmann, J.L.
 TITLE Novel proteins and nucleic acids encoding same
 JOURNAL Patent: WO 0174897-A 7 11-OCT-2001;
 Curagen Corporation (US)
 FEATURES Location/Qualifiers
 source
 1..439
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 <2..295
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="CAD10333.1"
 /db_xref="GI:16548915"
 /db_xref="REMBL:CAD10333"
 /translation="HGNKPGVPPLISNKNRVDVYGGIISPSMLCAGYLITGVDSQC
 GPSGGPLVCQERLKLVGATSFSGICAEVKNPGVYVTPSPWSTGTSRWREI"
 CDS
 0.8%; Score 18.6; DB 1; Length 439;
 Best Local Similarity 57.9%; Pred. No. 2.1e+02;
 Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
 Query Match
 QY 143 AGCTCTGTCGCAATACCTTCTGGGCTGCTGCTTCTCCCTGCTGATTCCTAGG 199
 |||||
 DB 174 AGCTCTCTCTTGTGACACACAGGGGGCCCCCGCTGTCCCTGGCAGCTGCCAG 118
 |||||

RESULT 193
 MACFPX/c
 LOCUS AX277375/1 439 bp DNA linear PAT 29-OCT-2001
 DEFINITION Sequence 33 from Patent WO0174897.
 ACCESSION AX277375
 VERSION AX277375.1 GI:16548940
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1
 REFERENCE Vernet, C.A., Burgess, C.E., Fernandes, E., Taupier, R.J., Quinlan, K.E.,
 AUTHORS Spytek, K.A., Rastelli, L. and Herrmann, J.L.
 TITLE Novel proteins and nucleic acids encoding same
 JOURNAL Patent: WO 0174897-A 33 11-OCT-2001;
 Curagen Corporation (US)
 FEATURES Location/Qualifiers
 source
 1..439
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 18.6; DB 1; Length 439;
 Best Local Similarity 57.9%; Pred. No. 2.1e+02;
 Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
 QY 143 AGCTCTGTCGCAATACCTTCTGGGCTGCTGCTTCTCCCTGCTGATTCCTAGG 199
 |||||
 DB 174 AGCTCTCTCTTGTGACACACAGGGGGCCCCCGCTGTCCCTGGCAGCTGCCAG 118
 |||||

RESULT 194
 MACFPX/c
 LOCUS AX277375/2 484 bp DNA linear PRI 05-FEB-1999
 DEFINITION Rhesus monkey gene for coagulation factor X, partial cds.
 ACCESSION D21214
 VERSION D21214.1 GI:415307
 KEYWORDS coagulation factor X.
 SOURCE Macaca mulatta (rhesus monkey)
 ORGANISM Macaca mulatta
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
 Cercopithecinae; Macaca.
 1 (bases 1 to 484)
 REFERENCE Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and
 AUTHORS Niho, Y.
 TITLE Analysis of the partial nucleotide sequences and deduced primary
 structures of the protease domains of mammalian blood coagulation
 factors VII and X
 JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
 MEDLINE 94222160
 PUBMED 8168596
 REFERENCE Murakawa, M.
 AUTHORS Direct Submission
 TITLE Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General
 JOURNAL Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
 Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
 COMMENT Submitted (18-Oct-1993) to DDBJ by:
 Masahiro Murakawa
 Division of Hematology
 Harasanshin General Hospital
 1-8 Taihaku-machi, Hakata-ku
 Fukuoka, Fukuoka 812
 Japan
 Phone: 092-291-3434
 Fax : 092-291-3266.
 FEATURES Location/Qualifiers
 source
 1..484
 /organism="Macaca mulatta"
 /mol_type="genomic DNA"

```
/db_xref="taxon:9544"
<1_>484
/product="coagulation factor X"
/protein_id="BAA04755.1"
/db_xref="GI:455395"
/translation="EGGEAVHEVEVLIKHNRFTKETYDFDIIVLRLKSPITFRMNVAP
ACLPEDMASTLMTQKIGIVSGRTHKGRQSTRLKMLEVPYVDNRNSCKLSSFFII
TQMFCAGYHAKQEDACQDGSGGPHVTRFDYFVTGIVSWGECGARKGYIYTKVT
A"

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 484;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAGCTGTGGTGTC 418
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 317 TGTTCGGTGATGATGAAGCTGCTGCAGAGCTTGCGAGCTGTTGCGGTC 269

RESULT 195
AX775014/c
LOCUS AX775014 546 bp DNA linear PAT 09-JUL-2003
DEFINITION Sequence 330 from Patent WO03038129.
ACCESSION AX775014
VERSION AX775014.1 GI:32486530
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Raponi,M.
TITLE Methods for assessing and treating leukemia
JOURNAL Patent: WO 03038129-A 330 08-MAY-2003;
Ortho-Clinical Diagnostics, Inc. (US)
FEATURES
source
1..546
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 546;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 143 AGCTCTGCTGGAATACCTCTCGGGCTGCTGCTTCTCCCTGCTGATTCCTAGG 199
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 336 AGCTCTCTCTTGACACACAGGGGCCCCCGCTGTCCCTGGCAGCTGCCAG 280

RESULT 196
AX335885/c
LOCUS AX335885 624 bp DNA linear PAT 09-JAN-2002
DEFINITION Sequence 6394 from Patent WO0194629.
ACCESSION AX335885
VERSION AX335885.1 GI:18126604
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Young,P.E., Augustus,M., Carter,K.C., Ebner,R., Endress,G.,
Horrigan,S., Soppet,D.R. and Weaver,Z.
TITLE Cancer gene determination and therapeutic screening using signature
gene sets
JOURNAL Patent: WO 0194629-A 6394 13-DEC-2001;
Avalon Pharmaceuticals (US)
FEATURES
source
1..624
/organism="Homo sapiens"
/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 624;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAGCTGTGGTGTC 418
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 351 TGTTCGGTGATGATGAAGCTGCTGCAGAGCTTGCGAGCTGTTGCGGTC 303

RESULT 197
HUMFX8/c
LOCUS HUMFX8 624 bp DNA linear PRI 09-NOV-1994
DEFINITION Human factor X (blood coagulation factor) gene, exon 8.
ACCESSION L29433 M14327 N00045
VERSION L29433.1 GI:459809
KEYWORDS Stuart factor; blood coagulation factor; factor X; glycoprotein;
serine protease.
SEGMENT 8 of 8
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Leytus,S.P., Foster,D.C., Kurachi,K. and Davie,E.W.
TITLE Gene for human factor X: a blood coagulation factor whose gene
organization is essentially identical with that of factor IX and
protein C
JOURNAL Biochemistry 25 (18), 5098-5102 (1986)
MEDLINE 87028600
PUBMED 3768336
COMMENT Original source text: Homo sapiens (tissue library: of Lawn et al.,
and Yoshitake et al.) DNA.
FEATURES
matp + 13 + 458 factor Xa heavy chain.
source
1..624
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="13q34"
/tissue_lib="of Lawn et al., and Yoshitake et al."
join(L00390.1:26..95,L00391.1:13..173,L00392.1:13..37,
L00393.1:13..126,L00394.1:13..144,L00395.1:13..257,
L00396.1:13..130,13..614)
/notes="preprofactor X"
/codon_start=1
/product="coagulation factor X"
/protein_id="AAA52764.1"
/db_xref="GI:182831"
/translation="MGRPLHLVLLSLAGLLGLLGLSFLIRREQANNILARVTRANSF
LEEMKKHLERECMEETCSYEAREVEFSDKTNEFNWYKDGQDQCTSPCQNGCK
DGLGYTCCTLEGEGKNCLEFTRKCLSDNGDCDFCHEEQNSVVCSCARGYTLADN
GKACIPTGVPCKGKOTLERKSVACQATSSSGEAPDSITWKPYDAADLPTEPNPDL
DFNQTPERGDNLRIVGGCKGECQWALLINEEGFCGTLSEFLYLTAH
CLYAKRFKRVGRDNRTEGEGEAVEVEVHKHNRFTKETYDFDIIVLRLKSPITF
RMNVAPACLPEDMASTLMTQKIGIVSGRTHKGRQSTRLKMLEVPYVDNRNSCKL
SSSFIITQMFCAGYHAKQEDACQDGSGGPHVTRFDYFVTGIVSWGECGARKGYK
IYTKVTAFLKWDKRLGRLPKAKSHAPEVITSSPLK"
join(L00395.1:57..257,L00396.1:13..130,13..458)
/product="coagulation factor X"
/notes="factor X light chain"
459..611
/product="activation peptide"
<1..12
/notes="FX intron G"
13..624
/notes="FX"
/number=8

mat_peptide
mat_peptide
intron
exon

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 624;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
```

[illegible]


```

Db      255 ATCTGGCAGCATTACAACTGCTCATTTGCCCTCAAGGACATGATGTTGGCTCTCCC 196
Qy      1766 AGTGTCTGTGGCTCCTGGAGTTT 1790
Db      195 AGTCTCACTGGATCGGGGACTTAT 171

RESULT 201
DOGTYPY  DOGTYPY
LOCUS     Dog pancreatic anionic trypsinogen mRNA.
DEFINITION
ACCESSION M11589
VERSION    M11589.1 GI:164094
KEYWORDS
SOURCE     Canis sp.
ORGANISM   Canis sp.
REFERENCE  1 (bases 1 to 819)
AUTHORS    Pinsky,S.D., LaForge,K.S. and Scheele,G.
TITLE      Differential regulation of trypsinogen mRNA translation:
            trypsinogen isoenzymes in the dog pancreas
JOURNAL    Mol. Cell. Biol. 5 (10), 2669-2676 (1985)
MEDLINE    86284628
PUBMED     3841794
COMMENT    Original source text: Dog pancreas, cDNA to mRNA, clone pT1.
FEATURES   source
            Location/Qualifiers
            1..819
            /organism="Canis sp."
            /mol_type="mRNA"
            /db_xref="taxon:9616"
            1..819
            /product="anionic trypsinogen mRNA"
            15..758
            /note="anionic trypsinogen precursor"
            /codon_start=1
            /protein_id="AAA30899.1"
            /db_xref="GI:164095"
            /translation="MNPILLILAFGLAAVATPTDDDDKIVGGYTCENSVFYQVSLNAG
            YHFCGSLISDQWVSAHCKYKRIQVRLGEYNIIDVLEGNQEFINSKVRHPNYSNW
            ILNDIMLIKLSPPAVLNARVATISLPACAAPTQCLISGWNTLSGGNYPELLQC
            LDAPILTQAOCSEASYPQITENMTCAGFLGGKDCSCGDSGGPWCNGELQGIVSWG
            YGCAQKNKPGYVTKVNFVMIQSTIANS"

Query Match      0.8%; Score 18.6; DB 1; Length 819;
Best Local Similarity 50.6%; Pred. No. 2.1e+02;
Matches 45; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy      882 GCTTGCTCTTAGGGCCATTGCTTAGAATATCTTTCCATCTTTACTCTAAGGTGAT 941
Db      531 GCCTCTACCCGCCGACATCAGGAGAACATATTTGCGCGGCTCTCTTGAGGGAGGC 590
Qy      942 GTCATCCATGGTAGGTGTCTTTTGG 970
Db      591 AAGGACTCCTGCCAGGCTGACTCTGTTGG 619

RESULT 202
PVTRYPSIN
LOCUS     P.vannamei mRNA for trypsin.
DEFINITION
ACCESSION X86369
VERSION    X86369.1 GI:785034
KEYWORDS   trypsin.
SOURCE     Litopenaeus vannamei (Pacific white shrimp)
ORGANISM   Litopenaeus vannamei
            Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;
            Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;
            Penaeidae; Litopenaeus.
REFERENCE  1
AUTHORS    Klein,B., Le Moullac,G., Sellos,D. and Van Wormhoudt,A.

```

```

TITLE      Molecular cloning and sequencing of trypsin cDNAs from Penaeus
vannamei (Crustacea, Decapoda): use in assessing gene expression
            during the moult cycle
JOURNAL    Int. J. Biochem. Cell Biol. 28 (5), 551-563 (1996)
MEDLINE    96252881
PUBMED     8697100
REFERENCE  2 (bases 1 to 854)
AUTHORS    Van Wormhoudt,A.E.
TITLE      Direct Submission
JOURNAL    CNRS, Laboratoire de Biologie Marine, BP 225, 29182 Concarneau,
            FRANCE
FEATURES   source
            Location/Qualifiers
            1..854
            /organism="Litopenaeus vannamei"
            /mol_type="mRNA"
            /db_xref="taxon:6689"
            /tissue_type="hepatopancreas"
            /dev_stage="adult"
            3..803
            /EC_number="3.4.21.4"
            /codon_start=1
            /product="trypsin"
            /protein_id="CAA60129.1"
            /db_xref="GI:785035"
            /db_xref="GOA:Q27761"
            /db_xref="SPTREMBL:Q27761"
            /translation="MKTLLICVLILAGAAFAAPSRKPTFRRLKIVGTGDTATPGELPYQ
            LSFQDISFPAWHFCGASIVNENWAI CAGHCVGEGNMNPDYLOVAVAGENODVDEGT
            EOTVILSKIIHQEDYNGFTISNDISLKLSQLSFNDNVRALDIPAGCHAASGDCIVS
            GWGTTSEGGSTPSVLQKVTVPVIVSDDEKRAYQSDIEDSMICAGVPEPGKDSQCQGDS
            GGPLACSDTASTYLAGIVSWGVCARGPGYGVVAEVSHYVDWIKANAV"
            3..41
            sig_peptide

Query Match      0.8%; Score 18.6; DB 1; Length 854;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy      719 TGTTTATGAACCTGGGTGACATGTTGTTGGTGCATAGACATTAAGAA 767
Db      797 TGTTTATCAAGTGTGTTTAAACATGACTTACCTTGAAGCAATAAGAA 845

RESULT 203
AF465268/c
LOCUS     Gallus gallus coagulation factor VII precursor (F7) mRNA, complete
DEFINITION cds.
ACCESSION AF465268
VERSION    AF465268.1 GI:28194007
KEYWORDS   Gallus gallus (chicken)
SOURCE     Gallus gallus
ORGANISM   Gallus gallus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE  1 (bases 1 to 1278)
AUTHORS    Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
            Tuddenham,E.G.D. and McVey,J.H.
TITLE      Comparative sequence analysis and molecular evolution of blood
            coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 1278)
AUTHORS    McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
TITLE      Direct Submission
JOURNAL    Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
            Centre, The Faculty of Medicine, Imperial College, Hammersmith
            Campus, Du Cane Road, London W12 0NN, UK
FEATURES   source
            Location/Qualifiers
            1..1278
            /organism="Gallus gallus"
            /mol_type="mRNA"
            /db_xref="taxon:9031"

```



```
Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTTTCGGGTC 1156

RESULT 206
A86886/c
LOCUS A86886 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION A86886
VERSION A86886.1 GI:6735677
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M. and Eibl,J.
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL PATENT: WO 9838317-A 26 03-SEP-1998;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
    source
        1..1467
            /organism="unidentified"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32644"
    CDS
        1..1467
            /notes="unnamed protein product"
            /codon_start=1
            /protein_id="CAB69368.1"
            /db_xref="GI:6735678"
            /db_xref="REMBL:CAB69368"
            /translations="MGRPLHLVLLSLASGLLLGLRSLFRREQANNILARVTRANSP
LEBMKGHLERECWEFTCSVEEARVFEVSDKTNFKNKYKDGDCQETSPCONQKCK
DGLGEYCTCLEGEGKNCFLFRKLCSLDNGCDQFCHEEQNVVCSARGYTLADN
GXACITGTPYPCQKDLERRKRSVAQTSNGSGEAPDSITWKPYDAADLDPENFDLL
DFNQTFERDNNLIRIVGQCKGECQPCWALLINEENEGFCGGTILSEFYLTAAH
CLYQAKRVKVRDRTNEQEGEAEVVEVWIKHNRFTKETVDFDIAVLRLKPTIF
RMNVAPACLPERDWAESTLTKTQTVISGFRTHKGRQSTRLKMLEVPPVDRNSCKL
SSSEFIITQNMFCAGYDKQEDACQSDSGSPHVTFRPKDVFVTGIVSWGESCARKYKG
IYTKVTAFLKNWIDRSMKTRGLPKAKSHAPVITSSPLK"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTTTCGGGTC 1156

RESULT 207
AR316969/c
LOCUS AR316969 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 43 from patent US 6562598.
ACCESSION AR316969
VERSION AR316969.1 GI:33696092
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Pfeleiderer,M., Falkner,F.-G., Eibl,J., Dorner,F.
and Schlokot,U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL PATENT: US 6562598-A 43 13-MAY-2003;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
    source
        1..1467
            /organism="unknown"
            /mol_type="mRNA"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTTTCGGGTC 1156

RESULT 208
AR340866/c
LOCUS AR340866 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6573071.
ACCESSION AR340866
VERSION AR340866.1 GI:33732713
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Schlokot,U., Dorner,F., Fisch,A. and Eibl,J.
TITLE Factor X analogues with a modified protease cleavage site
JOURNAL PATENT: US 6573071-A 26 03-JUN-2003;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
    source
        1..1467
            /organism="unknown"
            /mol_type="mRNA"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTTTCGGGTC 1156

RESULT 209
AX082959/c
LOCUS AX082959 1467 bp DNA linear PAT 28-FEB-2001
DEFINITION Sequence 1 from Patent WO0110896.
ACCESSION AX082959
VERSION AX082959.1 GI:13184880
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Himmelspach,M. and Schlokot,U.
TITLE Factor X analog with an improved ability to be activated
JOURNAL PATENT: WO 0110896-A 1 15-FEB-2001;
BAXTER AKTIENGESELLSCHAFT (AT)
FEATURES
    source
        1..1467
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTTTCGGGTC 1156

RESULT 210
BD070392/c
LOCUS BD070392 1467 bp DNA linear PAT 27-AUG-2002
DEFINITION Factor X-analogues with modified protease cleavage site.
```

ACCESSION BD070392
VERSION BD070392.1 GI:22615995
KEYWORDS JP 2001513631-A/26.
SOURCE unclassified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Schlokot,U., Dörner,F., Andreas, Fisch and Eibl,J.
TITLE Factor X-analogues with modified protease cleavage site
JOURNAL Patent: JP 2001513631-A 26 04-SEP-2001;
BAXTER AG
COMMENT OS Unidentified
PN JP 2001513631-A/26
LOCUS PD 04-SEP-2001
PF 27-FEB-1998 JP 1998537062
PR 27-FEB-1997 AT A 335/97
PI MICHELE HIMMELSPACH,UWE SCHLOKAT,FRIEDRICH DÖRNER,ANDREAS PI
FISCH,JOHANN EIBL
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X-analogues with modified protease cleavage site FH
Key CDS Location/Qualifiers
FT 1..1467.
CDS
1..1467
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTCTGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGGTC 1156
RESULT 211
BD070435/c
LOCUS BD070435 1467 bp DNA linear PAT 27-AUG-2002
DEFINITION Factor X deletion mutants and analogues thereof.
ACCESSION BD070435
VERSION BD070435.1 GI:22616038
KEYWORDS JP 2001513632-A/43.
SOURCE unclassified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Pfleiderer,M., Falkner,F.G., Eibl,J., Dörner,F. and
Schlokot,U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: JP 2001513632-A 43 04-SEP-2001;
BAXTER AG
COMMENT OS Unidentified
PN JP 2001513632-A/43
LOCUS PD 04-SEP-2001
PF 27-FEB-1998 JP 1998537063
PR 27-FEB-1997 AT A 336/97
PI MICHELE HIMMELSPACH,MICHAEL PFLEIDERER,FALKO GÜNTHER FALKNER,
JOHANN EIBL,
PI FRIEDRICH DÖRNER,UWE SCHLOKAT
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X deletion mutants and analogues thereof FH
Key CDS Location/Qualifiers
FT 1..1467.
CDS
1..1467
/organism="unidentified"
/mol_type="genomic DNA"

/db_xref="taxon:32644"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTCTGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGGTC 1156
RESULT 212
AF191307/c
LOCUS AF191307 1514 bp mRNA linear MAM 01-NOV-2000
DEFINITION Sus scrofa protein C mRNA, complete cds.
ACCESSION AF191307
VERSION AF191307.1 GI:11065893
KEYWORDS Sus scrofa (pig)
SOURCE Sus scrofa
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 1514)
AUTHORS Grimm,D.R., Colter,M.B. and Kim,H.
TITLE Cloning of the complete cDNA sequences encoding porcine factor V
and protein C
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1514)
AUTHORS Grimm,D.R., Colter,M.B. and Kim,H.
TITLE Direct Submission
JOURNAL Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
North Pine Drive, Tampa, FL 33612, USA
FEATURES
Location/Qualifiers
1..1514
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="92N.4; 58/86.2; 12N3.1"
/tissue type="liver"
22..1401
/note="serine protease"
/codon_start=1
/product="protein C"
/protein_id="AAG28380.1"
/db_xref="GI:11065894"
/translation="MWQLASLLILIIWVSVTPVPDVSFSSORAHQMLSKRANS
FLEELRPSLRECKEETCDPEAREIFQNTENTWAFWSKHGDCQAVSPPEHLCD
PCCGRGTCIDGLGFRCDCAQWEGRCFHEVRFNSCTENGCGCHYCLFEEGRCA
CAPGYRLGDDHLQCEPKVRPCGRGLNRMKRNKRDITDQVKEDQIDRLVNGK
QSPWGESPWQVILLDSKKKACGAVLIHVSWLTAACLDYKKLTVRLGEYDLRRRE
KWEVDLDIKELVHPNTYRSDNDIALRLAEPATFSQTIPICLPDSGLSERELTR
VQGETVTVGWYRSEAKTRNSFILNFIKVPVAPHNECVQAMHNKISENMLCAGILGDS
RDCEGDSGPMVASFRGTWFLVGLVSNWEGCGRLHNYGVYTKVSRYLWDIWHIRME
EAFHNQVP"
Query Match 0.8%; Score 18.6; DB 1; Length 1514;
Best Local Similarity 51.9%; Pred. No. 2e+02;
Matches 42; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 1948 CAGATTTCCTTCAGTTTGGTGTGTTTATTAATTAATTCACATTCAGTCTGCTGAAA 2007
DB 657 CGGATCTATTGGTCTCTCTTTTGTCACTGGTCTGTATCAGCTTCAAGTCTCTGCG 598
QY 2008 TGTCTTACTCAATTTCTCCCTCC 2028
DB 597 TTCTCTCCATGCGATTCCC 577
RESULT 213
HUMKALR4
LOCUS HUMKALR4 193 bp DNA linear PRI 06-JAN-1995
DEFINITION Human renal kallikrein, exon 4.
ACCESSION M33108


```

old_sequence      /replace="cctccccgcagagaattac"
                  249
                  /gene="DPB1"
                  /citation=[1]
                  /replace="cgccgaggtgagtgggct"

```

```

Query Match      0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

```

```

QY 1906 TTGCTCTGAGGTTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTG 1965
DB 218 TTGTGTCGCATCTCTGTCGGCACTGCCCGCTTCTCTCCAGGATGCTCTTGGGTG 159

```

```

RESULT 216
HUMDPBB/c       HUMDPBB       249 bp      DNA      linear      PRI 14-APR-2000
LOCUS          Human MHC class II HLA-DP beta, partial cds, clone:SSK2.
DEFINITION
ACCESSION      D10479.1 GI:219606
VERSION        HLA-DP beta; DPB1; MHC; human leukocyte antigen; major
KEYWORDS       histocompatibility complex class II molecule.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

```

REFERENCE      1 (sites)
AUTHORS        Mitsunaga,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K.,
Akaza,T., Mitomi,Y. and Juji,T.
TITLE          Family study on HLA-DPB1 polymorphism: linkage analysis with
HLA-DR/DQ and two 'new' alleles
JOURNAL        Hum. Immunol. 34 (3), 203-211 (1992)
MEDLINE        93053849
PUBMED         1359867
REFERENCE      2 (bases 1 to 249)
AUTHORS        Mitsunaga,S.
JOURNAL        Unpublished
COMMENT        Submitted (17-Feb-1992) to DDBJ by:
Katsushi Tokunaga
Dept. of Transfusion Medicine and
Immunohematology, Faculty of Medicine
The University of Tokyo
7-3-1 Hongo, Bunkyo-ku
Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.

```

```

FEATURES       source
                Location/Qualifiers
                1..249
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /isolate="THMI"
                /db_xref="taxon:9606"
                /chromosomes="6"
                /clone="SSK2"
                /cell_type="peripheral blood mononuclear cell"
                1..249
                /gene="DPB1"
                <1..>249
                /gene="DPB1"
                /codon_start=1
                /product="HLA-DP beta"
                /protein_id="BAA01282.1"
                /db_xref="GI:219607"
                /translation="VYQLQECYAFNGTQFLERYLYNREELVRFSDVGEFRAVTEL
GRPEAYWNSQDILEEKRAVDFMRCHNYELDEAVTLQ"

```

```

gene           /gene="DPB1"
                1..249
                /gene="DPB1"
                /number=2
                /gene="DPB1"
                /citation=[1]
CDS
exon
old_sequence

```

```

old_sequence      /replace="cctccccgcagagaattac"
                  249
                  /gene="DPB1"
                  /citation=[1]
                  /replace="cgccgaggtgagtgggct"

```

```

Query Match      0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1906 TTGCTCTGAGGTTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTG 1965
DB 218 TTGTGTCGCATCTCTGTCGGCACTGCCCGCTTCTCTCCAGGATGCTCTTGGGTG 159

```

```

RESULT 217
HUMDPBB/c       HUMDPBB       249 bp      DNA      linear      PRI 07-JAN-1995
LOCUS          Human MHC class II HLA-DP-beta gene, exon 2 allele DPB5.
DEFINITION
ACCESSION      M23680
VERSION        M23680.1 GI:188070
KEYWORDS       HLA-DP antigen; cell surface glycoprotein; class II gene; integral
membrane protein; major histocompatibility complex.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

```

REFERENCE      1 (bases 1 to 249)
AUTHORS        Bugawan,T.L., Horn,G.T., Long,C.M., Mickelson,B., Hansen,J.A.,
Ferrara,G.B., Angelini,G. and Erlich,H.A.
TITLE          Analysis of HLA-DP allelic sequence polymorphism using the in vitro
enzymatic DNA amplification of DP-alpha and DP-beta loci
JOURNAL        J. Immunol. 141 (11), 4024-4030 (1988)
MEDLINE        89035547
PUBMED         2460556
REFERENCE      Original
FEATURES       source text: Human DNA allele DPB5.
                Location/Qualifiers
                1..249
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /map="p21.3"
                1..249
                /gene="HLA-DPB1"
                <1..>249
                /gene="HLA-DPB1"
                /note="MHC DP-beta, allele DPB5"
                /number=2
                /codon_start=1
                /protein_id="AAA59745.1"
                /db_xref="GI:188071"
                /db_xref="GDB:G00-120-636"
                /translation="LFGQECYAFNGTQFLERYLYNREELVRFSDVGEFRAVTEL
GRPEAYWNSQDILEEKRAVDFMRCHNYELDEAVTLQ"

```

```

Query Match      0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1906 TTGCTCTGAGGTTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTG 1965
DB 218 TTGTGTCGCATCTCTGTCGGCACTGCCCGCTTCTCTCCAGGATGCTCTTGGGTG 159

```

```

RESULT 218
HUMDPBB/c       HUMDPBB       256 bp      DNA      linear      PRI 07-JAN-1995
LOCUS          Human MHC class II HLA-DP-beta (allele DPB5), partial cds.
DEFINITION
ACCESSION      M62333
VERSION        M62333.1 GI:188026
KEYWORDS       HLA-DP antigen; cell surface glycoprotein; class II gene; integral
membrane glycoprotein; major histocompatibility complex.
SOURCE         Homo sapiens (human)

```



```

Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTGAGGTTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 226 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGGCTG 167

RESULT 221
AF336224/c
LOCUS Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*3801
DEFINITION Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*3801
ACCESSION AF336224
VERSION AF336224.1 GI:13430229
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 283)
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Sequence of complete exon 2 and partial intron 2 of HLA-DPB1*3801
allele
JOURNAL Unpublished
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Direct Submission
JOURNAL Submitted (16-JAN-2001) Biochemistry Department, Zhongshan (Sun
Yat-sen) University, 135 W. Xingang Rd, Guangzhou, Guangdong
510275, P.R. China
FEATURES
source
1..283
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"
<1..>283
/gene="HLA-DPB1"
/allele="HLA-DPB1*3801"
<1..>264
/gene="HLA-DPB1"
<1..>264
/gene="HLA-DPB1"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AAK25779.1"
/db_xref="GI:13430230"
/translation="NYLFQGRQECYFPNGTQFLERYINREELVRFDSVDGEFRAVT
ELGRPEAEYWNQKIDLEKRAVPDRMCRHNYELDEAVTLQRR"
1..264
/gene="HLA-DPB1"
/number=2

Query Match 0.8%; Score 18.4; DB 1; Length 283;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTGAGGTTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 226 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGGCTG 167

RESULT 222
AF492638/c
LOCUS Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*0501
DEFINITION Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*0501
ACCESSION AF492638
VERSION AF492638.1 GI:29422764
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Luo,M., Mao,X., Shehzad,I., Jacobson,K., Kwan,L., Shroeder,M. and
Plummer,F.A.
TITLE Sequence-Based DPB Typing Fills the Missing Exon 2 Sequences of
Multiple HLA-DPB1 Alleles
JOURNAL Unpublished
AUTHORS Luo,M., Mao,X., Shehzad,I., Jacobson,K., Kwan,L., Shroeder,M. and
Plummer,F.A.
TITLE Direct Submission
JOURNAL Submitted (14-MAR-2002) Medical Microbiology, University of
Manitoba, R507 BMSB, 730 William Avenue, Winnipeg, Manitoba R3E
0W3, Canada
FEATURES
source
1..285
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
<1..>285
/gene="HLA-DPB1"
/allele="HLA-DPB1*0501"
<20..>283
/gene="HLA-DPB1"
/product="MHC class II antigen"
<20..>283
/gene="HLA-DPB1"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AA084763.1"
/db_xref="GI:29422765"
/translation="NYLFQGRQECYAFNGTQFLERYINREELVRFDSVDGEFRAVT
ELGRPEAEYWNQKIDLEKRAVPDRMCRHNYELDEAVTLQRR"
20..283
/gene="HLA-DPB1"
/number=2

Query Match 0.8%; Score 18.4; DB 1; Length 285;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTGAGGTTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 245 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGGCTG 186

RESULT 223
HUMHDPBZ/c
LOCUS Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
DEFINITION Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
ACCESSION M83912
VERSION M83912.1 GI:188106
KEYWORDS lymphocyte antigen; major histocompatibility complex.
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Kimura,A.
JOURNAL Unpublished (1991)
COMMENT Original source text: Homo sapiens (individual isolate SASBE41)
DNA.
FEATURES
source
1..285
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="SASBE41"
/db_xref="taxon:9606"
/map="6p"
/cell_type="granulocyte"
<1..19
/number=1

intron

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Luo,M., Mao,X., Shehzad,I., Jacobson,K., Kwan,L., Shroeder,M. and
Plummer,F.A.
TITLE Sequence-Based DPB Typing Fills the Missing Exon 2 Sequences of
Multiple HLA-DPB1 Alleles
JOURNAL Unpublished
AUTHORS Luo,M., Mao,X., Shehzad,I., Jacobson,K., Kwan,L., Shroeder,M. and
Plummer,F.A.
TITLE Direct Submission
JOURNAL Submitted (14-MAR-2002) Medical Microbiology, University of
Manitoba, R507 BMSB, 730 William Avenue, Winnipeg, Manitoba R3E
0W3, Canada
FEATURES
Location/Qualifiers
1..285
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
<1..>285
/gene="HLA-DPB1"
/allele="HLA-DPB1*0501"
<20..>283
/gene="HLA-DPB1"
/product="MHC class II antigen"
<20..>283
/gene="HLA-DPB1"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AA084763.1"
/db_xref="GI:29422765"
/translation="NYLFQGRQECYAFNGTQFLERYINREELVRFDSVDGEFRAVT
ELGRPEAEYWNQKIDLEKRAVPDRMCRHNYELDEAVTLQRR"
20..283
/gene="HLA-DPB1"
/number=2

Query Match 0.8%; Score 18.4; DB 1; Length 285;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTGAGGTTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 245 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGGCTG 186

RESULT 223
HUMHDPBZ/c
LOCUS Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
DEFINITION Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
ACCESSION M83912
VERSION M83912.1 GI:188106
KEYWORDS lymphocyte antigen; major histocompatibility complex.
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Kimura,A.
JOURNAL Unpublished (1991)
COMMENT Original source text: Homo sapiens (individual isolate SASBE41)
DNA.
FEATURES
Location/Qualifiers
1..285
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="SASBE41"
/db_xref="taxon:9606"
/map="6p"
/cell_type="granulocyte"
<1..19
/number=1

intron

```



```

<20..>283
/codon_start=3
/label=exon 2
/product="MHC HLA DPB1"
/protein_id="AAA36266.1"
/db_xref="GI:553571"
/translation="NYVYQURQECYAFNGTQRFLERYIYNRELVRFDSDVGEFRAV
ELGPEAEAYWNQSKDILLEKRAVPMCRHNYELDEAVTLQR"
284..>285
/number=2

intron

Query Match      0.8%; Score 18.4; DB 1; Length 285;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 1306 TTGTCTCTGAGGTCCTGTCGTGGTCTCTAATTTTTCATTTCCAGATTCCCTTCAGTTG 1965
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 245 TTGTGTCGCACATCCTGTCGGGACTGCCGCTCTCTCCAGGATGTCCTTCGTGCT 186
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 224
AF312826/c
LOCUS
DEFINITION
Luiddia foliolata sea star regeneration-associated protease SRAP
mRNA, complete cds.
ACCESSION
AF312826
VERSION
AF312826.1 GI:13183619
SOURCE
Luiddia foliolata
ORGANISM
Luiddia foliolata
Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Asterozoa;
Asteroidea; Valvatacea; Faxillosida; Luiddiidae; Luiddia.
1 (bases 1 to 804)
Vickery,M.C., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
Utilization of a novel deuterostome model for the study of
regeneration genetics: molecular cloning of genes that are
differentially expressed during early stages of larval sea star
regeneration
Gene 262 (1-2), 73-80 (2001)
JOURNAL
MEDLINE
21100442
PUBMED
11179669
REFERENCE
2 (bases 1 to 804)
Vickery,M.C.L., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
Direct Submission
Submitted (12-OCT-2000) Department of Biology, University of
Alabama at Birmingham, 1300 University Blvd., Birmingham, AL
35294-1170, USA
JOURNAL
FEATURES
Location/Qualifiers
1..804
/organism="Luiddia foliolata"
/mol_type="mRNA"
/db_xref="taxon:105861"
/dev_stage="larva"
1..804
/note="serine protease"
/codon_start=1
/product="sea star regeneration-associated protease SRAP"
/protein_id="AAK15274.1"
/db_xref="GI:13183620"
/translation="MLRLVLCALFAFYADCGVQVNPVLNKIVGDEAVPGSWPQ
VMFKRYWAGDYQFCGGTLLISEWASAHCFHNGTNHNTAVVGAHSDRSVDSTQT
TVGLGRVPHESYDSTLNDIALIKLSPVMSNYNSVCLPTAATPTGTCVVTWG
GBOETAVDPTLQQVYVYIISSEQNRAITPGVSEGINDMICAGFEKGKDSQQGDSG
PFVCSASGEYELGVWSNGYCADARKPGVYKVLNVYWNINLVARN"

Query Match      0.8%; Score 18.4; DB 1; Length 804;
Best Local Similarity 59.6%; Pred. No. 2.3e+02;
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Qy 623 TTGTTGAGATGACCTAACTGTTGGAGAGAAATCGGGTATTGAAGTAGCCCACT 674
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 251 TGGTTGATGTTGCCATAGTTATGGAGCAATCGGCAGCAGACAGCCCACT 200
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

```

```
source
1. .832
/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="ammocoete"
/tissue_lib="anterior intestine"
<1. .832
/gene="TRYPB1"
CDS
<1. .736
/gene="TRYPB1"
/codon_start=2
/product="trypsinogen B1"
/protein_id="AAB69656.1"
/db_xref="GI:2367499"
/translation="LIIFALLVGTAAAPYVEDHIVGVYCAHSPQWVSLNIGYHP
CGSLISEWVSAHCYQTASRISVRIGEHNIETEGTORIQASKAIRHPQYSSAT
IDNDIMLKLSPPATLQYQAQVLPSPSCVGTGVMCTISGMGTQTSVSGPDVLMCVQ
APVLSDTSCNSYPGDTNNMICLGLYEGGKSCQGDSPVVCNGQLQGITVSWGRGC
ALPNYPGVYKVCNYSNIASTMAAN"
<1. .37
/gene="TRYPB1"
/evidence=not_experimental
mat_peptide
38. .733
/gene="TRYPB1"
/product="trypsin b1"
/evidence=not_experimental

Query Match 0.8%; Score 18.4; DB 1; Length 832;
Best Local Similarity 78.6%; Pred. No. 2.3e+02;
Matches 22; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1685 TCTTTTGGTTTCTTCTGAAATATTTT 1712
| | | | | | | | | | | | | | | | | |
Db 832 TTTTCTTTTCTTTTATTTCAATATTTT 805

RESULT 227
AF465275/c 1293 bp mRNA linear VRT 02-FEB-2003
LOCUS Takifugu rubripes coagulation factor VIIC precursor, mRNA, complete
DEFINITION cds.
ACCESSION AF465275
VERSION AF465275.1 GI:28194021
KEYWORDS Takifugu rubripes (Fugu rubripes)
SOURCE Takifugu rubripes
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percormorpha; Tetraodontiformes;
Tetraodontidae; Tetraodontidae; Takifugu.
1 (bases 1 to 1293)
Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
2 (bases 1 to 1293)
McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
LOCATION/Qualifiers
1. .1293
/organism="Takifugu rubripes"
/mol_type="mRNA"
/db_xref="taxon:31033"
1. .1293
/EC_number="3.4.21.21"
/functions="serum prothrombinconversion accelerator"
/notes="vitamin K dependent serine protease; similar to
factor VII precursor; synthesized in liver; similar to
Fugu rubripes FVII and FVIII; contains 2 EGF-like domains;"

source
1. .1293
/organism="Takifugu rubripes"
/mol_type="mRNA"
/db_xref="taxon:31033"
1. .1293
/EC_number="3.4.21.21"
/functions="serum prothrombinconversion accelerator"
/notes="vitamin K dependent serine protease; similar to
factor VII precursor; synthesized in liver; similar to
Fugu rubripes FVII and FVIII; contains 2 EGF-like domains;"

member of peptidase family S1/trypsin family"
/codon_start=1
/product="coagulation factor VIIC precursor"
/protein_id="AA033370.1"
/db_xref="GI:28194022"
/translation="MASFSRGTRLRFIKLFIITVPCVSGFFPAGVEMKPEANVELH
RTRANFLFELKAGNLERECIEKSYEBAKEIFALPQOLEAFWRITYTAVDQCKLSP
CKNGATCRRFETVACKANGFHGNCDFVRLTSNGCRVNGGCEHCFRFPDRSYVC
FCAPGVLDKDNSTCLPQVPCGRQLQILFSPRVINGLIQKGCWQAMLSNNIYT
CGTILLSEOWULTAHCWKPKAHLFNVTYGHDEHREIFKTEQHRVIVKVLHPGYNK
TSSDKOLAMLKLHPYKVLGYVVICLPAONSTISRTLANIROSTVSGWGRLSRFGPP
ATIQRLTLPRVLPQECRLKLNITRNMLCAGLKTGCRDACEGSDSGPLVITYEYKTV
FLTGVSWGRCANENLYGVYVRVNFNLWIGNLIATN"

Query Match 0.8%; Score 18.4; DB 1; Length 1293;
Best Local Similarity 69.4%; Pred. No. 2.3e+02;
Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1750 CTTTGGTTTTGCATAGTCTCTGCTTCCTCGA 1785
| | | | | | | | | | | | | | | | | |
Db 115 CTTGGGTTTTTCCATAAAACCTCCGCTCCGAA 80

RESULT 228
AX523898 1505 bp DNA linear PAT 24-OCT-2002
LOCUS Sequence 105 from Patent WO02064799.
DEFINITION AX523898
ACCESSION AX523898
VERSION AX523898.1 GI:24412662
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Seidman,R.F., Miller,A.M. and Treco,D.S.
Optimized messenger rna
Patent: WO 02064799-A 105 22-AUG-2002;
TRANSCRIPTOMIC THERAPIES, INC. (US)
KEYWORDS Location/Qualifiers
1. .1505
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.4; DB 1; Length 1505;
Best Local Similarity 59.6%; Pred. No. 2.3e+02;
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1803 ATTGTAGCTTAACATTTTCTTTGACCAAGGTATCCATTTCTTCTATCTTGT 1854
| | | | | | | | | | | | | | | | | |
Db 1425 AATTGAATTAACAGGCGCTCTCACTAATACTATCATCTTCCCATCTTTGT 1476

RESULT 229
S78934 171 nt.
LOCUS (Factor IXMadrid 2) {exon IV and intron d} [human, Genomic Mutant,
DEFINITION 171 nt.].
ACCESSION S78934
VERSION S78934.1 GI:244109
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 171)
Solera,J., Magallon,M., Martin-villar,J. and Coloma,A.
Factor IXMadrid 2: a deletion/insertion in factor IX gene which
abolishes the sequence of the donor junction at the exon IV-intron
d splice site
Am. J. Hum. Genet. 50 (2), 434-437 (1992)
JOURNAL 92133619
MEDLINE
```


QY	1526	TTTTCCCTTGCATCTTTTAAATATCTCTTTTGTCTTATCTATCTTTAGTGAATTTGATTATT	1588
Db	836	TTTTTTTTTTTAACTTTTCAAAGGTTTATTCGTTTCATGGCATTTACAAACCATCATAGTG	777
QY	1586	ATGCATGTGGGAGATTTCTTTTCGGTCCATCTATTTGGTGTTTTGTATCTCTCTTG	1644
Db	776	CTTGTGCTCGGCAAGGTGGCTTCCGAGTGAGTCGCTCAGTTGGCAGCCATGGTGCTGG	718
RESULT 234			
AF542056/c			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
PUBMED			
REFERENCE			
TITLE			
JOURNAL			
FEATURES			
source			
1..987			
/organism="Mus musculus"			
/mol_type="mRNA"			
/strain="C57BL/6"			
/db_xref="taxon:10090"			
/chromosome="17"			
/map="17p6.32"			
/tissue_type="bladder"			
1..987			
/note="membrane anchored tryptic serine protease; marapsin; similar to human pancreasin"			
/codon_start=1			
/product="pancreasin"			
/protein_id="AA027572.1"			
/db_xref="GI:27923337"			
/translation="MRQPHIAALLLLPLLLRSGETARTLRACGHPFMFNRMYGGNA			
LEGEPWQVSIQRNHFICGSLIATPWLTAHCFNSTSDISIVOLLGALKLOQPG			
PHALYVPKQVKNPQYQGMASADVALQGPVTFNVLVCLPDPSPVIFESGN			
CWITGWSPSQDLNPRVLKLAFLIITPKNLNLYNKDVSDPOLKTIKDDMLCA			
GFAEGKXKACKDGGGLVCLVDQWQAGVISWEGCCARRNRPYIVRTSHHKIH			
QIIPELOFQGRAGTQQQKQSQQQLRAGNSAPCLAAHAWLALGALLRLIV"			
Query Match			
0.8%; Score 18.2; DB 1; Length 987;			
Best Local Similarity 48.5%; Pred. No. 2.6e+02;			
Matches 50; Conservative 0; Mismatches 53; Indels 0; Gaps 0;			
QY	298	TCTTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTTGGTTTCCATAGT	357
Db	608	TCAACATCTTGTGTTGACAGCAGGTTCACCTTGGCGGTGTCAATGATGGGCACGCAAGT	549
RESULT 235			
OCU49933/c			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
PUBMED			
REFERENCE			
TITLE			
JOURNAL			
FEATURES			
source			
1..836			
/organism="Petromyzon marinus"			
/mol_type="mRNA"			
/db_xref="taxon:7757"			
/dev_stage="ammocoete"			
/tissue_lib="anterior intestine"			
<1..836			
/gene="TRYPB2"			
<1..740			
/gene="TRYPB2"			
/codon_start=3			
/product="trypsinogen b2"			
/protein_id="AAB69657.1"			
/db_xref="GI:2367501"			
/translation="GLIFALLVGTAAAPYVEDHIVGVECAHSAQWPQVSLNIGYH			
FCGSLISEWVVAHCYQTASRISVRIGEHNFVTEGTEQRIQASKAIRHPQINSA			
TIDNDIMLIKSSPATLQYQAIIPLSPSCVGTGVNCTISGNGETQTSVSGSPDVLWC			
QAPVLSDTSCRNYPGDIITNNMICLGLYEGGKDCQDGGGFPVVCNQLQGIIVSWGRG			
CALPNYPGVYTKVCNYSWIASTMAAN"			
<1..41			
/gene="TRYPB2"			
/evidence=not_experimental			
42..737			
/gene="TRYPB2"			
/product="trypsin b2"			
/evidence=not_experimental			
sig_peptide			
mat_peptide			
Query Match			
0.8%; Score 18.2; DB 1; Length 836;			
Best Local Similarity 47.1%; Pred. No. 2.6e+02;			
Matches 56; Conservative 0; Mismatches 63; Indels 0; Gaps 0;			

DEFINITION Oryctolagus cuniculus vitamin K-dependent protein C precursor mRNA, partial cds.

ACCESSION U49933

VERSION U49933.1 GI:1236620

KEYWORDS Oryctolagus cuniculus (rabbit)

SOURCE Oryctolagus cuniculus

ORGANISM Oryctolagus cuniculus

REFERENCE 1 (bases 1 to 1558)

AUTHORS Shen,L., He,X. and Dahlback,B.

TITLE Molecular cloning of rabbit vitamin K-dependent protein C and demonstration of its mRNA in the reproductive organs

JOURNAL Unpublished

AUTHORS 2 (bases 1 to 1558)

TITLE Direct Submission

JOURNAL Submitted (26-FEB-1996) Lei Shen, Clinical Chemistry, Lund University, University Hospital, Malmö S-205 02, Sweden

FEATURES

source

1..1558

/organism="Oryctolagus cuniculus"

/mol_type="mRNA"

/db_xref="taxon:9986"

/tissue_type="liver"

/dev_stage="adult"

<1..1377

/codon_start=1

/product="vitamin K-dependent protein C precursor"

/protein_id="AAA92956.1"

/db_xref="GI:1236621"

/translation="IPDDVGYRNOKTASKEGVVUSKQDGNLTPRAKANSFLEEL
RESSLERECVEVCLDEAKEIFQSDVDLAFWYKVDGQCAALPSEHPSCSCCGH
GTCAISIGFCQCHGWGSGFCQYEVRENSVDNGCAHYCLEEAEGRSCSCAPY
ELADHLQCEAPVPCFGLKWKRIEKGKRNVRDLQVDEMDVPRIDGKLTGRG
DEPQVILLDSKKLACGAVLHVSVLTAHMCBEPKFLFVRLGYDLRRKRWELD
LNIQVELHPNTSRSTDDIALRLAQPATLSQITVPCLPDGLAERLMAQOET
VVTGWGYSRSEKAKRNTFILNFTTPVAPQNECEQVMSNIISENMLCAGILGDRR
DAGDGSQGPWASFRGTWFLVGLVSGSGCDLNNYGVTKVRYLDWIRSHIEKE
AAPESPAP"

<1..108

/note="putative; leader peptide"

sig_peptide

<109..1374

/product="vitamin K-dependent protein C"

/note="putative"

mat_peptide

Query Match 0.8%; Score 18.2; DB 1; Length 1558;

Best Local Similarity 66.7%; Pred. No. 2.5e+02;

Matches 26; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCTTTTACTCTAAGGTGATGTCTATCCATGCTAGGT 958

Db 1351 CCTCTTTTCTCGATGTGGCTGTGATCCATGCTGAGGT 1313

RESULT 236

S68634/c

LOCUS S68634

DEFINITION CRM+ factor IX Strasbourg 2-cross reacting material positive factor IX Strasbourg 2 (exon 2) [human, hemophilia B patient J-C L, blood, Genomic Mutant, 199 nt].

ACCESSION S68634

VERSION S68634.1 GI:545020

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 199)

AUTHORS de la Salle,C., Charmantier,J.L., Ravanat,C., Ohlmann,P., Hartmann,M.L., Schueller,S., Bischoff,R., Ebel,C., Roecklin,D., Balland,A. et al.

TITLE The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation

by factor Xia

JOURNAL Nouv. Rev. Fr. Hematol. 35 (5), 473-480 (1993)

MEDLINE 94126308

PUBMED 8295821

REMARK GenBank staff at the National Library of Medicine created this entry [NCBI gibbsq 143652] from the original journal article.

COMMENT G6365 to A transition.

FEATURES

source

1..199

/organism="Homo sapiens"

/mol_type="genomic DNA"

/isolate="hemophilia B patient J-C L"

/db_xref="taxon:9606"

/tissue_type="blood"

<4..>168

/note="cross reacting material positive factor IX Strasbourg 2; Arg-4 to Gln transition; Method: conceptual translation with partial peptide sequencing"

/codon_start=1

/product="CRM+ factor IX Strasbourg 2"

/protein_id="AAB29758.1"

/db_xref="GI:545021"

/translation="VFLDHENANKILNQPKRYNSGKLEBFVQGNLERECMEKCSFEE
AREVPENTERT"

Query Match 0.8%; Score 18; DB 1; Length 199;

Best Local Similarity 45.2%; Pred. No. 2.9e+02;

Matches 66; Conservative 0; Mismatches 80; Indels 0; Gaps 0;

QY 1634 TATGCTTCTTGACCTTGATAGCATCTCTTCTCAAGGTAGGAATTTTCTTTTGG 1693

Db 168 TGTCTTCTCAGTGTCTTCAAAAACCTCTCTGCTCTTCAAAACTACACTTTCTTCCAT 109

QY 1694 GTTTTCTGAAAATATTTTCCCTGCTTTTGACTGCTCTTCTCCCTCTCTCTATTCCTT 1753

Db 108 ACATCTCTCTCAAGTTCCTTGAACAACCTTCAATTTACCTGAATATACCTCTT 49

QY 1754 TGGTTTTTGCATAGTGTCTCTGCTT 1779

Db 48 TGGCTGATTCAGAAATTTTGTGGCGT 23

RESULT 237

I14646/c

LOCUS I14646

DEFINITION Sequence 123 from patent US 5451512.

ACCESSION I14646

VERSION I14646.1 GI:997129

KEYWORDS Unknown.

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 276)

AUTHORS Apple,R.J., Bugawan,T.L. and Erlich,H.A.

TITLE Methods and reagents for HLA class I A locus DNA typing

JOURNAL Patent: US 5451512-A 123 19-SEP-1995;

FEATURES

source

1..276

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.8%; Score 18; DB 1; Length 276;

Best Local Similarity 52.7%; Pred. No. 2.9e+02;

Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCTTTCTCTCTGATTCCTAGGTGAGGTAGGCTTACCACTGCTCTCTCTCC 228

Db 238 CTGCGAGCCACTCCACGACGTCGCCCTCCAGGTAGGCTCTCCACTGCTCGCCTCATGG 179

QY 229 TTCTCTTAACACTT 242

Db 178 GCGGTCTCCCACTT 165

```

RESULT 238
AY267909S2/c
LOCUS      276 bp      DNA      linear      PRI 12-MAY-2003
DEFINITION Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*3401 variant
            allele, exon 3 and partial cds.
ACCESSION  AY267910
VERSION     AY267910.1 GI:30525804
KEYWORDS   2 of 2
SEGMENT    Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 276)
AUTHORS   Steiner,N.K., Fernandez-Vina,M. and Hurley,C.K.
TITLE     Novel HLA-A Allele
JOURNAL   Unpublished
REFERENCE  2 (bases 1 to 276)
AUTHORS   Steiner,N.K., Fernandez-Vina,M. and Hurley,C.K.
TITLE     Direct Submission
JOURNAL   Submitted (03-APR-2003) Lombardi Cancer Center, Georgetown
            University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
            20007, USA
FEATURES   Location/Qualifiers
            source
            1..276
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /isolate="GN00431"
            /db_xref="taxon:9606"
            order(AV267909.1:<1..270,1..>276)
            /gene="HLA-A"
            /allele="HLA-A*3401 variant"
            join(AV267909.1:<1..270,1..>276)
            /gene="HLA-A"
            /product="MHC class I antigen"
            join(AV267909.1:<1..270,1..>276)
            /gene="HLA-A"
            /codon_start=3
            /product="MHC class I antigen"
            /protein_id="AAP32699.1"
            /db_xref="GI:30525805"
            /translation="SHSMRYFYTSVRPGRGEPRFIAGVYVDDTQVRFSDAASQRM
            EPRAPWFOEGPEYWDNRKVKASQSDRDVLDGLTGRYVYNQSDGSHTIORMYGCVD
            GPDGRFLRGIOQDAYDQKDYISLNEDLSRWTAADMAAQITQKWEAHEAQWRAYLE
            GTCVEWLRRLYENKGETLQRT"
            1..276
            /gene="HLA-A"
            /number=3
            exon

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCTTTCTCCCTGCTGCTGATTCCTAGGTGAGGTTACCACTGCTCTCTCTCCC 228
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 238 CTGGGAGCCACTCAGCAGCTGCCCTCCAGTAGGCTCTCCACTGCTCCGCTCATGG 179
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 229 TTCTCTAACACTT 242
      ||||| ||||| ||||| |||||
Db 178 GCCGCTCCCACTT 165
      ||||| ||||| ||||| |||||

RESULT 240
HSHLAAGN2/c
LOCUS      276 bp      DNA      linear      PRI 20-OCT-2000
DEFINITION Human MHC class I antigen HLA-A gene (A*2601 variant), exon 3 and
            partial cds.
ACCESSION  U90243
VERSION     U90243.1 GI:1905858
KEYWORDS   2 of 2
SEGMENT    Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 276)
AUTHORS   Hurley,C.K., Steiner,N., Kosman,C., Mitton,W., Koester,R., Bei,M.,
            Bush,J., McCormack,J., Hahn,A., Henson,V., Hoyer,R., Wade,J.A.,
            Hartzman,R.J. and Ng,J.
TITLE     Novel HLA-A and HLA-B alleles
JOURNAL   Tissue Antigens 52 (1), 84-87 (1998)
MEDLINE    98378282
PUBMED     9714480
REFERENCE  2 (bases 1 to 276)
AUTHORS   Bei,M. and Hurley,C.K.
TITLE     Direct Submission
JOURNAL   Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown
            University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
            20007, USA
FEATURES   Location/Qualifiers
            source
            1..276
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /isolate="GN00158"

```

```

ORGANISM Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Lebedeva,T.V., Huang,A., Janzen,M. and Yu,N.
TITLE     Identification of novel HLA Class I alleles using single allele
            sequencing
JOURNAL   Unpublished
REFERENCE  2 (bases 1 to 276)
AUTHORS   Lebedeva,T.V.
TITLE     Direct Submission
JOURNAL   Submitted (10-SEP-2002) Lebedeva T.V., HLA laboratory, American Red
            Cross New England Region, 180 Rustcraft Rd, Dedham, MA 02026, USA
FEATURES   Location/Qualifiers
            source
            1..276
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /chromosome="6"
            /map="6p21.3"
            1..276
            /gene="HLA-A"
            1..276
            /gene="HLA-A"
            /number=3
            /allele="HLA-A*34"
            /usedin="AJ507647:HLA-A*34_CDS"

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCTTTCTCCCTGCTGCTGATTCCTAGGTGAGGTTACCACTGCTCTCTCTCCC 228
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 238 CTGGGAGCCACTCAGCAGCTGCCCTCCAGTAGGCTCTCCACTGCTCCGCTCATGG 179
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 229 TTCTCTAACACTT 242
      ||||| ||||| ||||| |||||
Db 178 GCCGCTCCCACTT 165
      ||||| ||||| ||||| |||||

RESULT 240
HSHLAAGN2/c
LOCUS      276 bp      DNA      linear      PRI 20-OCT-2000
DEFINITION Human MHC class I antigen HLA-A gene (A*2601 variant), exon 3 and
            partial cds.
ACCESSION  U90243
VERSION     U90243.1 GI:1905858
KEYWORDS   2 of 2
SEGMENT    Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 276)
AUTHORS   Hurley,C.K., Steiner,N., Kosman,C., Mitton,W., Koester,R., Bei,M.,
            Bush,J., McCormack,J., Hahn,A., Henson,V., Hoyer,R., Wade,J.A.,
            Hartzman,R.J. and Ng,J.
TITLE     Novel HLA-A and HLA-B alleles
JOURNAL   Tissue Antigens 52 (1), 84-87 (1998)
MEDLINE    98378282
PUBMED     9714480
REFERENCE  2 (bases 1 to 276)
AUTHORS   Bei,M. and Hurley,C.K.
TITLE     Direct Submission
JOURNAL   Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown
            University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
            20007, USA
FEATURES   Location/Qualifiers
            source
            1..276
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /isolate="GN00158"

```

```

/db_xref="taxon:9606"
join(U90242.1:<1..270,1..>276)
/gene="HLA-A"
join(U90242.1:<1..270,1..>276)
/gene="HLA-A"
/product="MHC class I antigen"
join(U90242.1:<1..270,1..>276)
/gene="HLA-A"
/note="variant A*2601"
/codon_start=3
/product="MHC class I antigen"
/protein_id="AAB50149.1"
/db_xref="GI:1905860"
/translation="SHSMRYFTSVSRPGRCEPRFIAVGVDDTQFVREDSAASQRM
EPRAWIEQEGPEWDRNTRNVKAHSOTDRANLGLTRGYVNSQSDGSHITQRMTCGDV
GPDGRFLRGYQDDAYDKDYIALNEDLRSWTAADMAAQITQKWTAEHAEPQWRAYLE
GTCVWELRYLLENGKETLQRT"
1..276
/gene="HLA-A"
/number=3

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCTTTCTCCCTGTCTGATTCCTAGGTCGAGGTTACCACTGCTCTCTCTCCC 228
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 238 CTGGGAGCCACTCCACGACGTCCTCCAGTAGCTCTCCACTGCTCGGCTCATGG 179

QY 229 TTCTCTTAACACTT 242
      ||||| |||||
Db 178 GCCGTCTCCCACTT 165

RESULT 241
AR249144/c
LOCUS      AR249144      290 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 4503 from patent US 6476212.
ACCESSION  AR249144
VERSION     AR249144.1 GI:27297018
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 290)
AUTHORS    Lalgudi,R.V., Ito,I.Y. and Sherman,B.K.
TITLE      Polynucleotides and polypeptides derived from corn ear
JOURNAL    Patent: US 6476212-A 4503 05-NOV-2002;
FEATURES
  source
    1..290
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match      0.8%; Score 18; DB 1; Length 290;
Best Local Similarity 51.2%; Pred. No. 2.9e+02;
Matches 42; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 1671 GGTTAGGAATTTTCTTTTGGTTTCTTGAATAATTTCCCTGCTTTGACCTGCC 1730
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 218 GGCCGGAGATCTTGCCCTCTCGTCTCCAGGAGGCTCGGCTCTCCAGGGCTGAC 159

QY 1731 TTCTTCCCTTCTCTATTTCCT 1752
      ||||| ||||| ||||| |||||
Db 158 TGCAGCTCCATCTTCTCGGCT 137

RESULT 242
AX312474
LOCUS      AX312474      299 bp      DNA      linear      PAT 14-DEC-2001
DEFINITION Sequence 5459 from Patent WO0150366.
ACCESSION  AX312474
VERSION     AX312474.1 GI:17897467
KEYWORDS

```

```

SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Leach,M.D. and Shinkets,R.A.
TITLE      Human polynucleotides and polypeptides encoded thereby
JOURNAL    Patent: WO 0190366-A 5459 29-NOV-2001;
           Curagen Corporation (US)
FEATURES
  source
    1..299
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      0.8%; Score 18; DB 1; Length 299;
Best Local Similarity 54.5%; Pred. No. 2.9e+02;
Matches 36; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 1720 TTGACCTGGCTTCTCCCTTCTCTATTCTTGGTTTTCATAGTGTCTCTGGCTT 1779
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 220 TTGACGTGGCTTCACCCATCTCTCTCAATGACTACATGCTTCCAGTGTGCTCCGAAA 279

QY 1780 CCTGGA 1785
      |||||
Db 280 CCTGGA 285

RESULT 243
BTA271156/c
LOCUS      BTA271156      302 bp      mRNA      linear      MAM 27-JUL-2000
DEFINITION Bos taurus partial mRNA for haptoglobin (hp gene).
ACCESSION  AJ271156
VERSION     AJ271156.1 GI:9581738
KEYWORDS    haptoglobin; hp gene.
SOURCE      Bos taurus (cow)
ORGANISM    Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Bovinae; Bos.
REFERENCE   1
AUTHORS    Lavery,K.S., Gabler,C. and Killian,G.J.
TITLE      Expression and localization of haptoglobin in the bovine female
           reproductive tract
JOURNAL    Unpublished
REFERENCE   2 (bases 1 to 302)
AUTHORS    Lavery,K.S.
TITLE      Direct Submission
JOURNAL    Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science,
           Pennsylvania State University, The John O. Almqvist Research
           Center, Fox Hollow Road, University Park, USA
FEATURES
  source
    1..302
    /organism="Bos taurus"
    /mol_type="mRNA"
    /db_xref="taxon:9913"
    /sex="female"
    /cell_type="epithelial cell"
    /tissue_type="oviduct"
    /dev_stage="adult"
    1..302
    /gene="hp"
    <1..>302
    /gene="hp"
    /function="acute phase protein"
    /codon_start=3
    /product="haptoglobin"
    /protein_id="CAC00531.1"
    /db_xref="GI:9581739"
    /db_xref="GOA:Q9MYV8"
    /db_xref="SPTREMBL:Q9MYV8"
    /translation="KGSFPWQAKVMSQHNLSGATLINERWLLTTAKNLYLGHSSDKK
    AKDTPTLRLYVGNQLVEVEKVLHPDHSKVDIGLIKLRQKPVNDKVPICLPS"

```

```

Query Match          0.8%; Score 18; DB 1; Length 302;
Best Local Similarity 52.7%; Pred.No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

1644 GTACCTTGATAGGATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGTGTTTCTTGA 1703
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
297 GTAGGCAGATGGCAATTACCTTTGTCATGCACAGGTAACCTTCTGCTGAGTTGATGAGCC 238
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

1704 AAATAATTTTCCCTG 1717
||||| ||||| ||||| |||||
237 CAATGCTACCTTG 224
||||| ||||| ||||| |||||

RESULT 244
RSPLEX2/c
OCUS
DEFINITION
X95338
CESSION
X95338.1 GI:1171532
EYWORDS
SOURCE
ORGANISM
Takifugu rubripes (Fugu rubripes)
Takifugu rubripes
Takifugu rubripes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
Tetraodontoidea; Tetraodontidae; Takifugu.
1
REFERENCE
1
Lim,E.H. and Brenner,S.
Short-range linkage relationships, genomic organisation and
sequence comparisons of a cluster of five HSP70 genes in Fugu
rubripes
Cell. Mol. Life Sci. 55 (4), 668-678 (1999)
99284127
PUBMED
10357235
2 (bases 1 to 335)
Lim,E.H.
AUTHORS
Direct Submission
TITLE
Submitted (17-JAN-1996) E.H. Lim, Molecular Genetics, Dept. of
Medicine, Level 5, Addenbrookes Hospital, Hills Road, Cambridge CB2
2QQ, UK
FEATURES
source
1..335
/organism="Takifugu rubripes"
/mol_type="genomic DNA"
/db_xref="taxon:31033"
80..214
/product="serine protease-like protein"
exon
Query Match          0.8%; Score 18; DB 1; Length 335;
Best Local Similarity 80.8%; Pred.No. 2.9e+02;
Matches 21; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

30 TGAGGCTCCAATGGTGTGTGATGTGG 55
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
194 TCAGGATCCACTGGTGTGTGATCAGG 169
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 245
AF266240
LOCUS
DEFINITION
ACCESSION
AF266240
VERSION
AF266240.1 GI:10121759
EYWORDS
SOURCE
Gilllichthys seta
Gilllichthys seta
Gilllichthys seta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
Gobioidae; Gobiidae; Gilllichthys.
1 (bases 1 to 383)
Gracey,A.Y., Trolli,J.V. and Somero,G.N.
AUTHORS
REFERENCE

```


ACCESSION	M35672
VERSION	M35672.1 GI:180287
KEYWORDS	coagulation factor IX; serine protease.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 873) Warren,S.T. Jagadeeswaran,P., Lavelle,D.E., Kaul,R., Mohandas,T. and 6089357
COMMENT	Isolation and characterization of human factor IX cDNA: identification of Tag I polymorphism and regional assignment Sonat. Cell Mol. Genet. 10 (5), 465-473 (1984)
FEATURES	Original source text: Human adult liver, cDNA to mRNA. Location/Qualifiers 1..873
source	/organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /map="Xq26.3-q27.1"
gene	1..873 /gene="F9"
CDS	<1..>873 /gene="F9" /note="coagulation factor IX" /codon_start=1 /protein_id="AAAS1981.1" /db_xref="GI:180288" /db_xref="GDB:G00-119-900" /translation="NANKILNRPRVNSGLKEFFVOGNLRECMEEKSCFEAREVFVE NTERTTQKYYVDGSDNSPCLNGSGCKDINSYECWCPFGEGKNCELDTVCNIK NGRGEPCFNKAADNVKVCSTEGVRLAENOKSEPAVPFGGRVSQSQTSLKTRAEV FPDVVDYNSTEATILNDINTQTSQSFDFRVVGVEDAKPGQPFWVLINGKYDAFCG GSIVNEKWIVTAACHCVETGVKITVAAGEHNIEETEQRKNVIRIIPHNYNAALNK YNHDIALLELDPELV"
Query Match	0.8%; Score 18; DB 1; Length 873;
Best Local Similarity	64.3%; Pred.No. 2.3e+02;
Matches	27; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
QY	369 CTGTGGTTCTCGTTGTGTGTGTATTCTAGATTTAAGCTG 410
Db	476 CTGTTTTCTGTGATGGACTATGTAATACTTACTGAAGCTG 517
RESULT 248	
AF465274/C	
LOCUS	AF465274 1329 bp mRNA linear VRT 02-FEB-2003
DEFINITION	Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete cds.
ACCESSION	AF465274
VERSION	AF465274.1 GI:28194019
KEYWORDS	Takifugu rubripes (Fugu rubripes)
SOURCE	Takifugu rubripes
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percormorpha; Tetraodontiformes; Tetraodonotidea; Tetraodontidae; Takifugu. 1 (bases 1 to 1329) Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G., Tuddenham,E.G.D. and McVey,J.H. Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes Unpublished 2 (bases 1 to 1329) Mcvey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G. Direct Submission Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences Centre, The Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	

Search completed: August 9, 2004, 17:50:01
Job time : 698 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 17:38:45 ; Search time 892 Seconds
(without alignments)
3.871 Million cell updates/sec

Title: us-10-664-775-5

Perfect score: 2267

Sequence: 1 gatcactctctagtgaag.....ttgttaattctagtgctgat 2267

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1612 seqs, 761539 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	44.2	1.9	2422	1	AAQ80296 cDNA encoding Fact
C 2	44.2	1.9	2422	1	AAV02230 Homo sapiens cDNA
C 3	44.2	1.9	2422	1	AAZ57385 Factor VII encodin
C 4	44.2	1.9	2422	1	AAF57099 Human Factor VII p
C 5	44.2	1.9	2422	1	ADC24226 Human NOV8a encodi
C 6	44.2	1.9	2462	1	AAI15425 DNA encoding coagu
C 7	44.2	1.9	2462	1	AAI12968 DNA encoding Facto
C 8	44.2	1.9	2462	1	AAZ56118 Vitamin-K-dependen
C 9	44.2	1.9	2462	1	AAZ54032 Human factor VII c
C 10	44.2	1.9	2462	1	AAAG9784 DNA encoding coagu
C 11	44.2	1.9	2462	1	ABL87255 Thyroid cancer rel
C 12	44.2	1.9	2462	1	ABN95753 Gene #2251 used to
C 13	44.2	1.9	2483	1	AAAG60064 Factor VII cDNA of
C 14	44.2	1.9	2177	1	AAAG60063 Partial Factor VII
C 15	44.2	1.9	2438	1	AAAG60065 Factor IX/Factor V
C 16	32.4	1.4	300	1	AAZ12625 Human gene express
C 17	25.6	1.1	254	1	AAC16179 Human secreted pro
C 18	25.4	1.1	237	1	AAAG8927 DNA encoding novel
C 19	25.2	1.1	612	1	ABQ47969 Oligonucleotide fo
C 20	25.2	1.1	612	1	ABQ47968 Oligonucleotide fo
C 21	25.2	1.1	1843	1	AAZ54035 Human protein C co
C 22	25.2	1.1	1843	1	AAF54050 Human protein C ge
C 23	25.2	1.1	1843	1	ABN97175 Gene #3673 used to
C 24	24.2	1.1	267	1	AAK45604 Human bone marrow
C 25	24.2	1.1	267	1	AAK19599 Human brain expres
C 26	24.2	1.1	267	1	ABS45294 Human liver single
C 27	24.2	1.1	267	1	ABS19876 Human genome-deriv
C 28	23.8	1.0	868	1	AAK93580 Human cDNA clone r
C 29	23.8	1.0	868	1	AAK31631 Human cDNA 5'-end
C 30	23.6	1.0	433	1	ACH20452 Human adult liver
C 31	23.4	1.0	612	1	ABQ47966 Oligonucleotide fo
C 32	23.4	1.0	612	1	ABQ47967 Oligonucleotide fo
C 33	23.4	1.0	306	1	AAT40850 Serine protease nf

1	1507	1	AAA54031	Human factor X cod
1	1507	1	ABZ35322	Human gene express
1	1507	1	ADE84862	Farnesyl transfera
1	200	1	AAD37041	Targeting arm #2
1	1151	1	AAO08286	Human secreted pro
1	271	1	AAO71343	Single nucleotide
1	476	1	AAI11531	Probe #1464 for ge
1	476	1	ABA53212	Human foetal liver
1	476	1	AAI32810	Probe #1496 used t
1	476	1	ABA42785	Human breast cell
1	476	1	ABA22986	Probe #1452 for ge
1	476	1	AAK26907	Human bone marrow
1	476	1	AAK01461	Human brain expres
1	476	1	ABS26497	Human liver single
1	476	1	AAI01449	Probe #1440 used t
1	476	1	ABS01506	Human genome-deriv
1	223	1	AAC20296	Human secreted pro
1	301	1	AAI19676	Probe #9609 for ge
1	301	1	ABA64702	Human foetal liver
1	301	1	AAI44871	Probe #13557 used
1	301	1	ABA46822	Human breast cell
1	301	1	AAK31826	Probe #10292 for g
1	301	1	AAK38868	Human bone marrow
1	301	1	AAK13137	Human brain expres
1	301	1	ABS38453	Human liver single
1	301	1	AAI05395	Probe #5386 used t
1	301	1	ABS12949	Human genome-deriv
1	121	1	ABA79626	Factor IX mutation
1	121	1	ABA79623	Factor IX mutation
1	121	1	ABA79622	Factor IX mutation
1	121	1	ABA79634	Factor IX mutation
1	121	1	ABA79627	Factor IX mutation
1	121	1	ABA79631	Factor IX mutation
1	121	1	ABA79635	Factor IX mutation
1	121	1	ABA79638	Factor IX mutation
1	121	1	ABA79630	Factor IX mutation
1	121	1	ABA79639	Factor IX mutation
1	121	1	ABA79619	Factor IX mutation
1	121	1	ABA79618	Factor IX mutation
1	121	1	ABA79618	Factor IX mutation
1	385	1	AAC04575	Human secreted pro
1	253	1	AAV70944	Single nucleotide
1	254	1	ABV98470	Human pancreatic c
1	283	1	AAV28290	Galanin receptor G
1	283	1	AAV32651	Galanin receptor G
1	283	1	AAV44930	Galanin receptor G
1	283	1	AAK14060	Rat galanin recept
1	1129	1	AAZ21354	Human cDNA sequenc
1	1129	1	ACD23963	Novel human secret
1	1129	1	ACA67104	cDNA encoding huma
1	1129	1	ACA03713	cDNA encoding huma
1	1129	1	ABX89251	Human secreted/tra
1	1129	1	ACD41905	Human cDNA encodin
1	1129	1	ACA04134	Novel human secret
1	1129	1	ADA45740	Human PRO polynucl
1	1129	1	ADA76171	Human PRO polynucl
1	1129	1	ADA18821	Human PRO polynucl
1	1129	1	ADA61444	Homo sapiens. Nov
1	1129	1	ADB19229	Novel human secret
1	1129	1	ADB27770	cDNA encoding huma
1	1129	1	ADA86249	Novel human secret
1	1129	1	ADBI5813	Human PRO polynucl
1	1129	1	ADA47599	Human PRO polynucl
1	1129	1	ADA67394	Human PRO polynucl
1	1129	1	ADB30401	cDNA encoding huma
1	1129	1	ADA85697	Novel human secret
1	1129	1	ADA96909	Human PRO polynucl
1	1129	1	ADA79213	Human PRO polynucl
1	1129	1	ADA87352	Novel human secret
1	1129	1	ADBI6554	Human PRO polynucl
1	1129	1	ADA91646	Novel human secret
1	1129	1	ADBI4709	Human PRO polynucl
1	1129	1	ADBI8670	Novel human secret
1	1129	1	ADA93885	Human PRO polynucl

c 107	21.4	0.9	1129	1	AD819781	Novel human secret
c 108	21.4	0.9	1129	1	AD813093	Human PRO polynucle
c 109	21.4	0.9	1129	1	AD898534	Novel human secret
c 110	21.4	0.9	1129	1	AD874347	Human PRO polynucle
c 111	21.4	0.9	1129	1	AD824580	Human PRO polynucle
c 112	21.4	0.9	1129	1	AD82104	Human PRO polynucle
c 113	21.4	0.9	1129	1	AD875067	Human PRO polynucle
c 114	21.4	0.9	1129	1	AD885145	Novel human secret
c 115	21.4	0.9	1129	1	AD845593	Novel human secret
c 116	21.4	0.9	1129	1	AD829849	CDNA encoding huma
c 117	21.4	0.9	1129	1	AD80377	Human PRO polynucle
c 118	21.4	0.9	1129	1	AD875619	Human PRO polynucle
c 119	21.4	0.9	1129	1	AD846844	Human PRO polynucle
c 120	21.4	0.9	1129	1	AD825140	Human PRO polynucle
c 121	21.4	0.9	1129	1	AD893316	CDNA encoding huma
c 122	21.4	0.9	1129	1	AD826666	CDNA encoding huma
c 123	21.4	0.9	1129	1	AD830953	CDNA encoding huma
c 124	21.4	0.9	1129	1	AD80881	Novel human secret
c 125	21.4	0.9	1129	1	AD824028	Human PRO polynucle
c 126	21.4	0.9	1129	1	AD863557	Human PRO polynucle
c 127	21.4	0.9	1129	1	AD80929	Human PRO polynucle
c 128	21.4	0.9	1129	1	AD895805	Human PRO polynucle
c 129	21.4	0.9	1129	1	AD826114	CDNA encoding huma
c 130	21.4	0.9	1129	1	AD821599	Novel human secret
c 131	21.4	0.9	1129	1	AD87378	Human PRO polynucle
c 132	21.4	0.9	1129	1	AD818118	CDNA encoding huma
c 133	21.4	0.9	1129	1	AD868801	Novel human secret
c 134	21.4	0.9	1129	1	AD87904	Novel human secret
c 135	21.4	0.9	1129	1	AD846292	Novel human secret
c 136	21.4	0.9	1129	1	AD828322	CDNA encoding huma
c 137	21.4	0.9	1129	1	AD828874	CDNA encoding huma
c 138	21.4	0.9	1129	1	AD876826	Human PRO polynucle
c 139	21.4	0.9	1129	1	AD88456	Novel human secret
c 140	21.4	0.9	1129	1	AD897461	Human PRO polynucle
c 141	21.4	0.9	1129	1	AD827218	CDNA encoding huma
c 142	21.4	0.9	1129	1	AD82151	Novel human secret
c 143	21.4	0.9	1129	1	AD866842	Human PRO polynucle
c 144	21.4	0.9	1129	1	AD822703	Human PRO polynucle
c 145	21.4	0.9	1129	1	AD823476	Human PRO polynucle
c 146	21.4	0.9	1129	1	AD892198	Human PRO polynucle
c 147	21.4	0.9	1129	1	AD815261	Novel human secret
c 148	21.4	0.9	1129	1	AD838513	Novel human secret
c 149	21.4	0.9	1129	1	AD837961	Novel human secret
c 150	21.4	0.9	1129	1	AD866433	Novel human secret
c 151	21.4	0.9	1129	1	AD889513	Human PRO polynucle
c 152	21.4	0.9	1129	1	AD890245	Human PRO polynucle
c 153	21.4	0.9	1129	1	AD839346	Novel human secret
c 154	21.4	0.9	1129	1	AD846969	Novel human secret
c 155	21.4	0.9	1129	1	AD886576	Human PRO polynucle
c 156	21.4	0.9	1129	1	AD877181	Novel human secret
c 157	21.4	0.9	1129	1	AD834338	Human PRO polynucle
c 158	21.4	0.9	1129	1	AD835442	Human PRO polynucle
c 159	21.4	0.9	1129	1	AD833786	Human PRO polynucle
c 160	21.4	0.9	1129	1	AD834890	Human PRO polynucle
c 161	21.4	0.9	1129	1	AD835994	Human PRO polynucle
c 162	21.4	0.9	1129	1	AD846389	Novel human secret
c 163	21.4	0.9	1129	1	AD850262	Novel human secret
c 164	21.4	0.9	1129	1	AD871809	Novel human secret
c 165	21.4	0.9	1129	1	AD859788	Novel human secret
c 166	21.4	0.9	1129	1	AD852795	Novel human secret
c 167	21.4	0.9	1129	1	AD857149	Novel human secret
c 168	21.4	0.9	1129	1	AD860340	Novel human secret
c 169	21.4	0.9	1129	1	AD850815	Novel human secret
c 170	21.4	0.9	1129	1	AD865342	Human PRO polynucle
c 171	21.4	0.9	1129	1	AD854440	Novel human secret
c 172	21.4	0.9	1129	1	AD853401	Novel human secret
c 173	21.4	0.9	1129	1	AD858924	Novel human secret
c 174	21.4	0.9	1129	1	AD855802	Novel human secret
c 175	21.4	0.9	1129	1	AD858372	Novel human secret
c 176	21.4	0.9	1129	1	AD803046	Novel human secret
c 177	21.4	0.9	1129	1	AD890038	Novel human secret
c 178	21.4	0.9	1129	1	AD869457	CDNA encoding huma
c 179	21.4	0.9	1129	1	AD848346	Human PRO polynucle
c 180	21.4	0.9	1129	1	ADD09875	Human PRO polynucle
c 181	21.4	0.9	1129	1	ADD04450	Novel human secret
c 182	21.4	0.9	1129	1	AD80406	Novel human secret
c 183	21.4	0.9	1129	1	ADD10913	Human PRO polynucle
c 184	21.4	0.9	1129	1	AD847794	Human PRO polynucle
c 185	21.4	0.9	1129	1	AD879854	Novel human secret
c 186	21.4	0.9	1129	1	ADD09323	Human PRO polynucle
c 187	21.4	0.9	1129	1	ADD41036	Novel human secret
c 188	21.4	0.9	1129	1	ADD52175	CDNA encoding huma
c 189	21.4	0.9	1129	1	ADD52915	CDNA encoding huma
c 190	21.4	0.9	1129	1	ADD53467	Novel human secret
c 191	21.4	0.9	1129	1	ADD51623	CDNA encoding huma
c 192	21.4	0.9	1129	1	ADD02422	Human PRO polynucle
c 193	21.4	0.9	1129	1	ADD01856	Human PRO polynucle
c 194	21.4	0.9	1129	1	ADD54038	Human PRO polynucle
c 195	21.4	0.9	1129	1	ADD92355	Human PRO polynucle
c 196	21.4	0.9	1129	1	ADD91251	Human PRO polynucle
c 197	21.4	0.9	1129	1	ADE03865	Human PRO polynucle
c 198	21.4	0.9	1129	1	ADE32162	Novel human secret
c 199	21.4	0.9	1129	1	ADE22094	CDNA encoding huma
c 200	21.4	0.9	1129	1	ADD79318	CDNA encoding huma
c 201	21.4	0.9	1129	1	ADE41854	Human PRO polynucle
c 202	21.4	0.9	1129	1	ADE17671	Human PRO polynucle
c 203	21.4	0.9	1129	1	ADD91803	Human PRO polynucle
c 204	21.4	0.9	1129	1	ADE33266	Novel human secret
c 205	21.4	0.9	1129	1	ADE33818	Novel human secret
c 206	21.4	0.9	1129	1	ADD79870	CDNA encoding huma
c 207	21.4	0.9	1129	1	ADD92907	Human PRO polynucle
c 208	21.4	0.9	1129	1	ADE19327	Human PRO polynucle
c 209	21.4	0.9	1129	1	ADE18775	Human PRO polynucle
c 210	21.4	0.9	1129	1	ADE42971	Human PRO polynucle
c 211	21.4	0.9	1129	1	ADD95760	Human PRO polynucle
c 212	21.4	0.9	1129	1	ADE22646	CDNA encoding huma
c 213	21.4	0.9	1129	1	ADD78764	CDNA encoding huma
c 214	21.4	0.9	1129	1	ADE32714	Novel human secret
c 215	21.4	0.9	1129	1	ADE42406	Human PRO polynucle
c 216	21.4	0.9	1129	1	ADD80422	CDNA encoding huma
c 217	21.4	0.9	1129	1	ADD89450	Human PRO polynucle
c 218	21.4	0.9	1129	1	ADE40734	Human PRO polynucle
c 219	21.4	0.9	1129	1	ADE04533	Human PRO polynucle
c 220	21.4	0.9	1129	1	ADD80958	Novel human secret
c 221	21.4	0.9	1129	1	ADD76406	Human PRO polynucle
c 222	21.4	0.9	1129	1	ADD87770	Human PRO polynucle
c 223	21.4	0.9	1129	1	ADD86174	Human PRO polynucle
c 224	21.4	0.9	1129	1	ADE75622	CDNA encoding huma
c 225	21.4	0.9	1129	1	ADE23198	CDNA encoding huma
c 226	21.4	0.9	1129	1	ADE23750	CDNA encoding huma
c 227	21.4	0.9	1129	1	ADE24393	Human PRO polynucle
c 228	21.4	0.9	1129	1	ADD87218	Human PRO polynucle
c 229	21.4	0.9	1129	1	ADD89084	Human PRO polynucle
c 230	21.4	0.9	1129	1	ADE18223	Human PRO polynucle
c 231	21.4	0.9	1129	1	ADE88532	Human PRO polynucle
c 232	21.4	0.9	6098	1	ABX14193	Plasmid pIN174 for
c 233	21.4	0.9	121	1	ABA79647	Factor IX mutation
c 234	21.2	0.9	121	1	ABA79646	Factor IX mutation
c 235	21.2	0.9	121	1	ABA79642	Factor IX mutation
c 236	21.2	0.9	121	1	ABA79643	Factor IX mutation
c 237	21.2	0.9	305	1	AB68969	Novel murine polyn
c 238	21.1	0.9	286	1	ABL76556	Corn tassell-derive
c 239	21	0.9	267	1	AAV88446	EST clone BA90. H
c 240	21	0.9	372	1	ABX37095	Bovine EST associa
c 241	20.8	0.9	263	1	AAI20194	Probe #10127 for g
c 242	20.8	0.9	263	1	AA65223	Human foetal liver
c 243	20.8	0.9	263	1	AAI45394	Probe #14080 used
c 244	20.8	0.9	263	1	AA47338	Human breast cell
c 245	20.8	0.9	263	1	ABA32324	Human bone marrow
c 246	20.8	0.9	263	1	AAK39381	Human brain expres
c 247	20.8	0.9	263	1	AAK13640	Human liver single
c 248	20.8	0.9	263	1	AB838969	Probe #5889 used t
c 249	20.8	0.9	263	1	AAI05898	Human genome-deriv
c 250	20.8	0.9	263	1	AB813468	

Db 2167 GCACATGGAGTCAGCATCGGTGTTGTGCATCTGTGTGCATCTGTGTGTGATC 2108
Qy 1164 TGTCGTGTTCTGTCGTGTGTTGCTGTTGTTCTCTCCCTTCTTGATTG 1216
Db 2107 GGTGTGTGCCACTTGGTGTGTGTGTCATCCATGTGTGCAATCTG 2055

RESULT 5
ADC24226/c
ID ADC24226 standard; cDNA; 2422 BP.
XX AC ADC24226;
XX DT
XX DT
XX DT
DE 18-DEC-2003 (first entry)
XX Human NOV8a encoding cDNA SEQ ID NO:33.
KW human; NOVX; cardiac; antiarteriosclerotic; hypotensive; vasotropic;
KW dermatological; anorectic; immunosuppressive; cytostatic;
KW antifertility; haemostatic; anti-HIV; antiasthmatic; antiinflammatory;
KW neuroprotective; anabolic; nootropic; antiparkinsonian; gene therapy;
KW cardiomyopathy; atherosclerosis; hypertension; congenital heart defect;
KW pulmonary stenosis; scleroderma; obesity; metabolic disturbance; obesity;
KW transplantation; adrenoleukodystrophy; congenital adrenal hyperplasia;
KW prostate cancer; diabetes; metabolic disorder; neoplasm; adenocarcinoma;
KW fertility; haemophilia; graft versus host disease; AIDS;
KW bronchial asthma; Crohn's disease; multiple sclerosis;
KW infectious disease; anorexia; neurodegenerative disorder;
KW Alzheimer's disease; Parkinson's disease; immune disorder;
KW haematopoietic disorder; dyslipidaemia; wasting disorder; gene; ss.
XX XX
XX Homo sapiens.
XX OS
XX FH Location/Qualifiers
FT CDS 41..1375
FT FT /*tag= a
FT FT /product= "NOV8a"
XX XX
PN WC2003076584-A2.
XX XX
PD 18-SEP-2003.
XX XX
XX PF 06-MAR-2003; 2003WC-US006951.
XX PR 06-MAR-2002; 2002US-0361974P.
PR 19-MAR-2002; 2002US-0365477P.
PR 22-MAR-2002; 2002US-0366928P.
PR 06-AUG-2002; 2002US-0401661P.
PR 05-MAR-2003; 2003US-00401661.
XX XX
PA {CURA-} CURAGEN CORP.
PI Alsbrook JP, Burgess CE, Edinger SR, Gerlach VL, Ji W, Kekuda R;
PI Li L, MacDougall JR, Miller CE, Millet I, Patturajan M, Pena CE;
PI Rieger DK, Sciore P, Shenoy SG, Smithson G, Spytek KA, Stone DJ;
PI Voss EZ, Zhong M;
DR WPI; 2003-722330/68.
DR P-PSDB; ADC24227.
XX XX
PT New NOVX polypeptides and nucleic acids, useful for diagnosing or
PT treating e.g. cardiomyopathy, atherosclerosis, hypertension, scleroderma,
PT obesity, prostate cancer, AIDS, bronchial asthma, Crohn's disease, or
PT multiple sclerosis.
XX XX
XX Claim 20; SEQ ID NO 33; 229pp; English.

The present invention describes novel human proteins, designated NOVX proteins. The NOVX sequences have cardiant, antiarteriosclerotic, CC hypotensive, vasotropic, dermatological, anorectic, immunosuppressive, CC cytostatic, antifertility, haemostatic, anti-HIV, antiasthmatic, CC antiinflammatory, neuroprotective, anabolic, nootropic and

CC protease activity of Factor VIIa. The calcium binding domain comprises a
CC gene encoding Factor VII, IX, X, Protein C, prothrombin or Protein S. The
CC construct is used to transfect host cells to produce the protein which,
CC on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing
CC OS field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 2438 BP; 658 A; 670 C; 666 G; 444 T; 0 U; 0 Other;

Query Match 1.9%; Score 44; DB 1; Length 2438;
Best Local Similarity 63.0%; Pred. No. 5.3e-05;
Matches 68; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 1080 GTGTTTGCGATCTCTGTTATCTTGCACTGTGCAAGTGTGTGTGTGTGTGTGTGTG 1139
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1995 GTGTGCGTGCATGGCATGGCGTGCACCTCCATGTATATCTGTGTGTGCATCTGTGTG 1936

QY 1140 TGT 1187
Db 1935 TGCATATCTATGTGCGTGTGCATCGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1888

RESULT 16
AAZ12625
ID AAZ12625 standard; cDNA; 300 BP.
XX
AC AAZ12625;
XX
DT 12-OCT-1999 (first entry)
XX
DE Human gene expression product cDNA sequence SEQ ID NO:94.
XX
KW Human; gene; gene expression product; diagnosis; therapy; probe;
KW detection; mapping; tissue typing; profiling; forensic; cancer;
KW genetic analysis; colorectal cancer; breast cancer; lung cancer; ss.
XX
OS Homo sapiens.
XX
XX WO9938972-A2.
PN
XX 05-AUG-1999.
PD
XX 28-JAN-1999; 99WO-US001619.
PF
XX 28-JAN-1998; 98US-0072910P.
PR 24-FEB-1998; 98US-0075954P.
PR 31-MAR-1998; 98US-0080114P.
PR 03-APR-1998; 98US-0080515P.
PR 03-APR-1998; 98US-0080666P.
PR 21-OCT-1998; 98US-0105234P.
PR 28-OCT-1998; 98US-0105877P.
XX
XX (CHIR) CHIRON CORP.
PA (HYSB-) HYSBQ INC.
PA
XX
XX Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
PI Reinhard C, Glese K, Randazzo F, Kennedy GC, Pot D, Kassam A;
PI Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
PI Leshkowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;
XX
XX WPI; 1999-494092/41.
DR
XX
XX Novel human genes and their expression products which are differentially
PT expressed in different cell types.
PT
XX
XX Claim 1; Page 683; 2479pp; English.
PS
XX
XX The present invention describes a library of human polynucleotides
CC comprising the sequences given in AAZ12532 to AAZ17779. Also described is
CC a method of detecting differentially expressed genes correlated with the
CC cancerous state of a mammalian cell, comprising detecting at least one
CC differentially expressed gene product in a test sample from a cell
CC suspected of being cancerous, where the gene product is encoded by one of
CC the 5248 polynucleotide sequences given in AAZ12532 to AAZ17779. The

CC polynucleotides can be used as a source of primers and probes, which can
CC be used for a variety of purpose, e.g. detection of expression levels,
CC mapping, tissue typing or profiling, forensics, genetic analysis and
CC detection of polymorphisms. Polypeptides encoded by the polynucleotides
CC can be used for raising antibodies for experimental, diagnostic and
CC therapeutic purposes. The polynucleotides may also be used to construct
CC arrays for diagnostics (which may be used to determine function of an
CC encoded protein); and to detect differences in expression levels between
CC two cells (e.g. to identify abnormal or diseased tissue in a human, to
CC identify a genetic predisposition or susceptibility to a disease such as
CC cancer). The polynucleotides of the invention are especially used in the
CC diagnosis, prognosis and management of colorectal cancer, breast cancer,
CC and lung cancer. The polynucleotides can also be used to screen for
CC peptide analogues and antagonists
XX
SQ Sequence 300 BP; 41 A; 84 C; 105 G; 68 T; 0 U; 2 Other;

Query Match 1.4%; Score 32.4; DB 1; Length 300;
Best Local Similarity 78.0%; Pred. No. 0.049;
Matches 39; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1103 TGCACCTTGTGAAGT 1152
Db 89 TCCCTAGGCGCGTGCCTGTGCGTGTGCGTGTGCGTGTGTGTGTGTGTGTGTGTGT 138

RESULT 17
AAC16179
ID AAC16179 standard; cDNA; 254 BP.
XX
AC AAC16179;
XX
DT 06-OCT-2000 (first entry)
XX
DE Human secreted protein 5' EST, SEQ ID NO: 20254.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping; ss.
XX
OS Homo sapiens.
XX
XX EP1033401-A2.
PN
XX 06-SEP-2000.
PD
XX 21-FEB-2000; 2000EP-00200610.
PF
PR 26-FEB-1999; 99US-0122487P.
PR
XX (GEST) GENSET.
PA
XX
XX Dumas Milne Edwards J, Duclert A, Giordano J;
PI
XX WPI; 2000-500381/45.
DR
XX
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5' ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures.
PT
XX
XX Claim 1; SEQ ID NO 20254; 71pp + Sequence Listing; English.
PS
XX
XX The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. No ORF has yet been conclusively
CC identified within the present sequence. The 5' ESTs were prepared from
CC total human RNAs or polyA+ RNAs derived from 30 different tissues. EST
CC sequences usually correspond mainly to the 3' untranslated region (UTR)
CC of the mRNA because they are often obtained from oligo-dT primed cDNA
CC libraries. Such ESTs are not well suited for isolating cDNA sequences
CC derived from the 5' ends of mRNAs and even in those cases where longer
CC cDNA sequences have been obtained, the full 5' UTR is rarely included. 5'
CC ESTs are derived from mRNAs with intact 5' ends and can therefore be used
CC to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used in
CC diagnostic, forensic, gene therapy and chromosome mapping procedures.

CC They are used to obtain upstream regulatory sequences and to design
CC expression and secretion vectors
CC
SQ Sequence 254 BP; 74 A; 54 C; 52 G; 73 T; 0 U; 1 Other;
Query Match 1.1%; Score 25.6; DB 1; Length 254;
Best Local Similarity 60.6%; Pred. No. 3.2;
Matches 40; Conservative 1; Mismatches 25; Indels 0; Gaps 0;
QY 1014 CCCAGTATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTCAGTCAGTAATATCA 1073
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
68 CCAAGTTTGACCTTCACAGCTCATTTATGATCATTCATTCATATGATGACCTGATATA 127
QY 1074 TGAGCA 1079
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
128 TGAGCA 133
RESULT 18
AAS68927/c
ID AAS68927 standard; cDNA; 237 BP.
XX
AC AAS68927;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #4731.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US008631.
XX
PR 31-MAR-2000; 2000US-00540217.
PR 23-AUG-2000; 2000US-00649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; AEG04740.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity.
XX
PS Claim 1; SEQ ID NO 4731; 103pp; English.
XX
The invention relates to isolated polynucleotide (I) and polypeptide (II)
sequences. (I) is useful as hybridisation probes, polymerase chain
reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
and in recombinant production of (II). The polynucleotides are also used
in diagnostics as expressed sequence tags for identifying expressed
genes. (I) is useful in gene therapy techniques to restore normal
activity of (II) or to treat disease states involving (II). (II) is
useful for generating antibodies against it, detecting or quantitating a
polypeptide in tissue, as molecular weight markers and as a food
supplement. (II) and its binding partners are useful in medical imaging
of sites expressing (II). (I) and (II) are useful for treating disorders
involving aberrant protein expression or biological activity. The
polypeptide and polynucleotide sequences have applications in
diagnostics, forensics, gene mapping, identification of mutations
responsible for genetic disorders or other traits to assess biodiversity
and to produce other types of data and products dependent on DNA and
amino acid sequences. AAS64197-AAS94564 represent novel human diagnostic

CC coding sequences of the invention. Note: The sequence data for this
CC patent did not appear in the printed specification, but was obtained in
CC electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 237 BP; 97 A; 34 C; 82 G; 24 T; 0 U; 0 Other;
Query Match 1.1%; Score 25.4; DB 1; Length 237;
Best Local Similarity 51.3%; Pred. No. 3.6;
Matches 59; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 1456 CATTTTGAGTTTCTATTGGAAAAGTCAGGTGTAATCTTAATACATCTGCCTTATATGTT 1515
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
236 CATTTTGAGTTTCTATTGGTTGCTGCTGGGAGACCAATGCTCGGAGCTTCTTGTC 177
QY 1516 AATTGGTCTTTTCCCTTGATCTTTTAAATATCTTCTTGTGTTATATCTTT 1570
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
176 CAGTAATCCTTTCT 122
RESULT 19
ABQ47969/c
ID ABQ47969 standard; DNA; 612 BP.
XX
AC ABQ47969;
XX
DT 12-JUL-2002 (first entry)
XX
DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34560.
XX
KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX
OS Homo sapiens.
XX
PN WO200218632-A2.
XX
PD 07-MAR-2002.
XX
PF 01-SEP-2001; 2001WO-EP010074.
PR 01-SEP-2000; 2000DE-01043826.
PR 05-SEP-2000; 2000DE-01044543.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K, Guetig D;
XX
DR WPI; 2002-371829/40.
XX
PT Determining the degree of cytosine methylation in genomic DNA, useful for
PT diagnosis and prognosis, comprises selective hybridization of amplicons
PT from chemically treated DNA.
XX
PS Claim 12; 56pp + Sequence Listing; 56pp; German.
XX
This invention describes a novel method for determining the degree of
methylation of a particular cytosine in a motif 5'-CpG-3', present in a
genomic sample of DNA. The sample is treated chemically to convert
cytosine (C) but not methylated C, to uracil, then part of the genomic
DNA that contains the target C is amplified to form a labeled amplicon.
The amplicon is hybridised to two classes, each with at least one member,
of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
degree of hybridisation to both classes is determined from the label on
the amplicon. From the ratio of labels hybridised to the two classes of
oligomers, the degree of methylation is calculated. The method is used:
(i) for diagnosis and/or prognosis of side effects of therapeutic drugs
and of a wide range of diseases, e.g. cancer, disorders of the central
nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
particularly by detecting mutations or single nucleotide polymorphisms
(SNP's); and (ii) for differentiation of cell or tissue types and for

ID ABQ47966 standard; DNA; 612 BP.
XX ABQ47966;
AC
XX
XX
DT 12-JUL-2002 (first entry)
XX
DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34557.
XX
XX Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX
XX Homo sapiens.
OS
XX WO200218632-A2.
PN
XX 07-MAR-2002.
PD
XX
XX 01-SEP-2001; 2001WO-EP010074.
PF
XX 01-SEP-2000; 2000DE-01043826.
PR
XX 05-SEP-2000; 2000DE-01044543.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K, Guetig D;
PI WPI; 2002-371829/40.
DR
XX
XX Determining the degree of cytosine methylation in genomic DNA, useful for
PT diagnosis and prognosis, comprises selective hybridization of amplicons
PT from chemically treated DNA.
PT
XX Claim 12; 56pp + Sequence Listing; 56pp; German.
PS
XX This invention describes a novel method for determining the degree of
CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC genomic sample of DNA. The sample is treated chemically to convert
CC cytosine (C) but not methylated C, to uracil, then part of the genomic
CC DNA that contains the target C is amplified to form a labeled amplicon.
CC The amplicon is hybridised to two classes, each with at least one member,
CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC degree of hybridisation to both classes is determined from the label on
CC the amplicon. From the ratio of labels hybridised to the two classes of
CC oligomers, the degree of methylation is calculated. The method is used:
CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC and of a wide range of diseases, e.g. cancer, disorders of the central
CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC particularly by detecting mutations or single nucleotide polymorphisms
CC (SNPs); and (ii) for differentiation of cell or tissue types and for
CC investigating cell differentiation. The method allows the methylation
CC status of many C residues to be determined simultaneously. ABQ13410-
CC ABQ54121 represent genomic DNA sequences used to illustrate the method
CC for determining the degree of cytosine methylation described in the
CC disclosure of the invention
XX
SQ Sequence 612 BP; 88 A; 72 C; 216 G; 236 T; 0 U; 0 Other;
Query Match 1.0%; Score 23.4; DB 1; Length 612;
Best Local Similarity 46.2%; Pred. No. 15;
Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;
QY 1593 GTGGGAGTTCTTTTCGGTCCAAATCTATTTGGTGTCTTTGTATGCTTCTGTACCTGA 1652
DB 431 GGGGGTCGTTTTTCGTTCCGGGGAATTCGTTTTTTTGGCGGATGTTTTTATTTTAGG 490
QY 1653 TAGGCATCTCTTCTCAAGTTAGGAAATTTCTTTTGGTGTCTTTCTTCTGAAAATATTT 1712
DB 491 TAGCGCTTTTTCGTTCCGGTCTGATCGGCTATGCGGTTTTTATATAGAAATACGAT 550
QY 1713 CCTGCTTTGACCTGCTCTTCCCTCTCTATTCCTTTGTTT 1761

Db 551 TTGTAAGTATATTTAGGGTGTTTTTTTAAATTTTAAAGGAGTTTTT 599

RESULT 32
ABQ47967/c
ID ABQ47967 standard; DNA; 612 BP.
XX
XX ABQ47967;
AC
XX
XX 12-JUL-2002 (first entry)
DT
XX Oligonucleotide for detecting cytosine methylation SEQ ID NO 34558.
DE
XX Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX
XX Homo sapiens.
OS
XX WO200218632-A2.
PN
XX 07-MAR-2002.
PD
XX
XX 01-SEP-2001; 2001WO-EP010074.
PF
XX 01-SEP-2000; 2000DE-01043826.
PR
XX 05-SEP-2000; 2000DE-01044543.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K, Guetig D;
PI WPI; 2002-371829/40.
DR
XX
XX Determining the degree of cytosine methylation in genomic DNA, useful for
PT diagnosis and prognosis, comprises selective hybridization of amplicons
PT from chemically treated DNA.
PT
XX Claim 12; 56pp + Sequence Listing; 56pp; German.
PS
XX This invention describes a novel method for determining the degree of
CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC genomic sample of DNA. The sample is treated chemically to convert
CC cytosine (C) but not methylated C, to uracil, then part of the genomic
CC DNA that contains the target C is amplified to form a labeled amplicon.
CC The amplicon is hybridised to two classes, each with at least one member,
CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC degree of hybridisation to both classes is determined from the label on
CC the amplicon. From the ratio of labels hybridised to the two classes of
CC oligomers, the degree of methylation is calculated. The method is used:
CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC and of a wide range of diseases, e.g. cancer, disorders of the central
CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC particularly by detecting mutations or single nucleotide polymorphisms
CC (SNPs); and (ii) for differentiation of cell or tissue types and for
CC investigating cell differentiation. The method allows the methylation
CC status of many C residues to be determined simultaneously. ABQ13410-
CC ABQ54121 represent genomic DNA sequences used to illustrate the method
CC for determining the degree of cytosine methylation described in the
CC disclosure of the invention
XX
SQ Sequence 612 BP; 236 A; 216 C; 72 G; 88 T; 0 U; 0 Other;
Query Match 1.0%; Score 23.4; DB 1; Length 612;
Best Local Similarity 46.2%; Pred. No. 15;
Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;
QY 1593 GTGGGAGTTCTTTTCGGTCCAAATCTATTTGGTGTCTTTGTATGCTTCTGTACCTGA 1652
DB 431 GGGGGTCGTTTTTCGTTCCGGGGAATTCGTTTTTTTGGCGGATGTTTTTATTTTAGG 123
QY 1653 TAGGCATCTCTTCTCAAGTTAGGAAATTTCTTTTGGTGTCTTTCTTCTGAAAATATTT 1712

Db 122 TACGGTCTTTTTCGTCGGTCTGATCGTATGTCGTTTATATTAGAAATACGAT 63
Qy 1713 CCCGCTTTTACCTGCTTCTCCCTTCTCTATCTCTATCTTGGTTTTT 1761
Db 62 TTGTAAGTATATATTAGGTCGTTTTTTTAAATTTTAAAGGAGTTTTT 14

RESULT 33
AAT40850/c
ID AAT40850 standard; cDNA; 306 BP.
XX AC AAT40850;
XX DT 16-MAR-1997 (first entry)
XX DE Serine protease nSP8-299 gene.
XX KW Flea; midgut; serine protease; nSP8-299; recombinant vaccine;
XX KW domestic animal; infestation; insecticide; protease-inhibitor;
XX KW controlled release formulation; synergist; ss.
XX OS Siphonaptera sp.
XX PH Key Location/Qualifiers
XX FT unsure 1. .90
XX FT /tag= a
XX FT /note= "back-translated from N-terminal part of PfSP8-99
XX FT (AAW01205)"
XX FT unsure 91. .276
XX FT /tag= b
XX FT /note= "Corresponds to nSP8-186 (AAT40826, claim 70)"
XX FT unsure 277. .299
XX FT /tag= c
XX FT /note= "back-translated from C-terminal part of PfSP8-99
XX FT (AAW01205)"
XX PN WO9611706-A1.
XX PD 25-APR-1996.
XX PF 18-OCT-1995; 95WO-US014442.
XX PR 18-OCT-1994; 94US-00326773.
XX PR 07-JUN-1995; 95US-00482130.
XX PR 07-JUN-1995; 95US-00484211.
XX PR 07-JUN-1995; 95US-00485443.
XX PR 07-JUN-1995; 95US-00485455.
XX PA (HESK-) HESKA CORP.
XX PI Grieve RB, Rushlow KE, Hunter SW, Frank GR, Stiegler GL, Heath A;
XX PI Yamanaka M, Arfsten A, Dale B;
XX DR WPI; 1996-221762/22.
XX DR P-PSDB; AAW01205.
XX PT DNA encoding Flea serine protease and aminopeptidase - useful in vaccines
XX PT to protect animals from flea infestation.
XX PS Claim 70; Page 182; 241pp; English.
XX This sequence (nSP8-299) encodes a flea midgut serine protease (PfSP8-
XX 99), and has been isolated from a flea cDNA library by PCR using primers
XX AAT40826-63 and hybridisation with probe AAT40866, based on conserved
XX serine protease sequences. The sequence contains sequence AAT40826 (nSP8
XX -186), which spans 2 conserved serine protease sequences. The sequence
XX shown has been derived from the encoded protein sequence (N- and C-
XX terminal regions) and internal sequence AAT40826, since the appropriate
XX page is missing from the specification. The sequence may be used to
XX produce a recombinant vaccine for protection of domestic animals from
XX flea infestation, or in isolation of protease-inhibitors which may be
XX used in controlled release formulations to reduce the flea burden on and

CC around the animal. The inhibitors may be included in insecticidal
CC compositions to increase efficacy of other active compounds, by reducing
CC proteolytic activity in the flea midgut
XX Sequence 306 BP; 83 A; 30 C; 72 G; 56 T; 0 U; 65 Other;
SQ Query Match 1.0%; Score 23; DB 1; Length 306;
Best Local Similarity 58.5%; Pred. No. 17;
Matches 38; Conservative 1; Mismatches 26; Indels 0; Gaps 0;
Qy 248 CCAGGTAGGGGACACTACCGCATTCCTCTCTTCCAAACACTCTATCTTCGATTTC 307
Db 280 CYTGCAAGTCTCTTTCCACCATCAATTCCTCTGACACATCTGTGTTTCTACATTC 221
Qy 308 TATCT 312
Db 220 CATT 216

RESULT 34
AAA54031/c
ID AAA54031 standard; DNA; 1507 BP.
XX AC AAA54031;
XX DT 08-FEB-2001 (first entry)
XX DE Human factor X coding sequence.
XX KW Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric protein;
XX KW fusion protein; coagulation factor; Factor X; Factor VII; Protein S;
XX KW Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;
XX KW ds.
XX OS Homo sapiens.
XX PN WO200054787-A1.
XX PD 21-SEP-2000.
XX PF 16-MAR-2000; 2000WO-US006934.
XX PR 16-MAR-1999; 99US-0124609P.
XX PA (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX PA (UYN-) UNIV NORTH CAROLINA.
XX PI High KA, Camire RM, Larson PJ, Stafford DW;
XX DR WPI; 2000-638152/61.
XX PT Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent
XX PT protein useful for treating diseases associated with the protein,
XX PT comprises sequence encoding propeptide fused to sequence encoding the
XX PT protein.
XX PS Disclosure; Fig 6a; 60pp; English.
XX Efficient processing and release of mature two-chain factor X into the
XX circulation requires: removal of the signal sequence; formation of
XX disulfide bonds; modification of amino terminal glutamic acid residues,
XX to gamma-carboxylglutamic acid; modification of one aspartic acid in the
XX first epidermal growth factor (EGF) domain to beta-hydroxyaspartic acid;
XX addition of N- and O-linked oligosaccharides to the activation peptide;
XX removal of an internal tripeptide to yield two-chain factor X and removal
XX of the propeptide just prior to secretion. While some of these
XX modifications do not appear essential for factor X function the removal
XX of the signal sequence, propeptide, internal tripeptide and full gamma-
XX carboxylation are all steps which are important requisites for the
XX production of biologically active factor X/PXA. Isolated chimeric
XX polynucleotides are described which encode a propeptide fused to a
XX nucleic acid sequence encoding a vitamin K-dependent protein (VKDP). The
XX fusion proteins encoded are vitamin K-dependent protein gamma-

The invention relates to a gene expression profile comprising one or more genes (AB234889-AB235692) and generated from a cell type. The cell type is a coronary artery endothelium, umbilical artery or vein endothelium, aortic endothelium, dermal microvascular endothelium, pulmonary artery endothelium, myometrium microvascular endothelium, keratinocyte epithelium, bronchial epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, mammary epithelium, prostate epithelium, renal cortical epithelium, renal proximal tubule epithelium, small airway epithelium, renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery smooth muscle, bronchial smooth muscle, uterine smooth muscle, lung fibroblast,

The invention relates to a method of determining whether a patient will respond to treatment with a farnesyl transferase inhibitor (FTI), by analyzing the expression of gene that is differentially modulated in the presence of an FTI. The method is useful for determining whether a patient will respond to treatment with a FTI such as (B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2-(1H)quinoline, monitoring the therapy of a patient, treating

XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488897/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human placenta.
XX Claim 25; SEQ ID NO 1496; 654pp; English.
XX The present invention relates to single exon nucleic acid probes (SENP).
XX The present sequence is one such probe. The probes are useful for
XX producing a microarray for predicting, measuring and displaying gene
XX expression in samples derived from human placenta. The probes are useful
XX for antenatal diagnosis of human genetic disorders
XX
XX Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
SQ
Query March 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
Qy 2156 CTATTGTAATAGGGTTTTCAGGAGACATATGTCCTGGTTGTTATGTCGTGTTTTG 2215
Db 357 CCATTTAAACATGATGGATCCACACTGATCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2216 CTTTGGCATATAGACGGCTGAGTTGGGATGATTTGTAATTCCTAGTGCTGAT 2267
Db 297 AATTGGCAGCTAACTGTTAGAAATGCCCGTCTCCCTGTAGATACTCAT 246
RESULT 43
ABA42785/c
ID ABA42785 standard; DNA; 476 BP.
XX
XX ABA42785;
XX
XX 01-FEB-2002 (first entry)
XX Human breast cell single exon nucleic acid probe #1480.
XX
XX Human; microarray; single exon probe; gene expression; breast; disease;
XX cancer; ss.
XX
XX Homo sapiens.
XX OS
XX WO200157271-A2.
XX PN
XX
XX 09-AUG-2001.
XX PD
XX
XX 30-JAN-2001; 2001WO-US000662.
XX PF
XX
XX 04-FEB-2000; 2000US-0180312P.
XX PR
XX 26-MAY-2000; 2000US-0207456P.
XX PR
XX 30-JUN-2000; 2000US-00608408.
XX PR
XX 03-AUG-2000; 2000US-00632366.
XX PR
XX 21-SEP-2000; 2000US-0234687P.
XX PR
XX 27-SEP-2000; 2000US-0236359P.
XX PR
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-496933/54.
XX
XX New spatially-addressable set of single exon nucleic acid probes, useful
XX for measuring gene expression in sample derived from human breast,
XX PT comprises number of single exon nucleic acid probes.
XX
XX Claim 1; SEQ ID NO 1480; 327pp + Sequence Listing; English.
XX
XX The invention relates to a spatially-addressable set of single exon

XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: the sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTACAGGACATATGCTCTGGTTGTTATTGCTGCTGTTTG 2215
DB 357 CCATTAAACATGATGGATCGATCCACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
QY 2216 CTTTGGCATATAGCGCTGAGTTTGGGATGATTGTAATTCAGTGTCTGAT 2267
DB 297 AATTGGCAGTAACTGCTTAGAATGCCGGTCTCCCTGTAGATCTCAT 246
RESULT 45
AAK26907/c
ID AAK26907 standard; DNA; 476 BP.
XX
AC AAK26907;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed single exon probe SEQ ID NO: 1464.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US0000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 1464; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is one of

CC the probes of the invention
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTACAGGACATATGCTCTGGTTGTTATTGCTGCTGTTTG 2215
DB 357 CCATTAAACATGATGGATCGATCCACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
QY 2216 CTTTGGCATATAGCGCTGAGTTTGGGATGATTGTAATTCAGTGTCTGAT 2267
DB 297 AATTGGCAGTAACTGCTTAGAATGCCGGTCTCCCTGTAGATCTCAT 246
RESULT 46
AAK01461/c
ID AAK01461 standard; DNA; 476 BP.
XX
AC AAK01461;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe SEQ ID NO: 1452.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
KW ss.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US0000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
PS Example 4; SEQ ID NO 1452; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTACAGGACATATGCTCTGGTTGTTATTGCTGCTGTTTG 2215

```
Db 357 CCAATTAAACATGGATTGGACATCACCATGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2216 CTTTGGCATATAGACGGCTGAGTTGGAGATGATTGTAATTCTAGTGTGCTGAT 2267
Db 297 AATTGGCAGGTAAACTGCTTAGAATGCCGGTCCCTCCCTCTAGATACTCAT 246

RESULT 47
ID ABS26497/c
XX ABS26497 standard; DNA; 476 BP.
XX AC
XX ABS26497;
XX DT
XX 25-FEB-2003 (first entry)
XX DE
XX Human liver single exon probe, SEQ ID NO 1487.
XX KW
XX Human; single exon nucleic acid probe; liver; cirrhosis;
XX KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX KW coronary heart disease; ss.
XX OS
XX Homo sapiens.
XX PN
XX WO200157273-A2.
XX PD
XX 09-AUG-2001.
XX PF
XX 30-JAN-2001; 2001WO-US000664.
XX PR
XX 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.
XX DR
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human adult liver.
XX PT
XX Claim 1; SEQ ID NO 1487; 658pp; English.
XX CC
XX The invention relates to a single exon nucleic acid probe (SENP) (I) for
XX CC measuring human gene expression in a sample derived from human adult
XX CC liver, comprising one of 13109 defined nucleotide sequences given in the
XX CC specification (or complements/ fragments). The probe hybridises at high
XX CC stringency to a nucleic acid molecule expressed in the human adult liver.
XX CC (I) may be used for predicting, measuring and displaying gene expression
XX CC in samples derived from human adult liver. The genes identified may be
XX CC involved in genetic liver diseases such as cirrhosis,
XX CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX CC associated with coronary heart disease. ABS25011-ABS51005 represent human
XX CC liver single exon nucleic acid probes of the invention. Note: The
XX CC sequence information for this patent does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 2156 CTAATTGTAATAGGGTTTACGAGGACATATGCTCGTGTGTTATGTTCTGTGTTTGG 2215
Db 357 CCAATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
```

```
Qy 2216 CTTTGGCATATAGACGGCTGAGTTGGAGATGATTGTAATTCTAGTGTGCTGAT 2267
Db 297 AATTGGCAGGTAAACTGCTTAGAATGCCGGTCCCTCCCTCTAGATACTCAT 246

RESULT 48
AAI01449/c
ID AAI01449 standard; DNA; 476 BP.
XX AC
XX AAI01449;
XX DT
XX 09-OCT-2001 (first entry)
XX DE
XX Probe #1440 used to measure gene expression in human breast sample.
XX KW
XX Probe; human; breast disease; breast cancer; development disorder; ss;
XX KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX OS
XX Homo sapiens.
XX PN
XX WO200157270-A2.
XX PD
XX 09-AUG-2001.
XX PF
XX 29-JAN-2001; 2001WO-US000661.
XX PR
XX 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX DR
XX Novel single exon nucleic acid probe used to measuring gene expression in
XX PT a human breast.
XX PT
XX Claim 25; SEQ ID NO 1440; 322pp; English.
XX CC
XX The present invention relates to novel single exon nucleic acid probes.
XX CC The present sequence is one such probe. The probes are useful for
XX CC measuring human gene expression in a human breast sample, where the probe
XX CC hybridises at high stringency to a nucleic acid expressed in the human
XX CC breast. The probes are useful for predicting, diagnosing, grading,
XX CC staging, monitoring and prognosing diseases of the human breast,
XX CC particularly those diseases with polygenic aetiology. The diseases
XX CC include: breast cancer, disorders of development, inflammatory diseases
XX CC of the breast, fibrocystic changes, proliferative breast disease and non-
XX CC carcinoma tumours. Note: The sequence data for this patent did not form
XX CC part of the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 2156 CTAATTGTAATAGGGTTTACGAGGACATATGCTCGTGTGTTATGTTCTGTGTTTGG 2215
Db 357 CCAATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298

Qy 2216 CTTTGGCATATAGACGGCTGAGTTGGAGATGATTGTAATTCTAGTGTGCTGAT 2267
Db 297 AATTGGCAGGTAAACTGCTTAGAATGCCGGTCCCTCCCTCTAGATACTCAT 246
```



```

Db      217 TCTAGCT 211
|||
RESULT 53
AAI44871/c
ID AAI44871 standard; DNA; 301 BP.
XX
XX
AC AAI44871;
XX
XX 17-OCT-2001 (first entry)
XX
XX Probe #13557 used to measure gene expression in human placenta sample.
XX
XX Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
XX
XX Homo sapiens.
XX
XX WO200157272-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488597/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human placenta.
XX
XX Claim 25; SEQ ID NO 13557; 654pp; English.
XX
XX The present invention relates to single exon nucleic acid probes (SENP).
XX The present sequence is one such probe. The probes are useful for
XX producing a microarray for predicting, measuring and displaying gene
XX expression in samples derived from human placenta. The probes are useful
XX for antenatal diagnosis of human genetic disorders
XX
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 27;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACGCGCTCTTCCCTCCCTATTCCTTTGGTTTGGCATAGTCTCGGCTT 1779
Db 277 TCTCGCGCTGTACCTCTCGGCTCTCAATTTCTTCCCTCTCTCTCTCTGCGCT 218
QY 1780 CCTGGAT 1786
Db 217 TCTAGCT 211
|||
RESULT 54
ABA46822/c
ID ABA46822 standard; DNA; 301 BP.
XX
XX
AC ABA46822;
XX
XX 01-FEB-2002 (first entry)
XX
XX

```

```

DE XX Human breast cell single exon nucleic acid probe #5517.
KW XX Human; microarray; single exon probe; gene expression; breast; disease;
KW cancer; ss.
XX
XX Homo sapiens.
XX
XX WO200157271-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-496933/54.
XX
XX New spatially-addressable set of single exon nucleic acid probes, useful
XX for measuring gene expression in sample derived from human breast,
XX comprises number of single exon nucleic acid probes.
XX
XX Claim 4; SEQ ID NO 5517; 327pp + Sequence Listing; English.
XX
XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human breast and BT 474 cells. The method involves contacting the
XX probes with a collection of detectably labelled nucleic acids derived
XX from mRNA of human breast, and then measuring the label bound to each
XX probe of the microarray. The probes are useful for verifying the
XX expression of regions of genomic DNA predicted to encode proteins. They
XX are useful for gene discovery, and for determining predisposition and/or
XX prognosing breast disease. Gene expression analysis is useful for
XX assessing the toxicity of chemical agents on cells. The microarray of
XX this invention presents a far greater diversity of probes for measuring
XX gene expression, with far less bias than expressed sequence tag
XX microarrays. The method is suitable for rapid production of functional
XX information from genomic sequence. The present sequence is a single exon
XX nucleic acid probe of the invention. Note: The sequence data for this
XX patent did not form part of the printed specification, but was obtained
XX in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 27;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACGCGCTCTTCCCTCCCTATTCCTTTGGTTTGGCATAGTCTCGGCTT 1779
Db 277 TCTCGCGCTGTACCTCTCGGCTCTCAATTTCTTCCCTCTCTCTCTCTGCGCT 218
QY 1780 CCTGGAT 1786
Db 217 TCTAGCT 211
|||
RESULT 55
ABA31826/c
ID ABA31826 standard; DNA; 301 BP.
XX
XX
AC ABA31826;
XX
XX

```



```
DT 23-JAN-2002 (first entry)
XX
DE
DE
XX
XX
XX Probe #10292 for gene expression analysis in human heart cell sample.
KW Human; gene expression; heart; microarray; vascular system; probe;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease; ss.
XX
XX
OS Homo sapiens.
XX
XX WO200157274-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-48899/53.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX hearts.
XX
XX Claim 4; SEQ ID NO 10292; 530pp; English.
XX
XX The present invention relates to single exon nucleic acid probes for
XX measuring human gene expression in a sample derived from human heart. The
XX present sequence is one such probe. The probes may be used for
XX predicting, measuring and displaying gene expression in samples derived
XX from the human heart via microarrays. By measuring gene expression, the
XX probes are useful for predicting, diagnosing, grading, staging,
XX monitoring and prognosing diseases of the human heart and vascular system
XX e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
XX congenital heart disease. Note: The sequence data for this patent did not
XX form part of the printed specification, but was obtained in electronic
XX format directly from WIPO at ftp.wipo.int/pub/published_pat_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 27;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
XX
XX QY 1720 TTGACCTGCTTCTCCCTTCTCTATTCCTTTGTTTTCATAGTCTCTGCGCTT 1779
XX Db 277 TCTCGCTGTACCTCTGCGCTTCTCAATTCTTCTCTCTCTCTCTCTCTCTGCGCT 218
XX
XX QY 1780 CTTGGAT 1786
XX Db 217 TCTAGCT 211
XX
XX RESULT 56
XX AAK38868/c
XX ID AAK38868 standard; DNA; 301 BP.
XX
XX AC AAK38868;
XX
XX 06-NOV-2001 (first entry)
XX
XX Human bone marrow expressed single exon probe SEQ ID NO: 13425.
XX
XX Human; bone marrow expressed exon; gene expression analysis; probe;
XX
```

```
microarray; cancer; leukaemia; lymphoma; myeloma; ss.
KW
XX
OS Homo sapiens.
XX
XX WO200157276-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-48899/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human bone marrow.
XX
XX Example 4; SEQ ID NO 13425; 658pp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX bone marrow. They can be used to measure gene expression in bone marrow
XX samples, which may enable the improved diagnosis and treatment of cancers
XX such as lymphoma, leukaemia and myeloma. The present sequence is one of
XX the probes of the invention
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 27;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
XX
XX QY 1720 TTGACCTGCTTCTCCCTTCTCTATTCCTTTGTTTTCATAGTCTCTGCGCTT 1779
XX Db 277 TCTCGCTGTACCTCTGCGCTTCTCAATTCTTCTCTCTCTCTCTCTCTGCGCT 218
XX
XX QY 1780 CTTGGAT 1786
XX Db 217 TCTAGCT 211
XX
XX RESULT 57
XX AAK13137/c
XX ID AAK13137 standard; DNA; 301 BP.
XX
XX AC AAK13137;
XX
XX 05-NOV-2001 (first entry)
XX
XX Human brain expressed single exon probe SEQ ID NO: 13128.
XX
XX Human; brain expressed exon; gene expression analysis; probe; microarray;
XX Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
XX ss.
XX
XX Homo sapiens.
XX
XX WO200157275-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
```

```
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains.
XX Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX brain. They can be used to measure gene expression in brain cell samples,
XX which may enable the diagnosis and improved treatment of nervous system
XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX epilepsy and cancers. The present sequence is one of the probes of the
XX invention
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 27;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACCTGCTTCCTCCCTCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1779
DB 277 TCTGCGCTGCTTACCTCGCCTCTCAATTTCTTTCCCTCTCTCTCTCTCTCGCGT 218
QY 1780 CTGGAT 1786
DB 217 TCTAGCT 211
XX RESULT 58
XX ABS38453/c
XX ID ABS38453 standard; DNA; 301 BP.
XX AC ABS38453;
XX DT 25-FEB-2003 (first entry)
XX DE Human liver single exon probe, SEQ ID NO 13443.
XX Human; single exon nucleic acid probe; liver; cirrhosis;
XX hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX coronary heart disease; ss.
XX OS Homo sapiens.
XX PN WO200157273-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains.
XX Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX brain. They can be used to measure gene expression in brain cell samples,
XX which may enable the diagnosis and improved treatment of nervous system
XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX epilepsy and cancers. The present sequence is one of the probes of the
XX invention
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 27;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACCTGCTTCCTCCCTCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1779
DB 277 TCTGCGCTGCTTACCTCGCCTCTCAATTTCTTTCCCTCTCTCTCTCTCTCGCGT 218
QY 1780 CTGGAT 1786
DB 217 TCTAGCT 211
XX RESULT 59
XX AAI05395/c
XX ID AAI05395 standard; DNA; 301 BP.
XX AC AAI05395;
XX DT 09-OCT-2001 (first entry)
XX DE Probe #5386 used to measure gene expression in human breast sample.
XX Probe; human; breast disease; breast cancer; development disorder; ss;
XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX OS Homo sapiens.
XX PN WO200157270-A2.
XX PD 09-AUG-2001.
XX PF 29-JAN-2001; 2001WO-US000661.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human adult liver.
XX Claim 4; SEQ ID NO 13443; 658pp; English.
XX The invention relates to a single exon nucleic acid probe (SEN) (I) for
XX measuring human gene expression in a sample derived from human adult
XX liver, comprising one of 13109 defined nucleotide sequences given in the
XX specification (or complements/ fragments). The probe hybridises at high
XX stringency to a nucleic acid molecule expressed in the human adult liver.
XX (I) may be used for predicting, measuring and displaying gene expression
XX in samples derived from human adult liver. The genes identified may be
XX involved in genetic liver diseases such as cirrhosis,
XX hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX associated with coronary heart disease. ABG25011-ABS51005 represent human
XX liver single exon nucleic acid probes of the invention. Note: The
XX sequence information for this patent does not appear in the printed
XX specification but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
```


KW	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic; antilipemic; ss.
KW	Homo sapiens.
OS	Homo sapiens.
XX	WO200173002-A2.
XX	04-OCT-2001.
XX	27-MAR-2001; 2001WO-US009761.
XX	27-MAR-2000; 2000US-0192176P.
PR	27-MAR-2000; 2000US-0192179P.
PR	01-JUN-2000; 2000US-0208538P.
PR	30-OCT-2000; 2000US-0244989P.
XX	(UWDE) UNIV DELAWARE.
PA	Kmiec EB, Gamper HB, Rice MC;
XX	WPI; 2001-639230/73.
XX	Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.
XX	Claim 7; Page 184; 294pp; English.
XX	The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention
XX	Sequence 121 BP; 36 A; 23 C; 25 G; 37 T; 0 U; 0 Other;
XX	Query Match 1.0%; Score 22; DB 1; Length 121;
XX	Best Local Similarity 53.5%; Pred. No. 26;
XX	Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY	2156 CTATTGTAATAGGTTTACGAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTTC 2215
DB	88 CCATTAAACATGGATTGGACTCACACTGTCCTCACTTTGAGTAGGTTAAGAATTG 29
QY	2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB	28 AATTGGCAGCTAACTGCTTAGAATG 3
RESULT 62	
ABA79623	
ID ABA79623 standard; DNA; 121 BP.	
XX	
AC ABA79623;	

XX	24-JAN-2002 (first entry)
XX	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2469.
XX	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic; antilipemic; ss.
XX	Homo sapiens.
OS	Homo sapiens.
XX	WO200173002-A2.
XX	04-OCT-2001.
XX	27-MAR-2001; 2001WO-US009761.
XX	27-MAR-2000; 2000US-0192176P.
PR	27-MAR-2000; 2000US-0192179P.
PR	01-JUN-2000; 2000US-0208538P.
PR	30-OCT-2000; 2000US-0244989P.
XX	(UWDE) UNIV DELAWARE.
PA	Kmiec EB, Gamper HB, Rice MC;
XX	WPI; 2001-639230/73.
XX	Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.
XX	Claim 7; Page 184; 294pp; English.
XX	The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention
XX	Sequence 121 BP; 37 A; 24 C; 23 G; 37 T; 0 U; 0 Other;
XX	Query Match 1.0%; Score 22; DB 1; Length 121;
XX	Best Local Similarity 53.5%; Pred. No. 26;
XX	Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY	2156 CTATTGTAATAGGTTTACGAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTTC 2215
DB	35 CCATTAAACATGGATTGGACTCACACTGTCCTCACTTTGAGTAGGTTAAGAATTG 94
QY	2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB	95 AATTGGCAGCTAACTGCTTAGAATG 120

```
RESULT 63
ABA79622/c
ID ABA79622 standard; DNA; 121 BP.
XX
XX
AC ABA79622;
XX
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2468.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antickling; antianaemic; haemostatic;
KW antileptic; ss.
XX
OS Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192179P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX Claim 7; Page 184; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), presenilin-1 (PSEN1) and
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX Sequence 121 BP; 37 A; 23 C; 24 G; 37 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22; DB 1; Length 121;
XX Best Local Similarity 53.5%; Pred. No. 26;
XX Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
XX
XX 2156 CTATTGTAATAGGTTTACGAGGACATATCTCTGGTTGTATGCTGTTTGG 2215
DB 87 CCATTAAACATGGATTGGACACATGATCTCCATCTTGTAGATAGGTTAAGAAATG 28
```

```
QY 2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB 27 AATTGGCAGCTAAACTGCTTAGAATG 2
XX
XX
RESULT 64
ABA79634/c
ID ABA79634 standard; DNA; 121 BP.
XX
XX ABA79634;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2480.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antickling; antianaemic; haemostatic;
KW antileptic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192179P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX Claim 7; Page 184; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), presenilin-1 (PSEN1) and
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX Sequence 121 BP; 37 A; 23 C; 23 G; 38 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22; DB 1; Length 121;
XX Best Local Similarity 53.5%; Pred. No. 26;
XX Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
```



```
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 121 BP; 37 A; 26 C; 23 G; 35 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATGCTCTGTTTATTGTCGTGTTTGG 2215
DB 33 CCAATTAAACATGATTGGACTCACATCTCCATCTTTGAGATAGGTTAAGAAATG 92
QY 2216 CTTTGGCATATAGCGCTGAGTTTG 2241
DB 93 AATTGGCAGCTAAACTGCTTAGAATG 118
RESULT 67
ABA79635
ID ABA79635 standard; DNA; 121 BP.
XX
AC ABA79635;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2481.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PA (UYDE ) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PS Claim 7; Page 184; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
```

```
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSN1) and
CC presenilin-2 (PSN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATGCTCTGTTTATTGTCGTGTTTGG 2215
DB 36 CCAATTAAACATGATTGGACTCACATCTCTCCATCTTTGAGATAGGTTAAGAAATG 95
QY 2216 CTTTGGCATATAGCGCTGAGTTTG 2241
DB 96 AATTGGCAGCTAAACTGCTTAGAATG 121
RESULT 68
ABA79638/c
ID ABA79638 standard; DNA; 121 BP.
XX
AC ABA79638;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2484.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PA (UYDE ) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PS Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
PS Claim 7; Page 185; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
```

CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX Sequence 121 BP; 37 A; 23 C; 26 G; 37 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTTCAGGAGGACATATTGCTCTGGTGTGTTATTGCTGTGTTTGG 2215
DB 86 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 27
QY 2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB 26 AATTGGCAGTAAACTGCTTAGAATG 1
RESULT 69
ABA79630/c
ID ABA79630 standard; DNA; 121 BP.
XX
XX ABA79630;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2476.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
XX antileptic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US0009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192179P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX

XX
XX Claim 7; Page 184; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 35 A; 23 C; 26 G; 37 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTTCAGGAGGACATATTGCTCTGGTGTGTTATTGCTGTGTTTGG 2215
DB 89 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 30
QY 2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB 29 AATTGGCAGTAAACTGCTTAGAATG 4
RESULT 70
ABA79639
ID ABA79639 standard; DNA; 121 BP.
XX
XX ABA79639;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2485.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
XX antileptic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US0009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192179P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX


```
DR WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX Claim 7; Page 185; 294pp; English.
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
SQ Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTACGAGGACATATTCCTCGTGTGTTATGTCGTGTTTGG 2215
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2216 CTTTGGCATATACGCGCTGAGTTTG 2241
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 71
ABA79619
ID ABA79619 standard; DNA; 121 BP.
XX
AC ABA79619;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2465.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.

WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX Claim 7; Page 184; 294pp; English.
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
SQ Sequence 121 BP; 36 A; 25 C; 25 G; 35 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTACGAGGACATATTCCTCGTGTGTTATGTCGTGTTTGG 2215
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2216 CTTTGGCATATACGCGCTGAGTTTG 2241
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 72
ABA79618/c
ID ABA79618 standard; DNA; 121 BP.
XX
AC ABA79618;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2464.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
```

XX		27-MAR-2000; 2000US-0192176P.	
XX	PER	27-MAR-2000; 2000US-0192179P.	
XX	PPR	01-JUN-2000; 2000US-0208538P.	
XX	PPR	30-OCT-2000; 2000US-0244989P.	
XX		(UYDE) UNIV DELAWARE.	
XX	PPI	Kmiec EB, Gamper HB, Rice MC;	
XX	DR	WPI; 2001-639230/73.	
XX	PTT	Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.	
XX	PT		
XX	PS	Claim 7; Page 184; 294pp; English.	
XX		The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention	
XX	SQ	Sequence 121 BP; 35 A; 25 C; 25 G; 36 T; 0 U; 0 Other;	
		Query Match 1.0%; Score 22; DB 1; Length 121;	
		Best Local Similarity 53.5%; Pred. No. 26;	
		Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
Qy		2156 CTATTGTAATAGGGTTTTACAGGACATAATTCCTGGTTGTATTGTCGTGTTTG 2215	
Dd		91 CCATTAAACATGAATGGACTCACATGATCTCCATCTTTGAGATAGGTTAAGAAATTG 32	
Qy		2216 CTTTGGCANATACAGGCTGAGTTG 2241	
Dd		31 AAITGGCACGTAACCTTTAGAATG 6	
		RESULT 73	
ID		AAC04575/c	
ID		AAC04575 standard; cDNA; 385 BP.	
XX	AC	AAC04575;	
XX			
XX	DT	06-OCT-2000 (first entry)	
XX		Human secreted protein 5' EST, SEQ ID NO: 8650.	
XX	DE		
XX	DE		
XX	KW	Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation; gene therapy; chromosome mapping; ss.	
XX	KW		
XX	OS	Homo sapiens.	
XX	PN	EP1033401-A2.	
XX	PD	06-SEP-2000.	
XX	PF	21-FEB-2000; 2000EP-00200610.	
XX	PR	26-FEB-1999; 99US-012487P.	

Mon Aug 9 17:56:36 2004

10664775-5.rng

```

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TCTTAATTTTTCATTCAGATTCTTCAGTTTGGGTTTGGTTT 1975
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTATTTTATTTTTCAGTGGCACACAGGCTGGGTTTATT 1083

RESULT 81
ACD23963/c
ID ACD23963 standard; cDNA; 1129 BP.
XX AC ACD23963;
XX
DT 26-AUG-2003 (first entry)
DE Novel human secreted and transmembrane protein PR04327 cDNA.
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032156-A1.
XX
PD 13-FEB-2003.
XX
PF 06-MAY-2002; 2002US-00140474.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 20-MAR-1999; 99WO-US005190.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.

```

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

```

XX WPI; 2003-341980/32.
DR P-PSDB; ABO17726.
XX
XX New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
XX Claim 2; Fig 221; 560pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This sequence encodes a novel human secreted and transmembrane PRO
CC polypeptide
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match          0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTCATTTCAGATTTCCTTCAGTTGGGTTTGTGTT 1975
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 82
ID ACA67104/C
AC ACA67104 standard; cDNA; 1129 BP.
XX
XX ACA67104;
XX
XX 23-JUN-2003 (first entry)
XX
XX cDNA encoding human PRO polypeptide #11.
XX
XX Human; PRO polypeptide; secreted and transmembrane protein;
XX anti-PRO antibody; diagnostic assay; gene expression; diabetes;
XX bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
XX sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
XX hearing loss; coagulation disorder; stroke; heart attack; cardiac;
XX antidiabetic; anorectic; vulnerable; antiarthritic; osteopathic;
XX antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003004311-A1.
XX
XX 02-JAN-2003.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX 18-JUN-1997; 97US-0049911P.
XX 26-AUG-1997; 97US-0056974P.

```

```

PR 17-SEP-1997; 97US-00591113P.
PR 17-SEP-1997; 97US-00591115P.
PR 17-SEP-1997; 97US-00591127P.
PR 17-SEP-1997; 97US-00591222P.
PR 18-SEP-1997; 97US-0059184P.
PR 19-SEP-1997; 97US-0059283P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 27-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074082P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 31-MAR-1998; 98US-0079728P.
PR 12-JUN-1998; 98US-0080165P.
PR 14-JUL-1998; 98WO-US012456.
PR 28-AUG-1998; 98WO-US014552.
PR 10-SEP-1998; 98WO-US017888.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 16-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.

```


PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2000US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PR XX (GETH) GENENTECH INC. XX

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI PI Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX DR WPI; 2003-148238/14.
 DR DR P-PSDB; ABUS9761.
 XX XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX PS Claim 2; Fig 221; 659pp; English.
 XX XX The invention describes an isolated human PRO polypeptide. The PRO
 CC polypeptides are useful in detecting PRO polypeptides in a sample, in
 CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
 CC in modulating at least one biological activity of a cell expressing a PRO
 CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
 CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
 CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
 CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
 CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
 CC useful for treating conditions or disorders where angiogenesis would be
 CC beneficial, e.g. wound healing and antagonist of this polypeptide are
 CC useful for treating cancerous tumors. PRO812 inhibits vascular
 CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
 CC cells and is thus useful for inhibiting endothelial cell growth in
 CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
 CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
 CC stimulated T-lymphocytes and are therapeutically useful for enhancing
 CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
 CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
 CC rod photoreceptor cells) and therefore are useful for treating retinal
 CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
 CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
 CC and therefore are useful for treating kidney disorders associated with
 CC decreased mesangial cell function such as Berger disease or Crohn's
 CC nephropathies associated with dermatitis, herpeticiformis or Crohn's
 CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
 CC proliferation and/or redifferentiation of chondrocytes in culture and are
 CC thus useful for treating sports injuries, and arthritis. This sequence
 CC encodes a novel human PRO protein
 XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTGTT 1975
 DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGTTTATT 1083
 RESULT 85
 ACD41905/c
 ID ACD41905 standard; cDNA; 1129 BP.
 XX AC ACD41905;
 XX 05-SEP-2003 (first entry)
 XX Human secreted/transmembrane protein (PRO) cDNA #111.
 XX Human; ss; gene; PRO; secreted protein; transmembrane protein; tumour;
 KW cytototoxic; gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
 KW proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;
 KW PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
 KW chondrocyte cell proliferation; chondrocyte cell differentiation;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell; A-peptide; factor VIIa.
 XX XX

OS Homo sapiens.
XX US2003036179-A1.
XX PD 20-FEB-2003.
XX PF 10-MAY-2002; 2002US-00142431.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 02-DEC-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 10-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030939.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 17-MAY-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US020710.
PR 23-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US0006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001US-00921066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-466355/44.
DR P-PSDB; ABO24951.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 221; 659pp; English.
XX The invention relates to an isolated nucleic acid comprising at least 80%
CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
CC extracellular domain (with or without its associated signal peptide),
CC which comprises any of the 275 120-850 residue amino acid sequences,
CC given in the specification; (b) comprising any of the 275 300-3500
CC nucleotide sequences, given in the specification; or (c) comprising the
CC full-length coding sequence of the nucleotide sequences given in the
CC specification, or of the DNA deposited under any of the American Type
CC Culture Collection (ATCC) Accession Numbers listed in the specification.
CC Also included are a vector comprising the novel nucleic acid, a host cell
CC comprising the vector, producing a PRO polypeptide, the isolated PRO
CC polypeptides detailed above, a chimeric molecule comprising the PRO
CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC antibody, detecting a PRO polypeptide in a sample suspected of containing
CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulating at least one biological activity of a cell
CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC modulating the uptake of glucose or FFA by skeletal muscle cells or
CC adipocyte cells, stimulating the proliferation or differentiation of
CC chondrocyte cells (or proliferation of or gene expression in pericyte

CC cells), stimulating the proliferation of inner ear utricular supporting
CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC binding of A-peptide to factor VIIA, or differentiation of adipocyte
CC cells, detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences given
CC in the specification. The polynucleotide is useful in molecular biology,
CC including uses as hybridisation probes, in chromosome and gene mapping,
CC in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide may also be used in preparing PRO polypeptides by
CC recombinant techniques, and in generating either transgenic animals or
CC knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The PRO polypeptide or the
CC antibody is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The present sequence encodes a PRO polypeptide

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TTTTAAATTTTTCATTCAGATTCCTTCAGTTGGTTTGT 1975
Db 1129 TTTTATTTTTCATTCAGATTCCTTCAGTTGGTTTGT 1083

RESULT 86

ACA04134/c
ID ACA04134 standard; cDNA; 1129 BP.

XX AC ACA04134;

XX DT 27-MAY-2003 (first entry)

XX DE Human cDNA encoding a secreted/transmembrane protein, SEQ ID 221.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX inflammatory disease; organ failure; atherosclerosis; cardiac injury;
XX infertility; birth defects; premature aging; AIDS; biosensor;
XX acquired immunodeficiency syndrome; cancer; diabetic complication;
XX bioreactor; tumour.

XX OS Homo sapiens.

XX PN US2003032155-A1.

XX PD 13-FEB-2003.

XX PF 03-MAY-2002; 2002US-00137865.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 20-APR-1999; 99WO-US008615.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00870932.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019652.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.


```
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012552.
PR 08-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99WO-US023089.
PR 23-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006684.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020331.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-687639/65.
XX P-PSDB; ADA76172.
XX
XX New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTTCACAGATTTCCTTCAGTTGGTTGGTTTGT 1975
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
RESULT 89
ADA18921/C
ID ADA18921 standard; cDNA; 1129 BP.
XX
```

AC ADA18821;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
XX US2003054517-A1.
XX
XX 20-MAR-2003.
XX
XX 08-MAY-2002; 2002US-00141755.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-0074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-521854/49.
XX P-PSDB; ADA18822.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumors.
XX
XX Claim 2; Fig 221; 660pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
CC prostate, rectal, cervical and liver tumours). The polynucleotides are
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA and in
CC gene therapy. The polynucleotides may also be used in preparing PRO

Db	1129	TTTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTWTATT	1083
RESULT 97			
ADB30401/c			
ID	ADB30401	standard; cDNA; 1129 BP.	
XX			
XX	ADB30401;		
XX			
DT	20-NOV-2003	(first entry)	
DE		cDNA encoding human PRO polypeptide #111.	
XX			
KW	Human; gene; ss;	PRO; secreted polypeptide; transmembrane polypeptide;	
KW	tumour necrosis factor-alpha;	TNF-alpha; chondrocyte cell; tumour;	
KW	cancer; adrenal; lung; colon; breast;	prostate; rectum; kidney; cervix;	
KW	liver; microvascular endothelial cell;	glucose; FFA;	
KW	skeletal muscle cell; adipocyte cell;	pericyte cell;	
KW	inner ear utricular supporting cell;	T-lymphocyte cell;	
KW	endothelial cell tube formation;	bone disorder; cartilage disorder;	
KW	sports injury; proteoglycan;	articular cartilage defect; osteoarthritis;	
KW	rheumatoid arthritis;	haemoglobin-associated disorder thalassaemia;	
KW	immune system cell infiltration.		
XX			
OS	Homo sapiens.		
XX			
EN	US2003068794-A1.		
XX			
PD	10-APR-2003.		
XX			
PF	15-APR-2002;	2002US-00123155.	
XX			
PR	31-MAR-1997;	97WO-US005230.	
PR	12-JUN-1998;	98WO-US012456.	
PR	14-JUL-1998;	98WO-US014552.	
PR	28-AUG-1998;	98WO-US017888.	
PR	10-SEP-1998;	98WO-US018824.	
PR	14-SEP-1998;	98WO-US019093.	
PR	14-SEP-1998;	98WO-US019094.	
PR	14-SEP-1998;	98WO-US019177.	
PR	14-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98WO-US019437.	
PR	07-OCT-1998;	98WO-US021141.	
PR	29-OCT-1998;	98WO-US022991.	
PR	29-OCT-1998;	98WO-US022992.	
PR	20-NOV-1998;	98WO-US024855.	
PR	01-DEC-1998;	98WO-US025108.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	10-MAR-1999;	99WO-US005190.	
PR	20-APR-1999;	99WO-US008615.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	01-SEP-1999;	99WO-US020111.	
PR	08-SEP-1999;	99WO-US020594.	
PR	13-SEP-1999;	99WO-US020944.	
PR	15-SEP-1999;	99WO-US021090.	
PR	15-SEP-1999;	99WO-US021547.	
PR	05-OCT-1999;	99WO-US023089.	
PR	29-NOV-1999;	99WO-US028214.	
PR	30-NOV-1999;	99WO-US028313.	
PR	30-NOV-1999;	99WO-US028409.	
PR	01-DEC-1999;	99WO-US028301.	
PR	01-DEC-1999;	99WO-US028634.	
PR	02-DEC-1999;	99WO-US028851.	
PR	02-DEC-1999;	99WO-US028855.	
PR	02-DEC-1999;	99WO-US028564.	
PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	20-DEC-1999;	99WO-US030999.	
PR	22-DEC-1999;	99WO-US030720.	
PR	30-DEC-1999;	99WO-US031243.	
PR			
PR	30-DEC-1999;	99WO-US031274.	
PR	05-JAN-2000;	2000WO-US000219.	
PR	06-JAN-2000;	2000WO-US000277.	
PR	06-JAN-2000;	2000WO-US000376.	
PR	11-FEB-2000;	2000WO-US003565.	
PR	18-FEB-2000;	2000WO-US004341.	
PR	18-FEB-2000;	2000WO-US004342.	
PR	22-FEB-2000;	2000WO-US004414.	
PR	24-FEB-2000;	2000WO-US004914.	
PR	24-FEB-2000;	2000WO-US005004.	
PR	01-MAR-2000;	2000WO-US005601.	
PR	02-MAR-2000;	2000WO-US005746.	
PR	02-MAR-2000;	2000WO-US005841.	
PR	10-MAR-2000;	2000WO-US006319.	
PR	15-MAR-2000;	2000WO-US006884.	
PR	20-MAR-2000;	2000WO-US007377.	
PR	21-MAR-2000;	2000WO-US007532.	
PR	30-MAR-2000;	2000WO-US008439.	
PR	17-MAY-2000;	2000WO-US013705.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	30-MAY-2000;	2000WO-US014941.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	11-AUG-2000;	2000WO-US022031.	
PR	23-AUG-2000;	2000WO-US023522.	
PR	24-AUG-2000;	2000WO-US023328.	
PR	08-NOV-2000;	2000WO-US030952.	
PR	10-NOV-2000;	2000WO-US030873.	
PR	01-DEC-2000;	2000WO-US032678.	
PR	20-DEC-2000;	2000US-0074259.	
PR	28-FEB-2001;	2001US-00796498.	
PR	28-FEB-2001;	2001US-00796498.	
PR	01-MAR-2001;	2001WO-US006520.	
PR	09-MAR-2001;	2001US-00802706.	
PR	14-MAR-2001;	2001US-00808689.	
PR	22-MAR-2001;	2001US-00816744.	
PR	05-APR-2001;	2001US-00828366.	
PR	10-MAY-2001;	2001US-00854208.	
PR	10-MAY-2001;	2001US-00854280.	
PR	18-MAY-2001;	2001US-00860216.	
PR	25-MAY-2001;	2001US-00866028.	
PR	25-MAY-2001;	2001US-00866034.	
PR	01-JUN-2001;	2001US-00872035.	
PR	01-JUN-2001;	2001US-00872035.	
PR	05-JUN-2001;	2001US-00874503.	
PR	14-JUN-2001;	2001US-00882636.	
PR	19-JUN-2001;	2001US-00886342.	
PR	20-JUN-2001;	2001US-00887879.	
PR	21-JUN-2001;	2001US-00887879.	
PR	22-JUN-2001;	2001WO-US020116.	
PR	29-JUN-2001;	2001WO-US021066.	
PR	09-JUL-2001;	2001WO-US021735.	
PR	18-JUL-2001;	2001US-00908827.	
PR	06-AUG-2001;	2001US-00924419.	
PR	09-AUG-2001;	2001US-00927796.	
PR	16-AUG-2001;	2001US-00931836.	
PR	19-DEC-2001;	2001US-00028072.	
XX			
PA	(GETH)	GENENTECH INC.	
XX			
PI	Baker KP, Beresini M, Deforge L,	Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen ME, Goddard A, Godowski S;	Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D,	Watanabe CK, Wood WI, Zhang Z;	
XX			
DR	WPI; 2003-708391/67.		
DR	P-PSDB; ADB30402.		
XX			
PT	New isolated PRO polypeptides e.g. PRO1801 and PRO1114,	useful in the	
PT	preparation of a medicament for treating a condition	responsive to PRO	
PT	polypeptide, and as therapeutic agents e.g. vaccines.		
XX			

Claim 2; Fig 221; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1975
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGCTGGGTTTATT 1083

RESULT 98

ADA85697/c
ID ADA85697 standard; cDNA; 1129 BP.

AC ADA85697;

DT 20-NOV-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO4327 cDNA.

KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

PN US2003082693-A1.

PD 01-MAY-2003.

PF 22-APR-2002; 2002US-00127843.

XX

PR 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-786907/74.

XX P-PSDB; ADA85698.

PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF- α from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1975

DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGCTGGGTTTATT 1083

RESULT 99

ADA96909/c

ID ADA96909 standard; cDNA; 1129 BP.

XX ADA96909;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;

PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 24-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828368.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755116/71.
 DR P-PSDB; ADA79214.
 DR
 XX
 PA
 XX
 PI
 PI
 PI
 XX
 DR
 DR
 XX
 PT
 PT
 PT

XX

Claim 2; Fig 221; 659pp; English.

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

F	16-APR-2002;	200ZUS-001233907.	
X	31-MAR-1997;	97WO-US0055230.	
R	12-JUN-1998;	98WO-US0124556.	
R	14-JUL-1998;	98WO-US014552.	
R	28-AUG-1998;	98WO-US017888.	
R	10-SEP-1998;	98WO-US018824.	
R	14-SEP-1998;	98WO-US019093.	
R	14-SEP-1998;	98WO-US019094.	
R	14-SEP-1998;	98WO-US019177.	
R	16-SEP-1998;	98WO-US019330.	
R	17-SEP-1998;	98WO-US019437.	
R	07-OCT-1998;	98WO-US021141.	
R	29-OCT-1998;	98WO-US022991.	
R	29-OCT-1998;	98WO-US022992.	
R	20-NOV-1998;	98WO-US024855.	
R	01-DEC-1998;	98WO-US025108.	
R	05-JAN-1999;	99WO-US000106.	
R	08-MAR-1999;	99WO-US005028.	
R	10-MAR-1999;	99WO-US005190.	
R	20-APR-1999;	2000WO-US006319.	
R	20-APR-1999;	99WO-US008615.	
R	14-MAY-1999;	99WO-US010733.	
R	02-JUN-1999;	99WO-US012952.	
R	01-SEP-1999;	99WO-US020111.	
R	08-SEP-1999;	99WO-US020594.	
R	13-SEP-1999;	99WO-US020944.	
R	15-SEP-1999;	99WO-US021090.	
R	15-SEP-1999;	99WO-US021547.	
R	05-OCT-1999;	99WO-US023089.	
R	29-NOV-1999;	99WO-US028214.	
R	30-NOV-1999;	99WO-US028313.	
R	30-NOV-1999;	99WO-US028409.	
R	01-DEC-1999;	99WO-US028301.	
R	01-DEC-1999;	99WO-US028634.	
R	02-DEC-1999;	99WO-US028551.	
R	02-DEC-1999;	99WO-US028565.	
R	16-DEC-1999;	99WO-US030095.	
R	20-DEC-1999;	99WO-US030911.	
R	20-DEC-1999;	99WO-US030999.	
R	30-DEC-1999;	99WO-US030720.	
R	30-DEC-1999;	99WO-US031243.	
R	03-JAN-1999;	99WO-US031274.	
R	05-JAN-2000;	2000WO-US000219.	
R	06-JAN-2000;	2000WO-US000277.	
R	06-JAN-2000;	2000WO-US000376.	
R	11-FEB-2000;	2000WO-US000365.	
R	18-FEB-2000;	2000WO-US004341.	
R	18-FEB-2000;	2000WO-US004342.	
R	22-FEB-2000;	2000WO-US004414.	
R	24-FEB-2000;	2000WO-US004914.	
R	24-FEB-2000;	2000WO-US005004.	
R	01-MAR-2000;	2000WO-US005601.	
R	02-MAR-2000;	2000WO-US005746.	
R	12-MAR-2000;	2000WO-US005841.	
R	15-MAR-2000;	2000WO-US006894.	
R	20-MAR-2000;	2000WO-US007377.	
R	21-MAR-2000;	2000WO-US007532.	
R	30-MAR-2000;	2000WO-US008439.	
R	17-MAY-2000;	2000WO-US013705.	
R	22-MAY-2000;	2000WO-US014042.	
R	30-MAY-2000;	2000WO-US014941.	
R	02-JUN-2000;	2000WO-US015264.	
R	28-JUL-2000;	2000WO-US020710.	
R	11-AUG-2000;	2000WO-US022031.	
R	23-AUG-2000;	2000WO-US023522.	
R	24-AUG-2000;	2000WO-US023928.	
R	08-NOV-2000;	2000WO-US030952.	
R	10-NOV-2000;	2000WO-US030873.	
R	01-DEC-2000;	2000WO-US032678.	
R	20-DEC-2000;	2000US-00747259.	
R	20-DEC-2000;	2000WO-US004954.	

```
Query Match      0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TCTTAAATTTTTCATTTCCAGATTTTCCTTCAGTTTGGGTTTGT 1975
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083

RESULT 102
ADB16554/c
XX ADB16554 standard; cDNA; 1129 BP.
XX
XX ADB16554;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX OS
XX US2003087349-A1.
XX
XX 08-MAY-2003.
XX
XX 19-APR-2002; 2002US-00125928.
XX
XX 19-JUN-1998; 98US-0089947P.
XX
XX 02-JUN-1999; 99WO-0012252.
XX
XX 25-AUG-1999; 99US-00380137.
XX
XX 02-MAR-2000; 2000WO-US005841.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786940/74.
XX
XX P-PSDB; ADB16555.
XX
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
```


RESULT 110

ADA74347/c
ID ADA74347 standard; cDNA; 1129 BP.
XX
AC ADA74347;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003068798-A1.
PN
XX
PD 10-APR-2003.
XX
XX 07-MAY-2002; 2002US-00140928.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001WO-US006666.
PR 14-MAR-2001; 2001US-00802706.
PR 22-MAR-2001; 2001US-00808689.
PR 05-APR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001WO-US019692.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001WO-US021735.
PR 06-AUG-2001; 2001US-00908827.
PR 09-AUG-2001; 2001US-00924419.
PR 16-AUG-2001; 2001US-00927796.
PR 19-DEC-2001; 2001US-00931836.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625490/59.
DR P-PSDB; ADA74348.
XX
XX Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT encoding them, useful for treating bone disorders, arthritis, heart
PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT Factor-alpha from human blood.
XX
PS Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW	immune system cell infiltration.
XX	
OS	Homo sapiens.
PN	
XX	US2003082701-A1.
XX	
01	MAY-2003.
PD	
XX	
23	APR-2002; 2002US-00128686.
PF	
XX	
31	AUG-1998; 98US-0098525P.
PR	
16	SEP-1998; 98US-0100634P.
PR	
02	JUN-1999; 99WO-US012252.
PR	
25	AUG-1999; 99US-00380137.
PR	
30	MAR-2000; 2000WO-US008439.
PR	
02	JUN-2000; 2000WO-US015264.
PR	
01	DEC-2000; 2000WO-US032678.
PR	
19	DEC-2001; 2001US-00028072.
XX	
(GETH) GENENTECH INC.
PA	
XX	
Baker	KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	
WPI;	2003-755110/71.
DR	F-PSDB; ADA82105.
DR	

CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The accession data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1929 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTTTGTTT 1975
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCTGGTTTTTATT 1083

RESULT 113
ADA75067/c

ID ADA75067 standard; cDNA; 1129 BP.

XX AC ADA75067;

XX AC

DT 20-NOV-2003 (first entry)

XX XX

DE Human PRO polynucleotide #111.

XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; gliocyte; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

OS XX

PX US2003073216-A1.

XX XX

PD 17-APR-2003.

XX XX

PF 30-MAY-2002; 2002US-00160498.

XX XX

PR 11-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.

RR	02=DEC-1999;	99WO-US028564
PR	02=DEC-1999;	99WO-US028564

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-720081/68.
DR

cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TTCTTAATTTTTCATTTCCAGATTCTTCAGTTGGTTTCTTT 1975
Db 1129 TTTTTCATTTTTCATTTTTCAGTTGGTTTCTTTTATT 1083

RESULT 118
ADA75619/C
ID ADA75619 standard; cDNA; 1129 BP.
XX
AC ADA75619;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

OS Homo sapiens.
XX
XX US2003082703-A1.
XX
XX 01-MAY-2003.
XX
XX 23-APR-2002; 2002US-00128691.
XX
XX 09-DEC-1999; 99US-0170262P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755115/71.
XX
XX P-PSDB; ADA75620.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte

23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755115/71.
XX
XX P-PSDB; ADA80378.
XX
XX New PRO polypeptides useful for treating diabetes, hyper- or hypo-
insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
various coagulation disorders and tumors.
XX
XX Claim 2; Fig 221; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte

endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

Homo sapiens.

US2003092147-A1.

15-MAY-2003.

11-APR-2002; 2002US-00121051.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US007733.

02-JUN-1999; 99WO-US021252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028301.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

30-MAY-2000; 2000WO-US014941.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

11-AUG-2000; 2000WO-US022031.

23-AUG-2000; 2000WO-US023522.

24-AUG-2000; 2000WO-US023328.

08-NOV-2000; 2000WO-US030952.

10-NOV-2000; 2000WO-US030873.

01-DEC-2000; 2000US-00747259.

20-DEC-2000; 2000WO-US034956.

28-FEB-2001; 2001US-00796498.

28-FEB-2001; 2001WO-US006520.

01-MAR-2001; 2001WO-US006666.

09-MAR-2001; 2001US-00802706.

14-MAR-2001; 2001US-00808689.

22-MAR-2001; 2001US-00816744.

05-APR-2001; 2001US-00828366.

10-MAY-2001; 2001US-00854208.

18-MAY-2001; 2001US-00860216.

25-MAY-2001; 2001US-00866028.

25-MAY-2001; 2001US-00866034.

25-MAY-2001; 2001WO-US017092.

01-JUN-2001; 2001US-00872035.

05-JUN-2001; 2001WO-US017800.

14-JUN-2001; 2001US-00874503.

19-JUN-2001; 2001US-00882636.

20-JUN-2001; 2001US-00886342.

21-JUN-2001; 2001US-00887879.

22-JUN-2001; 2001WO-US020116.

29-JUN-2001; 2001WO-US021066.

09-JUL-2001; 2001WO-US021735.

18-JUL-2001; 2001US-00908827.

06-AUG-2001; 2001US-00924419.

09-AUG-2001; 2001US-00927796.

16-AUG-2001; 2001US-00931836.

19-DEC-2001; 2001US-00028072.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-777249/73.

P-PSDB; ADB26667.

Novel isolated PRO polypeptide useful for treating diabetes, hyper- or

hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart

attack, various coagulation disorders, tumors.

Claim 2; Fig 221; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The

invention also relates to an antibody which specifically binds to a PRO

polypeptide, a method for stimulating the release of tumour necrosis

factor-alpha (TNF-alpha) from human blood, a method for stimulating the

proliferation or differentiation of chondrocyte cells and a method for

detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

polynucleotides are useful in molecular biology, including uses as

hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also

be used in preparing PRO polypeptides by recombinant techniques and in

generating either transgenic animals or knock-out animals which are

useful in the development and screening of therapeutically useful

reagents. The PRO polypeptides or antibodies are used in preparing a

medicament for treating a condition responsive to the polypeptides or

antibodies, such as tumours, for stimulating and inhibiting proliferation

of human microvascular endothelial cells, for modulating the uptake of

PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US0005028.
 PR 10-MAR-1999; 98WO-US0005190.
 PR 20-APR-1999; 98WO-US0008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021147.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US0002179.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006319.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US0796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001WO-US0062706.
 PR 14-MAR-2001; 2001WO-US008689.
 PR 22-MAR-2001; 2001WO-US016744.
 PR 05-APR-2001; 2001WO-US028366.
 PR 10-MAY-2001; 2001WO-US0854208.
 PR 10-MAY-2001; 2001WO-US0854290.
 PR 18-MAY-2001; 2001WO-US0860216.
 PR 25-MAY-2001; 2001WO-US0866028.
 PR 25-MAY-2001; 2001WO-US0866034.

PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755114/71.
 P-PSDB; ADA95806.

New isolated PRO polypeptides, useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders and tumors.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAATTTTTCATTTCCAGATTCCTTCAGTTGGTTTGT 1975

CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, and
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1975

Db 1129 TTTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1083

RESULT 134

ADA87904/C

ID ADA87904 standard; cDNA; 1129 BP.

XX AC ADA87904;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX DE US2003082700-A1.

XX EN 01-MAY-2003.

XX PF 23-APR-2002; 2002US-00128684.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-786910/74.

XX DR P-PSDB; ADA87905.

XX PT New PRO nucleic acid, useful for preparing a composition for treating

XX PT e.g., tumor or for tissue typing.

XX PS Claim 2; Fig 221; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte

CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 56;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1975

Db 1129 TTTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1083

RESULT 135

ADA46292/C

ID ADA46292 standard; cDNA; 1129 BP.

XX AC ADA46292;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX DE US2003054516-A1.

XX PD 20-MAR-2003.

XX PF 12-APR-2002; 2002US-00121050.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 16-SEP-1998; 98WO-US019177.

XX PR 17-SEP-1998; 98WO-US019330.

XX PR 07-OCT-1998; 98WO-US019437.

XX PR 29-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

```
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 08-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 29-NOV-1999; 99WO-US021089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004344.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 03-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-521853/49.
DR P-PSDB; ADA46293.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor.
XX
XX Claim 2; Fig 221; 200pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. NO. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTCTTT 1975
DB 1129 TTTTTCATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTCTTT 1083

RESULT 136
ADB28322/c
ID ADB28322 standard; cDNA; 1129 BP.
XX
```

AC ADB28322;
XX 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003082699-A1.
XX 01-MAY-2003.
XX 22-APR-2002; 2002US-00127851.
XX 17-JUN-1998; 98US-0089599P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 30-NOV-1999; 99WO-US028313.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-777202/73.
XX P-PSDB; ADB28323.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTTCGGTTTCTTT 1975
DB 1129 TTTTTCATTTTTCATTTTCAGTCGGCACACAGCTGGGTTTATT 1083
RESULT 137
ADB28874/C
ID ADB28874 standard; cDNA; 1129 BP.
XX
XX ADB28874;
XX 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003082706-A1.
XX 01-MAY-2003.
XX 24-APR-2002; 2002US-00131836.
XX 09-DEC-1999; 99US-0170262P.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E;
PI Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-777203/73.
XX P-PSDB; ADB28875.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 56;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTCATTCACAGATTTCCTCAGTTGGGTTTGTTT 1975

DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGCTGGGTTTATT 1083

RESULT 138

ADA76826/c

ID ADA76826 standard; cDNA; 1129 BP.

XX AC

ADA76826;

XX DT

20-NOV-2003 (first entry)

XX DE

Human PRO polynucleotide #111.

XX KW

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS

Homo sapiens.

XX PN

US2003059909-A1.

XX XX

27-MAR-2003.

XX PF

10-MAY-2002; 2002US-00143032.

XX PR

31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US026214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 14-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

QY 1929 TTCTTAATTTTTCATTCCAGATTCCTTCAGTTGGGTTTTGTTT 1975
DB 1129 TTTTNTTTTTTTTTTTTTCAGCTGCACACAGCGTGCTTTTATT 1083

RESULT 139
ADA88456/C
ID ADA88456 standard; cDNA; 1129 BP.
XX AC ADA88456;
XX AC
XX AC
DT 20-NOV-2003 (first entry)
XX XX
DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW Cell proliferation stimulator; cell differentiation stimulator;
KW Lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003073213-A1.
PD 17-APR-2003.
XX PF 17-APR-2002; 2002US-00124819.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US020111.
PR 01-SEP-1999; 99WO-US020252.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.

10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US0172035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US0201116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GENE) GENENTECH INC.
XX PA
XX PI Baker KP, Berezins M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR MPI; 2003-540684/51.
XX P-PSDB; ADA76827.

DR XX
XX PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX PT
XX PS Claim 2; Fig 221; 660pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX membrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

XX PF 19-APR-2002; 2002US-00125926.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755106/71.
DR P-PSDB; ADA97462.
XX
XX Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 221; 666pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 65.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Oy 1929 TTCTTATTTTTCATTTCCAGATTCTCTCAGTTGGTTTCTTT 1975
Db 1129 TTTTTTTTTTTTTTTTCAGTGGCACACAGGCTGGTTTATT 1093

RESULT 141
ADB27218/c
ID ADB27218 standard; cDNA; 1129 BP.
XX
XX ADB27218;
XX

DT 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003022239-A1.
XX
XX 30-JAN-2003.
XX
XX 12-APR-2002; 2002US-00121049.
XX
XX 18-JUN-1997; 97US-0049911P.
XX 26-AUG-1997; 97US-0056974P.
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059352P.
XX 19-SEP-1997; 97US-0059588P.
XX 24-SEP-1997; 97US-0059836P.
XX 17-OCT-1997; 97US-0062250P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 17-OCT-1997; 97US-0063755P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063082P.
XX 27-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063561P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063733P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065846P.
XX 21-NOV-1997; 97US-0066364P.
XX 24-NOV-1997; 97US-0066453P.
XX 24-NOV-1997; 97US-0066511P.
XX 24-NOV-1997; 97US-0066770P.
XX 11-DEC-1997; 97US-0069212P.
XX 11-DEC-1997; 97US-0069278P.
XX 11-DEC-1997; 97US-0069334P.
XX 16-DEC-1997; 97US-0069694P.
XX 23-JAN-1998; 98US-0072320P.
XX 04-FEB-1998; 98US-0073612P.
XX 09-FEB-1998; 98US-0074086P.
XX 09-FEB-1998; 98US-0074092P.
XX 12-MAR-1998; 98US-0077791P.
XX 20-MAR-1998; 98US-0078910P.
XX 25-MAR-1998; 98US-0079294P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079728P.
XX 31-MAR-1998; 98US-0080165P.

cell proliferation stimulator; cell differentiation stimulator;	PR	07-MAY-1998;	98US-0084637P.
cell differentiation inhibitor; cytokine release stimulator; tumour;	PR	12-MAY-1998;	98US-0085149P.
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	PR	13-MAY-1998;	98US-0085323P.
cervical tumour; liver tumour; chromosome mapping; gene mapping;	PR	13-MAY-1998;	98US-0085338P.
gene therapy; chromosome identification; chromosome marker.	PR	13-MAY-1998;	98US-0085339P.
	PR	15-MAY-1998;	98US-0085579P.
	PR	15-MAY-1998;	98US-0085697P.
Homo sapiens.	PR	15-MAY-1998;	98US-0085704P.
	PR	22-MAY-1998;	98US-0086414P.
	PR	22-MAY-1998;	98US-0086430P.
	PR	28-MAY-1998;	98US-0087106P.
	PR	04-JUN-1998;	98US-0088026P.
	PR	10-JUN-1998;	98US-0088730P.
	PR	10-JUN-1998;	98US-0088741P.
	PR	11-JUN-1998;	98US-0088810P.
	PR	11-JUN-1998;	98US-0088858P.
	PR	12-JUN-1998;	98WO-US012456.
	PR	17-JUN-1998;	98US-0089532P.
	PR	17-JUN-1998;	98US-0089599P.
	PR	18-JUN-1998;	98US-0089907P.
	PR	19-JUN-1998;	98US-0089947P.
	PR	23-JUN-1998;	98US-0090349P.
	PR	23-JUN-1998;	98US-0090429P.
	PR	24-JUN-1998;	98US-0093044P.
	PR	24-JUN-1998;	98US-0090538P.
	PR	26-JUN-1998;	98US-0090863P.
	PR	01-JUL-1998;	98US-0091360P.
	PR	02-JUL-1998;	98US-0091519P.
	PR	07-JUL-1998;	98US-0091982P.
	PR	14-JUL-1998;	98WO-US014552.
	PR	20-JUL-1998;	98US-0093339P.
	PR	30-JUL-1998;	98US-0094651P.
	PR	04-AUG-1998;	98US-0095285P.
	PR	04-AUG-1998;	98US-0095301P.
	PR	04-AUG-1998;	98US-0095302P.
	PR	04-AUG-1998;	98US-0095325P.
	PR	11-AUG-1998;	98US-0096143P.
	PR	11-AUG-1998;	98US-0096146P.
	PR	12-AUG-1998;	98US-0096329P.
	PR	17-AUG-1998;	98US-0096768P.
	PR	17-AUG-1998;	98US-0096773P.
	PR	17-AUG-1998;	98US-0096791P.
	PR	17-AUG-1998;	98US-0096891P.
	PR	17-AUG-1998;	98US-0096895P.
	PR	18-AUG-1998;	98US-0096896P.
	PR	19-AUG-1998;	98US-0097141P.
	PR	20-AUG-1998;	98US-0097218P.
	PR	26-AUG-1998;	98US-0097951P.
	PR	26-AUG-1998;	98US-0097986P.
	PR	28-AUG-1998;	98WO-US017888.
	PR	31-AUG-1998;	98US-0098525P.
	PR	01-SEP-1998;	98US-0098750P.
	PR	09-SEP-1998;	98US-0099536P.
	PR	09-SEP-1998;	98US-0099598P.
	PR	10-SEP-1998;	98US-0099601P.
	PR	10-SEP-1998;	98US-0099729P.
	PR	10-SEP-1998;	98US-0099803P.
	PR	10-SEP-1998;	98US-0099816P.
	PR	10-SEP-1998;	98WO-US018824.
	PR	14-SEP-1998;	98US-0100262P.
	PR	14-SEP-1998;	98US-0100263P.
	PR	14-SEP-1998;	98WO-US019093.
	PR	14-SEP-1998;	98WO-US019094.
	PR	14-SEP-1998;	98WO-US019177.
	PR	15-SEP-1998;	98US-0100390P.
	PR	16-SEP-1998;	98US-0100634P.
	PR	16-SEP-1998;	98WO-US019330.
	PR	17-SEP-1998;	98US-0100710P.
	PR	17-SEP-1998;	98US-0100858P.
	PR	17-SEP-1998;	98WO-US019437.
	PR	23-SEP-1998;	98US-0101474P.
	PR	23-SEP-1998;	98US-0101477P.
	PR	24-SEP-1998;	98US-0101741P.
	PR	24-SEP-1998;	98US-0101741P.

R	07-MAY-1998	98US-00854637P.
R	12-MAY-1998	98US-00851493P.
R	13-MAY-1998	98US-00853232P.
R	13-MAY-1998	98US-0085338P.
R	13-MAY-1998	98US-0085339P.
R	15-MAY-1998	98US-0085579P.
R	15-MAY-1998	98US-0085693P.
R	22-MAY-1998	98US-0085704P.
R	22-MAY-1998	98US-0086414P.
R	22-MAY-1998	98US-0086430P.
R	28-MAY-1998	98US-0087106P.
R	04-JUN-1998	98US-0088026P.
R	10-JUN-1998	98US-0088730P.
R	10-JUN-1998	98US-0088743P.
R	11-JUN-1998	98US-0088810P.
R	11-JUN-1998	98US-0088858P.
R	12-JUN-1998	98WO-US012456
R	17-JUN-1998	98US-0093532P.
R	17-JUN-1998	98US-0093599P.
R	18-JUN-1998	98US-0089947P.
R	23-JUN-1998	98US-0090349P.
R	24-JUN-1998	98US-0090429P.
R	24-JUN-1998	98US-0090445P.
R	24-JUN-1998	98US-0090538P.
R	26-JUN-1998	98US-0090863P.
R	01-JUL-1998	98US-0091360P.
R	02-JUL-1998	98US-0091519P.
R	07-JUL-1998	98US-0091982P.
R	14-JUL-1998	98WO-US014552
R	14-JUL-1998	98US-0093339P.
R	30-JUL-1998	98US-0094651P.
R	04-AUG-1998	98US-0095285P.
R	04-AUG-1998	98US-0095301P.
R	04-AUG-1998	98US-0095302P.
R	04-AUG-1998	98US-0095325P.
R	11-AUG-1998	98US-0096143P.
R	11-AUG-1998	98US-0096146P.
R	12-AUG-1998	98US-0096329P.
R	17-AUG-1998	98US-0096769P.
R	17-AUG-1998	98US-0096773P.
R	17-AUG-1998	98US-0096791P.
R	17-AUG-1998	98US-0096891P.
R	18-AUG-1998	98US-0096960P.
R	19-AUG-1998	98US-0097141P.
R	20-AUG-1998	98US-0097218P.
R	26-AUG-1998	98US-0097951P.
R	26-AUG-1998	98US-0097986P.
R	28-AUG-1998	98WO-US017888
R	31-SEP-1998	98US-0098525P.
R	01-SEP-1998	98US-0098750P.
R	09-SEP-1998	98US-0098536P.
R	09-SEP-1998	98US-0099598P.
R	09-SEP-1998	98US-0099601P.
R	10-SEP-1998	98US-0099792P.
R	10-SEP-1998	98US-0099803P.
R	10-SEP-1998	98US-0099816P.
R	10-SEP-1998	98WO-US019824
R	14-SEP-1998	98US-0100263P.
R	14-SEP-1998	98US-0100263P.
R	14-SEP-1998	98WO-US019093
R	14-SEP-1998	98WO-US019094
R	16-SEP-1998	98US-0100710P.
R	17-SEP-1998	98US-0100858P.
R	17-SEP-1998	98WO-US019437
R	23-SEP-1998	98WO-US01474P.
R	23-SEP-1998	98US-0101477P.
R	24-SEP-1998	98US-0101741P.

PR	07-OCT-1998;	98US-0103315P.	XX	OS	Homo sapiens.
PR	07-OCT-1998;	98US-0103328P.	XX	PN	US2003068793-A1.
PR	07-OCT-1998;	98WO-US021141.	XX	PD	10-APR-2003.
PR	13-OCT-1998;	98US-0104080P.	XX	PF	15-APR-2002;
PR	20-OCT-1998;	98US-0104987P.	XX	PR	31-MAR-1997;
PR	22-OCT-1998;	98US-0105169P.	XX	PR	12-JUN-1998;
PR	28-OCT-1998;	98US-0106030P.	XX	PR	14-JUL-1998;
PR	29-OCT-1998;	98WO-US022391.	XX	PR	28-AUG-1998;
PR	30-OCT-1998;	98WO-US022992.	XX	PR	10-SEP-1998;
PR	03-NOV-1998;	98US-0106856P.	XX	PR	14-SEP-1998;
PR	10-NOV-1998;	98US-0106934P.	XX	PR	14-SEP-1998;
PR	17-NOV-1998;	98US-0108775P.	XX	PR	14-SEP-1998;
PR	17-NOV-1998;	98US-0108801P.	XX	PR	16-SEP-1998;
PR	17-NOV-1998;	98US-0108802P.	XX	PR	17-SEP-1998;
PR	20-NOV-1998;	98US-0108925P.	XX	PR	07-OCT-1998;
PR	20-NOV-1998;	98WO-US024855.	XX	PR	29-OCT-1998;
PR	01-DEC-1998;	98WO-US025108.	XX	PR	29-OCT-1998;
PR	15-DEC-1998;	98US-0112743P.	XX	PR	29-OCT-1998;
PR	16-DEC-1998;	98US-0112850P.	XX	PR	20-NOV-1998;
PR	22-DEC-1998;	98US-0113296P.	XX	PR	01-DEC-1998;
PR	22-DEC-1998;	98US-0113299P.	XX	PR	05-JAN-1999;
PR	22-DEC-1998;	98US-0113300P.	XX	PR	08-MAR-1999;
PR	22-DEC-1998;	98US-0113313P.	XX	PR	10-MAR-1999;
PR	22-DEC-1998;	98US-0113314P.	XX	PR	20-APR-1999;
PR	22-DEC-1998;	98US-0113315P.	XX	PR	14-MAY-1999;
PR	22-DEC-1998;	98US-0113510P.	XX	PR	02-JUN-1999;
PR	22-DEC-1998;	98US-0113511P.	XX	PR	01-SEP-1999;
PR	23-DEC-1998;	98US-0113605P.	XX	PR	13-SEP-1999;
PR	23-DEC-1998;	98US-0113621P.	XX	PR	18-SEP-1999;
PR	05-JAN-1999;	99WO-US000106.	XX	PR	15-SEP-1999;
PR	12-JAN-1999;	99US-0115549P.	XX	PR	05-OCT-1999;
PR	12-JAN-1999;	99US-0115557P.	XX	PR	29-NOV-1999;
PR	12-JAN-1999;	99US-0115560P.	XX	PR	30-NOV-1999;
PR	12-JAN-1999;	99US-0115562P.	XX	PR	30-NOV-1999;
PR	12-JAN-1999;	99US-0115564P.	XX	PR	01-DEC-1999;
PR	12-JAN-1999;	99US-0115630P.	XX	PR	01-DEC-1999;
PR	12-JAN-1999;	99US-0115705P.	XX	PR	02-DEC-1999;
PR	12-JAN-1999;	99US-0115733P.	XX	PR	02-DEC-1999;
PR	20-JAN-1999;	99US-0115533P.	XX	PR	02-DEC-1999;
PR	01-FEB-1999;	99US-0118210P.	XX	PR	02-DEC-1999;
Query Match			0.9%; Score 21.4; DB 1; Length 1129;		
Best Local Similarity			66.0%; Pred. No. 56;		
Matches			31; Conservative		
			0; Mismatches		
			16; Indels		
			0; Gaps		
Qy	1929	TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT	1975		
Db	1129	TTTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT	1083		
RESULT 143					
ADA66842/c					
ID	ADA66842 standard; cDNA; 1129 BP.				
XX					
XX	AC				
AC	ADA66842;				
XX	20-NOV-2003 (first entry)				
DT	Human PRO polynucleotide #11.				
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;				
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;				
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;				
KW	liver; microvascular endothelial cell; glucose; FFA;				
KW	skeletal muscle cell; adipocyte cell; pericyte cell;				
KW	inner ear utricular supporting cell; T-lymphocyte cell;				
KW	endothelial cell tube formation; bone disorder; cartilage disorder;				
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;				
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;				
KW	immune system cell infiltration.				

cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCCAGATTCCTTCAGTTGGTTTGT 1975
DB 1129 TTTTTCATTTTTCAGCTGGCACACAGCGCTGGTTTATT 1083

RESULT 144
ADB22703/c
ID ADB22703 standard; cDNA; 1129 BP.
AC ADB22703;
XX 20-NOV-2003 (first entry)
DE Human PRO polynucleotide #111.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US200307711-A1.
XX 24-APR-2003.
XX 22-APR-2002; 2002US-00127829.
XX 22-OCT-1998; 98US-0105169P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 30-NOV-1999; 99WO-US028313.
XX 18-FEB-2000; 2000WO-US004342.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755066/71.
XX P-PSDB; ADB22704.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, as diagnostic markers for the presence of a disease
XX condition, or as therapeutic targets for treating tumors, diabetes,
XX obesity or arthritis.

23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
03-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-695925/66.
XX P-PSDB; ADA66843.
XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
XX release of tumor necrosis factor-alpha from human blood and detecting the
XX presence of a tumor in a mammal.
XX Claim 2; Fig 221; 60pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumor necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiating of adipocyte cells, for stimulating cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating various mammalian haemoglobinopathies. PRO polypeptides are also useful for treating various conditions which associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.98; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.08; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TTCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTGTGTTT 1975
Db 1129 TTTTITTTTTTTTTTTTCAGTGGCACACAGCTGGGTTTATT 1083

RESULT 148
ADB38513/c

ID ADB38513 standard; cDNA; 1129 BP.

XX AC ADB38513;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082766-A1.

XX PD 01-MAY-2003.

XX PF 30-MAY-2002; 2002US-00158782.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 14-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019892.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786921/74.
 DR P-PSDB; ADB38514.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, detecting the presence of tumor in a mammal, or
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle
 PT cells or adipocyte cells.
 XX
 XX Claim 2; Fig 221; 660pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC cells, for stimulating the release of or gene expression in pericyte
 CC cells, for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 G; 335 C; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1929 TCTTAAATTTTTCATTCAGATTCTTCAGTTGGTTTGTGTTT 1975
 Db 1129 TTTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGCTGGTTTATT 1083
 RESULT 149

ADB37961/c
 ID ADB37961 standard; cDNA; 1129 BP.
 XX
 AC ADB37961;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene: ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003087347-A1.
 XX
 PD 08-MAY-2003.
 XX
 XX 19-APR-2002; 2002US-00125921.
 PF
 XX 17-AUG-1998; 98US-0096791P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786938/74.
 DR P-PSDB; ADB37962.
 XX
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 PT
 XX Claim 2; Fig 221; 637pp; English.
 PS
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC cells, for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of or gene expression in pericyte
 CC cells, for stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX

CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCAGATTTTCCTTCAGTTGGGTTTGT 1975
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCTGGTTTAT 1083

RESULT 150
ADB66433/c
ID ADB66433 standard; cDNA; 1129 BP.
XX AC ADB66433;
XX DT 04-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX DN US2003082689-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127831.

XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-0006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00887879.
PR 21-JUN-2001; 2001WO-US020116.
PR 22-JUN-2001; 2001WO-US021066.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

ADB90245/c
ID ADB90245 standard; cDNA; 1129 BP.
XX
AC ADB90245;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear intricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX
XX US2003082762-A1.
PN
XX
XX 01-MAY-2003.
PD
XX
XX 15-APR-2002; 2002US-00123235.
PF
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 27-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 20-MAY-2000; 2000WO-US014042.
PR 22-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 13-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001WO-US015692.
PR 22-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 08-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-743899/70.
P-PSDB; ADB90245.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, and in the detection and treatment of tumor in a mammal.

Claim 2; Fig 221; 649pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis

PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00870992.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001US-00891962.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001US-00892011.
 PR 29-JUN-2001; 2001US-00892011.
 PR 09-JUL-2001; 2001US-00892011.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00924419.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-786919/74.
 DR P-PSDB; ADB39347.
 XX
 XX New secreted and transmembrane PRO polypeptide useful for detecting the
 PT presence of tumor in a mammal, or modulating the uptake of glucose or
 PT free fatty acid by skeletal muscle cells or adipocyte cells.
 XX
 XX Claim 2; Fig 221; 659pp; English.
 PS
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumor in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1929 TCTTAAATTTTTCATTTCCAGATTCCTCAGTTGGGTTTGT 1975

Db 1129 TTTTTCATTTTTCATTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
 RESULT 154
 ADB46969/c
 ID ADB46969 standard; cDNA; 1129 BP.
 XX
 AC ADB46969;
 XX
 XX 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; Cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 XX US2003082687-A1.
 PN
 XX
 XX 01-MAY-2003.
 PD
 XX
 XX 19-APR-2002; 2002US-00125930.
 PF
 XX
 XX 05-JUN-2000; 2000US-0209832P.
 PR
 XX 01-DEC-2000; 2000WO-US032678.
 PR
 XX 19-DEC-2001; 2001US-00028072.
 PR
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-786904/74.
 DR P-PSDB; ADB46970.
 DR
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 XX Claim 2; Fig 221; 627pp; English.
 PS
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumor in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX

Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1975
||| ||||| ||| ||| ||| ||||| ||| ||||| |||
Db 1129 TTTTTCATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1083
||| ||||| ||| ||| ||| ||||| ||| ||||| |||

RESULT 158
ADB335442/C
ID ADB335442 standard; cDNA; 1129 BP.
XX
AC ADB335442;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 221.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077719-A1.
XX
XX 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131824.
XX
XX 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
FA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-755074/71.
DR P-PSDB; ADB35443.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumours,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 221; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a

medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1975
||| ||||| ||| ||| ||| ||||| ||| ||||| |||
Db 1129 TTTTTCATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1083
||| ||||| ||| ||| ||| ||||| ||| ||||| |||

RESULT 159
ADB33786/C
ID ADB33786 standard; cDNA; 1129 BP.
XX
AC ADB33786;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 221.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077716-A1.
XX
XX 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131813.
XX
XX 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
FA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

Yy 1929 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGTGTTGTTT 1975
Dd 1129 TTTTTTTTTTTTTTTTTCAGCTGCACACAGCGCTGGTTTATT 1083

RESULT 161
ADB35994/C
ID ADB35994 standard; cDNA; 1129 BP.
XX AC ADB35994;
XX DT 04-DEC-2003 (first entry)
XX DE Human PRO polynucleotide SEQ ID NO 221.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003077720-A1.
XX PD 24-APR-2003.
XX PF 24-APR-2002; 2002US-00131830.
XX PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
XX PA 19-DEC-2001; 2001US-00028072.
XX PT (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI; 2003-755075/71.
PS P-PSDB; ADB35995.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.
XX Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating

11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00805689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00871092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00913692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX XX
PA (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755073/71.
DR P-PSDB; ADB34891.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.
XX Claim 2; Fig 221; 638pp; English.

cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.
Homo sapiens.
US2003092106-A1.
15-MAY-2003.
24-APR-2002; 2002US-00131822.
19-AUG-1998; 98US-0097141P.
02-JUN-1999; 99WO-US012252.
25-AUG-1999; 99US-00380137.
30-MAR-2000; 2000WO-US008439.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-801171/75.
P-PSDB; ADC50263.
New secreted and transmembrane nucleic acid useful for treating
inflammation, organ failure, atherosclerosis, cardiac injury,
infertility, birth defects, premature aging, acquired immunodeficiency
syndrome or cancer.
Claim 2; Fig 221; 637pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating the proliferation of or gene expression in pericyte cells, for
treating various bone and/or cartilage disorders such as sports injuries
and arthritis. PRO polypeptides which stimulate the release of
proteoglycans from cartilage are useful for treating sports-related joint
problems, articular cartilage defects, osteoarthritis and rheumatoid
arthritis. PRO polypeptides are also useful for treating various
mammalian haemoglobin-associated disorders such as various thalassaemias
and conditions which may benefit from enhanced local immune system cell
infiltration. This sequence represents a human PRO polynucleotide of
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1929 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTTGGGTTTGTTT 1975
 |||||
 Db 1129 TTTTNTTTTTTTTTTTTTCAGCTGGCACACAGCTGGTTTTATT 1083
 |||||
 RESULT 164
 ADC71809/c
 ID ADC71809 standard; cDNA; 1129 BP.
 XX
 AC ADC71809;
 XX
 XX 18-DEC-2003 (first entry)
 XX
 XX Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.
 XX
 XX Homo sapiens.
 OS
 XX US2003092107-A1.
 XX
 XX 15-MAY-2003.
 PD
 XX
 XX 24-APR-2002; 2002US-00131828.
 PF
 XX 07-OCT-1998; 98US-0103315P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 FA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Falvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 XX
 DR WPI; 2003-8011172/75.
 DR P-PSDB; ADC71810.
 XX
 PT New secreted and transmembrane nucleic acids and polypeptides, designated
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
 PT cancer.
 XX
 PS Claim 2; Fig 221; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal lung).

KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS
XX Homo sapiens.
XX US2003087365-A1.
XX
PD 08-MAY-2003.
XX
XX 23-APR-2002; 2002US-00128689.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028584.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019892.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801150/75.
DR P-PsDB; ADC52796.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
XX Claim 2; SEQ ID NO 221; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the

```
CC invention.
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1975
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083

RESULT 167
ADC57149/c
ID ADC57149 standard; cDNA; 1129 BP.
XX ADC57149;
AC
XX
DT 18-DEC-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein cDNA Seq ID221.
XX human; PRO; membrane bound protein; membrane bound receptor;
XX cell proliferation; cell migration; cell differentiation;
XX mitogenic factor; survival factor; cytotoxic factor;
XX differentiation factor; neuropeptide; hormone; cell receptor;
XX receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
XX OS
XX US2003087366-A1.
XX PD
XX 08-MAY-2003.
XX
XX 23-APR-2002; 2002US-00128694.
XX
XX 02-MAR-2000; 2000WO-US005841.
XX
XX 30-MAY-2000; 2000WO-US014941.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen WF, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801151/75.
XX
XX P-PSDB; ADC57150.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor.
XX
XX Claim 2; SEQ ID NO 221; 637pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neuropeptides or hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytostatic activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a
```

```
PR 15-SEP-1999; 99WO-US021547.
PR 09-OCT-1999; 99WO-US023089.
PR 25-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 31-MAR-2000; 2000WO-US007532.
PR 31-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX MPI; 2003-801152/75.
XX P-PSDB; ADC60341.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 2; Fig 221; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassaemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polynucleotide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21.4; DB 1; Length 1129;
XX Best Local Similarity 66.0%; Pred. No. 56;
XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX
XX 1929 TCTTAAATTTTTCATTTCCAGATTCTTCAGTTGGGTTTGT 1975
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
XX
XX RESULT 169
XX ADC50815/c
XX ID ADC50815 standard; cDNA; 1129 BP.
XX
XX AC ADC50815;
XX
XX DT 18-DEC-2003 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
XX
```


immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.

Homo sapiens.

US2003092104-A1.

15-MAY-2003.

24-APR-2002; 2002US-00131817.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

27-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028301.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

28-JUL-2000; 2000WO-US020710.

11-AUG-2000; 2000WO-US022031.

23-AUG-2000; 2000WO-US023522.

24-AUG-2000; 2000WO-US023528.

08-NOV-2000; 2000WO-US030952.

10-NOV-2000; 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.

20-DEC-2000; 2000US-00747259.

20-DEC-2000; 2000WO-US034956.

28-FEB-2001; 2001US-00796498.

28-FEB-2001; 2001WO-US006520.

01-MAR-2001; 2001WO-US006666.

09-MAR-2001; 2001US-00802706.

14-MAR-2001; 2001US-00808689.

22-MAR-2001; 2001US-00816744.

05-APR-2001; 2001US-00828366.

10-MAY-2001; 2001US-00854208.

10-MAY-2001; 2001US-00854280.

18-MAY-2001; 2001US-00860216.

25-MAY-2001; 2001US-00866028.

25-MAY-2001; 2001US-00866034.

01-JUN-2001; 2001WO-US017092.

01-JUN-2001; 2001US-00872035.

01-JUN-2001; 2001WO-US017800.

05-JUN-2001; 2001US-00874503.

14-JUN-2001; 2001US-00882636.

19-JUN-2001; 2001US-00886342.

20-JUN-2001; 2001WO-US019692.

21-JUN-2001; 2001US-00887879.

22-JUN-2001; 2001WO-US020116.

29-JUN-2001; 2001WO-US021066.

09-JUL-2001; 2001WO-US021735.

18-JUL-2001; 2001US-00908827.

06-AUG-2001; 2001US-00924419.

09-AUG-2001; 2001US-00927796.

16-AUG-2001; 2001US-00931836.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801169/75.

P-PSDB; ADD03047.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

PRO4978, useful in molecular biology, chromosome and gene mapping, in

generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The

invention also relates to an antibody which specifically binds to a PRO

polypeptide, a method for stimulating the release of tumour necrosis

factor-alpha (TNF-alpha) from human blood, a method for stimulating the

proliferation or differentiation of chondrocyte cells and a method for

detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

polynucleotides are useful in molecular biology, including uses as

hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also

be used in preparing PRO polypeptides by recombinant techniques and in

generating either transgenic animals or knock-out animals which are

useful in the development and screening of therapeutically useful

reagents. The PRO polypeptides or antibodies are used in preparing a

medicament for treating a condition responsive to the polypeptides or

antibodies, such as tumours, for stimulating and inhibiting proliferation

of human microvascular endothelial cells, for modulating the uptake of

glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

cells, for stimulating differentiation of adipocyte cells, for

CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC	stimulating differentiation of adipocyte cells, for stimulating
CC	proliferation of or gene expression in pericyte cells, for stimulating
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC	cells, for inducing endothelial cell tube formation and for treating
CC	various bone and/or cartilage disorders such as sports injuries and
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC	from cartilage are useful for treating sports-related joint problems,
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC	polypeptides are also useful for treating various mammalian haemoglobin-
CC	associated disorders such as various thalassaemias and conditions which
CC	benefit from enhanced local immune system cell infiltration. This
CC	sequence represents a human PRO polynucleotide of the invention. Note:
CC	The sequence data for this patent is also available in electronic format
CC	from USPTO at seqdata.uspto.gov/sequence.html.
XX	
SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
	Query Match 0.%; Score 21.4; DB 1; Length 1129;
	Best Local Similarity 66.0%; Pred.No.56;
	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY	1929 TTCTTAATTTTTCATTTCAGATTTCTTTCAGTTGGGTTTGTTT 1975
Dd	1129 TTTTTTTTTTTTTTTTCAGCTGCACACAGCGTGGGTTTTATT 1083
RESULT 181	
ADD04450/c	
ID	ADD04450 standard; cDNA; 1129 BP.
AC	ADD04450;
XX	
DT	01-JAN-2004 (first entry)
XX	
DE	Novel human secreted and transmembrane protein PRO4327 cDNA.
KW	Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;
KW	glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW	cell differentiation; skeletal muscle cell; adipocyte cell;
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW	immune system cell infiltration; chromosome mapping; gene mapping;
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2003087354-A1.
XX	
PD	08-MAY-2003.
XX	
PF	22-APR-2002; 2002US-00127827.
XX	
PR	17-AUG-1998; 98US-0096991P.
PR	02-JUN-1999; 99WO-US012252.
PR	25-AUG-1999; 99US-00380137.
PR	30-MAR-2000; 2000WO-US008439.
PR	30-MAY-2000; 2000WO-US014941.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI	Grittisen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR	WPI: 2003-R01139/75

Db 1129 TTTTTCATTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 183
ADD10913/C
ID ADD10913 standard; cDNA; 1129 BP.
XX
AC ADD10913;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194774-A1.
XX
XX 16-OCT-2003.
XX
XX 21-MAY-2002; 2002US-00152399.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-852594/79.
XX
XX P-PSDB; ADD10914.
XX
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
XX for detecting a tumor, stimulating the proliferation or differentiation
XX of chondrocyte cells and stimulating the release of tumor necrosis factor
XX alpha.
XX
XX Claim 2; SEQ ID NO 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1975
Db 1129 TTTTTCATTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 184
ADC47794/C
ID ADC47794 standard; cDNA; 1129 BP.
XX
AC ADC47794;
XX
XX 01-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX OS
XX US2003194771-A1.
XX
XX 16-OCT-2003.
XX
XX 21-MAY-2002; 2002US-00152377.
XX
XX 09-DEC-1999; 99US-0170262P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Smith V;
XX Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-844454/78.
XX
XX P-PSDB; ADC47795.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids useful
XX for detecting a tumor, stimulating the release of proteoglycans from
XX cartilage and stimulating the proliferation of endothelial cells.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and

Claim 2; Fig 221; 637pp; English.

medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at segdata.uspto.gov.

stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at segdata.uspto.gov.

arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at segdata.uspto.gov.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

RESULT 189

ADD52913/C
ID ADD52915 standard: cDNA: 1129 BP.

AA ADD52915:

DT 15-JAN-2004 (first entry)

cdNA encoding human PRO polypeptide #1111.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

KW tumour necrosis factor- α -apna; INF- α -apna; monocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; Glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

KW liver; microvascular endothelial cell; glucoc; FF;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW

immune system cell infiltration.
KW XX OS XX PN XX PD XX PF XX
Homo sapiens.
US2003194792-A1.
16-OCT-2003.
15-APR-2002; 2002US-00123156.
31-MAR-1997; 97WO-US005230.
12-JUN-1998; 98WO-US012456.
14-JUL-1998; 98WO-US014552.
28-AUG-1998; 98WO-US017888.
10-SEP-1998; 98WO-US018824.
14-SEP-1998; 98WO-US019093.
14-SEP-1998; 98WO-US019094.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98WO-US019437.
07-OCT-1998; 98WO-US021141.
29-OCT-1998; 98WO-US022991.
29-OCT-1998; 98WO-US022992.
20-NOV-1998; 98WO-US024855.
01-DEC-1998; 98WO-US025108.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
10-MAR-1999; 99WO-US005190.
10-MAR-1999; 2000WO-US006319.
20-APR-1999; 99WO-US008615.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
01-SEP-1999; 99WO-US020111.
08-SEP-1999; 99WO-US020594.
13-SEP-1999; 99WO-US020944.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
30-NOV-1999; 99WO-US028313.
01-DEC-1999; 99WO-US028409.
01-DEC-1999; 99WO-US028401.
01-DEC-1999; 99WO-US028634.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028564.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.
22-DEC-1999; 99WO-US030720.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US0003565.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004514.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.
02-MAR-2000; 2000WO-US005841.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
21-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
XX XX
(GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI: 2003-852599/79.
P-PSDB; ADD52916.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in the treatment of cancer.
XX
PS Claim 2; Fig 221; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1975
 1129 TTTTATTTTATTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 190
 ADD53467/c
 ID ADD53467 standard; cDNA; 1129 BP.

AC ADD53467;
 DT 15-JAN-2004 (first entry)
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.

Human; secreted and transmembrane protein; PRO; gene; ss;
 Tumour necrosis factor alpha release; TNF-alpha release;
 Glucose uptake modulator; FFA uptake modulator;
 cell proliferation stimulator; cell differentiation stimulator;
 cell differentiation inhibitor; cytokine release stimulator; tumour;
 lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 cervical tumour; liver tumour; chromosome mapping; gene mapping;
 gene therapy; chromosome identification; chromosome marker.

Homo sapiens.
 US2003203437-A1.
 30-OCT-2003.
 15-MAY-2002; 2002US-00146728.
 01-JUL-1998; 98US-0091360P.
 02-JUN-1999; 99WO-US012252.
 01-DEC-2000; 2000US-00380137.
 01-DEC-2000; 2000WO-US032678.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-875644/81.
 P-PSDB; ADD53468.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; SEQ ID NO 221; 659pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and

transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from FMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1975
 1129 TTTTATTTTATTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 191
 ADD51623/c
 ID ADD51623 standard; cDNA; 1129 BP.

AC ADD51623;
 DT 15-JAN-2004 (first entry)
 DE cDNA encoding human PRO polypeptide #111.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 liver; microvascular endothelial cell; glucose; FFA;
 skeletal muscle cell; adipocyte cell; pericyte cell;
 inner ear utricular supporting cell; T-lymphocyte cell;
 endothelial cell tube formation; bone disorder; cartilage disorder;
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 immune system cell infiltration.

Homo sapiens.

US2003194779-A1.

16-OCT-2003.

30-MAY-2002; 2002US-00160500.

05-JUN-2000; 2000US-0209832P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX DE Human PRO polynucleotide #111.

XX DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

OS Homo sapiens.

XX US2003199055-A1.

XX 23-OCT-2003.

PD 12-APR-2002; 2002US-00121063.

PF 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-MAR-1999; 2000WO-US006319.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028401.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 02-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 30-DEC-1999; 99WO-US031274.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 06-JAN-2000; 2000WO-US000376.

XX 11-FEB-2000; 2000WO-US0003565.

XX 18-FEB-2000; 2000WO-US0004341.

XX 18-FEB-2000; 2000WO-US0004342.

XX 22-FEB-2000; 2000WO-US0004414.

XX 24-FEB-2000; 2000WO-US0004914.

XX 24-FEB-2000; 2000WO-US005004.

01-MAR-2000; 2000WO-US005601.

02-MAR-2000; 2000WO-US005746.

02-MAR-2000; 2000WO-US005841.

15-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.

17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.

30-MAY-2000; 2000WO-US014941.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

11-AUG-2000; 2000WO-US022031.

23-AUG-2000; 2000WO-US023522.

24-AUG-2000; 2000WO-US023328.

08-NOV-2000; 2000WO-US030952.

10-NOV-2000; 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.

20-DEC-2000; 2000US-00747259.

20-DEC-2000; 2000WO-US034956.

28-FEB-2001; 2001US-00796496.

28-FEB-2001; 2001WO-US006520.

01-MAR-2001; 2001WO-US006665.

09-MAR-2001; 2001US-00802706.

14-MAR-2001; 2001US-00808689.

22-MAR-2001; 2001US-00816744.

05-APR-2001; 2001US-00828366.

10-MAY-2001; 2001US-00854208.

18-MAY-2001; 2001US-00854280.

25-MAY-2001; 2001US-00860216.

25-MAY-2001; 2001US-00866028.

25-MAY-2001; 2001US-00866034.

25-MAY-2001; 2001WO-US017092.

01-JUN-2001; 2001US-00872035.

01-JUN-2001; 2001WO-US017800.

05-JUN-2001; 2001US-00874503.

14-JUN-2001; 2001US-00882636.

19-JUN-2001; 2001US-00886342.

20-JUN-2001; 2001WO-US019692.

21-JUN-2001; 2001US-00887879.

22-JUN-2001; 2001WO-US020116.

29-JUN-2001; 2001WO-US021066.

09-JUL-2001; 2001WO-US021735.

18-JUL-2001; 2001US-00908827.

06-AUG-2001; 2001US-00924419.

09-AUG-2001; 2001US-00927796.

16-AUG-2001; 2001US-00931836.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-300165/82.

P-PSDB; ADD91252.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,

useful for treating pericyte-associated tumors, diabetes and various bone

and/or cartilage disorders, e.g. arthritis.

Claim 2; SEQ ID NO 221; 636pp; English.

The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The

invention also relates to an antibody which specifically binds to a PRO

polypeptide, a method for stimulating the release of tumour necrosis

factor-alpha (TNF-alpha) from human blood, a method for stimulating the

proliferation or differentiation of chondrocyte cells and a method for

detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

polynucleotides are useful in molecular biology, including uses as

PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-900167/82.
 DR P-PSDB; ADE03866.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; Fig 221; 637pp; English.
 PS The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems.
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAAATTTTTCATTTCCAGATTTCTTCAGTTGGGTTTGT 1975
 DB 1129 TTTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083
 RESULT 198
 ADE32162/c
 ID ADE32162 standard; cDNA; 1129 BP.
 XX
 AC ADE32162;
 DT 29-JAN-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO4327 cDNA.
 DE Humur; secreted and transmembrane protein; PRO; gene; ss;
 XX Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX Homo sapiens.
 OS
 XX US2003194765-A1.
 PN
 XX 16-OCT-2003.
 PD
 XX 09-MAY-2002; 2002US-00142889.
 PF
 XX 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-999784/82.
 DR P-PSDB; ADE32163.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 221; 636pp; English.
 PS The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and

PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-900166/82.
 DR P-PSDB; ADE22095.
 XX
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX
 XX Claim 2; Fig 221; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1929 TTTCTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGGTTT 1975
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCGTGGGTTTATT 1083
 RESULT 200
 ID ADD79318/c
 XX ADD79318 standard; cDNA; 1129 BP.
 XX
 AC ADD79318;
 XX
 DT 29-JAN-2004 (first entry)
 XX cDNA encoding human PRO polypeptide #111.
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003203428-A1.
 XX
 PD 30-OCT-2003.
 XX
 XX 22-APR-2002; 2002US-00127852.
 XX
 XX 09-DEC-1999; 99US-0170262P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-875635/81.
 DR P-PSDB; ADD79319.
 XX
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX
 PS Claim 2; Fig 221; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

```
Query Match          0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TCTTAATTTTTCATTTCCAGATTCTTCAGTTGGTGTGTTT 1975
    ||| ||||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTTCATTTTTCAGTGGCACACAGGCTGGTGTGTTTATT 1083

RESULT 201
ADE41854/c
ID ADE41854 standard; cDNA; 1129 BP.
XX AC ADE41854;
XX AC ADE41854;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX OS Homo sapiens.
XX PN US2003194772-A1.
XX XX 16-OCT-2003.
XX XX 21-MAY-2002; 2002US-00152386.
XX PF 03-MAR-2000; 2000US-0187202P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX XX (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-899788/82.
XX DR P-PSDB; ADE41855.
XX XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX Claim 2; Fig 221; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
```

```
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match          0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TCTTAATTTTTCATTTCCAGATTCTTCAGTTGGTGTGTTT 1975
    ||| ||||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTTCATTTTTCAGTGGCACACAGGCTGGTGTGTTTATT 1083

RESULT 202
ADE17671/c
ID ADE17671 standard; cDNA; 1129 BP.
XX AC ADE17671;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX OS Homo sapiens.
XX PN US2003199023-A1.
XX XX 23-OCT-2003.
XX XX 17-APR-2002; 2002US-00124821.
XX PR 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 28-AUG-1998; 98WO-US014552.
XX PR 14-SEP-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 16-SEP-1998; 98WO-US019177.
XX PR 17-SEP-1998; 98WO-US019330.
XX PR 07-OCT-1998; 98WO-US019437.
XX PR 29-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
XX PR 20-NOV-1998; 98WO-US022392.
XX PR 20-NOV-1998; 98WO-US024855.
```


XX	Sequence	1129 BP;	231 A;	369 C;	335 G;	194 T;	0 U;	0 Other;
QA	Query Match	0.9%; Score 21.4; DB 1; Length 112						
	Best Local Similarity	66.0%; Pred. No. 56;						
	Matches	31; Conservative 0; Mismatches 16; Indels						
QY	1929	TTCTTAATTTTTTCAATTCAGATTTCTCTTCAGTTGGGTTTGTGTTT	19					
DB	1129	TTTTTTTTTTTTTTTTTTTTCAGCTGGGCACAGGCTGTTTTTTTATT	10					

RESULT 203
ID ADD91803/C
XX ADD91803 standard; cDNA; 1129 BP.
AC ADD91803;
XX
DT 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003199053-A1.
XX
PD 23-OCT-2003.
XX
PE 12-APR-2002; 2002US-00121053.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022591.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard AJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-900164/82.
XX P-PSDB, ADD91804.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 221; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

Human, secreted and transmembrane protein; PRO; gene; ss;
KW
KW
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW
KW glucose uptake modulator; FFA uptake modulator;
KW
KW cell proliferation stimulator; cell differentiation stimu-

cell differentiation inhibitor; cytokine release stimulator; tumour;
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.
XX PN US2003194791-A1.
XX PD 16-OCT-2003.
XX PP 11-APR-2002; 2002US-00121046.
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
FA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-899790/82.
DR P-PSDB; ADEJ3819.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; SEQ ID NO 221; 636pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage,
CC for stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome


```
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match          0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAAATTTTCATTCACAGATTCCTTCAGTTGGGTTTGT 1975
Db 1129 TTTTITTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 208
ADE1927/c
ID ADE19327 standard; cDNA; 1129 BP.
XX
AC ADE19327;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199025-A1.
XX
PD 23-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152385.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-900156/82.
DR P-PSDB; ADE19328.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 221; 648pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
```

```
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match          0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAAATTTTCATTCACAGATTCCTTCAGTTGGGTTTGT 1975
Db 1129 TTTTITTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 209
ADE18775/c
ID ADE18775 standard; cDNA; 1129 BP.
XX
AC ADE18775;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199026-A1.
XX
PD 23-OCT-2003.
XX
PF 20-MAY-2002; 2002US-00152393.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-900157/82.
DR
```


PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	18-FEB-2000;	2000WO-US004342.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001US-00891692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00908827.
PR	06-AUG-2001;	2001US-00924419.
PR	03-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00028072.
XX		
PA	(GETH)	GENENTECH INC.
XX		
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI; 2003-900168/82.	
DR	P-PSDB; ADD95761.	
XX		
XX		
PT	Two hundred and seventy five nucleic acids encoding PRO polypeptides,	
PT	useful for treating pericyte-associated tumors, diabetes and various bone	
PT	and/or cartilage disorders, e.g. arthritis.	
XX		
PS	Claim 2; Fig 221; 638pp; English.	
XX		
CC	The invention relates to isolated human PRO polypeptides (secreted and	
CC	transmembrane polypeptides) and the polynucleotides encoding them. The	

XX

16-APR-1997;	97WU-US05052320;
31-MAR-1997;	98WU-US05012456;
12-JUN-1998;	98WU-US014552;
14-JUL-1998;	98WU-US017888;
28-AUG-1998;	98WU-US018824;
10-SEP-1998;	98WU-US019093;
14-SEP-1998;	98WU-US019177;
14-SEP-1998;	98WU-US019330;
16-SEP-1998;	98WU-US019437;
17-SEP-1998;	98WU-US021141;
27-OCT-1998;	98WU-US022991;
29-OCT-1998;	98WU-US022992;
29-OCT-1998;	98WU-US024855;
20-NOV-1998;	98WU-US025108;
01-DEC-1998;	98WU-US025108;
05-JAN-1999;	99WU-US000106;
08-MAR-1999;	99WU-US005002;
10-MAR-1999;	99WU-US005191;
20-APR-1999;	99WU-US008615;
14-MAY-1999;	99WU-US010733;
22-JUN-1999;	99WU-US012252;
01-SEP-1999;	99WU-US020111;
08-SEP-1999;	99WU-US020594;
13-SEP-1999;	99WU-US020944;
15-SEP-1999;	99WU-US021090;
15-SEP-1999;	99WU-US021547;
05-OCT-1999;	99WU-US023089;
29-NOV-1999;	99WU-US028214;
30-NOV-1999;	99WU-US028313;
30-NOV-1999;	99WU-US028409;
01-DEC-1999;	99WU-US028301;
01-DEC-1999;	99WU-US028634;
02-DEC-1999;	99WU-US028551;
02-DEC-1999;	99WU-US028564;
02-DEC-1999;	99WU-US028565;
16-DEC-1999;	99WU-US030095;
20-DEC-1999;	99WU-US030911;
20-DEC-1999;	99WU-US030999;
22-DEC-1999;	99WU-US030720;
30-DEC-1999;	99WU-US031243;
30-DEC-1999;	99WU-US031274;
05-JAN-2000;	2000WU-US000219;
06-JAN-2000;	2000WU-US000277;
06-JAN-2000;	2000WU-US000376;
11-FEB-2000;	2000WU-US003565;
18-FEB-2000;	2000WU-US004341;
22-FEB-2000;	2000WU-US004342;
28-FEB-2000;	2000WU-US004414;
24-FEB-2000;	2000WU-US004914;
24-FEB-2000;	2000WU-US005104;
01-MAR-2000;	2000WU-US005601;
02-MAR-2000;	2000WU-US005746;
02-MAR-2000;	2000WU-US005841;
10-MAR-2000;	2000WU-US006319;
15-MAR-2000;	2000WU-US006684;
20-MAR-2000;	2000WU-US007377;
21-MAR-2000;	2000WU-US007532;
30-MAR-2000;	2000WU-US008439;
17-MAY-2000;	2000WU-US013705;
22-MAY-2000;	2000WU-US023521;
24-AUG-2000;	2000WU-US023328;
08-NOV-2000;	2000WU-US030952;
10-NOV-2000;	2000WU-US030873;
21-DEC-2000;	2000WU-US032678;
20-DEC-2000;	2000US-00747259;

02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028564

02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.
30-DEC-1999; 99WO-US031243.

30-DEC-1999; 99WO-US031274.
05-JAN-2000: 2000WO-US000219

06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US0003565

11-FEB-2000; 2000WO-US003363;
18-FEB-2000; 2000WO-US004341;

18-FEB-2000; 2000WO-US004342.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US005004.
01-MAR-2000: 2000WO-US005001

01-MAR-2000; 2000WC-US003601.
02-MAR-2000: 2000WC-US005746.

02-MAR-2000; 2000WO-US005841.

10-MAR-2000; 2000WO-US006319;
15-MAR-2000; 2000WO-US006884;
20-MAR-2000; 2000WO-US007377;
21-MAR-2000; 2000WO-US007532;
30-MAR-2000; 2000WO-US008439;
17-MAY-2000; 2000WO-US013705;
22-MAY-2000; 2000WO-US014042;
30-MAY-2000; 2000WO-US014941;
02-JUN-2000; 2000WO-US015264;
28-JUL-2000; 2000WO-US020710;
11-AUG-2000; 2000WO-US020331;
23-AUG-2000; 2000WO-US023522;
24-AUG-2000; 2000WO-US023328;
08-NOV-2000; 2000WO-US030932;
10-NOV-2000; 2000WO-US030873;
01-DEC-2000; 2000WO-US032678;
20-DEC-2000; 2000US-0074259;
2000US-00747259;

23-AUG-2000; 2000WO-US023522.
24-AUG-2000: 2000WO-US023329

08=NOV=2000; 2000WO=US030952.
10=NOV=2000; 2000WO=US030873

01-DEC-2000; 2000MO=05032678.
20-DEC-2000: 2000IS=00747259

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

PR 20-DEC-2000; 200UWO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WU-US006520.
PR 01-MAR-2001; 2001WU-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00916744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WU-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WU-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WU-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WU-US020116.
PR 29-JUL-2001; 2001WU-US021066.
PR 09-AUG-2001; 2001WU-US021735.
PR 18-JUL-2001; 2001US-00308827.
PR 06-AUG-2001; 2001US-00324419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TX, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI : 2004-008956/01.
XX P-PSDB; ADD76407.

XX
XX New PRO nucleic acid, useful for recombinantly producing a PRO
XX polypeptide and for manufacturing a medicament for diagnosing or treating
XX a tumor.

XX Claim 2; Fig 221; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO-
XX polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTTGTTT 1975
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTTTTTTTTTTTTTTTTCAGCTGCACACAGCGTGGTTTTATY 1083

RESULT 222
ADD87770/C

ID ADD87770 standard; cDNA; 1129 BP.

XX AC ADD87770;

XX DT 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #111.

DE XX

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; procoagulant; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

OS XX

XX US2003092113-A1.

XX PD 15-MAY-2003.

XX PF 16-MAY-2002; 2002US-00147523.

XX PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart RA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-020237/02.
DR P-PSDB; ADD87771.

XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003211571-A1.
XX 13-NOV-2003.
XX 20-MAY-2002; 2002US-00152405.
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-051576/05.
XX P-PSDB; ADE75623.
XX New secreted and transmembrane PRO polypeptide and nucleic acid encoding
XX it, for use in gene therapy, as diagnostic markers for the presence of a
XX disease condition, or as therapeutic targets for treating tumors,
XX diabetes, or arthritis.
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGTTGGTTGTTT 1975
DB 1129 TTTTTCATTTTTCATTTTCAGTTTCAGTTGGTTGGTTGTTT 1083
RESULT 225
ADE23198/c
ID ADE23198 standard; cDNA; 1129 BP.
XX
XX ADE23198;
XX
XX 29-JAN-2004 (first entry)
XX cDNA encoding human PRO polypeptide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003092108-A1.
XX 15-MAY-2003.
XX 24-APR-2002; 2002US-00131835.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-020234/02.
XX P-PSDB; ADE23199.
XX New secreted and transmembrane nucleic acids and polypeptides, designated
XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,
XX cardiac injury, infertility, birth defects, premature aging, AIDS, or
XX cancer.
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX PF 03-MAY-2002; 2002US-00137869.
XX PF 03-MAR-2000; 2000US-0187202P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX XX WPI; 2004-020236/02.
XX DR P-PSDB; ADE24394.
XX XX New secreted and transmembrane nucleic acid useful for treating
XX PT inflammation, organ failure, atherosclerosis, cardiac injury,
XX PT infertility, birth defects, premature aging, acquired immunodeficiency
XX PT syndrome, or cancer.
XX XX Claim 2; Fig 221; 637pp; English.
XX XX The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating differentiation of adipocyte cells, for stimulating
XX CC the proliferation of or gene expression in pericyte cells, for stimulating
XX CC cells, for inducing endothelial cell tube formation and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems,
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence encodes a human PRO polypeptide of the invention. Note: The
XX CC sequence data for this patent is also available in electronic format from
XX CC the USPTO website at seqdata.uspto.gov.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCCTAATTTTTCATTCACATTCCTTCAGTTGGGTTTGGTTT 1975
DB 1129 TTTTTCATTTTTCATTCACATTCCTTCAGTTGGGTTTGGTTT 1083
RESULT 228
ADD87218/c
ID ADD87218 standard; cDNA; 1129 BP.
XX AC ADD87218;

XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX KW liver; microvascular endothelial cell; glucose; FFA;
XX KW skeletal muscle cell; adipocyte cell; pericyte cell;
XX KW inner ear utricular supporting cell; T-lymphocyte cell;
XX KW endothelial cell tube formation; bone disorder; cartilage disorder;
XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
XX KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003203439-A1.
XX XX 30-OCT-2003.
XX PF 17-MAY-2002; 2002US-00147499.
XX PR 04-AUG-1998; 98US-0095301P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 30-MAR-2000; 2000US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX XX WPI; 2004-021362/02.
XX DR P-PSDB; ADD87219.
XX XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX PT generating antisense RNA and DNA, and in gene therapy.
XX PS Claim 2; Fig 221; 648pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating differentiation of adipocyte cells, for stimulating
XX CC the proliferation of or gene expression in pericyte cells, for stimulating
XX CC cells, for inducing endothelial cell tube formation and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems,
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence encodes a human PRO polypeptide of the invention. Note: The
XX CC sequence data for this patent is also available in electronic format from
XX CC the USPTO website at seqdata.uspto.gov.

PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US0008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	18-MAY-2001;	2001US-00854280.
PR	25-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	01-JUN-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00908827.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00028072.
XX		
XX	(GETH) GENENTECH INC.	
XX		
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI; 2004-021079/02.	
DR	P-PSDB; ADE18224.	
XX		
PT	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or	
PT	PRO4978, for use in molecular biology, chromosome and gene mapping, in	
PT	generating antisense RNA and DNA, and in gene therapy.	
XX		
PS	Claim 2; SEQ ID NO 221; 638pp; English.	
XX		
CC	The invention relates to isolated human PRO polypeptides (secreted and	
CC	transmembrane polypeptides) and the polynucleotides encoding them. The	
CC	invention also relates to an antibody which specifically binds to a PRO	
CC	polypeptide, a method for stimulating the release of tumour necrosis	
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the	
CC	proliferation or differentiation of chondrocyte cells and a method for	
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,	
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The	
CC	polynucleotides are useful in molecular biology, including uses as	
CC	hybridisation probes, in chromosome and gene mapping, in generating	
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	
CC	be used in preparing PRO polypeptides by recombinant techniques and in	
CC	generating either transgenic animals or knock-out animals which are	
CC	useful in the development and screening of therapeutically useful	

RESULT 232
 ABX14193
 ID ABX14193 standard; DNA; 6098 BP.
 XX
 AC ABX14193;
 XX
 11-MAR-2003 (first entry)
 XX
 DE Plasmid pLN174 for expressing human coagulation Factor VII.
 XX
 KW Human; coagulation; Factor VIIa; Factor VIIa; blood coagulation;
 KW fibrin clot; haemostatic; tissue factor; zymogen; Factor IX; Factor X;
 KW prothrombin; thrombin; Factor V; Factor VIII; fibrinogen; fibrin;
 KW plasma factor; bleeding episode; haemophilia A; haemophilia B; thrombus;
 KW intimal hyperplasia; restenosis; cardiogenic embolism; stroke;
 KW platelet deposition; percutaneous transluminal coronary angioplasty; PTCA;
 KW cancer; tumour; angiogenesis; ischaemia; reperfusion; thrombolysis;
 KW rheumatoid arthritis; arteriosclerosis; inflammation; septic shock;
 KW hypotension; adult respiratory distress syndrome; ARDS;
 KW myocardial infarction; vasotropic; cerebroprotective; antibacterial;
 KW immunosuppressive; cardiant; gene therapy; ds; pLN174.
 XX
 OS Homo sapiens.
 OS Unidentified.
 OS Synthetic.
 XX
 PH Key Location/Qualifiers
 FT CDS 285..1505
 FT /*tag= a
 FT /product= "Coagulation Factor VII"
 FT /partial
 FT /transl_except= (pos:300..305,aa:Xaa-Xaa)
 FT /transl_except= (pos:324..326,aa:Xaa)
 FT /transl_except= (pos:330..332,aa:Xaa)
 FT /transl_except= (pos:339..344,aa:Xaa-Xaa)
 FT /transl_except= (pos:357..362,aa:Xaa-Xaa)
 FT /transl_except= (pos:369..371,aa:Xaa)
 FT /transl_except= (pos:387..389,aa:Xaa)
 FT /notes= "No start codon shown. Xaa = gamma carboxylated
 Glutamic acid"
 FT XX
 XX WO200277218-A1.
 PN
 XX
 PD 03-OCT-2002.
 XX
 PF 21-MAR-2002; 2002WO-DK000189.
 XX
 PR 22-MAR-2001; 2001DK-00000477.
 XX
 PA (NOVO) NOVO NORDISK AS.
 XX
 XX Persson E;
 PI
 DR WPI; 2003-058374/05.
 DR P-PSDB; ABG73119.
 XX
 PT Novel factor VII polypeptide, its derivatives useful for preparing
 PT medicament for treating bleeding episodes, or for enhancing normal
 PT hemostatic system, especially for treating hemophilia.
 XX
 PS Disclosure; Page 82-85; 96pp; English.
 XX
 CC The invention discloses a human factor VII polypeptide, or a variant or
 CC derivative of it, where an amino acid has been modified. This change
 CC results in a polypeptide with the same or an increased activity when
 CC compared to recombinant wild type human factor VIIa. Blood coagulation
 CC consists of a complex interaction of various blood components that
 CC eventually give rise to a fibrin clot. Initiation of the haemostatic
 CC process is mediated by the formation of a complex between tissue factor
 CC and Factor VIIa (the active form of the factor VII zymogen). This complex
 CC activates Factors IX and X, converting prothrombin to thrombin, which
 CC activates Factors V and VIII leading to a full thrombin burst. The

thrombin converts fibrinogen to fibrin resulting in formation of a fibrin
 clot. The Factor VII zymogen, or its derivative, can be modified in its
 catalytic centre to inhibit the ability of the Factor VII polypeptide to
 activate plasma factor X or IX. The factor VII derivative is useful for
 preparing a medicament for the treatment of bleeding episodes, for the
 enhancement of the normal haemostatic system, especially for the
 treatment of haemophilia A or B and for inhibiting thrombus formation.
 The inactivated factor VII derivatives are useful for treating intimal
 hyperplasia, restenosis, cardiogenic emboli, platelet deposition
 disorders, percutaneous transluminal coronary angioplasty (PTCA), stroke,
 cancer, tumour metastasis, angiogenesis, ischaemia/reperfusion,
 rheumatoid arthritis, thrombolysis, arteriosclerosis, acute and chronic
 indications, such as inflammation, septic shock, hypotension, adult
 respiratory distress syndrome (ARDS) and myocardial infarction. The
 sequence presented is the plasmid, pLN174, which expresses the
 inactivated human coagulation Factor VII polypeptide
 SQ Sequence 6098 BP; 1413 A; 1587 C; 1623 G; 1475 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 6098;
 Best Local Similarity 49.5%; Pred. No. 68;
 Matches 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
 QY 1630 TTTGTATGCTTCTGTACCTTGATAGGCATCTCTTCTCAAGTTAGGAATTTTCTT 1689
 DB 4429 TTTTACGGTTCCTGCGCTTTTCTGCTGCTTTTCTGCTGCTTTTCTGCTGCTTATCC 4488
 QY 1690 TTTGGTTCCTTCAAAATATTTTCCCTGCTTTTGACCTGCTCTTCTTCCCT 1740
 DB 4489 CCTGATTCGTGATACCGTATTACCGCTTTTGAGTGAGCTGATACCGCT 4539
 RESULT 233
 ABA79647
 ID ABA79647 standard; DNA; 121 BP.
 XX
 AC ABA79647;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2493.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Ganper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for

PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX
PS Claim 7; Page 185; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX Sequence 121 BP; 39 A; 24 C; 22 G; 36 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 43;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTTCAGGGACATATTGCTCGTGTATTCTGTGTTTGG 2215
DB 39 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 98
QY 2216 CTTTGGCATATAGACGGCTGAG 2237
DB 99 AATTGGCACGTAACCTGCTTAG 120
RESULT 234
ABA79646/C
ID ABA79646 standard; DNA; 121 BP.
XX ABA79646;
XX
XX 24-JAN-2002 (first entry)
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2492.
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX

PI Kmiec EB, Camper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX Claim 7; Page 185; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC UGT1, amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX Sequence 121 BP; 36 A; 22 C; 24 G; 39 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 43;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTTCAGGGACATATTGCTCGTGTATTCTGTGTTTGG 2215
DB 83 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 24
QY 2216 CTTTGGCATATAGACGGCTGAG 2237
DB 23 AATTGGCACGTAACCTGCTTAG 2
RESULT 235
ABA79642/C
ID ABA79642 standard; DNA; 121 BP.
XX ABA79642;
XX
XX 24-JAN-2002 (first entry)
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2488.
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192179P.
XX

```
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PA (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 185; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 36 A; 22 C; 24 G; 39 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21.2; DB 1; Length 121;
XX Best Local Similarity 53.7%; Pred. No. 43;
XX Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
XX
QY 2156 CTATTGTAATAGGTTTTCAGGGACATATCTCTGGTTGTATTGTTCTGTGTTTGG 2215
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2216 CTTTGGCATATAGCGGCTGAG 2237
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX
XX RESULT 236
XX ABA79643
XX ID ABA79643 standard; DNA; 121 BP.
XX AC ABA79643;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2489.
XX
XX Human; gene therapy: adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma, BRCA1, BRCA2, CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APC; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cystostatic; antislaking; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192179P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 185; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 39 A; 24 C; 22 G; 36 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21.2; DB 1; Length 121;
XX Best Local Similarity 53.7%; Pred. No. 43;
XX Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
XX
QY 2156 CTATTGTAATAGGTTTTCAGGGACATATCTCTGGTTGTATTGTTCTGTGTTTGG 2215
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2216 CTTTGGCATATAGCGGCTGAG 2237
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX
XX RESULT 237
XX ABS68969/c
XX ID ABS68969 standard; DNA; 305 BP.
XX AC ABS68969;
XX
XX 21-NOV-2002 (first entry)
XX
XX Novel murine polynucleotide isolated using gene trap technology #32.
XX
XX Mouse; gene trapped sequence; GTS; functional genomic analysis;
XX phage display system; gene chip; temporal gene expression;
XX tissue specific gene expression; antisense inhibition; gene targeting;
XX development disorder; cell differentiation disorder; aging; cancer;
XX autoimmune disease; lupus; inflammatory disorder; skin disorder;
XX degenerative disorder; ds.
XX
XX Mus musculus.
XX
XX OS
XX
XX US2002102543-A1.
XX
```

PN US2001051335-A1.
XX
PD 13-DEC-2001.
XX
PF 16-APR-1999; 99US-00294093.
XX
PR 21-APR-1998; 98US-0082567P.
XX
PA (IALG/) LALGUDI R V.
PA (ITOL/) ITO L Y.
PA (SHER/) SHERMAN B K.
XX
PI Lalgudi RV, Ito LY, Sherman BK;
XX
DR WPI; 2002-163647/21.
XX
XX Novel purified corn tassell-derived polynucleotide useful for determining
PT altered gene expression, to recover regulatory elements and to follow
PT inheritance of desirable characteristics through hybrid breeding
PT programs.
XX
PS Claim 1; SEQ ID NO 6030; 201pp; English.
XX
XX The present sequence describes a purified corn tassell-derived
CC polynucleotide sequence (cdps) comprising a nucleic acid sequence
CC selected from those given in ABL70627 to ABL76833. The cdps sequences
CC encode corn tassell-derived polypeptides (CDPs). The cdps sequences (I)
CC can be used for determining altered gene expression, to recover
CC regulatory elements and to follow inheritance of desirable
CC characteristics through hybrid breeding programs. (I) are also useful in
CC the evaluation, and alteration of desired characteristics associated with
CC growth and development, disease resistance, environmental adaptability,
CC quality and yield, and as molecular markers for studying inheritance of
CC multigenic traits in a plant breeding program. (I) can be used to produce
CC a tassell-specific profile of gene transcription, a transcript image, to
CC clone regulatory elements for use in transformation vectors, to express a
CC polypeptide, to identify, isolate or extend identical or related corn
CC tassell nucleic acid sequences from DNA libraries, in nucleic acid
CC hybridisation or amplification technologies, as query sequences to
CC determine homology of known sequences, as probe for use in Southern or
CC Northern hybridisation, and to identify the presence of and/or to
CC determine the degree of similarity between two (or more) nucleic acid
XX sequences
XX SQ Sequence 286 BP; 96 A; 73 C; 89 G; 27 T; 0 U; 1 Other;
Query Match 0.9%; Score 21.1; DB 1; Length 286;
Best Local Similarity 46.0%; Pred. No. 54; Mismatches 119; Indels 3; Gaps 1;
Matches 104; Conservative 0;
QY 1688 TTTTGGTTTCTTGAAATATTTTCCCTGCTTTTGACCTGCTCTTCTCCCTCTCTA 1747
Db 261 TTTGTCTTGTGGTTCGCGGACTTTCGCGGTGCTGCGGTGCTTCTGCTGATCTT 202
QY 1748 TTCCCTTGGTTTTCGATAGTGTCTCTGCTCTTCTGCGATGTTTATGCTGATATTTT 1807
Db 201 CTCCACGATGCTCTTGTGCTGCTGCTGCTGCTCTTCTTGTGCTGCTGCTGCTCTT 142
QY 1808 AGACTTACATTTTCTTTGACCAAGTATCCATTTTCTTCTATCTTCTCTACTGCTCA 1867
Db 141 GTGGTGTCTCTCGCCCTT---CTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 85
QY 1868 GATTCT 1913
Db 84 GAGCGTCTCTCTGATCTTCTGATGATGATGATGATGATGATGATGATGATGATGATG 39
RESULT 239
AAV88246/c
ID AAV88246 standard; cDNA; 267 BP.
XX
AC AAV88246;
XX

PD 01-AUG-2002.
XX
PF 30-NOV-2000; 2000US-00728445.
XX
PR 01-DEC-1999; 99US-0168358P.
XX
PA (FRIE/) FRIEDRICH G.
PA (ZAMB/) ZAMBROWICZ B.
PA (SAND/) SANDS A T.
XX
PI Friedrich G, Zambrowicz B, Sands AT;
XX
DR WPI; 2002-690598/74.
XX
XX Novel murine polynucleotides that individually identify novel genes into
PT which a retroviral gene trap vector has integrated, useful in genomic
PT analysis and in discovery, development of therapeutic and diagnostic
PT agents.
XX
PS Claim 1; Page 36; 296pp; English.
XX
XX The invention describes an isolated murine polynucleotide (I) comprising
CC a contiguous stretch of at least 60 nucleotides of one of 265-677
CC nucleotide 891 OMNIBANK gene trapped sequences (GTSS) (S), given in the
CC specification. The novel genes and cells are useful in functional genomic
CC analysis and in the discovery and development of new therapeutic and
CC diagnostic agents and methods. (I) is useful for identifying the coding
CC regions of the murine genome, to isolate cDNAs, genomic clones, or full-
CC length genes/polynucleotides or homologues, heterologues, paralogues, or
CC orthologues that are capable of hybridising to one or more of the GTSS
CC under stringent conditions. (I) can be incorporated into a phage display
CC system that can be used to screen for proteins, or other ligands, that
CC are capable of binding an amino acid sequence encoded by an
CC oligonucleotide or polynucleotide sequence in at least one of the TS
CC sequences. (I) is useful in addressable arrays, such as gene chips, to
CC identify and characterise temporal and tissue specific gene expression,
CC to identify the gene of interest from many sources and for genetic
CC manipulations such as antisense inhibition and gene targeting. Decreasing
CC the level of expression of (I) and/or down regulating the activity of
CC peptides or proteins encoded by (I) is useful for treating development
CC and cell differentiation disorders, aging, cancer, autoimmune disease,
CC lupus, inflammatory disorders, skin disorders and degenerative disorders.
CC This sequence represents a murine cDNA isolated using gene trap
XX technology
XX SQ Sequence 305 BP; 72 A; 96 C; 66 G; 70 T; 0 U; 1 Other;
Query Match 0.9%; Score 21.2; DB 1; Length 305;
Best Local Similarity 60.3%; Pred. No. 51; Mismatches 23; Indels 0; Gaps 0;
Matches 35; Conservative 0;
QY 148 CTGCTGCAATATCTCTGGGCTGCTGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 205
Db 284 CTGCTCTCAGAACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 227
RESULT 238
ABL76656/c
ID ABL76656 standard; cDNA; 286 BP.
XX
AC ABL76656;
XX
XX 14-MAY-2002 (first entry)
XX
DE Corn tassell-derived polynucleotide (cdps) SEQ ID NO:6030.
XX
XX Corn; corn tassell-derived polynucleotide; cdps; hybrid breeding; CDPs;
KW inheritance; characteristic; growth; development; disease resistance;
KW environmental adaptability; quality; yield; molecular marker;
KW multigenic trait; plant breeding; corn tassell; gene; ss.
XX
OS Zea mays.
XX

DT 12-FEB-1999 (first entry)
 XX EST clone EA90.
 DE
 XX
 XX Expressed sequence tag; secreted protein; haematopoiesis regulator;
 KW tissue growth; activin; inhibin; tumour invasion suppressor; EST; human;
 KW chemotaxis; chemokines; haemostasis; gene therapy; thrombolysis;
 KW receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO9845437-A2.
 PN
 XX
 XX 15-OCT-1998.
 PD
 XX
 XX 10-APR-1998; 98WO-US006956.
 PF
 XX
 XX 10-APR-1997; 97US-00837312.
 PR
 XX
 XX (GEMY) GENETICS INST INC.
 PA
 XX
 XX Jacobs K, McCoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;
 PI Spaulding V, Agostino MJ;
 PI
 XX WPI; 1999-070078/06.
 DR
 XX
 XX New polynucleotides encoding human secreted proteins - derived from e.g.
 PT human blood, kidney, foetal lung, placenta, testes, brain, ovary,
 PT pituitary, retina and colon cDNA libraries.
 PT
 XX
 XX Claim 1; Page 332; 641pp; English.
 PS
 XX
 XX The present sequence represents an expressed sequence tag (EST), and is a
 CC polynucleotide of the invention. The polynucleotides of the invention are
 CC all secreted EST sequences isolated from a variety of human tissue
 CC sources. The EST sequences and proteins encoded by them are predicted to
 CC have useful biological activities which would make them suitable for
 CC treating, preventing or ameliorating medical conditions in humans and
 CC animals, although no supporting data is given. Suggested activities
 CC include nutritional activity, immune stimulating or suppressing activity,
 CC haematopoiesis regulating activity, tissue growth activity,
 CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
 CC activity. The EST sequences are also stated to be useful for gene therapy
 XX
 XX Sequence 267 BP; 75 A; 45 C; 90 G; 57 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 21; DB 1; Length 267;
 Best Local Similarity 49.5%; Pred. No. 56;
 Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 1637 GCTTCTTGACCTGTATAGGATCTCTTCTCAAGGTTAGGAATTTCTTTTGGTT 1696
 DB 243 GATGCATTCACCTCAACACTCTCTCAGTATCCATTCTGTGGATTCTTCTCAATC 184
 QY 1697 TTCTTGAAATATTTCCCTGCTTTTACCTGCTCTTCCCTTCCTC 1745
 DB 183 TTCTTCAAAAAGTCACCTTGGCTGTCTTCTTCTTCGCCATTGCAC 135
 RESULT 240
 ID ABX37095/c
 XX ABX37095 standard; cDNA; 372 BP.
 XX
 AC ABX37095;
 XX
 XX 20-FEB-2003 (first entry)
 DT
 XX
 XX Bovine EST associated with lactation/muscle/fat deposition #2260.
 DE
 XX Bovine; ss; EST; expressed sequence tag; lactation; LMPD;
 KW muscle deposition; fat deposition; genome mapping; gene identification;
 KW

gene analysis; cattle breeding.
 KW
 XX Bos Taurus.
 OS
 XX
 XX US2002137139-A1.
 PN
 XX
 XX 26-SEP-2002.
 PD
 XX
 XX 24-SEP-2001; 2001US-00960352.
 PF
 XX
 XX 12-JAN-1999; 99US-0115707P.
 PR
 XX
 XX 11-JAN-2000; 2000US-00480902.
 XX
 XX (BYAT/) BYATT J C.
 PA (MATH/) MATHIALAGAN N.
 PA (TAON/) TAO N.
 PA (WARR/) WARREN W C.
 XX
 XX Byatt JC, Mathialagan N, Tao N, Warren WC;
 PI
 XX WPI; 2003-110599/10.
 DR
 XX
 XX New nucleic acid associated with lactation, and muscle and fat
 PT deposition, useful for genome mapping, gene identification and analysis,
 PT cattle breeding, or for genetically improving cattle.
 PT
 XX
 XX Claim 2; SEQ ID NO 2260; 245pp; English.
 PS
 XX
 XX The invention relates to a purified nucleic acid molecule associated with
 CC lactation or muscle and fat deposition (designated LMPD), derived from
 CC cattle, and the LMPD nucleic acid can specifically hybridise to a second
 CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
 CC appearing as ABX34836-ABX4947, or complements of them. Also included are
 CC ; (1) a transformed cell having a nucleic acid comprising an LMPD nucleic
 CC acid linked to a promoter and a 3' non-translated sequence that
 CC functions in the cell to cause termination of transcription and addition
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
 CC (2) determining a level or pattern of a molecule in a bovine cell or
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
 CC of the 15112 nucleic acid sequences or its complement or fragment) with a
 CC complementary nucleic acid molecule obtained from the bovine cell or
 CC tissue, where hybridisation between the marker nucleic acid and the
 CC complementary nucleic acid permits the detection of the molecule; and (b)
 CC detecting the level or pattern of the complementary nucleic acid, where
 CC the detection of the complementary nucleic acid is predictive of the
 CC level or pattern of the molecule. The LMPD nucleic acid is used for
 CC determining a level or pattern of a molecule in a bovine cell or tissue.
 CC It is useful for genome mapping, gene identification and analysis, cattle
 CC breeding, preparation of constructs for use in cattle gene expression, or
 CC for genetically improving cattle. The present sequence is one of the
 CC 15112 bovine LMPD EST (expressed sequence tag) nucleic acids. Note: The
 CC present sequence was not shown in the specification but was obtained in
 CC electronic format from the USPTO web site:
 CC seqdata.uspto.gov/sequence.html?DocID=20020137139
 XX
 XX Sequence 372 BP; 113 A; 73 C; 87 G; 99 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 21; DB 1; Length 372;
 Best Local Similarity 56.5%; Pred. No. 60;
 Matches 39; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
 QY 1663 TTCTCAAGGTTAGGAATTTCTTTTGGTTTCTTTTGTGAAATATTTTCCCTGTTTT 1722
 DB 317 TATTTTCAGCCTCAGAAGAATTTTCATAGTTCGTATTGGAAAAATAGTCTCAGACGGGT 258
 QY 1723 GACCTGCGCT 1731
 DB 257 GAGCTTCCT 249
 RESULT 241
 ID AAI20194/c
 ID AAI20194 standard; DNA; 263 BP.

XW		Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX		Homo sapiens.
OS		WO200157277-A2.
PN		09-AUG-2001.
XX		30-JAN-2001; 2001WO-US000669.
PD		04-FEB-2000; 2000US-0180312P.
XX		26-MAY-2000; 2000US-0207456P.
XX		30-JUN-2000; 2000US-00608408.
PR		03-AUG-2000; 2000US-00632366.
PR		21-SEP-2000; 2000US-0234687P.
PR		27-SEP-2000; 2000US-0236359P.
PR		04-OCT-2000; 2000GB-00024263.
PA		(MOLE-) MOLECULAR DYNAMICS INC.
XX		Penn SG, Hanzel DK, Chen W, Rank DR;
PI		WFI; 2001-483447/52.
DR		Human genome-derived single exon nucleic acid probes useful for analyzing gene expression in human fetal liver.
PT		Claim 4; SEQ ID NO 13528; 639pp + Sequence Listing; English.
PS		The invention relates to a single exon nucleic acid probe for measuring human gene expression in a sample derived from human foetal liver. The single exon nucleic acid probes may be used for predicting, measuring and displaying gene expression in samples derived from human fetal liver. The present sequence is a single exon nucleic acid probe of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
CC		Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;
CC		Query Match 0.9%; Score 20.8; DB 1; Length 263; Best Local Similarity 52.3%; Pred. No. 64; Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0
QY	1708	ATTTCCTCGTTTGACCTGCTTCCCTCCTATGCCCTTGGTTTTGCATAG 1767
Dd	251	AATTTCTTCTCCTCCTCCTCCTCTCTGTGCGGTTTAGTCCGCTGCTTTTCAGTTG 192
Qy	1768	TGCTCTGGCTTCTCGATGTTTATGC 1795
Dd	191	CTTCTCCAGTTCACAGTTGTCCTTTGCGC 164
RESULT 243		
ID	AAI45394/c	
ID	AAI45394 standard; DNA; 263 BP.	
XX	AAI45394;	
DT	17-OCT-2001 (first entry)	
DE	Probe #14080 used to measure gene expression in human placenta sample.	
KX	Probe; microarray; human; placenta; antenatal diagnosis;	
KW	genetic disorder; ss.	
OS	Homo sapiens.	
FN	WO200157272-A2.	
XX	09-AUG-2001.	
PF	30-JAN-2001; 2001WO-US000663.	


```
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match          0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred. No. 64;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

Qy 1708 ATTTTCCTGCTTTGAGCTGCTTCTTCCCTTCTCTATCTCTTGGTTTGGCATAG 1767
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 251 AATTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 192
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 1768 TGTCTCTGGCTTCTGGATGTTTATGC 1795
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 191 CTCTCCAGTTCAGTTGCTTTTGGCGC 164

RESULT 248
ABS38969/c
ID ABS38969 standard; DNA; 263 BP.
XX
AC ABS38969;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver single exon probe, SEQ ID No 13959.
XX
KW Human; single exon nucleic acid probe; liver; cirrhosis;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW coronary heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-48898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 4; SEQ ID NO 13959; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABS35011-ABS51005 represent human
CC liver single exon nucleic acid probes of the invention. Note: The
CC sequence information for this patent does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
```

```
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match          0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred. No. 64;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

Qy 1708 ATTTTCCTGCTTTGAGCTGCTTCTTCCCTTCTCTATCTCTTGGTTTGGCATAG 1767
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 251 AATTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 192
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Qy 1768 TGTCTCTGGCTTCTGGATGTTTATGC 1795
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 191 CTCTCCAGTTCAGTTGCTTTTGGCGC 164

RESULT 249
AAI05898/c
ID AAI05898 standard; DNA; 263 BP.
XX
AC AAI05898;
XX
DT 09-OCT-2001 (first entry)
XX
DE Probe #5889 used to measure gene expression in human breast sample.
XX
KW Probe; human; breast disease; breast cancer; development disorder; ss;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-476286/51.
XX
PT Novel single exon nucleic acid probe used to measuring gene expression in
PT a human breast.
XX
PS Claim 25; SEQ ID NO 5889; 322pp; English.
XX
CC The present invention relates to novel single exon nucleic acid probes.
CC The present sequence is one such probe. The probes are useful for
CC measuring human gene expression in a human breast sample, where the probe
CC hybridises at high stringency to a nucleic acid expressed in the human
CC breast. The probes are useful for predicting, diagnosing, grading,
CC staging, monitoring and prognosing diseases of the human breast,
CC particularly those diseases with polygenic aetiology. The diseases
CC include: breast cancer, disorders of development, inflammatory diseases
CC of the breast, fibrocystic changes, proliferative breast disease and non-
CC carcinoma tumours. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match          0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred. No. 64;
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:57:03 ; Search time 11 Seconds
(without alignments)
3.802 Million cell updates/sec

Title: us-10-664-775-5

Perfect score: 2267

Sequence: 1 gatcactctctagtgaag.....ttgtaattctaggtgtgat 2267

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 20 seqs, 9225 residues

Total number of hits satisfying chosen parameters: 40

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rniadb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20.6	0.9	1440	1	US-07-882-202A-3
C 2	20.6	0.9	1440	1	Sequence 3, Appli
C 3	20.6	0.9	1440	1	Sequence 3, Appli
C 4	20.6	0.9	1440	1	Sequence 3, Appli
C 5	20.6	0.9	1440	1	Sequence 13, Appl
C 6	20.6	0.9	1440	1	Sequence 13, Appl
C 7	16.6	0.7	1440	1	Sequence 3, Appli
C 8	16.6	0.7	1440	1	Sequence 3, Appli
C 9	16.6	0.7	1440	1	Sequence 3, Appli
C 10	16.6	0.7	1440	1	Sequence 3, Appli
C 11	16.6	0.7	1440	1	Sequence 13, Appl
C 12	16.6	0.7	1440	1	Sequence 13, Appl
C 13	14	0.6	38	1	Sequence 3, Appli
C 14	12.8	0.6	141	1	Sequence 4, Appli
C 15	12.6	0.6	141	1	Sequence 6, Appli
C 16	12	0.5	38	1	Sequence 4, Appli
C 17	11.2	0.5	27	1	Sequence 17, Appl
C 18	11	0.5	27	1	Sequence 17, Appl
C 19	10.6	0.5	42	1	Sequence 8, Appli
C 20	10.6	0.5	45	1	Sequence 13, Appl
C 21	10.4	0.5	45	1	Sequence 13, Appl
C 22	10	0.4	35	1	Sequence 7, Appli
C 23	10	0.4	35	1	Sequence 7, Appli
C 24	10	0.4	35	1	Sequence 7, Appli
C 25	10	0.4	35	1	Sequence 7, Appli
C 26	9.8	0.4	27	1	Sequence 16, Appl
C 27	9.4	0.4	27	1	Sequence 17, Appl
C 28	9.4	0.4	35	1	Sequence 7, Appli
C 29	9.4	0.4	35	1	Sequence 7, Appli
C 30	9.4	0.4	35	1	Sequence 7, Appli
C 31	9.4	0.4	35	1	Sequence 7, Appli
C 32	9.4	0.4	36	1	Sequence 9, Appli
C 33	9.4	0.4	36	1	Sequence 10, Appl

Sequence 22, Appl
Sequence 20, Appl
Sequence 8, Appli
Sequence 22, Appl
Sequence 20, Appl
Sequence 9, Appli
Sequence 10, Appl

ALIGNMENTS

RESULT 1

US-07-882-202A-3/c
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"

US-07-882-202A-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;

Best Local Similarity 59.3%; Pred. No. 0.99;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGTCCTTTATCTGCGAGACTTCTTTGTTTGAATATGTAATTTTGG 498

Db 659 TTGCTGGCATTCCTTTTCTTAGAATAGTATTTTCCACATGGATATTCACACTGG 601

RESULT 2
US-08-021-615A-3/c
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021.615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-021-615A-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99; Mismatches 0; Gaps 0;
Matches 35; Conservative 0; Indels 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAATAATGTAATTCATTTGG 498
DB 659 TTGCTGGCAATTCCTTTTCTAGATAGTATTTTCCACATGGATATTCACACTGG 601

RESULT 3
US-08-321-777-3/c
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified

; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-321-777-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99; Mismatches 0; Gaps 0;
Matches 35; Conservative 0; Indels 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAATAATGTAATTCATTTGG 498
DB 659 TTGCTGGCAATTCCTTTTCTAGATAGTATTTTCCACATGGATATTCACACTGG 601

RESULT 4
US-09-009-217-13/c
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; NUMBER OF SEQUENCES: 27
; TITLE OF INVENTION: AND TUMOR TREATMENT
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas

```
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCATGTCGTCGAGACTGCTTTGTTTGAATATGTAATTCATTTGG 498
Db 659 TTGCTGGCATTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGG 601

RESULT 5
US-09-009-656-13/c
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-656-13

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCATGTCGTCGAGACTGCTTTGTTTGAATATGTAATTCATTTGG 498
Db 659 TTGCTGGCATTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGG 601

RESULT 6
PCT-US93-04493-3/c
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
```


QY 1749 TCCTTTGGTTTGGCATAGTCTCTGGCTTCTCTGGATG 1787
|||||
Db 58 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCGCTGCTG 96
|||||

RESULT 9

US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp. Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cdna"
US-08-321-777-3

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGGCATAGTCTCTGGCTTCTCTGGATG 1787
|||||
Db 58 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCGCTGCTG 96
|||||

RESULT 10

US-09-009-217-13
; Sequence 13, Application US/09009217

; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210

COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGGCATAGTCTCTGGCTTCTCTGGATG 1787
|||||
Db 58 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCGCTGCTG 96
|||||

RESULT 11

US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433

```
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-09-009-656-13
;
; Query Match 0.7%; Score 16.6; DB 1; Length 1440;
; Best Local Similarity 64.1%; Pred. No. 12;
; Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
;
; QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATG 1787
; ||||| ||||| ||||| ||||| ||||| ||||| |||||
; Db 58 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCTGGCTG 96
;
; RESULT 12
; PCT-US93-04493-3
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
```

```
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /product= "Tissue Factor"
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cdna"
; OTHER INFORMATION: /citation= ([1])
;
; PCT-US93-04493-3
;
; Query Match 0.7%; Score 16.6; DB 1; Length 1440;
; Best Local Similarity 64.1%; Pred. No. 12;
; Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
;
; QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATG 1787
; ||||| ||||| ||||| ||||| ||||| ||||| |||||
; Db 58 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCTGGCTG 96
;
; RESULT 13
; US-09-558-027-4
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
; US-09-558-027-4
;
; Query Match 0.6%; Score 14; DB 1; Length 38;
; Best Local Similarity 77.3%; Pred. No. 8;
; Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
;
; QY 3 TCACCTCCTCTAGTGAAGGTGG 24
; ||||| ||||| ||||| |||||
; Db 8 TCACCTAGTCTAGGGAATGGG 29
;
; RESULT 14
; US-08-849-248-6/c
```

```
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
; US-08-849-248-6

Query Match 0.6%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 65;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 147 TCTGTGGCAATACCTCTGGGGCT 170
DB 25 TCAGCTGGTCATCTCTGGGGCT 2

RESULT 15
US-08-849-248-6
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
; US-08-849-248-6

Query Match 0.6%; Score 12.6; DB 1; Length 141;
Best Local Similarity 55.8%; Pred. No. 73;
Matches 24; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1382 TTCTAAGTCAGTAGTCTGGCCCTGACATCTGTAGTCTCTTGGGA 1424
DB 97 TGCACAGGGGTACTCTCTGTGGCAGACGGGGTGTCTCTGCA 139

RESULT 16
US-09-558-027-4/C
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565 204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
; US-09-558-027-4

Query Match 0.5%; Score 12; DB 1; Length 38;
Best Local Similarity 75.0%; Pred. No. 45;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 893 AGGGCCATTGCTTAGAATA 912
DB 31 AGCCCATTCCTAGACTA 12

RESULT 17
US-08-293-778-17/c
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560o No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
```

;; PRIOR APPLICATION DATA: US/08/104,509
;; APPLICATION NUMBER: DK 3235/87
;; FILING DATE: 25-JUN-1987
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/434,149
;; FILING DATE: 13-NOV-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: PCT/DK88/00103
;; FILING DATE: 24-JUN-1988
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/898,248
;; FILING DATE: 12-JUN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Agriis, Cheryl H.
;; REGISTRATION NUMBER: 34,086
;; REFERENCE/DOCKET NUMBER: 3129.224-US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 212-867-0123
;; TELEFAX: 212-867-0298
;; INFORMATION FOR SEQ ID NO: 17:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 27 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
US-08-293-778-17

Query Match 0.5%; Score 11.2; DB 1; Length 27;
Best Local Similarity 81.2%; Pred. No. 63;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1776 GCTTCCTGGAGTGT 1791
Db 23 GCGTCTGGAGATT 8

RESULT 18
US-08-293-778-16
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149

;; FILING DATE: 13-NOV-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: PCT/DK88/00103
;; FILING DATE: 24-JUN-1988
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/898,248
;; FILING DATE: 12-JUN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Agriis, Cheryl H.
;; REGISTRATION NUMBER: 34,086
;; REFERENCE/DOCKET NUMBER: 3129.224-US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 212-867-0123
;; TELEFAX: 212-867-0298
;; INFORMATION FOR SEQ ID NO: 16:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 27 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
US-08-293-778-16

Query Match 0.5%; Score 11; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2075 TCITCAAGGAC 2085
Db 11 TCITCAAGGAC 21

RESULT 19
US-08-955-636-8
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8

Query Match 0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 238 CACTTCGGCCAGGCTAGGGGAC 262
Db 2 CACTCCCGCTCAGGCTCTGGGAC 26

RESULT 20
US-08-756-506-13/c
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.

;; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
;; TITLE OF INVENTION: ANIMALS
;; NUMBER OF SEQUENCES: 25
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: ZymoGenetics, Inc.
;; STREET: 1201 Eastlake Avenue East
;; CITY: Seattle
;; STATE: WA
;; COUNTRY: USA
;; ZIP: 98102
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/756,506
;; FILING DATE:
;; CLASSIFICATION: 800
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sawislak, Deborah A
;; REGISTRATION NUMBER: 37,438
;; REFERENCE/DOCKET NUMBER: 95-28
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-442-6672
;; TELEFAX: 206-442-6678
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 45 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; IMMEDIATE SOURCE:
;; CLONE: ZC6337
;; US-08-756-506-13

Query Match 0.5%; Score 10.6; DB 1; Length 45;
Best Local Similarity 57.6%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 241 TTCTGGCCAGGCTAGGGCACTACCGCACTCC 273
Db 35 TGCTGCAACGGCGCAAGCGCGCACTCCTTCC 3

RESULT 21
US-08-756-506-13
;; Sequence 13, Application US/08756506
;; Patent No. 5905185
;; GENERAL INFORMATION:
;; APPLICANT: Garner, Ian
;; APPLICANT: Cottingham, Ian R.
;; APPLICANT: Temperley, Simon M.
;; APPLICANT: Foster, Donald C.
;; APPLICANT: Sprecher, Cindy A.
;; APPLICANT: Prunkard, Donna E.
;; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
;; TITLE OF INVENTION: ANIMALS
;; NUMBER OF SEQUENCES: 25
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: ZymoGenetics, Inc.
;; STREET: 1201 Eastlake Avenue East
;; CITY: Seattle
;; STATE: WA
;; COUNTRY: USA
;; ZIP: 98102
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/756,506

;; FILING DATE:
;; CLASSIFICATION: 800
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sawislak, Deborah A
;; REGISTRATION NUMBER: 37,438
;; REFERENCE/DOCKET NUMBER: 95-28
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-442-6672
;; TELEFAX: 206-442-6678
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 45 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; IMMEDIATE SOURCE:
;; CLONE: ZC6337
;; US-08-756-506-13

Query Match 0.5%; Score 10.4; DB 1; Length 45;
Best Local Similarity 60.7%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 642 GTTGAGAGAAATGGGTATTGAAGTAGC 669
Db 10 GTTGGCGCGCTTCCCGGTTCGAGACC 37

RESULT 22
US-07-998-972A-7/c
;; Sequence 7, Application US/07998972A
;; Patent No. 5476777
;; GENERAL INFORMATION:
;; APPLICANT: Holly, Richard D.
;; APPLICANT: Foster, Donald C.
;; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
;; NUMBER OF SEQUENCES: 48
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Townsend and Townsend
;; STREET: One Market Plaza, Stewart Street Tower,
;; CITY: Twentieth Floor
;; CITY: San Francisco
;; STATE: CA
;; COUNTRY: USA
;; ZIP: 94105
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/998,972A
;; FILING DATE: 19921230
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/860,701
;; FILING DATE: 31-MAR-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/816,281
;; FILING DATE: 31-DEC-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Parmelee, Steven W
;; REGISTRATION NUMBER: 31,990
;; REFERENCE/DOCKET NUMBER: 13952-12-2
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-467-9600
;; TELEFAX: 415-543-5043
;; INFORMATION FOR SEQ ID NO: 7:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 35 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear

;
;
US-07-998-972A-7

Query Match	0.4%	Score 10;	DB 1;	Length 35;
Best Local Similarity	72.2%	Pred. No. 2e+02;		
Matches 13;	Conservative 0;	Mismatches 5;	Indels	

QY 1390 GCAGTAGTCTGGCCTGAC 1407
Db 21 GGAGTTGGCTCGCCCGGAC 4

RESULT 23

```

US-08-463-953-7/C
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,953
; FILING DATE:

```

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels

QY
1390 GCAGTAGTCTGGCCTGAC 1407

Dd
21 GGAGTTGGCTCGCCGGAC 4

RESULT 24

US-08-462-261-7/c

```

; Sequence 7, Application US/00462261
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
;
; US-08-462-261-7

```

Query Match	0.4%	Score 10;	DB 1;	Length 35;
Best Local Similarity	72.2%;	Pred. No. 28+02;		
Matches 13;	Conservative	0;	Mismatches 5;	Indels 0;
				Gaps 0;

QY 1390 GCAGTAGTCTGGCCTGAC 1407
||| ||| ||| ||| |||
Db 21 GGAGTTGGCTCGCCGGAC 4

RESULT 25

PCT-US92-11357-7/c
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA

ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/11357
FILING DATE: 19921230
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
PCT-US92-11357-7

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1390 GCAGTAGTCTGGCCTGAC 1407
DB 21 GGAGTTGGCTGCCGGAC 4

RESULT 26
US-08-293-778-16/c
Sequence 16, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaisen, Else M.
APPLICANT: Bjorn, Soren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESS: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,248
FILING DATE: 12-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Agris, Cheryl H.
REGISTRATION NUMBER: 34,086
REFERENCE/DOCKET NUMBER: 3129.224-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-867-0298
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cdna
US-08-293-778-16

Query Match 0.4%; Score 9.8; DB 1; Length 27;
Best Local Similarity 66.7%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 553 GTCGTAAATATCTCTAGGTC 573
DB 21 GTCCTGAAGATCTCCCGGC 1

RESULT 27
US-08-293-778-17
Sequence 17, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaisen, Else M.
APPLICANT: Bjorn, Soren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESS: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87
FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988

;; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agris, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-17

Query Match 0.4%; Score 9.4; DB 1; Length 27;
Best Local Similarity 90.9%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2075 TCTTCAAGGAC 2085
Db 11 TCTTCCAGGAC 21

RESULT 28
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/998,972A
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

;; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-07-998-972A-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTTCTGGATG 1787
Db 21 CTTCTGGAGG 31

RESULT 29
US-08-463-953-7
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,953
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-463-953-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTTCTGGATG 1787
Db 21 CTTCTGGAGG 31

RESULT 30
US-08-462-261-7


```
; Sequence 7, Application US/08462261
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-462-261-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTTCCTGGATG 1787
Db 21 CTTCCTGGAGG 31

RESULT 31
PCT-US92-11357-7
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTTCCTGGATG 1787
Db 21 CTTCCTGGAGG 31

RESULT 31
PCT-US92-11357-7
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
```

```
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11357
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; PCT-US92-11357-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTTCCTGGATG 1787
Db 21 CTTCCTGGAGG 31

RESULT 32
US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-9

Query Match 0.4%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 259 GCACTACCGCATTCCTCTCT 277
Db 13 GCCGTGCCGCGAGCTCTCT 31

RESULT 33
```

US-08-955-636-10/c
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.4%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 259 GCACTACCGCATTCCTCT 277
Db 24 GCCGTGCGAGCTCTCT 6

RESULT 34
US-08-293-778-22/c
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0298
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs

; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-22

Query Match 0.4%; Score 9.2; DB 1; Length 26;
Best Local Similarity 78.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1908 GTCTCTGAGGTTC 1921
Db 25 GTCTCCGACCTTC 12

RESULT 35
US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agris, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-293-778-20

Query Match 0.4%; Score 8.6; DB 1; Length 27;
Best Local Similarity 60.9%; Pred. No. 4.2e+02;
Matches 14; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 509 AGGGTCTGACAGACGTACAG 531
|||||
DB 27 AGGCGCTGGCGCCAGGTCCAG 5

RESULT 39
US-08-955-636-9/c
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955.636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-9

Query Match 0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 158 TACTTCTGGGCTGCTGC 175
|||||
DB 35 TCCTAGAGGAGCTCGGC 18

RESULT 40
US-08-955-636-10
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955.636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35

; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 158 TACTTCTGGGCTGCTGC 175
|||||
DB 2 TCCTAGAGGAGCTCGGC 19

Search completed: August 9, 2004, 16:57:15
Job time : 12 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:57:41 ; Search time 31 Seconds

(without alignments)

3.677 Million cell updates/sec

Title: us-10-664-775-5

Perfect score: 2267

Sequence: 1 gatactctctagtgaaag.....ttgtaattctaggctgtgt 2267

Scoring table: IDENTITY NUC

Gapop 10.0 , Capext 0.5

Searched: 61 seqs, 25143 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rnpbdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20.6	0.9	1332	1	US-10-411-037-7
C 2	20.6	0.9	1332	1	US-10-411-026-7
C 3	20.6	0.9	1332	1	US-10-410-962-7
C 4	20.6	0.9	1332	1	US-10-411-049-7
C 5	20.6	0.9	1332	1	US-10-410-930-7
C 6	20.6	0.9	1332	1	US-10-410-997-7
C 7	20.6	0.9	1332	1	US-10-411-012-7
C 8	20.6	0.9	1332	1	US-10-287-994-7
C 9	20.6	0.9	1332	1	US-10-410-913-7
C 10	20.6	0.9	1440	1	US-10-375-741-13
C 11	20.6	0.9	2040	1	US-10-617-619-12
C 12	20.6	0.9	2106	1	US-10-617-619-9
C 13	19.4	0.9	1361	1	US-10-382-248-35
C 14	17.2	0.8	1361	1	US-10-382-248-35
C 15	17	0.7	483	1	US-09-918-995-8429
C 16	17	0.7	1332	1	US-10-411-037-7
C 17	17	0.7	1332	1	US-10-411-026-7
C 18	17	0.7	1332	1	US-10-410-962-7
C 19	17	0.7	1332	1	US-10-411-049-7
C 20	17	0.7	1332	1	US-10-410-930-7
C 21	17	0.7	1332	1	US-10-410-997-7
C 22	17	0.7	1332	1	US-10-411-012-7
C 23	17	0.7	1332	1	US-10-287-994-7
C 24	17	0.7	1332	1	US-10-410-913-7
C 25	17	0.7	2040	1	US-10-617-619-12
C 26	16.6	0.7	1338	1	US-09-782-587B-2
C 27	16.6	0.7	1357	1	US-09-782-587B-4
C 28	16.6	0.7	1440	1	US-10-375-741-13
C 29	16.6	0.7	2106	1	US-10-617-619-9
C 30	16.4	0.7	483	1	US-09-918-995-8429
C 31	14.8	0.7	555	1	US-10-029-386-9623
C 32	14.6	0.6	222	1	US-10-029-386-23323
C 33	14.6	0.6	555	1	US-10-029-386-9623

0.6	60	1	US-10-272-665-22	Sequence 22, Appl
0.6	60	1	US-10-273-321-22	Sequence 22, Appl
0.6	60	1	US-10-272-756-22	Sequence 22, Appl
0.6	60	1	US-10-273-228-22	Sequence 22, Appl
0.6	100	1	US-10-272-665-107	Sequence 107, Appl
0.6	100	1	US-10-273-321-107	Sequence 107, Appl
0.6	100	1	US-10-272-756-107	Sequence 107, Appl
0.6	100	1	US-10-273-228-107	Sequence 107, Appl
0.6	100	1	US-10-272-665-106	Sequence 106, Appl
0.6	100	1	US-10-273-321-106	Sequence 106, Appl
0.6	100	1	US-10-272-756-106	Sequence 106, Appl
0.6	100	1	US-10-273-228-106	Sequence 106, Appl
0.6	1338	1	US-09-782-587B-2	Sequence 2, Appl
0.6	1357	1	US-09-782-587B-4	Sequence 4, Appl
0.6	222	1	US-10-029-386-23323	Sequence 23323, A
0.5	54	1	US-10-349-858-8	Sequence 8, Appl
0.5	32	1	US-10-281-727-6	Sequence 6, Appl
0.5	32	1	US-10-281-727-7	Sequence 7, Appl
0.5	38	1	US-10-398-422A-20	Sequence 20, Appl
0.5	38	1	US-09-969-357-2	Sequence 2, Appl
0.5	38	1	US-10-254-394-2	Sequence 2, Appl
0.5	60	1	US-10-272-665-22	Sequence 22, Appl
0.5	60	1	US-10-273-321-22	Sequence 22, Appl
0.5	60	1	US-10-272-756-22	Sequence 22, Appl
0.5	60	1	US-10-273-228-22	Sequence 22, Appl
0.5	100	1	US-10-272-665-107	Sequence 107, Appl
0.5	100	1	US-10-273-321-107	Sequence 107, Appl
0.5	100	1	US-10-272-756-107	Sequence 107, Appl
0.5	100	1	US-10-273-228-107	Sequence 107, Appl
0.5	100	1	US-10-272-665-106	Sequence 106, Appl
0.5	100	1	US-10-273-321-106	Sequence 106, Appl
0.5	100	1	US-10-272-756-106	Sequence 106, Appl
0.5	100	1	US-10-273-228-106	Sequence 106, Appl
0.5	33	1	US-09-951-121A-14	Sequence 14, Appl
0.5	33	1	US-09-951-121A-15	Sequence 15, Appl
0.5	33	1	US-10-295-682-14	Sequence 14, Appl
0.5	33	1	US-10-295-682-15	Sequence 15, Appl
0.5	36	1	US-09-951-121A-8	Sequence 8, Appl
0.5	36	1	US-09-951-121A-9	Sequence 9, Appl
0.5	36	1	US-10-255-032-8	Sequence 8, Appl
0.5	36	1	US-10-255-032-9	Sequence 9, Appl
0.5	36	1	US-10-295-682-8	Sequence 8, Appl
0.5	36	1	US-10-295-682-9	Sequence 9, Appl
0.5	42	1	US-09-803-810-8	Sequence 8, Appl
0.5	42	1	US-10-298-330-8	Sequence 8, Appl
0.5	60	1	US-10-272-665-23	Sequence 23, Appl
0.5	60	1	US-10-273-321-23	Sequence 23, Appl
0.5	60	1	US-10-272-756-23	Sequence 23, Appl
0.5	60	1	US-10-273-228-23	Sequence 23, Appl
0.5	36	1	US-10-281-727-2	Sequence 2, Appl
0.5	36	1	US-10-281-727-3	Sequence 3, Appl
0.4	32	1	US-10-281-727-6	Sequence 6, Appl
0.4	32	1	US-10-281-727-7	Sequence 7, Appl
0.4	36	1	US-09-951-121A-8	Sequence 8, Appl
0.4	36	1	US-09-951-121A-9	Sequence 9, Appl
0.4	36	1	US-10-255-032-8	Sequence 8, Appl
0.4	36	1	US-10-255-032-9	Sequence 9, Appl
0.4	36	1	US-10-295-682-8	Sequence 8, Appl
0.4	36	1	US-10-295-682-9	Sequence 9, Appl
0.4	38	1	US-10-398-422A-20	Sequence 20, Appl
0.4	38	1	US-09-969-357-2	Sequence 2, Appl
0.4	38	1	US-10-254-394-2	Sequence 2, Appl
0.4	35	1	US-10-109-498-5	Sequence 5, Appl
0.4	35	1	US-10-109-498-6	Sequence 6, Appl
0.4	54	1	US-10-349-858-8	Sequence 8, Appl
0.4	60	1	US-10-272-665-23	Sequence 23, Appl
0.4	60	1	US-10-273-321-23	Sequence 23, Appl
0.4	60	1	US-10-272-756-23	Sequence 23, Appl
0.4	60	1	US-10-273-228-23	Sequence 23, Appl
0.4	35	1	US-10-109-498-5	Sequence 5, Appl
0.4	35	1	US-10-109-498-6	Sequence 6, Appl
0.4	35	1	US-10-109-498-5	Sequence 5, Appl
0.4	31	1	US-10-017-122-4	Sequence 4, Appl
0.4	34	1	US-09-951-121A-2	Sequence 2, Appl


```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match          0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGACACTGCTTTGTTTGAATAATGATTTCAATTGG 498
Db 558 TTTCGTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGTGG 500

RESULT 7
US-10-411-012-7/c
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match          0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGACACTGCTTTGTTTGAATAATGATTTCAATTGG 498
Db 558 TTTCGTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGTGG 500

RESULT 8
US-10-287-994-7/c
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
```

```
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match          0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGACACTGCTTTGTTTGAATAATGATTTCAATTGG 498
Db 558 TTTCGTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGTGG 500

RESULT 9
US-10-410-913-7/c
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
```



```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match      0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 558 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 500

RESULT 10
US-10-375-741-13/c
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Bojing
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match      0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 2.4;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 659 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 601

RESULT 11
US-10-617-619-12/c
; Sequence 12, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match      0.9%; Score 20.6; DB 1; Length 2040;
Best Local Similarity 59.3%; Pred. No. 3.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 558 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 500

RESULT 12
US-10-617-619-9/c
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      0.9%; Score 20.6; DB 1; Length 2106;
Best Local Similarity 59.3%; Pred. No. 3.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 624 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 566

RESULT 13
US-10-382-248-35/c
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
```

; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

Query Match 0.9%; Score 19.4; DB 1; Length 1361;
Best Local Similarity 55.1%; Pred. No. 6.2;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 2148 CTCAGGCGCTATTGTAATAGGTTTACGAGGACATATTCCTCGTGTGTTGTTATGTCGTG 2207
Db 1312 CTGCTGGCTAGGAATGGGCTCGCAGGAGGACTCCTGGCGTGGCTCTGAGCGCATG 1253

QY 2208 TGTTTTGC 2216
Db 1252 AGCTTTTGC 1244

RESULT 14
US-10-382-248-35
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

Query Match 0.8%; Score 17.2; DB 1; Length 1361;
Best Local Similarity 51.3%; Pred. No. 26;
Matches 40; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 6 CTCCTCTAGTAAAGTGGGGCTCTGAGGCTCCAATGTTCTGATGTTGATGGTAGATATCT 65
Db 441 CTCCTCTGCTTCGAGGGCGGAACTGTGAGACGCTTGAATATCCATGTGGAAAAATACCT 500
QY 66 CATACAGGATAGCACT 83
Db 501 ATTCTAGAAAAAGAAAT 518

RESULT 15
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076

; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match 0.7%; Score 17; DB 1; Length 483;
Best Local Similarity 59.2%; Pred. No. 19;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 1749 TCCTTTGGTTTTTCATAGTGTCTCTGGCTTCCTGGATGTTTATGCCT 1797
Db 122 TCCTCTGCCTTCCTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 170

RESULT 16
US-10-411-037-7
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match 0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 1749 TCCTTTGGTTTTTCATAGTGTCTCTGGCTTCCTGGATGTTTATGCCT 1797
Db 23 TCCTCTGCCTTCCTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 17
US-10-411-026-7
; Sequence 7, Application US/10411026

```
/ Publication No. US20040063911A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: DeFrees, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
/ APPLICANT: Hakes, David
/ APPLICANT: Chen, Xi
/ TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
/ TITLE OF INVENTION: METHODS
/ FILE REFERENCE: 040853-01-5053
/ CURRENT APPLICATION NUMBER: US/10/411,026
/ CURRENT FILING DATE: 2003-04-09
/ PRIOR APPLICATION NUMBER: US 60/328,523
/ PRIOR FILING DATE: 2001-10-10
/ PRIOR APPLICATION NUMBER: US 60/344,692
/ PRIOR FILING DATE: 2001-10-19
/ PRIOR APPLICATION NUMBER: US 60/387,292
/ PRIOR FILING DATE: 2002-06-07
/ PRIOR APPLICATION NUMBER: US 60/391,777
/ PRIOR FILING DATE: 2002-06-25
/ PRIOR APPLICATION NUMBER: US 60/396,594
/ PRIOR FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US 60/404,249
/ PRIOR FILING DATE: 2002-08-16
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ PRIOR FILING DATE: 2002-08-28
/ NUMBER OF SEQ ID NOS: 75
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 7
/ LENGTH: 1332
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-411-026-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 18
US-10-410-962-7
/ Sequence 7, Application US/10410962
/ Publication No. US2004007836A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: DeFrees, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
/ APPLICANT: Hakes, David
/ APPLICANT: Chen, Xi
/ APPLICANT: Bowe, Caryn
/ TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
/ TITLE OF INVENTION: GLYCOCONJUGATION OF G-CSF
/ FILE REFERENCE: 040853-01-5054
/ CURRENT APPLICATION NUMBER: US/10/410,962
/ CURRENT FILING DATE: 2003-04-09
/ PRIOR APPLICATION NUMBER: US 60/328,523
/ PRIOR FILING DATE: 2001-10-10
/ PRIOR APPLICATION NUMBER: US 60/344,692
/ PRIOR FILING DATE: 2001-10-19
/ PRIOR APPLICATION NUMBER: US 60/387,292
/ PRIOR FILING DATE: 2002-06-07
/ PRIOR APPLICATION NUMBER: US 60/391,777
/ PRIOR FILING DATE: 2002-06-25
/ PRIOR APPLICATION NUMBER: US 60/396,594
/ PRIOR FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US 60/404,249
/ PRIOR FILING DATE: 2002-08-16
```

```
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ PRIOR FILING DATE: 2002-08-28
/ NUMBER OF SEQ ID NOS: 75
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 7
/ LENGTH: 1332
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-410-962-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 19
US-10-411-049-7
/ Sequence 7, Application US/10411049
/ Publication No. US20040082026A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: DeFrees, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
/ APPLICANT: Hakes, David
/ APPLICANT: Chen, Xi
/ APPLICANT: Bowe, Caryn
/ TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
/ TITLE OF INVENTION: ALPHA
/ FILE REFERENCE: 040853-01-5055
/ CURRENT APPLICATION NUMBER: US/10/411,049
/ CURRENT FILING DATE: 2003-04-09
/ PRIOR APPLICATION NUMBER: US 60/328,523
/ PRIOR FILING DATE: 2001-10-10
/ PRIOR APPLICATION NUMBER: US 60/344,692
/ PRIOR FILING DATE: 2001-10-19
/ PRIOR APPLICATION NUMBER: US 60/387,292
/ PRIOR FILING DATE: 2002-06-07
/ PRIOR APPLICATION NUMBER: US 60/391,777
/ PRIOR FILING DATE: 2002-06-25
/ PRIOR APPLICATION NUMBER: US 60/396,594
/ PRIOR FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US 60/404,249
/ PRIOR FILING DATE: 2002-08-16
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ PRIOR FILING DATE: 2002-08-28
/ NUMBER OF SEQ ID NOS: 75
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 7
/ LENGTH: 1332
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-411-049-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 20
US-10-410-930-7
/ Sequence 7, Application US/10410930
/ Publication No. US20040115168A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
```

```
; APPLICANT: DePrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; TITLE OF INVENTION: BETA
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match          0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCCTTGGTTTTCATAGTCTCTCGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 23 TCCCTGCTTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 21
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DePrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; TITLE OF INVENTION: FSH
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
```

```
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match          0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCCTTGGTTTTCATAGTCTCTCGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 23 TCCCTGCTTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 22
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DePrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryne
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match          0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCCTTGGTTTTCATAGTCTCTCGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 23 TCCCTGCTTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 23
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DePrees, Shawn
; APPLICANT: Zopf, David
```

```
; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; FILE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match          0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTGTCTCTGGCTTCTCTGGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCTGCGCTGAGTCTTCGT 71

RESULT 24
US-10-410-913-7
; Sequence 7; Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
```

```
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match          0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTGTCTCTGGCTTCTCTGGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCTGCGCTGAGTCTTCGT 71

RESULT 25
US-10-617-619-12
; Sequence 12; Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match          0.7%; Score 17; DB 1; Length 2040;
Best Local Similarity 59.2%; Pred. No. 24;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTGTCTCTGGCTTCTCTGGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCTGCGCTGAGTCTTCGT 71

RESULT 26
US-09-782-587B-2/c
; Sequence 2; Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match          0.7%; Score 16.6; DB 1; Length 1338;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1216 GCCTGGAATATTATTATTCATATTTCTTTGAATGTG 1254
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 567 GCCTGGGTTTGTAGCGTTCCGCTTTCTAGAATGGG 529

RESULT 27
US-09-782-587B-4/c
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match          0.7%; Score 16.6; DB 1; Length 1357;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1216 GCCTGGAATATTATTATTCATATTTCTTTGAATGTG 1254
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 580 GCCTGGGTTTGTAGCGTTCCGCTTTCTAGAATGGG 542

RESULT 28
US-10-375-741-13
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Honing
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
```

```
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match          0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 31;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1749 TCCTTTGGTTTTGCATAGTGTCTCTGGCTTCCTGGATG 1787
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 58 TCCTCTGCCTTCTGCTGGGCTTCAGGGCTGCCTGGCTG 96

RESULT 29
US-10-617-619-9
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match          0.7%; Score 16.6; DB 1; Length 2106;
Best Local Similarity 64.1%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1749 TCCTTTGGTTTTGCATAGTGTCTCTGGCTTCCTGGATG 1787
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCTGCTGGGCTTCAGGGCTGCCTGGCTG 61

RESULT 30
US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
```


FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-665-22

Query Match 0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1753
| | | | | | | | | | | | | | | | | | | | | |
Db 58 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 35

US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-321-22

Query Match 0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1753
| | | | | | | | | | | | | | | | | | | | | |
Db 58 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 36

US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-321-22

US-10-272-756-22/c
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

Query Match 0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1753
| | | | | | | | | | | | | | | | | | | | | |
Db 58 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 37

US-10-273-228-22/c
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

Query Match 0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy	1719	TTTTGACCTGCCTCTTCCCCCTTCTTATTCCTT	1753
Db	58	TGTGGGCTCCACTGTCCCCCTTGACGAGTCCTT	24

```

RESULT 38
US-10-272-665-107/c
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING
; TYPE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

```

Query Match	0.6%	Score 14.2;	DB 1;	Length 100;
Best Local Similarity	62.9%	Pred. No. 53;		
Matches 22;	Conservative	0;	Mismatches 13;	Indels 0;
Matches				Gaps 0;

Qy 1719 TTTTGAGCTGCCCTTCTTCCCTTCCTATTCCTT 1753
| | | | | | | | | | | | | |
Dδ 38 TGTGGGCTCCACTGTCCCCCTTGACGAGTGCCTT 4
| | | | | | | | | | | | | |

```

RESULT 39
US-10-273-321-107/c
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-107

```

```

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0

Qy      1719 TTTTGACCTGCCTTCTTCCGCTTCCTCTATTGCTT 1753
          ||| ||| ||| ||| ||| ||| ||| |||
Db      38  TGTGGGCGCTCACTGCCCCCTTGCAGGAGTGCTT 4

RESULT 40
US-10-272-756-107/c
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1

```

```

RESULT 40
US-10-272-756-107/c
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

```

Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels

Qy 1719 TTTTGACGTGCCTTCTTCCCTTCCCTTATTCCTT 1753

Dδ 38 TGTGGGCTCCACTGTCCCTTCAGAGTCCTT 4

```

RESULT 41
US-10-273-228-107/c
? Sequence 107, Application US/10273228
? Publication No. US20030207297A1
? GENERAL INFORMATION:
? APPLICANT: Braun et al.
? TITLE OF INVENTION: METHODS FOR GENERATING
? TITLE OF INVENTION: GENETIC MARKERS
? FILE REFERENCE: 24736-2033D
? CURRENT APPLICATION NUMBER: US/10/273,228
? CURRENT FILING DATE: 2002-10-15
? PRIOR APPLICATION NUMBER: 09/687,483
? PRIOR FILING DATE: 2000-07-10
? PRIOR APPLICATION NUMBER: 60/217,658
? PRIOR FILING DATE: 2000-07-10
? PRIOR APPLICATION NUMBER: 60/159,176
? PRIOR FILING DATE: 1999-10-13
? PRIOR APPLICATION NUMBER: 60/217,251
? PRIOR FILING DATE: 2000-07-10
? PRIOR APPLICATION NUMBER: 09/663,968
? PRIOR FILING DATE: 2000-09-19
? NUMBER OF SEQ ID NOS: 118
? SOFTWARE: FastSeq for Windows Version 4.0
? SEQ ID NO 107
? LENGTH: 100
? TYPE: DNA

```

```
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTCCCTTCCTCTATTCCTT 1753
    |||||
Db 38 TGTGGGCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 42
US-10-272-665-106/c
; Sequence 106, Application US/10272665
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTCCCTTCCTCTATTCCTT 1753
    |||||
Db 38 TGTGGGCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 43
US-10-273-321-106/c
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTCCCTTCCTCTATTCCTT 1753
    |||||
Db 38 TGTGGGCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 44
US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTCCCTTCCTCTATTCCTT 1753
    |||||
Db 38 TGTGGGCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 45
US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1719 TTTTGACCTGCCTCTCTCCCTCTCTCTCTCTCTCTCT 1753
Db      ||||| ||||| ||||| ||||| ||||| ||||| |||||
38 TGTGGCCCTCCACTGTCCCTCTCTCTCTCTCTCTCTCTCT 4

RESULT 46
US-09-782-587B-2
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIITA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match      0.6%; Score 14.2; DB 1; Length 1338;
Best Local Similarity 70.4%; Pred. No. 38;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATCTCTCTGGGCTGCTG 174
Db      ||||| ||||| ||||| ||||| ||||| |||||
22 CTCCTGTGCTCTCTCTGGGCTGCTG 48

RESULT 47
US-09-782-587B-4
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIITA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
```

```
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match      0.6%; Score 14.2; DB 1; Length 1357;
Best Local Similarity 70.4%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATCTCTCTGGGCTGCTG 174
Db      ||||| ||||| ||||| ||||| ||||| |||||
35 CTCCTGTGCTCTCTCTGGGCTGCTG 61

RESULT 48
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match      0.5%; Score 12; DB 1; Length 222;
Best Local Similarity 58.3%; Pred. No. 2.2e+02;
Matches 21; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 763 AAGAATTGCAATGCTCTCTGTGATTTTCCTTTG 798
Db      ||||| ||||| ||||| ||||| ||||| |||||
112 ACGAAGGCCAGCGCTCTCTCAGAGAAGCGTCGCTG 147

RESULT 49
US-10-349-858-8/c
; Sequence 8, Application US/10349858
; Publication No. US2003020247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
```

```
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.5%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.6%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1913 TGAGGTTCCCTGTCGGTCTCTAA 1935
      ||| ||| ||| ||| ||| ||| |||
DB 29 TGGCCTTCCCTCGGTTACGAA 7

RESULT 50
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1987 TTCCACTTTCAGGTCCTG 2004
      ||| ||| ||| ||| ||| |||
DB 26 TCCACCTTCGTTCCCTG 9

RESULT 51
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1987 TTCCACTTTCAGGTCCTG 2004
      ||| ||| ||| ||| ||| |||
DB 26 TCCACCTTCGTTCCCTG 9

RESULT 52
US-10-398-422A-20
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTCTTGAAGCCTCTCTGTGC 155
      ||| ||| ||| ||| ||| ||| |||
DB 10 TAAACCGCTTCTCTGGAGAGCTCGGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
```

APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
APPLICANT: Pingel, Hans K
APPLICANT: Klausen, Niels K
TITLE OF INVENTION: Factor VII Glycoforms
FILE REFERENCE: 6207.510-US
CURRENT FILING DATE: 2002-10-02
PRIORITY APPLICATION NUMBER: US/09/969,357
PRIORITY FILING DATE: 2000-10-02
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2000 01456
PRIORITY FILING DATE: 2001-02-16
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00262
PRIORITY FILING DATE: 2001-03-14
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00430
PRIORITY FILING DATE: 2001-05-14
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00751
PRIORITY FILING DATE: 2000-10-10
PRIORITY APPLICATION NUMBER: US 60/238,944
PRIORITY FILING DATE: 2000-10-10
PRIORITY APPLICATION NUMBER: US 60/271,581
PRIORITY FILING DATE: 2001-02-26
PRIORITY APPLICATION NUMBER: US 60/276,322
PRIORITY FILING DATE: 2001-03-16
NUMBER OF SEQ ID NOS: 2
SOFTWARE: Patent in version 3.2
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTCTTGAAGCCTCTGCTGGC 155
DB 10 TAAACGCTTCTCTGGAGGAGCTGCGCC 38

RESULT 54
US-10-254-394-2
Sequence 2, Application US/10254394
Publication No. US20030096366A1
GENERAL INFORMATION:
APPLICANT: Knudsen, Ida Molgaard
TITLE OF INVENTION: Method for Production of Recombinant
Proteins in Eukaryote Cells
FILE REFERENCE: 6480.500-US
CURRENT FILING DATE: 2002-09-25
PRIORITY APPLICATION NUMBER: US/10/254,394
PRIORITY FILING DATE: 2001-10-02
PRIORITY APPLICATION NUMBER: PCT/DK01/00632
PRIORITY FILING DATE: 2001-10-02
PRIORITY APPLICATION NUMBER: PCT/DK01/00634
PRIORITY FILING DATE: 2001-10-02
PRIORITY APPLICATION NUMBER: PA 2002 00460
PRIORITY FILING DATE: 2002-03-26
PRIORITY APPLICATION NUMBER: 60/374,855
PRIORITY FILING DATE: 2002-10-04
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-10-254-394-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTCTTGAAGCCTCTGCTGGC 155
DB 10 TAAACGCTTCTCTGGAGGAGCTGCGCC 38

RESULT 55
US-10-272-665-22
Sequence 22, Application US/10272665
Publication No. US20030180748A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
FILE REFERENCE: 24736-2033E
CURRENT FILING DATE: 2002-10-15
PRIORITY APPLICATION NUMBER: US/10/272,665
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/687,483
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/217,658
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/159,176
PRIORITY FILING DATE: 1999-10-13
PRIORITY APPLICATION NUMBER: 60/217,251
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/663,968
PRIORITY FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:
OTHER INFORMATION: Probe
US-10-272-665-22

Query Match 0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2150 CAGGCGCTATTGTAATAGGTTTGTAGCAGGACATAT 2186
DB 23 CAAGGACTCTCGAAGGGGGACAGTGGAGGCCACAT 59

RESULT 56
US-10-273-321-22
Sequence 22, Application US/10273321
Publication No. US20030180749A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
FILE REFERENCE: 24736-2033B
CURRENT FILING DATE: 2002-10-15
PRIORITY APPLICATION NUMBER: US/10/273,321
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/687,483
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/217,658
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/159,176
PRIORITY FILING DATE: 1999-10-13
PRIORITY APPLICATION NUMBER: 60/217,251
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/663,968
PRIORITY FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:

```
; OTHER INFORMATION: Probe
US-10-273-321-22

Query Match      0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2150 CAGGGCCTATTGTAATAGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 59

RESULT 57
US-10-272-756-22
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

Query Match      0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2150 CAGGGCCTATTGTAATAGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 59

RESULT 58
US-10-273-228-22
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
```

```
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

Query Match      0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2150 CAGGGCCTATTGTAATAGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 59

RESULT 59
US-10-272-665-107
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

Query Match      0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2150 CAGGGCCTATTGTAATAGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 60
US-10-273-321-107
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
```



```
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; SOFTWARE: FastSEQ for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 118
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match          0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGCAGGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 65
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; SOFTWARE: FastSEQ for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 118
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match          0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGCAGGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 66
US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match          0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGCAGGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 67
US-09-951-121A-14/c
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1389 TGCAGTAGTCTGCGCTGACATCTG 1412
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 31 TGCAGGAGTCTCTGCGCCATCCG 8

RESULT 68
US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
```



```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1389 TGCAGTAGTCTGGCCTGACATCTG 1412
      ||||| ||||| ||||| ||||| |||||
Db      3 TGCAGGAGTCCTTGCGCCATCCG 26

RESULT 69
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1389 TGCAGTAGTCTGGCCTGACATCTG 1412
      ||||| ||||| ||||| ||||| |||||
Db      31 TGCAGGAGTCCTTGCGCCATCCG 8

RESULT 70
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; SEQ ID NO 9

; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGTCTCGAA 2006
      ||||| ||||| ||||| |||||
Db      33 CACGTTGAGGACCTGGA 17

RESULT 72
US-09-951-121A-9
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
```

1 LENGTH: 36
2 TYPE: DNA
3 ORGANISM: Artificial Sequence
4 FEATURE:
5 OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match 0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 4 CACGTTGAGGACCTGGA 20

RESULT 73
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: NO. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match 0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 33 CACGTTGAGGACCTGGA 17

RESULT 74
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: NO. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match 0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 4 CACGTTGAGGACCTGGA 20

RESULT 75
US-10-295-682-8/c
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match 0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 33 CACGTTGAGGACCTGGA 17

RESULT 76
US-10-295-682-9
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match 0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 4 CACGTTGAGGACCTGGA 20

```
RESULT 77
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 238 CACTTCTGGCCAGGTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGTGTGGGAC 26

RESULT 78
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 238 CACTTCTGGCCAGGTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGTGTGGGAC 26

RESULT 79
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCTTGTATCTTGCACTTGTGAAGTGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 80
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCTTGTATCTTGCACTTGTGAAGTGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 81
US-10-272-756-23/c
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```



```
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; PRIOR FILING DATE: 2002-10-28
; PRIOR FILING DATE: 2001-11-02
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match          0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 16 GAAAGTGGGGTCT 30
DB 16 GGAAGTGGGAGACT 30

RESULT 86
US-10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR FILING DATE: 2001-11-02
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match          0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 16 GAAAGTGGGGTCT 30
DB 17 GGAAGTGGGAGACT 3

RESULT 87
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
```

```
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8
```

Query Match 0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
DB 9 CTGGTGCTCCAGGT 23

```
RESULT 88
US-09-951-121A-9/c
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9
```

Query Match 0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
DB 28 CTGGTGCTCCAGGT 14

```
RESULT 89
US-10-253-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A1c No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
```

```
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
Db 9 CCTGGTGTCCAGGT 23

RESULT 90
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
Db 9 CCTGGTGTCCAGGT 23

RESULT 90
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
Db 28 CCTGGTGTCCAGGT 14

RESULT 91
US-10-255-032-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```

```
US-10-295-682-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
Db 9 CCTGGTGTCCAGGT 23

RESULT 92
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
Db 28 CCTGGTGTCCAGGT 14

RESULT 93
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 141 GAAGCCTCTCTGCGCAATACTTCTGGGGCTG 171
Db 34 GCAGCTCTCCAGAAAGCGTTTATAGCGCG 4

RESULT 94
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match          0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 141 GAAGCCTCTCTGCGCAATACTTCTGGGGCTG 171
Db 34 GCAGCTCTCCAGAAAGCGTTTATAGCGCG 4

RESULT 95
US-10-254-394-2/c
; Sequence 2, Application US/10254394
; Publication No. US20030096366A1
; GENERAL INFORMATION:
; APPLICANT: Knudsen, Ida Molgaard
; TITLE OF INVENTION: Method for Production of Recombinant
; TITLE OF INVENTION: Proteins in Eukaryote Cells
; FILE REFERENCE: 6480.500-US
; CURRENT APPLICATION NUMBER: US/10/254,394

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 141 GAAGCCTCTCTGCGCAATACTTCTGGGGCTG 171
Db 34 GCAGCTCTCCAGAAAGCGTTTATAGCGCG 4

RESULT 96
US-10-109-498-5/c
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match          0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 579 GTGTGTGAGGTCAATATGTGATTTTAGCTGTAGC 712
Db 34 GTCAGTGAGGACCAACGGGACAGTCGACGGCGGAGC 1

RESULT 97
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
```

```

; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6

Query Match          0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 679 GTGTGTCAGGTCATATGTGATTTAGCTGTAGC 712
Db 2  GTCAGTAGGACCACGGGACAGTCAGCGGAGC 35

RESULT 98
US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.4%; Score 9.8; DB 1; Length 54;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 117 AGAGACTTCATAA 129
Db 1  AGAGTCTTCGTAA 13

RESULT 99
US-10-272-665-23
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match          0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGTGAGGT 689
Db 4  CCCACTACCGGGGCACGTGGT 24

RESULT 100
US-10-273-321-23
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match          0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGTGAGGT 689
Db 4  CCCACTACCGGGGCACGTGGT 24

RESULT 101
US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
```



```
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23

Query Match      0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 7; Gaps 0;

QY 669 CCCACTATCTGTGTGAGGT 689
Db 4 CCCACTACCGGGGCACGTGTT 24

RESULT 102
US-10-273-228-23
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23

Query Match      0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 7; Gaps 0;

QY 669 CCCACTATCTGTGTGAGGT 689
Db 4 CCCACTACCGGGGCACGTGTT 24

RESULT 103
US-10-109-498-5
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
```

```
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match      0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 8.8e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 6; Gaps 0;

QY 1587 TGCACGTGGGGAGTTTCT 1605
Db 9 TGCACGTCCCGTGTCT 27

RESULT 104
US-10-109-498-6/c
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6

Query Match      0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 8.8e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 6; Gaps 0;

QY 1587 TGCACGTGGGGAGTTTCT 1605
Db 27 TGCACGTCCCGTGTCT 9

RESULT 105
US-10-017-122-4
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
```

```

; ORGANISM: Homo sapiens
US-10-017-122-4
Query Match      0.4%; Score 9.2; DB 1; Length 31;
Best Local Similarity 56.7%; Pred. No. 9.6e+02;
Matches 17; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1608 TCCGGTCCATCATTTGGTGTGTTGATG 1637
Db 2 TCTGTGCGTCCATGAGGGGTACTCTCTG 31

RESULT 106
US-09-951-121A-2
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2
Query Match      0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 107
US-09-951-121A-3/c
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3
Query Match      0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 108
US-10-295-682-2
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2
Query Match      0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 32 GAATTGTGGGGCGCGGTGTG 11

RESULT 109
US-10-295-682-3/c
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3
Query Match      0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 32 GAATTGTGGGGCGCGGTGTG 11
```

RESULT 110
US-10-281-727-2
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match 0.4%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 9.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 968 TGGATGCAGCAGTA 981
||| |||||
Db 2 TGCCTGCAGCAGGA 15

RESULT 111
US-10-281-727-3/c
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3

Query Match 0.4%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 9.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 968 TGGATGCAGCAGTA 981
||| |||||
Db 35 TGCCTGCAGCAGGA 22

RESULT 112

US-09-951-121A-14
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match 0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGGTGAGGGTTACCACCTGCT 217
||| |||||
Db 4 TACTCGGATGGCGGCAAGGACTCCT 28

RESULT 113
US-09-951-121A-15/c
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match 0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGGTGAGGGTTACCACCTGCT 217
||| |||||
Db 30 TACTCGGATGGCGGCAAGGACTCCT 6

RESULT 114
US-10-295-682-14
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon

US-10-017-122-4

Query Match 0.4%; Score 8.2; DB 1; Length 31;
Best Local Similarity 61.9%; Pred. No. 1.4e+03;
Matches 13; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1372 CAGAAAGTTTCTTAAGTCA 1392
Db 31 CAGAGAGTACCCCTCATGGCA 11
||||| ||| ||| |||

RESULT 119
US-09-951-121A-2/c
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTGTGTGCATA 756
Db 31 TTGGGGCACA 21
||||| ||| |||

RESULT 120
US-09-951-121A-3
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTGTGTGCATA 756
Db 4 TTGGGGCACA 14
||||| ||| |||

RESULT 121
US-10-295-682-2/c
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTGTGTGCATA 756
Db 31 TTGGGGCACA 21
||||| ||| |||

RESULT 122
US-10-295-682-3
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTGTGTGCATA 756
Db 4 TTGGGGCACA 14
||||| ||| |||

10664775-5.rnpb

Mon Aug 9 17:56:37 2004

Search completed: August 9, 2004, 16:58:13
Job time : 32 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:58:32 ; Search time 3 Seconds
(without alignments)
4.164 Million cell updates/sec

Title: us-10-664-775-5
Perfect score: 2267

Sequence: 1 gatcactcctctagtgaag.....ttgtaattctagtgctgat 2267

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 4 segs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database: rstdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	20.6	0.9	1201	1	AL531727	ACCESSION:AL531727
C 2	19.8	0.9	645	1	AI116939	ACCESSION:AI116939
C 3	18	0.8	1201	1	AL531727	ACCESSION:AL531727
C 4	17	0.7	300	1	AU099140	ACCESSION:AU099140
C 5	16.3	0.7	609	1	AI099321	ACCESSION:AI099321
C 6	14.4	0.6	609	1	AI099321	ACCESSION:AI099321
C 7	13.8	0.6	645	1	AI116939	ACCESSION:AI116939
C 8	13.6	0.6	300	1	AU099140	ACCESSION:AU099140

ALIGNMENTS

RESULT 1
AL531727/c
LOCUS
DEFINITION
AL531727 Homo sapiens FETAL LIVER EST 23-MAY-2003
CSODM003YI01 5-PRIME, mRNA sequence.
ACCESSION
AL531727.2 GI:31069559
KEYWORDS
EST.
SOURCE
Homo sapiens (human)

ORGANISM
Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1201)
Li.W.B., Gruber,C., Jessee,J. and Polayes,D.
Full-length cDNA libraries and normalization
Unpublished (2001)
JOURNAL
On Feb 13, 2001 this sequence version replaced gi:12795220.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France

Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 7252.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODM003AE01QI&cluster=7252.f. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CSODM003AE01QI1.
Location/Qualifiers
1..1201

FEATURES source

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODM003YI01"
/tissue_type="FETAL LIVER"
/dev stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/notes="Organ: liver; Vector: pCMVSPORT_6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."

Query Match 0.9%; Score 20.6; DB 1; Length 1201;
Best Local Similarity 59.3%; Pred. No. 0.31;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTGAATATGTAATTTGG 498
DB 648 TTGCTGGCAATTTCTTTTCTAGATAGGATTTTCCACATGGATATCAACTGTGG 590

RESULT 2

AI116939/c

LOCUS

DEFINITION

ue29g08.y1 Sugano mouse liver mla Mus musculus cDNA clone

IMAGE:1481822 5' similar to gb:M13232 COAGULATION FACTOR VII

PRECUSOR (HUMAN); mRNA sequence.

ACCESSION

AI116939

VERSION

AI116939.1 GI:3517263

KEYWORDS

EST.

SOURCE

Mus musculus (house mouse)

ORGANISM

Mus musculus

REFERENCE

1 (bases 1 to 645)

AUTHORS

Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,

Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,

Scheilenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,

Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and

Waterston,R.

TITLE

The WashU-HMI Mouse EST Project

JOURNAL

Unpublished (1996)

COMMENT

Contact: Marra M/Mouse EST Project

WashU-HMI Mouse EST Project

Washington University School

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: mouseest@watson.wustl.edu

This clone is available royalty-free through LNL ; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.

MGI:930178

Seq primer: custom primer used

High quality sequence stop: 483.

Location/Qualifiers

1..645

/organism="Mus musculus"

/mol_type="mRNA"

/strain="C57BL"

/db_xref="taxon:10090"

/clone="IMAGE:1481822"

```
/sex="female"
/dev stage="adult"
/lab host="DH10B"
/clone lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCCCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTGG and 3' end
primer CGACCTGCAGCTGAGCACA."
```

Query Match 0.9%; Score 19.8; DB 1; Length 645;
Best Local Similarity 69.2%; Pred. No. 0.87;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 1860 CTGCTGAGTCTCTCTTCTATCTCTGTATTCTGTCA 1898
Db 586 CTGCTGAGTCTCTTTCTTACACAGCATTTCTCCA 548

RESULT 3
AL531727 1201 bp mRNA linear EST 23-MAY-2003
LOCUS AL531727 Homo sapiens FETAL LIVER Homo sapiens cDNA clone
DEFINITION CSODM003YI01 5-PRIME, mRNA sequence.
ACCESSION AL531727
VERSION AL531727.2 GI:31069559
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1201)
AUTHORS Li W.B., Gruber C., Jessee J. and Polayes D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On Feb 13, 2001 this sequence version replaced gi:12795220.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 7252.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODM003AE01Q1&cluster=7252.f. Contact :
Feng Liang Email: fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Paradise Avenue Genoscope sequence ID : CSODM003AE01Q1.
Location/Qualifiers
1. 1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODM003YI01"
/tissue type="FETAL LIVER"
/dev stage="fetal"
/clone lib="Homo sapiens FETAL LIVER"
/notes="Organ: liver; Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."

Query Match 0.8%; Score 18; DB 1; Length 1201;
Best Local Similarity 52.4%; Pred. No. 1.1;

```
Matches 22; Conservative 7; Mismatches 13; Indels 0; Gaps 0;
Qy 1665 TCTCAGGTTAGGAAATTTTCTTTTGTGGTTCTTCTTGAATA 1706
Db 1148 TCCCAAAWHAGGAKAAATTTTTCGCTTGTGTTGAGGAAA 1189

RESULT 4
AU099140 300 bp mRNA linear EST 05-APR-2001
LOCUS AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HVI12463, mRNA sequence.
ACCESSION AU099140
VERSION AU099140.1 GI:13550269
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 300)
AUTHORS Suzuki Y., Tsunoda T., Taira H., Mizushima-Sugano J., Sese J.,
Hata H., Ota T., Isogai T., Tanaka T., Nakamura Y., Morishita S.,
Okubo K., Suyama A. and Sugano S.
TITLE In silico mapping of the 5'-ends of human mRNAs using full-length
enriched and 5'-end enriched cDNA libraries constructed by
Oligo-capping method
JOURNAL Unpublished (2001)
COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ims.u-tokyo.ac.jp
Suzuki Y., Yoshitomo-Nakagawa K., Maruyama K., Suyama A. and
Sugano S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
Location/Qualifiers
1. 300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone lib="Sugano Homo sapiens cDNA library"

Query Match 0.7%; Score 17; DB 1; Length 300;
Best Local Similarity 59.2%; Pred. No. 6.6;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
Qy 1749 TCCTTGTGTTTTCATAGTGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
Db 57 TCCTCTGCTTCTGCTTGGCTTCAGGCTGCTGCTGCTGCTCTTGT 105

RESULT 5
AI099321/c 609 bp mRNA linear EST 20-AUG-1998
LOCUS ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:1482509 5' similar to gb:M1232 COAGULATION FACTOR VII
PRECURSOR (HUMAN);, mRNA sequence.
ACCESSION AI099321
VERSION AI099321.1 GI:3448846
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 609)
AUTHORS Marra M., Hillier L., Allen M., Bowles M., Dietrich N., Dubuque T.,
Geisel S., Kucaba T., Lacy M., Le M., Martin J., Morris M.,
Schellenberg K., Steptoe M., Tan F., Underwood K., Moore B.,
Theising B., Wylie T., Lennon G., Soares B., Wilson R. and
Waterston R.
```


Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LInL ; contact the
IWAG Consortium (info@image.llnl.gov) for further information.
MGI:930178

Seq primer: custom primer used
High quality sequence stop: 483.

```

FEATURES
source
Location/Qualifiers
1..645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1481822"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse"
/note="Organ: liver; Vec
(CACGTGTG) : Site 2: Dra
was primed with an oligo
TAATGACCTTTTCTTTTCTTTT
ligated to a DraIII adap
and cloned into distinct
vector (5' site CACTGTGT
be used to isolate the c
performed to exclude fra
constructed by Dr. Sumio
Institute of Medical Sci
sequencing: 5' end prime
primer CGACCTGCAGCTTCGAGC

```

	Query Match	0.6%;	Score 13.8;	DB 1;	Length 645;
	Best Local Similarity	56.4%;	Pred. No. 7.7;	32;	Gaps 1;
	Matches 44;	Conservative 0;	Mismatches	2;	Indels
QY	2117	TCCTTGCCCTTGCTTCAGCTATGTTGCATTCACAGGC--	CTATTGTAATAGGGTTT	2174	
Db	50	TTCTCTGCTTTCTGCTCCAGCTCCAGGACCTC	TAGGACTGCAGTTTTCATACCCAGGA	109	
QY	2175	GCAGGGACATATTGTCCT		2192	
Db	110	GGAAGCACATGGTGTCT		127	

RESULT 8	linear	EST 05-APR-2001
AAU099140/c		
LOCUS	300 bp	mRNA
DEFINITION	AAU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone	
	HEP20983 similar to Human factor VII serine protease precursor mRNA	
	clone lambda-HV112463, mRNA sequence.	
ACCESSION	AAU099140	
VERSION	AAU099140.1	GI:13550269
KEYWORDS	EST.	
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
REFERENCE	1 (bases 1 to 300)	
AUTHORS	Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J., Hata,H., Oka,T., Isegai,T., Tanaka,T., Nakamura,Y., Morishita,S., Okubo,K., Suyama,A. and Sugano,S.	
TITLE	In silico mapping of the 5'-ends of human mRNAs using full-length enriched and 5'-end enriched cDNA libraries constructed by Oligo-capping method	
	Unpublished (2001)	
JOURNAL	Contact: Yutaka Suzuki	
COMMENT	Department of Virology	
	Institute of Medical Science, University of Tokyo	
	4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan	
	Email: yusuzuki@ims.u-tokyo.ac.jp	
	Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2):	

```

149-156 (1997).
Location/Qualifiers
1. .300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone_lib="Sugano Homo sapiens cDNA library"

Query Match          0.6%; Score 13.6; DB 1; Length 300;
Best Local Similarity 61.1%; Pred. No. 17;
Matches 22; Conservative 0; Mismatches 14; Indels 0

QY 756 AGACATTAAGAAATGCAATGTCCTCTGGTGGAATT 791
||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 277 AGAAATCCAGAACACGCTTCGTCCTCTCCGGCTCCTT 242

Search completed: August 9, 2004, 16:58:35
Job time : 3 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:59:13 ; Search time 728 Seconds
(without alignments)
3.781 Million cell updates/sec

Title: us-10-664-775-4
Perfect score: 2279
Sequence: 1 gatcacctcctagtgaag.....ttgtaattctaggtgtgat 2279

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database : rgedb.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	44.7	2.0	289	1	AR162089
C 2	44.7	2.0	289	1	AR166614
C 3	43	1.9	2422	1	AR030786
C 4	43	1.9	2422	1	AR045090
C 5	43	1.9	2422	1	AR052946
C 6	43	1.9	2422	1	AR122899
C 7	43	1.9	2422	1	AR127821
C 8	43	1.9	2462	1	AR095304
C 9	43	1.9	2462	1	AR103988
C 10	43	1.9	2462	1	AR335083
C 11	43	1.9	2462	1	AX409604
C 12	43	1.9	2462	1	HUMFVII
C 13	43	1.9	2483	1	E01076
C 14	43	1.9	2483	1	I07990
C 15	41.6	1.8	2177	1	E01075
C 16	41.6	1.8	2438	1	I07991
C 17	37.4	1.6	1573	1	BC040125
C 18	32.4	1.4	300	1	BD211952
C 19	28	1.2	1403	1	BC009726
C 20	27.2	1.2	1792	1	BC034377
C 21	25.2	1.1	1843	1	AR390799
C 22	25.2	1.1	1843	1	AX411026
C 23	25.2	1.1	1843	1	HSPROT
C 24	24.4	1.1	251	1	AY083553
C 25	24	1.1	1499	1	MUSCP
C 26	24	1.1	1580	1	AF318182
C 27	24	1.1	1603	1	BC013896
C 28	23.8	1.0	364	1	AR425705
C 29	23.8	1.0	364	1	BD121258
C 30	23.8	1.0	394	1	AX839180
C 31	23.8	1.0	868	1	BD124660
C 32	23.8	1.0	868	1	BD124660
C 33	23.6	1.0	1671	1	AY040345

ACCESSION:AR425705
ACCESSION:BD121258
ACCESSION:AF465274
ACCESSION:AX774765
ACCESSION:M57285
ACCESSION:AX395271
ACCESSION:AB062462
ACCESSION:AB062463
ACCESSION:AX265077
ACCESSION:AX265078
ACCESSION:AX265081
ACCESSION:AX265082
ACCESSION:AX265085
ACCESSION:AX265086
ACCESSION:AX265089
ACCESSION:AX265090
ACCESSION:AX265093
ACCESSION:AX265094
ACCESSION:AX265073
ACCESSION:AX265074
ACCESSION:MX3108
ACCESSION:K02050
ACCESSION:AX892787
ACCESSION:BD028320
ACCESSION:AX839163
ACCESSION:AF306920
ACCESSION:AF011898
ACCESSION:AF011352
ACCESSION:BC061149
ACCESSION:BC061149
ACCESSION:AX839181
ACCESSION:AX839181
ACCESSION:AX464088
ACCESSION:AX359106
ACCESSION:AX565990
ACCESSION:AX265101
ACCESSION:AX265102
ACCESSION:AX265097
ACCESSION:AX265098
ACCESSION:AX265098
ACCESSION:BC046125
ACCESSION:BD060364
ACCESSION:AR162089
ACCESSION:AR166614
ACCESSION:AF515269
ACCESSION:D21215
ACCESSION:AX524243
ACCESSION:AX552981
ACCESSION:E63001
ACCESSION:E63002
ACCESSION:E62997
ACCESSION:E62998
ACCESSION:E62999
ACCESSION:E63000
ACCESSION:AR112953
ACCESSION:AR112969
ACCESSION:I19358
ACCESSION:I19360
ACCESSION:BD194674
ACCESSION:AX565990
ACCESSION:AX908508
ACCESSION:BD044041
ACCESSION:AF306917
ACCESSION:AF306917
ACCESSION:AF306913
ACCESSION:AF306914
ACCESSION:AF306915
ACCESSION:AF306919
ACCESSION:AX839180
ACCESSION:AF465269
ACCESSION:AF272774
ACCESSION:AF272774
ACCESSION:AY155152
ACCESSION:AB083386
ACCESSION:AB084901
ACCESSION:AY022473
ACCESSION:AY023221

C 107	20.2	0.9	272	1	HUMPROS01	ACCESSION:M36551 J
C 108	20.2	0.9	352	1	HUMPS02	ACCESSION:M57841 J
C 109	20.2	0.9	885	1	AR108139	ACCESSION:AR108139
C 110	20.2	0.9	1543	1	AX401899	ACCESSION:AX401899
C 111	20.2	0.9	1543	1	RNPROC	ACCESSION:X64336 S
C 112	20	0.9	855	1	AF011899	ACCESSION:AF011899
C 113	20	0.9	1130	1	AR234337	ACCESSION:AR234337
C 114	20	0.9	1142	1	AR219285	ACCESSION:AR219285
C 115	20	0.9	1166	1	AR221273	ACCESSION:AR221273
C 116	20	0.9	1169	1	AR219284	ACCESSION:AR219284
C 117	20	0.9	1722	1	AF515269	ACCESSION:AF515269
C 118	19.8	0.9	254	1	AX587861	ACCESSION:AX587861
C 119	19.8	0.9	268	1	BSLKB1EJ7	ACCESSION:AF055326
C 120	19.8	0.9	384	1	BD095271	ACCESSION:BD095271
C 121	19.8	0.9	394	1	DLA14618	ACCESSION:AX814618
C 122	19.8	0.9	535	1	DLA6882	ACCESSION:AJ006882
C 123	19.8	0.9	556	1	BV036036	ACCESSION:BVO36036
C 124	19.8	0.9	813	1	PIGPIXA	ACCESSION:M26235
C 125	19.8	0.9	873	1	HUMCFIX	ACCESSION:M35672
C 126	19.8	0.9	1850	1	MMU44795	ACCESSION:U44795
C 127	19.6	0.9	484	1	HAMCFX	ACCESSION:D21216
C 128	19.6	0.9	596	1	AX193364	ACCESSION:AX193364
C 129	19.6	0.9	609	1	AX763043	ACCESSION:AX763043
C 130	19.6	0.9	882	1	AX675583	ACCESSION:AX675583
C 131	19.6	0.9	1142	1	AR219285	ACCESSION:AR219285
C 132	19.6	0.9	1161	1	AX675581	ACCESSION:AX675581
C 133	19.6	0.9	1169	1	AR219284	ACCESSION:AR219284
C 134	19.6	0.9	1373	1	BOVPBC	ACCESSION:K02435
C 135	19.4	0.9	177	1	AR109618	ACCESSION:AR109618
C 136	19.4	0.9	177	1	AR150638	ACCESSION:AR150638
C 137	19.4	0.9	177	1	E16187	ACCESSION:E16187
C 138	19.4	0.9	177	1	E27213	ACCESSION:E27213
C 139	19.4	0.9	177	1	E28271	ACCESSION:E28271
C 140	19.4	0.9	177	1	AR100928	ACCESSION:AR100928
C 141	19.4	0.9	204	1	AR109885	ACCESSION:AR109885
C 142	19.4	0.9	204	1	AR150703	ACCESSION:AR150703
C 143	19.4	0.9	249	1	AJ586104	ACCESSION:AJ586104
C 144	19.4	0.9	290	1	AX839191	ACCESSION:AX839191
C 145	19.4	0.9	352	1	HUMPS02	ACCESSION:M57841 J
C 146	19.4	0.9	471	1	DOGA2	ACCESSION:D43751
C 147	19.4	0.9	823	1	SHPTIXA	ACCESSION:M26233
C 148	19.4	0.9	829	1	BC061135	ACCESSION:BC061135
C 149	19.4	0.9	1126	1	AR095306	ACCESSION:AR095306
C 150	19.4	0.9	1126	1	AR103990	ACCESSION:AR103990
C 151	19.4	0.9	1126	1	HUMFX	ACCESSION:A93124
C 152	19.4	0.9	1404	1	HUMCFX	ACCESSION:AX147505
C 153	19.4	0.9	1414	1	HUMCFX	ACCESSION:U44795
C 154	19.4	0.9	1551	1	AX147505	ACCESSION:U44795
C 155	19.4	0.9	1850	1	MMU44795	ACCESSION:BC061149
C 156	19.4	0.9	1869	1	BC061149	ACCESSION:M96427 M
C 157	19.2	0.8	281	1	MUSACROS02	ACCESSION:D43752
C 158	19.2	0.8	471	1	GOT3	ACCESSION:BV094002
C 159	19.2	0.8	596	1	RV094002	ACCESSION:RV094002
C 160	19.2	0.8	826	1	RABTHRO	ACCESSION:M81396
C 161	19.2	0.8	1302	1	AF465270	ACCESSION:AF465270
C 162	19.2	0.8	1341	1	AF532184	ACCESSION:AF532184
C 163	19.2	0.8	1619	1	OCU77477	ACCESSION:U77477 S
C 164	19	0.8	244	1	HSCRYBB2S3	ACCESSION:U72402
C 165	18.8	0.8	340	1	AR263850	ACCESSION:AR263850
C 166	18.8	0.8	340	1	AR263851	ACCESSION:AR263851
C 167	18.8	0.8	352	1	DMU58868	ACCESSION:U58868
C 168	18.8	0.8	596	1	AX193364	ACCESSION:AX193364
C 169	18.8	0.8	882	1	AX675583	ACCESSION:AX675583
C 170	18.8	0.8	1161	1	AX675581	ACCESSION:AX675581
C 171	18.8	0.8	1505	1	AX523898	ACCESSION:AX523898
C 172	18.8	0.8	1671	1	AY040345	ACCESSION:AY040345
C 173	18.6	0.8	168	1	AR077689	ACCESSION:AR077689
C 174	18.6	0.8	168	1	AR081819	ACCESSION:AR081819
C 175	18.6	0.8	168	1	AR098999	ACCESSION:AR098999
C 176	18.6	0.8	168	1	AR116830	ACCESSION:AR116830
C 177	18.6	0.8	168	1	AR127061	ACCESSION:AR127061
C 178	18.6	0.8	168	1	AR141647	ACCESSION:AR141647
C 179	18.6	0.8	168	1	AR151537	ACCESSION:AR151537
C 180	18.6	0.8	180	1	ACCESSION:M36551 J	ACCESSION:M36551 J
C 181	18.6	0.8	174	1	HUMPROS01	ACCESSION:M57841 J
C 182	18.6	0.8	189	1	AX135778S1	ACCESSION:AX135778S1
C 183	18.6	0.8	189	1	AX135796S1	ACCESSION:AX135796S1
C 184	18.6	0.8	200	1	AR047835	ACCESSION:AR047835
C 185	18.6	0.8	222	1	AX260845	ACCESSION:AX260845
C 186	18.6	0.8	241	1	HS88A12F	ACCESSION:Z63614
C 187	18.6	0.8	427	1	AX524284	ACCESSION:AX524284
C 188	18.6	0.8	427	1	AX553022	ACCESSION:AX553022
C 189	18.6	0.8	439	1	AX277349	ACCESSION:AX277349
C 190	18.6	0.8	439	1	AX277375	ACCESSION:AX277375
C 191	18.6	0.8	484	1	MACCFX	ACCESSION:D21214
C 192	18.6	0.8	546	1	AX775014	ACCESSION:AX775014
C 193	18.6	0.8	624	1	AX335885	ACCESSION:AX335885
C 194	18.6	0.8	624	1	HUMFX8	ACCESSION:L29433 M
C 195	18.6	0.8	711	1	BD173590	ACCESSION:BD173590
C 196	18.6	0.8	773	1	AX827818	ACCESSION:AX827818
C 197	18.6	0.8	773	1	RNTRY2	ACCESSION:X827818
C 198	18.6	0.8	819	1	DOGTRVPA	ACCESSION:X86369
C 199	18.6	0.8	854	1	PVTRVPSIN	ACCESSION:M11589
C 200	18.6	0.8	1278	1	AF465268	ACCESSION:AF465268
C 201	18.6	0.8	1443	1	HUMFXM	ACCESSION:X03194
C 202	18.6	0.8	1467	1	A86886	ACCESSION:A86886
C 203	18.6	0.8	1467	1	AR316969	ACCESSION:AR316969
C 204	18.6	0.8	1467	1	AR340866	ACCESSION:AR340866
C 205	18.6	0.8	1467	1	AX082959	ACCESSION:AX082959
C 206	18.6	0.8	1467	1	BD070392	ACCESSION:BD070392
C 207	18.6	0.8	1467	1	BD070435	ACCESSION:BD070435
C 208	18.6	0.8	1514	1	AF191307	ACCESSION:AF191307
C 209	18.6	0.8	1514	1	HUMKALR4	ACCESSION:M33108
C 210	18.4	0.8	193	1	HUMDPB1A	ACCESSION:M77674
C 211	18.4	0.8	249	1	HUMDPBA	ACCESSION:D10478
C 212	18.4	0.8	249	1	HUMDPBB	ACCESSION:D10479
C 213	18.4	0.8	249	1	HUMHDDPH	ACCESSION:M23680
C 214	18.4	0.8	249	1	HUMHDDPH	ACCESSION:M62333
C 215	18.4	0.8	256	1	AF180970	ACCESSION:AF180970
C 216	18.4	0.8	257	1	HUMDPB1KT	ACCESSION:D10882
C 217	18.4	0.8	264	1	AF306907	ACCESSION:AF306907
C 218	18.4	0.8	279	1	AF306908	ACCESSION:AF306908
C 219	18.4	0.8	279	1	AF306912	ACCESSION:AF306912
C 220	18.4	0.8	283	1	AF336224	ACCESSION:AF336224
C 221	18.4	0.8	283	1	AF492638	ACCESSION:AF492638
C 222	18.4	0.8	285	1	HUMHDDPBZ	ACCESSION:M83912
C 223	18.4	0.8	285	1	AF312826	ACCESSION:AF312826
C 224	18.4	0.8	804	1	SHPTIXA	ACCESSION:M26233
C 225	18.4	0.8	832	1	AF011900	ACCESSION:AF011900
C 226	18.4	0.8	1293	1	AF465275	ACCESSION:AF465275
C 227	18.4	0.8	1293	1	AX523898	ACCESSION:AX523898
C 228	18.4	0.8	1505	1	S78934	ACCESSION:S78934
C 229	18.2	0.8	171	1	AX318568	ACCESSION:AX318568
C 230	18.2	0.8	240	1	AY083553	ACCESSION:AY083553
C 231	18.2	0.8	251	1	HSTCRB9	ACCESSION:X74849
C 232	18.2	0.8	265	1	AF011901	ACCESSION:AF011901
C 233	18.2	0.8	836	1	AF542056	ACCESSION:AF542056
C 234	18.2	0.8	987	1	OCU49933	ACCESSION:U49933
C 235	18.2	0.8	1558	1	S68634	ACCESSION:S68634
C 236	18	0.8	199	1	I14646	ACCESSION:I14646
C 237	18	0.8	276	1	AY267909S2	ACCESSION:AY267910
C 238	18	0.8	276	1	HSAS07648	ACCESSION:AY507648
C 239	18	0.8	276	1	HSLLAAGN2	ACCESSION:U90243
C 240	18	0.8	276	1	AR249144	ACCESSION:AR249144
C 241	18	0.8	290	1	AX312474	ACCESSION:AX312474
C 242	18	0.8	299	1	ETA271156	ACCESSION:AJ271156
C 243	18	0.8	302	1	RFSPLEX2	ACCESSION:X95338
C 244	18	0.8	335	1	AF266240	ACCESSION:AF266240
C 245	18	0.8	383	1	AX921761	ACCESSION:AX921761
C 246	18	0.8	815	1	HUMCFIX	ACCESSION:W35672
C 247	18	0.8	873	1	AF465274	ACCESSION:AF465274
C 248	18	0.8	1329	1	E02492	ACCESSION:E02492
C 249	18	0.8	1389	1	AX381010	ACCESSION:AX381010
C 250	17.8	0.8	177	1	AX381010	ACCESSION:AX381010

[illegible][illegible]


```

MEDLINE      86205965
PUBMED      3486420
COMMENT      Original source text: Homo sapiens liver cDNA to mRNA.
              Draft entry and sequence in computer-readable form for [1] kindly
              provided by F.S.Hagen.
              [1] sequenced two alternatively spliced mRNAs that produced
              shortened signal peptides. One is presented as factor VIIb below.

FEATURES
  source
    1..2462
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /tissue_type="liver"
      <1..2462
      /product="FVIIa mRNA"
      36..1436
      /note="precursor for factor VIIa and b"
      /codon_start=1
      /product="coagulation factor VII"
      /protein_id="AA88040.1"
      /db_xref="GI:182801"
      /translation="MVSQLRLCLLLGLGCLAGVAKASGGTRDMPKPGPHRV
        FVTOREAHVLRHRRANAFLEELRPGSLEREKERCQCFEARETFKDAERTKLFMI
        SVSDGDCASSPCQNGCKDQLOSVICFLPAFEGRCNCTHKDQLICVNGGCEQ
        YCSDHRTKRSRCRCHGSHLLADGVSCTFVYPCGKIPILEKRNASKPGQRLVGGKV
        CPKGCDFWVLLLVNQAQLCGGTLINTIIVWSAAHCFDKIKNRNLIAVLGEHDLSEH
        DGEQSRVAQVLIIPSTYVPGTTHDIALLRHLPQVLTVDHVVPLCLPRTFSERTLA
        FVRFSLVSGWGLLDGATALEMLVNLVPLMTQDCLQSRKVGDSFNITFYMFCAGY
        SDGSKDCKGSGGPHATHYRGTYWLTGIVSGQCATVGHGVYTRVSVQYIEWLQKL
        MRSEPRPGVLLRAPFP"
    36..215
      /note="factor VIIa signal peptide"
      /join(36..99,166..1436)
      /notes="preprofactor VIIb"
      /codon_start=1
      /protein_id="AA88041.1"
      /db_xref="GI:182800"
      /translation="MVSQLRLCLLLGLGCLAGVAVTQBEAHGVLRHRRANAFLE
        ELRPGSLEREKERCQCFEARETFKDAERTKLFMISYSDGDCASSPCQNGSKDQ
        LQSYICFLPAFEGRCNCTHKDQLICVNGGCEQYCSHDGTRKRSRCRCHGSHLLA
        DGVSCTFVYPCGKIPILEKRNASKPGQRLVGGKVPKGCDFWVLLLVNQAQLCGG
        TLINTIIVWSAAHCFDKIKNRNLIAVLGEHDLSEHGDQSRVAQVLIIPSTYVPGT
        THDIALLRHLPQVLTVDHVVPLCLPRTFSERTLAIVRFSLVSGWGLLDGATALE
        LMLVNLVPLMTQDCLQSRKVGDSFNITFYMFCAGYSDGSKDCKGSGGPHATHYRG
        TWLTGIVSGWGLLDGATVGHGVYTRVSVQYIEWLQKLMRSEPRPGVLLRAPFP"
      /join(36..99,166..215)
      /note="factor VIIb signal peptide"
    216..671
      /product="coagulation factor VII"
      /note="light chain"
      672..1433
      /product="coagulation factor VII"
      /note="heavy chain"
      <36..99
      /note="preprofactor VIIb"
      /number=1
      100..165
      /note="alternate exon; putative"
      166..2462
      /note="factor VIIb"
      /number=2

Query Match      1.9%; Score 43; DB 1; Length 2462;
Best Local Similarity 58.0%; Pred. No. 0.00012;
Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

Qy 1058 TGTGAGAAATATCAATGACGAGTGTGTGTTGGATTCTTGTATCTTGCACTTGGAAGTG 1117
Db 2007 TGTGCATATCTCTATGCGGTGTCATCGGTGTGTTGGATTCTCTGTGTGACCATCTG 1948

Qy 1118 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1177
Db 1947 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1177
Qy 1178 TGTGTGTGTGT 1188
Db 1887 TCCATGTGTGT 1877

RESULT 14
107990/c
LOCUS
```

```

Qy 1178 TCTGTGTCTGT 1188
Db 1887 TCCATGTGTGT 1877

RESULT 13
E01076/c
LOCUS      E01076      2483 bp      RNA      linear      PAT 29-SEP-1997
DEFINITION CDNA sequence of Factor VII fragment.
ACCESSION  E01076
VERSION    E01076.1 GI:2169335
KEYWORDS   JP 1987000283-A/2.
SOURCE     unidentified
           unclassified.
           ORGANISM
REFERENCE  1 (bases 1 to 2483)
AUTHORS   Furedetsu, E.H., Maaku, J.M., Shiyaroon, J.B., Kiyasuriin, E.B.,
           Maagaratsuto, W.I., Richiyaado, J.U. and Chiyaaruzu, E.G.
TITLE     DNA ENCODING FACTOR VII
JOURNAL    Patent: JP 1987000283-A 2 06-JAN-1987;
           HEMOJENETITISUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD,
           TOYO SODA MFG CO LTD
           PN JP 1987000283-A/2
           PD 06-JAN-1987
           PF 16-APR-1986 JP 1986087861
           PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI
           FUREDITSUKU ESU HAAGEN, MAAKU JIEI MARII,
           PI SHIYAARON JIEI BAZUBII,
           PI KIIYASURIIN ERU BAKUNAA, MAAGARETSUTO WAI INSUREE, PI
           RICHIAAADO JII UTSUDOBHERII, CHIYAARUZU ERU GUREI PC
           C12N15/00,A61K37/465,C12N5/00,C12N9/50,(C12N9/50,C12R1:91); CC
           strandedness: Double;
           CC topology: Linear;
           CC hypothetical: No;
           CC anti-sense: No;
           CC *source: library=cDNA library;
           CC *source: clone=lambdaviI 2463;
           FH Key Location/Qualifiers
           FT 5'UTR 1..35
           FT sig_peptide 36..215
           FT CDS 216..1436
           FT /product='factor VII'
           FT 3'UTR 1437..2462
           FT misc_recomb 2462..<2480
           FT /note='polyA tail'.

FEATURES
  source
    1..2483
      /organism="unidentified"
      /mol_type="genomic RNA"
      /db_xref="taxon:32644"

Query Match      1.9%; Score 43; DB 1; Length 2483;
Best Local Similarity 58.0%; Pred. No. 0.00012;
Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

Qy 1058 TGTGAGAAATATCAATGACGAGTGTGTGTTGGATTCTTGTATCTTGCACTTGGAAGTG 1117
Db 2007 TGTGCATATCTCTATGCGGTGTCATCGGTGTGTTGGATTCTCTGTGTGACCATCTG 1948

Qy 1118 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1177
Db 1947 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1177
Qy 1178 TGTGTGTGTGT 1188
Db 1887 TCCATGTGTGT 1877

RESULT 14
107990/c
LOCUS
```


[illegible]


```

PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL
REMARK
COMMENT

12477932
2 (bases 1 to 1403)
Strausberg,R.
Direct Submission
Submitted (29-JUN-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Life Technologies, Inc.
DNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNL)
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www-shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/ILNL at: http://image.llnl.gov
Series: IRAK Plate: 14 Row: 1 Column: 15
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 21614535.
Location/Qualifiers
1. .1403
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:9599 IMAGE:3899480"
/tissue_type="pancreas, epithelioid carcinoma"
/clone_lib="NIH_MGC_70"
/lab_host="DH10B"
/notes="vector: pCMV-SPORT6"
1. .1403
/genes="PRSS22"
/notes="synonyms: BSSP-4, MGC9599, SP0011A, hbSSP-4"
/db_xref="LocusID:64063"
39 - 992
/codon_start=1
/product="protease, serine, 22"
/protein_id="AAH09726.1"
/db_xref="GI:16307275"
/db_xref="LocusID:64063"
/translaton="MVVSGAPPALGGCLGTFSTLLASTAILNARIIPVPACGKP
QLNRVVGSDSDSEMPFIVSIQKNGTHCAGSLTSRWITAAHCFKDNLNKPYLF
SVLLGAWQLGNSRQKGVAVWPHFVYSWKEGACADIALVRLERSIQFSRVLPI
CLPDASIHLPNTHCISWGSIQDGVLPHPQTLQKLVPIIDSEVCSHLYWRGAGQ
GPTEDMLCAGYLEGERDACLGDSGGLMCGVDGAWLLAGIISWGECAERNRPVYI
SLSAHRSWBEKIVQGVQLRGAQGGALRAPSGSGNAARS"
186 902
/misc_feature
/notes="Tryp_Spc; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 1.2%; Score 28; DB 1; Length 1403;
Best Local Similarity 63.2%; Pred. No. 0.87;
Matches 43; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 1530 TTGGTCCTTTTCCTGCACTTTTAAATATCTTTCTTTCTTACCTTTTAGTGATT 1589
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1402 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTT 1343
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1590 TGATTATT 1597
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1342 AAATAATT 1335

RESULT 20
BC034377/c
LOCUS
DEFINITION Homo sapiens protein C (inactive) of coagulation factors Va and

```

```

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL
REMARK
COMMENT

```

```

VIIIa), mRNA (CDNA clone MGC:34565 IMAGE:5188604), complete cds.
BC034377.1 GI:21707770
MGC.
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1792)
Klausner,R.D., Collins,F.S., Wagner,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L.H., Derge,J.G.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
Stapleton,M., Brownstein,M.B., Bonaldo,M.F., Casavant,T.L.,
Schaefer,C.F., Brownstein,M.B., Bonaldo,M.F., Casavant,T.L.,
Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,K.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,
McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Korley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Fahey,J., Helton,E., Kettman,M., Madan,A., Rodriguez,S.,
Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalish,D.E.,
Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
2388257
12477932
2 (bases 1 to 1792)
Strausberg,R.
Direct Submission
Submitted (02-JUL-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNL)
DNA Sequencing by: Baylor College of Medicine Human Genome
Sequencing Center
Center code: BCM-HGSC
Web site: http://www.hgsc.bcm.tmc.edu/cdna/
Contact: amg@bcm.tmc.edu
Gunaratne, P.H., Garcia, A.M., Lu, X., Hulyk, S.W., Lounseged, H.,
Kowis, C.R., Sneed, A.J., Martin, R.G., Muzny, D.M., Nanavati,
A.N., Gibbs, R.A.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/ILNL at: http://image.llnl.gov
Series: IRAK Plate: 50 Row: h Column: 4
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 4506114.
Location/Qualifiers
1. .1792
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:34565 IMAGE:5188604"
/tissue_type="Colon, Kidney, Stomach, adult, whole pooled"
/clone_lib="NIH_MGC_116"
/lab_host="DH10B"
/notes="vector: pCMV-SPORT6"
1. .1792
/genes="PROC"
/db_xref="LocusID:5624"
/db_xref="MIM:176860"

```


10664775-4.rge

Db 716 TCGTTGACTCCTGATGCTGGTTCACAGTTCATCTTCTTAAGTCTGTGCTGCTGTTGAG 657

QY 2011 GTCCTGAATGTTTACTCATTTTCTCTCCAGTATTACA 2050

Db 656 GATCTTGGGTTTCTTCTCTATCCACCTCCAGTTTCCCA 617

RESULT 27

BC013896 1603 bp mRNA linear ROD 03-OCT-2003

Mus musculus protein C, mRNA (cDNA clone MGC:13870 IMAGE:4211329), complete cds.

ACCESSION BC013896

VERSION BC013896.1 GI:15530229

KEYWORDS MGC.

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 1603)

AUTHORS Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.P., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.P., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S., Carninci, P., Brange, C., Raha, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullaly, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shvetchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalusz, D.E., Scherch, A., Schein, J.E., Jones, S.J. and Marra, M.A.

TITLE Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

MEDLINE 22388257

PUBMED 12477932

REFERENCE 2 (bases 1 to 1603)

AUTHORS Strausberg, R.

TITLE Direct Submission

JOURNAL Submitted (07-SEP-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>

COMMENT Contact: MGC help desk

Email: cgaps-remail.nih.gov

Tissue Procurement: Jeffrey E. Green, M.D.

cDNA Library Preparation: Life Technologies, Inc.

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Institute for Systems Biology

<http://www.systemsbio.org>

contact: amadan@systemsbio.org

Anup Madan, Jessica Fahney, Erin Helton, Mark Kettelman, Anuradha Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

Series: IRAC Plate: 18 Row: n Column: 8

This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6579476.

FEATURES

Location/Qualifiers

1..1603

/organism="Mus musculus"

/mol_type="mRNA"

/db_xref="FVB/N"

/db_xref="taxon:10090"

source

Query Match 1.1%; Score 24; DB 1; Length 1499;

Best Local Similarity 46.9%; Pred. No. 9.5;

Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1891 CTATCTCTGTTTCTGTCAGTGGCTTGTCTGAGGTTCTGTTGGTTCCTTAATT 1950

Db 715 CTTCTCTGAGTCCAGAGGATTGCTGCGCAAGACTGCACCTGCTGTCAGCGT 656

QY 1951 TTTCATTTCCAGATTCCTTCAGTTGGTGTGTTTATTAATTCATTTCCACTTTGAG 2010

Db 655 TCGGTTGACTATCTTGGATCTGTTCCAGTTTCATCTTAAAGTCTGTGTCGTTGAG 596

QY 2011 GTCCTGAATGTTTACTCATTTTCTCTCCAGTATTACA 2050

Db 595 GATCTTGGGTTTCTTCTATCCACCTCCAGTTTCCCA 556

RESULT 26

AF318182/c

LOCUS AF318182 1580 bp mRNA linear ROD 14-FEB-2001

DEFINITION Mus musculus anticoagulant protein C mRNA, complete cds.

ACCESSION AF318182

VERSION AF318182.1 GI:12802522

KEYWORDS Mus musculus (house mouse)

SOURCE Mus musculus

ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 1580)

AUTHORS Korf, I.

TITLE Complete sequence of UC72A01

JOURNAL Unpublished

AUTHORS Korf, I.

TITLE Direct Submission

JOURNAL Submitted (02-NOV-2000) Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, MO 63108, USA

FEATURES

Location/Qualifiers

1..1580

/organism="Mus musculus"

/mol_type="mRNA"

/strain="C57BL"

/db_xref="dbEST:AA986009"

/db_xref="taxon:10090"

72..1454

/codon_start=1

/product="anticoagulant protein C"

/protein_id="AAK07918.1"

/db_xref="GI:12802523"

/translations="MQFRVFLLMGTGISTPAHPDPVFSSEHAHQVLRVRANS
FLFEMPSPSLERMEICDLERQFONVEDTLAFWKVPDGDSCAPPLDHCDS
PCGHGTCDIGISFSCDKNEGFCQELRQDCRVNNGSLCYLSESGRCA
CAPGELADDMKRCSTVNPFCGLRWIKRRIKRLKRDLEDELPDRIYNGILT
KQDPSQWAILLDKSKLACGLVLIHTSVLTAACVGEFKLTVRIGEDYLRDRHW
ELDLDIKEILLVHPNTRSSNDIALRLAQPATLSKTIPICLPNNGLAQLTQAGQ
ETVVTGMYQSDRIKQGRNRRTILFIRIPLVARNECVEMKNVSENNMLCAGIIG
TRACDGDSDGSPVFRPGTWFLVLGLVSGEGCGHTNNYGIYTKVGSYLKWIHSYIE
KGVSLKSKQL"

Query Match 1.1%; Score 24; DB 1; Length 1580;

Best Local Similarity 46.9%; Pred. No. 9.5;

Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1891 CTATCTCTGTTTCTGTCAGTGGCTTGTCTGAGGTTCTGTTGGTTCCTTAATT 1950

Db 776 CTTCTCTGAGTCCAGAGGATTGCTGCGCAAGACTGCACCTGCTGTCAGCGT 717

QY 1951 TTTCATTTCCAGATTCCTTCAGTTGGTGTGTTTATTAATTCATTTCCACTTTGAG 2010

```
/clone="MGC:13870 IMAGE:4211329"
/tissue type="Liver, normal. 5 month old male mouse."
/clone_lib="NCI CGAP_Li9"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"
1..1603
/gene="Proc"
/note="synonym: PC"
/db_xref="LocusID:19123"
/db_xref="GI:15530230"
100..1482
/codon_start=1
/product="protein C"
/protein_id="AAH13896.1"
/db_xref="GI:15530230"
/db_xref="LocusID:19123"
/translation="MWQFRVFLLLMSWGISSIPAHDPDPVSSSEHAHQVLRVRANS
FLEMRPGSLRECMEEICDFEEAQEIQNVEDTAFWIKYFDGQCSAPPLDHQCD
PCGGHGTIDIGISFSCDKGWEGKQQQLRFQDCRVNNGCLHYCLBESNGRCA
CAGYELADHMRCSTVNFPCGKLGIWIEKKRILKRDITDLELDPDRIVNGTIL
KQGPSWQAILLDKSKKACCGVLIHTSWLTAACHVGTGKLTVRLEGVLDLREDHW
ELDLIDKEILVHPNVTSSSDNDIALLRLAQPATLSKTIIVPICLPNGLAQELTQAG
ETVVTGCGYOSDRIDKGRNRFTFLFIRIELVARNECEVKKNVWSENMLCAGIIGD
TRDACDSDSGPMVFFRGTWFLVGLVSWEGGCHTNNYGIYTKVSYLKWHSYIGE
KGVSLKSKQL"
175..357
/note="GLA; Region: Domain containing Gla
(gamma-carboxylglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
400..489
/note="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
730..1431
/note="Tryp_SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"

Query Match 1.1%; Score 24; DB 1; Length 1603;
Best Local Similarity 46.9%; Pred. No. 9.5;
Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1891 CTATCTCTGATTCGTGAGGCTTGCTCTGAGGTTCTGTTGGGTTCTTAATT 1950
DB 804 CTCTCTCTGAGTCCAGAGGATGCTGCCAAGGACTGCACCTGCTTCGTCAGCGT 745
QY 1951 TTTCATTTCCAGATTCCTTCAGTTGGGTTTGTATTATTAATTCATTTCCACTTTCAG 2010
DB 744 TCGGTGACTATCCTTGAGTCTGGTTCAGTTTCATCTTCAAGTCTGTCTGCTGTTGAG 685
QY 2011 GTCTCGAAATGTTTACTCATTTTCTCCAGATTTTACA 2050
DB 684 GATCTGCGTTTCTCTATCCACTCCCAAGTTTCCCA 645

RESULT 28
AR425705
LOCUS 364 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 17202 from patent US 6639063.
ACCESSION AR425705
VERSION AR425705.1 GI:40180815
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 364)
```

```
AUTHORS Edwards, J.-B.D.M., Jobert, S. and Giordano, J.-Y.
TITLE ESR's and encoded human proteins
JOURNAL Patent: US 6639063-A 17202 28-OCT-2003;
FEATURES
    source
        1..364
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match 1.0%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 9.7;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;

QY 194 CCTAGGTTGAGGTTACCACTGCTCTCTCTCCCTTCTTCCAAACACTTCTATTCTTG 302
DB 27 MCKSSRSYGRSSCCGSGMWSGCSKRSRSCRCMKSMWSMMYMRSMKYKSTCASCCK 86
QY 254 TAGGGGCACCTACCGCATTCCTCTCTCTCTCCAAACACTTCTATTCTTG 302
DB 87 YKGGKMACMTGWSGMYRYMASYWCYSYMARYTTCYSKYRMMKYCYR 135

RESULT 29
BD121258
LOCUS 364 bp DNA linear PAT 18-SEP-2002
DEFINITION EST and encoded human protein..
ACCESSION BD121258
VERSION BD121258.1 GI:23216168
KEYWORDS JP 2002010789-A/13335.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
    Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 364)
AUTHORS Edwards, J.B.D.M., Jobert, S. and Giordano, J.E.
TITLE EST and encoded human protein
JOURNAL Patent: JP 2002010789-A 13335 15-JAN-2002;
GENSET CORP
COMMENT OS Homo sapiens (human)
PN JP 2002010789-A/13335
PD 15-JAN-2002
PF 07-AUG-2000 JP 2000280989
PR 05-AUG-1999 US 60/147499
PI JEAN BAPTISTE DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
GIORDANO
PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
C12N1/21,
PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
C12N15/00
CC EST and encoded human protein
FH Key Location/Qualifiers
FT source 1..364
    /organism="Homo sapiens (human)"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"

FEATURES
    source
        1..364
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"

Query Match 1.0%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 9.7;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;

QY 194 CCTAGGTTGAGGTTACCACTGCTCTCTCTCCCTTCTTCCAAACACTTCTATTCTTG 302
DB 27 MCKSSRSYGRSSCCGSGMWSGCSKRSRSCRCMKSMWSMMYMRSMKYKSTCASCCK 86
QY 254 TAGGGGCACCTACCGCATTCCTCTCTCTCTCCAAACACTTCTATTCTTG 302
DB 87 YKGGKMACMTGWSGMYRYMASYWCYSYMARYTTCYSKYRMMKYCYR 135

RESULT 30
AX839180
```

LOCUS AX839180 394 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 23 from Patent WO03076610.
ACCESSION AX839180
VERSION AX839180.1 GI:39922629
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Bracco,L., Brinkman,B. and Coignard,F.
AUTHORS Variants of human kallikrein-2 and kallikrein-3 and uses thereof
TITLE Patent: WO 03076610-A 23 18-SEP-2003;
JOURNAL Exonhit Therapeutics S.A. (PR)
FEATURES
1. 394
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 23.8; DB 1; Length 394;
Best Local Similarity 48.2%; Pred. No. 9.8;
Matches 57; Conservative 0; Mismatches 72; Indels 0; Gaps 0;
QY 1074 TGAGCAGTGTTCGAGTCTTCTTATCTTGCACCTGTGACGTGTGTGTGTGTG 1133
Db 203 TGCCCACTGCATCAGGAATCTCCATATCCCCCTCTCTGTGCTCTAGTCCCTCT 262
QY 1134 TGT 1193
Db 263 CTAGCCAGGTGTGTCTACCTGTGTCTCTCTGTCAGGCTGTGTCTCGGTCTCTGTC 322
QY 1194 GTGTGTGTGTGTCTCTCC 1212
Db 323 ACCTGTGCTTCTCCCTAC 341
RESULT 31
LOCUS BD124660 868 bp DNA linear PAT 18-SEP-2002
DEFINITION Primer for synthesizing full-length cDNA and use thereof.
ACCESSION BD124660
VERSION BD124660.1 GI:23219605
KEYWORDS JP 2002017375-A/91.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.
TITLE Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
JOURNAL Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
COMMENT Koga,H.
Primer for synthesizing full-length cDNA and use thereof
PATENT: JP 2002017375-A 91 22-JAN-2002;
HELIX RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002017375-A/91
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO
PI ISHII,
PI YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI,HISASHI KOGA
PC C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
10, C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
Primer for synthesizing full-length cDNA and use thereof FH Key
Location/Qualifiers
FT source 1. 868
/organism="Homo sapiens"
/db_xref="taxon:9606"
FEATURES
source
1. 868
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 23.8; DB 1; Length 868;
Best Local Similarity 57.3%; Pred. No. 10;
Matches 43; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
QY 487 ATTCAATTTGGAGAGTTTCATAGGTTCTGACAGAAGGTACAGTCTTTGTTTGGT 546
Db 107 ATTGGAAGTTGCAAGATTTCATTGAGGGAGCAAGAGGAGGAGGAGGAGGAGGAGG 166
QY 547 GAAATAGTCTGTAAA 561
Db 167 GCTTTCCTTTTAAA 181
RESULT 32
LOCUS BD126609 868 bp DNA linear PAT 18-SEP-2002
DEFINITION Primer for synthesizing full-length cDNA and use thereof.
ACCESSION BD126609
VERSION BD126609.1 GI:23221554
KEYWORDS JP 2002017375-A/2040.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.
TITLE Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
JOURNAL Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
COMMENT Koga,H.
Primer for synthesizing full-length cDNA and use thereof
PATENT: JP 2002017375-A 2040 22-JAN-2002;
HELIX RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002017375-A/2040
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO
PI ISHII,
PI YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI,HISASHI KOGA
PC C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
10, C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
Primer for synthesizing full-length cDNA and use thereof FH Key
Location/Qualifiers
FT source 1. 868
/organism="Homo sapiens"
/db_xref="taxon:9606"
FEATURES
source
1. 868
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 23.8; DB 1; Length 868;
Best Local Similarity 57.3%; Pred. No. 10;
Matches 43; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
QY 487 ATTCAATTTGGAGAGTTTCATAGGTTCTGACAGAAGGTACAGTCTTTGTTTGGT 546
Db 107 ATTGGAAGTTGCAAGATTTCATTGAGGGAGCAAGAGGAGGAGGAGGAGGAGGAGG 166
QY 547 GAAATAGTCTGTAAA 561
Db 167 GCTTTCCTTTTAAA 181
RESULT 33

LOCUS AX839180 394 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 23 from Patent WO03076610.
ACCESSION AX839180
VERSION AX839180.1 GI:39922629
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Bracco,L., Brinkman,B. and Coignard,F.
AUTHORS Variants of human kallikrein-2 and kallikrein-3 and uses thereof
TITLE Patent: WO 03076610-A 23 18-SEP-2003;
JOURNAL Exonhit Therapeutics S.A. (PR)
FEATURES
1. 394
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 23.8; DB 1; Length 394;
Best Local Similarity 48.2%; Pred. No. 9.8;
Matches 57; Conservative 0; Mismatches 72; Indels 0; Gaps 0;
QY 1074 TGAGCAGTGTTCGAGTCTTCTTATCTTGCACCTGTGACGTGTGTGTGTGTG 1133
Db 203 TGCCCACTGCATCAGGAATCTCCATATCCCCCTCTCTGTGCTCTAGTCCCTCT 262
QY 1134 TGT 1193
Db 263 CTAGCCAGGTGTGTCTACCTGTGTCTCTCTGTCAGGCTGTGTCTCGGTCTCTGTC 322
QY 1194 GTGTGTGTGTGTCTCTCC 1212
Db 323 ACCTGTGCTTCTCCCTAC 341
RESULT 31
LOCUS BD124660 868 bp DNA linear PAT 18-SEP-2002
DEFINITION Primer for synthesizing full-length cDNA and use thereof.
ACCESSION BD124660
VERSION BD124660.1 GI:23219605
KEYWORDS JP 2002017375-A/91.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.
TITLE Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
JOURNAL Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
COMMENT Koga,H.
Primer for synthesizing full-length cDNA and use thereof
PATENT: JP 2002017375-A 91 22-JAN-2002;
HELIX RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002017375-A/91
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO
PI ISHII,
PI YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI,HISASHI KOGA
PC C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
10, C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
Primer for synthesizing full-length cDNA and use thereof FH Key
Location/Qualifiers
FT source 1. 868
/organism="Homo sapiens"
/db_xref="taxon:9606"
FEATURES
source
1. 868
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 23.8; DB 1; Length 868;
Best Local Similarity 57.3%; Pred. No. 10;
Matches 43; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
QY 487 ATTCAATTTGGAGAGTTTCATAGGTTCTGACAGAAGGTACAGTCTTTGTTTGGT 546
Db 107 ATTGGAAGTTGCAAGATTTCATTGAGGGAGCAAGAGGAGGAGGAGGAGGAGGAGG 166
QY 547 GAAATAGTCTGTAAA 561
Db 167 GCTTTCCTTTTAAA 181
RESULT 33


```
AY040345/c
LOCUS       AY040345               1671 bp      mRNA      linear      VRT 25-JUL-2001
DEFINITION   Danio rerio coagulation factor VII mRNA, complete cds.
ACCESSION    AY040345
VERSION      AY040345.1  GI:15020317
KEYWORDS
SOURCE       Danio rerio (zebrafish)
ORGANISM     Danio rerio
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
              Cypriniformes; Cyprinidae; Danio.
REFERENCE    1 (bases 1 to 1671)
AUTHORS      Sheehan,J., Templer,M., Gregory,M., Hanumanthaiah,R., Troyer,D.,
              Phan,T., Thankavel,B. and Jagadeeswaran,P.
TITLE        Demonstration of the extrinsic coagulation pathway in teleostei:
              identification of zebrafish coagulation factor VII
JOURNAL      Proc. Natl. Acad. Sci. U.S.A. 98 (15), 8768-8773 (2001)
MEDLINE      21353085
PUBMED       11459993
REFERENCE    2 (bases 1 to 1671)
AUTHORS      Sheehan,J., Templer,M., Gregory,M., Hanumanthaiah,R., Troyer,D.,
              Phan,T., Thankavel,B. and Jagadeeswaran,P.
TITLE        Direct Submission
JOURNAL      Submitted (14-JUN-2001) Cellular and Structural Biology, University
              of Texas Health Science Center at San Antonio, 7703 Floyd Curl
              Drive, San Antonio, TX 78229, USA
FEATURES     source
              1..1671
              Location/Qualifiers
              /organism="Danio rerio"
              /mol_type="mRNA"
              /db_xref="taxon:7955"
              1..1302
              /codon_start=1
              /product="coagulation factor VII"
              /protein_id="AAK74192.1"
              /db_xref="GI:15020318"
              /translation="MSLLVFLSLWSLHCHSAAFVHRDEAHEVLIRKRSANGWFE
              ELATGNLERCLCEKESYEAREVFTEATNEFWKIYDVKHCASSPCEHDLCTTQ
              NADSYNCLCAPSGSRHCEQSIGDVLDSCLHNGGCEHFCOEODGRNCSADGYLD
              NSQKCRSHVFPFGCVPLLOAGKAADHVDLRSRVIGSGCEPKGHPQVLLKYGEK
              GFCGGVYKPTWLTAAHCLKLVKFLRVAGEHDLVDEGEQLIQVDMTHFAY
              VSTADSLALLRLTFPIVSYAVPCLPLREMAERELWAVSKHTVSGWKGKSEDP
              TSLRLRLLVPRTRTQECQVSNLTLSNNFCAGYIEGRQDSCKGSDGSGPLVTRYRDT
              AFLLGVSWKGKSGSGYITRVSNYLQWIRQTNTTIH"
Query Match      1.0%; Score 23.6; DB 1; Length 1671;
Best Local Similarity 54.7%; Pred. No. 12;
Matches 47; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 1319 TGNAGATAGATATCTTTCACTGATTTTATCTTAGAATGCTTTCTTTCTCCTCAACTAT 1378
Db 1436 TTAATAATAAATATTTTATTTTCAATAAATTTTCTATTTTACAAACATTAATAT 1377
QY 1379 TGTGACAGAAAGTTTCTTAAGTCCA 1404
Db 1376 AATAGTAATAATTTGTAAATGTCCA 1351
RESULT 34
AR425705/c
LOCUS       AR425705               364 bp      DNA      linear      PAT 18-DEC-2003
DEFINITION   Sequence 17202 from patent US 6639063.
ACCESSION    AR425705
VERSION      AR425705.1  GI:40180815
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
              1 (bases 1 to 364)
AUTHORS      Edwards,J.-B.D.M., Jobert,S. and Giordano,J.-Y.
TITLE        EST's and encoded human proteins
JOURNAL      Patent: US 6639063-A 17202 28-OCT-2003;
FEATURES     Location/Qualifiers
              1..364
              /organism="Homo sapiens"
              /mol_type="genomic DNA"
              /db_xref="taxon:9606"
Query Match      1.0%; Score 23; DB 1; Length 364;
Best Local Similarity 10.5%; Pred. No. 16;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;
QY 660 TTGAAGTAGCCCACTATCTGTGTGAGGTCAATATGTGATTTAGCTGTAGCTGTGCTT 719
Db 277 WTGRSMWKKSTYKRWSRAGSWMTGYRMSKMWMTGSTRSCTSKKKRKGSTSSKYASTSGK 218
QY 720 GTTTTATGAACCTTGGGTGACATTTGTTTGGTGACATAGACATTAAGAAATTCATGCTCT 779
Db 217 SSKYMSCTCRSSKKCRYSATYYSCMMKWKYCMMSATYSGCMMRWYCYSCMMSRYSGCT 158
QY 780 CTGTGCTGATTTT 792
Db 157 SYSRGKCSCTGWK 145
RESULT 35
BD121258/c
LOCUS       BD121258               364 bp      DNA      linear      PAT 18-SEP-2002
DEFINITION   EST and encoded human protein.
ACCESSION    BD121258
VERSION      BD121258.1  GI:23216168
KEYWORDS     JP 2002010789-A/13335.
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 364)
AUTHORS      Edwards,J.B.D.M., Jobert,S. and Giordano,J.E.
TITLE        EST and encoded human protein
JOURNAL      Patent: JP 2002010789-A 13335 15-JAN-2002;
              GENSET CORP
COMMENT      OS Homo sapiens (human)
              PN JP 2002010789-A/13335
              PD 15-JAN-2002
              PF 07-AUG-2000 JP 2000280989
              PR 05-AUG-1999 US 60/147499
              PI JEAN BAPTISTE DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
              GIORDANO
              PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
              C12N1/21,
              PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
              C12N15/00
              CC EST and encoded human protein
              FH Key Location/Qualifiers
              FT source
              1..364
              /organism="Homo sapiens (human)"
              Location/Qualifiers
              1..364
              /organism="Homo sapiens"
              /mol_type="genomic DNA"
              /db_xref="taxon:9606"
Query Match      1.0%; Score 23; DB 1; Length 364;
Best Local Similarity 10.5%; Pred. No. 16;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;
QY 660 TTGAAGTAGCCCACTATCTGTGTGAGGTCAATATGTGATTTAGCTGTAGCTGTGCTT 719
Db 277 WTGRSMWKKSTYKRWSRAGSWMTGYRMSKMWMTGSTRSCTSKKKRKGSTSSKYASTSGK 218
QY 720 GTTTTATGAACCTTGGGTGACATTTGTTTGGTGACATAGACATTAAGAAATTCATGCTCT 779
Db 217 SSKYMSCTCRSSKKCRYSATYYSCMMKWKYCMMSATYSGCMMRWYCYSCMMSRYSGCT 158
QY 780 CTGTGCTGATTTT 792
Db 157 SYSRGKCSCTGWK 145
```

RESULT 36	AF465274	1329 bp	mRNA	linear	VRT 02-FEB-2003
LOCUS	Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete cds.				
DEFINITION	AF465274				
VERSION	AF465274.1	GI:28194019			
KEYWORDS	Takifugu rubripes (Fugu rubripes)				
SOURCE	Takifugu rubripes				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percormorpha; Tetraodontiformes; Tetraodontidae; Tetraodontidae; Takifugu.				
REFERENCE	1 (bases 1 to 1329)				
AUTHORS	Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G., Tuddenham,E.G.D. and McVey,J.H.				
TITLE	Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes				
JOURNAL	Unpublished				
AUTHORS	2 (bases 1 to 1329)				
TITLE	McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G. Direct Submission				
JOURNAL	Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences Centre, The Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK				
FEATURES	Location/Qualifiers				
source	1..1329				
	/organism="Takifugu rubripes"				
	/mol_type="mRNA"				
	/db_xref="taxon:31033"				
	1..1329				
	/EC_number="3.4.21.21"				
	/function="serum prothrombinconversion accelerator"				
	/note="vitamin K dependent serine protease; similar to Fugu rubripes FVII; synthesized in liver; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"				
	/codon_start=1				
	/product="coagulation factor VIIb precursor"				
	/protein_id="AA033369.1"				
	/db_xref="GI:28194020"				
	/translation="MLIRICCTVMILFSATAAAVFERDDASTVLQRRRANSGLFEMOQNLKRECEICNIEBEAREVFEDDAQTRKFETYNRHPDCVMPQNGVCVSMGNTYQCHPEGFGQCEKARDFLKLQNGOCQHFCDGSGARCKFCAGHYTLASDGRCTAEVFPQQLPPEPDPQTVVGOTRLVGNHCPKGECPWVLVOLHGQSHCGGVLRPDWITAAHCVTGKQPHLSVVAHEHNLDDGTEQKIPVARVEAHEGYVSETGDKDIALHLNASVTNLNRGVIPVLCPLKDLAERLLMTRVTVSGKRTNGNEHDGVNNTAPVSPFLRPSVPIIPNQCPSRQFNFTDMPFCAGLEGNQOQSGDDGSLVTLYGSTHFLIGVVGWGRGCPNPGYGYVTNMGNFVDWANGIMMAANKST"				
CDS					
	Query Match	1.08;	Score 23;	DB 1;	Length 1329;
	Best Local Similarity	74.48;	Pred. No. 17;		
	Matches	25;	Conservative	0;	Mismatches 10;
					Indels 0;
					Gaps 0;
QY	1585	TGATTTCATTATTCAGCTGTGGGAGTTCCTTTCCG	1623		
Db	5	TGATTAGATTTCGTCGACTTTGGATTCTCTTTCCG	43		
RESULT 37	AX774765/c				
LOCUS	AX774765	1507 bp	DNA	linear	PAT 09-JUL-2003
DEFINITION	Sequence 81 from Patent WO03038129.				
ACCESSION	AX774765				
VERSION	AX774765.1	GI:32486281			
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1				
AUTHORS	Raponi,M.				
TITLE	Methods for assessing and treating leukemia				
JOURNAL	Patent: WO 03038129-A 81 08-MAY-2003;				
Ortho-Clinical Diagnostics, Inc. (US)					
FEATURES	Location/Qualifiers				
source	1..1507				
	/organism="Homo sapiens"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:9606"				
Query Match	1.08;	Score 23;	DB 1;	Length 1507;	
Best Local Similarity	60.38;	Pred. No. 17;			
Matches	38;	Conservative	0;	Mismatches 25;	Indels 0;
					Gaps 0;
QY	1634	TTTGGTGTTCATGCTCTTGTACCTTGATAGCATCTCTTTCACAGTTAGGAAT	1693		
Db	1506	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTGGGATCTCATTATATGGAGGACGT	1447		
QY	1694	TTT	1696		
Db	1446	TAT	1444		
RESULT 38	HUMFACX	1507 bp	mRNA	linear	PRI 08-NOV-1994
LOCUS	Human coagulation factor X (F10) mRNA, complete cds.				
DEFINITION	M57285				
ACCESSION	M57285.1	GI:182389			
VERSION					
KEYWORDS	coagulation factor X.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1 (bases 1 to 1507)				
AUTHORS	Messier,T.L., Pittman,D.D., Long,G.L., Kaufman,R.J. and Church,W.R.				
TITLE	Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X				
JOURNAL	Gene 99 (2), 291-294 (1991)				
MEDLINE	91216473				
PUBMED	1902434				
COMMENT	Original				
FEATURES	source text: Human, cDNA to mRNA.				
source	Location/Qualifiers				
	1..1507				
	/organism="Homo sapiens"				
	/mol_type="mRNA"				
	/db_xref="taxon:9606"				
	/map="13q34"				
	/tissue_type="liver"				
	1..1507				
	/gene="F10"				
	1..1467				
	/gene="F10"				
	/EC_number="3.4.21.6"				
	/codon_start=1				
	/product="coagulation factor X"				
	/protein_id="AA52421.1"				
	/db_xref="GI:182390"				
	/db_xref="GDB:G00-119-890"				
	/translation="MGRPLHLVLLSASLAGLLLGSLFIRREQANNILARVTRANSFLBMKKHLEECMEETCSYEAREVFEDSDKTNEFNWYKDGDCQETSQOQKCKDLGGEVTCCTCGEGKNCBLFKLCLSDNGCDQFCHEQNSVVCSCARGYTLADNKGACIPGPVPCGKOTLERKRSVAOTSSGAPDSITWKPYDAALDPTNPFDLLDFNQTPERGDNNILTRVGGQCKDGCEPQWALLINEENEGFCGCTILSFYILTAAHCLYQAKRFKVRVGRNTEQEGEAHVEVVIKNEFTKTYDFDIAVLELKTPTIFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSVFIIITQNMFCAGYTDKQDQCGSGGSHVTFKDTYFTVGTIVSWGEGCARCKGYIYTKVTAFLKWDIRSMKTRGLPKAKSHAPEVITSSPLK"				
	1004..1060				
	/gene="F10"				
	/note="putative Bacteriophage lambda (J02459); putative"				
misc_feature					

<hr/>					
Query Match					
Best Local Similarity 1.0%; Score 23; DB 1; Length 1507;					
Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;					
<hr/>					
Qy	1634	TTTGGTGTTTTGATGCTTCTGTACCTTGATAGGCATCTCTTCTCAAGTTAGGAAT	1693		
Db	1506	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGTGGGATCTCACTTTAATGGAGGACGT	1447		
<hr/>					
Qy	1694	TTT 1696			
Db	1446	TAT 1444			
<hr/>					
RESULT 39					
AX395271/c					
LOCUS AX395271					
DEFINITION Sequence 8 from Patent WO203787.					
ACCESSION AX395271					
VERSION AX395271.1 GI:21066295					
KEYWORDS synthetic construct					
SOURCE synthetic construct					
ORGANISM artificial sequences.					
REFERENCE 1					
AUTHORS Allen,K.D. and Leviten,M.W.					
TITLE Transgenic mice containing targeted gene disruptions					
JOURNAL Patent: WO 0203787-A 8 17-JAN-2002;					
DELTAGEN, Inc. (US)					
FEATURES					
source Location/Qualifiers					
1..200					
/organism="synthetic construct"					
/mol_type="unassigned DNA"					
/db_xref="taxon:32630"					
/note="Targeting Vector"					
<hr/>					
Query Match					
Best Local Similarity 1.0%; Score 22.8; DB 1; Length 200;					
Matches 7; Conservative 0; Mismatches 82; Indels 0; Gaps 0;					
<hr/>					
Qy	3	TCACTCCTCTAGTCAAAGGTGGGGGCTGAGGCTCCAATGGTTGTGTGATGTGTAGTA	62		
Db	198	TCCTCTCCCTGTATCCAGGTGTGCATGTCCGGCATCCCTGTGGGTGTTGTGTGGCTG	139		
<hr/>					
Qy	63	TCTCATACAGAGATAGCACATAGATGCTGTCGGACATAGTAAGCTTTCACAGAGAC	122		
Db	138	TCTGTCCAGTCTCTATACCCTAGTGTCTTTGATCCAGTCCCAGTCCCAGGAGCC	79		
<hr/>					
Qy	123	TTCCATAATATATTTTCTTGAAGCCTCTGCTGCCA	156		
Db	78	TTCTGTACAGCGCTGGCTTGTCTCTGAGCGCA	45		
<hr/>					
RESULT 40					
AB0624583/c					
LOCUS AB0624583					
DEFINITION Pan troglodytes F9 gene for coagulation factor XI, exon 4,					
isolate:504.					
ACCESSION AB062462					
VERSION AB062462.1 GI:14270094					
KEYWORDS					
SEGMENT					
SOURCE 3 of 7					
ORGANISM Pan troglodytes (chimpanzee)					
Pan troglodytes					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.					
1 Satta,Y.					
REFERENCE Comparison of DNA and protein polymorphisms between humans and					
AUTHORS chimpanzees					
TITLE Genes Genet. Syst. (2001) In press					
JOURNAL 2 (bases 1 to 210)					
REFERENCE Satta,Y.					
AUTHORS					

Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;	
QY 2168	CTATTGTAATAGGGTTTACAGGGACATATTGCTCGTGTGTTATTCTCTGTGTTTGG 2227
Db 133	CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 94
QY 2228	CTTTGGCATATAGCGGCTGAGTTG 2253
Db 73	AATTGGCACGTAACACTGCTTAGAATG 120
RESULT 44	
AX265081/c	
LOCUS	AX265081 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	Sequence 2472 from Patent WO0173002.
ACCESSION	AX265081
VERSION	AX265081.1 GI:16513880
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2472 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US)
source	Location/Qualifiers
1..121	
/organism="Homo sapiens"	
/mol_type="unassigned DNA"	
/db_xref="taxon:9606"	
Query Match 1.0%; Score 22; DB 1; Length 121;	
Best Local Similarity 53.5%; Pred. No. 26;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
QY 2168	CTATTGTAATAGGGTTTACAGGGACATATTGCTCGTGTGTTATTCTCTGTGTTTGG 2227
Db 88	CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 29
QY 2228	CTTTGGCATATAGCGGCTGAGTTG 2253
Db 28	AATTGGCACGTAACACTGCTTAGAATG 3
RESULT 45	
AX265082	
LOCUS	AX265082 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	Sequence 2473 from Patent WO0173002.
ACCESSION	AX265082
VERSION	AX265082.1 GI:16513881
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2473 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US)
source	Location/Qualifiers
1..121	
/organism="Homo sapiens"	
/mol_type="unassigned DNA"	
/db_xref="taxon:9606"	
Query Match 1.0%; Score 22; DB 1; Length 121;	
Best Local Similarity 53.5%; Pred. No. 26;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
QY 2168	CTATTGTAATAGGGTTTACAGGGACATATTGCTCGTGTGTTATTCTCTGTGTTTGG 2227
Db 87	CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 28
QY 2228	CTTTGGCATATAGCGGCTGAGTTG 2253
Db 27	AATTGGCACGTAACACTGCTTAGAATG 2
RESULT 43	
AX265078	
LOCUS	AX265078 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	Sequence 2469 from Patent WO0173002.
ACCESSION	AX265078
VERSION	AX265078.1 GI:16513877
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2469 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US)
source	Location/Qualifiers
1..121	
/organism="Homo sapiens"	
/mol_type="unassigned DNA"	
/db_xref="taxon:9606"	
Query Match 1.0%; Score 22; DB 1; Length 121;	
Best Local Similarity 53.5%; Pred. No. 26;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTCCTGGTGTGTTATTCCTGCTGTTTGG 2227
 Db 34 CCAITTAACATGATTGGACTCAGCTCCTCATCTTTGAGATAGTTAAGAAATTG 93
 QY 2228 CTTTGGCATATAGCGCTGAGTTTG 2253
 Db 94 AATTGGCAGCTAAACTGCTTAGAATG 119

RESULT 46
 LOCUS AX265085/c 121 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 2476 from Patent WO0173002.
 ACCESSION AX265085
 VERSION AX265085.1 GI:16513884
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 2476 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..121
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 26;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
 QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTCCTGGTGTGTTATTCCTGCTGTTTGG 2227
 Db 89 CCAITTAACATGATTGGACTCAGCTCCTCATCTTTGAGATAGTTAAGAAATTG 30
 QY 2228 CTTTGGCATATAGCGCTGAGTTTG 2253
 Db 29 AATTGGCAGCTAAACTGCTTAGAATG 4

RESULT 47
 LOCUS AX265086 121 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 2477 from Patent WO0173002.
 ACCESSION AX265086
 VERSION AX265086.1 GI:16513885
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 2477 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..121
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 26;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
 QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTCCTGGTGTGTTATTCCTGCTGTTTGG 2227

Db 33 CCAITTAACATGATTGGACTCAGCTCCTCATCTTTGAGATAGTTAAGAAATTG 92
 QY 2228 CTTTGGCATATAGCGCTGAGTTTG 2253
 Db 93 AATTGGCAGCTAAACTGCTTAGAATG 118

RESULT 48
 LOCUS AX265089/c 121 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 2480 from Patent WO0173002.
 ACCESSION AX265089
 VERSION AX265089.1 GI:16513888
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 2480 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..121
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 26;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
 QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTCCTGGTGTGTTATTCCTGCTGTTTGG 2227
 Db 86 CCAITTAACATGATTGGACTCAGCTCCTCATCTTTGAGATAGTTAAGAAATTG 27
 QY 2228 CTTTGGCATATAGCGCTGAGTTTG 2253
 Db 26 AATTGGCAGCTAAACTGCTTAGAATG 1

RESULT 49
 LOCUS AX265090 121 bp DNA linear PAT 26-OCT-2001
 DEFINITION Sequence 2481 from Patent WO0173002.
 ACCESSION AX265090
 VERSION AX265090.1 GI:16513889
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 2481 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source 1..121
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 26;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
 QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTCCTGGTGTGTTATTCCTGCTGTTTGG 2227

Db 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 95

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 96 AATTGGCACGTAACACTGCTTAGAATG 121

RESULT 50

AX265093/c

LOCUS 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2484 from Patent WO0173002.

ACCESSION AX265093

VERSION AX265093.1 GI:16513892

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2484 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

source

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTTCAGGGACATATGCTCGGTTGTTATTGTCGTGTTTTC 2227

Db 86 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 27

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 26 AATTGGCACGTAACACTGCTTAGAATG 1

RESULT 51

AX265094

LOCUS 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2485 from Patent WO0173002.

ACCESSION AX265094

VERSION AX265094.1 GI:16513893

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2485 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

source

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTTCAGGGACATATGCTCGGTTGTTATTGTCGTGTTTTC 2227

Db 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 95

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 96 AATTGGCACGTAACACTGCTTAGAATG 121

RESULT 52

AX265073/c

LOCUS 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2464 from Patent WO0173002.

ACCESSION AX265073

VERSION AX265073.1 GI:16513872

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2464 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

source

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTTCAGGGACATATGCTCGGTTGTTATTGTCGTGTTTTC 2227

Db 91 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 32

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 31 AATTGGCACGTAACACTGCTTAGAATG 6

RESULT 53

AX265074

LOCUS 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2465 from Patent WO0173002.

ACCESSION AX265074

VERSION AX265074.1 GI:16513873

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2465 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

source

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTTCAGGGACATATGCTCGGTTGTTATTGTCGTGTTTTC 2227

Db 31 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTCAGATAGGTTAAGAAATTG 90

QY 2228 CTTTGGCATATAGACGCTGAGTTTG 2253
||||| |||||
Db 91 AATTGCCACGTAAACTGCTTAGAATG 116

RESULT 54
HUMKALR4/c
LOCUS HUMKALR4 193 bp DNA linear PRI 06-JAN-1995
DEFINITION Human renal kallikrein, exon 4.
ACCESSION M33108
VERSION M33108.1 GI:186648
KEYWORDS kallikrein; kininogenase.
SEGMENT 4 of 5
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 193)
AUTHORS Evans,B.A., Yun,Z.X., Close,J.A., Tregear,G.W., Kitamura,N., Nakanishi,S., Callen,D.F., Baker,E., Hyland,V.J., Sutherland,G.R., and Richards,R.I.
TITLE Structure and chromosomal localization of the human renal kallikrein gene
JOURNAL Biochemistry 27 (9), 3124-3129 (1988)
MEDLINE 88263498
PUBMED 2898948
COMMENT Original source text: Human parotid gland, cDNA to mRNA.

FEATURES
source Location/Qualifiers
prim_transcript 1..>193
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /map="19q13.3"
introns <1..>193
 /gene="KLK1"
 /note="kallikrein mRNA and introns"

exon <1..>29
 /gene="KLK1"
 /notes="kallikrein intron C"
 /number=4
 /note="G00-120-118"
 /number=4
 /gene="KLK1"
 /note="kallikrein intron D"

Query Match 1.0%; Score 22; DB 1; Length 193;
Best Local Similarity 67.4%; Pred. No. 27;
Matches 31; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 953 GTAGGTTGTCCTTTTTGGATGCAGCAGTAGGATGGATCTGTTC 998
Db 104 GGACGTGGCGCTTTTGGCACTCATCATTAAGCAGGAATTGAGGTC 59

RESULT 55
HUMFIXG3/c
LOCUS HUMFIXG3 240 bp DNA linear PRI 01-DEC-1994
DEFINITION Human factor IX gene, exon 4.
ACCESSION K02050
VERSION K02050.1 GI:182616
KEYWORDS Christmas factor; factor IX.
SEGMENT 3 of 6
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 240)
AUTHORS Anson,D.S., Choo,K.H., Rees,D.J., Giannelli,F., Gould,K., Huddleston,J.A. and Brownlee,G.G.
TITLE The gene structure of human anti-haemophilic factor IX
JOURNAL EMBO J. 3 (5), 1053-1060 (1984)

[illegible]

TITLE The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 860)
AUTHORS Roach, J.C.
TITLE Direct Submission
JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of Washington, Seattle, WA 98195, USA
FEATURES
source
1. .860
/organism="Petryomyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="ammocoete"
/tissue_lib="anterior intestine"
1. .860
/gene="TRYP2"
6. .749
/gene="TRYP2"
/codon_start=1
/product="trypsinogen a2"
/protein_id="AAB69654.1"
/db_xref="GI:2367495"
/translation="MHGLILALLGVAAAPYMYEDHIVGSECAHSPQWQVSLNIG YHFCGSLINSQWVSAHCHYQASRISVRIGEHNI FVNEGTEQIQOAKAIQHPQYN SWITDNDIMLIKSSPATLNOYAOAIAPSSCVNTGYMCTISGNETQTSIGSPDVLN CVOAPVLSDTSCRNSYPGDI TNMMLICGLYEGGKSCQGDGSGPVCNGELQGVSWG RGCALPNYPGVYTKVCYNWIAQTIAAN"
6. .50
sig_peptide
/gene="TRYP2"
evidence=not_experimental
51. .746
mat_peptide
/gene="TRYP2"
evidence=not_experimental

Query Match 0.98; Score 21.6; DB 1; Length 860;
Best Local Similarity 68.2%; Pred. No. 38;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1552 TTTTAAATATCTTCTTTGTTCTATCTATCTTTAGTGATTGATTA 1595
|||||
Db 860 TTTTATATATGTTTATGTTTCACTTTTATTCATTTGGTTA 817
|||||

RESULT 61
AF011352/c
LOCUS
DEFINITION Petromyzon marinus trypsinogen A1 mRNA, complete cds.
ACCESSION AF011352
VERSION AF011352.1 GI:2293477
KEYWORDS
SOURCE Petromyzon marinus (sea lamprey)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia; Petromyzoniformes; Petromyzontidae; Petromyzon.
REFERENCE
AUTHORS Roach, J.C.
TITLE The molecular evolution of the vertebrate trypsinogenase
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 861)
AUTHORS Roach, J.C.
TITLE Direct Submission
JOURNAL Submitted (25-JUN-1997) Molecular Biotechnology, University of Washington, Seattle, WA 98195, USA
FEATURES
source
1. .861
/organism="Petryomyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/tissue_type="anterior intestine"
/dev_stage="ammocoete"
6. .749
/codon_start=1
/product="trypsinogen A1"

/protein_id="AAB65411.1"
/db_xref="GI:2293478"
/translation="MHGLILALLGVAAAPYMYEDHIVGSECAHSPQWQVSLNIG YHFCGSLINSQWVSAHCHYQASRISVRIGEHNI FVNEGTEQIQOAKAIQHPQYN SWITDNDIMLIKSSPATLNOYAOAIAPSSCVNTGYMCTISGNETQTSIGSPDVLN CVOAPVLSDTSCRNSYPGDI TNMMLICGLYEGGKSCQGDGSGPVCNGELQGVSWG RGCALPNYPGVYTKVCYNWIAQTIAAN"
6. .50
sig_peptide
evidence=not_experimental
51. .746
mat_peptide
/product="trypsin A1"
evidence=not_experimental

Query Match 0.98; Score 21.6; DB 1; Length 861;
Best Local Similarity 68.2%; Pred. No. 38;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1552 TTTTAAATATCTTCTTTGTTCTATCTATCTTTAGTGATTGATTA 1595
|||||
Db 860 TTTTATATATGTTTATGTTTCACTTTTATTCATTTGGTTA 817
|||||

RESULT 62
BC061149/c
LOCUS
DEFINITION Mus musculus coagulation factor VII, mRNA (cdna clone MGC:74281 INAGB:30305571), complete cds.
ACCESSION BC061149
VERSION BC061149.1 GI:38511701
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 1869)
AUTHORS Klausner, R.D., Feingold, E.A., Grouse, L.H., Derge, J.G., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Udwin, T.B., Toshiyuki, S., Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullany, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Helton, E., Kettelman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalls, D.E., Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
12477932
JOURNAL MEDLINE
PUBMED
REFERENCE 2 (bases 1 to 1869)
AUTHORS Strausberg, R.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA
REMARK
COMMENT NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgapbs@mail.nih.gov
Tissue Procurement: Dr. Michael Brownstein
cDNA Library Preparation: Michael Brownstein / Ted Usdin
Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LINL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome

Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: <http://www-shgc.stanford.edu>
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAL Plate: 53 Row: n Column: 1
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6753805.

FEATURES
source
1..1869
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="MGC:74281 IMAGE:30305571"
/tissue_type="Liver, mouse"
/clone_lib="NIH MGC_177"
/lab_host="DH10B"
/note="Vector: pDNR-LTB"

gene
1..1869
/gene="F7"
/note="Synonyms: FVII, mfVII"
/db_xref="LocuSID:14068"
/db_xref="MGI:109325"
10..1350
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAH61149.1"
/db_xref="GI:38511702"
/db_xref="LocuSID:14068"
/translation="VWPAQHLLLCFLQLQPLGTAFTVITQEEAHGVHLRQRANS
LLEELWPGLEBCEOCFEAREIFKSPERTKOFWIVSDQDCAQNPQNGGTC
QHLKSYVCFCLDEGRNCKSKNQLICANENGDCDOYCRDHVTKRTCSCHEDYT
LPDEVSCKPVEYPCGRIPVVEKNSRQGRIVGNVCPKGECPMAVLKINGILL
CGAVLDAAWIVTAHCFDNIYRWGNITVWGEHDFSEKDGDEQVRVTVQVIMPKYI
RGKINHDIALLRLMTQDCLRAKHSNTPKITENMFCAGYMDGTDKACKDGGGPHAT
ALELMSIEYPLWMTQDCLRAKHSNTPKITENMFCAGYMDGTDKACKDGGGPHAT
YHGTWLTGWSWEGCAAGHIGVYTRVSYQVLDLVRHMDSKLQGVFRLPL"

misc_feature
79..264
/note="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues"
/db_xref="CDD:smart00069"
268..378
/note="EGF CA; Region: Calcium-binding EGF-like domain,
present in a large number of membrane-bound and
extracellular (mostly animal) proteins. Many of these
proteins require calcium for their biological function and
calcium-binding sites have been found to be located at the
N-terminus of particular EGF-like domains"
/db_xref="CDD:cd00054"

misc_feature
589..1302
/note="Tryp SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 0.9%; Score 21.6; DB 1; Length 1869;
Best Local Similarity 68.2%; Pred. No. 39;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1593 TTTTCTTTTGGTTCTTGAATAATATTTCCCTGCTTTGA 1736
Db 1860 TTTTCTTTTGGTTCTTGAATAATATTTCTCAATTAATGA 1817

RESULT 63
AX839181
LOCUS AX839181 328 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 24 from Patent WO03076610.
ACCESSION AX839181
VERSION AX839181.1 GI:39922630
KEYWORDS Homo sapiens (human)
SOURCE

Query Match 0.9%; Score 21.6; DB 1; Length 1869;
Best Local Similarity 68.2%; Pred. No. 39;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1593 TTTTCTTTTGGTTCTTGAATAATATTTCCCTGCTTTGA 1736
Db 1860 TTTTCTTTTGGTTCTTGAATAATATTTCTCAATTAATGA 1817

RESULT 63
AX839181
LOCUS AX839181 328 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 24 from Patent WO03076610.
ACCESSION AX839181
VERSION AX839181.1 GI:39922630
KEYWORDS Homo sapiens (human)
SOURCE

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Bracco, L., Brinkman, B. and Coignard, F.
Variants of human kallikrein-2 and kallikrein-3 and uses thereof
Patent: WO 03076610-A 24 18-SEP-2003;
Exonhit Therapeutics S.A. (FR)
Location/Qualifiers
1..328
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.4; DB 1; Length 328;
Best Local Similarity 52.9%; Pred. No. 40;
Matches 46; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

Qy 2136 CTGTGCTTACGCTATGTTGCAATTCAGGGCTATTGTAATAGGTTTACAGGACA 2195
Db 190 CTGGTGACCCCACTGGTCTCTCAGCTGCCCTCATCAGGAAGTAGTAGGGCC 249

Qy 2196 TATTGTCCTGGTTGTTATTGTCGTGT 2222
Db 250 TGGGCTCTGGGAGCAGGTGCTGTGT 276

RESULT 64
AX464088/c
LOCUS AX464088 1129 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 221 from Patent WO0140466.
ACCESSION AX464088
VERSION AX464088.1 GI:21899060
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,
Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L.,
Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K.,
Wood, W.L. and Zhang, Z.
Secreted and transmembrane polypeptides and nucleic acids encoding
same
Patent: WO 0140466-A 221 07-JUN-2001;
Genentech Inc. (US)
Location/Qualifiers
1..1129
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 43;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1987
Db 1129 TTTTCTTTTTCATTTTCAGATTTCCTTCAGTTGGTTTGT 1083

RESULT 65
AY359106/c
LOCUS AY359106 1129 bp mRNA linear PRI 03-OCT-2003
DEFINITION Homo sapiens clone DNA99391 MPN (UNQ1884) mRNA, complete cds.
ACCESSION AY359106
VERSION AY359106.1 GI:37183328
KEYWORDS FLI CDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 43;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1987
Db 1129 TTTTCTTTTTCATTTTCAGATTTCCTTCAGTTGGTTTGT 1083

RESULT 65
AY359106/c
LOCUS AY359106 1129 bp mRNA linear PRI 03-OCT-2003
DEFINITION Homo sapiens clone DNA99391 MPN (UNQ1884) mRNA, complete cds.
ACCESSION AY359106
VERSION AY359106.1 GI:37183328
KEYWORDS FLI CDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE	1 (bases 1 to 1129)
AUTHORS	Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J., Chen,J., Chow,B., Chui,C., Crowley,C., Currell,B., Deuel,B., Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E., Heldens,S., Huang,A., Kim,H.S., Kilmowski,L., Jin,Y., Johnson,S., Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C., Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V., Stinson,J., Vagts,A., Vandlen,R., Watanabe,C., Wicand,D., Woods,K., Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z., Goddard,A., Wood,W.I. and Godowski,P.
TITLE	The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment
JOURNAL	Genome Res. 13 (10), 2265-2270 (2003)

PUBMED
12975309
REFERENCE
2 (bases 1 to 1129)
AUTHORS
Clark, H.F.
TITLE
Direct Submission
JOURNAL
Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
Inc., 1 DNA Way, South San Francisco, CA 94080, USA

FEATURES	source
Location/Qualifiers	
1..1129	
/organism="Homo sapiens"	
/mol_type="mRNA"	
/db_xref="taxon:9606"	
/clone="DNA93391"	
1..1129	
/locus tag="UNQ1884"	
36..908	
/locus tag="UNQ1884"	
/note="PRO4327"	
/codon_start=1	
/product="MPN"	
/protein_id="AAQ89454.1"	
/db_xref="GI:37183329"	
/translation="MRPRAVPLLLLCFSQRAKATACGRPMLNRWVGQDTQEG EWPQVSIQRNGSHFCGGSLIAEQWLTAHCFRNTSETSLYQLLGARQLVQVGGHHA MTARVQSNPLIYQTASSADVALVEAPFTNYILPVCILPDPFSVIFETGMNCWV TWGVSDEDLPEPRLIQKLAVPIIDTPKNNLLYSKDTDFGYQPKTIKNDMLCAGFE EGKKDAGKDGSGGGLVCLYQSGMLQAGVISWEGCARQNRNPYIVRTAHNNWTHRII PKLQFQAPRLGGOK"	

	Query Match	0.9%	Score 21.4;	DB 1;	Length 1129;
	Best Local Similarity	66.0%;	Pred. No. 43;		
	Matches 31;	Conservative 0;	Mismatches 16;	Indels 0;	Gaps 0;
QY	1941	TTCTTAATTTTTTCATTTCCAGATTCCCTTCAGTTTGGGTTTTGGTT	1987		
DB	1129	TTTTTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGCTGGGTTTTTATT	1083		

[illegible]

```

FEATURES
source
Location/Qualifiers
1..6098
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Plasmid DNA pLN174"

```

	Query Match Best Local Similarity Matches	0.9%; Score 21.4; DB 1; Length 6098; 49.5%; Pred. No. 44; 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0
QY	1642	TTTGTATGCTTCTGTACCTTGATAGCATCTCTTCTCAAGGTTAGGAATTTTCTTT 1701
Db	4429	TTTTACGGTTCCTGGCCCTTTGGTGCCCTTTTGCTCACATGTTCTTTCCTCGCGTATCC 4488
QY	1702	TTTGGTTTTCTTGAAATAATTTTCCCTGCCTTTTACCTGCTCTTCTTCGCCCT 1752
Db	4489	CCTGATCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCT 4539
RESULT 67		
AX265101/c		
LOCUS	AX265101	121 bp DNA linear PAT 26-OCT-2001
DEFINITION	Sequence 2492 from Patent W00173002.	

ACCESSION	AX265101
VERSION	AX265101.1
KEYWORDS	GI:16513900
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Kniec, E.B., Gamber, H.B. and Rice, M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2492 04-OCT-2001; UNIVERSITY OF DELAWARE (US)
FEATURES	Location/Qualifiers
source	1. .121

Query Match	0.9%;	Score 21.2;	DB 1;	Length 121;
Best Local Similarity	53.7%;	Pred. No. 42;		
Matches 44;	Conservative 0;	Mismatches 38;	Indels 0;	Gaps 0;
<pre> /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606" </pre>				
QY	2168	CTATTGTAATAGGGTTTTAGCAGGACAVATTGCTCGTGGTTGTTATGTCGTGTTTTG	2227	
Db	83	CCATTAAACATGGATTGGACTCACACTGATCCATCTTTGAGATAGGTTAGAAATTG	24	
QY	2228	CTTTGGCATATAGCGGCTGAG	2249	
Db	23	AATTGGCAGGTAACGCTTAG	2	

RESULT	68
AX265102	
LOCUS	121 bp DNA linear PAT 26-OCT-2001
DEFINITION	Sequence 2493 from Patent WO0173002.
ACCESSION	AX265102
VERSION	AX265102.1 GI:16513901
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Kmiec,E.B., Gamper,H.B. and Rice,M.C. Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
AUTHORS	Patent: WO 0173002-A 2493 04-OCT-2001;
TITLE	UNIVERSITY OF DELAWARE (US)
JOURNAL	Location/Qualifiers
FEATURES	1 121
	source

```

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

Query Match 0.9%; Score 21.2; DB 1; Length 121;

REFERENCE AUTHORS

[illegible]

AX524243
LOCUS AX524243 341 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 273 from Patent EP1236798.
ACCESSION AX524243
VERSION AX524243.1 GI:25169339
KEYWORDS
SOURCE
ORGANISM Mus musculus (house mouse)
REFERENCE
AUTHORS 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE Hofer, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and Schluter, T.
JOURNAL Gene library and method for its production
PATENT: EP 1236798-A 273 04-SEP-2002;
LION Bioscience AG (DE)
FEATURES
source
1. .341
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.9%; Score 20.6; DB 1; Length 341;
Best Local Similarity 53.0%; Pred. No. 64;
Matches 44; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 2133 TGCCTTGTGCTTCAGCTATGTTGCTATCTCAGGCGCTATTGTAATAGGTTTACGAGG 2192
Db 213 TGTCTTGTGCTTCAGCTATCTCCTGCACACATGACATCTGTGACTTCTGTAGGT 272
QY 2193 ACATATGTCCTGTTGTTATTG 2215
Db 273 AGACTTGGCACAGTTCTCATTG 295
RESULT 78
AX552981
LOCUS AX552981 341 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 273 from Patent WO02074953.
ACCESSION AX552981
VERSION AX552981.1 GI:25896981
KEYWORDS
SOURCE
ORGANISM Mus musculus (house mouse)
REFERENCE
AUTHORS 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE Hofer, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and Schluter, T.
JOURNAL Gene library and a method for producing the same
PATENT: WO 02074953-A 273 26-SEP-2002;
LION Bioscience AG (DE)
FEATURES
source
1. .341
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.9%; Score 20.6; DB 1; Length 341;
Best Local Similarity 53.0%; Pred. No. 64;
Matches 44; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 2133 TGCCTTGTGCTTCAGCTATGTTGCTATCTCAGGCGCTATTGTAATAGGTTTACGAGG 2192
Db 213 TGTCTTGTGCTTCAGCTATCTCCTGCACACATGACATCTGTGACTTCTGTAGGT 272
QY 2193 ACATATGTCCTGTTGTTATTG 2215
Db 273 AGACTTGGCACAGTTCTCATTG 295
RESULT 79
E63001/c

E63001
LOCUS E63001 1206 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63001
VERSION E63001.1 GI:18633643
KEYWORDS JP 2001061479-A/5.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 1206)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 5 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/5
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR
PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO NAKAGAKI,
SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC A61K37/465
CC
FH Key Location/Qualifiers
FT source 1. .1206
/organism="Artificial Sequence".
FEATURES
source
1. .1206
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTGTTGAAATATGTAATTTGG 498
Db 444 TTTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGG 386
RESULT 80
E63002/c
LOCUS E63002 1206 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63002
VERSION E63002.1 GI:18633644
KEYWORDS JP 2001061479-A/6.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 1206)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 6 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/6
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR
PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO NAKAGAKI,
SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC A61K37/465
CC
FH Key Location/Qualifiers
FT source 1. .1206
/organism="Artificial Sequence".
FEATURES
source
1. .1206

/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.9%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 69; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATTCAAATTTGG 498
DB 444 TTGCTGGCAATTCCTTTTCTAGAATAGGTATTTTCCACATGGATATTCAACTGTGG 386

RESULT 81
E62997/c
LOCUS Hemocoagulation factor VII modification. linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62997
VERSION E62997.1 GI:18633639
KEYWORDS JP 2001061479-A/1.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 1 13-MAR-2001;
JURIDICAL FOUNDATION THE CHERO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS blood coagulation factor VII
PN JP 2001061479-A/1
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
PI NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism="synthetic construct"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:32630"

FEATURES
source

Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 69; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATTCAAATTTGG 498
DB 444 TTGCTGGCAATTCCTTTTCTAGAATAGGTATTTTCCACATGGATATTCAACTGTGG 386

RESULT 82
E62998/c
LOCUS Hemocoagulation factor VII modification. linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62998
VERSION E62998.1 GI:18633640
KEYWORDS JP 2001061479-A/2.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 2 13-MAR-2001;
JURIDICAL FOUNDATION THE CHERO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence

PN JP 2001061479-A/2
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
PI NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism="synthetic construct"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:32630"

FEATURES
source

Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 69; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATTCAAATTTGG 498
DB 444 TTGCTGGCAATTCCTTTTCTAGAATAGGTATTTTCCACATGGATATTCAACTGTGG 386

RESULT 83
E62999/c
LOCUS Hemocoagulation factor VII modification. linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62999
VERSION E62999.1 GI:18633641
KEYWORDS JP 2001061479-A/3.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 3 13-MAR-2001;
JURIDICAL FOUNDATION THE CHERO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/3
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
PI NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism="synthetic construct"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:32630"

FEATURES
source

Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 69; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATTCAAATTTGG 498
DB 444 TTGCTGGCAATTCCTTTTCTAGAATAGGTATTTTCCACATGGATATTCAACTGTGG 386

RESULT 84

E63000/c
LOCUS AR112969/c
DEFINITION AR112969
ACCESSION AR112969
VERSION AR112969.1
KEYWORDS GI:14093291
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Combined tissue factor and factor VIIA methods and compositions for
JOURNAL coagulation and tumor treatment
COMMENT Patent: US 6132730-A 13 17-OCT-2000;
PN JP 2001061479-A/4
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAAKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred.No.69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCATTTGG 498
Db
444 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 386
RESULT 85
AR112953/c
LOCUS AR112953
DEFINITION AR112953
ACCESSION AR112953
VERSION AR112953.1
KEYWORDS GI:14093275
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Combined tissue factor and chemotherapeutic methods and
JOURNAL compositions for coagulation and tumor treatment
COMMENT Patent: US 6132729-A 13 17-OCT-2000;
PN JP 2001061479-A/4
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAAKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred.No.69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCATTTGG 498
Db
444 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 386
RESULT 86
AR112953/c
LOCUS AR112953
DEFINITION AR112953
ACCESSION AR112953
VERSION AR112953.1
KEYWORDS GI:14093275
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Combined tissue factor and chemotherapeutic methods and
JOURNAL compositions for coagulation and tumor treatment
COMMENT Patent: US 6132729-A 13 17-OCT-2000;
PN JP 2001061479-A/4
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAAKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred.No.69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCATTTGG 498
Db
444 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 386
RESULT 86
AR112953/c
LOCUS AR112953
DEFINITION AR112953
ACCESSION AR112953
VERSION AR112953.1
KEYWORDS GI:14093275
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Combined tissue factor and chemotherapeutic methods and
JOURNAL compositions for coagulation and tumor treatment
COMMENT Patent: US 6132729-A 13 17-OCT-2000;
PN JP 2001061479-A/4
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAAKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

AR112969/c
LOCUS AR112969
DEFINITION AR112969
ACCESSION AR112969
VERSION AR112969.1
KEYWORDS GI:14093291
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Combined tissue factor and factor VIIA methods and compositions for
JOURNAL coagulation and tumor treatment
COMMENT Patent: US 6132730-A 13 17-OCT-2000;
PN JP 2001061479-A/4
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAAKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred.No.69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCATTTGG 498
Db
659 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 601
RESULT 87
I19358/c
LOCUS I19358
DEFINITION I19358
ACCESSION I19358
VERSION I19358.1
KEYWORDS GI:1599713
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Morrissey,J.H. and Comp,P.C.
TITLE Treatment of bleeding with modified tissue factor in combination
JOURNAL with an activator of FVII
COMMENT Patent: US 5504064-A 3 02-APR-1996;
PN US 5504064-A 3 02-APR-1996;
PD 02-APR-1996
PF 02-APR-1996
PR Morrissey,J.H. and Comp,P.C.
NA Morrissey,J.H. and Comp,P.C.
PI Morrissey,J.H. and Comp,P.C.
PC US 5504064-A 3 02-APR-1996;
CC
FH Key Location/Qualifiers
FT source 1..1440
FT /organism="unknown"
FT /mol_type="unassigned DNA"
FEATURES
source
Location/Qualifiers
1..1440
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred.No.69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCATTTGG 498
Db
659 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 601
RESULT 88
I19360/c
LOCUS I19360
DEFINITION I19360
ACCESSION I19360
VERSION I19360.1
KEYWORDS GI:1599715
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Morrissey,J.H. and Comp,P.C.
TITLE Treatment of bleeding with modified tissue factor in combination
JOURNAL with FVII
COMMENT Patent: US 5504067-A 3 02-APR-1996;
PN US 5504067-A 3 02-APR-1996;
PD 02-APR-1996
PF 02-APR-1996
PR Morrissey,J.H. and Comp,P.C.
NA Morrissey,J.H. and Comp,P.C.
PI Morrissey,J.H. and Comp,P.C.
PC US 5504067-A 3 02-APR-1996;
CC
FH Key Location/Qualifiers
FT source 1..1440
FT /organism="unknown"
FT /mol_type="unassigned DNA"
FEATURES
source
Location/Qualifiers
1..1440
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred.No.69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCATTTGG 498
Db
659 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 601
RESULT 89
I19360/c
LOCUS I19360
DEFINITION I19360
ACCESSION I19360
VERSION I19360.1
KEYWORDS GI:1599715
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1440)
AUTHORS Morrissey,J.H. and Comp,P.C.
TITLE Treatment of bleeding with modified tissue factor in combination
JOURNAL with FVII
COMMENT Patent: US 5504067-A 3 02-APR-1996;
PN US 5504067-A 3 02-APR-1996;
PD 02-APR-1996
PF 02-APR-1996
PR Morrissey,J.H. and Comp,P.C.
NA Morrissey,J.H. and Comp,P.C.
PI Morrissey,J.H. and Comp,P.C.
PC US 5504067-A 3 02-APR-1996;
CC
FH Key Location/Qualifiers
FT source 1..1440
FT /organism="unknown"
FT /mol_type="unassigned DNA"
FEATURES
source
Location/Qualifiers
1..1440
/organism="unknown"
/mol_type="unassigned DNA"

```

source
1. .1440
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1440;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTTCAATTGG 498
Db 659 TTTCGCTGCAATTCCTTTTCTAGATAGGATTTTCCACATGGATATTCACCTGG 601

RESULT 89
BD194674/c
LOCUS BD194674
DEFINITION Tissue factor methods and compositions for coagulation and tumor treatment.
ACCESSION BD194674
VERSION BD194674.1 GI:33004420
KEYWORDS JP 2002514201-A/3.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Tissue factor methods and compositions for coagulation and tumor treatment
JOURNAL Patent: JP 2002514201-A 3 14-MAY-2002;
BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
COMMENT OS Mammalian
PN JP 2002514201-A/3
PD 14-MAY-2002
PR 20-JAN-1998 JP 1998534630
PR 22-JAN-1997 US 60/035920,27-JAN-1997 US 60/036205 PR
27-MAR-1997 US 60/042427
PI PHILIP E THORPE,STEVEN W KING,BONING GAO
PC A61K47/48
CC Tissue factor methods and compositions for coagulation and CC
tumor treatment

FH Key Location/Qualifiers
FT source 1. .1440
FT /organism="Mammalian".

FEATURES
source
Location/Qualifiers
1. .1440
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1440;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTTCAATTGG 498
Db 659 TTTCGCTGCAATTCCTTTTCTAGATAGGATTTTCCACATGGATATTCACCTGG 601

RESULT 90
AX565990/c
LOCUS AX565990
DEFINITION Sequence 2 from Patent WO02077218.
ACCESSION AX565990
VERSION AX565990.1 GI:26001242
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Persson,E.
TITLE Coagulation factor vii derivatives
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;
NOVO NORDISK A/S (DK)

source
1. .6098
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Plasmid DNA pLN174"

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 6098;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTTCAATTGG 498
Db 728 TTTCGCTGCAATTCCTTTTCTAGATAGGATTTTCCACATGGATATTCACCTGG 670

RESULT 91
AX908508
LOCUS AX908508
DEFINITION Sequence 24371 from Patent EP1033401.
ACCESSION AX908508
VERSION AX908508.1 GI:40064588
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE Expressed sequence tags and encoded human proteins
JOURNAL Patent: EP 1033401-A 24371 06-SEP-2000;
Genset (FR)

FEATURES
source
Location/Qualifiers
1. .223
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 20.4; DB 1; Length 223;
Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1102 TTGCACCTTGTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1161
Db 4 TTGCACCTTGTGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 63
QY 1162 TG 1163
Db 64 AG 65

RESULT 92
BD044041
LOCUS BD044041
DEFINITION Sequence tag and encoded human protein.
ACCESSION BD044041
VERSION BD044041.1 GI:22585783
KEYWORDS JP 2001269182-A/20287.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 223)
AUTHORS Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
TITLE Sequence tag and encoded human protein
JOURNAL Patent: JP 2001269182-A 20287 02-OCT-2001;
GENSET
COMMENT OS Homo sapiens (human)
PN JP 2001269182-A/20287
PD 02-OCT-2001
PF 24-FEB-2000 JP 2000118773
PF 26-FEB-1999 US 60/122487
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,EIMERIC DUCLAIR,JEAN YVES

```

FEATURES

RESULT 97

```

QY 38 CAATGGTGTGTTGATGTGGTAGTATCTCATACAGAGGATAGCACTAGATGCTGTCTGGG 97
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
272 CACTGGCTAGAGAGGACTAGAGAGGACAGAGAGAGGGGGGATATGGATCTCTGAT 213

QY 98 ACATAGGTAACTTTCAGAGAGACT 123
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 99
AF465269/c 1416 bp mRNA linear VRT 02-FEB-2003
LOCUS
DEFINITION Gallus gallus coagulation factor IX precursor (F9) mRNA, complete
cds.
ACCESSION AF465269
VERSION AF465269.1 GI:28194009
KEYWORDS
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus
1 (bases 1 to 1416)
Davidson,C.J., Hirte,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
2 (bases 1 to 1416)
McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
FEATURES
Location/Qualifiers
1..1416
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1..1416
/genes="F9"
1..1416
/gene="F9"
/EC number="3.4.21.22"
/function="converts factor X to its active form in the
presence of Ca++ ions, phospholipids, and factor VIIIa"
/note="vitamin K dependent serine protease; chistmas
factor; contains 2 EGF-like domains; member of peptidase
family S1/trypsin family"
/codon_start=1
/product="coagulation factor IX precursor"
/protein_id="AA033364.1"
/db_xref="GI:28194010"
/translations="MAKIPULIFCLLEAPLGAESTVFIENKEASTVLSRTRGNSNR
LEELIPGNLERECIEKCEFEAREVENTKTEFWKIYIDGQNSNPCKNGLGVCK
DGVSVEYCCPGYGRNEIDSTCATKGGCHFCRHDTPOKAVCSAGYKLHEDG
KSKCAPVPYPCGRITAPENMRGKVTRENTIERNWITAHDEGAHDAIDITEPPPTT
TSAAPAKIYVPIKNDTRVGVYDVKQQLPWQVHLVDSRGLFCGSGIINEKRVVTA
HCLRGDNTAVAGENTKEDDTEQRQVKKLPYPTNRTNRKHHNDLLELDQP
LIFNSTVTPICIGSRDFTNNLNSGPTVSGWGMYSRISAILQVLTVPFVDRVC
LKSTSTLILHSMFCAGTYAGGDKTCGDSGGPYTNSIGETWLTGTSWGECAKPGK
YGIYTKVYKVIWIRETRLT"

Query Match 0.9%; Score 20.4; DB 1; Length 1416;
Best Local Similarity 53.8%; Pred. No. 77;
Matches 42; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 24 GGGGCTGAGGCTCCCAATGTTGTTGATGTGGTAGATATCTCATACAGAGGATAGCACT 83
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
408 GTGCTCGAGCCCCCATTTTCTGATAGACAGATAGATCTATCTCAGATCTCTGCTCTC 349

QY 84 AGATGCTGTCTGGGACAT 101
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

```

```

Db 348 ATAACCAGGTGGGCACAT 331
2072 bp mRNA linear PRI 07-FEB-2003
LOCUS
DEFINITION Homo sapiens factor VII active site mutant immunoconjugate mRNA,
complete cds.
ACCESSION AF272774
VERSION AF272774.2 GI:28269793
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 2072)
Hu,Z. and Garen,A.
Targeting tissue factor on tumor vascular endothelial cells and
tumor cells for immunotherapy in mouse models of prostatic cancer
Proc. Natl. Acad. Sci. U.S.A. 98 (21), 12180-12185 (2001)
21477448
PUBMED 11593034
2 (bases 1 to 2072)
Hu,Z. and Garen,A.
Direct Submission
Submitted (26-MAY-2000) Department of Molecular Biophysics and
Biochemistry, Yale University, 266 Whitney Ave., New Haven, CT
06520, USA
3 (bases 1 to 2072)
Hu,Z. and Garen,A.
Direct Submission
Submitted (07-FEB-2003) Department of Molecular Biophysics and
Biochemistry, Yale University, 266 Whitney Ave., New Haven, CT
06520, USA
REMARK
COMMENT On Feb 7, 2003 this sequence version replaced gi:14279677.
FEATURES
Location/Qualifiers
1..2072
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
22..2061
/note="hVITasm"
/codon_start=1
/product="factor VII active site mutant immunoconjugate"
/protein_id="AAK58686.2"
/db_xref="GI:28269794"
/translations="MVSOALRLCLLGLGCLAAVFTQEEAHGVLHRRRANAFLE
ELRPGSLERECEEQCSFEAREHFKDAERTKLFWISYSDGQCASSPQNGSCDKQ
LQSYICFLPAPEGRNCEHKKDQLICVNEGCEQYCSHDHTGKSCRCHEGYSLLA
DGVSCTPTVEYPCGKIPILKRNASKPQGRIVGGKVCPRGECTPWVLLVNGAQLCGG
TLNTIIVWSAAACFDKIKNRNLIAVGEHDLSEHDGDEQRRVAQVLIIPSTVPGT
TNHIDALLHQVVLTDHVPCLPRTFERTLAFVFSLVSGWGLLDGRTALE
LWLVNVRMTQDCLQSKRVGDSNPIEYMFCAYSKDSKSCAGSGGPHATHYRG
TWLVGIVSWGCGCATVGFHYTRVSVQIEMLQKMRSEPRFGLVLRAPFPQSAEPK
SDKHTGCPFAPELLGGSVFLFPFKDKTLMISRTPEVTVCVVVDVSHDEDEVFKN
WYWDVENVNAKTRPEEQYNSYTRVSVLTHQDLNGKEYKCVSKNALPAPIEK
TTSKAGQPREPQVTLTPSRDELTKNQSLATCLVKGFPSPDIADVWESNGQENNVK
TTPPVLDSGSPFLYSKLTVDKSRMQQGVFSCSVNHEALHNHYTKSLSLSPGK"

Query Match 0.9%; Score 20.4; DB 1; Length 2072;
Best Local Similarity 61.1%; Pred. No. 77;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 445 TTGCTCTTTTATCTGTCGAGACTTGTCTTTTGAATATGATTCATTTGCG 498
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
574 TGGCATTTCTTTTCTAGAAAGTAGTATTTTCCACATGATGATTCACATGTGG 521

RESULT 101
AF272773/c 2078 bp mRNA linear SYN 17-AUG-2000
LOCUS
DEFINITION Synthetic construct mutated mouse factor VII molecule

```


[illegible]

<p>RESULT 106</p>		<p>AY023221 227 bp DNA linear PLN 07-FEB-2001</p>	
<p>LOCUS Oryza sativa microsatellite MRG5546 containing (GCT)X9, closest to marker G132, genomic sequence.</p>			
<p>ACCESSION AY023221 GI:12706437</p>			
<p>KEYWORDS Oryza sativa</p>			
<p>SOURCE Oryza sativa</p>			
<p>ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoidae; Oryzeae; Oryza.</p>			
<p>REFERENCE 1 (bases 1 to 227)</p>			
<p>AUTHORS Tao,N., Barbazuk,W.B., Liu,J., Wu,K. and Barry,G.F.</p>			
<p>TITLE Simple sequence repeats from Monsanto rice genomic sequences unpublished</p>			
<p>JOURNAL JOURNAL</p>			
<p>REFERENCE 2 (bases 1 to 227)</p>			
<p>AUTHORS Tao,N., Barbazuk,W.B., Liu,J., Wu,K. and Barry,G.F.</p>			
<p>JOURNAL Direct Submission</p>			
<p>TITLE Submitted (10-JAN-2001) Genomics, Monsanto, 800 North Lindbergh Blvd., Creve Coeur, MO 63167, USA</p>			
<p>COMMENT Derived from rice genomic sequences generated from the Monsanto Rice Genome Sequencing project. Please see http://www.rice-research.org for more information. The sequence data were produced primarily in the laboratories of Dr. Leroy Hood at the University of Washington in Seattle.</p>			
<p>FEATURES</p>			
<p>source Location/Qualifiers</p>			
<p>1..227 /organism="Oryza sativa"</p>			
<p>/mol_type="genomic DNA"</p>			
<p>/db_xref="taxon:4530"</p>			
<p>repeat_region 1..227</p>			
<p>/note="microsatellite MRG5546"</p>			
<p>/rpt_type=tandem</p>			
<p>/rpt_unit="gct"</p>			
<p>Query Match 0.9%; Score 20.2; DB 1; Length 227;</p>			
<p>Best Local Similarity 63.3%; Pred. No. 80;</p>			
<p>Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;</p>			
<p>Qy 140 TGAAGCCTCTCGTGCATATCTTCGGGCTGCTGCTTTCCCTCTC 188</p>			
<p>Db 103 TGCTGCTCTGCTGTCTGCTACTGCTGCTGCTCTCTCTCTCTGTC 151</p>			
<p>RESULT 107</p>			
<p>HUMPS01/c</p>			
<p>LOCUS Homo sapiens protein S alpha (PROS1) gene, exon 2.</p>			
<p>DEFINITION M36551 J02918</p>			
<p>ACCESSION M36551.1 GI:190427</p>			
<p>VERSION i of 14</p>			
<p>KEYWORDS Homo sapiens (human)</p>			
<p>SEGMENT</p>			
<p>SOURCE</p>			
<p>ORGANISM Homo sapiens</p>			
<p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>			
<p>REFERENCE 1 (bases 1 to 272)</p>			
<p>AUTHORS Ploos van Amstel,H.K., Reitsma,P.H., van der Logt,C.P. and Bertina,R.M.</p>			
<p>TITLE Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution</p>			
<p>JOURNAL Biochemistry 29 (34), 7853-7861 (1990)</p>			
<p>MEDLINE 91084445</p>			
<p>PUBMED 2148111</p>			
<p>COMMENT Original source text: Human DNA. Draft entry and computer-readable sequence for [Biochemistry 29, 7853-4861 (1990)] kindly submitted by H.K.Ploos van Amstel, 13-JUL-1990.</p>			


```

RESULT 109
ARI08139/c
LOCUS
DEFINITION
Sequence 1 from patent US 6110721.
ACCESSION
ARI08139
VERSION
ARI08139.1 GI:12823626
KEYWORDS
SOURCE
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 885)
AUTHORS
Gibbs,C.S., Leung,L.L.K. and Tsiang,M.
TITLE
Polypeptides and coagulation therapy
JOURNAL
Patent: US 6110721-A 1 29-AUG-2000;
FEATURES
Location/Qualifiers
source
1..885
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 20.2; DB 1; Length 885;
Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 167 GGCTGCGCTTCTCCCTGTCGATTCCTAGGCTGAGGTTACCACTG 215
|||||
Db 489 GGCTGCGCTTCTCCCTGTCGCGCAGACACACAGGCTGAATGTAGTCACTG 441

RESULT 110
AX401899/c
LOCUS
DEFINITION
Sequence 1575 from Patent WO0210453.
ACCESSION
AX401899
VERSION
AX401899.1 GI:21338079
KEYWORDS
SOURCE
Rattus norvegicus (Norway rat)
ORGANISM
Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE
1
AUTHORS
Mendrick,D., Porter,M.W., Johnson,K.R., Castile,A.L. and
Eliashoff,M.R.
TITLE
Molecular Toxicology modeling
JOURNAL
Patent: WO 0210453-A 1575 07-FEB-2002;
Gene Logic, Inc. (US)
FEATURES
Location/Qualifiers
source
1..1543
/organism="Rattus norvegicus"
/mol_type="unassigned DNA"
/db_xref="taxon:10116"
/noe="EMBL/GenBank Accession No. NM_012803"

Query Match
Best Local Similarity 0.9%; Score 20.2; DB 1; Length 1543;
Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCCCTTTTACTAGGTGATGCTCTCATCGTAGGTTG 960
|||||
Db 1408 CATCCCTTTTCCCTATGTAGTGTGATCCATTGAGGTAG 1368

RESULT 111
RNPROC/c
LOCUS
DEFINITION
Rattus norvegicus mRNA for protein C precursor.
ACCESSION
X64336 S40352
VERSION
X64336.1 GI:56962
KEYWORDS
protein C.
SOURCE
Rattus norvegicus (Norway rat)
ORGANISM
Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

RESULT 112
AF011899/c
LOCUS
DEFINITION
Petromyzon marinus trypsinogen a3 (TRYP3) mRNA, complete cds.
ACCESSION
AF011899
VERSION
AF011899.1 GI:2367496
KEYWORDS
SOURCE
Petromyzon marinus (sea lamprey)
ORGANISM
Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE
1 (bases 1 to 855)
AUTHORS
Roach,J.C.
TITLE
The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL
Unpublished
REFERENCE
2 (bases 1 to 855)
AUTHORS
Roach,J.C.
TITLE
Direct Submission
JOURNAL
Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA
FEATURES
Location/Qualifiers

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 1543)
Okaforji,T., Maekawa,K., Nawa,K. and Marumoto,Y.
The cDNA cloning and mRNA expression of rat protein C
Biochim. Biophys. Acta 1131 (3), 329-332 (1992)
92329550
PUBMED
1627650
2 (bases 1 to 1543)
Okaforji,T.
Direct Submission
Submitted (03-FEB-1992) Okaforji,T., Mol Biology Research Lab,
Daiichi Pharmaceutical Co LTD, 16-13 Kitakasai 1-Chome, Edogawa-ku,
Tokyo 134, JAPAN
On Nov 19, 2003 this sequence version replaced gi:251769.
Location/Qualifiers
1..1543
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Wistar"
/db_xref="taxon:10116"
/clone="28000"
49..1434
/codon_start=1
/product="protein C precursor"
/protein_id="CAA45617.1"
/db_xref="GI:56963"
/db_xref="GOA:P31394"
/db_xref="SWISS-PROT:P31394"
/translators="MQPRIFLLPASTWIGISVSAHPDPVFSSEGAHQVLRVRANS
FLBVRAGSLERECMEICDFEAQIFQNVEDTLAFWIKYFDQDQSTPLDQCDSD
PCGGTCTDGLGFGSCDQKWEFGQCDKVRKNGCYHCLBETRRGROR
CAPGYELADHMHCRPTVPCGKLRKTRKIDPDELELGPRIVNGTL
TKQDSPQWAILDLSKKLACGGVLIHTSWLTAACHLESSKLTVRLGEVLRDRDP
WELDLDIKEVLVHPNVTNSNDIALRLSOPATLSKTLVPICLNSGLAELSQAG
QETVVTGWSQSKVDGRNRFTILFIRIPLAARNDCQVWNVVSENNLCAIGIG
DTRDADCGSGGPMVFFRGTWELVGLVSGEGCHLNNGVYTKVGSYLKWIHSYIG
ERDVSLKSPKL"
49..147
mat_peptide
169..1431
/product="protein C"
polyA_signal
1514..1519

Query Match
Best Local Similarity 0.9%; Score 20.2; DB 1; Length 1543;
Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCCCTTTTACTAGGTGATGCTCTCATCGTAGGTTG 960
|||||
Db 1408 CATCCCTTTTCCCTATGTAGTGTGATCCATTGAGGTAG 1368

RESULT 113
AF011899/c
LOCUS
DEFINITION
Petromyzon marinus trypsinogen a3 (TRYP3) mRNA, complete cds.
ACCESSION
AF011899
VERSION
AF011899.1 GI:2367496
KEYWORDS
SOURCE
Petromyzon marinus (sea lamprey)
ORGANISM
Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE
1 (bases 1 to 855)
AUTHORS
Roach,J.C.
TITLE
The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL
Unpublished
REFERENCE
2 (bases 1 to 855)
AUTHORS
Roach,J.C.
TITLE
Direct Submission
JOURNAL
Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA
FEATURES
Location/Qualifiers

```

	<pre>Unclassified. 1 (bases 1 to 1142) Darrow,A., Qi,J. and Andrade-Grodon,P. Zymogen activation system TITLE JOURNAL Patent: US 6420157-A 8 16-JUL-2002; FEATURES Location/Qualifiers source 1..1142 /organism="unknown" /mol_type="genomic DNA"</pre>	Query Match 0.9%; Score 20; DB 1; Length 1142; Best Local Similarity 58.3%; Pred. No. 96; Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
	<pre>QY 715 TGCCTGTTTATGAACCTGGGTGCACATTGTTTGTCAGCATTAAGAATTGCAAT 774 Db 1071 TGCITTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAAT 1130</pre>	
	<pre>RESULT 115 AR221273 AR221273 1166 bp DNA linear PAT 26-SEP-2002 LOCUS Sequence 2 from patent US 6426199. DEFINITION AR221273 ACCESSION AR221273 VERSION AR221273.1 GI:23328188 KEYWORDS Unknown. SOURCE Unknown.</pre>	
	<pre>REFERENCE Unclassified. AUTHORS Darrow,A., Qi,J. and Andrade-Grodon,P. TITLE DNA JOURNAL Patent: US 6426199-A 2 30-JUL-2002; FEATURES Location/Qualifiers source 1..1166 /organism="unknown" /mol_type="genomic DNA"</pre>	Query Match 0.9%; Score 20; DB 1; Length 1166; Best Local Similarity 58.3%; Pred. No. 96; Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
	<pre>QY 715 TCCTTGTTTTATGAACCTGGGTGCACATTGTTTGTCAGCATTAAGAATTGCAAT 774 Db 1095 TGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAAT 1154</pre>	
	<pre>RESULT 116 AR219284 AR219284 1169 bp DNA linear PAT 25-SEP-2002 LOCUS Sequence 7 from patent US 6420157. DEFINITION AR219284 ACCESSION AR219284 VERSION AR219284.1 GI:23320254 KEYWORDS Unknown. SOURCE Unknown.</pre>	
	<pre>REFERENCE Unclassified. AUTHORS Darrow,A., Qi,J. and Andrade-Grodon,P. TITLE Zymogen activation system JOURNAL Patent: US 6420157-A 7 16-JUL-2002; FEATURES Location/Qualifiers source 1..1169 /organism="unknown" /mol_type="genomic DNA"</pre>	Query Match 0.9%; Score 20; DB 1; Length 1169; Best Local Similarity 58.3%; Pred. No. 96; Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
	<pre>QY 715 TCCTTGTTTATGAACCTGGGTGCACATTGTTTGTCAGCATTAAGAATTGCAAT 774 Db 1098 TGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAAT 1157</pre>	
	<pre>Db</pre>	

	<pre>1..855 /organism="Petromyzon marinus" /mol_type="mRNA" /db_xref="taxon:7757" /dev_stage="ammocoete" /tissue_lib="anterior intestine" 1..855 /gene="TRYPA3" 1..744 /gene="TRYPA3" /codon_start=1 /product="trypsinogen a3" protein_id="AAB69655.1" /db_xref="GI:2367497" translation="MHGLIALLCVAAAAPVMVEDHIVGSSECAAHSOPMQWSLINIG YHFCCSLINSOWVAASHCYQTASRISVRIGEHNIFVNEGTQQIQASKALQHPOYN SWTIDNIMLKLSPPATLNOYAIAIPSSCVNTGVMTCSGWGETQTSVGSDFLM CVOADPLDSITSRNYPGDITNNMICLGYLEGGKDCSQSGSPVPVCNGELQGIVSWG RGCALPNPVGVTYKVCNYNAMIAQAIAAN" 1..45 /gene="TRYPA3" evidence=not_experimental 46..741 /gene="TRYPA3" /product="trypsin a3" evidence=not_experimental</pre>	Query Match 0.9%; Score 20; DB 1; Length 855; Best Local Similarity 65.9%; Pred. No. 96; Matches 29; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
	<pre>QY 1552 TTITTATATCTTCTTTGTTCTATACTTTTAGTGATTGGATTA 1595 Db 855 TTTTITTTTITTTGTTAGTTTCACATTTTATTCATTTGGITA 812</pre>	
	<pre>RESULT 113 AR234337 AR234337 1130 bp DNA linear PAT 20-DEC-2002 LOCUS Sequence 8 from patent US 6458564. DEFINITION AR234337 ACCESSION AR234337 VERSION AR234337.1 GI:2727021 KEYWORDS Unknown. SOURCE Unknown.</pre>	
	<pre>REFERENCE Unclassified. AUTHORS Darrow,A., Qi,J. and Andrade-Grodon,P. TITLE DNA encoding the human serine protease T JOURNAL Patent: US 6458564-A 8 01-OCT-2002; FEATURES Location/Qualifiers source 1..1130 /organism="unknown" /mol_type="genomic DNA"</pre>	Query Match 0.9%; Score 20; DB 1; Length 1130; Best Local Similarity 58.3%; Pred. No. 96; Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
	<pre>QY 715 TCCTTGTTTATGAACCTGGGTGCACATTGTTTGTCAGCATTAAGAATTGCAAT 774 Db 1059 TGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAAT 1118</pre>	
	<pre>RESULT 114 AR219285 AR219285 1142 bp DNA linear PAT 25-SEP-2002 LOCUS Sequence 8 from patent US 6420157. DEFINITION AR219285 ACCESSION AR219285 VERSION AR219285.1 GI:23320255 KEYWORDS Unknown. SOURCE Unknown.</pre>	

[illegible]

```

RESULT 117
AF515269/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AF515269
Danio rerio coagulation factor VIII mRNA, complete cds.
AF515269
AF515269.1 GI:25005098
Danio rerio (zebrafish)
Danio rerio
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
Cypriniformes; Cyprinidae; Danio.
1 (bases 1 to 1722)
Hanumanthaiah, R., Day, K. and Jagadeeswaran, P.
Comprehensive analysis of blood coagulation pathways in teleostei:
Evolution of coagulation factor genes and identification of
zebrafish factor VIII
2 (bases 1 to 1722)
Blood Cells Mol. Dis. (2002) In press
Jagadeeswaran, P. and Hanumanthaiah, R.
Direct Submission
Submitted (24-MAY-2002) Cellular & Structural Biology, University
of Texas Health Science Center at San Antonio, 7703 Floyd Curl
Drive, San Antonio, TX 78229, USA
Location/Qualifiers
1..1722
/organism="Danio rerio"
/mol_type="mRNA"
/db_xref="taxon:7955"
27..1358
/notes="clotting factor"
/codon_start=1
/product="coagulation factor VIII"
/protein_id="AA017000.1"
/db_xref="GI:125005099"
EMBL|NCBI|ECC|DDB|EBI|FBI|GDB|HDB|JGI|KNA|LDB|PDB|SDB|TDB|VDB|WDB|YDB|ZDB|
TRANSLATION="MTLGAVALLLCVLTSTSAVFLSKDEASALLQRRFRANSGLFLE
ADSYCLCESEYGEKYEKLETLKQYNGCEQFCDSGARRSCSAGYALADD
GTSVQVDPYPCQKIPVKNTSONQFLGHCPRGCPQWLVLDYNGESVCGGALLDG
PWLTAHCHQKADTFLKAVTGDEHLDVLDGSEEPYSAVFIFHNPDPETLDSLA
LKLRLVPSRLSYAVPICLPTPOLARSELMAARFHTLSGWTGTAGHNLRRKELKGP
ASGLQLRALVPLPAACQGNANTTANNFCAGYEGDHASCGRHDSGLVTRYGETSFL
TGVVSWGRGCGPGYWIYTKVENFLIMDVTWKTNEDKSEQIANVSKN"

Query Match
Best Local Similarity 0.9%; Score 20; DB 1; Length 1722;
Matches 50; Conservative 0; Mismatches 50; Indels 0; Gaps 0;

QY 964 TTTTGGATGCACAGTAGGATGATCTTTGTTTATATCCATTCCTGTTACCCAGATCTT 1023
Db 1354 TTTTGTGGAACATAGCAATCTGCTGCTCTTATCTTCAGTGTGTCTTCATAACC 1295

QY 1024 TTTTGTAGAGAAATTAAGATCATGAGTCATGATGTGA 1063
Db 1294 GTGTCCATCCAGATCAGGAAGTCTCCACCTTAGTGTAGA 1255

RESULT 118
AX587861/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AX587861
Sequence 331 from Patent WO0246467.
AX587861
AX587861.1 GI:27656555
synthetic construct
synthetic construct
artificial sequences.
1
REFERENCE
AUTHORS
Bertucci, F., Houlgatte, R., Birnbaum, D., Nguyen, C., Viens, P. and
Fert, V.
TITLE
Gene expression profiling of primary breast carcinomas using arrays

of candidate genes
Patent: WO 0246467-A 331 13-JUN-2002;
Ipsogen (FR)
Location/Qualifiers
1..254
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="primer"
1..254
/notes="3' terminal sequence, macrophage stimulating
(hepatocyte growth factor-like) (MSRI) gene."

Query Match
Best Local Similarity 0.9%; Score 19.8; DB 1; Length 254;
Matches 45; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 1148 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1207
Db 136 TGTCTTACCGGTCTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 77

QY 1208 TCCTCCCTCTTTGATTTTGGCTGG 1234
Db 76 GCCAGCCTTGATGCCATATGCCCTGG 50

RESULT 119
HSLKB1PJ7/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

HSLKB1PJ7
Homo sapiens Peutz-Jeghers syndrome protein (LKB1) gene, exon 8.
AF055326
AF055326.1 GI:3063582
7 of 8
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 268)
Avizienyte, E., Roth, S., Loukola, A., Hemminki, A., Lothe, R.A.,
Stenwig, A.E., Fossa, S.D., Salovaara, R.E. and Aaltonen, L.A.
Somatic mutations in LKB1 are rare in sporadic colorectal and
testicular tumors
Cancer Res. (1998) In press
2 (bases 1 to 268)
Bignell, G.R., Barfoot, R., Seal, S., Collins, N., Warren, W. and
Stratton, M.R.
Low frequency of somatic mutations in the LKB1/Peutz-Jeghers
syndrome gene in sporadic breast cancer
Cancer Res. 58 (7), 1384-1386 (1998)
98196525
PUBMED
9537235
REFERENCE
3 (bases 1 to 268)
Avizienyte, E., Roth, S., Loukola, A., Hemminki, A., Bignell, G.R.,
Warren, W., Stratton, M.R. and Aaltonen, L.A.
Direct Submission
Submitted (25-MAR-1998) Department of Medical Genetics, Haartman
Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3),
Helsinki FIN-00014, Finland
Location/Qualifiers
1..268
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="19"
/map="19p13.3"
41..228
/gene="LKB1"
/number=8

Query Match
Best Local Similarity 0.9%; Score 19.8; DB 1; Length 268;
Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

```

```
QY 938 TGATGTCATCCATGAGTGGTGTCTTTTGGATGCAGCAGTAGGATGATCTT 992
Db 105 TGGTGTCTGGGCTGGTGGATGGCACTGGTGTCTTACGCGGAGGATGTTCTT 51

RESULT 120
BD095271/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD095271
384 bp DNA linear PAT 27-AUG-2002
Structural coordinate and NMR chemical shift of protein and
utilization thereof.
BD095271
BD095271.1 GI:22640859
WO 0142453-A/3.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
Koda,D., Hiroaki,H. and Sumimoto,H.
Structural coordinate and NMR chemical shift of protein and
utilization thereof
Patent: WO 0142453-A 3 14-JUN-2001;
BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE,DAISUKE KODA, HIDEKAZU
HIROAKI, HIDEKI SUMIMOTO
OS Homo sapiens (human)
PN WO 0142453-A/3
PD 14-JUN-2001
PF 01-DEC-2000 WO 2000JP008501
PR 06-DEC-1999 JP 99P 346193
PI DAISUKE KODA,HIDEKAZU HIROAKI,HIDEKI SUMIMOTO PC
C12N15/09,C12N9/02,G06F17/30,G06F17/50,G01N33/68,G01N24/02 CC
Structural coordinate and NMR chemical shift of protein and CC
utilization
CC thereof
FH Key
FT source
FT Location/Qualifiers
1. .336
/organism="Homo sapiens (human)".

FEATURES
source
1. .384
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.8; DB 1; Length 384;
Best Local Similarity 77.4%; Pred. No. 1e+02;
Matches 24; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1686 TAGGAATTTTCTTTTGGTTTCTTGAA 1716
Db 178 TAGGGAACATTTCTTTAAGGTTTATGGAA 148

RESULT 121
AX814618/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .394
/organism="Homo sapiens"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.8; DB 1; Length 535;
Best Local Similarity 54.9%; Pred. No. 1.1e+02;
Matches 39; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 53 TGGTAGAGTATCTCATACAGAGATAGCATTAGTCTGTGGACATAGTAACTTT 112
Db 414 TGGCATGATCACTGATGCTATGTTCTGCGTGGATCTTGGAGGAGGCAAGGACTCTTG 473

QY 113 CCAGAGAGACT 123
Db 474 CCAGGGTGACT 484

RESULT 123
BV036036
LOCUS
DEFINITION
```

```
/db_xref="taxon:9606"
misc_feature
1. .394
/note="exon 14"

Query Match 0.9%; Score 19.8; DB 1; Length 394;
Best Local Similarity 60.0%; Pred. No. 1e+02;
Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 1161 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCTCCCT 1215
Db 391 GTAGCTGGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCTCCCT 337

RESULT 122
DLA6882
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .535
/organism="Dacentrarchus labrax"
/mol_type="mRNA"
/db_xref="taxon:13489"
/dev_stage="larvae"
<1. ->535
/EC_number="3.4.21.4"
/codon_start=1
/product="trypsin"
/protein_id="CAA07315.1"
/db_xref="GI:3242120"
/db_xref="GOA:O93594"
/db_xref="SPTREMBL:O93594"
/translation="OVSLNSGVHFCGSLVNNVWSAAHCKSRVVEVLGEHNRVIT
ENTEQFISRSRVIRHERYSYNDINDIMLIKSLKPATLNQYQVPALPTSCAPAGTMC
TVSGWNTSSADNRKIQCLNIPILSFKDCDINSYFGMTDMFCAGYLEGGKDCQ9
DSGGPVVNCNGELQGVVSW"

Query Match 0.9%; Score 19.8; DB 1; Length 535;
Best Local Similarity 54.9%; Pred. No. 1.1e+02;
Matches 39; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 53 TGGTAGAGTATCTCATACAGAGATAGCATTAGTCTGTGGACATAGTAACTTT 112
Db 414 TGGCATGATCACTGATGCTATGTTCTGCGTGGATCTTGGAGGAGGCAAGGACTCTTG 473

QY 113 CCAGAGAGACT 123
Db 474 CCAGGGTGACT 484

RESULT 123
BV036036
LOCUS
DEFINITION
```

COMMENT
Original source text: Pig liver, cDNA to mRNA.

Query Match 0.9%; Score 19.8; DB 1; Length 873;
Best Local Similarity 45.7%; Pred. No. 1.1e-02;
Matches 69; Conservative 0; Mismatches 82; Indels 0; Gaps 0;

Qy 1989 TTAATTCATTTCACATTCAGTCCGAAATGTTTACTCATTTCTCCGCCGATTTA 2048
Db 749 TCAATATTATTGTCACGCGCAACTGTATTTTAAACACAGTTTCAACAGTGGCA 690
Qy 2049 CATTTTCATAGTTTCTTTTAAATGATTTTATTCATTTCTCTTCAAGACCTTTTAAGAT 2108
Db 699 GCAGTTACAAATTCATTTTCAATACAGTAGAGCTCCACAGATGATCACTTACCA 630
Qy 2109 TCATAAAATGATTAAGTTCCTTGCCTTG 2139
Db 629 TTTCAAAACAACCTGCCAAGGAATTGACCTG 599

RESULT 126
MMU44795/c 1850 bp mRNA linear ROD 23-MAY-1996
LOCUS Mus musculus coagulation factor VII (fVII) mRNA, complete cds.
DEFINITION U44795
ACCESSION U44795
VERSION U44795.1 GI:1184738
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 1850)
Castellino, F.J.
TITLE Characterization of a cDNA encoding murine coagulation factor VII
JOURNAL Thromb. Haemost. 75 (3), 481-487 (1996)
MEDLINE 8701412
PUBMED
AUTHORS Rosen, E.D., Idusogie, E., Carmeliet, P., Collen, D. and
Castellino, F.J.
TITLE Direct Submission
JOURNAL Submitted (05-JAN-1996) Elliot D. Rosen, Chemistry, Univ. of Notre
Dame, Notre Dame, IN 46556, USA
FEATURES
source
1. .1850 Location/Qualifiers
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/tissue_type="liver"
gene
1. .1850
/gene="fVII"
CDS
16. .1356
/gene="fVII"
/notes="initiation of extrinsic pathway of blood
coagulation; serine protease"
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAC52579.1"
/db_xref="GI:1184739"
translation="MVPQAHGLLLCLFLQLQGLPLGFAVITQEEAHGVHLHRRANS
LLEELMPSLERECNEOCSEAREIFKSPERTKQFWIVSDGDCASNPQNVGTC
ODHKSVCFLILDFFGRNCKSKNEOLICANENGDCDYCRDHVGPRTCSCHEDYT
LQDEVSCKLPYPCGRI PVVKNSSSQGRIVGVNCPKGECPWQVAKINGLL
CGVLLDARWIVTAACHDFNIRWGNITVVMGHDSEKGDQVREVTQVIMPKYI
RGKINHIALRLRPVFTDYVVPCLPCKPSEFTLARIKRSVSGWQLLDRGAT
ALEHMSIEVPLMTQDCLHAKMSNTPKTFNNFCDMGDKTADCKGDSGGPHATH
YHGTWYLTGVVSGEGCAALIGHIVTVRSQYIDWLVRHMDSKLQGVGFRPLPL"
polyA_site
1850
/gene="fVII"
/note="54 A nucleotides"

Query Match 0.9%; Score 19.8; DB 1; Length 1850;
Best Local Similarity 69.2%; Pred. No. 1.1e-02;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 1872 CTGCTGAGATTCTCTCTTCTATCTCTTGTATTCTGTCA 1910
Db 581 CTGCTGAGATTCTCTCTTCTATCTCTTGTATTCTGTCA 543

RESULT 127
HAMCFX/c 484 bp DNA linear ROD 05-FEB-1999
LOCUS Syrian hamster gene for coagulation factor X, partial cds.
DEFINITION D21216
ACCESSION D21216.1 GI:415304
VERSION coagulation factor X.
KEYWORDS Mesocricetus auratus (golden hamster)
SOURCE
ORGANISM Mesocricetus auratus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;
Mesocricetus.
REFERENCE
1 (bases 1 to 484)
MURAKAWA, M., OKAMURA, T., KAMURA, T., KUROIWA, M., HARADA, M. and
NIHO, Y.
TITLE Analysis of the partial nucleotide sequences and deduced primary
structures of the protease domains of mammalian blood coagulation
factors VII and X
JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
MEDLINE 94222160
PUBMED 8168596
REFERENCE
2 (bases 1 to 484)
MURAKAWA, M.
AUTHORS Direct Submission
TITLE Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General
Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-Ku,
Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
JOURNAL Submitted (18-Oct-1993) to DDBJ by:
COMMENT Masahiro Murakawa
Division of Hematology
Harasanshin General Hospital
1-8 Taihaku-machi, Hakata-ku
Fukuoka, Fukuoka 812
Japan
Phone: 092-291-3434
Fax : 092-291-3266.
FEATURES
source
1. .484 Location/Qualifiers
/organism="Mesocricetus auratus"
/mol_type="genomic DNA"
/db_xref="taxon:10036"
/db_xref="GI:455393"
/codon_start=2
/product="coagulation factor X"
/protein_id="BAA04757.1"
/db_xref="GI:455393"
translation="EGNEMTHEVDVVKHNKVFRETYDFDIIVLRKLTPIFRMNVP
ACLPEKDWAEATLMTQKSGIVSGFGRTHKGROSHILKLEVPYVDRNTCKLSFTI
TONMFCAGYDAKPEDACQSDSGGPHVTRKDYTFVTGIVSWGECARKGKGIYTKVT
A"
CDS
Query Match 0.9%; Score 19.6; DB 1; Length 484;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

Qy 740 ATTGTGTTGGTGCATAGACATTAAGAAATTCGATTCCTCTGCTGATTTTCCTTTGA 799
Db 114 AATATGATGGGGTCTTCAGCTGAGCAGCGGATGCGAAGTCGTAGGTCCTCCCTCACA 55
Qy 800 TGCCTATGATGATTTCTTCCCAATCTCATCTGCTTACT 837
Db 54 AACTGTGTGTTTATGACACCGTCCACCTCATGTGT 17

RESULT 128
AX193364 596 bp DNA linear PAT 15-AUG-2001
LOCUS AX193364
DEFINITION Sequence 931 from Patent WO0149716.

```

ACCESSION AX193364
VERSION AX193364.1 GI:15211315
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Eisingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1..596
Location/Qualifiers
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 596;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTGCATAGACATTAAAGATTGCAATGCTCTTGG 784
Db 122 GATGTAGCGGGAGAGGTGATGGTCTGCTGAGTTGGAGGAGTCAATGTGCCCTGG 179

RESULT 129
AX763043
LOCUS AX763043 609 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 37 from Patent WO03040393.
ACCESSION AX763043
VERSION AX763043.1 GI:32257659
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Martinez,R.A. and Sigurdsson,G.T.
TITLE Nucleic acids encoding proteases
JOURNAL Patent: WO 03040393-A 37 15-MAY-2003;
Decode Genetics EHF. (IS)
FEATURES
source
1..609
Location/Qualifiers
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 609;
Best Local Similarity 54.1%; Pred. No. 1.2e+02;
Matches 40; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
QY 435 ATTATTCAATTGCTTTTATCTGTCGAGACTTGCCTTTGTTTGAATAATGATTCAAAT 494
Db 142 ATTATTGCCATATATTAGATCATGCTGTGGCCCTTTGTTTGGCAATTTCTTCATT 201
QY 495 TTGGAGAGTTTCAT 508
Db 202 TGGAAATGGGAACAT 215

RESULT 130
AX765583/c
LOCUS AX765583 882 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 33 from Patent WO02055704.
ACCESSION AX765583
VERSION AX765583.1 GI:29333568
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Eisingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1..882
Location/Qualifiers
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 882;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTGCATAGACATTAAAGATTGCAATGCTCTTGG 784
Db 456 GATGTAGCGGGAGAGGTGATGGTCTGCTGAGTTGGAGGAGTCAATGTGCCCTGG 399

RESULT 132
AX675581/c
LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:29333567
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Eisingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1..882
Location/Qualifiers
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 1142;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTGCATAGACATTAAAGATTGCAATGCTCTTGG 784
Db 456 GATGTAGCGGGAGAGGTGATGGTCTGCTGAGTTGGAGGAGTCAATGTGCCCTGG 399

RESULT 133
AX675581/c
LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:29333567
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Eisingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1..882
Location/Qualifiers
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 1142;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTGCATAGACATTAAAGATTGCAATGCTCTTGG 784
Db 456 GATGTAGCGGGAGAGGTGATGGTCTGCTGAGTTGGAGGAGTCAATGTGCCCTGG 399

```

Edingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source Location/Qualifiers
1..1161
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 1161;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTGCTTTGGTGCATAGACATTAGCAATTGCAATGCTCTCTGG 784
Db 657 GATGTAGCGGGAGAGGTGATGGTCTGCTGAGTTGGAGAGTGCAATGTCGCCCTGG 600
RESULT 133
AR219284/c
LOCUS AR219284 1169 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 7 from patent US 6420157.
ACCESSION AR219284
VERSION AR219284.1 GI:23320254
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 1169)
AUTHORS Darrow,A., Qi,J. and Andrade-Grodon,P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 7 16-JUL-2002;
FEATURES
source Location/Qualifiers
1..1169
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 19.6; DB 1; Length 1169;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTGCTTTGGTGCATAGACATTAGCAATTGCAATGCTCTCTGG 784
Db 483 GATGTAGCGGGAGAGGTGATGGTCTGCTGAGTTGGAGAGTGCAATGTCGCCCTGG 426
RESULT 134
BOVPBC/c
LOCUS BOVPBC 1373 bp mRNA linear MAM 27-APR-1993
DEFINITION Bovine protein C mRNA.
ACCESSION K02435
VERSION K02435.1 GI:163486
KEYWORDS autoproteolysin IIA; protein C; serine protease.
SOURCE Bos taurus (cow)
ORGANISM Bos taurus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Bovinae; Bos.
1 (bases 1 to 1373)
AUTHORS Long,G.L., Belagaje,R.M. and MacGillivray,R.T.
TITLE Cloning and sequencing of liver cDNA coding for bovine protein C
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)
MEDLINE 85014826
PUBMED 6091100
COMMENT Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and
pBC-7.
The sequence reported in [1] included homopolymeric tails on the 5'
and 3' ends (not shown here).
FEATURES
source Location/Qualifiers

1..1373
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
CDS
1..1370
/note="protein C prepropeptide"
/codon_start=3
/protein_id="AAA30685.1"
/db_xref="GI:163487"
/translation="TSLLLFTVIMGISSTAPPDSVFSSQRAHQVLIRKANSFLE
BLRPNVERECSEEEVEFEAREIFQNTEDTMAFWSKYSDGDQEDRSGSPCDLPCC
GRGICDGLGFRCDCAEGWEGFCLHEVRFSNGSAENGCAHYCMEEGRRHSCAP
GYLEDHQLCVSKVTRPCGRIGKMEKKRTKLDKRDNOVDKQDLDRIVDGQAGW
GESPWQVLLDSKKLVCGAVLIHVSWLTVAHCLDSRKLIVRLGEYDMRWESWEV
LDDIKELIHNENYTKSTSDNIDALLRLAKPATLSOTIYPICLPSGLSERKLTQVQE
TVVWGVRDETRKRTFVLSFIKVPVFNACVHAKMENKLSENMLCAGILGDDPDAC
ESGGPMVTFRTGTFVLVGLVSWGEGCGRLYNGVYTKVSRYLWDIYHIKAQEAFL
ESQVP"
sig_peptide 1..86
/note="protein C signal peptide"
mat_peptide 117..581
/product="protein C light chain"
mat_peptide 588..1367
/product="protein C inactive heavy chain"
mat_peptide 630..1367
/product="protein C active heavy chain"
Query Match 0.9%; Score 19.6; DB 1; Length 1373;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
QY 2081 ATTTCCTCTCAAGGACCTTTTATGAATTCATAAAATGATGTTAGGTCCTTGCTTGT 2140
Db 895 ATGTCGTCTCACTGCTGCTCTTGGTATAGTTAGGTGGATGATGACCTCTTGATGTC 836
QY 2141 GCTTCAGCTATGTTGCATTTCTCAGGCGCTATTGTATA 2178
Db 835 AGGTCCACCTCCAGCTCTCCAGCGCGCATGTCATA 798
RESULT 135
AR109618
LOCUS AR109618 177 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 30 from patent US 6114139.
ACCESSION AR109618
VERSION AR109618.1 GI:12825894
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 177)
AUTHORS Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.
TITLE G-protein coupled receptor protein and a DNA encoding the receptor
JOURNAL Patent: US 6114139-A 30 05-SEP-2000;
FEATURES
source Location/Qualifiers
1..177
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1727 CTGCTTTTGACCTGCTCTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1786
Db 7 CTGCTGGTACCTTACCTGCT 66
QY 1787 G 1787
Db 67 G 67
RESULT 136

AR150638	AR150638	Sequence 25 from patent US 6228984.	177 bp	DNA	linear	PAT 08-AUG-2001
LOCUS	AR150638					
DEFINITION	AR150638					
ACCESSION	AR150638					
VERSION	AR150638.1	GI:15115229				
KEYWORDS						
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 177)					
AUTHORS	Hinuma,S., Habata,Y., Kawamata,Y., Hosoya,M., Fujii,R., Fukusumi,S.					
TITLE	Polypeptides their production and use					
JOURNAL	Patent: US 6228984-A 25 08-MAY-2001;					
FEATURES	Location/Qualifiers					
source	1..177					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	0.9%;	Score 19.4;	DB 1;	Length 177;		
Best Local Similarity	57.4%;	Pred. No. 1.3e+02;				
Matches	35;	Conservative 0;	Mismatches 26;	Indels 0;	Gaps 0;	
QY	1727	CTGCTTTGACCTGCCTCTCTCCCTTCCTCTATTCCTTTGGTTTGGCATAGTGTCTT	1786			
Db	7	CTGCTGTCACCTACCTGCTCCCTCTCTCTGCTGTCATCTCTCTTACGTCGGGTGCA	66			
QY	1787	G 1787				
Db	67	G 67				
RESULT 137						
E16187	E16187	Partial sequence of cDNA encoding G protein-coupled receptor.	177 bp	DNA	linear	PAT 28-JUL-1999
LOCUS	E16187					
DEFINITION	E16187					
ACCESSION	E16187.1	GI:5710870				
VERSION	JP 1998146192-A/11.					
KEYWORDS	Homo sapiens (human)					
SOURCE	Homo sapiens					
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE	1 (bases 1 to 177)					
AUTHORS	Hinuma,K., Habatake,Y., Kawamata,Y., Hosoya,M., Fujii,A., Fukuzumi,M. and Kitada,C.					
TITLE	NEW PHYSIOLOGICALLY ACTIVE SUBSTANCE, ITS PRODUCTION AND USE					
JOURNAL	Patent: JP 1998146192-A 11 02-JUN-1998;					
COMMENT	TAKEDA CHEM IND LTD					
	OS Homo sapiens (human)					
	PN JP 1998146192-A/11					
	PD 02-JUN-1998					
	PF 26-DEC-1996 JP 1996348328					
	PR 28-DEC-1995 JP 95P 343371, 15-MAR-1996 JP 96P 59419, PR					
	12-AUG-1996 JP 96P 211805, 18-SEP-1996 JP 96P 246573 PI					
	HINUMA KUNIJU, HABATAKE YUUGO, KAWAMATA YUJI, HOSOYA MASAKI, FI					
	FUJII AKIRA,					
	PI FUKUZUMI MASASHI, KITADA CHIEKO					
	PC C12N15/09,A61K31/70,A61K31/70,A61K31/70,A61K31/70,A61K31/70,					
	PC A61K31/70,					
	PC A61K35/76,A61K38/00,A61K48/00,C07H21/00,C07K14/47,C12N5/10, PC					
	C12P21/02,					
	PC C12Q1/02,G01N33/566, (C12N5/10,C12R1.91), (C12P21/02,C12R1.91);					
	CC strandedness: Double;					
	CC topology: Linear;					
	CC hypothetical: No;					
	CC anti-sense: No;					
	FH Key					
	FH Location/Qualifiers					
	FT source					
	FT 1..177					
	/organism='Homo sapiens'					
	/tissue_type='pituitary gland'.					
FEATURES	Location/Qualifiers					

QY	1727	CTGCTTTTGACCTGCTCTTCCCTCTCTATTCCTTTGGTTTTCATAGTCTCT	1786
LOCUS	7	CTGCTGGTCACTTACCTGCTCTCTGCTGGTCACTCTCTCTTACGTCGGGTGCA	66
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
Query Match	0.9%	Score 19.4; DB 1; Length 204;	
Best Local Similarity	57.4%;	Pred. No. 1.3e+02;	
Matches	35;	Conservative 0; Mismatches 26; Indels 0; Gaps 0;	
QY	1727	CTGCTTTTGACCTGCTCTTCCCTCTCTATTCCTTTGGTTTTCATAGTCTCT	1786
Db	7	CTGCTGGTCACTTACCTGCTCTCTGCTGGTCACTCTCTTACGTCGGGTGCA	66
QY	1787	G 1787	
Db	67	G 67	
RESULT 141			
AR109885			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
Query Match	0.9%;	Score 19.4; DB 1; Length 204;	
Best Local Similarity	57.4%;	Pred. No. 1.3e+02;	
Matches	35;	Conservative 0; Mismatches 26; Indels 0; Gaps 0;	
QY	1727	CTGCTTTTGACCTGCTCTTCCCTCTCTATTCCTTTGGTTTTCATAGTCTCT	1786
Db	7	CTGCTGGTCACTTACCTGCTCTCTGCTGGTCACTCTCTTACGTCGGGTGCA	66
QY	1787	G 1787	
Db	67	G 67	
RESULT 142			
AR150703			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
Query Match	0.9%;	Score 19.4; DB 1; Length 204;	
Best Local Similarity	57.4%;	Pred. No. 1.3e+02;	
Matches	35;	Conservative 0; Mismatches 26; Indels 0; Gaps 0;	
QY	1727	CTGCTTTTGACCTGCTCTTCCCTCTCTATTCCTTTGGTTTTCATAGTCTCT	1786
Db	7	CTGCTGGTCACTTACCTGCTCTCTGCTGGTCACTCTCTTACGTCGGGTGCA	66
QY	1787	G 1787	
Db	67	G 67	
RESULT 143			
AR150703			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
Query Match	0.9%;	Score 19.4; DB 1; Length 204;	
Best Local Similarity	57.4%;	Pred. No. 1.3e+02;	
Matches	35;	Conservative 0; Mismatches 26; Indels 0; Gaps 0;	
QY	1727	CTGCTTTTGACCTGCTCTTCCCTCTCTATTCCTTTGGTTTTCATAGTCTCT	1786
Db	7	CTGCTGGTCACTTACCTGCTCTCTGCTGGTCACTCTCTTACGTCGGGTGCA	66
QY	1787	G 1787	
Db	67	G 67	
RESULT 144			
AR150703			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
Query Match	0.9%;	Score 19.4; DB 1; Length 204;	
Best Local Similarity	57.4%;	Pred. No. 1.3e+02;	
Matches	35;	Conservative 0; Mismatches 26; Indels 0; Gaps 0;	
QY	1727	CTGCTTTTGACCTGCTCTTCCCTCTCTATTCCTTTGGTTTTCATAGTCTCT	1786
Db	7	CTGCTGGTCACTTACCTGCTCTCTGCTGGTCACTCTCTTACGTCGGGTGCA	66

```

RESULT 143
AJ586104/c
LOCUS
DEFINITION
    Lolium multiflorum partial mRNA for putative 4-coumarate coA ligase
    (4cl gene).
AJ586104
ACCESSION
AJ586104.1 GI:37805458
VERSION
4-coumarate coA ligase; 4cl gene.
KEYWORDS
Lolium multiflorum (Italian ryegrass)
SOURCE
Lolium multiflorum
ORGANISM
    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
    Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
    Poideae; Poae; Lolium.
REFERENCE
1
    Bettany,A.J.E. and Morris,P.
    cDNA and genomic clones of Festuca arundinacea and Lolium
    multiflorum
    Unpublished
REFERENCE
2 (bases 1 to 249)
    Bettany,A.J.E.
    Direct Submission
    Submitted (13-OCT-2003) Bettany A.J.E., Plant, Animal & Microbial
    Science, Inst. Grassland & Environmental Research, Plas Gogerddan,
    Aberystwyth, Ceredigion SY23 3EB, UNITED KINGDOM
FEATURES
    source
    1..249
        /organism="Lolium multiflorum"
        /mol_type="mRNA"
        /cultivar="Trident"
        /db_xref="taxon:4521"
        /tissue_type="young leaves with leaf bases"
        /dev_stage="seedlings"
    1..249
        /gene="4cl"
        /gene="4cl"
        /EC_number="6.2.1.12"
        /function="activation of thioester substrates for
        phenylpropanoid synthesis"
        /codon_start=3
        /product="putative 4-coumarate coA ligase"
        /protein_id="CAE51882.1"
        /db_xref="GI:37805459"
        /translation="PFKVKSGSGTGVVRNAEFLKVDPDTGASLGRNOPGEICVRGKQI
        MLGYLNPSTKNTIDKXGWLHTGDI GLVDDDEIFIV"
    Query Match
    Best Local Similarity 60.4%; Score 19.4; DB 1; Length 249;
    Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Qy 1892 TATCTCTTGATTCTGCAGTGAGCGTGTCTCTCGAGGTCTCTGTGGTTCT 1944
    |||||
    |||||
Db 210 TGTCTCGGTGTGCAGCGACGCGTCTGTGCGATGGTCTCTGTGGTCACTCT 158

    Query Match
    Best Local Similarity 0.9%; Score 19.4; DB 1; Length 249;
    Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

RESULT 144
AX839191/c
LOCUS
DEFINITION
    Sequence 34 from Patent WO03076610.
ACCESSION
AX839191
VERSION
AX839191.1 GI:39922640
KEYWORDS
Homo sapiens (human)
SOURCE
    Homo sapiens
    Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
    Bracco,L., Brinkman,B. and Coignard,F.
    Variants of human kallikrein-2 and kallikrein-3 and uses thereof
    Patent: WO 03076610-A 34 18-SEP-2003;
    Exonhit Therapeutics S.A. (FR)

```

```

FEATURES
    source
    1..290
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
    Query Match
    Best Local Similarity 55.1%; Score 19.4; DB 1; Length 290;
    Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 217 TCTCTCTCTCCCTTTCTCTAACACTTCTGGGCCAGGGTAGGGCACTACCGCAATCCCTC 276
    |||||
    |||||
Db 113 TCTGCACTCCAGCTCCCAATCGAGACAGGATGAGGGGTGCAGCCCAATCCACG 54
    |||||
    |||||
Qy 277 TCTCTTCCA 285
    |||||
    |||||
Db 53 TCACGGACA 45

RESULT 145
HUMPS02
LOCUS
DEFINITION
    Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION
M57841 J02917
VERSION
M57841.1 GI:190535
KEYWORDS
S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT
2 of 14
SOURCE
    Homo sapiens (human)
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 352)
    Schmidt,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
    Organization of the human protein S genes
    Biochemistry 29 (34), 7845-7852 (1990)
    91084444
    PUBMED 2148110
COMMENT
    Original
    source text: Human liver DNA.
FEATURES
    source
    1..352
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /map="3p11-q11.2"
        /tissue_type="liver"
    join(M57840.1:837..912,135..181)
    /gene="PS-alpha"
    order(M57840.1:913..1014,1..134)
    /gene="PROS1"
    /number=1
    135..292
    /gene="PROS1"
    /note="G00-120-721"
    /number=2
    sig_peptide
    intron
    exon

    Query Match
    Best Local Similarity 55.1%; Score 19.4; DB 1; Length 352;
    Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 1321 AAGTAGATATCTTTTACATCTGATTTATCTTAGAATGTTCTTTTCCCAACTATG 1380
    |||||
    |||||
Db 80 AATATATTTTACATGGAAATGATTAATTCATATAACTGATTTGTTCTTCAGTTTG 139
    |||||
    |||||
Qy 1381 TGACAGAAA 1389
    |||||
    |||||
Db 140 TCRAAGCAA 148

RESULT 146
DOG2/c
LOCUS
DEFINITION
    Dog gene for protein C (precursor of vitamin K-dependent serine
    protease), partial cds (catalytic region).

```

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>


```

source
1. .1126
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="13q34"
1. .1126
/gene="F10"
<1. .1126
/gene="F10"
/product="factor X mRNA"
<1. .1116
/gene="F10"
/feature="factor X precursor peptide"
/codon_start=1
/protein_id="AA52486.1"
/db_xref="GI:182821"
/translation="GPEGKNCLEFTRKCLSLDNGDCDFCHEEQNSVWCARGYTLA
DNKGACIPGPGYPCGQTRIVGGCEKDCPCWQALLINEENSGFCGGTILSFYILTA
LIDFNQTPERGDNNTIRVGGCEKDCPCWQALLINEENSGFCGGTILSFYILTA
AHCLYCAKFECDNRNTEQESGEAEVHEVWLKNEFTKETDYDFDIARLKLPTIFR
MNVAPACLERDWAESTLMTQKTGIVSGFRGTHKGRQSTRKLMLIEVPYVDNSCKLS
SFVITQNNFCAGDYTKQBDACQSGGSHVTRFKDTYFVTGIVSWGEGCARGKGYGI
YTKVTAFLKLDMSKTRGLPKAKSHAPEVITSSPLK"
mat_peptide
<1. .195
/gene="F10"
/product="factor X light chain"
205. .1113
/gene="F10"
/product="factor X heavy chain"
361. .1113
/gene="F10"
/product="factor Xa heavy chain"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.4e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGGTGAATAGTCTGTAAATATCTCTAGGTCCACTTGGTTTATGACATCAGTTAGCTCC 601
DB 596 TTGTGNAACGGTGTGCTTGATGACACCCTCCACCTCGTGACCGCTCACCGCCCTCC 537

QY 602 AGCATTTCTCTGTTTCGTTTTTTTGTGTGAGANGACCTAACTGTTGTGAGAGAAATGGGT 658
DB 536 TCCTGTCTCGTGTTCGGTCCCTTCGAATCTCTTGGCTTGGTAGACACAGTGGGCT 480

RESULT 152
A93124 LOCUS A93124.1 GI:6741514
DEFINITION Sequence 15 from Patent WO9747737.
ACCESSION A93124
VERSION A93124.1
KEYWORDS
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 1404)
AUTHORS Kopecki, E. and Hopfinger, K.
TITLE RECOMBINANT BLOOD-COAGULATION PROTEASES
JOURNAL Patent: WO 9747737-A 15 18-DEC-1997;
KOPETZKI ERHARD (DE); ROHRINGER MANNHEIM GMBH (DE)
FEATURES
source
1. .1404
/organism="unclassified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 19.4; DB 1; Length 1404;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGGTGAATAGTCTGTAAATATCTCTAGGTCCACTTGGTTTATGACATCAGTTAGCTCC 601

```

NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Dr. Michael Brownstein

cDNA Library Preparation: Michael Brownstein / Ted Uesdin
 Laboratory
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LINL)
 DNA Sequencing by: Sequencing Group at the Stanford Human
 Genome Center, Stanford University School of Medicine, Stanford, CA 94305
 Web site: <http://www.shgc.stanford.edu>
 Contact: (Dickson, Mark) mcd@paxil.stanford.edu
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
 R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAL Plate: 53 Row: n Column: 1
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6753805.

FEATURES

```

1. .1869
/location/Qualifiers
/organism="Mus musculus"
/mol_type="mRNA"
/db xref="taxon:10090"
/clone="MGC:74281.10090"
/tissue_type="Liver, mouse"
/clone_lib="NIH MGC_177"
/lab_host="DH10E"
/notes_vector="pDNR-LIB"
1. .1869
/genes="F7"
/notes="synonyms: FVII, mfVII"
/db xref="LocusID:14068"
/db xref="MGI:109325"

```

CDS

```

10. codon_start=1
    /product="coagulation factor VII"
    /protein_id="AAH61149.1"
    /db_xref="GI:38511702"
    /db_xref="LocusID:14068"
    /translation="MVPOAHGLLCLFLCPLGTVAVFTQEEAGVHLHRRRANS
    LLEELMPGISLERECNEQCSFEAREILFKSPERTQFVIWISDQACASHPNCGNGTC
    QDHLKSVYCVCLLDPRGRNCEKSKNEQLICANENGDCDQYCRDHVGKFKTCKSCHEDT
    QGLVDSEKPKVYPCGRIPVPEKRNSSRGSRVWGNVGNPKGFCQVAILVGNLGLL
    CGAVLDARWIVTAAACHFTVDYVYVLCPLFKFSKSNLIARIFRSGVSGQLDRGAT
    ALEMLSDIALLRLHMTQCLSEAHKSSNTPKLTENMFECAGYMDGTDXACKGSGGPHAT
    YHGTVITLVGVSWGEGCAIGHGVYTRVSQYIDMLVRHMSKLVQGVGFRLPLI."
79. 79..264

```

misc feature

3. .407
/note="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues"
/db_xref="CDD:smart00069"
268. .378
/note="EGF CA; Region: Calcium-binding EGF-like domain,
present in a large number of membrane-bound and
extracellular (mostly animal) proteins. Many of these
proteins require calcium for their biological function and
calcium-binding sites have been found to be located at the
N-terminus of particular EGF-like domains"
/db_xref="CDD:CG00054"
589. .1302

misc feature

```

/DB xref="CDP:cd00190"
/note="Tryp_Spc; Region: Trypsin-like serine protease"

```

Query Match 0.9%; Score 19.4; DB 1; Length 1869;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32: Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Qy	TGTGTTGGTGTGTGTGTGTGTGTGTGTGTGTGTCTTGTCCTTGTGTGC	1200
Dδ	TGCATGTGCGTGCCTGTGTGCCATCATTTGGCACTGTGCTCATTGTGCTTC	1794

REGISTRATION 157

RESULT 157				
MUSACROS02				
LOCUS	MUSACROS02	281 bp	DNA	linear
DEFINITION	Mouse acrosin gene, exon 2.			
				ROD 27-APR-1993

ACCESSION

ACCESSION	M56427.1	GI:191636
VERSION	2 of 5	
KEYWORDS	proacrosin.	
SEGMENT	2 of 5	
SOURCE	Mus musculus (house mouse)	
ORGANISM	Mus musculus	
REFERENCE	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.	
AUTHORS	1 (bases 1 to 281) Kremling, H., Keime, S., Wilhelm, K., Adham, I. M., Hameister, H. and Engel, W.	
TITLE	House proacrosin gene: nucleotide sequence, diploid expression, and chromosomal localization	
JOURNAL	Genomics 11 (4), 828-834 (1991)	
MEDLINE	92147126	
PUBMED	1783391	
COMMENT	Original	source text: Mus musculus (library: Stratagene) DNA.
FEATURES	Location/Qualifiers	
SOURCE	1..281	

intron

exon

```
03. .205
/gene="acrosin"
/number=2
```

Query M:

Query Match	0.88;	Score 19.2;	DB 1;	Length 201;
Best Local Similarity	62.5%;	Pred. No. 1.5e+02;		
Matches 30:	Conservative	0:	Mismatches 18:	Indels 0:
Gaps	0:			

Oy

d

QY
1099
|||||
|||CCTGATTCAGATTGTCCGCCCGTGGTTCTGCCTCATGTTGCTCCCTTGTTGGGT76

nB
29
TTTTCCCCAACGAGACAGATTTCTGGTCTCTCTCCTCAGTGGTCCCCTGTGGGT76

25

RESULT 158
GOT3/c
LOCUS GOT3 471 bp DNA linear MAM 09-FEB-1999
DEFINITION Goat gene for protein C (precursor of vitamin k-dependent serine protease), partial cds (catalytic region).

ACCESSION

VERSION D43752.1 GI:601887
KEYWORDS protein C; blood coagulation-related; serine protease zymogen; vitamin K-dependent serine protease.

SOURCE

SOURCE	ORGANISM	REFERENCE
Capra hircus (goat)	Capra hircus	1 (bases 1 to 471)
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Caprinae; Capra.		

REFERENCE

AUTHORS
Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Niho, Y.

TITLE

JOURNAL
III
A comparative study of paracrine primary
region of mammalian protein C
Br. J. Haematol. 86 (3): 590-600 (1994)

JOURNAL
OF
MEDICAL
NURSING

MEDLINE 94318474
PURMED 8043441

REFERENCES

2 (Pages 1 to 4/1)
Murakawa, M.
AUTHORS
Direct Submission
TITLE
Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General
Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
JOURNAL
Fukuoka, Location/Qualifiers
FEATURES

FEATURES

```

source
1. .471
/organism="Capra hircus"
/mol_type="genomic DNA"
/db_xref="taxon:9925"

```



```

<1..>471
/function="regulation of blood coagulation"
/note="catalytic region"
/codon_start=1
/product="protein C"
/protein_id="BAA07809.1"
/db_xref="GI:1304082"
/transformation="ESWEVLDLKEIVIRPNYTKSDNDIALHLAKPATLSOTIYP
ICLPDGLSLERLTQVGRTVTGWRDETKKNTSILNFKIPVSYNACVHAMEN
KVSENMLCAGILGNPRDACEGDSGGPMVTFEFGTWFLVLVSWGEGGRLLNYGI"

Query Match
Best Local Similarity 0.8%; Score 19.2; DB 1; Length 471;
Matches 48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 1838 GACAAGGATTCATTCTTCTATCTTGCTTCACTGCCTCAGATTTCTCTTCTATCTC 1897
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 246 GATGGAGGTGCGGTTTTCTTGCTCTCGACGGTAGCCCGACCTGTCACCACAGTCTC 187

QY 1898 TTGTATCTGTGAGTGAGCTGTCTCTCAGGTTCC 1933
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 186 CTGCCGCACTGATGAGCTTGCGCTCAGAGGCGC 151

RESULT 159
BV094002/c
LOCUS BV094002
DEFINITION RPAMSEQ005940 Roche Palo Alto Mus musculus STS genomic, sequence
tagged site.
ACCESSION BV094002
VERSION BV094002.1 GI:37671481
KEYWORDS STS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS Usuka,J., Liao,G., Cheng,J., Nguyen,A., Bach,C., Puech,A.,
McPherson,J.D., Foernzler,D. and Peltz,G.
TITLE Mus musculus SNPs
JOURNAL Unpublished (2003)
COMMENT Contact: Jonathan Usuka
Roche Palo Alto Genetics and Genomics Department
Roche Palo Alto
3431 Hillview Ave, Mailstop S3-1, Palo Alto, CA 94024, USA
Tel: 6508555807
Email: Jonathan.Usuka@roche.com
Primer A: No primer submitted
Primer B: No primer submitted.
Location/Qualifiers
1..596
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/map="18-10864-9474-AC126686.3.1.232817"
/clone_lib="Roche Palo Alto"
/note="SNPs developed from assay sequences derived from 15
different strains-of mice (as of October 1, 2003). Those
strains include A/J, A/HeJ -129/Sv, AKR/J, B10.D2-H2/Osnu,
BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, -CAST/Ei, DBA/2J,
MRJ/MpJ, NZB/BinJ, NZW/Lac, SPRET/Ei.-"
<1..>596

STS
Query Match
Best Local Similarity 0.8%; Score 19.2; DB 1; Length 596;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TCTTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGATTTGTTGGTTTCCATAAG 356
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 555 TTCTGGCTCTNAAGGAGACACCCITTTCCCACATGAAGTGAATCACTTGTAGGTAG 496

QY 357 TTGTGAAGTTTCTGTGTTTCTGTGTTGTTGTTGT 393
```

Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
unpublished
2 (bases 1 to 1302)
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
Location/Qualifiers
1. .1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1. .1302
/gene="PROC"
1. .1302
/gene="PROC"
/EC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/note="vitamin K dependent serine protease;
autoprothrombin Iia; coagulation factor XIV; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AA033365.1"
/db_xref="GI:28194012"
/translation="MWKLITIGVLLAASSPVCHASIFYSYKDANQVILKIRKANSFL
BELKPGSVRENECRNEPFEASEIFETKEATLEFWSKYVDGQCAQPCSNACKDN
LGSYSCIDKMGEGACNVYKNCSDVNGGCOHEFKEDPAKQRCVCSAGSYLTN
DNNCTPVVEFCGVRMDYTEGKAEPNRLIGNSGGEGFSPWMLONLKGKELCG
GVLIHPSVLTAAHCVTGETULRIGLRKIENISEQTLIRVKYVREHYNTKLISD
NDIAMLHAEPYMYKALPICLPTFDLAHELTGKQMLVIGWGSTSDENRYSAL
LSYIPIVPKNECAQWNTITSDNMLCAGSLGDRKSCSGSGSGFPMATKYKDTWFLV
GLVSWGEGCKKEKFGVYTKVSQYLEWQHINKKSGSWRG"

Query Match 0.8%; Score 19.2; DB 1; Length 1302;
Best Local Similarity 56.2%; Pred. No. 1.5e+02;
Matches 36; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 1055 TGATGTGAGAAATATCAATGACGAGTGTGTTGGATTCTTGTATCTTGTGCACTTGTGAA 1114
DB 617 TTATGCTGAAATCTGAAGGAGATTTCTGTGTGAGGTGTTCTCATCCATCCGTCCT 676

QY 1115 GTGT 1118
DB 677 GGGT 680

RESULT 162
AF532184 1341 bp mRNA linear ROD 21-AUG-2002
LOCUS Rattus norvegicus coagulation factor VII mRNA, complete cds.
DEFINITION AF532184
ACCESSION AF532184.1 GI:22347744
VERSION
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 1341)
Murphy, K. and Ramaker, M.
Nucleotide sequence of the cDNA encoding rat coagulation factor VII
unpublished
JOURNAL
REFERENCE 2 (bases 1 to 1341)
Murphy, K. and Ramaker, M.

Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
unpublished
2 (bases 1 to 1302)
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
Location/Qualifiers
1. .1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1. .1302
/gene="PROC"
1. .1302
/gene="PROC"
/EC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/note="vitamin K dependent serine protease;
autoprothrombin Iia; coagulation factor XIV; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AA033365.1"
/db_xref="GI:28194012"
/translation="MWKLITIGVLLAASSPVCHASIFYSYKDANQVILKIRKANSFL
BELKPGSVRENECRNEPFEASEIFETKEATLEFWSKYVDGQCAQPCSNACKDN
LGSYSCIDKMGEGACNVYKNCSDVNGGCOHEFKEDPAKQRCVCSAGSYLTN
DNNCTPVVEFCGVRMDYTEGKAEPNRLIGNSGGEGFSPWMLONLKGKELCG
GVLIHPSVLTAAHCVTGETULRIGLRKIENISEQTLIRVKYVREHYNTKLISD
NDIAMLHAEPYMYKALPICLPTFDLAHELTGKQMLVIGWGSTSDENRYSAL
LSYIPIVPKNECAQWNTITSDNMLCAGSLGDRKSCSGSGSGFPMATKYKDTWFLV
GLVSWGEGCKKEKFGVYTKVSQYLEWQHINKKSGSWRG"

Query Match 0.8%; Score 19.2; DB 1; Length 1302;
Best Local Similarity 56.2%; Pred. No. 1.5e+02;
Matches 36; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 1055 TGATGTGAGAAATATCAATGACGAGTGTGTTGGATTCTTGTATCTTGTGCACTTGTGAA 1114
DB 617 TTATGCTGAAATCTGAAGGAGATTTCTGTGTGAGGTGTTCTCATCCATCCGTCCT 676

QY 1115 GTGT 1118
DB 677 GGGT 680

RESULT 162
AF532184 1341 bp mRNA linear ROD 21-AUG-2002
LOCUS Rattus norvegicus coagulation factor VII mRNA, complete cds.
DEFINITION AF532184
ACCESSION AF532184.1 GI:22347744
VERSION
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 1341)
Murphy, K. and Ramaker, M.
Nucleotide sequence of the cDNA encoding rat coagulation factor VII
unpublished
JOURNAL
REFERENCE 2 (bases 1 to 1341)
Murphy, K. and Ramaker, M.

Direct Submission
Submitted (24-JUL-2002) Biotechnology, Bristol-Myers Squibb, P.O.
Box 80336, Wilmington, DE 19880-0336, USA
Location/Qualifiers
1. .1341
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strains="Sprague-Dawley"
/db_xref="taxon:10116"
1. .1341
/codon_start=1
/product="coagulation factor VII"
/protein_id="AA095967.1"
/db_xref="GI:22347745"
/translation="MVPQTHGLLLYFLQLQPLGAVVFTQBEAHGVILRRQRANSFL
LLEELWSSLERECNECRNEPFEAREIFKSPERTKQFWITVSDGQCAASNPCQNGTIC
QDHLKSYVCFPLDPEGRIKNEKNEQICANENGDCDQYCRDHVGTGRTKTSCHEDYV
LQPDVEVSKPKVEYPCGRIPVVEKFNFSRPGRIVGGVCPGQVQALVLFNEALL
CGAVLLDTRWIVTAAHCFDKFKLVNITVLGEHDFSEKTEQVRLVEQVILMPKRYT
RGRDHDIALVLRHPVTFETDYVVPVLCI-PERAFSENTLASIFRSVWGQQLLDGAT
ALELMVIEVPRMLTQDCLLEHAKHSANTPRITENMECAGYMDGTCKDACKDGGPHATH
YHGTWYLTGVVSWGEGCAAIGHIVYTRVSQIIDLWLVKIMDKLKVGISRVSL"

Query Match 0.8%; Score 19.2; DB 1; Length 1341;
Best Local Similarity 58.9%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 1 GATCACTCTCTAGTGAAGGGGGGCTGAGGCTCCAAATGGTTGTCATGTGGT 56
DB 751 GAACACGACTTCAGTGAGAGGAGGAGGACTGAGCAAGTACGGCTGTGGAACAGGT 806

RESULT 163
OCU77477 1619 bp mRNA linear MAM 08-FEB-2002
LOCUS Oryctolagus cuniculus coagulation factor VII mRNA, complete cds.
DEFINITION U77477 S56300
ACCESSION U77477.1 GI:1698964
VERSION
KEYWORDS Oryctolagus cuniculus (rabbit)
SOURCE Oryctolagus cuniculus
ORGANISM Oryctolagus cuniculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
1 (bases 1 to 1619)
Brothers, A.B., Clarke, B.J., Sheffield, W.P. and Blajchman, M.A.
Complete nucleotide sequence of the cDNA encoding rabbit
coagulation factor VII
Thromb. Res. 69 (2), 231-238 (1993)
93190306
8383365
2 (bases 1 to 1619)
Ruiz, S.R., Blajchman, M.A. and Clarke, B.J.
Direct Submission
Submitted (05-NOV-1996) Pathology, McMaster University, 1200 Main
St. West, Hamilton, ONT L8N 3Z5, Canada
On Feb 8, 2002 this sequence version replaced gi:266294.
Location/Qualifiers
1. .1619
/organism="Oryctolagus cuniculus"
/mol_type="mRNA"
/db_xref="taxon:9986"
/tissue type="liver"
22. .1356
/codon_start=1
/product="coagulation factor VII"
/protein_id="AA037326.1"
/db_xref="GI:1698965"
/translation="MAPQARGLGLCSLLAQASLAAVFTQBEAHSVILRRQRANSFL
EBLRPGSLRECKELCSPEAREVFQSTERTKQFWITVSDGQCAASNPCQNGSCEED
QIQSYICFLADPEGRNCKNNDOLICMVENGCGQYCSQSDHVQSRSCRCHEGYTLL
PAGVSCPTVDYPCGKVPALEKRGASNPQRIVGGKVCPEKCEPQVQALVLMNGSTLLCG
GSLDTHWVWSAACHCFDKLSSLNLTIVLGEHDLSEHGGDEQVHVAQLMPKYPVPG
KTDDHDIALRLQLQPAALTNVNVPLCLPERNFSESTLIATIRFSVWGQQLLYRGALAR

Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
unpublished
2 (bases 1 to 1302)
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
Location/Qualifiers
1. .1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1. .1302
/gene="PROC"
1. .1302
/gene="PROC"
/EC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/note="vitamin K dependent serine protease;
autoprothrombin Iia; coagulation factor XIV; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AA033365.1"
/db_xref="GI:28194012"
/translation="MWKLITIGVLLAASSPVCHASIFYSYKDANQVILKIRKANSFL
BELKPGSVRENECRNEPFEASEIFETKEATLEFWSKYVDGQCAQPCSNACKDN
LGSYSCIDKMGEGACNVYKNCSDVNGGCOHEFKEDPAKQRCVCSAGSYLTN
DNNCTPVVEFCGVRMDYTEGKAEPNRLIGNSGGEGFSPWMLONLKGKELCG
GVLIHPSVLTAAHCVTGETULRIGLRKIENISEQTLIRVKYVREHYNTKLISD
NDIAMLHAEPYMYKALPICLPTFDLAHELTGKQMLVIGWGSTSDENRYSAL
LSYIPIVPKNECAQWNTITSDNMLCAGSLGDRKSCSGSGSGFPMATKYKDTWFLV
GLVSWGEGCKKEKFGVYTKVSQYLEWQHINKKSGSWRG"

Query Match 0.8%; Score 19.2; DB 1; Length 1302;
Best Local Similarity 56.2%; Pred. No. 1.5e+02;
Matches 36; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 1055 TGATGTGAGAAATATCAATGACGAGTGTGTTGGATTCTTGTATCTTGTGCACTTGTGAA 1114
DB 617 TTATGCTGAAATCTGAAGGAGATTTCTGTGTGAGGTGTTCTCATCCATCCGTCCT 676

QY 1115 GTGT 1118
DB 677 GGGT 680

RESULT 162
AF532184 1341 bp mRNA linear ROD 21-AUG-2002
LOCUS Rattus norvegicus coagulation factor VII mRNA, complete cds.
DEFINITION AF532184
ACCESSION AF532184.1 GI:22347744
VERSION
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 1341)
Murphy, K. and Ramaker, M.
Nucleotide sequence of the cDNA encoding rat coagulation factor VII
unpublished
JOURNAL
REFERENCE 2 (bases 1 to 1341)
Murphy, K. and Ramaker, M.

PUBMED 9108060
REFERENCE 2 (bases 1 to 352)
AUTHORS Chen, L., DeVries, A. and Cheng, C.
TITLE Direct Submision
JOURNAL Physiology, University of Illinois, 524 Burrill Hall, 407 S.
Goodwin Ave, Urbana, IL 61801, USA
FEATURES Location/Qualifiers
source 1..352
/organism="Discothichus mawsoni"
/mol_type="mRNA"
/db_xref="taxon:36200"
/tissue_type="pancreas"
1..352
/gene="DM-AFGP"
<1..102
/gene="DM-AFGP"
/function="inhibits ice crystal growth"
/codon_start=1
/product="antifreeze glycoprotein precursor"
/protein_id="AAB57730.1"
/db_xref="GI:1399809"
/translation="AATPALNFVATPATAATAATAATAATAAARG"

Query Match 0.8%; Score 18.8; DB 1; Length 352;
Best Local Similarity 52.6%; Pred. No. 1.9e+02;
Matches 41; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 1990 TAATTCATTTCCACATTCAGGTCCTGAAATGTTTACATTTCTCTCCAGTATTAC 2049
Db 249 TAAAGAAATACAGTTATTTCTCTCACTTCTCCACATGGTTCAGACCCGTGTTTA 308

QY 2050 ATTTTCATAGGTTCTTT 2067
Db 309 TTTTCTGTCCTCTCT 326

RESULT 168
AX193364/c
LOCUS AX193364 596 bp DNA linear PAT 15-AUG-2001
DEFINITION Sequence 931 from Patent WO0149716.
ACCESSION AX193364
VERSION AX193364.1 GI:15211315
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Xu, J., Lodes, M.J., Secrist, H., Benson, D.R., Meagher, M.J., Stolk, J.A., King, G.E., Wang, T. and Jiang, Y.
TITLE Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
JOURNAL Patent: WO 0149716-A 931 12-JUL-2001;
CORIXA CORPORATION (US)
FEATURES Location/Qualifiers
source 1..596
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.8; DB 1; Length 596;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 345 GGTTTCCATAAGTTTCTGTTGTTTCTGTTTCTGTTGTTGTTGTTATCT 398
Db 376 GGCGTCCATGTTGTTGGTCTCTCGTCTCAGACAGGGGTGCTGTCAGCT 323

RESULT 169
AX675583
LOCUS AX675583 882 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:29333567
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S., Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M., Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X., Boldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V., Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J., Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the same
JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;
Curagen Corporation (US)
FEATURES Location/Qualifiers
source 1..1161
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.8; DB 1; Length 1161;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 345 GGTTTCCATAAGTTTCTGTTGTTTCTGTTTCTGTTGTTGTTGTTATCT 398
Db 403 GGCGTCCATGTTGTTGGTCTCTCGTCTCAGACAGGGGTGCTGTCAGCT 456

DEFINITION Sequence 33 from Patent WO02055704.
ACCESSION AX675583
VERSION AX675583.1 GI:29333568
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S., Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M., Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X., Boldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V., Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J., Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES Location/Qualifiers
source 1..882
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.8; DB 1; Length 882;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 345 GGTTTCCATAAGTTTCTGTTGTTTCTGTTTCTGTTGTTGTTGTTATCT 398
Db 115 GGCGTCCATGTTGTTGGTCTCTCGTCTCAGACAGGGGTGCTGTCAGCT 168

RESULT 170
AX675581
LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:29333567
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S., Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M., Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X., Boldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V., Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J., Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the same
JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;
Curagen Corporation (US)
FEATURES Location/Qualifiers
source 1..1161
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

QY 1658 ACCTTGATAGGCACTCTTTCTCAAGGTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGGTAATATTAGTCCTTCATTCCATATAT 91
QY 1718 ATATTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 175
AR098999/c
LOCUS AR098999 168 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 28 from patent US 6077687.
ACCESSION AR098999
VERSION AR098999.1 GI:12808765
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L.
TITLE Flea aminopeptidase nucleic acid molecules and uses thereof
JOURNAL Patent: US 6077687-A 28 20-JUN-2000;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0

QY 1658 ACCTTGATAGGCACTCTTTCTCAAGGTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGGTAATATTAGTCCTTCATTCCATATAT 91
QY 1718 ATATTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 176
AR116830/c
LOCUS AR116830 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6139840.
ACCESSION AR116830
VERSION AR116830.1 GI:14097736
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and Stiegler,G.L.
TITLE Methods of eliciting an antibody response using flea protease proteins and homologs thereof
JOURNAL Patent: US 6139840-A 28 31-OCT-2000;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0

QY 1658 ACCTTGATAGGCACTCTTTCTCAAGGTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGGTAATATTAGTCCTTCATTCCATATAT 91
QY 1718 ATATTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

Db 90 AGTTTGGCACTGAGTCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 177
AR127061/c
LOCUS AR127061 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6180383.
ACCESSION AR127061
VERSION AR127061.1 GI:14113654
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea leucine aminopeptidase proteins and uses thereof
JOURNAL Patent: US 6180383-A 28 30-JAN-2001;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0

QY 1658 ACCTTGATAGGCACTCTTTCTCAAGGTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGGTAATATTAGTCCTTCATTCCATATAT 91
QY 1718 ATATTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 178
AR141647/c
LOCUS AR141647 168 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 28 from patent US 6146870.
ACCESSION AR141647
VERSION AR141647.1 GI:15101163
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea protease proteins
JOURNAL Patent: US 6146870-A 28 14-NOV-2000;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0

QY 1658 ACCTTGATAGGCACTCTTTCTCAAGGTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGGTAATATTAGTCCTTCATTCCATATAT 91
QY 1718 ATATTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 179
AR151537/c
LOCUS AR151537 168 bp DNA linear PAT 08-AUG-2001


```
exon
1..189
/ gene="HCR"
/ number=14

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 189;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTCTGCTGCAATACCTTCTGGGCTGCTGCTTCTCCCT 185
Db 52 TCTGCTCCAGCTGCTGGCCACCTTGTCTCAGCTGCTGCCGCTGCTCCT 4

RESULT 183
AX135796S1/c 189 bp DNA linear PRI 23-SEP-2002
LOCUS
DEFINITION Pongo pygmaeus HCR (HCR) gene, exon 14.
ACCESSION AY135809
VERSION AY135809.1 GI:23296145
KEYWORDS
SOURCE 14 of 18
ORGANISM Pongo pygmaeus (orangutan)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pongo.
REFERENCE
AUTHORS Asumalahti,K. and Kere,J.
TITLE HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and
orangutan
JOURNAL Unpublished
AUTHORS 2 (bases 1 to 189)
TITLE Direct Submission
JOURNAL Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum,
University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki
FIN-00014, Finland
FEATURES
source
1..189
/organism="Pongo pygmaeus"
/mol_type="genomic DNA"
/db_xref="taxon:9600"
exon
1..189
/ gene="HCR"
/ number=14

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 189;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTCTGCTGCAATACCTTCTGGGCTGCTGCTTCTCCCT 185
Db 52 TCTGCTCCAGCTGCTGGCCACCTTGTCTCAGCTGCTGCCGCTGCTCCT 4

RESULT 184
AR047835/c 200 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 1 from patent US 5817798.
ACCESSION AR047835
VERSION AR047835.1 GI:5969300
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 200)
AUTHORS Gundling,G.J.
TITLE Rapid RNA isolation procedure in the presence of a transition metal
ion
JOURNAL Patent: US 5817798-A 1 06-OCT-1998;
FEATURES
source
1..200
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 200;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 217 TCTCTCTCCCTTCTTCTTACACTTCTGGGCCAGGCTAGGGCAGCTACCGCATTC 273
Db 60 TCTCGACTCCAGCTCCCAATCCAGATCCGAGACAGATGAGGGTGCAGCACCAATCC 4

RESULT 185
AX260845 222 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 496 from Patent WO0173027.
ACCESSION AX260845
VERSION AX260845.1 GI:16509812
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Meagher,M.J., Xu,J. and King,G.E.
TITLE Compositions and methods for therapy and diagnosis of colon cancer
JOURNAL Patent: WO 0173027-A 496 04-OCT-2001;
CORIXA CORPORATION (US)
FEATURES
source
1..222
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 18.6; DB 1; Length 222;
Matches 39; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 414 TGGTCAGATAGACATAGATTATTTCATTTCTTTTATCTCTCGAGACTTGCTTTG 473
Db 138 TGGTTGGGGTGTCTCAGAGGATGTTTTCGGCTTAGTCTCTGGCGGATGCTTTG 197
QY 474 TTTTGAAATATGT 486
Db 198 TTATGCAGAACT 210

RESULT 186
HS88A12F 241 bp DNA linear PRI 22-OCT-1995
LOCUS
DEFINITION H.sapiens CpG island DNA genomic MseI fragment, clone 88a12,
forward read cp98a12.ft1a.
ACCESSION Z63614
VERSION Z63614.1 GI:1035992
KEYWORDS CpG island; genomic MseI fragment.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Cross,S.H., Charlton,J.A., Nan,X. and Bird,A.P.
TITLE Purification of CpG islands using a methylated DNA binding column
JOURNAL Nat. Genet. 6 (3), 236-244 (1994)
MEDLINE 94282070
PUBMED 8012384
REFERENCE
2 (bases 1 to 241)
AUTHORS MacDonald,M., Huckle,B., Wilkinson,P. and Micklem,G.
TITLE Direct Submission
JOURNAL Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire,
CB10 1RQ, England. E-mail contact: humquery@sanger.ac.uk
COMMENT
Vector: pGEM-5zf(-)
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: biohelp@hgmp.mrc.ac.uk.
```


Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 Vernet,C.A., Burgess,C.E., Fernandes,E., Taupier,R.J., Quinn,K.E.,
Szytek,K.A., Rastelli,L. and Herrmann,J.L.
Novel proteins and nucleic acids encoding same
Patent: WO 0174897-A 33 11-OCT-2001;
Curagen Corporation (US).

FEATURES
source
1..439
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 439;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 143 AGCCTCTGCGCAATCTCTGGGCTGCTGCCCTTCTCCCTGCTGATTCCTAGG 199
|||||
Db 174 AGCCTCTCTCTTGACACACACAGGGGGCCCCCGCTGCTCCCTGGCAGCTGTCACG 118
|||||

RESULT 191
MACCFX/c
LOCUS Rhesus monkey gene for coagulation factor X, partial cds.
DEFINITION D21214
ACCESSION D21214.1 GI:415307
VERSION coagulation factor X.
KEYWORDS Macaca mulatta (rhesus monkey)
SOURCE Macaca mulatta
ORGANISM
1 (bases 1 to 484)
Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
Niho,Y.
Analysis of the partial nucleotide sequences and deduced primary
structures of the protease domains of mammalian blood coagulation
factors VII and X
Eur. J. Haematol. 52 (3), 162-168 (1994)

REFERENCE
AUTHORS Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
Niho,Y.
TITLE Analysis of the partial nucleotide sequences and deduced primary
structures of the protease domains of mammalian blood coagulation
factors VII and X
JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
MEDLINE 94222160
PUBMED 8168596
REFERENCE 2 (bases 1 to 484)
AUTHORS Murakawa,M.
TITLE Direct Submission
JOURNAL Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General
Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
Submitted (18-Oct-1993) to DDBJ by:
Masahiro Murakawa
Division of Hematology
Harasanshin General Hospital
1-8 Taihaku-machi, Hakata-ku
Fukuoka, Fukuoka 812
Japan
Phone: 092-291-3434
Fax : 092-291-3266.

FEATURES
source
1..484
/organism="Macaca mulatta"
/mol_type="genomic DNA"
/db_xref="taxon:9544"
<1..>484
/codon_start=2
/product="coagulation factor X"
/protein_id="BA04755.1"
/db_xref="GI:455395"
/translation="EGGEAVHEVVIKHNRFKETYDPDIARLKLSPITRMNVAP
ACLPKDAEESTLMTQKIGVSGFRHKGQSRILKMLEVYVDNRSCKLSSEFII
TQNMFCAGYHAKQEDACQSGGPHVTRFKDTYFVTGIVSWGEGCARKKGIYIKTV
A"

Query Match 0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGTGC 418
|||||
Db 351 TGTTCCTGGTGATGATGAACCTGCTGGACAGCTTGACGCTGTTCGGGTC 303
|||||

RESULT 192
AX775014/c
LOCUS Sequence 330 from Patent WO03038129.
DEFINITION AX775014
ACCESSION AX775014
VERSION AX775014.1 GI:32486530
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Raponi,M.
TITLE Methods for assessing and treating leukemia
JOURNAL Patent: WO 03038129-A 330 08-MAY-2003;
Ortho-Clinical Diagnostics, Inc. (US)

FEATURES
source
1..546
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 546;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 143 AGCCTCTGCTGGCAATCTCTGGGCTCTCTGCCCTTCTCCCTGCTGATTCCTAGG 199
|||||
Db 336 AGCCTCTCTCTTGACACACACAGGGGGCCCCCGCTGCTCCCTGGCAGCTGTCACG 280
|||||

RESULT 193
AX335885/c
LOCUS Sequence 6394 from Patent WO0194629.
DEFINITION AX335885
ACCESSION AX335885
VERSION AX335885.1 GI:18126604
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Young,P.E., Augustus,M., Carter,K.C., Ebner,R., Endress,G.,
Hortigan,S., Soppet,D.R. and Weaver,Z.
TITLE Cancer gene determination and therapeutic screening using signature
gene sets
JOURNAL Patent: WO 0194629-A 6394 13-DEC-2001;
Avalon Pharmaceuticals (US)

FEATURES
source
1..624
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGTGC 418
|||||
Db 351 TGTTCCTGGTGATGATGAACCTGCTGGACAGCTTGACGCTGTTCGGGTC 303
|||||

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 Vernet,C.A., Burgess,C.E., Fernandes,E., Taupier,R.J., Quinn,K.E.,
Szytek,K.A., Rastelli,L. and Herrmann,J.L.
Novel proteins and nucleic acids encoding same
Patent: WO 0174897-A 33 11-OCT-2001;
Curagen Corporation (US).

FEATURES
source
1..439
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 439;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 143 AGCCTCTGCGCAATCTCTGGGCTGCTGCCCTTCTCCCTGCTGATTCCTAGG 199
|||||
Db 174 AGCCTCTCTCTTGACACACACAGGGGGCCCCCGCTGCTCCCTGGCAGCTGTCACG 118
|||||

RESULT 191
MACCFX/c
LOCUS Rhesus monkey gene for coagulation factor X, partial cds.
DEFINITION D21214
ACCESSION D21214.1 GI:415307
VERSION coagulation factor X.
KEYWORDS Macaca mulatta (rhesus monkey)
SOURCE Macaca mulatta
ORGANISM
1 (bases 1 to 484)
Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
Niho,Y.
Analysis of the partial nucleotide sequences and deduced primary
structures of the protease domains of mammalian blood coagulation
factors VII and X
Eur. J. Haematol. 52 (3), 162-168 (1994)

REFERENCE
AUTHORS Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
Niho,Y.
TITLE Analysis of the partial nucleotide sequences and deduced primary
structures of the protease domains of mammalian blood coagulation
factors VII and X
JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
MEDLINE 94222160
PUBMED 8168596
REFERENCE 2 (bases 1 to 484)
AUTHORS Murakawa,M.
TITLE Direct Submission
JOURNAL Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General
Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
Submitted (18-Oct-1993) to DDBJ by:
Masahiro Murakawa
Division of Hematology
Harasanshin General Hospital
1-8 Taihaku-machi, Hakata-ku
Fukuoka, Fukuoka 812
Japan
Phone: 092-291-3434
Fax : 092-291-3266.

FEATURES
source
1..484
/organism="Macaca mulatta"
/mol_type="genomic DNA"
/db_xref="taxon:9544"
<1..>484
/codon_start=2
/product="coagulation factor X"
/protein_id="BA04755.1"
/db_xref="GI:455395"
/translation="EGGEAVHEVVIKHNRFKETYDPDIARLKLSPITRMNVAP
ACLPKDAEESTLMTQKIGVSGFRHKGQSRILKMLEVYVDNRSCKLSSEFII
TQNMFCAGYHAKQEDACQSGGPHVTRFKDTYFVTGIVSWGEGCARKKGIYIKTV
A"

Query Match 0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGTGC 418
|||||
Db 351 TGTTCCTGGTGATGATGAACCTGCTGGACAGCTTGACGCTGTTCGGGTC 303
|||||

```

RESULT 194
HUMEX8/c
LOCUS      624 bp      DNA      linear      PRI 09-NOV-1994
DEFINITION Human factor X (blood coagulation factor) gene, exon 8.
ACCESSION L29433.M4327.N00045
VERSION    L29433.1 GI:459809
KEYWORDS   Stuart factor; blood coagulation factor; factor X; glycoprotein;
           serine protease.
SEGMENT    8 of 8
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 624)
AUTHORS   Leytus,S.P., Foster,D.C., Kurachi,K. and Davie,E.W.
TITLE     Gene for human factor X: a blood coagulation factor whose gene
           organization is essentially identical with that of factor IX and
           protein C
JOURNAL   Biochemistry 25 (18), 5098-5102 (1986)
MEDLINE   87026600
PUBMED    3768336
COMMENT    Original source text: Homo sapiens (tissue library: of Lawn et al.,
           and Yoshitake et al.) DNA.
           matp + 13 + 458 factor Xa heavy chain.
FEATURES   source
            Location/Qualifiers
            1..624
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /map="13q34"
            /tissue_lib="of Lawn et al., and Yoshitake et al."
            join(L00390.1:26..95,L00391.1:13..173,L00392.1:13..37,
            L00393.1:13..126,L00394.1:13..144,L00395.1:13..257,
            L00396.1:13..130,13..614)
            /notes="preprofactor X"
            /codon_start=1
            /product="coagulation factor X"
            /protein_id="AAA52764.1"
            /db_xref="GI:182831"
            /translation="MRPLHLVLLSLAGLLGLLGLSFLRREQNNILARVTRANSF
            LEMKKGLHRECMETCSYEAREVFEDSKTFNPNKYKDGDCQETSPCQNGKCK
            DGLGYTCLEGFEGKNCLELFRKLCSLNDGCDQFCHEEQNSVVCARGYTLADN
            GKACIPGYPGCKQLERRKSRVAQATSSGEAPDSITWKPYDAADLDPTENPFDLL
            DFNOTPERGNNLITVGGQCKDCGPQWALLINEEGFCGGTILSEFYLLTAAH
            CLYQARFKRVGDRNTEOEGGEAVEVEVLKHNRFKETYDEPDIARLKTPTF
            RNVAACILPERDWAESTLMTQKTGIVSGFGTHKGRQSTRLMLEVPYVDNRSCKL
            SSSFLITQNMFCGYDTKQEDACQSGSGPHVTRFRDTPYVTGIVSWGCGCAKRGKYG
            IYKVTAFKLWIDRSMTKRLPKAKSHAPEVITSSPLK"
            join(L00395.1:57..257,L00396.1:13..130,13..458)
            /product="coagulation factor X"
            /notes="factor X light chain"
            459..611
            /product="activation peptide"
            <1..12
            /notes="FX intron G"
            13..624
            /notes="FX"
            /number=8

Query Match      0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY  370 TGTGTTCTGTTGTTGTTGTTGTTATCTAGATTAGCTGCTGGTC 418
Db  351 TGTCTGGGATGATGAAGCTCGACAGCTTGCAGCTGTGCGGTC 303

RESULT 195
BD173590/c
LOCUS      711 bp      DNA      linear      PAT 18-FEB-2003
DEFINITION Novel serine protease MP493.
ACCESSION BD173590

```

```

VERSION    BD173590.1 GI:28414921
KEYWORDS   WO 02059295-A/3.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 711)
AUTHORS   Nakamura,Y., Sugano,S., Matsusue,T., Okamoto,A. and Okawa,K.
TITLE     Novel serine protease MP493
JOURNAL    MOCHIDA PHARMACEUTICAL CO LTD,YUSUKE NAKAMURA,SUMIO SUGANO,
            TOMOKAZU MATSUSUE,ATSUSHI OKAMOTO,KAZUFUMI OKAWA
COMMENT    OS Homo sapiens (human)
            PN WO 02059295-A/3
            PD 01-AUG-2002
            PF 23-JAN-2002 WO 2002JP000465
            PI 23-JAN-2001 JP 01P 014963
            PR YUSUKE NAKAMURA,SUMIO SUGANO,TOMOKAZU MATSUSUE,ATSUSHI
            OKAMOTO.
            PI KAZUFUMI OKAWA
            PC C12N15/09,C12N15/12,C12N9/64,C12N1/15,C12N1/19,C12N1/21 PC
            ,C12N5/10,C07K16/40,
            PC C12Q1/02
            CC Novel serine protease MP493
            FH Key Location/Qualifiers
            FT source 1..711
            /organism="Homo sapiens (human)"'.
FEATURES   source
            Location/Qualifiers
            1..711
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 18.6; DB 1; Length 711;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY  143 AGCCTCTGTCGCAATCTCTGGGCTGCTGCTTCTCCCTGCTGATCTCTAGG 199
Db  594 AGCCTCTCTCTTTGACACACACAGGGGGCCCCCGCTGTCCTCCGCTGTCACG 528

RESULT 196
AX827818/c
LOCUS      773 bp      DNA      linear      PAT 12-DEC-2003
DEFINITION Sequence 552 from Patent EP1344834.
ACCESSION AX827818
VERSION    AX827818.1 GI:39838006
KEYWORDS   Rattus norvegicus (Norway rat)
SOURCE     Rattus norvegicus
ORGANISM   Rattus norvegicus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
            Rattus.
REFERENCE  1
AUTHORS   Boess,F., Suter-Dick,L. and Wolf,D.
TITLE     Methods for the toxicity prediction of a compound
JOURNAL    Patent: EP 1344834-A 552 17-SEP-2003;
            F. HOFFMANN-LA ROCHE AG (CH)
FEATURES   source
            Location/Qualifiers
            1..773
            /organism="Rattus norvegicus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:10116"

Query Match      0.8%; Score 18.6; DB 1; Length 773;
Best Local Similarity 45.5%; Pred. No. 2.1e+02;
Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;

QY  1658 ACCTTGATAGGATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGTGTTTCTTGAAA 1717
Db  315 AGCTTGATCAGCATGATGTCATTGTTTCAGGGTCTTCTCTATCGAAGTTGGATGCTTG 256

```

Qy	1718	ATATTTCCCTGCTTTTGACCTGCTCTTTCCCTCTATCTCTTGTTTGGTTTTCAT	1777
Db	255	ATCTTGGCAGCATTTGACAACTGCTCATTCGCCCTCAAGGACATGTAGTTGTGCTCTCCC	196
Qy	1778	AGTGCTCTCGGCTTCTCGGATGTTT	1802
Db	195	AGTCTCACCTTGGATGCGGGACTTAT	171

RESULT	197
RNTRY2/c	
LOCUS	RNTRY2 773 bp mRNA linear
DEFINITION	Rat mRNA encoding pancreatic trypsinogen II.
ACCESSION	V01274
VERSION	V01274.1 GI:57410
KEYWORDS	complementary DNA; signal peptide; trypsin.

ORGANISM
Rattus norvegicus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.

REFERENCE	1 (bases 1 to 773)
AUTHORS	MacDonald, R. J., Stary, S. J. and Swift, G. H.
TITLE	Two similar but nonallelic rat pancreatic trypsinogens. Nucleotide sequences of the cloned cDNAs
JOURNAL	J. Biol. Chem. 257 (16), 9724-9732 (1982)
MEDLINE	82265624
PUBMED	6896710

```

FEATURES             Location/Qualifiers
     1..773
     /organism="Rattus norvegicus"
     /mol_type="mRNA"
     /db_xref="taxon:10116"
     <1..773
     /product="messenger RNA"
     <1..718
     /note="unnamed protein product; trypsinogen (1 is 3rd base
     in codon)"

```

```

/codon_start=2
/protein_id="CAA24581.1"
/db_xref="GI:758266"
/db_xref="GOA:P00763"
/db_xref="SWISS-PROT:P00763"
/translation="LVGAAVAFFVDDDDKIVGGYTCQENSVYPQVLNSGVHFCGGSLSL
INDOWVSAAHCYKRISQVRIGEHNNVLNEGEQFVNAAKIIRKHPDFRKLNNIDML
IKLSPVKLNARATVALPSCAPAGTQCILISGWNTLSGVEVDLCILDALPLPQ
ADCEASPGKITDNMVCVFEGEGLCGDCOGDSGGPVNCGNEGLOGIVSGYGCALPDNP

```

```

sig_peptide
<1..25
/note="signal peptide"
773
polyA_site
/note="polyA addition site"

```

Query Match	0.8%;	Score 18.6;	DB 1;	Length 773;
Best Local Similarity	45.5%;	Pred. No. 2.1e+02;		

Qy 1658 ACCCTGATAGGCATCTCTTTCTCAAGGTTAGGAAATTTTTCTTTTTCGTTTCTCTTGAA 1717

D6 315 AGCTTGATCAGCATGATCTCATTTGTCAAGGTCCTTCATCGAAGTTCGGATGCTTGATG 256

Qy 1718 ATATTTCCCGCTTTTGACCTGCCTCTCCCTCTATTCTTGGTTTTCAT 1777

Db 255 ATCTGGCAGCATTCACAACTGCTCATTTGCCCTCAAGCATTGATCTGTCTCCC 196

QY 1778 AGTGCTCTGGCTTCCTGGATGTTT 1802

Dh 195 AGTTCACATTGGATGGGGACTTAT 171

	DGSTRYP	819 bp	mRNA	linear	MAM 27-APR-1993
RESULT 198	DGSTRYP				
I/OCTIS.					

DEFINITION Dog pancreatic anionic trypsinogen mRNA.
ACCESSION M11589
VERSION M11589.1 GI:164094
KEYWORDS
SOURCE Canis sp.
ORGANISM Canis sp.

REFERENCE
PINSKY, S. D., LAPOERGE, K. S. and SCHEELE, G.
1 (bases 1 to 819)
Differential regulation of trypsinogen mRNA translation:
full-length mRNA sequences encoding two oppositely charged
trypsinogen isoenzymes in the dog pancreas
Mol. Cell. Biol. 5 (10), 2669-2676 (1985)
AUTHORS
TITLE
JOURNAL

MEDLINE	86284628	source text: Dog pancreas, cDNA to mRNA, clone pT1.
FURNED	3841794	Location/Qualifiers
COMMENT	Original	1..819
FEATURES		source

```

/organism="Canis sp."
/mol_type="mRNA"
/db_xref="taxon:9616"
1..819
mRNA
/product="anionic trypsinogen mRNA"
15..758
CDS

```

```

/note="anionic trypsinogen precursor"
/codon_start=1
/protein_id="AAA30899.1"
/db_xref="GI:164095"
/translation="MNPLILAFALGAAVATPTDDDKIVGGTYCTENSVPYQVSLNAG
YHFGGSLSDQWVSAAGHCYKRSIQVRLGEYNI DYLENGEQFINSAKVRHPNYSN
LIDNDMLIKLSPALVNARVATISLPRAACAPGTQLISGGWNTLSSTGTNPYELLQC
LDAPILITQACRASYPGQTENNMCAGFLGGKDKSCQDGGGVPVVCNGELQGVSGY
GCAOKNKGVTYKVCNEVNIQSTIAANS"

```

Query Match	0.8%	Score 18.6;	DB 1;	Length 819;
Best Local Similarity	50.6%;	Pred. No. 2.1le+02;		
Matches 45;	Conservative	0;	Mismatches 44;	Indels 0;
Gaps 0;				

Qy 882 GCTTGCTTCTYAGGGCCATTTCCTTACAATATCTTTTCCATCCTCTTACTCTAAAGGTGAT 941

Db 531 GCCTCTTACCCCGGCCAGATCAGGAGAACATGATTTGCGCGGCTTCCTTAGGGGAGGC 590

Qy 942 GTCTATCCATGGTAGGTGCTCTTTTGG 970
| | | | |
Db 591 AAGACTCTCSCCAGGCGTACTCTGGTGG 619

RESULT 199			
PVTRYPSIN			
LOCUS	854 bp		
DEFINITION	P.vannameli mRNA for trypsin.	linear	INV 01-OCT-1996

ACCESSION	X86369
VERSION	X86369.1
KEYWORDS	GI:785034
SOURCE	trypsin.
ORGANISM	Litopenaeus vannamei (pacific white shrimp)
	Litopenaeus vannamei
	Litopenaeus vannamei
	Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;
	Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;
	Penaeidae; Litopenaeus.

1 Klein, B., Le Moullac, G., Sellos, D. and Van Wormhoudt, A.
 Authors Molecular cloning and sequencing of trypsin cDNAs from Penaeus
 Title vannamei (Crustacea, Decapoda): use in assessing gene expression
 during the moult cycle
 Journal Int. J. Biochem. Cell Biol. 28 (5), 551-563 (1996)
 Medline 96252881

8697100
2 (bases 1 to 854)
Van Wormhoudt, A.E.
Direct Submission
Submitted (18-APR-1995) A.E. Van Wormhoudt, College de France /
CNRS, Laboratoire de Biologie Marine, Bp 225, 29182 Concarneau,
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL

FEATURES	FRANCE	
	Location/Qualifiers	
source	1. .854	/protein_id="AA033363.1"
	/db_xref="GI:28194008"	
CDS	/translation="MVSRCVALLCFLPLVPSLEAVFLKQBEANSIFQRHRRANSF FEEIKGLPERECIEEKSCFEAREIYRDDERTKEFWHIYSDPNQCDSPCQNGSCD DQFDYVCRPPYEGKSCETAENLKCIDYNGGCEQYCADEQSEKRVCFCAEGYAL ASDVSCIPOVKYPCGTIPVIAENKTTAAGRIYGVVTCPPGCEPMDALIIDOKGKCG GSLSPWVVTAAHCLDYAHSKOLRVLEISYKVAEKTEQESVSKLIHREYTTGQ VNHDIALLKLETFVNLIDFWVPCLEKPFAPVTELSIKFSFMSVSGWGLDDGGATSTF LMRVHLPRVKTOCEKQANLNIENMFCAGLDTGKDKSCKGSDGGPHATKYKNTWFLT GIVSWGKCAVEGSGYVTVRSRYINWLKHEME"	
	Query Match 0.8%; Score 18.6; DB 1; Length 1278; Best Local Similarity 57.9%; Pred. No. 2.1e+02; Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;	
sig_peptide	442 CAATGCTTTTATCTGTCGAGACTTCTTTGTTTGAATATGATATCAATTGG	498
	562 CAGTTGATTTCTTCTTCCAGCACTGGTATCGTCCACAAGGTTATTTCACTTGG	506
RESULT 201	HUMEXM 1443 bp mRNA linear PRI 08-NOV-1994	
	LOCUS Human factor X mRNA, partial signal pept and complete mature pept	
DEFINITION	cds.	
	ACCESSION K03194	
VERSION	K03194.1 GI:182840	
	KEYWORDS blood coagulation factor; factor X.	
SOURCE	Homo sapiens	
	ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.	
REFERENCE	1 (bases 1 to 2)	
	AUTHORS MacGillivray, R.T.A.	
JOURNAL	Unpublished (1985)	
	REFERENCE 2 (bases 3 to 1443)	
AUTHORS	Fung, M.R., Hay, C.W. and MacGillivray, R.T.	
	TITLE Characterization of an almost full-length cDNA coding for human blood coagulation factor X	
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 82 (11), 3591-3595 (1985)	
	MEDLINE 85216545	
PUBMED	2582420	
	COMMENT Original source text: Human adult liver, cDNA to mRNA, clones pCHX[5,9,14]. During conversion of factor X to factor X-a, a glycopeptide of 52 amino acids (encoded by positions 513-668 in this sequence) is released. A polyadenylation signal is located at position 1424-1429. This sequence was kindly submitted over electronic mail by R.T.A. MacGillivray (23-SEP-1985).	
FEATURES	Location/Qualifiers	
	source	
gene	1. .1443	
	/organism="Homo sapiens"	
mRNA	/mol_type="mRNA"	
	/db_xref="taxon:9606"	
CDS	/map="13q34"	
	1. .1443	
/gene="F10"	<1. .1443	
	/gene="F10"	
/product="X mRNA"	1. .1433	
	/gene="F10"	
/note="factor X prepeptide"	/codon_start=3	
	/protein_id="AAA52490.1"	
/db_xref="GI:182841"	/db_xref="GI:182841"	
	/translation="SLAGLLILGESLFIIRQANNILARVTVANSFLFEMKKHGLERE CMEEFTCYEEAREVEDSDKTFNFWNKYDQCECTSPCQNGCKDGLGYTCLE GPEGKNCBLFRKLCSLDGDCDFCHEEQNSVCGSCARGYTLADGKACIPGYPVC GKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLPTENPFDLLDFTQTPERGDN NLTRIVGGQCKDGECPQALLINEENEGFCGGTILSEFYILTAHCLYQAKRFKRV	

LOCUS A86886 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION A86886
VERSION A86886.1 GI:6735677
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M. and Eibl, J.
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL Patent: WO 9838317-A 26 03-SEP-1998;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/translation="MGRPLHLVLLSASLAGLLLSGLFIRREQANNILARVTRANSF
LEEMKGLHRECMETCSYEAREVFEDSKTNEFWNKYKDGOCETSPCONQKCK
DGLGYTCTCLGFEKNCLEFTRKLCSLDNGDCDFCHEONSVVCSARGVTLADN
GKACIPGYFCGKQTLERRKSAQAATSSGEAPDSITWKPYDAADLDPTNPFLL
DNQTPGERGNNLIRIVGGQCKGECFQWALLINEENEGCGTILSEFYLITAAH
CLYQAKRFVYVGRNTEQEGEAVEVVKHNRTKETYDFDIARLKPTITF
RMNVAPACLPERDWAESTLMTQKTVISGFGRTHEKQSTRKMLEVYVDRNSCKL
SSSFIITQMFACAGYDTKQEDACQDGGPHVTRPKDVFVTVGIWSWGESCARCKGYG
IYTKVTAFLKWDIRSMKTRGLPKAKSHAPEVITSSPLK"

Query Match 0.8%; Score 18.6; DB 1; Length 1443;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1170 TGTTCGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1122
RESULT 202
A86859/c
LOCUS A86859 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 43 from Patent WO9838318.
ACCESSION A86859
VERSION A86859.1 GI:6735650
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Falkner, F. and Himmelspach, M.
TITLE FACTOR X DELETION MUTANTS AND ANALOGUES THEREOF
JOURNAL Patent: WO 9838318-A 43 03-SEP-1998;
FALKNER FALKO GUENTER (AT); HIMMELSPACH MICHELE (AT)
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB69367.1"
/db_xref="GI:6735651"
/translation="MGRPLHLVLLSASLAGLLLSGLFIRREQANNILARVTRANSF
LEEMKGLHRECMETCSYEAREVFEDSKTNEFWNKYKDGOCETSPCONQKCK
DGLGYTCTCLGFEKNCLEFTRKLCSLDNGDCDFCHEONSVVCSARGVTLADN
GKACIPGYFCGKQTLERRKSAQAATSSGEAPDSITWKPYDAADLDPTNPFLL
DNQTPGERGNNLIRIVGGQCKGECFQWALLINEENEGCGTILSEFYLITAAH
CLYQAKRFVYVGRNTEQEGEAVEVVKHNRTKETYDFDIARLKPTITF
RMNVAPACLPERDWAESTLMTQKTVISGFGRTHEKQSTRKMLEVYVDRNSCKL
SSSFIITQMFACAGYDTKQEDACQDGGPHVTRPKDVFVTVGIWSWGESCARCKGYG
IYTKVTAFLKWDIRSMKTRGLPKAKSHAPEVITSSPLK"

RESULT 204
A8316969/c
LOCUS AR316969 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 43 from patent US 6562598.
ACCESSION AR316969
VERSION AR316969.1 GI:33696092
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M., Pfeleiderer, M., Falkner, F.-G., Eibl, J., Dorner, F. and Schlokat, U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: US 6562598-A 43 13-MAY-2003;
FEATURES
source
1..1467
/organism="unknown"
/mol_type="mRNA"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTTCGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156
RESULT 205
A86886/c

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTTCGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156
RESULT 203
A86886/c

LOCUS A86886 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION A86886
VERSION A86886.1 GI:6735677
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M. and Eibl, J.
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL Patent: WO 9838317-A 26 03-SEP-1998;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/translation="MGRPLHLVLLSASLAGLLLSGLFIRREQANNILARVTRANSF
LEEMKGLHRECMETCSYEAREVFEDSKTNEFWNKYKDGOCETSPCONQKCK
DGLGYTCTCLGFEKNCLEFTRKLCSLDNGDCDFCHEONSVVCSARGVTLADN
GKACIPGYFCGKQTLERRKSAQAATSSGEAPDSITWKPYDAADLDPTNPFLL
DNQTPGERGNNLIRIVGGQCKGECFQWALLINEENEGCGTILSEFYLITAAH
CLYQAKRFVYVGRNTEQEGEAVEVVKHNRTKETYDFDIARLKPTITF
RMNVAPACLPERDWAESTLMTQKTVISGFGRTHEKQSTRKMLEVYVDRNSCKL
SSSFIITQMFACAGYDTKQEDACQDGGPHVTRPKDVFVTVGIWSWGESCARCKGYG
IYTKVTAFLKWDIRSMKTRGLPKAKSHAPEVITSSPLK"

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTTCGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156

RESULT 204
A8316969/c
LOCUS AR316969 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 43 from patent US 6562598.
ACCESSION AR316969
VERSION AR316969.1 GI:33696092
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M., Pfeleiderer, M., Falkner, F.-G., Eibl, J., Dorner, F. and Schlokat, U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: US 6562598-A 43 13-MAY-2003;
FEATURES
source
1..1467
/organism="unknown"
/mol_type="mRNA"

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTTCGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156

RESULT 205
A86886/c

AR340866/c
LOCUS AR340866 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6573071.
ACCESSION AR340866
VERSION AR340866.1 GI:33732713
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Schlokot,U., Dörner,F., Fisch,A. and Eibl,J.
TITLE Factor X analogues with a modified protease cleavage site
JOURNAL Patent: US 6573071-A 26 03-JUN-2003;
FEATURES
source
1. .1467
/organism="unknown"
/mol_type="mRNA"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCGAGCTGTTCGGGTC 1156
RESULT 206
AX082959/c
LOCUS AX082959 1467 bp DNA linear PAT 28-FEB-2001
DEFINITION Sequence 1 from Patent WO0110896.
ACCESSION AX082959
VERSION AX082959.1 GI:13184880
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Himmelspach,M. and Schlokot,U.
TITLE Factor X analog with an improved ability to be activated
JOURNAL Patent: WO 0110896-A 1 15-FEB-2001;
Baxter Aktiengesellschaft (AT)
FEATURES
source
1. .1467
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCGAGCTGTTCGGGTC 1156
RESULT 207
BD070392/c
LOCUS BD070392 1467 bp DNA linear PAT 27-AUG-2002
DEFINITION Factor X-analogues with modified protease cleavage site.
ACCESSION BD070392
VERSION BD070392.1 GI:22615995
KEYWORDS JP 2001513631-A/26.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Schlokot,U., Dörner,F., Andreas, Fisch and Eibl,J.
TITLE Factor X-analogues with modified protease cleavage site
JOURNAL Patent: JP 2001513631-A 26 04-SEP-2001;
BAXTER AG

COMMENT OS Unidentified
PN JP 2001513631-A/26
PD 04-SEP-2001
PF 27-FEB-1998 JP 1998537062
PR 27-FEB-1997 AT A 335/97
PI MICHELE HIMMELSPACH,UWE SCHLOKAT,FRIEDRICH DÖRNER,ANDREAS FI
FISCH,JOHANN EIBL
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X-analogues with modified protease cleavage site PH
Key Location/Qualifiers
FT CDS 1..1467.
Location/Qualifiers
1. .1467
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCGAGCTGTTCGGGTC 1156
RESULT 208
BD070435/c
LOCUS BD070435 1467 bp DNA linear PAT 27-AUG-2002
DEFINITION Factor X deletion mutants and analogues thereof.
ACCESSION BD070435
VERSION BD070435.1 GI:22616038
KEYWORDS JP 2001513632-A/43.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Pfeleiderer,M., Falkner,F.G., Eibl,J., Dörner,F. and Schlokot,U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: JP 2001513632-A 43 04-SEP-2001;
BAXTER AG
COMMENT OS Unidentified
PN JP 2001513632-A/43
PD 04-SEP-2001
PF 27-FEB-1998 JP 1998537063
PR 27-FEB-1997 AT A 336/97
PI MICHELE HIMMELSPACH,MICHAEL PFELEIDERER,FALKO GÜNTHER FALKNER,
JOHANN EIBL,
FRIEDRICH DÖRNER,UWE SCHLOKAT
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X deletion mutants and analogues thereof FH Key
FT CDS 1..1467.
Location/Qualifiers
1. .1467
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCGAGCTGTTCGGGTC 1156

RESULT 209
AF191307/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Sus scrofa (pig)
Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE
AUTHORS
TITLE
JOURNAL
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. 1514
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="92N.4; 58/86.2; 12N3.1"
/tissue_type="liver"
22. 1401
/note="serine protease"
/codon_start=1
/product="protein C"
/protein_id="AAG28380.1"
/db_xref="GI:11065894"
/translation="MWQLASLLILLIIVAVSTPVPPVSSVFSSORAHOMLSKREANS
FLEELRPSLEKEETCDREAREIFPONTENTWAFNSKYHGDQCAVPPPEHLCD
PCGGRTGIDGFCDCQACWEGFCLHEVRFNCSTENGCGCAHYCLBESGGRCA
CAPGYLDHDIQCFKVPKPCGRGLNRRKRRKLRDIDQDKEDQIDPRLVNGK
QSPWGESPWQVILLDSKKKACGAVLIHVSMTAAHCLDDYKLTFRIGYDLRRRE
KNEVDLDKEFLVHNTRYSTRSDNDIALRLAEPATFSQTIPIICLPDSGLSERLTR
VGQETVTCGWVRSKATKNSFILNFKVPVAPHNECVQAMENKISENNMLCAGILGDS
RDACGDSGSPVASFPGTFLVGLVSGEGCGRLHNYGVYTKVSYLDWIHGRME
EAFHNQVP"
Query Match 0.8%; Score 18.6; DB 1; Length 1514;
Best Local Similarity 51.9%; Pred. No. 2e+02;
Matches 42; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 1960 CAGATTTCCTTCAGTTGGGTTTGTATTATTCTATTTCACATTCAGGCTCTGCG 2019
DB 657 CGGATCTATTGTCTCTTTTGTGCACTGCTGTATCAGCTTCAAGTTCTTGG 598
QY 2020 TGTTTTACTCATTTCTCTCC 2040
DB 597 TTCTTCTCATGCGATTCC 577
RESULT 210
HUMKALR4
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SEGMENT
SOURCE
ORGANISM
Human renal kallikrein, exon 4.
M33108
M33108.1 GI:186648
kallikrein; kininogenase.
4 of 5
Homo sapiens (human)
Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
TITLE
JOURNAL
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. 193
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
/cell_type="lymphocyte"
/tissue_type="blood"
1. 249
/gene="HLA-DPB1"
/note="HLA-DPB1"
/note="G00-120-636"
Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTCAGAGTTCCTGTTGGGTTCTTAATTTTTCATTCAGATTCTTCAGTTG 1977

TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT
FEATURES
source
Structure and chromosomal localization of the human renal
kallikrein gene
Biochemistry 27 (9), 3124-3129 (1988)
88269498
2898948
Original
Location/Qualifiers
1. 193
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="19q13.3"
prim_transcript
1. .>193
/gene="KLK1"
/note="kallikrein mRNA and introns"
intron
1. .>29
/gene="KLK1"
/note="kallikrein intron C"
30. 166
/gene="KLK1"
/note="G00-120-118"
intron
167. .>193
/gene="KLK1"
/note="kallikrein intron D"
Query Match 0.8%; Score 18.4; DB 1; Length 193;
Best Local Similarity 69.4%; Pred. No. 2.3e+02;
Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 1944 TTAATTTTTCATTCACAGATTTCCTTCAGTTGGG 1979
DB 23 TTCGTAGTCTCATTCACAGATCATCCAGTGTGTG 58
RESULT 211
HUMDPB1/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Human DPB1 protein gene, partial cds.
M77674
M77674.1 GI:181735
DPB1 protein.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT
FEATURES
source
1. 249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
/cell_type="lymphocyte"
/tissue_type="blood"
1. 249
/gene="HLA-DPB1"
/note="HLA-DPB1"
/note="G00-120-636"
Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTCAGAGTTCCTGTTGGGTTCTTAATTTTTCATTCAGATTCTTCAGTTG 1977

Db 218 TTGTCCTGCACATCTCTCCGCGCACTGCCCGCTTCTCCTCCAGATGCTCTTGGCTG 159

RESULT 212
HUMDPBA/c
LOCUS Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK1.
DEFINITION D10478
ACCESSION D10478.1 GI:219604
VERSION HLA-DP beta; DPB1; MHC; human leukocyte antigen; major
KEYWORDS histocompatibility complex class II molecule.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (sites)
AUTHORS Mitsunaga,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K.,
Akaza,T., Mitomi,Y. and Juji,T.
TITLE Family study on HLA-DPB1 polymorphism: linkage analysis with
HLA-DR/DQ and two 'new' alleles
JOURNAL Hum. Immunol. 34 (3), 203-211 (1992)
MEDLINE 93053849
PUBMED 1358867
REFERENCE 2 (bases 1 to 249)
AUTHORS Mitsunaga,S.
JOURNAL Unpublished
COMMENT Submitted (17-Feb-1992) to DDBJ by:
Katsushi Tokunaga
Dept. of Transfusion Medicine and
Immunohematology, Faculty of Medicine
The University of Tokyo
7-3-1 Hongo, Bunkyo-ku
Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.

FEATURES
source
1. .249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="THKK"
/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK1"
/cell_type="peripheral blood mononuclear cell"
1. .249
/gene="DPB1"
<1. .>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01281.1"
/db_xref="GI:219604"
/translation="LFGQKQECVPPNGTQRFLELYLYNREELVRPDSVGEFRAVTEL
GRPEAYWNSQKDILLEKRAVPDRMCRHNYELDEAVTLQ"
1. .249
/gene="DPB1"
/number=2
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cctccccgcagagaattac"
249
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgagggtc"

Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCCTGCAGGTCTCTGTTGGGTCTTAATTTTTCATTTCAGATTCCTTCAGTTTG 1977

Db 218 TTGTCCTGCACATCTCTCCGCGCACTGCCCGCTTCTCCTCCAGATGCTCTTGGCTG 159

RESULT 213
HUMDPBB/c
LOCUS Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK2.
DEFINITION D10479
ACCESSION D10479.1 GI:219606
VERSION HLA-DP beta; DPB1; MHC; human leukocyte antigen; major
KEYWORDS histocompatibility complex class II molecule.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (sites)
AUTHORS Mitsunaga,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K.,
Akaza,T., Mitomi,Y. and Juji,T.
TITLE Family study on HLA-DPB1 polymorphism: linkage analysis with
HLA-DR/DQ and two 'new' alleles
JOURNAL Hum. Immunol. 34 (3), 203-211 (1992)
MEDLINE 93053849
PUBMED 1358867
REFERENCE 2 (bases 1 to 249)
AUTHORS Mitsunaga,S.
JOURNAL Unpublished
COMMENT Submitted (17-Feb-1992) to DDBJ by:
Katsushi Tokunaga
Dept. of Transfusion Medicine and
Immunohematology, Faculty of Medicine
The University of Tokyo
7-3-1 Hongo, Bunkyo-ku
Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.

FEATURES
source
1. .249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="THMI"
/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK2"
/cell_type="peripheral blood mononuclear cell"
1. .249
/gene="DPB1"
<1. .>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01282.1"
/db_xref="GI:219607"
/translation="VVLQECVANGTQRFLELYLYNREELVRPDSVGEFRAVTEL
GRPEAYWNSQKDILLEKRAVPDRMCRHNYELDEAVTLQ"
1. .249
/gene="DPB1"
/number=2
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cctccccgcagagaattac"
249
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgagggtc"

Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCCTGCAGGTCTCTGTTGGGTCTTAATTTTTCATTTCAGATTCCTTCAGTTTG 1977

Db 218 TTGTCTGTGCACATCTCTCGGCACTGCCGCTTCTCTCCAGGATGCTCTTGGCTG 159

RESULT 214
HUMHDPBH/c
LOCUS
DEFINITION Human MHC class II HLA DP-beta gene, exon 2 allele DPB5.
ACCESSION M23680
VERSION M23680.1 GI:188070
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Bugawan,T.L., Horn,G.T., Long,C.M., Mickelson,E., Hansen,J.A., Ferrara,G.B., Angelini,G. and Erlich,H.A.
TITLE Analysis of HLA-DP allelic sequence polymorphism using the in vitro enzymatic DNA amplification of DP-alpha and DP-beta loci
J. Immunol. 141 (11), 4024-4030 (1988)
JOURNAL 89035547
MEDLINE
PUBMED 2460556
COMMENT Original source text: Human DNA allele DPB5.
FEATURES
source
1. .249
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
1. .249
/gene="HLA-DPB1"
/db_xref="GI:188070"
/note="MHC DP-beta, allele DPB5"
/number=2
/codon_start=1
/protein_id="AAAS9745.1"
/db_xref="GI:188071"
/db_xref="GDB:G00-120-636"
/translation="LFGQRCYAFNGTQFLERYLYNREELVRFDSDVGEFRAVTEL
GRPEAYWNSQKDILEKRAVDRMCRHNYELDEAVTLQ"
Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTGTAGGTTCTGTGGTCTTAAATTTTCATTTCCAGATTTCTTCAGTTG 1977
|||||
Db 218 TTGTGTGTGCACATCTCTCGGCACTGCCGCTTCTCTCCAGGATGCTCTTGGCTG 159

RESULT 215
HUMHDPBH/c
LOCUS
DEFINITION Human MHC class II HLA DP-beta (allele DPB5), partial cds.
ACCESSION M62333
VERSION M62333.1 GI:188026
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane glycoprotein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Bugawan,T.L., Begovich,A.B. and Erlich,H.A.
TITLE Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence-specific oligonucleotide probes
Immunogenetics 32 (4), 231-241 (1990)
JOURNAL 91055805
MEDLINE
PUBMED 2242906
COMMENT Original source text: Human DNA allele DPB5.
FEATURES
source
1. .256
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
1. .256
/gene="HLA-DPB1"
/codon_start=1
/product="MHC class II HLA-DP-beta-1"
/protein_id="AAAS9726.1"
/db_xref="GI:553549"
/db_xref="GDB:G00-120-636"
/translation="LFGQRCYAFNGTQFLERYLYNREELVRFDSDVGEFRAVTEL
GRPEAYWNSQKDILEKRAVDRMCRHNYELDEAVTLQRR"
Query Match 0.8%; Score 18.4; DB 1; Length 256;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTGTAGGTTCTGTGGTCTTAAATTTTCATTTCCAGATTTCTTCAGTTG 1977
|||||
Db 218 TTGTGTGTGCACATCTCTCGGCACTGCCGCTTCTCTCCAGGATGCTCTTGGCTG 159

RESULT 216
AF180970/c
LOCUS
DEFINITION Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1 variant allele, partial cds.
ACCESSION AF180970
VERSION AF180970.1 GI:14279142
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 (bases 1 to 257)
XU,A., HUANG,H., LIU,Z., CHEN,W., PAN,D., LIN,J., XU,K., CHEN,S., WANG,X. and CHEN,R.
TITLE A novel HLA-DPB1 allele in Chinese people
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 257)
XU,A., HUANG,H., LIU,Z., CHEN,W., PAN,D., LIN,J., XU,K., CHEN,S., WANG,X. and CHEN,R.
TITLE Direct Submission
JOURNAL Submitted (26-AUG-1999) Biochemistry, School of Life Science, 135 Xingangxi Road, Guangzhou, Guangdong 510275, P.R.China
FEATURES
source
1. .257
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"
1. .257
/gene="HLA-DPB1"
/allele="HLA-DPB1 variant"
1. .257
/gene="HLA-DPB1"
/product="MHC class II antigen"
1. .257
/gene="HLA-DPB1"
/note="membrane protein"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AAK58508.1"
/db_xref="GI:14279143"
/translation="NYLFGQRCYAFNGTQFLERYLYNREELVRFDSDVGEFRAVTEL
ELGRPEAYWNSQKDILEKRAVDRMCRHNYELDEAVTLQ"
1. .257
exon

```

/gene="HLA-DPB1"
/number=2

Query Match      0.8%; Score 18.4; DB 1; Length 257;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGCTCTGAGGTTCCCTGTTGGTCTTAATTTTTCATTTCCAGATTCCCTTCAGTTTG 1977
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 226 TTGTGCTGCACATCCCTGTCGGCACTGCCCGCTTCTCTCCAGGATGCTCTTGGCTG 167

RESULT 217
LOCUS HUMDPB1KT 264 bp DNA linear PRI 14-APR-2000
DEFINITION Human MHC classII HLA-DPB1 gene allele DPB1*KT.
ACCESSION D10882
VERSION D10882.1 GI:219602
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral
SOURCE membrane protein; major histocompatibility complex.
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 264)
AUTHORS Ogawa,K., Itho,H., Nakajyo,S., Kobayashi,K., Sekiguchi,S.,
TITLE Koshizaka,T., Taguchi,M., Onishi,H., Kobayashi,S. and Inoko,H.
JOURNAL A novel HLA-DPB1 allele, DPB1*3601 (DPB1*KT)
MEDLINE Tissue Antigens 44 (2), 134-136 (1994)
PUBMED 95117110
REFERENCE 2 (bases 1 to 264)
AUTHORS Koshizaka,T.
TITLE Direct Submission
JOURNAL Submitted (06-APR-1992) Takuya Koshizaka, Sumitomo Metal
Industries, Ltd.; 14-15 Kobuchi 2-chome, Sagamihara, Kanagawa 229,
Japan (Tel:0427-51-7568, Fax:0427-51-7519)
COMMENT Submitted (06-Apr-1992) to DDBJ by:
Takuya Koshizaka
Sumitomo Metal Industries, Ltd.
14-15 Kobuchi 2-chome
Sagamihara, Kanagawa 229
Japan
Phone: 0427-51-7568
Fax: 0427-51-7519.
LOCATION/Qualifiers
FEATURES
source
1. .264
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
<1. .>264
/codon_start=3
/product="HLA-DPB1"
/protein_id="BAA01704.1"
/db_xref="GI:219603"
/translation="NTVYQLRQCYAFNGTQRELYVYNRELVRFDSDVGEFRAVT
ELGRPEAEVWNSQDILEEKRAVPDRMCRHNYELDEAVTLQRR"
1. .264
/number=2

exon

Query Match      0.8%; Score 18.4; DB 1; Length 264;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGCTCTGAGGTTCCCTGTTGGTCTTAATTTTTCATTTCCAGATTCCCTTCAGTTTG 1977
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 226 TTGTGCTGCACATCCCTGTCGGCACTGCCCGCTTCTCTCCAGGATGCTCTTGGCTG 167

RESULT 218
LOCUS AF306907 279 bp DNA linear VRT 23-JAN-2001
DEFINITION Brachyramphus marmoratus MMC ribosomal protein 40 gene,
intron 5 and partial sequence.
ACCESSION AF306907
VERSION AF306907.1 GI:12382279
KEYWORDS Brachyramphus marmoratus
ORGANISM Brachyramphus marmoratus
REFERENCE 1 (bases 1 to 279)
AUTHORS Pacheco,N.M. and Friesen,V.L.
TITLE A molecular investigation of hybridization in Brachyramphus
murrelets
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 279)
AUTHORS Pacheco,N.M. and Friesen,V.L.
TITLE Direct Submission
JOURNAL Submitted (21-SEP-2000) Department of Biology, Queen's University,
Kingston, ON K7L 3N6, Canada
FEATURES
source
1. .279
/organism="Brachyramphus marmoratus"
/mol_type="genomic DNA"
/db_xref="taxon:28694"
/haplotype="MMC"
join(<1. .14,263. .>279)
/product="ribosomal protein 40"
/notes="coding region not determined"
15. .262
/number=5

mRNA
intron

Query Match      0.8%; Score 18.4; DB 1; Length 279;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 356 GTTTGTAAGTTTCTGTTCTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 415
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 147 GTTAATTAGTTTGTAGTTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 206

RESULT 219
LOCUS AF306908 279 bp DNA linear VRT 23-JAN-2001
DEFINITION Brachyramphus marmoratus haplotype MMD ribosomal protein 40 gene,
intron 5 and partial sequence.
ACCESSION AF306908
VERSION AF306908.1 GI:12382280
KEYWORDS Brachyramphus marmoratus
ORGANISM Brachyramphus marmoratus
REFERENCE 1 (bases 1 to 279)
AUTHORS Pacheco,N.M. and Friesen,V.L.
TITLE A molecular investigation of hybridization in Brachyramphus
murrelets
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 279)
AUTHORS Pacheco,N.M. and Friesen,V.L.
TITLE Direct Submission
JOURNAL Submitted (21-SEP-2000) Department of Biology, Queen's University,
Kingston, ON K7L 3N6, Canada
FEATURES
source
1. .279
/organism="Brachyramphus marmoratus"
/mol_type="genomic DNA"
/db_xref="taxon:28694"
/haplotype="MMD"
join(<1. .14,263. .>279)
/product="ribosomal protein 40"
/notes="coding region not determined"
15. .262
/number=5

mRNA
intron

```

RESULT	221
AF336224/C	
LOCUS	283 bp DNA linear PRI 22-MAR-2000
DEFINITION	Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*3801 allele, exon 2 and partial cds.
ACCESSION	AF336224
VERSION	AF336224.1 GI:13430229
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE	1 (bases 1 to 283)
AUTHORS	Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE	Sequence of complete exon 2 and partial intron 2 of HLA-DPB1*3801 allele
JOURNAL	Unpublished
REFERENCE	2 (bases 1 to 283)

```

CDS
    /product="MHC class II antigen"
    <20..>283
    /gene="HLA-DPB1"
    /codon_start=3
    /product="MHC class II antigen"
    /protein_id="AA084763.1"
    /db_xref="GI:29422765"
    /translation="NYVQLRQECYAFNGTQFLERYIYNREELVRFDSVGVGEFRAVT
    ELGRPEAEYWNQKIDLEKRAVPDRMCRHNYELDAVTLQRR"
    exon
        20..283
        /gene="HLA-DPB1"
        /number=2

Query Match
Best Local Similarity 56.7%; Score 18.4; DB 1; Length 285;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGTCCTCAGGTCCTCGTGGTCTTAATTTTCATTTCCAGATTTCCTTCAGTTG 1977
|||||
Db 245 TTGTGTCGACATCCTCTCGGCACCTGCCGCTTCTCTCCAGGATGCTCTTCTGCTG 186
|||||

RESULT 223
HUMHDPBZ/c
LOCUS HUMHDPBZ 285 bp DNA linear PRI 13-JUL-1993
DEFINITION Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
ACCESSION M83912
VERSION M83912.1 GI:188106
KEYWORDS lymphocyte antigen; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
    1 (bases 1 to 285)
    Kimura A.
    Unpublished (1991)
    Original source text: Homo sapiens (individual isolate SASBE41)
    DNA.
FEATURES
    source
        1..285
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /isolate="SASBE41"
        /db_xref="taxon:9606"
        /map="6p"
        /cell_type="granulocyte"
        <1..79
        /number=1
        /codon_start=3
        /label=exon 2
        /product="MHC HLA DPB1"
        /protein_id="AAA36266.1"
        /db_xref="GI:553571"
        /translation="NYVQLRQECYAFNGTQFLERYIYNREELVRFDSVGVGEFRAVT
        ELGRPEAEYWNQKIDLEKRAVPDRMCRHNYELDAVTLQRR"
        284..>285
        /number=2

intron
CDS
    /product="MHC class II antigen"
    <20..>283
    /gene="HLA-DPB1"
    /codon_start=3
    /product="MHC class II antigen"
    /protein_id="AAA36266.1"
    /db_xref="GI:29422765"
    /translation="NYVQLRQECYAFNGTQFLERYIYNREELVRFDSVGVGEFRAVT
    ELGRPEAEYWNQKIDLEKRAVPDRMCRHNYELDAVTLQRR"
    284..>285
    /number=2

intron
Query Match
Best Local Similarity 56.7%; Score 18.4; DB 1; Length 285;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGTCCTCAGGTCCTCGTGGTCTTAATTTTCATTTCCAGATTTCCTTCAGTTG 1977
|||||
Db 245 TTGTGTCGACATCCTCTCGGCACCTGCCGCTTCTCTCCAGGATGCTCTTCTGCTG 186
|||||

RESULT 224
AF312826/c
LOCUS AF312826 804 bp mRNA linear INV 02-MAR-2001
DEFINITION Luidia foliolata sea star regeneration-associated protease SRAP
mRNA, complete cds.

```

```

ACCESSION AF312826
VERSION AF312826.1 GI:13183619
KEYWORDS Luidia foliolata
SOURCE Luidia foliolata
ORGANISM
    Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Asterozoa;
    Asteroidea; Valvatacea; Paxillosida; Luidiidae; Luidia.
REFERENCE
    1 (bases 1 to 804)
    Vickery M.C., Vickery M.S., McClintock J.B. and Amsler, C.D.
    Utilization of a novel deuterostome model for the study of
    regeneration genetics: molecular cloning of genes that are
    differentially expressed during early stages of larval sea star
    regeneration
    Gene 262 (1-2), 73-80 (2001)
JOURNAL MEDLINE
MEDLINE 21100442
PUBMED 11179669
REFERENCE
    2 (bases 1 to 804)
    Vickery M.C.L., Vickery M.S., McClintock J.B. and Amsler, C.D.
    Direct Submission
    TITLE Submitted (12-OCT-2000) Department of Biology, University of
    Alabama at Birmingham, 1300 University Blvd., Birmingham, AL
    JOURNAL 35294-1170, USA
FEATURES
    source
        1..804
        /organism="Luidia foliolata"
        /mol_type="mRNA"
        /db_xref="taxon:105861"
        /dev_stage="larva"
        1..804
        /note="serine protease"
        /codon_start=1
        /product="sea star regeneration-associated protease SRAP"
        /protein_id="AAK15274.1"
        /db_xref="GI:13183620"
        /translation="MLRLVLCALAAAFVYVADCGVQVNPVINKIVGDEAVPGSWPQ
        WVERKQWAGDYQFCGGTLLSDPEWVSAACHFNHYNINHYAVGAHDESDVDTQT
        TVGLGKVFVHESYDTSTLNDALIKLSFVSMNSYNSVCLTATPTGTCVTVGM
        GQETAVDDPTLQQVVPVPIISBQCNRAIYWGGEINDMICAGFKGGKDCQCGDSGG
        PFVCSASGEYELVGVSWGYGCADARKPGVAKVLNYSVINNLVARN"
        0.8%; Score 18.4; DB 1; Length 804;
        Best Local Similarity 59.6%; Pred. No. 2.4e+02;
        Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 623 TTGTCGATGACCTAAGTGTGGAGAGATGGGGTATTGAAGTAGCCCACT 674
|||||
Db 251 TGGTTGATGTGCCATAGTATGGAAGCAATGGCGACAGACAGACGCCCACT 200
|||||

RESULT 225
SHPFIXA
LOCUS SHPFIXA 823 bp mRNA linear MAM 27-APR-1993
DEFINITION Sheep factor IX mRNA, partial cds.
ACCESSION M26233
VERSION M26233.1 GI:165878
KEYWORDS factor IX.
SOURCE Ovis aries (sheep)
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
    Bovidae; Caprinae; Ovis.
REFERENCE
    1 (bases 1 to 823)
    Sarkar G., Kosher, D.D. and Sommer, S.S.
    Direct sequencing of the activation peptide and the catalytic
    domain of the factor IX gene in six species
    Genomics 6 (1), 133-143 (1990)
JOURNAL MEDLINE
MEDLINE 90152675
PUBMED 2303254
COMMENT Original source text: Sheep liver, cDNA to mRNA.
    Draft entry and computer-readable sequence for [1] kindly provided
    by G.Sarkar, 18-JUL-1989.
FEATURES
    source
        1..823

```

CDS	/organism="Ovis aries"		/evidence=not_experimental		
	/mol_type="mRNA"		0.8%; Score 18.4; DB 1; Length 832;		
	<1..>823		Best Local Similarity 78.6%; Pred. No. 2.3e+02;		
	/note="factor IX"		Matches 22; Conservative 0; Mismatches 6; Indels 0; Gaps 0;		
CDS	/codon_start=1		1697 TCTTTTGGTTTCTTCTGAAATATTTT 1724		
	/protein_id="AAA31520.1"		832 TTTTITTTTTTTTATTTCAATATTTT 805		
	/db_xref="GI:552419"		RESULT 227		
	/translation="RASVLHTSKLTRAETIFSNMNYENSEAEIINDNVTSQNSQSPD		AP465275/c		
CDS	DNRVVGGEAARGQFPWOLLGHEIAAPCGSIVNEKWWVTAACHIKPGVKITVAG		LOCUS		
	BHNTEKPTQKNVIRAI PVHYNASINKYSYSHDIALLEDEPLELNSYVTPICIA		AP465275		
	REYNIFLFGYGVSGWRVNRGRSASILQYLKVLVDRATCLRSKFTLYNMFEC		DEFINITION		
	AGYHEGGKDSQQSGGPHVTEVGTSLTGLISWGEECAAMKGIYIKVSRREV"		Takisfugu rubripes coagulation factor VIIC precursor, mRNA, complete cds.		
CDS	Query Match		AP465275		
	Best Local Similarity 49.0%; Score 18.4; DB 1; Length 823;		VERSION		
	Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;		AF465275.3		
	295 ATTCTTGATTTCTATCTGGCTCATTTTAACTCAGTAGTGGTGTGGTTTCCATA 354		KEYWORDS		
CDS	207 AATTGCTGCATCTGTGGAGGTTCATCGTTAATGAAAATGGTGTGAACGTGCCCA 266		SOURCE		
	355 AGTTTGTAAGTTTCTGTGTTTCTGCTGCTGTGTTGTTGTTT 394		Takisfugu rubripes (Fugu rubripes)		
	267 CTGCATCAAGCTGGTGTTAAATTAATCTGTTGTTGCAGGT 306		Takisfugu rubripes		
CDS	RESULT 226		ORGANISM		
	AF011900/c		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
	LOCUS		Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;		
	DEFINITION		Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;		
CDS	AF011900		Tetraodontidae; Takifugu.		
	Petryomyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.		1 (bases 1 to 1293)		
	AF011900.1		Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,		
	Petryomyzon marinus (sea lamprey)		Tuddenham, E.G.D. and McVey, J.H.		
CDS	Petryomyzon marinus		Comparative sequence analysis and molecular evolution of blood		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;		coagulation genes from Gallus gallus and Fugu rubripes		
	Petryomyzontiformes; Petromyzontidae; Petromyzon.		Unpublished		
	1 (bases 1 to 832)		2 (bases 1 to 1293)		
CDS	The Molecular Evolution of the Vertebrate Trypsinogens		McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.		
	Roach, J.C.		Direct Submission		
	Unpublished		Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences		
	2 (bases 1 to 832)		Centre, The Faculty of Medicine, Imperial College, Hammersmith		
CDS	Roach, J.C.		Campus, Du Cane Road, London W12 0NN, UK		
	Direct Submission		Location/Qualifiers		
	Submitted (01-JUL-1997) Molecular Biotechnology, University of		1..1293		
	Washington, Seattle, WA 98195, USA		/organism="Takifugu rubripes"		
CDS	Location/Qualifiers		/mol_type="mRNA"		
	1..832		/db_xref="taxon:31033"		
	/organism="Petryomyzon marinus"		1..1293		
	/mol_type="mRNA"		/EC number="3.4.21.21"		
CDS	/dev_stage="ammocoete"		/function="serum prothrombin conversion accelerator"		
	/tissue_lib="anterior intestine"		/note="vitamin K dependent serine protease; similar to	factor VII precursor; synthesized in liver; similar to	
	<1..832				
	/gene="TRYPB1"		Fugu rubripes FVII and FVIIIB; contains 2 EGF-like domains;		
CDS	<1..736		member of peptidase family S1/trypsin family"		
	/gene="TRYPB1"		/codon_start=1		
	/codon_start=2		/product="coagulation factor VIIC precursor"		
	/product="trypsinogen B1"		/protein_id="AA033370.1"		
CDS	/protein_id="AAB69656.1"		/db_xref="GI:28194022"		
	/db_xref="GI:2367499"		/translation="WASFSRGTGRLLFFIKLITVPCSGFFPAGVFMKPEANVFLH		
	/translation="LIFALLVGTAAAPYVYEDHIVGGVECAHNSQFWQVSLNIGHTF		RTRRANFLFEELKAGNLECEIEKCYEAKEIFALPQLEAFWRTYTAADQCKLSP		
	CGSLISSWVWSAAHCYQTSIVRIGEHNFVTEGTQRIQASKAIRHPQYSAT		KNGATCTRRFFTYACKCANGHNCQVRLTNSGRYNGGCEHCFRFPDRSYVC		
CDS	IDNMLIKLSSPAINQYAAVPLSPSCVGTGVMCTISGWTQTQSVGSPDVMCVQ		FCAPGYRLDKDSTCLPVQVPCGLQILFSPRVINGLIPCQKHCQWQMLSENNTYT		
	APVLSTCRNSYPGDITNNMICLGLYLEGKDSQCGDSGPPVVCNGQLQGVSWGRGC		CGTIIILSEQWLTAHCVWRKPAHLENTVVGEDHREIFEKTEQHRVIVKLIHPGYNK		
	ALNYPGVYTKVCNYSWIASTMAAN"		TSSDKDLAMKLKLRHVKGLYVVPICLPAQNSTITRILANRQSTVSGWRLSRPGPP		
	<1..37		ATILQRLTLPRVLPQECRLHNTNMLCAGLKTGGRDACGDSGGLVITYIEKTM		
CDS	/gene="TRYPB1"		FLTGVSWGKCANENLYGVYVRVTNFDLWIGNIATN"		
	/evidence=not_experimental		Query Match		
	38..733		Best Local Similarity 69.4%; Pred. No. 2.3e+02;		
	/gene="TRYPB1"		Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;		
CDS	/product="trypsin B1"		1762 CTTTGGTTTTTCATAGTGTCTCTGCTTCTCTGGA 1797		
	sig_peptide		115 CCTCGGTTTTTCCATAAAACTCCCGCTTCGGAA 80		
	mat_peptide		RESULT 228		
	AX523898		AX523898		

LOCUS AX523898 1505 bp DNA linear PAT 24-OCT-2002
DEFINITION Sequence 105 from Patent WO02064799.
ACCESSION AX523898
VERSION AX523898.1 GI:24412662
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Seldon, R.F., Miller, A.M. and Treco, D.S.
AUTHORS Optimized messenger rna
TITLE Patent: WO 02064799-A 105 22-AUG-2002;
JOURNAL TRANSLARYOTIC THERAPIES, INC. (US)
FEATURES
Location/Qualifiers
source
1..1505
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.4; DB 1; Length 1505;
Best Local Similarity 59.6%; Pred. No. 2.3e+02;
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 1815 ATTTAGACTTAACATTTCTTTGACCAAGGTATCCATTTCTTCTATCTTCT 1866
|||||
Db 1425 AATTGAAATTAACAGGGCTCTCACTAACTAATCACTTTCCCATCTTTTCT 1476
|||||
RESULT 229
S78934
LOCUS S78934 171 bp DNA linear PRI 07-MAY-1993
DEFINITION (Factor IXMadrin 2) (exon IV and intron d) [human, Genomic Mutant,
171 nt].
ACCESSION S78934
VERSION S78934.1 GI:244109
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 171)
AUTHORS Solera, J., Magallon, M., Martin-Villar, J. and Coloma, A.
TITLE Factor IXMadrin 2: a deletion/insertion in factor IX gene which
abolishes the sequence of the donor junction at the exon IV-intron
d splice site
JOURNAL Am. J. Hum. Genet. 50 (2), 434-437 (1992)
MEDLINE 92133619
PUBMED 1346483
REMARK GenBank staff at the National Library of Medicine created this
entry [NCBI gibbsq 78934] from the original journal article.
This sequence comes from Fig 3A.
FEATURES
Location/Qualifiers
source
1..171
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.2; DB 1; Length 171;
Best Local Similarity 51.9%; Pred. No. 2.5e+02;
Matches 41; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 533 CTTTGTTTGGTGAATAGTCTGTAATAATCTCTAGGTCCACTGCTTTATGACATCA 592
|||||
Db 84 CCTTTGATTTGAAGGAAGAACTGTGAATTTCCAGTTTCAACTGTTTTCAGAGGAAA 143
|||||
QY 593 GTTAGCTCCAGATTTCTC 611
Db 144 CTTTGAACCATGAGTATTC 162
|||||
RESULT 230
AX318568

LOCUS AX318568 240 bp DNA linear PAT 06-JUL-2002
DEFINITION Sequence 73 from Patent WO0177155.
ACCESSION AX318568
VERSION AX318568.2 GI:21713338
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Fernandes, E., Vernet, C.A., Mishnu, V.S., Leach, M.D., Shimkets, R.A.,
Zerhusen, B.D. and Kekuda, R.
AUTHORS Orfx polynucleotides and polypeptides
TITLE Patent: WO 0177155-A 73 18-OCT-2001;
JOURNAL Curagen Corporation (US)
COMMENT On Jul 8, 2002 this sequence version replaced gi:17900986.
FEATURES
Location/Qualifiers
source
1..240
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.2; DB 1; Length 240;
Best Local Similarity 58.2%; Pred. No. 2.6e+02;
Matches 32; Conservative 0; Mismatches 23; Indels 0; Gaps 0;
QY 1752 TTCTCTATTCCTTTGTTTGTTCATAGTGTCTCTGCTTCTCTGATGTTTATG 1806
|||||
Db 26 TCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCTGCTCCCGATAGTTGGTG 80
|||||
RESULT 231
AY083553
LOCUS AY083553 251 bp DNA linear PRI 13-APR-2002
DEFINITION Macaca mulatta growth associated protein 43 (GAP43) gene, 3' UTR.
ACCESSION AY083553
VERSION AY083553.1 GI:20146915
KEYWORDS
SOURCE Macaca mulatta (rhesus monkey)
ORGANISM Macaca mulatta
Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
Cercopithecoidea; Macaca.
REFERENCE
1 (bases 1 to 251)
AUTHORS Norgren, R.B. Jr., Zink, M.A., Jia, Y., Ojeda, S.R. and Spindel, E.R.
TITLE Construction of a targeted thes macaque microarray
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 251)
AUTHORS Norgren, R.B. Jr., Zink, M.A., Jia, Y., Ojeda, S.R. and Spindel, E.R.
TITLE Direct Submission
JOURNAL Submitted (11-MAR-2002) Molecular and Cellular Biology Core, Oregon
Regional Primate Research Center, 505 NW 185th Avenue, Beaverton,
OR 97006, USA
FEATURES
Location/Qualifiers
source
1..251
/organism="Macaca mulatta"
/mol_type="genomic DNA"
/db_xref="taxon:9544"
<1..>251
/genes="GAP43"
<1..>251
/genes="GAP43"
/product="growth associated protein 43"
<1..>251
/genes="GAP43"
3'UTR
Query Match 0.8%; Score 18.2; DB 1; Length 251;
Best Local Similarity 55.6%; Pred. No. 2.6e+02;
Matches 35; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1006 TTCTGTACCCAGTATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTGATGTTGAGA 1065
|||||
Db 147 TTTTGTCTTGTGTTGTTATGGCGAGTTTGTGTAATGATTCATTCATTTGGGA 206
|||||

DEFINITION Petromyzon marinus trypsinogen b2 (TRYPB2) mRNA, partial cds.
ACCESSION AF011901 GI:2367500
VERSION AF011901.1
KEYWORDS
SOURCE
ORGANISM Petromyzon marinus (sea lamprey)
Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE
AUTHORS Roach, J.C.
TITLE The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL Unpublished
AUTHORS
REFERENCE 2 (bases 1 to 836)
AUTHORS Roach, J.C.
TITLE Direct Submission
JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA
FEATURES
Source
1..836
/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="ammocoete"
/tissue_lib="anterior intestine"
<1..836
/gene="TRYPB2"
<1..740
/gene="TRYPB2"
/codon_start=3
/product="trypsinogen b2"
/protein_id="AAB69657.1"
/db_xref="GI:2367501"
/translation="GLIFALLVCTRAAAPVMVEDHIVGGVECAHSPQVOVSLNIGVH
FCGSLISSEWVSAHCVQTSRISVRIGENHIVTEGTORIQASKAIRHPQYNVA
TIDNDIMLKSLPATLQYQAIPSPSCVGVGVMCTISGWGETQTSVGSPLVMCV
QAPVLSDTSCNSYPGDIITNMICLGYLEGKDCQDGGVVCVNGQLQGLVSGWRG
CALPNYPGVYTKVCYNYSWIASTMAAN"
sig_peptide
1..41
/gene="TRYPB2"
/evidence=not_experimental
42..737
/gene="TRYPB2"
/product="trypsin b2"
/evidence=not_experimental
mat_peptide
Query Match 0.8%; Score 18.2; DB 1; Length 836;
Best Local Similarity 47.1%; Pred. No. 2.6e+02;
Matches 56; Conservative 0; Mismatches 63; Indels 0; Gaps 0;
Qy 1538 TTTTCCCTTCATCTTTAATATTCTTTCTTTCTTCTATCTTTTGTGATTGATTATT 1597
Db 836 TTTTCTTTTAACTTTTCAAGTTTATTCGTTTCATGCAATACCAACCATCATAGT 777
Qy 1598 ATGCATGTGGGGAGTTTCTTTCCGTCGCAATATTGTTGTTGTGTTCTTGTG 1656
Db 776 CTCTGTCGCGCAAGGTGGCTCCGAGTCAGTCGCTGAGTCGATGGTGGTGG 718
RESULT 234
AF542056/c
LOCUS AF542056 987 bp mRNA linear ROD 28-JAN-2003
DEFINITION Mus musculus pancreasin mRNA, complete cds.
ACCESSION AF542056
VERSION AF542056.1 GI:27923336
KEYWORDS
SOURCE
ORGANISM Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 987)
AUTHORS Bhagwandin, V.J., Hau, L.W., Mallen-St Clair, J., Wolters, P.J. and
Caughney, G.H.
TITLE Structure and activity of human pancreasin, a novel tryptic serine

Qy 1066 ATT 1068
Db 207 AAT 209
RESULT 232
HSTCRB9
LOCUS HSTCRB9 265 bp mRNA linear PRI 22-DEC-1993
DEFINITION H.sapiens (3.2) mRNA for T-cell receptor beta chain.
X74849
ACCESSION X74849.1 GI:407455
KEYWORDS T-cell receptor beta chain; TCR-b gene.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 265)
AUTHORS Jores, R. and Meo, T.
TITLE Few V gene segments dominate the T cell receptor beta-chain
reertoire of the human thymus
JOURNAL J. Immunol. 151 (11), 6110-6122 (1993)
MEDLINE 94065165
PUBMED 8245454
REFERENCE 2 (bases 1 to 265)
AUTHORS Jores, R.
TITLE Direct Submission
JOURNAL Submitted (11-AUG-1993) R. Jores, Institut Pasteur, Unite
d'Immunogenetique, Dept d'Immunologie, 25, rue du Dr. Roux, 75015
Paris, FRANCE
FEATURES
Location/Qualifiers
1..265
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="3.2"
/tissue_type="thymus"
/clone_lib="human thymus cDNA"
1..265
/gene="TCR-b"
38..265
/gene="TCR-b"
/codon_start=1
/product="T-cell receptor beta chain"
/protein_id="CAA52841.1"
/db_xref="GI:407456"
/db_xref="EMBL:CAA52841"
/translation="MLSPDLPDSANWTRLLCRVWMLCLLGAGSVAAGVIQSPRLIKEK
RETATLKYPIPRHDTVYVYQQAEDLNVPFP"
sig_peptide
38..124
/gene="TCR-b"
125..265
/gene="TCR-b"
/product="T-cell receptor beta chain"
125..238
/gene="TCR-b"
/note="Vb23"
239..265
/gene="TCR-b"
/note="Cb2"
C_region
Query Match 0.8%; Score 18.2; DB 1; Length 265;
Best Local Similarity 58.2%; Pred. No. 2.6e+02;
Matches 32; Conservative 0; Mismatches 23; Indels 0; Gaps 0;
Qy 1182 TGTCTGCTCTGTCGTGTCGTCTCTCCCTCTTTTGTGTTTGGCTGGAA 1236
Db 58 TGACTCTCCCTGGGAACACAGGCTCTCTGCGGTGTCAGCTTGTCTCTCGGA 112
RESULT 233
AF011901/c
LOCUS AF011901 836 bp mRNA linear VRT 09-SEP-1997


```
Query Match      0.8%; Score 18; DB 1; Length 199;
Best Local Similarity 45.2%; Pred. No. 2.9e+02;
Matches 66; Conservative 0; Mismatches 80; Indels 0; Gaps 0;

QY 1646 TATGCTTCTTACCTGATAGGATCTCTTCTCAAGTTAGGAAATTTTCTTTTG 1705
DB 168 TGTCTTTTCAAGTGTTCACAAACTTCGTCCTCTCTCAAACTACACTTTCTCCAT 109
QY 1706 GTTTCTCTGAAATATTTCCCTGCTTTTGACCTGCTCTTCCCTCTCTATTCCTT 1765
DB 108 ACAATCTCTCAAGTTCCTTGACAACTTCCAACTTACCTGAATTATACCTCTT 49
QY 1766 TGGTTTTCATAGTGTCTCTGCTT 1791
DB 48 TGGCTCAATCAGAAATTTTGTGGCGT 23

RESULT 237
I14646/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .276
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
order (AY267909.1:1..270,1..276)
/gene="HLA-A"
/allele="HLA-A*3401 variant"
join (AY267909.1:1..270,1..276)
/gene="HLA-A"
/product="MHC class I antigen"
join (AY267909.1:1..270,1..276)
/gene="HLA-A"
/codon_start=3
/product="MHC class I antigen"
/protein_id="AAP32699.1"
/db_xref="GI:30525805"
/translation="SHSMRYFYTSVRPGRGEPRFIAVGYDDTQFVRFSDAASQRM
EPRAPWIRQEGPEYWDNRTRKVAQSQTDRVDLGLTRGYNQSGDSHTIQMYGCDV
GPDGFLRGYQODAYDGKDYLSLNEDLSRWTAADMAAQITQRKWEHAEQWRAYLE
GTCVEWLRRYLENGKETLQRT"
1. .276
/gene="HLA-A"
/number=3

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCCTTCTCCCTGCTGATTCCTAGGCTGAGGGTTACACCTGCTCTCTCTCC 228
DB 238 CTGCGGAGCCTCTCAGCAGCTGCCTCCAGGTAGGCTCTCCACTGCTCCGCTCATGG 179
QY 229 TTTCTCTAACACTT 242
DB 178 GCGGTCTCCACTT 165

RESULT 239
HSA507648/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .276
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"
1. .276
/gene="HLA-A"
/number=3

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCCTTCTCCCTGCTGATTCCTAGGCTGAGGGTTACACCTGCTCTCTCTCC 228
DB 238 CTGCGGAGCCTCTCAGCAGCTGCCTCCAGGTAGGCTCTCCACTGCTCCGCTCATGG 179
QY 229 TTTCTCTAACACTT 242
DB 178 GCGGTCTCCACTT 165

RESULT 238
AY267909S2/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
2 of 2
Homo sapiens (human)
Homo sapiens
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 276)
Steiner,N.K., Fernandez-Vina,M. and Hurley,C.K.
Novel HLA-A Allele
Unpublished
2 (bases 1 to 276)
Steiner,N.K., Fernandez-Vina,M. and Hurley,C.K.
Direct Submission
TITLE
Submitted (03-APR-2003) Lombardi Cancer Center, Georgetown
JOURNAL
University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
20007, USA
Location/Qualifiers

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCCTTCTCCCTGCTGATTCCTAGGCTGAGGGTTACACCTGCTCTCTCTCC 228
DB 238 CTGCGGAGCCTCTCAGCAGCTGCCTCCAGGTAGGCTCTCCACTGCTCCGCTCATGG 179
QY 229 TTTCTCTAACACTT 242
DB 178 GCGGTCTCCACTT 165

RESULT 238
AY267909S2/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
2 of 2
Homo sapiens (human)
Homo sapiens
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 276)
Steiner,N.K., Fernandez-Vina,M. and Hurley,C.K.
Novel HLA-A Allele
Unpublished
2 (bases 1 to 276)
Steiner,N.K., Fernandez-Vina,M. and Hurley,C.K.
Direct Submission
TITLE
Submitted (03-APR-2003) Lombardi Cancer Center, Georgetown
JOURNAL
University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
20007, USA
Location/Qualifiers
```

```

/allele="HLA-A*34"
/usedin=AJ507647:HLA-A*34_CDS

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 169 CTGCTGCTTCTCTCTGATTCTTAGGGTGAGGGTTACCACTGCTCTCTCTCCC 228
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 238 CTGGGAGCCACTCCACGACGTGCCCTCCAGGTAGGCTCTCCACTGCTCGGCTCATGG 179

Qy 229 TTTCTCTAAACTTT 242
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 178 GCCGTCTCCCACTT 165

RESULT 240
HSHLAAGN2/c
LOCUS      HSHLAAGN2      276 bp      DNA      linear      PRI 20-OCT-2000
DEFINITION Human MHC class I antigen HLA-A gene (A*2601 variant), exon 3 and
ACCESSION U90243
VERSION    U90243.1 GI:1905858
KEYWORDS   Novel HLA-A and HLA-B alleles
SEGMENT    Tissue Antigens 52 (1), 84-87 (1998)
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 276)
AUTHORS    Hurley,C.K., Steiner,N., Kosman,C., Mitton,W., Koester,R., Bei,M.,
            Hurley,J., McCormack,J., Hahn,A., Henson,V., Hoyer,R., Wade,J.A.,
            Hartzman,R.J. and Ng,J.
TITLE      Novel HLA-A and HLA-B alleles
JOURNAL    Tissue Antigens 52 (1), 84-87 (1998)
MEDLINE    98378282
REFERENCE  2 (bases 1 to 276)
AUTHORS    Bei,M. and Hurley,C.K.
TITLE      Direct Submission
JOURNAL    Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown
            University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
            20007, USA
FEATURES   Location/Qualifiers
            source
            1..276
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /isolate="GN00158"
            /db_xref="taxon:9606"
            join(U90242.1:<1..270,1..>276)
            /gene="HLA-A"
            join(U90242.1:<1..270,1..>276)
            /gene="HLA-A"
            /product="MHC class I antigen"
            join(U90242.1:<1..270,1..>276)
            /gene="HLA-A"
            /note="variant A*2601"
            /codon_start=3
            /product="MHC class I antigen"
            /protein_id="AAB50149.1"
            /db_xref="GI:1905860"
            /translation="SHSMRYFYTSVSRPGRGEPRFIAVGYYDDTQFVRFDSDAASQRM
            EPRAPWLEQSGPEVNDNRNKAHSOTDRANGLTGLGYNQSDGSHITQRYMGDV
            GPCRFLRGYQQDAYDKDYLALNEDLRSWTADMAAQITQKRWETAHEAQWRYALE
            GTCVWURRYLNGKETLQRT"
            1..276
            /gene="HLA-A"
            /number=3

exon
Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 169 CTGCTGCTTCTCTCTGATTCTTAGGGTGAGGGTTACCACTGCTCTCTCTCCC 228
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 238 CTGGGAGCCACTCCACGACGTGCCCTCCAGGTAGGCTCTCCACTGCTCGGCTCATGG 179

Qy 229 TTTCTCTAAACTTT 242
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 178 GCCGTCTCCCACTT 165

RESULT 240
HSHLAAGN2/c
LOCUS      HSHLAAGN2      276 bp      DNA      linear      PRI 20-OCT-2000
DEFINITION Human MHC class I antigen HLA-A gene (A*2601 variant), exon 3 and
ACCESSION U90243
VERSION    U90243.1 GI:1905858
KEYWORDS   Novel HLA-A and HLA-B alleles
SEGMENT    Tissue Antigens 52 (1), 84-87 (1998)
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 276)
AUTHORS    Hurley,C.K., Steiner,N., Kosman,C., Mitton,W., Koester,R., Bei,M.,
            Hurley,J., McCormack,J., Hahn,A., Henson,V., Hoyer,R., Wade,J.A.,
            Hartzman,R.J. and Ng,J.
TITLE      Novel HLA-A and HLA-B alleles
JOURNAL    Tissue Antigens 52 (1), 84-87 (1998)
MEDLINE    98378282
REFERENCE  2 (bases 1 to 276)
AUTHORS    Bei,M. and Hurley,C.K.
TITLE      Direct Submission
JOURNAL    Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown
            University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
            20007, USA
FEATURES   Location/Qualifiers
            source
            1..276
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /isolate="GN00158"
            /db_xref="taxon:9606"
            join(U90242.1:<1..270,1..>276)
            /gene="HLA-A"
            join(U90242.1:<1..270,1..>276)
            /gene="HLA-A"
            /product="MHC class I antigen"
            join(U90242.1:<1..270,1..>276)
            /gene="HLA-A"
            /note="variant A*2601"
            /codon_start=3
            /product="MHC class I antigen"
            /protein_id="AAB50149.1"
            /db_xref="GI:1905860"
            /translation="SHSMRYFYTSVSRPGRGEPRFIAVGYYDDTQFVRFDSDAASQRM
            EPRAPWLEQSGPEVNDNRNKAHSOTDRANGLTGLGYNQSDGSHITQRYMGDV
            GPCRFLRGYQQDAYDKDYLALNEDLRSWTADMAAQITQKRWETAHEAQWRYALE
            GTCVWURRYLNGKETLQRT"
            1..276
            /gene="HLA-A"
            /number=3

exon
Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 169 CTGCTGCTTCTCTCTGATTCTTAGGGTGAGGGTTACCACTGCTCTCTCTCCC 228
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 238 CTGGGAGCCACTCCACGACGTGCCCTCCAGGTAGGCTCTCCACTGCTCGGCTCATGG 179

Qy 229 TTTCTCTAAACTTT 242
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 178 GCCGTCTCCCACTT 165

RESULT 241
AR249144/c
LOCUS      AR249144      290 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 4503 from patent US 6476212.
ACCESSION AR249144
VERSION    AR249144.1 GI:27297018
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified
REFERENCE  1 (bases 1 to 290)
AUTHORS    Lalgudi,R.V., Ito,L.Y. and Sherman,B.K.
TITLE      Polynucleotides and polypeptides derived from corn ear
JOURNAL    Patent: US 6476212-A 4503 05-NOV-2002;
            Location/Qualifiers
FEATURES   source
            1..290
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 18; DB 1; Length 290;
Best Local Similarity 51.2%; Pred. No. 2.9e+02;
Matches 42; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

Qy 1683 GGTAGGAATTTCTTTTGGTTTCTTGAATAATTTCCCTGCTTTGACCTGCC 1742
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 218 GGCGGGAGATCTTGCCTCTCTGCTCCAGGAGGCTCGGCTCTCCAGGGCTGAC 159

Qy 1743 TTCTTCCCTTCCCTATTCT 1764
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 158 TGCAGTCCATCTTCTCGGCT 137

RESULT 242
AX312474
LOCUS      AX312474      299 bp      DNA      linear      PAT 14-DEC-2001
DEFINITION Sequence 5459 from Patent WO0190366.
ACCESSION AX312474
VERSION    AX312474.1 GI:17897467
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Leach,M.D. and Shimkets,R.A.
TITLE      Human polynucleotides and polypeptides encoded thereby
JOURNAL    Patent: WO 0190366-A 5459 29-NOV-2001;
            Curagen Corporation (US)
            Location/Qualifiers
FEATURES   source
            1..299
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 18; DB 1; Length 299;
Best Local Similarity 54.5%; Pred. No. 2.9e+02;
Matches 36; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

Qy 1732 TTTCAGCTGCTTCTTCCCTCTCTATTCTTGGTTTTCATAGTGTCTGTGCTT 1791
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 220 TTGCAGTGGCTTCACCCATCTCCTTCAATGACTACATGCTCCAGTCTCCCTCCCGAAA 279

Qy 1792 CCTGGA 1797
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
```

Db	280	CCTGGA	285
RESULT 243	BTA271156/c		
LOCUS	BTA271156	302 bp	mRNA linear MAM 27-JUL-2000
DEFINITION	Bos taurus partial mRNA for haptoglobin (hp gene).		
ACCESSION	AJ271156		
VERSION	AJ271156.1	GI:9581738	
KEYWORDS	haptoglobin; hp gene.		
SOURCE	Bos taurus (cow)		
ORGANISM	Bos taurus		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovinae; Bos.		
REFERENCE	Lavery, K.S., Gabler, C. and Killian, G.J.		
AUTHORS	Expression and localization of haptoglobin in the bovine female reproductive tract		
TITLE	Unpublished		
JOURNAL	2 (bases 1 to 302)		
REFERENCE	Lavery, K.S.		
AUTHORS	Direct Submission		
TITLE	Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science, Pennsylvania State University, The John O. Almquist Research Center, Fox Hollow Road, University Park, USA		
JOURNAL	Location/Qualifiers		
FEATURES	source		
	1..302	/organism="Bos taurus"	
		/mol_type="mRNA"	
		/db_xref="taxon:9913"	
		/sex="female"	
		/cell_type="epithelial cell"	
		/tissue_type="oviduct"	
		/dev_stage="adult"	
	1..302	/gene="hp"	
	<1..>302	/function="acute phase protein"	
		/codon_start=3	
		/product="haptoglobin"	
		/protein_id="CAC00531.1"	
		/db_xref="GI:9581739"	
		/db_xref="GOA:Q9MYV8"	
		/db_xref="SPTRMBL:Q9MYV8"	
		/translation="KGSFPFQAQKVVSQHNLISATLINERWLLTAKNLYGHSSDKK AKDITPRLYLVGNQLVEVEKVLHPDHSHKDVLGLKLKQKVPNDKWPEICLPs"	
Query Match	0.8%; Score 18; DB 1; Length 302;		
Best Local Similarity	52.7%; Pred. No. 2.9e+02;		
Matches	39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
OY	1656	GTAACCTTGATGGCATCTTTCTCAAGGTAGGAATTTCCTTTTGTCTTCTGA	1715
Db	297	GTAGCGCAGTGGCCATTACTTGTCTTGCATGACAGGTACCTTCTGCTGATTTGATGACC	238
OY	1716	AAATATTTTCCCTG	1729
Db	237	CAATGCTACCTTG	224
RESULT 244	FRSPLEX2/c		
LOCUS	FRSPLEX2	335 bp	DNA linear VRT 28-OCT-2000
DEFINITION	F.rubripes serine protease-like exon (335bp).		
ACCESSION	X95338		
VERSION	X95338.1	GI:1171532	
KEYWORDS	Takifugu rubripes (fugu rubripes)		
SOURCE	Takifugu rubripes		
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;		
REFERENCE	Lavery, K.S., Gabler, C. and Killian, G.J.		
AUTHORS	Expression and localization of haptoglobin in the bovine female reproductive tract		
TITLE	Unpublished		
JOURNAL	2 (bases 1 to 302)		
REFERENCE	Lavery, K.S.		
AUTHORS	Direct Submission		
TITLE	Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science, Pennsylvania State University, The John O. Almquist Research Center, Fox Hollow Road, University Park, USA		
JOURNAL	Location/Qualifiers		
FEATURES	source		
	1..302	/organism="Bos taurus"	
		/mol_type="mRNA"	
		/db_xref="taxon:9913"	
		/sex="female"	
		/cell_type="epithelial cell"	
		/tissue_type="oviduct"	
		/dev_stage="adult"	
	1..302	/gene="hp"	
	<1..>302	/function="acute phase protein"	
		/codon_start=3	
		/product="haptoglobin"	
		/protein_id="CAC00531.1"	
		/db_xref="GI:9581739"	
		/db_xref="GOA:Q9MYV8"	
		/db_xref="SPTRMBL:Q9MYV8"	
		/translation="KGSFPFQAQKVVSQHNLISATLINERWLLTAKNLYGHSSDKK AKDITPRLYLVGNQLVEVEKVLHPDHSHKDVLGLKLKQKVPNDKWPEICLPs"	
Query Match	0.8%; Score 18; DB 1; Length 302;		
Best Local Similarity	52.7%; Pred. No. 2.9e+02;		
Matches	39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
OY	1656	GTAACCTTGATGGCATCTTTCTCAAGGTAGGAATTTCCTTTTGTCTTCTGA	1715
Db	297	GTAGCGCAGTGGCCATTACTTGTCTTGCATGACAGGTACCTTCTGCTGATTTGATGACC	238
OY	1716	AAATATTTTCCCTG	1729
Db	237	CAATGCTACCTTG	224
REFERENCE	Lavery, K.S., Gabler, C. and Killian, G.J.		
AUTHORS	Expression and localization of haptoglobin in the bovine female reproductive tract		
TITLE	Unpublished		
JOURNAL	2 (bases 1 to 302)		
REFERENCE	Lavery, K.S.		
AUTHORS	Direct Submission		
TITLE	Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science, Pennsylvania State University, The John O. Almquist Research Center, Fox Hollow Road, University Park, USA		
JOURNAL	Location/Qualifiers		
FEATURES	source		
	1..302	/organism="Bos taurus"	
		/mol_type="mRNA"	
		/db_xref="taxon:9913"	
		/sex="female"	
		/cell_type="epithelial cell"	
		/tissue_type="oviduct"	
		/dev_stage="adult"	
	1..302	/gene="hp"	
	<1..>302	/function="acute phase protein"	
		/codon_start=3	
		/product="haptoglobin"	
		/protein_id="CAC00531.1"	
		/db_xref="GI:9581739"	
		/db_xref="GOA:Q9MYV8"	
		/db_xref="SPTRMBL:Q9MYV8"	
		/translation="KGSFPFQAQKVVSQHNLISATLINERWLLTAKNLYGHSSDKK AKDITPRLYLVGNQLVEVEKVLHPDHSHKDVLGLKLKQKVPNDKWPEICLPs"	
Query Match	0.8%; Score 18; DB 1; Length 302;		
Best Local Similarity	52.7%; Pred. No. 2.9e+02;		
Matches	39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
OY	1656	GTAACCTTGATGGCATCTTTCTCAAGGTAGGAATTTCCTTTTGTCTTCTGA	1715
Db	2		


```
Query Match          0.8%; Score 18; DB 1; Length 1329;
Best Local Similarity 52.7%; Pred. No. 2.8e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 1503 TCTATACATCGCCCTTATATGTAATGGTCTTTTTCCTTGTCATCTTTTAATATTC 1562
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 209 TCGATACCTTCGAGCTTCCTCGTAGTTGCAGATCTCTCGATCTCTCTTCAGG 150
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 1563 TTCTTTTGTCTPAT 1576
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 149 TTTCCTTGTTCAT 136
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 249
E02492/c
LOCUS          E02492          1389 bp      DNA      linear      PAT 29-SEP-1997
DEFINITION    DNA encoding protein C mutant.
ACCESSION     E02492
VERSION       E02492.1 GI:2170722
KEYWORDS      JP 1990167096-A/1.
SOURCE        synthetic construct
              synthetic construct
              artificial sequences.
REFERENCE     1 (bases 1 to 1389)
              Hashimoto,T. and Sato,M.
              HUMAN PROTEIN C MUTANT AND ITS PRODUCTION
              Patent: JP 1990167096-A 1 27-JUN-1990;
              HOECHST JAPAN LTD
COMMENT       OS Artificial gene
              OC Artificial sequence; Genes.
              OS Homo sapiens (human)
              PN JP 1990167096-A/1
              PD 27-JUN-1990
              PF 13-JUL-1989 JP 1989179140
              PR 26-JUL-1988 JP 88P 184538
              PI HASHIMOTO TAMOTSU, SATO MASAHIRO
              PC C12P21/02,C07K13/00,C12N15/12//A61K37/465,(C12P21/02,PC
              C12R1:91);
              CC strandedness: Single;
              CC topology: Linear;
              CC anti-sense: No;
              PH Key
              PH Key Location/Qualifiers
              FT sig_peptide 1..126
              FT /product='signal peptide of protein' FT
              mat_peptide 127..1383
              FT /product='protein c mutant'
              FT CDS 1..1389
              FT /product='protein c mutant'
              FT mutation replace(592..597,')
              FT /product='protein c mutant'
              FT mutation replace(592..594,')
              FT /product='protein c mutant'
              FT mutation replace(595..597,')
              FT /product='protein c mutant'
              FT Location/Qualifiers
              source 1..1389
              /organism='synthetic construct'
              /mol_type='genomic DNA'
              /db_xref='taxon:32630'

Query Match          0.8%; Score 18; DB 1; Length 1389;
Best Local Similarity 60.0%; Pred. No. 2.8e+02;
Matches 30; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1833 TCTTTGACCAAGGATCCATTTCTTCTATCTTTGTCTTCATCGCTCGAGAT 1882
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 641 TCAATGACGCGGAGTCTACTTGGTCTTCTTGTCTTCTGTGTCGAGTT 592
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 250
AX381010/c
LOCUS          AX381010          177 bp      DNA      linear      PAT 18-MAR-2002
```

```
DEFINITION      Sequence 51 from Patent WO0212456.
ACCESSION       AX381010
VERSION         AX381010.1 GI:19575845
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE       1
AUTHORS         Drucker,D.J., Rosen,C.F. and Lefebvre,D.L.
TITLE           Ampk-related serine/threonine kinase, designated snark
JOURNAL         Patent: WO 0212456-A 51 14-FEB-2002;
                1149336 ONTARIO INC. (CA)
FEATURES        Location/Qualifiers
                source 1..177
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match          0.8%; Score 17.8; DB 1; Length 177;
Best Local Similarity 58.5%; Pred. No. 3.2e+02;
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATACTTCTGGGGCTGCTTCTCCCTCTCTGATTCCTTAGGG 200
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 93 CCGCAGTTGTCTGTGTGGTGGTGGCTTACCGCGCTTCTTCTTCTTAGGG 41
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Search completed: August 9, 2004, 17:11:26
Job time : 733 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 17:04:56 ; Search time 885 Seconds

(without alignments)

3.922 Million cell updates/sec

Title: us-10-664-775-4

Perfect score: 2279

Sequence: 1 gatcactcctctagtgaag.....ttgtaattctagggtctgat 2279

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1612 seqs, 761539 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	43	1.9	2422	1	CDNA encoding Fact
C 2	43	1.9	2422	1	Hom sapiens cDNA
C 3	43	1.9	2422	1	Factor VII encoding
C 4	43	1.9	2422	1	Human Factor VII p
C 5	43	1.9	2422	1	Human NOV8a encodi
C 6	43	1.9	2462	1	DNA encoding coagu
C 7	43	1.9	2462	1	DNA encoding Facto
C 8	43	1.9	2462	1	Vitamin-K-dependen
C 9	43	1.9	2462	1	Human factor VII c
C 10	43	1.9	2462	1	DNA encoding coagu
C 11	43	1.9	2462	1	Thyroid cancer rel
C 12	43	1.9	2462	1	Gene #2251 used to
C 13	43	1.9	2483	1	Factor VII cDNA of
C 14	41.6	1.8	2177	1	Partial Factor VII
C 15	41.6	1.8	2438	1	Factor IX/Factor V
C 16	32.4	1.4	300	1	Human gene expres
C 17	25.6	1.1	254	1	Human secreted pro
C 18	25.4	1.1	237	1	DNA encoding novel
C 19	25.2	1.1	1843	1	Human protein C co
C 20	25.2	1.1	1843	1	Human protein C ge
C 21	25.2	1.1	1843	1	Gene #3673 used to
C 22	24.2	1.1	267	1	Human bone marrow
C 23	24.2	1.1	267	1	Human brain expres
C 24	24.2	1.1	267	1	Human liver single
C 25	24.2	1.1	267	1	Human genome-deriv
C 26	23.8	1.0	868	1	Human cDNA clone r
C 27	23.8	1.0	868	1	Human cDNA 5'-end
C 28	23.4	1.0	612	1	Oligonucleotide fo
C 29	23.4	1.0	612	1	Oligonucleotide fo
C 30	23	1.0	306	1	Serine protease ni
C 31	23	1.0	1507	1	Human factor X cod
C 32	23	1.0	1507	1	Human gene expres
C 33	23	1.0	1507	1	Farnesyl transfera

C 34	22.8	1.0	200	1	Targetting arm #2
C 35	22.8	1.0	433	1	Human adult liver
C 36	22.8	1.0	1151	1	Human secreted pro
C 37	22.4	1.0	271	1	Single nucleotide
C 38	22.4	1.0	476	1	Probe #1464 for ge
C 39	22.4	1.0	476	1	Human foetal liver
C 40	22.4	1.0	476	1	Probe #1496 used t
C 41	22.4	1.0	476	1	Human breast cell
C 42	22.4	1.0	476	1	Probe #1452 for ge
C 43	22.4	1.0	476	1	Human bone marrow
C 44	22.4	1.0	476	1	Human brain expres
C 45	22.4	1.0	476	1	Human liver single
C 46	22.4	1.0	476	1	Probe #1440 used t
C 47	22.4	1.0	476	1	Human genome-deriv
C 48	22.2	1.0	301	1	Probe #9609 for ge
C 49	22.2	1.0	301	1	Human foetal liver
C 50	22.2	1.0	301	1	Probe #13557 used
C 51	22.2	1.0	301	1	Human breast cell
C 52	22.2	1.0	301	1	Probe #10292 for g
C 53	22.2	1.0	301	1	Human bone marrow
C 54	22.2	1.0	301	1	Human brain expres
C 55	22.2	1.0	301	1	Human liver single
C 56	22.2	1.0	301	1	Probe #5386 used t
C 57	22.2	1.0	301	1	Human genome-deriv
C 58	22	1.0	121	1	Factor IX mutation
C 59	22	1.0	121	1	Factor IX mutation
C 60	22	1.0	121	1	Factor IX mutation
C 61	22	1.0	121	1	Factor IX mutation
C 62	22	1.0	121	1	Factor IX mutation
C 63	22	1.0	121	1	Factor IX mutation
C 64	22	1.0	121	1	Factor IX mutation
C 65	22	1.0	121	1	Factor IX mutation
C 66	22	1.0	121	1	Factor IX mutation
C 67	22	1.0	121	1	Factor IX mutation
C 68	22	1.0	121	1	Factor IX mutation
C 69	22	1.0	121	1	Factor IX mutation
C 70	22	1.0	385	1	Human secreted pro
C 71	22	1.0	612	1	Oligonucleotide fo
C 72	22	1.0	612	1	Oligonucleotide fo
C 73	21.6	0.9	253	1	Single nucleotide
C 74	21.6	0.9	254	1	Human pancreatic c
C 75	21.4	0.9	283	1	Galanin receptor G
C 76	21.4	0.9	283	1	Galanin receptor G
C 77	21.4	0.9	283	1	Galanin receptor G
C 78	21.4	0.9	283	1	Rat galanin recept
C 79	21.4	0.9	1129	1	Human cDNA sequen
C 80	21.4	0.9	1129	1	Novel human secret
C 81	21.4	0.9	1129	1	CDNA encoding huma
C 82	21.4	0.9	1129	1	CDNA encoding huma
C 83	21.4	0.9	1129	1	DNA encoding novel
C 84	21.4	0.9	1129	1	Human secreted/tra
C 85	21.4	0.9	1129	1	Human cDNA encodin
C 86	21.4	0.9	1129	1	Novel human secret
C 87	21.4	0.9	1129	1	Human PRO polynucl
C 88	21.4	0.9	1129	1	Human PRO polynucl
C 89	21.4	0.9	1129	1	Human PRO polynucl
C 90	21.4	0.9	1129	1	Novel human secret
C 91	21.4	0.9	1129	1	CDNA encoding huma
C 92	21.4	0.9	1129	1	Novel human secret
C 93	21.4	0.9	1129	1	Human PRO polynucl
C 94	21.4	0.9	1129	1	Human PRO polynucl
C 95	21.4	0.9	1129	1	Human PRO polynucl
C 96	21.4	0.9	1129	1	CDNA encoding huma
C 97	21.4	0.9	1129	1	Novel human secret
C 98	21.4	0.9	1129	1	Human PRO polynucl
C 99	21.4	0.9	1129	1	Human PRO polynucl
C 100	21.4	0.9	1129	1	Novel human secret
C 101	21.4	0.9	1129	1	Human PRO polynucl
C 102	21.4	0.9	1129	1	Novel human secret
C 103	21.4	0.9	1129	1	Human PRO polynucl
C 104	21.4	0.9	1129	1	Human PRO polynucl
C 105	21.4	0.9	1129	1	Human PRO polynucl
C 106	21.4	0.9	1129	1	Novel human secret

C 107	21.4	0.9	1129	1	ADBI3093	Human PRO polynucle
C 108	21.4	0.9	1129	1	ACD98534	Novel human secret
C 109	21.4	0.9	1129	1	ADA74347	Human PRO polynucle
C 110	21.4	0.9	1129	1	ADB24580	Human PRO polynucle
C 111	21.4	0.9	1129	1	ADA82104	Human PRO polynucle
C 112	21.4	0.9	1129	1	ADA75067	Human PRO polynucle
C 113	21.4	0.9	1129	1	ADA85145	Novel human secret
C 114	21.4	0.9	1129	1	ADA84593	Novel human secret
C 115	21.4	0.9	1129	1	ADB29849	cDNA encoding huma
C 116	21.4	0.9	1129	1	ADA80377	Human PRO polynucle
C 117	21.4	0.9	1129	1	ADA75619	Human PRO polynucle
C 118	21.4	0.9	1129	1	ADA46844	Human PRO polynucle
C 119	21.4	0.9	1129	1	ADB25140	Human PRO polynucle
C 120	21.4	0.9	1129	1	ADA93316	Human PRO polynucle
C 121	21.4	0.9	1129	1	ADB26666	cDNA encoding huma
C 122	21.4	0.9	1129	1	ADB30953	cDNA encoding huma
C 123	21.4	0.9	1129	1	ADA60881	Homo sapiens, Nov
C 124	21.4	0.9	1129	1	ADB34028	Human PRO polynucle
C 125	21.4	0.9	1129	1	ADA96357	Human PRO polynucle
C 126	21.4	0.9	1129	1	ADA80929	Human PRO polynucle
C 127	21.4	0.9	1129	1	ADA95805	Human PRO polynucle
C 128	21.4	0.9	1129	1	ADB26114	cDNA encoding huma
C 129	21.4	0.9	1129	1	ADB21599	Novel human secret
C 130	21.4	0.9	1129	1	ADA77378	Human PRO polynucle
C 131	21.4	0.9	1129	1	ADBI8118	cDNA encoding huma
C 132	21.4	0.9	1129	1	ADA86801	Novel human secret
C 133	21.4	0.9	1129	1	ADA87904	Novel human secret
C 134	21.4	0.9	1129	1	ADA46292	Novel human secret
C 135	21.4	0.9	1129	1	ADB28322	cDNA encoding huma
C 136	21.4	0.9	1129	1	ADB28874	cDNA encoding huma
C 137	21.4	0.9	1129	1	ADA76826	Human PRO polynucle
C 138	21.4	0.9	1129	1	ADA88456	Novel human secret
C 139	21.4	0.9	1129	1	ADA97461	Human PRO polynucle
C 140	21.4	0.9	1129	1	ADB27218	cDNA encoding huma
C 141	21.4	0.9	1129	1	ADB22151	Novel human secret
C 142	21.4	0.9	1129	1	ADA66842	Human PRO polynucle
C 143	21.4	0.9	1129	1	ADB22703	Human PRO polynucle
C 144	21.4	0.9	1129	1	ADB23476	Human PRO polynucle
C 145	21.4	0.9	1129	1	ADA92198	Novel human secret
C 146	21.4	0.9	1129	1	ADBI5261	Human PRO polynucle
C 147	21.4	0.9	1129	1	ADB38513	Novel human secret
C 148	21.4	0.9	1129	1	ADB37961	Novel human secret
C 149	21.4	0.9	1129	1	ADB66433	Novel human secret
C 150	21.4	0.9	1129	1	ADB89513	Human PRO polynucle
C 151	21.4	0.9	1129	1	ADB90245	Human PRO polynucle
C 152	21.4	0.9	1129	1	ADB33346	Novel human secret
C 153	21.4	0.9	1129	1	ADB46969	Novel human secret
C 154	21.4	0.9	1129	1	ADB86576	Human PRO polynucle
C 155	21.4	0.9	1129	1	ADB77181	Novel human secret
C 156	21.4	0.9	1129	1	ADB34338	Human PRO polynucle
C 157	21.4	0.9	1129	1	ADB35442	Human PRO polynucle
C 158	21.4	0.9	1129	1	ADB33786	Human PRO polynucle
C 159	21.4	0.9	1129	1	ADB34890	Human PRO polynucle
C 160	21.4	0.9	1129	1	ADB35994	Human PRO polynucle
C 161	21.4	0.9	1129	1	ADB46389	Novel human secret
C 162	21.4	0.9	1129	1	ADC50262	Novel human secret
C 163	21.4	0.9	1129	1	ADC71809	Novel human secret
C 164	21.4	0.9	1129	1	ADC59788	Novel human secret
C 165	21.4	0.9	1129	1	ADC52795	Novel human secret
C 166	21.4	0.9	1129	1	ADC57149	Novel human secret
C 167	21.4	0.9	1129	1	ADC60340	Novel human secret
C 168	21.4	0.9	1129	1	ADC50815	Novel human secret
C 169	21.4	0.9	1129	1	ADC65342	Human PRO polynucle
C 170	21.4	0.9	1129	1	ADC54440	Novel human secret
C 171	21.4	0.9	1129	1	ADC53401	Novel human secret
C 172	21.4	0.9	1129	1	ADC58924	Novel human secret
C 173	21.4	0.9	1129	1	ADC55802	Novel human secret
C 174	21.4	0.9	1129	1	ADC58372	Novel human secret
C 175	21.4	0.9	1129	1	ADD03046	Novel human secret
C 176	21.4	0.9	1129	1	ADC90038	Novel human secret
C 177	21.4	0.9	1129	1	ADC69457	cDNA encoding huma
C 178	21.4	0.9	1129	1	ADC48346	Human PRO polynucle
C 179	21.4	0.9	1129	1	ADD09875	Human PRO polynucle
C 180	21.4	0.9	1129	1	ADD04450	Novel human secret
C 181	21.4	0.9	1129	1	ADC80406	Novel human secret
C 182	21.4	0.9	1129	1	ADD10913	Human PRO polynucle
C 183	21.4	0.9	1129	1	ADC47794	Human PRO polynucle
C 184	21.4	0.9	1129	1	ADC79854	Human PRO polynucle
C 185	21.4	0.9	1129	1	ADD09323	Novel human secret
C 186	21.4	0.9	1129	1	ADD41036	Novel human secret
C 187	21.4	0.9	1129	1	ADD52175	cDNA encoding huma
C 188	21.4	0.9	1129	1	ADD52915	cDNA encoding huma
C 189	21.4	0.9	1129	1	ADD53467	Novel human secret
C 190	21.4	0.9	1129	1	ADD51623	cDNA encoding huma
C 191	21.4	0.9	1129	1	ADD02422	Human PRO polynucle
C 192	21.4	0.9	1129	1	ADD01856	Human PRO polynucle
C 193	21.4	0.9	1129	1	ADD54038	Novel human secret
C 194	21.4	0.9	1129	1	ADD92355	Human PRO polynucle
C 195	21.4	0.9	1129	1	ADD91251	Human PRO polynucle
C 196	21.4	0.9	1129	1	ADE03865	Human PRO polynucle
C 197	21.4	0.9	1129	1	ADE32162	Novel human secret
C 198	21.4	0.9	1129	1	ADE22094	cDNA encoding huma
C 199	21.4	0.9	1129	1	ADD79318	cDNA encoding huma
C 200	21.4	0.9	1129	1	ADE41854	Human PRO polynucle
C 201	21.4	0.9	1129	1	ADE17671	Human PRO polynucle
C 202	21.4	0.9	1129	1	ADD91803	Human PRO polynucle
C 203	21.4	0.9	1129	1	ADE33266	Novel human secret
C 204	21.4	0.9	1129	1	ADE33818	Novel human secret
C 205	21.4	0.9	1129	1	ADD79870	cDNA encoding huma
C 206	21.4	0.9	1129	1	ADD92907	Human PRO polynucle
C 207	21.4	0.9	1129	1	ADE19327	Human PRO polynucle
C 208	21.4	0.9	1129	1	ADE18775	Human PRO polynucle
C 209	21.4	0.9	1129	1	ADE42971	Human PRO polynucle
C 210	21.4	0.9	1129	1	ADD95760	Human PRO polynucle
C 211	21.4	0.9	1129	1	ADE22646	cDNA encoding huma
C 212	21.4	0.9	1129	1	ADD78764	cDNA encoding huma
C 213	21.4	0.9	1129	1	ADE32714	Novel human secret
C 214	21.4	0.9	1129	1	ADE42406	Human PRO polynucle
C 215	21.4	0.9	1129	1	ADD80422	cDNA encoding huma
C 216	21.4	0.9	1129	1	ADD89450	Human PRO polynucle
C 217	21.4	0.9	1129	1	ADE40734	Human PRO polynucle
C 218	21.4	0.9	1129	1	ADE04533	Human PRO polynucle
C 219	21.4	0.9	1129	1	ADC80958	Novel human secret
C 220	21.4	0.9	1129	1	ADD76406	Human PRO polynucle
C 221	21.4	0.9	1129	1	ADD87770	Human PRO polynucle
C 222	21.4	0.9	1129	1	ADD86174	Human PRO polynucle
C 223	21.4	0.9	1129	1	ADE75622	Human PRO polynucle
C 224	21.4	0.9	1129	1	ADE23198	cDNA encoding huma
C 225	21.4	0.9	1129	1	ADE23750	cDNA encoding huma
C 226	21.4	0.9	1129	1	ADD87218	Human PRO polynucle
C 227	21.4	0.9	1129	1	ADD89084	Human PRO polynucle
C 228	21.4	0.9	1129	1	ADE18223	Human PRO polynucle
C 229	21.4	0.9	1129	1	ADE88532	Human PRO polynucle
C 230	21.4	0.9	1129	1	ABX14193	Plasmid pLN174 for
C 231	21.4	0.9	6098	1	ABA79647	Factor IX mutation
C 232	21.2	0.9	121	1	ABA79646	Factor IX mutation
C 233	21.2	0.9	121	1	ABA79642	Factor IX mutation
C 234	21.2	0.9	121	1	ABA79643	Factor IX mutation
C 235	21.2	0.9	305	1	ABX68969	Novel murine polyn
C 236	21.2	0.9	286	1	ABL76656	Corn tassell-derive
C 237	21.1	0.9	267	1	ABV8246	EST clone EA90. H
C 238	21	0.9	267	1	ABV8246	Bovine EST associa
C 239	21	0.9	372	1	ABX37095	Probe #10127 for g
C 240	20.8	0.9	263	1	AAI20194	Human foetal liver
C 241	20.8	0.9	263	1	ABA65223	Probe #14080 used
C 242	20.8	0.9	263	1	AAI45394	Human breast cell
C 243	20.8	0.9	263	1	ABA47338	Probe #10790 for g
C 244	20.8	0.9	263	1	ABA32324	Human bone marrow
C 245	20.8	0.9	263	1	AAK33381	Human brain expres
C 246	20.8	0.9	263	1	AAK13640	Human liver single
C 247	20.8	0.9	263	1	ABS38969	Probe #5889 used t
C 248	20.8	0.9	263	1	AAI05898	Human genome-deriv
C 249	20.8	0.9	263	1	ABS13468	Human breast cance
C 250	20.8	0.9	280	1	AAI22285	

[illegible]

1118 y

Db 1886 TGTGTGATCCGTTGTGTGCATATCTCTGTGTGTGTGCATGCGGTGTGTGTGTGCA 1827

QY 1178 TCTGTGTCTGT 1188

Db 1826 TCCATGTGTGT 1816

RESULT 3

AAZ57385/C

ID AAZ57385 standard; cDNA; 2422 BP.

XX AAZ57385;

DT 05-APR-2000 (first entry)

XX

DE Factor VII encoding cDNA SEQ ID NO:1.

XX

KW Factor VII; catalytic active site; blood coagulation; plasma; Factor X;

KW Factor IX; vasotropic; antiischaemic; anticoagulant; myocardial injury;

KW post-ischaemic reperfusion; platelet deposition; thrombus formation;

KW vascular potency; ss.

XX

OS Unidentified.

XX

FH Key Location/Qualifiers

FT CDS 28..1375

FT /*tag= a

FT /product= "Factor VII"

XX

XX US5997864-A.

XX

PD 07-DEC-1999.

XX

PF 06-JUN-1997; 97US-00871003.

XX

PR 28-FEB-1991; 91US-00662920.

PR 21-MAY-1993; 93US-00065725.

PR 23-MAY-1994; 94WO-US005779.

PR 24-OCT-1994; 94US-00327690.

PR 07-JUN-1995; 95US-00475845.

PR 07-JUN-1996; 96US-00660289.

XX

XX (NOVO) NOVO-NORDISK AS.

PA (ZYMO) ZYMOGENETICS INC.

XX

XX Hart CE, Petersen LC, Hedner U, Rasmussen ME;

XX

DR WPI; 2000-104599/09.

DR P-PSDB; AAY67967.

XX

FT Inhibition or minimization of myocardial injury associated with post-ischemic reperfusion.

XX

ES Disclosure; Col 43-48; 34pp; English.

XX

CC The present invention describes a method for the inhibition or minimisation of myocardial injury associated with post-ischaemic reperfusion by administering factor VII, which has at least 1 modification in its catalytic triad (therefore inhibiting the ability of factor VII to activate plasma factor X or IX). The method can be used for inhibiting or minimising myocardial injury and for imparting regional myocardial blood flow associated with post-ischaemic reperfusion. It can also be used for inhibiting blood coagulation, platelet deposition, thrombus formation and maintaining or improving vascular potency. Factor VII can be administered at relatively low doses and does not produce undesirable side effects. Further it acts specifically at sites of injury. The present sequence encodes Factor VII

XX

SQ Sequence 2422 BP; 596 A; 712 C; 692 G; 422 T; 0 U; 0 Other;

Query Match 1.9%; Score 43; DB 1; Length 2422;

Best Local Similarity 58.0%; Pred. No. 8.5e-05;

Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 1058 TGTGAGAAATTAATCAATGACGAGTGTGTGTGATTTCTTGTATCTTGCACTTGTGAAGTG 1117

Db 1946 TGTGCATATCTCTATGTGCGGTGTGCATCGGTGTGTTCGCGTATCTCTGTGTGACCATCTG 1887

QY 1118 TG 1177

Db 1886 TGTGTGCATCCGTTGTGTGTGCATATCTCTGTGTGTGTGCATTCGCGGTGTGTGTGTGCA 1827

QY 1178 TCTGTGTCTGT 1188

Db 1826 TCCATGTGTGT 1816

RESULT 4

AAF57099/C

ID AAF57099 standard; cDNA; 2422 BP.

XX AAF57099;

XX 14-MAY-2001 (first entry)

XX

DE Human Factor VII polypeptide encoding cDNA.

XX

KW Factor VIIa; thrombus; vascular patency; blood coagulation; Factor X;

KW plasma factor; Factor IX; myocardial injury; human; Factor VII; ss.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT CDS 41..1375

FT /*tag= a

FT sig_peptide 41..154

FT /*tag= b

FT mat_peptide 155..1372

FT /*tag= c

XX

XX US6183743-B1.

XX

PD 06-FEB-2001.

XX

PF 20-AUG-1999; 99US-00378907.

XX

PR 28-FEB-1991; 91US-00662920.

PR 28-FEB-1992; 92WO-US001636.

PR 21-MAY-1993; 93US-00065725.

PR 23-MAY-1994; 94WO-US005779.

PR 24-OCT-1994; 94US-00327690.

PR 07-JUN-1995; 95US-00475845.

PR 07-JUN-1996; 96US-00660289.

PR 06-JUN-1997; 97US-00871003.

XX

XX (ZYMO) ZYMOGENETICS INC.

PA (NOVO) NOVO-NORDISK AS.

XX

XX Hart CE, Petersen LC, Hedner U, Rasmussen ME;

XX

DR WPI; 2001-201993/20.

DR P-PSDB; AAB61992.

XX

FT Use of modified human factor VIIa with a covalent modification in its catalytic center, to inhibit thrombus formation or to maintain vascular patency.

XX

PS Example; Col 43-48; 34pp; English.

XX

CC The invention relates to the use of modified human Factor VIIa for inhibiting thrombus formation, or maintaining or improving vascular patency in a patient. The modified factor VIIa comprises a covalent modification in its catalytic center which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma factor IX or X. The modified Factor VIIa can be used for preventing or treating myocardial injury

KW pyogenic granuloma retrolental fibroplasia; scleroderma; trachoma;
 KW vascular adhesion; coagulation factor; factor VII/VIIa; ss.
 OS Homo sapiens.
 XX US5877289-A.
 PN 02-MAR-1999.
 XX 07-JUN-1995; 95US-00479733.
 PD 05-MAR-1992; 92US-00846349.
 XX 02-MAR-1994; 94US-00205330.
 PR 11-JUL-1994; 94US-00273567.
 XX (SCRI) SCRIPPS RES INST.
 PA (TEXA) UNIV TEXAS SYSTEM.
 PA Edgington TS, Thorpe PE;
 XX WPI; 1999-189722/16.
 XX Tissue factor binding ligands - comprising first binding region which
 XX binds to vasculature, particularly of tumours, and tissue factor
 XX construct.
 XX Example 9; Col 125-128; 83pp; English.
 XX The present sequence encodes a coagulation factor. The specification
 XX describes tissue factor binding ligands which comprise a binding region
 XX which binds to vasculature, particularly of tumours, and a tissue factor
 XX construct. The binding ligands can be used for stimulating coagulation in
 XX disease-associated vasculature, particularly for the treatment of
 XX tumours. The products can also be used for treating e.g. benign prostatic
 XX hyperplasia, diabetic-retinopathy, vascular restenosis, arteriovenous
 XX malformations (AVM), meningioma, hemangioma, neovascular glaucoma,
 XX psoriasis, synovitis, dermatitis, endometriosis, angiofibroma, rheumatoid
 XX arthritis, atherosclerotic plaques, corneal graft neovascularisation,
 XX haemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic
 XX granuloma retrolental fibroplasia, scleroderma, trachoma, or vascular
 XX adhesions. The products can also be used in binding assays
 XX
 XX Sequence 2462 BP; 590 A; 724 C; 721 G; 427 T; 0 U; 0 Other;
 XX
 XX Query Match 1.9%; Score 43; DB 1; Length 2462;
 XX Best Local Similarity 58.0%; Pred. No. 8.5e-05;
 XX Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 1058 TGTGAGAAATATCAATGAGCAGTGTGTTGTGATCTTTGTGATCTTGTGACATCTGGAAGTG 1117
 DB 2007 TGTGCATATCTATGTGCGTGCATCGGTGTTTGGTATCTCTGTGACCATCTG 1948
 QY 1118 TG 1177
 DB 1947 TGTGTGCATCCGTGTGTGTGTGCATATCTCTGTGTGTGTGCATCTGCGGTGTGTGTGTGCA 1888
 QY 1178 TCTGTGTCTGT 1188
 DB 1887 TCCAATGTGTGT 1877
 RESULT 7
 ID AAA12968/c
 ID AAA12968 standard; DNA; 2462 BP.
 XX AAA12968;
 XX 18-JUL-2000 (first entry)
 XX DNA encoding Factor VII/VIIa, SEQ ID NO:25.
 XX Truncated tissue factor; tTF; human; blood coagulation;
 KW tumour vasculature; bispecific antibody; targetting; cancer;

KW vascularised tumour; PCR primer; ss.
 XX Homo sapiens.
 XX US6036955-A.
 XX 14-MAR-2000.
 XX 07-JUN-1995; 95US-00479727.
 XX 05-MAR-1992; 92US-00846349.
 PR 02-MAR-1994; 94US-00205330.
 PR 11-JUL-1994; 94US-00273567.
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA (SCRI) SCRIPPS RES INST.
 PA Edgington TS, Thorpe PE;
 XX WPI; 2000-269871/23.
 XX Kit for inducing coagulation in tumor vasculature, useful for treating
 XX malignant or benign growths, contains ligand, linked to coagulation
 XX agent, that targets tumor marker.
 XX Example 9; Col 127-130; 86pp; English.
 XX The invention relates to the induction of blood coagulation specifically
 XX within tumour vasculature. This is achieved by the use of a bispecific
 XX molecule, which comprises a region capable of binding to intratumoral
 XX vascular or stromal cells linked to a coagulation factor or to a region
 XX capable of binding to a coagulation factor. An example of such a
 XX bispecific molecule is a bispecific antibody, where one arm binds a
 XX tumour antigen, and the other arm binds a coagulation factor. The
 XX expression of certain proteins (tumour antigens) is upregulated in tumour
 XX vasculature; such proteins include vascular endothelial growth factor
 XX (VEGF) and members of the fibroblast growth factor (FGF) family. An
 XX antibody or antibody fragment against VEGF or basic FGF (bFGF) may be
 XX incorporated into the bispecific molecule in order to target coagulation
 XX to tumour vasculature. The coagulation factor-binding portion of the
 XX bispecific molecule may be, for example, directed to tissue factor (TF).
 XX A preferred form of TF used in the invention is a truncated form (tTF,
 XX AA81498) which lacks the cytoplasmic and transmembrane domains. Although
 XX tTF can associate with Factor VIIa, the tTF/Factor VIIa complex cannot
 XX alone initiate the coagulation cascade as the complex has to be
 XX associated with a phospholipid surface for coagulation to occur. However,
 XX binding of tTF to tumour vasculature via a tumour antigen/tTF bispecific
 XX antibody brings tTF into close enough proximity with the cell membrane to
 XX enable the initiation of coagulation. Kits for the induction of tumour
 XX vasculature-specific coagulation may be used to treat malignant or benign
 XX diseases associated with a vascular component, particularly cancers, but
 XX also benign growths, prostatic hypertrophy, restenosis, psoriasis,
 XX glaucoma, rheumatoid arthritis. Coagulation is induced selectively in the
 XX tumour vasculature, minimising side effects. Such kits are likely to be
 XX effective against many different types of cancer. Sequences AAA12945-
 XX AAA12952, AAA12954-A12963 and AAA12971-A12972 represent PCR primers used
 XX in exemplifications of the present invention to generate constructs
 XX encoding tTF, tTF variants or tTF dimers
 XX
 XX Sequence 2462 BP; 590 A; 724 C; 721 G; 427 T; 0 U; 0 Other;
 XX
 XX Query Match 1.9%; Score 43; DB 1; Length 2462;
 XX Best Local Similarity 58.0%; Pred. No. 8.5e-05;
 XX Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 1058 TGTGAGAAATATCAATGAGCAGTGTGTTGTGATCTTTGTGATCTTGTGACATCTGGAAGTG 1117
 DB 2007 TGTGCATATCTATGTGCGTGCATCGGTGTTTGGTATCTCTGTGACCATCTG 1948
 QY 1118 TG 1177
 DB 1947 TGTGTGCATCCGTGTGTGTGTGCATATCTCTGTGTGTGTGCATCTGCGGTGTGTGTGTGCA 1888
 QY 1178 TCTGTGTCTGT 1188
 DB 1887 TCCAATGTGTGT 1877

CC polynucleotides are described which encode a propeptide fused to a
CC nucleic acid sequence encoding a vitamin K-dependent protein (VKDP). The
CC fusion proteins encoded are vitamin K-dependent protein gamma-
CC carboxylation enhancers and are useful for optimising the gamma-
CC carboxylation of a VKDP to produce a fully gamma-carboxylated VKDP. The
CC fusion proteins and recombinant cells expressing them are useful for
CC alleviating a VKDP associated disease. The fusion constructs result in
CC the production of fully gamma-carboxylated mature VKDPs, which are
CC biologically active. The invention encompasses all combinations of
CC propeptide sequences (modified or not) and VKDP's. This sequence encodes
CC the signal, propeptide and mature protein sequence of human Factor VII
XX
XX Sequence 2462 BP; 590 A; 724 C; 721 G; 427 T; 0 U; 0 Other;

Query Match 1.9%; Score 43; DB 1; Length 2462;
Best Local Similarity 58.0%; Pred. No. 8.5e-05;
Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 1058 TGTGAGAAATTATCAATGACGAGTGTGTTGTGGATTCTTGTGATCTTGTGCACTTGTGAAGTG 1117
DB 2007 TGTGCATATCTCTATGTGCGGTGTCATCGGTTGTTTCCGATCTCTGTGTGACCATCTG 1948
QY 1118 TG 1177
DB 1947 TGTGTGCATCGGTG 1888
QY 1178 TCTGTGTCTGT 1188
DB 1887 TCCATGTGTGT 1877

RESULT 10

AAA89784/C
ID AAA89784 standard; DNA; 2462 BP.

XX AC AAA89784;

XX DT 14-DEC-2000 (first entry)

XX DE DNA encoding coagulation factor VII/VIIa.

XX KW Tissue factor protein; truncated tissue factor; tTF; cytostatic;
XX KW coagulant; diabetic retinopathy; arteriovenous malformation; meningioma;
XX KW hemangioma; neovascular glaucoma; psoriasis; synovitis; endometriosis;
XX KW hemophylic joint; hypertrophic scar; vascular adhesion; tumour; cancer;
XX KW ligand; human; factor VII; ds.

XX OS Homo sapiens.

XX PN US6093399-A.

XX PD 25-JUL-2000.

XX PF 07-JUN-1995; 95US-00482369.

XX PR 05-MAR-1992; 92US-00846349.

XX PR 02-MAR-1994; 94US-00205330.

XX PR 11-JUL-1994; 94US-00273567.

XX PA (SRI) SCRIPPS RES INST.

XX PA (TEXA) UNIV TEXAS SYSTEM.

XX PI Edgington TS, Thorpe PE;

XX DR WPI; 2000-531471/48.

XX PT New immunological and growth factor-based bispecific binding ligands,
XX PT useful for stimulating coagulation in vasculature-associated diseases,
XX PT e.g. for treating both benign and malignant diseases (e.g. meningioma or
XX PT hemangioma).

XX PS Example 9; Col 125-128; 83pp; English.

CC The present invention relates to a binding ligand with a first binding
CC region that is operatively linked to either a coagulation factor or a
CC second binding region that binds to a coagulation factor. The first
CC binding region binds to a component on the surface of a tumour. The
CC second binding region is all or part of an antibody. An example of a
CC coagulation factor for use in the invention is human truncated tissue
CC factor. Truncated tissue factor (tTF) is the extracellular domain of the
CC mature tissue factor protein (see AAB15019). The binding ligand of the
CC invention is useful for stimulating coagulation in vasculature associated
CC diseases. Particularly, the binding ligand is useful for treating both
CC benign and malignant diseases that have a vascular component. These
CC diseases include benign growths (e.g. BPH), diabetic retinopathy,
CC arteriovenous malformations, meningioma, hemangioma, neovascular
CC glaucoma, psoriasis, synovitis, endometriosis, hemophylic joints,
CC hypertrophic scars or vascular adhesions. The present binding ligands
CC offer the advantage that even limited damage to the tumour vasculature
CC could produce an avalanche of tumour cell death because each capillary
CC provides oxygen and nutrients for thousands of tumour cells. The present
CC sequence is DNA encoding coagulation factor VII/VIIa. This factor was
CC used in the invention

XX Sequence 2462 BP; 590 A; 724 C; 721 G; 427 T; 0 U; 0 Other;

Query Match 1.9%; Score 43; DB 1; Length 2462;

Best Local Similarity 58.0%; Pred. No. 8.5e-05;

Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 1058 TGTGAGAAATTATCAATGACGAGTGTGTTGTGGATTCTTGTGATCTTGTGCACTTGTGAAGTG 1117

DB 2007 TGTGCATATCTCTATGTGCGGTGTCATCGGTTGTTTCCGATCTCTGTGTGACCATCTG 1948

QY 1118 TG 1177

DB 1947 TGTGTGCATCGGTG 1888

QY 1178 TCTGTGTCTGT 1188

DB 1887 TCCATGTGTGT 1877

RESULT 11

ABL67255/C

ID ABL67255 standard; DNA; 2462 BP.

XX AC ABL67255;

XX DT 15-MAY-2002 (first entry)

XX DE Thyroid cancer related gene sequence SEQ ID NO:5592.

XX KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
XX KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
XX KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
XX KW gene; ds.

XX OS Homo sapiens.

XX PN WO200194629-A2.

XX PD 13-DEC-2001.

XX PF 30-MAY-2001; 2001WO-US010838.

XX PR 05-JUN-2000; 2000US-0209473P.

XX PR 18-SEP-2000; 2000US-0233133P.

XX PR 18-SEP-2000; 2000US-0233617P.

XX PR 20-SEP-2000; 2000US-0234009P.

XX PR 20-SEP-2000; 2000US-0234034P.

XX PR 22-SEP-2000; 2000US-0234052P.

XX PR 22-SEP-2000; 2000US-0234509P.

XX PR 25-SEP-2000; 2000US-0234567P.

XX PR 25-SEP-2000; 2000US-0234923P.

Year	Sequence
1947	TGATGTCATCCGCTGTGTGTCATATCTCTGTGTGTGTCATTCGCTGTGTGTGTGCA
1178	TCTGTGTCTGT
1887	TCCATGTGTGT

RESULT 13	
AAN60064/c	
ID	AAN60064 standard; DNA; 2483 BP.
XX	
XX	AAN60064;
XX	
XX	
DT	25-MAR-2003 (revised)
DT	31-OCT-2002 (revised)
DT	23-MAY-1991 (first entry)
XX	
XX	Factor VII cDNA of lambda VII2463.
DE	
XX	
XX	Factor VII; Factor VIIa; DNA construct.
XX	
OS	Unidentified.
XX	
XX	
Key	Location/Qualifiers
FH	36. .1436
FT	/*tag= a
FT	
XX	
PN	EP200421-A.
XX	
PD	10-DEC-1986.
XX	
XX	
XX	16-APR-1986; 86EP-00302855.
PF	
XX	
PR	17-APR-1985; 85US-00724311.
PR	16-DEC-1985; 85US-00810002.
XX	
XX	(ZYMO) ZYMOGENETICS INC.
PA	
XX	
PI	Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;
XX	
DR	WPI; 1986-326899/50.
DR	P-PSDB; AAP60056.
XX	
XX	DNA construct used to transfect hosts - to produce protein which
PT	activates to give factor VIIa.
PT	
XX	
PS	Disclosure; Fig 1B; 55pp; English.
PS	
XX	
CC	The partial factor VII cDNA sequence is from cDNA clonl lambda VII2463.
CC	It is used in a DNA construct which contains a nucleotide sequence
CC	encoding a protein which, on activation, has the same biological activity
CC	for blood coagulation as Factor Ila. The nucleotide codes at least
CC	partially for Factor VII and comprises sequence encoding a calcium
CC	binding domain joined to a second sequence downstream of this encoding a
CC	catalytic domain for the serine protease activity of Factor VIIa. The
CC	calcium binding domain comprises a gene encoding Factor VII, IX, X,
CC	Protein C, prothrombin or Protein S. The construct is used to transfect
CC	host cells to produce the protein which, on activation, yields Factor
CC	VIIa. (Updated on 31-OCT-2002 to add missing OS field.) (Updated on 25-
CC	MAR-2003 to correct PA field.)
XX	
XX	Sequence 2483 BP; 611 A; 725 C; 720 G; 427 T; 0 U; 0 Other;
XX	

Db 1947 TGTGTGCATCCGTTGTGTGCATATCTGTGTGTGCATTGGCGTGTGTGTGTGCA 1888

Qy 1178 TCTGTGTCTGT 1188

Db 1887 TCCATGTGTGT 1877

RESULT 14	
AAAN60063/c	
ID	AAAN60063 standard; cDNA; 2177 BP.
XX	
XX	AAAN60063;
XX	
XX	25-MAR-2003 (revised)
DT	
DT	31-OCT-2002 (revised)
DT	23-MAY-1991 (first entry)
XX	
XX	Partial Factor VII cDNA.
DE	
XX	
XX	Factor VII; Factor VIIa; DNA construct.
KW	
XX	
OS	Homo sapiens.
XX	
XX	
FH	Key Location/Qualifiers
FT	13. .1128
FT	/*tag= a
XX	
PN	EP200421-A.
XX	
PD	10-DEC-1986.
XX	
XX	16-APR-1986; 86EP-00302855.
PF	
XX	
PR	17-APR-1985; 85US-00724311.
PR	16-DEC-1985; 85US-00810002.
XX	
PA	(ZYMO) ZYMOGENETICS INC.
XX	
PI	Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;
XX	
DR	WPI; 1986-326899/50.
DR	P-PSDE; AAP60055.
XX	
PT	DNA construct used to transfect hosts - to produce protein which
PT	activates to give factor VIIa.
XX	
PS	Disclosure; Fig 1A; 55pp; English.
XX	
CC	The partial factor VII cDNA sequence is produced by joining portions of
CC	cDNA clones lambda VII1215 and lambda VII1923. It is used in a DNA
CC	construct which contains a nucleotide sequence encoding a protein which,
CC	on activation, has the same biological activity for blood coagulation as
CC	Factor Ila. The nucleotide codes at least partially for Factor VII and
CC	comprises a sequence encoding a calcium binding domain joined to a second
CC	sequence downstream of this encoding a catalytic domain for the serine
CC	protease activity of Factor VII. IX. X. Protein C, prothrombin or Protein S. The
CC	gene encoding Factor VII, IX, X, Protein C, prothrombin or Protein S. The
CC	construct is used to transfect host cells to produce the protein which,
CC	on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing
CC	OS field.) (Updated on 25-MAR-2003 to correct PA field.)
XX	
SQ	Sequence 2177 BP: 569 A; 624 C; 605 G; 379 T; 0 U; 0 Other;

Db 1695 TGCATATCTATGCGGTGCATCGGTGTGTTTCGCTACTCTGTGTGACCATCTGTGT 1636
QY 1200 CTGTGTTTC 1207
Db 1635 GTGCATCC 1628

RESULT 15
AAN60065/c
ID AAN60065 standard; DNA; 2438 BP.
XX
AC AAN60065;
XX
DT 25-MAR-2003 (revised)
DT 31-OCT-2002 (revised)
DT 23-MAY-1991 (first entry)
XX
DE Factor IX/Factor VII cDNA fusion.
XX
XX Factor VII; Factor IX; DNA construct.
KW Factor VII; Factor IX; DNA construct.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT CDS 7..1368
FT /*tag= a
XX
PN EP200421-A.
XX
PD 10-DEC-1986.
XX
PF 16-APR-1986; 86EP-00302855.
XX
PR 17-APR-1985; 85US-00724311.
PR 16-DEC-1985; 85US-00810002.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;
XX
DR WPI; 1986-326899/50.
DR P-PSDB; AAP60057.
XX
XX DNA construct used to transfect hosts - to produce protein which
PT activates to give factor VIIa.
XX
PS Disclosure; Fig 7; 55pp; English.
XX
CC The cDNA is a fusion of Factor IX and Factor VII. It is used to express
CC Factor IX and Factor VII. cDNA encoding Factor VII can be used in DNA
CC construct which contains a nucleotide sequence encoding a protein which,
CC on activation, has the same biological activity for blood coagulation as
CC Factor Ila. The nucleotide codes at least partially for Factor VII and
CC comprises a sequence encoding a calcium binding domain joined to a second
CC sequence downstream of this encoding a catalytic domain for the serine
CC protease activity of Factor VIIa. The calcium binding domain comprises a
CC gene encoding Factor VII, IX, X, Protein C, prothrombin or Protein S. The
CC construct is used to transfect host cells to produce the protein which,
CC on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing
CC OS field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 2438 BP; 658 A; 670 C; 666 G; 444 T; 0 U; 0 Other;
Query Match 1.8%; Score 41.6; DB 1; Length 2438;
Best Local Similarity 57.8%; Pred. No. 0.0002;
Matches 74; Conservative 0; Mismatches 54; Indels 0; Gaps 0;
QY 1080 GGTGTTGGATCTGTTATCTTCACCTTGCAGTGTGTGTGTGTGTGTGTGTGTG 1139
Db 1995 GTGTGCGTCATGGCAGTGGCGTGCACGCCACCCAGGTATATCTGTGTGTCATCTGTGTG 1936
QY 1140 TGT 1199

Db 1935 TGCATATCTATGCGGTGCATCGGTGTGTTTCGCTACTCTGTGTGACCATCTGTGT 1876
QY 1200 CTGTGTTTC 1207
Db 1875 GTGCATCC 1868

RESULT 16
AAZ12625
ID AAZ12625 standard; cDNA; 300 BP.
XX
AC AAZ12625;
XX
DT 12-OCT-1999 (first entry)
XX
DE Human gene expression product cDNA sequence SEQ ID NO:94.
XX
KW Human; gene; gene expression product; diagnosis; therapy; probe;
KW detection; mapping; tissue typing; profiling; forensic; cancer;
KW genetic analysis; colorectal cancer; breast cancer; lung cancer; ss.
XX
OS Homo sapiens.
XX
PN WO9938972-A2.
XX
PD 05-AUG-1999.
XX
PF 28-JAN-1999; 99WO-US001619.
XX
PR 28-JAN-1998; 98US-0072910P.
PR 24-FEB-1998; 98US-0075954P.
PR 31-MAR-1998; 98US-0080114P.
PR 03-APR-1998; 98US-0080515P.
PR 03-APR-1998; 98US-0080666P.
PR 21-OCT-1998; 98US-0105234P.
PR 28-OCT-1998; 98US-0105877P.
XX
PA (CHIR) CHIRON CORP.
PA (HYSE-) HYSEQ INC.
XX
PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
PI Reinhard C, Giese K, Randazzo F, Kennedy GC, Pot D, Kassam A;
PI Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Kabat I;
PI Leskowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;
XX
DR WPI; 1999-494092/41.
XX
PT Novel human genes and their expression products which are differentially
PT expressed in different cell types.
XX
PS Claim 1; Page 683; 2479pp; English.
XX
CC The present invention describes a library of human polynucleotides
CC comprising the sequences given in AAZ12532 to AAZ1779. Also described is
CC a method of detecting differentially expressed genes correlated with the
CC cancerous state of a mammalian cell, comprising detecting at least one
CC differentially expressed gene product in a test sample from a cell
CC suspected of being cancerous, where the gene product is encoded by one of
CC the 5248 polynucleotide sequences given in AAZ12532 to AAZ1779. The
CC polynucleotides can be used as a source of primers and probes, which can
CC be used for a variety of purpose, e.g. detection of expression levels,
CC mapping, tissue typing or profiling, forensics, genetic analysis and
CC detection of polymorphisms. Polypeptides encoded by the polynucleotides
CC can be used for raising antibodies for experimental, diagnostic and
CC therapeutic purposes. The polynucleotides may also be used to construct
CC arrays for diagnostics (which may be used to determine function of an
CC encoded protein); and to detect differences in expression levels between
CC two cells (e.g. to identify abnormal or diseased tissue in a human, to
CC identify a genetic predisposition or susceptibility to a disease such as
CC cancer). The polynucleotides of the invention are especially used in the
CC diagnosis, prognosis and management of colorectal cancer, breast cancer,
CC and lung cancer. The polynucleotides can also be used to screen for


```
XX SQ Sequence 267 BP; 3 A; 151 C; 4 G; 109 T; 0 U; 0 Other;
Query Match 1.1%; Score 24.2; DB 1; Length 267;
Best Local Similarity 45.5%; Pred. No. 7.3;
Matches 86; Conservative 0; Mismatches 103; Indels 0; Gaps 0;

QY 1726 CQTGCTTTTGACCTGCTCTCTCCCTTCTCCCTCTATTCCTTTGGTTTTCATAGTGTCTC 1785
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
78 CTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 137

QY 1786 TGGCTTCTCTGGATGTTTATGCTGGAATTAATTTAGACTTAACATTTCTTTGACCAAGG 1845
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
138 TCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 197

QY 1846 TATCCATTTCTTCTATCTGTTCTTCACTGCGCGAGATCTCTCTTCTATCTCTTGATTC 1905
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
198 COTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 257

QY 1906 TGTCAGTGA 1914
Db 258 TTCCTGGGA 266

RESULT 24
ABS45294
ID ABS45294 standard; DNA; 267 BP.
XX AC ABS45294;
XX DT 25-FEB-2003 (first entry)
XX DE Human liver single exon probe, SEQ ID NO 20284.
XX KW Human; single exon nucleic acid probe; liver; cirrhosis;
XX KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX KW coronary heart disease; ss.
XX OS Homo sapiens.
XX PN WO200157273-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488998/53.
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PS gene expression in human adult liver.
XX PS Claim 4; SEQ ID NO 20284; 658pp; English.
XX CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
XX CC measuring human gene expression in a sample derived from human adult
XX CC liver, comprising one of 13109 defined nucleotide sequences given in the
XX CC specification (or complements/ fragments). The probe hybridises at high
XX CC stringency to a nucleic acid molecule expressed in the human adult liver.
XX CC (I) may be used for predicting, measuring and displaying gene expression
XX CC in samples derived from human adult liver. The genes identified may be
XX CC involved in genetic liver diseases such as cirrhosis,
XX CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
```



```
DE Human cDNA clone representative sequence, SEQ ID NO: 2040.
XX
KW Human; full length cDNA; cDNA synthesis; oligo-capping; ss.
XX
OS Homo sapiens.
XX
PN EP1130094-A2.
XX
XX 05-SEP-2001.
XX
XX 07-JUL-2000; 2000EP-00114089.
XX
XX 08-JUL-1999; 99JP-00194486.
XX
PR 11-JAN-2000; 2000JP-00118774.
XX
PR 02-MAY-2000; 2000JP-00183765.
XX
XX (HELI-) HELIX RES INST.
XX
XX Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR WPI; 2001-524255/58.
XX
XX 830 Primers useful for synthesizing full length cDNA clones and their use
PT in genetic manipulation.
XX
XX Claim 2; SEQ ID NO 91; 1380pp + Sequence Listing; English.
XX
XX The invention relates to primers for synthesising full length cDNA
CC clones. 830 cDNA molecules encoding a human protein have been isolated
CC and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
CC been determined. Primers for synthesising the full length cDNA are useful
CC for clarifying the function of the protein encoded by the cDNA. The full
CC length clones were obtained by construction of full length enriched cDNA
CC libraries that were synthesised by the oligo-capping method. The primers
CC enable the production of the full length cDNA easily without any special
CC methods. The present sequence is the nucleotide sequence of the 5'-end of
CC a cDNA provided in the invention. Note: The sequence data for this patent
CC did not form part of the printed specification, but was obtained in CD-
CC ROM format directly from EPO
XX
SQ Sequence 868 BP; 199 A; 220 C; 254 G; 190 T; 0 U; 5 Other;
Query Match 1.0%; Score 23.8; DB 1; Length 868;
Best Local Similarity 57.3%; Pred. No. 12;
Matches 43; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
Qy 487 ATTCAATTTTGGAGAGTTTCATAGGGTGCTGACAAAGGTACAGTCTTTGTTTGGT 546
Db 107 ATTGGAAGTTGCAAGATTCATTGAGGGGAGCAAGGAAGGAGGAGCCTCAGCCTTAGGA 166
Qy 547 GAAATAGTCTGTAAA 561
Db 167 GCTTTCCTTTTAAA 181
RESULT 28
ABQ47966
ID ABQ47966 standard; DNA; 612 BP.
XX
AC ABQ47966;
XX
XX 12-JUL-2002 (first entry)
XX
DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34557.
XX
XX Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX
OS Homo sapiens.
XX
XX WO200218632-A2.
XX
XX 07-MAR-2002.
XX
PD 01-SEP-2001; 2001WO-EP010074.
XX
XX 01-SEP-2000; 2000DE-01043826.
XX
PR 05-SEP-2000; 2000DE-01044543.
XX
```

```
DE Human cDNA clone representative sequence, SEQ ID NO: 2040.
XX
KW Human; full length cDNA; cDNA synthesis; oligo-capping; ss.
XX
OS Homo sapiens.
XX
PN EP1130094-A2.
XX
XX 05-SEP-2001.
XX
XX 07-JUL-2000; 2000EP-00114089.
XX
XX 08-JUL-1999; 99JP-00194486.
XX
PR 11-JAN-2000; 2000JP-00118774.
XX
PR 02-MAY-2000; 2000JP-00183765.
XX
XX (HELI-) HELIX RES INST.
XX
XX Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR WPI; 2001-524255/58.
XX
XX 830 Primers useful for synthesizing full length cDNA clones and their use
PT in genetic manipulation.
XX
XX Example 11; SEQ ID NO 2040; 1380pp + Sequence Listing; English.
XX
XX The invention relates to primers for synthesising full length cDNA
CC clones. 830 cDNA molecules encoding a human protein have been isolated
CC and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
CC been determined. Primers for synthesising the full length cDNA are useful
CC for clarifying the function of the protein encoded by the cDNA. The full
CC length clones were obtained by construction of full length enriched cDNA
CC libraries that were synthesised by the oligo-capping method. The primers
CC enable the production of the full length cDNA easily without any special
CC methods. The present sequence was used as the representative sequence
CC from a human clone which was used in homology searches to identify the
CC clone. Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in CD-ROM format directly from
CC EPO
XX
SQ Sequence 868 BP; 199 A; 220 C; 254 G; 190 T; 0 U; 5 Other;
Query Match 1.0%; Score 23.8; DB 1; Length 868;
Best Local Similarity 57.3%; Pred. No. 12;
Matches 43; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
Qy 487 ATTCAATTTTGGAGAGTTTCATAGGGTGCTGACAAAGGTACAGTCTTTGTTTGGT 546
Db 107 ATTGGAAGTTGCAAGATTCATTGAGGGGAGCAAGGAAGGAGGAGCCTCAGCCTTAGGA 166
Qy 547 GAAATAGTCTGTAAA 561
Db 167 GCTTTCCTTTTAAA 181
RESULT 27
AAK91631
ID AAK91631 standard; cDNA; 868 BP.
XX
AC AAK91631;
XX
XX 06-NOV-2001 (first entry)
XX
XX Human cDNA 5'-end sequence, SEQ ID NO: 91.
XX
XX Human; full length cDNA; cDNA synthesis; oligo-capping; ss.
XX
OS Homo sapiens.
XX
XX EP1130094-A2.
XX
```



```
XX DR WPI; 2000-611722/58.
XX PT Nucleic acid selected from one of 106 genes comprising single nucleotide
XX PT polymorphisms, allele-specific oligonucleotides to the genes are useful
XX PT for phenotypic correlations, forensics, paternity testing, medicine and
XX PT genetic analysis.
XX PS Claim 1; Fig 5; 214pp; English.
XX CC The present invention is concerned with a number of human single
XX CC nucleotide polymorphisms (SNPs) which the inventors identified in human
XX CC genes. These SNPs can be used in disease diagnosis and prediction of an
XX CC individual's susceptibility to disease, in forensic and paternity testing
XX CC and in genetic mapping. In particular, the SNPs of the invention can be
XX CC used to diagnose susceptibility to diseases of the cardiovascular,
XX CC endocrine and neurological systems, such as coronary artery disease,
XX CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
XX CC diseases. Note: The degenerate codon within the sequence represents the
XX CC position of an SNP, for example the letter S represents a polymorphism
XX CC where the nucleotide may be C or G
XX SQ Sequence 271 BP; 82 A; 43 C; 62 G; 83 T; 0 U; 1 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 271;
Best Local Similarity 50.0%; Pred. No. 23;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGGTTTACAGGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2227
DB 114 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGCTTAAGAAATTG 55
QY 2228 CTTTGGCATATAGCGGCTGAGTTGGGATGATTGTAATCTAGGTGCTGAT 2279
DB 54 AATTGCACGTAACCTGCTTAGAATGCCCGGTCCTCCCTGTAGATACTCAT 3
RESULT 38
AAI11531/c
ID AAI11531 standard; DNA; 476 BP.
AC AAI11531;
XX 12-OCT-2001 (first entry)
XX DE Probe #1464 for gene expression analysis in human cervical cell sample.
XX KW Probe; human; microarray; gene expression; cervical epithelial cell;
XX KW cervical cancer; ss.
XX OS Homo sapiens.
XX FN WO200157278-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000670.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488901/53.
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human cervical epithelial cells.
PS Claim 25; SEQ ID NO 1464; 487pp; English.
XX CC The present invention relates to human single exon nucleic acid probes
XX CC (SENPs). The present sequence is one such probe. The SENPs are derived
XX CC from human HeLa cells. The SENPs can be used to produce a single exon
XX CC microarray, which can be used for measuring human gene expression in a
XX CC sample derived from human cervical epithelial cells. By measuring gene
XX CC expression, the probes are therefore useful in grading and/or staging of
XX CC diseases of the cervix, notably cervical cancer. Note: The sequence data
XX CC for this patent did not form part of the printed specification, but was
XX CC obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGGTTTACAGGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2227
DB 357 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGCTTAAGAAATTG 298
QY 2228 CTTTGGCATATAGCGGCTGAGTTGGGATGATTGTAATCTAGGTGCTGAT 2279
DB 297 AATTGCACGTAACCTGCTTAGAATGCCCGGTCCTCCCTGTAGATACTCAT 246
RESULT 39
ABA53212/c
ID ABA53212 standard; DNA; 476 BP.
XX AC ABA53212;
XX DT 01-FEB-2002 (first entry)
XX DE Human foetal liver single exon nucleic acid probe #1517.
XX KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX OS Homo sapiens.
XX FN WO200157277-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000669.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483447/52.
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human fetal liver.
XX PS Claim 1; SEQ ID NO 1517; 639pp + Sequence Listing; English.
XX CC The invention relates to a single exon nucleic acid probe for measuring
XX CC human gene expression in a sample derived from human foetal liver. The
XX CC single exon nucleic acid probes may be used for predicting, measuring and
XX CC displaying gene expression in samples derived from human fetal liver.
```

CC present sequence is a single exon nucleic acid probe of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGTTTACAGGACATATGTCCTGGTCTTATGTCGTGTTTGG 2227
DB 357 CCATTTAAACATGATGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATG 298
QY 2228 CTTTGGCATATAGACGGCTGAGTTGGATGATTTGTAATTTCTAGGTCGTGAT 2279
DB 297 AATTGGCAGTAAACTGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246
RESULT 41
AAI32810/c
ID AAI32810 standard; DNA; 476 BP.
XX
AC AAI32810;
XX
DT 17-OCT-2001 (first entry)
XX
DE Probe #1496 used to measure gene expression in human placenta sample.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
XX Homo sapiens.
XX
FN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 30-JUN-2000; 2000US-00608408.
XX
PR 03-AUG-2000; 2000US-00632366.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-48897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 25; SEQ ID NO 1496; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP).
CC The present sequence is one such probe. The probes are useful for
CC producing a microarray for predicting, measuring and displaying gene
CC expression in samples derived from human placenta. The probes are useful
CC for antenatal diagnosis of human genetic disorders
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGTTTACAGGACATATGTCCTGGTCTTATGTCGTGTTTGG 2227

DB 357 CCATTTAAACATGATGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATG 298
QY 2228 CTTTGGCATATAGACGGCTGAGTTGGATGATTTGTAATTTCTAGGTCGTGAT 2279
DB 297 AATTGGCAGTAAACTGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246
RESULT 41
ABA42785/c
ID ABA42785 standard; DNA; 476 BP.
XX
AC ABA42785;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human breast cell single exon nucleic acid probe #1480.
XX
KW Human; microarray; single exon probe; gene expression; breast; disease;
KW cancer; ss.
XX Homo sapiens.
XX
FN WO200157271-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000662.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 30-JUN-2000; 2000US-00608408.
XX
PR 03-AUG-2000; 2000US-00632366.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-496933/54.
XX
PT New spatially-addressable set of single exon nucleic acid probes, useful
PT for measuring gene expression in sample derived from human breast,
XX comprises number of single exon nucleic acid probes.
XX
PS Claim 1; SEQ ID NO 1480; 327pp + Sequence Listing; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BT 474 cells. The method involves contacting the
CC probes with a collection of detectably labelled nucleic acids derived
CC from mRNA of human breast, and then measuring the label bound to each
CC probe of the microarray. The probes are useful for verifying the
CC expression of regions of genomic DNA predicted to encode proteins. They
CC are useful for gene discovery, and for determining predisposition and/or
CC prognosing breast disease. Gene expression analysis is useful for
CC assessing the toxicity of chemical agents on cells. The microarray of
CC this invention presents a far greater diversity of probes for measuring
CC gene expression, with far less bias than expressed sequence tag
CC microarrays. The method is suitable for rapid production of functional
CC information from genomic sequence. The present sequence is a single exon
CC nucleic acid probe of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

```
QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2279
Db 357 CCAITTAACATGGATTGGACTCACACATGATCTCCATCTTTAGATAGGTTAAGAAATTG 298

QY 2228 CTTTGGCATATAGCGGCTGAGTTTGGGATGATTGTAATTTCTAGGTGCTGAT 2279
Db 297 AATTGGCACGTAACATGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246

RESULT 42
ID ABA22986/c
XX ABA22986 standard; DNA; 476 BP.
AC ABA22986;
XX
DT 23-JAN-2002 (first entry)
DE Probe #1452 for gene expression analysis in human heart cell sample.
XX
KW Human; gene expression; heart; microarray; vascular system; probe;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157274-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000666.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
XX hearts.
XX
PS Claim 1; SEQ ID NO 1452; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
XX measuring human gene expression in a sample derived from human heart. The
XX present sequence is one such probe. The probes may be used for
XX predicting, measuring and displaying gene expression in samples derived
XX from the human heart via microarrays. By measuring gene expression, the
XX probes are useful for predicting, diagnosing, grading, staging,
XX monitoring and prognosing diseases of the human heart and vascular system
XX e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
XX congenital heart disease. Note: The sequence data for this patent did not
XX form part of the printed specification, but was obtained in electronic
XX format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2279
Db 357 CCAITTAACATGGATTGGACTCACACATGATCTCCATCTTTAGATAGGTTAAGAAATTG 298

RESULT 44
ID ABA22986/c
XX ABA22986 standard; DNA; 476 BP.
AC ABA22986;
XX
DT 23-JAN-2002 (first entry)
DE Probe #1452 for gene expression analysis in human heart cell sample.
XX
KW Human; gene expression; heart; microarray; vascular system; probe;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157274-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000666.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
XX hearts.
XX
PS Claim 1; SEQ ID NO 1452; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
XX measuring human gene expression in a sample derived from human heart. The
XX present sequence is one such probe. The probes may be used for
XX predicting, measuring and displaying gene expression in samples derived
XX from the human heart via microarrays. By measuring gene expression, the
XX probes are useful for predicting, diagnosing, grading, staging,
XX monitoring and prognosing diseases of the human heart and vascular system
XX e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
XX congenital heart disease. Note: The sequence data for this patent did not
XX form part of the printed specification, but was obtained in electronic
XX format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2279
Db 357 CCAITTAACATGGATTGGACTCACACATGATCTCCATCTTTAGATAGGTTAAGAAATTG 298
```

```
QY 2228 CTTTGGCATATAGCGGCTGAGTTTGGGATGATTGTAATTTCTAGGTGCTGAT 2279
Db 297 AATTGGCACGTAACATGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246

RESULT 43
ID AAK26907/c
XX AAK26907 standard; DNA; 476 BP.
AC AAK26907;
XX
DT 06-NOV-2001 (first entry)
DE Human bone marrow expressed single exon probe SEQ ID NO: 1464.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 1464; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX bone marrow. They can be used to measure gene expression in bone marrow
XX samples, which may enable the improved diagnosis and treatment of cancers
XX such as lymphoma, leukaemia and myeloma. The present sequence is one of
XX the probes of the invention
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 357 CCAITTAACATGGATTGGACTCACACATGATCTCCATCTTTAGATAGGTTAAGAAATTG 298

QY 2228 CTTTGGCATATAGCGGCTGAGTTTGGGATGATTGTAATTTCTAGGTGCTGAT 2279
Db 297 AATTGGCACGTAACATGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246

RESULT 44
ID AAK01461/c
XX AAK01461 standard; DNA; 476 BP.
AC AAK01461;
XX
```

```
DT 05-NOV-2001 (first entry)
XX Human brain expressed single exon probe SEQ ID NO: 1452.
DE
XX Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
KW ss.
XX Homo sapiens.
XX
XX WO200157275-A2.
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains.
XX
XX Example 4; SEQ ID NO 1452; 650pp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX brain. They can be used to measure gene expression in brain cell samples,
XX which may enable the diagnosis and improved treatment of nervous system
XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX epilepsy and cancers. The present sequence is one of the probes of the
XX invention
XX
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
Qy 2168 CTATTGTAATAGGGTTTGTAGCAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTTG 2227
Db 357 CCATTAAACATGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2228 CTTTGGCATATAGCGCTGAGTTGGATGATGTAATTCCTAGTGTCTGAT 2279
Db 297 AATTGGCAGCTAAACTGCTTAGAATGCCCGTCTCCCTGTAGATACTCAT 246
RESULT 45
ABS26497/C
XX ID ABS26497 standard; DNA; 476 BP.
XX AC
XX ABS26497;
XX
XX 25-FEB-2003 (first entry)
XX
XX Human liver single exon probe, SEQ ID No 1487.
XX
XX Human; single exon nucleic acid probe; liver; cirrhosis;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW coronary heart disease; ss.
XX
XX Homo sapiens.
XX
OS
```

```
XX WO200157273-A2.
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human adult liver.
XX
XX Claim 1; SEQ ID NO 1487; 658pp; English.
XX
XX The invention relates to a single exon nucleic acid probe (SENp) (I) for
XX measuring human gene expression in a sample derived from human adult
XX liver, comprising one of 13109 defined nucleotide sequences given in the
XX specification (or complements/ fragments). The probe hybridises at high
XX stringency to a nucleic acid molecule expressed in the human adult liver.
XX (I) may be used for predicting, measuring and displaying gene expression
XX in samples derived from human adult liver. The genes identified may be
XX involved in genetic liver diseases such as cirrhosis
XX hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX associated with coronary heart disease. ABS25011-ABS51005 represent human
XX liver single exon nucleic acid probes of the invention. Note: The
XX sequence information for this patent does not appear in the printed
XX specification but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
Qy 2168 CTATTGTAATAGGGTTTGTAGCAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTTG 2227
Db 357 CCATTAAACATGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2228 CTTTGGCATATAGCGCTGAGTTGGATGATGTAATTCCTAGTGTCTGAT 2279
Db 297 AATTGGCAGCTAAACTGCTTAGAATGCCCGTCTCCCTGTAGATACTCAT 246
RESULT 46
AAI01449/C
XX ID AAI01449 standard; DNA; 476 BP.
XX AC AAI01449;
XX
XX 09-OCT-2001 (first entry)
XX
XX Probe #1440 used to measure gene expression in human breast sample.
XX
XX Probe; human; breast disease; breast cancer; development disorder; ss;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
XX Homo sapiens.
XX
XX WO200157270-A2.
XX
```



```

PD 09-AUG-2001.
PF 29-JAN-2001; 2001WO-US000661.
XX
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX
XX Novel single exon nucleic acid probe used to measuring gene expression in
XX a human breast.
XX
XX Claim 25; SEQ ID NO 1440; 322pp; English.
XX
XX The present invention relates to novel single exon nucleic acid probes.
XX The present sequence is one such probe. The probes are useful for
XX measuring human gene expression in a human breast sample, where the probe
XX hybridizes at high stringency to a nucleic acid expressed in the human
XX breast. The probes are useful for predicting, diagnosing, grading,
XX staging, monitoring and prognosing diseases of the human breast,
XX particularly those diseases with polygenic aetiology. The diseases
XX include: breast cancer, disorders of development, inflammatory diseases
XX of the breast, fibrocystic changes, proliferative breast disease and non-
XX carcinoma tumours. Note: The sequence data for this patent did not form
XX part of the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
XX
XX
XX Query Match 1.0%; Score 22.4; DB 1; Length 476;
XX Best Local Similarity 50.0%; Pred. No. 25;
XX Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
XX
XX Qy 2168 CTATTGTAATAGGGTTTACGAGGACATATGCTGCTGTTTATGCTGCTGTTTGG 2227
XX Db 357 CCATTAAACATGATTGGACTCAGCTCAGCTCCTCTTGGAGATAGTTAAGAAATTG 298
XX
XX Qy 2228 CTTTGGCATATAGCGCTGAGTTGGATGATGATTTATTTAGTGTCTGAT 2279
XX Db 297 AATTGGCAGTAACTGCTTAGAATGCCGCTCCCTCTGATAGTACTCAT 246
XX
XX
XX RESULT 47
XX ABS01506/C
XX ID ABS01506 standard; DNA; 476 BP.
XX
XX AC ABS01506;
XX
XX
XX 19-AUG-2002 (first entry)
XX
XX Human genome-derived single exon probe from lung SEQ ID No 1497.
XX
XX Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;
XX chronic obstructive pulmonary disease; interstitial lung disease;
XX familial idiopathic pulmonary fibrosis; neurofibromatosis;
XX tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
XX Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
XX pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;
XX pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
XX primary ciliary dyskinesia; pulmonary hypertension;
XX hyaline membrane disease.
XX
XX Homo sapiens.
XX
XX

```

```

PN WO200186003-A2.
XX
XX 15-NOV-2001.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2002-114183/15.
XX
XX Spatially-addressable set of single exon nucleic acid probes, used to
XX measure gene expression in human lung samples.
XX
XX Claim 1; SEQ ID NO 1497; 634pp; English.
XX
XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human lung comprising single exon nucleic acid probes having one of
XX 12614 nucleic acid sequences mentioned in the specification, or their
XX complements or the 12387 open reading frames derived from the 12614
XX probes. Also included are a microarray comprising the novel set of probes
XX; the novel set of probes which hybridise at high stringency to a nucleic
XX acid expressed in the human lung; measuring gene expression in a sample
XX derived from human lung, comprising (a) contacting the array with a
XX collection of detectably labeled nucleic acids derived from human lung
XX mRNA, and (b) measuring the label detectably bound to each probe of the
XX array; identifying exons in a eukaryotic genome, comprising (a)
XX algorithmically predicting at least one exon from genomic sequences of
XX the eukaryote; and (b) detecting specific hybridisation of detectably
XX labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
XX having a fragment identical to the predicted exon, the probe is included
XX in the above mentioned microarray; assigning exons to a single gene,
XX comprising (a) identifying exons from genomic sequence by the method
XX above and (b) measuring the expression of each of the exons in several
XX tissues and/or cell types using hybridisation to a single exon
XX microarrays having a probe with the exon, where a common pattern of
XX expression of the exons in the tissues and/or cell types indicates that
XX the exons should be assigned to a single gene; a peptide comprising one
XX of 12011 sequences, mentioned in the specification, or encoded by the
XX probes/open reading frames (ORF). The probes are used for gene expression
XX analysis, and for identifying exons in a gene, particularly using human
XX lung derived mRNA and for the study of lung diseases such as asthma, lung
XX cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
XX disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
XX tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
XX Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
XX histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
XX Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
XX dyskinesia, pulmonary hypertension and hyaline membrane disease. The
XX present sequence is a single exon probe of the invention. Note: The
XX sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
XX
XX
XX Query Match 1.0%; Score 22.4; DB 1; Length 476;
XX Best Local Similarity 50.0%; Pred. No. 25;
XX Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
XX
XX Qy 2168 CTATTGTAATAGGGTTTACGAGGACATATGCTGCTGTTTATGCTGCTGTTTGG 2227
XX Db 357 CCATTAAACATGATTGGACTCAGCTCAGCTCCTCTTGGAGATAGTTAAGAAATTG 298
XX

```



```
KW Genetic disorder; ss.
XX
OS Homo sapiens.
XX
XX WO200157272-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-48897/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human placenta.
XX
XX Claim 25; SEQ ID NO 13557; 654pp; English.
XX
XX The present invention relates to single exon nucleic acid probes (SENP).
XX The present sequence is one such probe. The probes are useful for
XX producing a microarray for predicting, measuring and displaying gene
XX expression in samples derived from human placenta. The probes are useful
XX for antenatal diagnosis of human genetic disorders
XX
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 26;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
XX
XX QY 1732 TTGACCTGGCTTCCCTTCCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1791
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 277 TCTGCGCTGCTTACCTCTGCGCTCTCAATTCTTCTCTCTCTCTCTCTCTCTCTCT 218
XX
XX QY 1792 CTTGGAT 1798
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 217 TCTAGCT 211
XX
XX RESULT 51
XX ABA46822/c
XX ID ABA46822 standard; DNA; 301 BP.
XX
XX AC ABA46822;
XX
XX DT 01-FEB-2002 (first entry)
XX
XX DE Human breast cell single exon nucleic acid probe #5517.
XX
XX KW Human; microarray; single exon probe; gene expression; breast; disease;
XX cancer; ss.
XX
XX OS Homo sapiens.
XX
XX XX WO200157271-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX PF
XX
XX PR
```

```
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-496933/54.
XX
XX New spatially-addressable set of single exon nucleic acid probes, useful
XX for measuring gene expression in sample derived from human breast,
XX comprises number of single exon nucleic acid probes.
XX
XX Claim 4; SEQ ID NO 5517; 327pp + Sequence Listing; English.
XX
XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human breast and BT 474 cells. The method involves contacting the
XX probes with a collection of detectably labelled nucleic acids derived
XX from mRNA of human breast, and then measuring the label bound to each
XX probe of the microarray. The probes are useful for verifying the
XX expression of regions of genomic DNA predicted to encode proteins. They
XX are useful for gene discovery, and for determining predisposition and/or
XX prognosing breast disease. Gene expression analysis is useful for
XX assessing the toxicity of chemical agents on cells. The microarray of
XX this invention presents a far greater diversity of probes for measuring
XX gene expression, with far less bias than expressed sequence tag
XX microarrays. The method is suitable for rapid production of functional
XX information from genomic sequence. The present sequence is a single exon
XX nucleic acid probe of the invention. Note: The sequence data for this
XX patent did not form part of the printed specification, but was obtained
XX in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 26;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
XX
XX QY 1732 TTGACCTGGCTTCCCTTCCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1791
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 277 TCTGCGCTGCTTACCTCTGCGCTCTCAATTCTTCTCTCTCTCTCTCTCTCTCTCT 218
XX
XX QY 1792 CTTGGAT 1798
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 217 TCTAGCT 211
XX
XX RESULT 52
XX ABA31826/c
XX ID ABA31826 standard; DNA; 301 BP.
XX
XX AC ABA31826;
XX
XX DT 23-JAN-2002 (first entry)
XX
XX DE Probe #10292 for gene expression analysis in human heart cell sample.
XX
XX KW Human; gene expression; heart; microarray; vascular system; probe;
XX cardiovascular disease; hypertension; cardiac arrhythmia;
XX congenital heart disease; ss.
XX
XX OS Homo sapiens.
XX
XX XX WO200157274-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX PF
```

XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX Claim 4; SEQ ID NO 10292; 530pp; English.
XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1732 TTGACCTGCTTCTCCCTCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCGT 218
Qy 1792 CCTGGAT 1798
Db 217 TCTAGCT 211
RESULT 53
AAK38868/c
ID AAK38868 standard; DNA; 301 BP.
AC AAK38868;
XX
DT 06-NOV-2001 (first entry)
XX Human bone marrow expressed single exon probe SEQ ID NO: 13425.
DE Human; bone marrow expressed exon; gene expression analysis; probe;
XX microarray; cancer; leukaemia; lymphoma; myeloma; ss.
KW Homo sapiens.
XX WO200157276-A2.
PN 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX Claim 4; SEQ ID NO 10292; 530pp; English.
XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1732 TTGACCTGCTTCTCCCTCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCGT 218
Qy 1792 CCTGGAT 1798
Db 217 TCTAGCT 211
RESULT 53
AAK38868/c
ID AAK38868 standard; DNA; 301 BP.
AC AAK38868;
XX
DT 06-NOV-2001 (first entry)
XX Human bone marrow expressed single exon probe SEQ ID NO: 13425.
DE Human; bone marrow expressed exon; gene expression analysis; probe;
XX microarray; cancer; leukaemia; lymphoma; myeloma; ss.
KW Homo sapiens.
XX WO200157276-A2.
PN 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.

PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX Example 4; SEQ ID NO 13425; 658pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is one of
CC the probes of the invention
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1732 TTGACCTGCTTCTCCCTCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCGT 218
Qy 1792 CCTGGAT 1798
Db 217 TCTAGCT 211
RESULT 54
AAK13137/c
ID AAK13137 standard; DNA; 301 BP.
XX
AC AAK13137;
XX
DT 05-NOV-2001 (first entry)
XX Human brain expressed single exon probe SEQ ID NO: 13128.
DE Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
XX ss.
XX Homo sapiens.
XX WO200157275-A2.
PN 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.

```
PT brains.
XX
PS Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention
XX
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
    Query Match      1.0%; Score 22.2; DB 1; Length 301;
    Best Local Similarity 58.2%; Pred. No. 26;
    Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1732 TTGACCTGCGCTTCCTCCCTCTATTCCTTTGGTTTGGCATAGTGTCTCGGCTT 1791
    |||||
DB 277 TCTGCGCTGTACCTCTCGGCTCTCAATTCTTTCCTCTCTCTCTCTCTGCGGT 218
    |||||
QY 1792 CTTGGAT 1798
    |||||
DB 217 TCTAGCT 211

RESULT 55
ABS38453/c
ID ABS38453 standard; DNA; 301 BP.
XX
AC ABS38453;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver single exon probe, SEQ ID NO 13443.
XX
KW Human; single exon nucleic acid probe; liver; cirrhosis;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW coronary heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 30-JUN-2000; 2000US-00608408.
XX
PR 03-AUG-2000; 2000US-00632366.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 4; SEQ ID NO 13443; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC

CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABS25011-ABS51005 represent human
CC liver single exon nucleic acid probes of the invention. Note: The
CC sequence information for this patent does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
    Query Match      1.0%; Score 22.2; DB 1; Length 301;
    Best Local Similarity 58.2%; Pred. No. 26;
    Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1732 TTGACCTGCGCTTCCTCCCTCTATTCCTTTGGTTTGGCATAGTGTCTCGGCTT 1791
    |||||
DB 277 TCTGCGCTGTACCTCTCGGCTCTCAATTCTTTCCTCTCTCTCTCTCTGCGGT 218
    |||||
QY 1792 CTTGGAT 1798
    |||||
DB 217 TCTAGCT 211

RESULT 56
AAI05395/c
ID AAI05395 standard; DNA; 301 BP.
XX
AC AAI05395;
XX
DT 09-OCT-2001 (first entry)
XX
DE Probe #5386 used to measure gene expression in human breast sample.
XX
KW Probe; human; breast disease; breast cancer; development disorder; ss;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 30-JUN-2000; 2000US-00608408.
XX
PR 03-AUG-2000; 2000US-00632366.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
WPI; 2001-476286/51.
XX
PT Novel single exon nucleic acid probe used to measuring gene expression in
PT a human breast.
XX
PS Claim 25; SEQ ID NO 5386; 322pp; English.
XX
CC The present invention relates to novel single exon nucleic acid probes.
CC The present sequence is one such probe. The probes are useful for
CC measuring human gene expression in a human breast sample, where the probe
CC hybridises at high stringency to a nucleic acid expressed in the human
CC breast. The probes are useful for predicting, diagnosing, grading,
CC staging, monitoring and prognosing diseases of the human breast,
CC particularly those diseases with polygenic aetiology. The diseases
CC include: breast cancer, disorders of development, inflammatory diseases
```


PD	XX	04-OCT-2001.
PF	XX	27-MAR-2001; 2001WO-US009761.
PR	XX	27-MAR-2000; 2000US-0192176P.
PR	XX	27-MAR-2000; 2000US-0192179P.
PR	XX	01-JUN-2000; 2000US-0208538P.
PR	XX	30-OCT-2000; 2000US-0244989P.
PA	XX	(UYDE) UNIV DELAWARE.
PI	XX	Kmiec EB, Gamper HB, Rice MC;
PT	XX	WPI; 2001-639230/73.
PS	XX	Claim 7; Page 184; 294pp; English.
CC	XX	The present invention provides single-stranded oligonucleotides which can
CC	XX	be used for the targeted alteration of genomic sequences, where the
CC	XX	oligonucleotide has at least one mismatch compared with the genomic
CC	XX	sequence to be altered. In particular, these sequences are directed at
CC	XX	the following genes: adenosine deaminase, p53, beta-globin,
CC	XX	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC	XX	(CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC	XX	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC	XX	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC	XX	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC	XX	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC	XX	such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC	XX	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC	XX	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC	XX	various syndromes. The present sequence is one of the gene correcting
CC	XX	oligonucleotides of the invention
SQ	XX	Sequence 121 BP; 36 A; 23 C; 25 G; 37 T; 0 U; 0 Other;
		Query Match 1.0%; Score 22; DB 1; Length 121;
		Best Local Similarity 53.5%; Pred. No. 25;
		Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY	2168	CTATTGTAATAGGGTTTAGCAGGCACATATTGTCTCGTGTTTATTGTCTGTGTTTTT 2227
Db	88	CCATTTAAACATGATTTGGACTCACACTGATCTCCATCTTTGATAGATTAGAATTG 29
QY	2228	CTTTGGCATATAGCGCTGAGTTTG 2253
Db	28	AATTTGCACGTAAACTGCTTAGAATG 3
RESULT 59		
ABA79623		
ID	ABA79623	standard; DNA; 121 BP.
AC	ABA79623;	
XX		
DT	24-JAN-2002	(first entry)
DE	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2469.	
XX		
KW	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;	
KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;	
KW	cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;	
KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;	
KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;	
KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein B; LDLR;	
KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;	
KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;	
KW	Alzheimer's disease; cytostatic; anticisplating; antianaemic; haemostatic;	
KW	antileptic; ss.	

OS	XX	Homo sapiens.
PN	XX	W0200173002-A2.
XX	XX	04-OCT-2001.
PF	XX	27-MAR-2001; 2001WO-US009761.
PR	XX	27-MAR-2000; 2000US-0192176P.
PR	XX	27-MAR-2000; 2000US-0192179P.
PR	XX	01-JUN-2000; 2000US-0208538P.
PR	XX	30-OCT-2000; 2000US-0244989P.
PA	XX	(UYDE) UNIV DELAWARE.
PI	XX	Kmiec EB, Gamper HB, Rice MC;
PT	XX	WPI; 2001-639230/73.
PS	XX	Claim 7; Page 184; 294pp; English.
CC	XX	The present invention provides single-stranded oligonucleotides which can
CC	XX	be used for the targeted alteration of genomic sequences, where the
CC	XX	oligonucleotide has at least one mismatch compared with the genomic
CC	XX	sequence to be altered. In particular, these sequences are directed at
CC	XX	the following genes: adenosine deaminase, p53, beta-globin,
CC	XX	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC	XX	(CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC	XX	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC	XX	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC	XX	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC	XX	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC	XX	such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC	XX	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC	XX	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC	XX	various syndromes. The present sequence is one of the gene correcting
CC	XX	oligonucleotides of the invention
SQ	XX	Sequence 121 BP; 37 A; 24 C; 23 G; 37 T; 0 U; 0 Other;
		Query Match 1.0%; Score 22; DB 1; Length 121;
		Best Local Similarity 53.5%; Pred. No. 25;
		Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY	2168	CTATTGTAATAGGGTTTAGCAGGCACATATTGTCTCGTGTTTATTGTCTGTGTTTTT 2227
Db	35	CCATTTAAACATGATTTGGACTCACACTGATCTCCATCTTTGATAGATTAGAATTG 94
QY	2228	CTTTGGCATATAGCGCTGAGTTTG 2253
Db	95	AATTTGCACGTAAACTGCTTAGAATG 120
RESULT 60		
ABA79622/c		
ID	ABA79622	standard; DNA; 121 BP.
AC	ABA79622;	
XX		
DT	24-JAN-2002	(first entry)
DE	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2468.	
XX		
KW	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;	
KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;	
KW	cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;	
KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;	
KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;	
KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein B; LDLR;	
KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;	
KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;	
KW	Alzheimer's disease; cytostatic; anticisplating; antianaemic; haemostatic;	
KW	antileptic; ss.	

KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.

OS Homo sapiens.

DN WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US009761.

XX 27-MAR-2000; 2000US-0192176P.

PR 27-MAR-2000; 2000US-0192179P.

PR 01-JUN-2000; 2000US-0208538P.

PR 30-OCT-2000; 2000US-0244989P.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.

PS Claim 7; Page 184; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention

XX Sequence 121 BP; 37 A; 23 C; 24 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 25;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGTCCTGGTGTGTTATTCCTGCTGTTTGTG 2227
 DB 87 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 28

QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253

DB 27 AATTGGCACGTAACACTGCTTAGAATG 2

RESULT 61

ABA79634/C

ID ABA79634 standard; DNA; 121 BP.

XX ABA79634;

XX 24-JAN-2002 (first entry)

DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2480.

XX

KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.

XX Homo sapiens.

XX WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US009761.

PR 27-MAR-2000; 2000US-0192176P.

PR 27-MAR-2000; 2000US-0192179P.

PR 01-JUN-2000; 2000US-0208538P.

PR 30-OCT-2000; 2000US-0244989P.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.

PS Claim 7; Page 184; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention

XX Sequence 121 BP; 37 A; 23 C; 23 G; 38 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 25;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGTCCTGGTGTGTTATTCCTGCTGTTTGTG 2227
 DB 86 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 27

QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253

DB 26 AATTGGCACGTAACACTGCTTAGAATG 1

RESULT 62

ABA79627

ID ABA79627 standard; DNA; 121 BP.

XX ABA79627;

AC ABA79627;

QY	2228	CTTTGGCATATAGACGGCTGAGTTTG	2253	
Db	93	AATTGGCAGCTAACTGCTTAGAATG	118	
RESULT 64				
ABA79635				
ID	ABA79635	standard; DNA; 121 BP.		
XX	AC	ABA79635;		
XX	24-JAN-2002	(first entry)		
XX	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2481.			
XX	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;			
KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;			
KW	cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;			
KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;			
KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;			
KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;			
KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;			
KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;			
KW	Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;			
KW	antileptic; ss.			
OS	Homo sapiens.			
XX	WO200173002-A2.			
PN	04-OCT-2001.			
PD	27-MAR-2001; 2001WO-US009761.			
PF	27-MAR-2000; 2000US-0192176P.			
XX	27-MAR-2000; 2000US-0192176P.			
PR	01-JUN-2000; 2000US-0208538P.			
PR	30-OCT-2000; 2000US-0244989P.			
XX	(UYDE) UNIV DELAWARE.			
PA	Kmiec EB, Gamper HB, Rice MC;			
XX	WPI; 2001-639230/73.			
XX	Oligonucleotide for targeted alterations of genetic sequences and for			
PT	treating cystic fibrosis, comprises at least one mismatch and chemical			
PT	modification.			
XX	Claim 7; Page 184; 294pp; English.			
PS	The present invention provides single-stranded oligonucleotides which can			
XX	be used for the targeted alteration of genomic sequences, where the			
CC	oligonucleotide has at least one mismatch compared with the genomic			
CC	sequence to be altered. In particular, these sequences are directed at			
CC	the following genes: adenosine deaminase, p53, beta-globin,			
CC	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A			
CC	(CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus			
CC	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,			
CC	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase			
CC	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and			
CC	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases			
CC	such as cancer, adenosine deaminase deficiency, cystic fibrosis,			
CC	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,			
CC	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and			
CC	various syndromes. The present sequence is one of the gene correcting			
CC	oligonucleotides of the invention			
XX	Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;			
SQ	Query Match	1.0%;	Score 22; DB 1; Length 121;	
XX	Best Local Similarity	53.5%;	Pred. No. 25;	
XX	Matches 46; Conservative	0;	Mismatches 40; Indels	0; Gaps 0;

QY	2168	CTATTGTATAGGTTTACGAGGCATATTTCTCTGGTTGTTTATTTCTCTGTTTTTG	2227	
Db	36	CCATTAAACATGGATTGGACTCAGCTCCTCACTTTTGATAGTAGTTAAGAAATTG	95	
RESULT 65				
ABA79638/c				
ID	ABA79638	standard; DNA; 121 BP.		
XX	AC	ABA79638;		
XX	24-JAN-2002	(first entry)		
XX	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2484.			
XX	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;			
KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;			
KW	cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;			
KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;			
KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;			
KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;			
KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;			
KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;			
KW	Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;			
KW	antileptic; ss.			
OS	Homo sapiens.			
XX	WO200173002-A2.			
PN	04-OCT-2001.			
PD	27-MAR-2001; 2001WO-US009761.			
PF	27-MAR-2000; 2000US-0192176P.			
XX	27-MAR-2000; 2000US-0192176P.			
PR	01-JUN-2000; 2000US-0208538P.			
PR	30-OCT-2000; 2000US-0244989P.			
XX	(UYDE) UNIV DELAWARE.			
PA	Kmiec EB, Gamper HB, Rice MC;			
XX	WPI; 2001-639230/73.			
XX	Oligonucleotide for targeted alterations of genetic sequences and for			
PT	treating cystic fibrosis, comprises at least one mismatch and chemical			
PT	modification.			
XX	Claim 7; Page 185; 294pp; English.			
PS	The present invention provides single-stranded oligonucleotides which can			
XX	be used for the targeted alteration of genomic sequences, where the			
CC	oligonucleotide has at least one mismatch compared with the genomic			
CC	sequence to be altered. In particular, these sequences are directed at			
CC	the following genes: adenosine deaminase, p53, beta-globin,			
CC	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A			
CC	(CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus			
CC	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,			
CC	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase			
CC	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and			
CC	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases			
CC	such as cancer, adenosine deaminase deficiency, cystic fibrosis,			
CC	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,			
CC	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and			
CC	various syndromes. The present sequence is one of the gene correcting			
CC	oligonucleotides of the invention			
XX	Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;			

SQ Sequence 121 BP; 37 A; 23 C; 23 G; 38 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 25;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

OY 2168 CTAATTGTAATAGGGTTTACAGGACATATTGTCCTGCTGTTCTTATTGTCGTGTTTGG 2227
 DB 86 CCATTAAACATGGATTGGACTCACACTGATCCTTTGAGTAGTAAAGAAATTG 27

OY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
 DB 26 AATTGGCAGTAAACTGCTTAGAATG 1

RESULT 66
 ABA79630/c
 ID ABA79630 standard; DNA; 121 BP.

AC ABA79630;
 XX
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2476.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antislacking; antianaemic; haemostatic;
 KW antilipemic; ss.

XX OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 XX PD 04-OCT-2001.
 XX
 XX PF 27-MAR-2001; 2001WO-US009761.
 XX
 XX PR 27-MAR-2000; 2000US-0192176P.
 XX PR 27-MAR-2000; 2000US-0192179P.
 XX PR 01-JUN-2000; 2000US-0208538P.
 XX PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 XX
 XX PA Kmiec EB, Gamper HB, Rice MC;
 XX PI WPI; 2001-639230/73.
 XX DR
 XX PS
 XX PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 184; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,

CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention

XX Sequence 121 BP; 35 A; 23 C; 26 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
 Best Local Similarity 53.5%; Pred. No. 25;
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

OY 2168 CTAATTGTAATAGGGTTTACAGGACATATTGTCCTGCTGTTCTTATTGTCGTGTTTGG 2227
 DB 89 CCATTAAACATGGATTGGACTCACACTGATCCTTTGAGTAGTAAAGAAATTG 30

OY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
 DB 29 AATTGGCAGTAAACTGCTTAGAATG 4

RESULT 67
 ABA79639
 ID ABA79639 standard; DNA; 121 BP.

AC ABA79639;
 XX
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2485.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antislacking; antianaemic; haemostatic;
 KW antilipemic; ss.

XX OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 XX PD 04-OCT-2001.
 XX
 XX PF 27-MAR-2001; 2001WO-US009761.
 XX
 XX PR 27-MAR-2000; 2000US-0192176P.
 XX PR 27-MAR-2000; 2000US-0192179P.
 XX PR 01-JUN-2000; 2000US-0208538P.
 XX PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 XX
 XX PA Kmiec EB, Gamper HB, Rice MC;
 XX PI WPI; 2001-639230/73.
 XX DR
 XX PS
 XX PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 185; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,

CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 25;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGCTGGTGTATTGTCGTGTTTGG 2227
Db 36 CCATTTAAACATGGATTGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 95

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253
Db 96 AATTGGCAGCTAAACTGCTTAGAATG 121

RESULT 68
ABA79619
ID ABA79619 standard; DNA; 121 BP.
XX
AC ABA79619;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2465.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytosatic; antickling; antianaemic; haemostatic;
KW antileptic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
XX
PR 27-MAR-2000; 2000US-0192176P.
XX
PR 01-JUN-2000; 2000US-0208538P.
XX
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 184; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the

CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 121 BP; 36 A; 25 C; 25 G; 35 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 25;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGCTGGTGTATTGTCGTGTTTGG 2227
Db 31 CCATTTAAACATGGATTGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 90

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253
Db 91 AATTGGCAGCTAAACTGCTTAGAATG 116

RESULT 69
ABA79618/c
ID ABA79618 standard; DNA; 121 BP.
XX
AC ABA79618;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2464.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytosatic; antickling; antianaemic; haemostatic;
KW antileptic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
XX
PR 27-MAR-2000; 2000US-0192176P.
XX
PR 01-JUN-2000; 2000US-0208538P.
XX
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.

CC the amplicon. From the ratio of labels hybridised to the two classes of
CC oligomers, the degree of methylation is calculated. The method is used:
CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC and of a wide range of diseases, e.g. cancer, disorders of the central
CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC particularly by detecting mutations or single nucleotide polymorphisms
CC (SNP's); and (ii) for differentiation of cell or tissue types and for
CC investigating cell differentiation. The method allows the methylation
CC status of many C residues to be determined simultaneously. ABQ13410-
CC ABQ54121 represent genomic DNA sequences used to illustrate the method
CC for determining the degree of cytosine methylation described in the
CC disclosure of the invention
XX
SQ Sequence 612 BP; 232 A; 219 C; 72 G; 89 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 612;
Best Local Similarity 49.2%; Pred. No. 34;
Matches 58; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1067 TTATCAATGAGCAGTGTGGGATCTTGTATCTTGCACCTGTGAAGTGTGTGTGT 1126
Db 258 TTTGAGGAGTATGTTTTTTTGTATTTTTTTTAGGAGTTCGGTCGTAGTTTTT 199
QY 1127 GT 1184
Db 198 TTAGGAACGGCTTGGCGGTCGGCTCGGTGTAGGACGTCGTGGGTTTTTTTTGGGT 141

RESULT 72
ABQ47968
ID ABQ47968 standard; DNA; 612 BP.
AC ABQ47968;
XX
DT 12-JUL-2002 (first entry)
DE
DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34559.
KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX
OS Homo sapiens.
XX
XX WO200218632-A2.
XX
XX PD 07-MAR-2002.
XX
XX PF 01-SEP-2001; 2001WO-EP010074.
XX
XX PR 01-SEP-2000; 2000DE-01043826.
XX
XX PR 05-SEP-2000; 2000DE-01044543.
XX
XX PA (EPTG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;
XX
XX DR WPI; 2002-371829/40.
XX
XX PT Determining the degree of cytosine methylation in genomic DNA, useful for
XX PT diagnosis and prognosis, comprises selective hybridization of amplicons
XX PT from chemically treated DNA.
XX
XX PS Claim 12; 56pp + Sequence Listing; 56pp; German.
XX

CC This invention describes a novel method for determining the degree of
CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC genomic sample of DNA. The sample is treated chemically to convert
CC cytosine (C) but not methylated C, to uracil, then part of the genomic
CC DNA that contains the target C is amplified to form a labeled amplicon.
CC The amplicon is hybridised to two classes, each with at least one member,
CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the

CC degree of hybridisation to both classes is determined from the label on
CC the amplicon. From the ratio of labels hybridised to the two classes of
CC oligomers, the degree of methylation is calculated. The method is used:
CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC and of a wide range of diseases, e.g. cancer, disorders of the central
CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC particularly by detecting mutations or single nucleotide polymorphisms
CC (SNP's); and (ii) for differentiation of cell or tissue types and for
CC investigating cell differentiation. The method allows the methylation
CC status of many C residues to be determined simultaneously. ABQ13410-
CC ABQ54121 represent genomic DNA sequences used to illustrate the method
CC for determining the degree of cytosine methylation described in the
CC disclosure of the invention
XX
SQ Sequence 612 BP; 89 A; 72 C; 219 G; 232 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 612;
Best Local Similarity 49.2%; Pred. No. 34;
Matches 58; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1067 TTATCAATGAGCAGTGTGGGATCTTGTATCTTGCACCTGTGAAGTGTGTGTGT 1126
Db 355 TTTGAGGAGTATGTTTTTTTGTATTTTTTTTAGGAGTTCGGTCGTAGTTTTT 414
QY 1127 GT 1184
Db 415 TTAGGAACGGCTTGGCGGTCGGCTCGGTGTAGGACGTCGTGGGTTTTTTTTGGGT 472

RESULT 73
AAC70944/c
ID AAC70944 standard; DNA; 253 BP.
XX
AC AAC70944;
XX
DT 09-FEB-2001 (first entry)
DE
DE Single nucleotide polymorphism containing sequence #258.
XX
XX Single nucleotide polymorphism; SNP; human; genetic disease;
KW disease susceptibility; cardiovascular system; endocrine system;
KW neurological system; forensic testing; paternity testing; ds.
XX
OS Homo sapiens.
XX
XX WO200058519-A2.
XX
XX PD 05-OCT-2000.
XX
XX PF 30-MAR-2000; 2000WO-US008440.
XX
XX PR 31-MAR-1999; 99US-0127248P.
XX
XX PA (WHEE) WHITEHEAD INST BIOMEDICAL RES.
XX
XX PA (AFFY-) AFFYMETRIX INC.
XX
XX PI Altschuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
XX PI Lipshutz RJ, Patil N, Sklar P;
XX
XX DR WPI; 2000-611722/58.
XX

XX Nucleic acid selected from one of 106 genes comprising single nucleotide
XX polymorphisms, allele-specific oligonucleotides to the genes are useful
XX for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.

XX Claim 1; Fig 5; 214pp; English.

XX The present invention is concerned with a number of human single
XX nucleotide polymorphisms (SNPs) which the inventors identified in human
XX genes. These SNPs can be used in disease diagnosis and prediction of an
XX individual's susceptibility to disease, in forensic and paternity testing
XX and in genetic mapping. In particular, the SNPs of the invention can be

used to diagnose susceptibility to diseases of the cardiovascular, endocrine and neurological systems, such as coronary artery disease, schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's diseases. Note: the degenerate codon within the sequence represents the position of an SNP, for example the letter S represents a polymorphism where the nucleotide may be C or G

Sequence 253 BP; 92 A; 41 C; 58 G; 61 T; 0 U; 1 Other;

Query Match 0.9%; Score 21.6; DB 1; Length 253;
Best Local Similarity 53.6%; Pred. No. 37;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

1641 TTTTGTATCTCTTGTACCTTGATAGGACATCTTTCTCAAGGTAGGAATTTTCTT 1700
141 TATGGTTATTTATGTCTCTGTATCTCTTCTTGGCAGCTTCTGTTGGTCATTAAGGTA 82

1701 TTTTGGTTTCTTGAAATATTTT 1724
81 TCTTGGCTTCTGGAGATTTT 58

RESULT 74
ABV98470/c
ID ABV98470 standard; cDNA; 254 BP.
XX
AC ABV98470;
XX
DT 14-JAN-2003 (first entry)
XX
DE Human pancreatic cancer expressed cDNA SEQ ID NO 3878.
XX
KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
KW cystostatic; tumour; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200260317-A2.
XX
PD 08-AUG-2002.
XX
PF 30-JAN-2002; 2002WO-US002781.
XX
PR 30-JAN-2001; 2001US-0265305P.
PR 31-JAN-2001; 2001US-0265682P.
PR 09-FEB-2001; 2001US-0267568P.
PR 21-MAR-2001; 2001US-0278651P.
PR 28-APR-2001; 2001US-0287112P.
PR 16-MAY-2001; 2001US-0291631P.
PR 12-JUL-2001; 2001US-0305484P.
PR 20-AUG-2001; 2001US-0313999P.
PR 27-NOV-2001; 2001US-0333626P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;
PI WPI; 2002-627435/67.
XX
XX New isolated polynucleotide and pancreatic tumor polypeptides, useful for diagnosing, preventing and/or treating cancer, particularly pancreatic cancer.
XX
PS Claim 1; SEQ ID NO 3878; 300pp + Sequence Listing; English.
XX
XX The invention relates to an isolated polynucleotide (I) comprising: (a) any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b) complements of (a); (c) sequences consisting of at least 20 contiguous residues of (a); (d) sequences that hybridize to (a), under moderately stringent conditions; (e) sequences having at least 75% or 90% identity to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer in a patient and compositions comprising polypeptides, polynucleotides,

antibodies, fusion proteins, T cell populations and antigen presenting cells expressing the polypeptide are useful in treating pancreatic cancer and stimulating an immune response. The polynucleotides can be used as probes or primers for nucleic acid hybridisation, in the design and preparation of ribozyme molecules for inhibiting expression of the tumour polypeptides and proteins in the tumour cells, in vaccines and for gene therapy. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 254 BP; 61 A; 74 C; 84 G; 35 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.6; DB 1; Length 254;
Best Local Similarity 47.7%; Pred. No. 37;
Matches 63; Conservative 0; Mismatches 69; Indels 0; Gaps 0;

1848 TCCATTCTCTCATCTTGTCTTCACTGCTGAGATTCTCTTCTATCTCTGTATTCTG 1907
247 TCAGTTCCCTCTCTCTTGTGGCGTGTGCTCAGGCTATGCCACCTTCTCTGCCCTT 188

1908 TCAGTGAGGCTTGCTCTGAGGTTCTCTGTTGGTTCCTTAATTTTTCATTTCAGATTTC 1967
187 CCAGGCCGCGTTGTCAATGGTGAGGATCGGTCCCTACAGCTGGCCCTGGCAGGTTCC 128

1968 CTTTCAGTTGGG 1979
127 CTGCAGTATGAG 116

RESULT 75
AAV28290
ID AAV28290 standard; cDNA; 283 BP.
XX
AC AAV28290;
XX
DT 24-NOV-1998 (first entry)
XX
DE Galanin receptor GALR2 DNA probe.
XX
KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
KW cognitive disorder; therapy; probe; ss.
XX
OS Rattus sp.
XX
PN WO9829440-A1.
XX
PD 09-JUL-1998.
XX
PF 18-DEC-1997; 97WO-US023891.
XX
PR 27-DEC-1996; 96US-0033851P.
XX
PA (MERI) MERCK & CO INC.
PA (UYTE-) UNIV TEXAS HEALTH SCI SAN ANTONIO.
XX
PI Tan CP, Kolakowski LF;
XX
DR WPI; 1998-388038/33.
DR P-PSDB; AAW61461.
XX
PT New mouse galanin receptor, GALR2, - useful to identify agonists and antagonists to treat conditions involving galanin, e.g. for treating obesity, pain or cognitive disorders.
XX
PS Example 1; Fig 6; 56pp; English.
XX
XX This PCR fragment was used as a probe to screen a rat hypothalamus cDNA library. 2 independent clones, named 27A (see AAV28288) and 16.6, were obtained. Clone 27A codes for a novel full-length rat galanin receptor, designated GALR2 (see AAW61461). The invention provides methods for identifying ligands particular to mouse GALR2 (see AAW61463). Such ligands may be useful therapeutically e.g. to treat obesity or cognitive disorders involving excess galanin or to treat pain or anorexia involving

```

CC insufficient galanin
XX
SQ Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match      0.9%; Score 21.4; DB 1; Length 283;
Best Local Similarity 61.8%; Pred. No. 43;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 164 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGTGAGGGTTACCACTGCTC 218
Db 112 TCGGGCCGCTGCTGCGGCTGTCCCTCTACGTGGGCGAGGGCTGCACCTACGC 166

RESULT 76
AAV32651
ID AAV32651 standard; cDNA; 283 BP.
XX
AC AAV32651;
XX
DT 24-NOV-1998 (first entry)
XX
DE Galanin receptor GALR2 DNA probe.
XX
KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
XX cognitive disorder; therapy; probe; ss.
XX
OS Rattus sp.
XX
EN WO9829439-A1.
XX
PD 09-JUL-1998.
XX
PF 18-DEC-1997; 97WO-US023890.
XX
PR 27-DEC-1996; 96US-0033851P.
XX
PA (MERI ) MERCK & CO INC.
XX (UYTE-) UNIV TEXAS HEALTH SCI CENT SAN ANTONIO.
XX (UTOR ) UNIV TORONTO.
XX
PI Sullivan K, Kolakowski LF, Odowd B;
XX
DR WPI; 1998-388037/33.
XX
PT New human galanin receptor, GALR2, - useful to identify agonists and
XX antagonists to treat conditions involving galanin, e.g. for treatment of
XX obesity or cognitive disorders.
XX
PS Example 1; Fig 6; 57pp; English.
XX
CC This PCR fragment was used as a probe to screen a rat hypothalamus cDNA
XX library. 2 Independent clones, named 27A (see AAV44929) and 16.6, were
XX obtained. Clone 27A codes for a novel full-length rat galanin receptor,
XX designated GALR2 (see AAW61385). The invention provides methods for
XX identifying ligands particular to human GALR2 (see AAW61386). Such
XX ligands may be useful therapeutically e.g. to treat obesity or cognitive
XX disorders involving excess galanin or to treat pain or anorexia involving
XX insufficient galanin
XX
SQ Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match      0.9%; Score 21.4; DB 1; Length 283;
Best Local Similarity 61.8%; Pred. No. 43;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 164 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGTGAGGGTTACCACTGCTC 218
Db 112 TCGGGCCGCTGCTGCGGCTGTCCCTCTACGTGGGCGAGGGCTGCACCTACGC 166

RESULT 77
AAV44930
ID AAV44930 standard; cDNA; 283 BP.
XX
AC AAV44930;
XX
DT 08-MAY-2002 (first entry)
XX
DE Rat galanin receptor 2 (GALR2) cDNA probe.
XX
KW Galanin receptor 2; GALR2; probe; ss; rat; obesity; pain; anorectic;
XX cognitive disorder; analgesic; neuroprotective.
XX
OS Rattus sp.
XX
PN US6337206-B1.
XX
PD 08-JAN-2002.
XX
PF 18-DEC-1997; 97US-00993424.
XX

```


ACD23963/c
ID ACD23963 standard; cDNA; 1129 BP.
XX
AC ACD23963;
XX
DT 26-AUG-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003032156-A1.
XX
XX 13-FEB-2003.
XX
XX 06-MAY-2002; 2002US-00140474.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031274.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00860208.
PR 25-MAY-2001; 2001US-0086034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerriksen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-341980/32.
DR P-PSDB; ABO17726.
XX
XX New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
XX Claim 2; Fig 221; 660pp; English.
PS
XX The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one


```
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
XX XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX XX
DR WPI; 2003-352836/33.
DR P-PSDB; ABU80980.
XX
XX New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT heart attack.
XX
XX Claim 2; Fig 221; 643pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the treatment of diabetes, bone and/or cartilage disorders
CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC assays for PRO, by detecting its expression in specific cells, tissues or
CC serum, and for affinity purification of PRO from recombinant cell culture
CC or natural sources. ACA66994-ACA67268 represent cDNA sequences encoding
CC the human PRO polypeptides of the invention. Note: The sequence data for
CC this patent was obtained in electronic format directly from the USPTO web
CC site at seqdata.uspto.gov/psipdidentry.html
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTGTT 1987
Db 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
RESULT 82
ACA03713/c
ID ACA03713 standard; cDNA; 1129 BP.
XX
AC ACA03713;
XX
DT 23-MAY-2003 (first entry)
XX
XX cDNA encoding human PRO polypeptide #111.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic; gene;
KW ss.
XX
XX Homo sapiens.
XX
XX US2003036180-A1.
XX
```


PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030939.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030872.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-466355/44.
DR P-PSDB; ABO24951.
XX
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 221; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising at least 80%
CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
CC extracellular domain (with or without its associated signal peptides),
CC which comprises any of the 275 120-850 residue amino acid sequences,
CC given in the specification; (b) comprising any of the 275 300-3500
CC nucleotide sequences, given in the specification; or (c) comprising the
CC full-length coding sequence of the nucleotide sequences given in the
CC specification, or of the DNA deposited under any of the American Type
CC Culture Collection (ATCC) Accession Numbers listed in the specification.
CC Also included are a vector comprising the novel nucleic acid, a host cell
CC comprising the vector, producing a PRO polypeptide, the isolated PRO
CC polypeptides detailed above, a chimaeric molecule comprising the PRO
CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC antibody, detecting a PRO polypeptide in a sample suspected of containing
CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulating at least one biological activity of a cell
CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC modulating the uptake of glucose or FFA by skeletal muscle cells or
CC adipocyte cells, stimulating the proliferation or differentiation of
CC chondrocyte cells (or proliferation of or gene expression in pericyte
CC cells), stimulating the proliferation of inner ear utricular supporting
CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC binding of A-peptide to factor VIIa, or differentiation of adipocyte
CC cells, detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences given
CC in the specification. The polynucleotide is useful in molecular biology,
CC including uses as hybridisation probes, in chromosome and gene mapping,
CC in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide may also be used in preparing PRO polypeptides by
CC recombinant techniques, and in generating either transgenic animals or
CC knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The PRO polypeptide or the
CC antibody is used in preparing a medicament for treating a condition


```
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US003376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-687639/65.
DR P-PSDB; ADA76172.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 221; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TTCCTTAATTTTTCAGATTCCTTCAGTTTGGTTTGT 1987
Db 1129 TTTTTCATTTTTCAGTGGCACACAGCTGGTTTATT 1083
RESULT 88
ADAL8821/c
ID ADAL8821 standard; cDNA; 1129 BP.
XX ADAL8821;
AC
XX 20-NOV-2003 (first entry)
DT
XX Human PRO polynucleotide #111.
DE
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
```



```
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006686.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695927/66.
DR P-PSDB; ADB19230.
XX
XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX
PS Claim 2; Fig 221; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TTCTTAATTTTTCATTCACAGATTTCCTTCAGTTGGTTTGTGTT 1987
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083
RESULT 91
ADB27770/c
ID ADB27770 standard; cDNA; 1129 BP.
XX
AC ADB27770;
XX
XX 20-NOV-2003 (first entry)
DT
```

```
XX
DE cDNA encoding human PRO polypeptide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003082704-A1.
XX
PD 01-MAY-2003.
XX
XX 24-APR-2002; 2002US-00131819.
XX
XX 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-765415/72.
DR P-PSDB; ADB27771.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
PT
XX Claim 2; Fig 221; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format
CC the USPTO website at seqdata.uspto.gov.
```

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTATT 1987
Db 1129 TTTTTCATTTTTCATTTTCAGTGGCACACAGGCTGGGTTTATT 1083
RESULT 92
ADA86249/c
ID ADA86249 standard; cDNA; 1129 BP.
XX AC ADA86249;
XX DT 20-NOV-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003082711-A1.
XX PD 01-MAY-2003.
XX PF 16-MAY-2002; 2002US-00147508.
XX PR 02-JUL-1998; 98US-0091519P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 07-JUL-1999; 99US-0143048P.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786914/74.
XX P-PSDB; ADA86250.
XX PT New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumor or for tissue typing.
XX PS Claim 2; Fig 221; 637pp; English.
XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (II) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTATT 1987
Db 1129 TTTTTCATTTTTCATTTTCAGTGGCACACAGGCTGGGTTTATT 1083
RESULT 93
ADB15813/c
ID ADB15813 standard; cDNA; 1129 BP.
XX AC ADB15813;
XX DT 20-NOV-2003 (first entry)
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003087350-A1.
XX PD 08-MAY-2003.
XX PF 22-APR-2002; 2002US-00127821.
XX PR 04-AUG-1998; 98US-0095301P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786914/74.
XX P-PSDB; ADB15814.

PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX XX
(GETH) GENENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-644801/61.
DR P-PSDB; ADA47600.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.

Claim 2; Fig 221; 659pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1987
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACAGCGCTGGTTTATT 1083

RESULT 95

ADA67394/c

ID ADA67394 standard; cDNA; 1129 BP.

XX AC ADA67394;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX US2003068795-A1.

XX PD 10-APR-2003.

XX PF 15-APR-2002; 2002US-00123236.

XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.

xx Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
xx
OS Homo sapiens.
xx
xx US2003068794-A1.
xx
xx 10-APR-2003.
xx
xx 15-APR-2002; 2002US-00123155.
xx
xx 31-MAR-1997; 97WO-US005230.
xx 12-JUN-1998; 98WO-US012456.
xx 14-JUL-1998; 98WO-US014552.
xx 28-AUG-1998; 98WO-US017888.
xx 10-SEP-1998; 98WO-US018824.
xx 14-SEP-1998; 98WO-US019093.
xx 14-SEP-1998; 98WO-US019094.
xx 14-SEP-1998; 98WO-US019177.
xx 16-SEP-1998; 98WO-US019330.
xx 17-SEP-1998; 98WO-US019437.
xx 07-OCT-1998; 98WO-US021141.
xx 29-OCT-1998; 98WO-US022991.
xx 29-OCT-1998; 98WO-US022992.
xx 20-NOV-1998; 98WO-US024855.
xx 01-DEC-1998; 98WO-US025108.
xx 05-JAN-1999; 99WO-US000106.
xx 08-MAR-1999; 99WO-US005028.
xx 10-MAR-1999; 99WO-US005190.
xx 20-APR-1999; 99WO-US008615.
xx 14-MAY-1999; 99WO-US010733.
xx 02-JUN-1999; 99WO-US012252.
xx 01-SEP-1999; 99WO-US020111.
xx 08-SEP-1999; 99WO-US020594.
xx 13-SEP-1999; 99WO-US020944.
xx 15-SEP-1999; 99WO-US021090.
xx 15-SEP-1999; 99WO-US021547.
xx 05-OCT-1999; 99WO-US023089.
xx 29-NOV-1999; 99WO-US028214.
xx 30-NOV-1999; 99WO-US028313.
xx 30-NOV-1999; 99WO-US028409.
xx 01-DEC-1999; 99WO-US028301.
xx 01-DEC-1999; 99WO-US028634.
xx 02-DEC-1999; 99WO-US028551.
xx 02-DEC-1999; 99WO-US028564.
xx 02-DEC-1999; 99WO-US028565.
xx 16-DEC-1999; 99WO-US030095.
xx 20-DEC-1999; 99WO-US030911.
xx 20-DEC-1999; 99WO-US030999.
xx 22-DEC-1999; 99WO-US030720.
xx 30-DEC-1999; 99WO-US031243.
xx 30-DEC-1999; 99WO-US031274.
xx 05-JAN-2000; 2000WO-US000219.
xx 06-JAN-2000; 2000WO-US000277.
xx 06-JAN-2000; 2000WO-US000376.
xx 11-FEB-2000; 2000WO-US003565.
xx 18-FEB-2000; 2000WO-US004341.
xx 18-FEB-2000; 2000WO-US004342.
xx 22-FEB-2000; 2000WO-US004414.
xx 24-FEB-2000; 2000WO-US004914.
xx 24-FEB-2000; 2000WO-US005004.
xx 01-MAR-2000; 2000WO-US005601.
xx 02-MAR-2000; 2000WO-US005746.
xx 02-MAR-2000; 2000WO-US005841.
xx
xx 10-MAR-2000; 2000WO-US006319.
xx 15-MAR-2000; 2000WO-US006884.
xx 20-MAR-2000; 2000WO-US007377.
xx 21-MAR-2000; 2000WO-US007532.
xx 30-MAR-2000; 2000WO-US008439.
xx 17-MAY-2000; 2000WO-US013705.
xx 22-MAY-2000; 2000WO-US014042.
xx 30-MAY-2000; 2000WO-US014941.
xx 02-JUN-2000; 2000WO-US015264.
xx 28-JUL-2000; 2000WO-US020710.
xx 11-AUG-2000; 2000WO-US022031.
xx 23-AUG-2000; 2000WO-US023522.
xx 24-AUG-2000; 2000WO-US023328.
xx 08-NOV-2000; 2000WO-US030952.
xx 10-NOV-2000; 2000WO-US033873.
xx 01-DEC-2000; 2000WO-US032878.
xx 20-DEC-2000; 2000US-00747259.
xx 20-DEC-2000; 2000WO-US034956.
xx 28-FEB-2001; 2001US-00796498.
xx 28-FEB-2001; 2001WO-US006520.
xx 01-MAR-2001; 2001WO-US006666.
xx 09-MAR-2001; 2001US-00802706.
xx 14-MAR-2001; 2001US-00808689.
xx 22-MAR-2001; 2001US-00816744.
xx 05-APR-2001; 2001US-00828366.
xx 10-MAY-2001; 2001US-00854208.
xx 10-MAY-2001; 2001US-00854280.
xx 18-MAY-2001; 2001US-00860216.
xx 25-MAY-2001; 2001US-00866028.
xx 25-MAY-2001; 2001US-00866034.
xx 25-MAY-2001; 2001WO-US017092.
xx 01-JUN-2001; 2001US-00872035.
xx 05-JUN-2001; 2001WO-US017800.
xx 05-JUN-2001; 2001US-00874503.
xx 14-JUN-2001; 2001US-00882836.
xx 19-JUN-2001; 2001US-00886342.
xx 20-JUN-2001; 2001WO-US019692.
xx 21-JUN-2001; 2001US-00887879.
xx 22-JUN-2001; 2001WO-US020116.
xx 29-JUN-2001; 2001WO-US021066.
xx 09-JUL-2001; 2001WO-US021735.
xx 18-JUL-2001; 2001US-00908827.
xx 06-AUG-2001; 2001US-00924419.
xx 09-AUG-2001; 2001US-00927796.
xx 16-AUG-2001; 2001US-00931836.
xx 19-DEC-2001; 2001US-00028072.
xx
xx (GETH) GENENTECH INC.
xx
xx Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
xx Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
xx Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
xx
xx WPI; 2003-708391/67.
xx P-ESDB; ADB30402.
xx
xx New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
xx preparation of a medicament for treating a condition responsive to PRO
xx polypeptide, and as therapeutic agents e.g. vaccines.
xx
xx Claim 2; Fig 22i; 660pp; English.
xx
xx The invention relates to isolated human PRO polypeptides (secreted and
xx transmembrane polypeptides) and the polynucleotides encoding them. The
xx invention also relates to an antibody which specifically binds to a PRO
xx polypeptide, a method for stimulating the release of tumour necrosis
xx factor-alpha (TNF-alpha) from human blood, a method for stimulating the
xx proliferation or differentiation of chondrocyte cells and a method for
xx detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
xx colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
xx polynucleotides are useful in molecular biology, including uses as
xx hybridisation probes, in chromosome and gene mapping, in generating
xx antisense RNA and DNA and in gene therapy. The polynucleotides may also


```
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US022993.
PR 01-DEC-1998; 98WO-US025108.
PR 08-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007332.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00829366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.

10664775-4.rng
01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786937/74.
DR P-ESDB; ADA87353.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
XX Claim 2; Fig 221; 638pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGTTCCTTTT 1987
Db 1129 TTTTTCATTTTTCATTCAGATTTCCTTCAGTTGGTTCCTTTT 1083
RESULT 101
ADB16554/c
ID ADB16554 standard; cDNA; 1129 BP.
```


KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX US2003077722-A1.
XX
XX 24-APR-2003.
XX
XX 03-MAY-2002; 2002US-00137872.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755077/71.
DR P-PSDB; ADA93886.
XX
XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match

0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCCAGATTTTCCTTCAGTTGGGTTTGT 1987
Db 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083

RESULT 106

ADB19781/c
ID ADB19781 standard; cDNA; 1129 BP.

XX
AC ADB19781;

XX
DT 20-NOV-2003 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX

OS Homo sapiens.

XX US2003082691-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127838.

XX 17-NOV-1998; 98US-0108802P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 18-FEB-2000; 2000WO-US004342.

XX 02-JUN-2000; 2000WO-US015264.

XX 23-AUG-2000; 2000WO-US023522.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755108/71.

XX P-PSDB; ADB19782.

XX PRO nucleic acid, useful for preparing a composition for treating e.g.,

XX tumor or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage,
CC for stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBM cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or

PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 17-OCT-1998; 98WO-US021141.
 PR 23-OCT-1998; 98WO-US022991.
 PR 23-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US00106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020344.
 PR 13-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 15-SEP-1999; 98WO-US023089.
 PR 05-OCT-1999; 98WO-US028214.
 PR 29-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030311.
 PR 20-DEC-1999; 98WO-US030399.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 98WO-US000219.
 PR 06-JAN-2000; 98WO-US000277.
 PR 06-JAN-2000; 98WO-US000376.
 PR 11-FEB-2000; 98WO-US003565.
 PR 18-FEB-2000; 98WO-US004341.
 PR 18-FEB-2000; 98WO-US004342.
 PR 22-FEB-2000; 98WO-US004414.
 PR 24-FEB-2000; 98WO-US004914.
 PR 24-FEB-2000; 98WO-US005004.
 PR 01-MAR-2000; 98WO-US005601.
 PR 02-MAR-2000; 98WO-US005746.
 PR 10-MAR-2000; 98WO-US005841.
 PR 10-MAR-2000; 98WO-US006319.
 PR 15-MAR-2000; 98WO-US006884.
 PR 20-MAR-2000; 98WO-US007377.
 PR 21-MAR-2000; 98WO-US007532.
 PR 30-MAR-2000; 98WO-US008439.
 PR 17-MAY-2000; 98WO-US013705.
 PR 22-MAY-2000; 98WO-US014042.
 PR 30-MAY-2000; 98WO-US014941.
 PR 02-JUN-2000; 98WO-US015264.
 PR 28-JUL-2000; 98WO-US020710.
 PR 11-AUG-2000; 98WO-US022031.
 PR 23-AUG-2000; 98WO-US023522.
 PR 24-AUG-2000; 98WO-US023328.
 PR 08-NOV-2000; 98WO-US030952.
 PR 10-NOV-2000; 98WO-US030873.
 PR 01-DEC-2000; 98WO-US032678.
 PR 20-DEC-2000; 98WO-US047259.
 PR 20-DEC-2000; 98WO-US034956.
 PR 28-FEB-2001; 98WO-US0796498.
 PR 28-FEB-2001; 98WO-US006520.
 PR 01-MAR-2001; 98WO-US006666.
 PR 09-MAR-2001; 98WO-US0062706.
 PR 14-MAR-2001; 98WO-US0080689.
 PR 22-MAR-2001; 98WO-US0816744.
 PR 05-APR-2001; 98WO-US0828366.
 PR 10-MAY-2001; 98WO-US0854208.
 PR 10-MAY-2001; 98WO-US0854280.
 PR 18-MAY-2001; 98WO-US0860216.

PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-492275/46.
 DR P-PSDB; ABO43259.
 XX
 XX New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX
 PS Claim 2; Fig 221; 660pp; English.
 XX
 CC The invention describes an isolated nucleic acid encoding a PRO (secreted
 CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
 CC used to generate either transgenic animals or knock-out animals useful in
 CC developing and screening of therapeutically useful reagents. The nucleic
 CC acids may also be used in gene therapy, in chromosome identification, as
 CC chromosome markers, or in generating probes. The PRO polypeptides are
 CC useful as molecular markers for protein electrophoresis, and the isolated
 CC nucleic acids may be used for recombinantly expressing those markers. The
 CC PRO polypeptides and nucleic acids may also be used in tissue typing.
 CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. This sequence encodes a novel human secreted and transmembrane
 CC PRO polypeptide
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCCAGATTCTTCAGTTGGTTTGTGTTT 1987
 |||||
 Db 1129 TTTTTCATTTTTCATTTTCAGTTGGTTTGTGTTTATT 1083

RESULT 109
 ADA74347/C
 ID ADA74347 standard; cDNA; 1129 BP.
 XX
 AC ADA74347;
 XX
 XX 20-NOV-2003 (first entry)
 DT
 XX Human PRO polynucleotide #11.
 DE
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003068798-A1.
PN PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140928.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 08-MAR-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-625490/59.
DR P-FSDB; ADA74348.
XX
XX Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT encoding them, useful for treating bone disorders, arthritis, heart
PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT Factor-alpha from human blood.
XX
PS Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a


```
XX US2003082701-A1.
XX PN
XX PD
XX PF 01-MAY-2003.
XX FF 23-APR-2002; 2002US-00128685.
XX FF 31-AUG-1998; 98US-0098525P.
XX PR 16-SEP-1998; 98US-0100634P.
XX PR 02-JUN-1999; 98WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX XX (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX DR WPI; 2003-755110/71.
XX DR P-PSDB; ADA82105.
XX PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX PT tumor or for tissue typing.
XX PS Claim 2; Fig 221; 637pp; English.
XX CC
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating differentiation of adipocyte cells, for stimulating
XX CC the proliferation of or gene expression in pericyte cells, for stimulating
XX CC cells, for inducing endothelial cell tube formation and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems,
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassaemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence represents a human PRO polynucleotide of the invention. Note:
XX CC The sequence data for this patent is also available in electronic format
XX CC from USPTO at seqdata.uspto.gov/sequence.html.
XX CC
XX CC Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX CC
XX CC Query Match 0.9%; Score 21.4; DB 1; Length 1129;
XX CC Best Local Similarity 66.0%; Pred. No. 55;
XX CC Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX CC
XX CC 1941 TCTTTAATTTTTCATTTCCAGATTCCTCAGTTGGTGTGTTT 1987
XX CC ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX CC 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGTGTATT 1083
```

RESULT 112
ADA75067/c
ID ADA75067 standard; cDNA; 1129 BP.
XX
AC ADA75067;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073216-A1.
XX
PD 17-APR-2003.
XX
PF 30-MAY-2002; 2002US-00160498.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US0003565.
18-FEB-2000; 2000WO-US0004341.
18-FEB-2000; 2000WO-US0004342.
22-FEB-2000; 2000WO-US0004411.
24-FEB-2000; 2000WO-US0004914.
24-FEB-2000; 2000WO-US0005004.
01-MAR-2000; 2000WO-US0005601.
02-MAR-2000; 2000WO-US0005746.
02-MAR-2000; 2000WO-US0005841.
10-MAR-2000; 2000WO-US0006319.
15-MAR-2000; 2000WO-US0006884.
20-MAR-2000; 2000WO-US0007377.
21-MAR-2000; 2000WO-US0007532.
30-MAR-2000; 2000WO-US0008439.
17-MAY-2000; 2000WO-US0013705.
22-MAY-2000; 2000WO-US0114042.
30-MAY-2000; 2000WO-US0114941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023522.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US0006520.
01-MAR-2001; 2001WO-US0006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00865028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-765392/72.
P-PSDB; ADA75068.
New secreted and transmembrane PRO polypeptides useful for stimulating
the release of tumor necrosis factor alpha in human blood and detecting
the presence of tumor in a mammal.
Claim 2; Fig 221; 638pp; English.
PS
XX

XX ADB29849;
AC 20-NOV-2003 (first entry)
XX CDNA encoding human PRO polypeptide #111.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
OS Homo sapiens.
XX US2003073214-A1.
XX 17-APR-2003.
XX 17-APR-2002; 2002US-00124822.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018924.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 22-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 06-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
XX WPI; 2003-720081/68.
DR P-PSDB; ADB29850.
DR Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX Claim 2; Fig 221; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.

XX
XX
(GETH) GENENTECH INC.

Baker KP, Bersesini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-755115/71.
P-PSDB; ADA80378.

New PRO polypeptides useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders and tumors.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as varicous thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
XX
Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022391.
PR 29-OCT-1998; 98WO-US022392.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 08-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005001.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 17-MAY-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796458.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 03-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 23-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00891962.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908927.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI: 2003-777249/73.
P-PSDB; ADB26667.
Novel isolated PRO polypeptide useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders, tumors.
Claim 2; Fig 221; 660pp; English.
The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung). The colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The

PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786990/74.
XX P-PSDB; ADB30954.
XX
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
XX hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
XX attack, various coagulation disorders, tumors.
XX
XX Claim 2; Fig 221; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence encodes a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.
XX
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TCTTAATTTTTCATTCAGATTCCTTCAGTTGGTTTCTT 1987
Db 1129 TTTTTCATTTTTCATTCAGATTCCTTCAGTTGGTTTCTT 1083
RESULT 123
ADA6081/c
ID ADA6081 standard; cDNA; 1129 BP.
XX
XX ADA6081;
XX
XX DT 20-NOV-2003 (first entry)
XX
XX Homo sapiens.
XX
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Novel.
XX human.
XX secreted.
XX and.
XX transmembrane.
XX protein.
XX PRO4327.
XX cDNA.
XX
XX US2003049817-A1.
XX
XX PD 13-MAR-2003.
XX
XX PF 10-MAY-2002; 2002US-00142423.
XX
XX PR 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
XX PR 29-OCT-1998; 98WO-US022992.
XX PR 20-NOV-1998; 98WO-US024855.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 20-APR-1999; 99WO-US008615.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 02-JUN-1999; 99WO-US020111.
XX PR 08-SEP-1999; 99WO-US020594.
XX PR 13-SEP-1999; 99WO-US020944.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 15-SEP-1999; 99WO-US021547.
XX PR 05-OCT-1999; 99WO-US023089.
XX PR 29-NOV-1999; 99WO-US028214.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 30-NOV-1999; 99WO-US028409.
XX PR 01-DEC-1999; 99WO-US028301.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 02-DEC-1999; 99WO-US028564.
XX PR 02-DEC-1999; 99WO-US028565.
XX PR 16-DEC-1999; 99WO-US030095.
XX PR 20-DEC-1999; 99WO-US030911.
XX PR 20-DEC-1999; 99WO-US030999.
XX PR 22-DEC-1999; 99WO-US030720.
XX PR 30-DEC-1999; 99WO-US031243.
XX PR 05-JAN-2000; 99WO-US031274.
XX PR 06-JAN-2000; 2000WO-US000219.
XX PR 06-JAN-2000; 2000WO-US000277.
XX PR 06-JAN-2000; 2000WO-US000376.
XX PR 11-FEB-2000; 2000WO-US003565.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 18-FEB-2000; 2000WO-US004342.
XX PR 22-FEB-2000; 2000WO-US004414.
XX PR 24-FEB-2000; 2000WO-US004914.
XX PR 24-FEB-2000; 2000WO-US005004.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005746.
XX PR 15-MAR-2000; 2000WO-US005841.
XX PR 15-MAR-2000; 2000WO-US006884.
XX PR 20-MAR-2000; 2000WO-US007377.

are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTCATTCCAGATTTCCTTCAGTTGGGTTTTGT 1987
||| ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTITTTTTTTTTTTTTCAGTGCGACACAGGCTGGTTTTATT 1083

RESULT 124
ADB24028/c

ID ADB24028 standard; cDNA; 1129 BP.
AC ADB24028;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 221.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077714-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127901.
XX
PR 17-JUN-1998; 98US-0089599P.
XX
PR 02-JUN-1999; 99WO-US012252.
XX
PR 25-AUG-1999; 99US-00380137.
XX
PR 30-NOV-1999; 99WO-US028313.
XX
PR 30-MAR-2000; 2000WO-US008439.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-755069/71.
DR P-PSDB; ADB24029.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and methods

XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; hemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX
FN US2003082760-A1.
XX
PD 01-MAY-2003.
XX
PF 12-APR-2002; 2002US-00121056.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritson ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-777204/73.
DR P-PSDB; ADB26115.
DR
XX
XX
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
XX
XX Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating

DR WPI: 2003-755106/71.
DR P-PSDB; ADA97462.
XX
PT Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX
XS Claim 2; Fig 221; 666pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1941 TTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTGGTGTGTTT 1987
DB 1129 TTTTATTTTATTTTTCAGTGGACACAGGCTGGTTTATT 1083

RESULT 140
ADB27218/c
ID ADB27218 standard; cDNA; 1129 BP.
XX
AC ADB27218;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

KW immune system cell infiltration.
XX
XX Homo sapiens.
XX US2003022239-A1.
XX PD 30-JAN-2003.
XX
XX PF 12-APR-2002; 2002US-00121049.
XX
XX 18-JUN-1997; 97US-0049911P.
XX 26-AUG-1997; 97US-0056974P.
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059263P.
XX 19-SEP-1997; 97US-0059352P.
XX 19-SEP-1997; 97US-0059588P.
XX 24-SEP-1997; 97US-0059836P.
XX 17-OCT-1997; 97US-0062250P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 17-OCT-1997; 97US-0063755P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063082P.
XX 24-OCT-1997; 97US-0063127P.
XX 27-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063561P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063733P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065846P.
XX 21-NOV-1997; 97US-0066364P.
XX 24-NOV-1997; 97US-0066453P.
XX 24-NOV-1997; 97US-0066511P.
XX 24-NOV-1997; 97US-0066770P.
XX 11-DEC-1997; 97US-0069212P.
XX 11-DEC-1997; 97US-0069278P.
XX 11-DEC-1997; 97US-0069334P.
XX 16-DEC-1997; 97US-0069694P.
XX 23-JAN-1998; 98US-0072320P.
XX 04-FEB-1998; 98US-0073612P.
XX 09-FEB-1998; 98US-0074086P.
XX 09-FEB-1998; 98US-0074092P.
XX 12-MAR-1998; 98US-0077791P.
XX 20-MAR-1998; 98US-0078910P.
XX 25-MAR-1998; 98US-0079294P.
XX 27-MAR-1998; 98US-0079663P.
XX 31-MAR-1998; 98US-0079728P.
XX 09-APR-1998; 98US-0080165P.
XX 14-APR-1998; 98US-0081223P.
XX 15-APR-1998; 98US-0081695P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081818P.
XX 24-APR-1998; 98US-0082999P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083545P.
XX 07-MAY-1998; 98US-0084600P.
XX 07-MAY-1998; 98US-0084627P.
XX 07-MAY-1998; 98US-0084637P.
XX 12-MAY-1998; 98US-0085149P.
XX 13-MAY-1998; 98US-0085323P.
XX 13-MAY-1998; 98US-0085338P.

XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059358P.
PR 24-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062827P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 31-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088028P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 11-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98US-008912456.
PR 17-JUN-1998; 98US-0089332P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98US-00914552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98US-0097988P.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98US-0099816P.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100390P.
PR 14-SEP-1998; 98US-0100390P.
PR 15-SEP-1998; 98US-0100390P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100930.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103328P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105169P.
PR 29-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98US-01062991.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.

PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001US-00886342.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001US-00887879.
 PR 29-JUN-2001; 2001US-00902016.
 PR 29-JUN-2001; 2001US-00902016.
 PR 09-JUL-2001; 2001US-00908827.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-695925/66.
 DR P-PSDB; ADA66843.

PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
 PT Release of tumor necrosis factor-alpha from human blood and detecting the
 PT presence of a tumor in a mammal.

PS Claim 2; Fig 221; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumor in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1941 TTCTTAATTTTTCATTTTCAGATTTCCTTCAGTTGGGTTTGT 1987
 Db 1129 TTTTTCATTTTTCATTTTCAGATTTCCTTCAGTTGGGTTTGT 1083

RESULT 143

ID ADB22703/C

ID ADB22703 standard; cDNA; 1129 BP.

XX ADB22703;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003077711-A1.

XX 24-APR-2003.

XX 22-APR-2002; 2002US-00127829.

XX 22-OCT-1998; 98US-0105169P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 30-NOV-1999; 99WO-US028313.

XX 18-FEB-2000; 2000WO-US004342.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755066/71.

XX P-PSDB; ADB22704.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, as diagnostic markers for the presence of a disease
 PT condition, or as therapeutic targets for treating tumors, diabetes,
 PT obesity or arthritis.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumor in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082712-A1.

XX 01-MAY-2003.

XX 16-MAY-2002; 2002US-00147512.

XX 15-MAY-1998; 98US-0085697P.

XX 08-MAR-1999; 99WO-US005028.

XX 25-AUG-1999; 99US-00380138.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786915/74.

XX P-PSDB; ADA92199.

XX New PRO nucleic acid, useful for preparing a composition for treating

XX e.g., tumor or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and

XX transmembrane) polypeptides (I). (I) is useful for stimulating the

XX release of TNF-alpha from human blood, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating the proliferation or differentiation of chondrocyte cells,

XX cells, for stimulating the proliferation of or gene expression in pericyte

XX cells, for stimulating the proliferation of inner ear utricular supporting cells,

XX stimulating the proliferation of T-lymphocyte cells, for stimulating

XX the release of a cytokine from PMBC cells, for inhibiting the binding of

XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

XX cells, for stimulating proliferation of endothelial cells, for detecting

XX the presence of tumour in a mammal. The tumour is lung, colon, breast,

XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes

XX are useful for isolating genomic and cDNA nucleotide sequences or

XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful

XX in assays to identify other proteins or molecules involved in binding

XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome

XX and gene mapping, in generation of antisense RNA and DNA, in the

XX preparation of PRO polypeptide, for generating transgenic animals or

XX knockout animals which in turn are useful in the development and

XX screening of therapeutically useful reagents, in gene therapy, for

XX chromosome identification, as chromosome marker, and for generating

XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

XX detecting its expression in specific cells, tissues or serum, and for

XX affinity purification of PRO from recombinant cell culture or natural

XX sources. (I) and (II) are useful for tissue typing. This sequence encodes

XX a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

XX Query Match 0.9%; Score 21.4; DB 1; Length 1129;

XX Best Local Similarity 66.0%; Pred. No. 55;

XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

XX QY 1941 TTCTTAATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTGT 1987

XX DB 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT

XX RESULT 146

ADBI5261/c

ID ADBI5261 standard; cDNA; 1129 BP.

XX ADBI5261;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003087352-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127824.

XX 17-AUG-1998; 98US-0096891P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-786943/74.
 XX P-PSDB; ADBI5262.

XX New PRO nucleic acid, useful for producing a recombinant PRO polypeptide

XX and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful
 XX reagents. The PRO polypeptides or antibodies are used in preparing a
 XX medicament for treating a condition responsive to the polypeptides or
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation
 XX of human microvascular endothelial cells, for modulating the uptake of
 XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
 XX stimulating differentiation of adipocyte cells, for stimulating
 XX proliferation of or gene expression in pericyte cells, for stimulating
 XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
 XX cells, for inducing endothelial cell tube formation and for treating

RESULT 149
ADB66433/c
ID ADB66433 standard; cdna; 1129 BP.
XX
XX
AC ADB66433;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4327 cdna.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX
XX US2003082689-A1.
XX
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127831.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-786905/74.
P-FSDB; ADB66434.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
e.g. tumor or for tissue typing.
XX
PS Claim 2; Fig 22i; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or PFA by skeletal muscle cells or adipocyte cells, for

KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX
 XX
 XX
 PD 01-MAY-2003.
 XX
 XX
 PF 15-APR-2002; 2002US-00123235.
 XX
 PF 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US000528.
 PR 10-MAR-1999; 99WO-US000519.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000365.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006566.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Deenoysers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-743893/70.
 DR P-PSDB; ADB90246.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 in gene therapy, and in the detection and treatment of tumor in a mammal.
 PT
 XX
 PS Claim 2; Fig 22i; 649pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC

CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTTCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGTGTT 1987
Db 1129 TTTTCTTTTTCATTTTCAGTGGCACACAGGCTGGTTTATT 1083

RESULT 152

ADB39346/C

ID ADB39346 standard; cDNA; 1129 BP.

XX AC ADB39346;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX US2003082764-A1.

XX PD 01-MAY-2003.

XX PF 03-MAY-2002; 2002US-00137868.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808699.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.

Db 1129 TTTTTCAGTGGCAGACAGCTGGTTTATT 1083

RESULT 154

ADB86576/c
ID ADB86576 standard; cDNA; 1129 BP.

AC ADB86576;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide #111.

XX XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX FN US2003082697-A1.

XX XX 01-MAY-2003.

XX XX 22-APR-2002; 2002US-00127849.

XX XX 20-OCT-1998; 98US-0104987P.

XX XX 01-SEP-1999; 99WO-US020111.

XX XX 18-OCT-1999; 99US-00403297.

XX XX 18-FEB-2000; 2000WO-US004342.

XX XX 01-DEC-2000; 2000WO-US032678.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-743895/70.
XX P-PSDB; ADB86577.

XX XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis
XX XX and treatment of cancer.

XX XX Claim 2; Fig 221; 637pp; English.

XX XX The invention relates to isolated human PRO polypeptides (secreted and
XX XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX XX invention also relates to an antibody which specifically binds to a PRO
XX XX polypeptide, a method for stimulating the release of tumour necrosis
XX XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX XX proliferation or differentiation of chondrocyte cells and a method for
XX XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX XX polynucleotides are useful in molecular biology, including uses as
XX XX hybridisation probes, in chromosome and gene mapping, in generating
XX XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX XX be used in preparing PRO polypeptides by recombinant techniques and in
XX XX generating either transgenic animals or knock-out animals which are
XX XX useful in the development and screening of therapeutically useful
XX XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX XX medicament for treating a condition responsive to the polypeptides or
XX XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX XX of human microvascular endothelial cells, for modulating the uptake of
XX XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ

Query Match 0.98; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred.No.55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Oy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGTTTCTTT 1987
Db 1129 TTTTTCAGTGGCAGACAGCTGGTTTATT 1083

RESULT 155

ADB77181/c

ID ADB77181 standard; cDNA; 1129 BP.

XX AC ADB77181;

XX DT 04-DEC-2003 (first entry)

XX XX Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX FN US2003082696-A1.

XX XX 01-MAY-2003.

XX XX 22-APR-2002; 2002US-00127848.

XX XX 03-NOV-1998; 98US-0106934P.

XX XX 26-JUL-1999; 99US-0145698P.

XX XX 01-SEP-1999; 99WO-US020111.

XX XX 18-OCT-1999; 99US-00403297.

XX XX 05-JAN-2000; 2000WO-US000219.

XX XX 18-FEB-2000; 2000WO-US004342.

XX XX 01-DEC-2000; 2000WO-US032678.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755109/71.
XX P-PSDB; ADB77182.

XX XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX tumor or for tissue typing.

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1941 TTCCTAAATTTTCATCCAGATTTCCTTCAGTTGGGTTTGT 1987
 |||||
 Db 1129 TTTTATTTTTCATCCAGTTTCCTTCAGTTGGGTTTGT 1083
 |||||

RESULT 159

ADB34890/c

ID ADB34890 standard; cDNA; 1129 BP.

AC ADB34890;

DT 04-DEC-2003 (first entry)

XX Human PRO polynucleotide SEQ ID NO 221.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US200307718-A1.

PN 24-APR-2003.

XX 24-APR-2002; 2002US-00131823.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 16-SEP-1998; 98WO-US019177.
 PR 17-SEP-1998; 98WO-US019330.
 PR 07-OCT-1998; 98WO-US019437.
 PR 29-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.

PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US013093.
 PR 14-SEP-1998; 98WO-US013094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 99WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US003355.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 11-AUG-2000; 2000WO-US020710.
 PR 23-AUG-2000; 2000WO-US022031.
 PR 24-AUG-2000; 2000WO-US023522.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00736498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00871092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801150/75.

P-PSDB; ADCS2796.

New PRO nucleic acid, useful for manufacturing a medicament for
 diagnosing or treating tumor.

Claim 2; SEQ ID NO 221; 637pp; English.

This invention relates to novel nucleic acids encoding human PRO secreted
 and transmembrane proteins. Extracellular proteins play important roles
 in the formation, differentiation and maintenance of multicellular
 organisms. The fate of many individual cells (for example proliferation,
 migration or differentiation) is typically governed by information
 received from other cells and the immediate environment. The information
 is often transmitted by secreted polypeptides (for example mitogenic
 factors, survival factors, cytotoxic factors, differentiation factors,
 neurotrophins and hormones) which are received and interpreted by diverse
 cell receptors or membrane bound proteins. These membrane bound proteins
 as in the blocking of receptor-ligand interactions. The current invention
 provides the amino acid sequences of novel human membrane bound receptors
 and proteins, along with the cDNA sequences encoding them. The novel
 proteins of the invention may have cytostatic activities through the
 stimulation of chondrocytes. The nucleic acids of the invention may be
 useful for the manufacture of a medicament for diagnosing or treating a
 tumor in a mammal. In addition, they may be useful for measuring or
 detecting the expression of a tumor associated gene. The present
 sequence is a cDNA sequence which encodes a human PRO protein of the
 invention.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1987
 |||||
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCTGGGTTTATT 1083

Sequence 1129 BP: 231 A: 369 C: 335 G: 194 T: 0 U: 0 Other;

RESULT 170

ADC54440;

Novel human secreted and transmembrane protein cDNA Seq ID221.

Homo sapiens.

08-MAY-2003.

10-SEP-1998: 98US-0099816P.

18-OCT-1999; 9903-00403237;
18-FEB-2000: 2000WO-US004342;

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

WPI: 2003-801148/75.

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PP and for manufacturing a medicament for diagnosing or treating tumor.

This invention relates to novel nucleic

Claim 2; SEQ ID NO 221; 637pp; English.

CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC invention is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1987
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGGCTGGTTTATT 1083

RESULT 172

ADCS58924/c
 ID ADCS58924 standard; cDNA; 1129 BP.

XX AC ADCS58924;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.

XX KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.

XX OS Homo sapiens.

XX FN US2003087359-A1.

XX PD 08-MAY-2003.

XX PF 22-APR-2002; 2002US-00127834.

XX PR 17-SEP-1998; 98US-0100710P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX FA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX XX WPI; 2003-801144/75.

XX DR P-PSDB; ADCS58925.

XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 and for manufacturing a medicament for diagnosing or treating tumor.

XX PS Claim 2; SEQ ID NO 221; 637pp; English.

XX CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular

CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC invention is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1987
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGGCTGGTTTATT 1083

RESULT 173

ADCS5802/c
 ID ADCS5802 standard; cDNA; 1129 BP.

XX AC ADCS5802;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.

XX KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.

XX OS Homo sapiens.

XX FN US2003087360-A1.

XX PD 08-MAY-2003.

XX PF 22-APR-2002; 2002US-00127836.

XX PR 17-NOV-1998; 98US-0108802P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 02-JUN-2000; 2000WO-US015264.

XX PR 23-AUG-2000; 2000WO-US023522.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX FA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX XX WPI; 2003-801145/75.

XX DR P-PSDB; ADCS5803.

XX PT New PRO nucleic acid, useful for manufacturing a medicament for

PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 27-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 01-DEC-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 08-MAR-1999; 99WO-US000106.
 PR 10-MAR-1999; 99WO-US005028.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US003376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006319.
 PR 20-MAR-2000; 2000WO-US006894.
 PR 21-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US007532.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-JUN-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-FEB-2001; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 01-MAR-2001; 2001WO-US006520.
 PR 09-MAR-2001; 2001WO-US006666.
 PR 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808699.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-801169/75.
 DR P-PSDB; ADD03047.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; Fig 221; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Claim 2; Fig 221; 637pp; English.

Claim 2: Fig 221; 637pp; English.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred.No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTTTCATTCCAGATTTCCTTCAGTTTGCGTTTGTGTT 1987
 ||||| ||||| ||||| ||||| ||||| ||
Db 1129 TTTTITTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTTATT 1083

RESULT 183
ADC47794/c
ID ADC47794 standard; cDNA; 1129 BP.
XX AC
XX AC
XX AC
XX AC
XX AD
DE DE
XX XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.
XS US2003194771-A1.
XX XX
XX 16-OCT-2003.
XX XX
XX 21-MAY-2002; 2002US-00152377.
XX XX
XX 03-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX XX
XX (GETH) GENENTECH INC.
XX PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Gurney SL, Smith V;
PI Stewart TA, Tomas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-844454/78.
DR P-PSDB; ADC47795.
XX XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT for detecting a tumor, stimulating the release of proteoglycans from
FT cartilage and stimulating the proliferation of endothelial cells.
XX Claim 2; Fig 221; 637pp; English.
XX XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful

Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; PFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassemia; immune system cell infiltration.

Homo sapiens.

US2003194774-A1.

16-OCT-2003.

21-MAY-2002; 2002US-00152399.

03-MAR-2000; 2000US-0187202P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI: 2003-852594/79.

P-PSDB; ADL0914.

New secreted and transmembrane PRO nucleic acids and polypeptides, useful for detecting a tumor, stimulating the proliferation or differentiation of chondrocyte cells and stimulating the release of tumor necrosis factor alpha.

Claim 2; SEQ ID NO 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis

PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005619.
PR 10-MAR-1999; 98WO-US006319.
PR 20-APR-1999; 98WO-US010733.
PR 14-MAY-1999; 98WO-US012252.
PR 02-JUN-1999; 98WO-US020111.
PR 01-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 23-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 98WO-US000219.
PR 06-JAN-2000; 98WO-US000277.
PR 06-JAN-2000; 98WO-US000376.
PR 11-FEB-2000; 98WO-US0003565.
PR 18-FEB-2000; 98WO-US004341.
PR 18-FEB-2000; 98WO-US004342.
PR 22-FEB-2000; 98WO-US004414.
PR 24-FEB-2000; 98WO-US004914.
PR 01-MAR-2000; 98WO-US005004.
PR 02-MAR-2000; 98WO-US005601.
PR 02-MAR-2000; 98WO-US005746.
PR 02-MAR-2000; 98WO-US005841.
PR 15-MAR-2000; 98WO-US006884.
PR 20-MAR-2000; 98WO-US007377.
PR 21-MAR-2000; 98WO-US007532.
PR 30-MAR-2000; 98WO-US008439.
PR 17-MAY-2000; 98WO-US013705.
PR 22-MAY-2000; 98WO-US014042.
PR 30-MAY-2000; 98WO-US014941.
PR 02-JUN-2000; 98WO-US015264.
PR 28-JUL-2000; 98WO-US020710.
PR 11-AUG-2000; 98WO-US022031.
PR 23-AUG-2000; 98WO-US023522.
PR 24-AUG-2000; 98WO-US023328.
PR 08-NOV-2000; 98WO-US030952.
PR 10-NOV-2000; 98WO-US030873.
PR 01-DEC-2000; 98WO-US032678.
PR 20-DEC-2000; 98WO-US00747259.
PR 20-DEC-2000; 98WO-US034956.
PR 28-FEB-2001; 98WO-US00796498.
PR 28-FEB-2001; 98WO-US006520.
PR 01-MAR-2001; 98WO-US006666.
PR 09-MAR-2001; 98WO-US00802706.
PR 14-MAR-2001; 98WO-US0080689.
PR 22-MAR-2001; 98WO-US00816744.
PR 05-APR-2001; 98WO-US00828366.
PR 10-MAY-2001; 98WO-US00854208.
PR 10-MAY-2001; 98WO-US00854280.
PR 18-MAY-2001; 98WO-US00860216.
PR 25-MAY-2001; 98WO-US0086028.
PR 25-MAY-2001; 98WO-US00866034.
PR 25-MAY-2001; 98WO-US017092.
PR 01-JUN-2001; 98WO-US00872035.
PR 01-JUN-2001; 98WO-US017800.
PR 05-JUN-2001; 98WO-US00874503.
PR 14-JUN-2001; 98WO-US00882636.
PR 19-JUN-2001; 98WO-US00886342.
PR 20-JUN-2001; 98WO-US019692.
PR 21-JUN-2001; 98WO-US00887879.
PR 22-JUN-2001; 98WO-US020116.
PR 23-JUN-2001; 98WO-US021066.
PR 09-JUL-2001; 98WO-US021735.
PR 18-JUL-2001; 98WO-US008827.
PR 06-AUG-2001; 98WO-US024419.
PR 09-AUG-2001; 98WO-US00927796.
PR 16-AUG-2001; 98WO-US00931836.
PR 19-DEC-2001; 98WO-US0028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852599/79.
DR P-PSDB; ADD52916.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PC4978, useful in chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in the treatment of cancer.
XX
PS Claim 2; Fig 221; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC various bone and/or cartilage disorders which stimulate the release of proteoglycans
CC from cartilage. PRO polypeptides are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format
CC the USPTO website at seqdata.uspto.gov.
XX

Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTTGTGTT 1987
DB 1129 TTTTTCATTTTTCAGTTTCAGTGGCACACAGGCTGGTTTATT 1083

RESULT 191
ADD02422/c
ID ADD02422 standard; cDNA; 1129 BP.
XX
AC ADD02422;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss: PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203431-A1.
XX
PD 30-OCT-2003.
XX

PF 24-APR-2002; 2002US-00131820.
XX
XX 28-OCT-1998; 98US-0106030P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-06403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENEVECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-875638/81.
DR P-PSDB; ADD02423.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTTGTGTT 1987
DB 1129 TTTTTCATTTTTCAGTTTCAGTGGCACACAGGCTGGTTTATT 1083

RESULT 192
ADD01856/c
ID ADD01856 standard; cDNA; 1129 BP.

XX OS Homo sapiens.
 XX PN US2003199055-A1.
 XX PD 23-OCT-2003.
 XX PF 12-APR-2002; 2002US-00121063.
 XX PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 01-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028401.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 XX PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00806889.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX MPI: 2003-900165/82.
 P-PSDB; ADD91252.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 221; 636pp; English.
 PS The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

PR 14-MAY-1999; 99WO-US010733.

PR	31-MAR-1997;	97WO-US005230.	PR	01-MAR-2001;	2001WO-US006666.
PR	12-JUN-1998;	98WO-US012456.	PR	09-MAR-2001;	2001US-00802706.
PR	14-JUL-1998;	98WO-US014552.	PR	14-MAR-2001;	2001US-00808689.
PR	28-AUG-1998;	98WO-US017888.	PR	22-MAR-2001;	2001US-00816744.
PR	10-SEP-1998;	98WO-US018824.	PR	05-APR-2001;	2001US-00828366.
PR	14-SEP-1998;	98WO-US018093.	PR	10-MAY-2001;	2001US-00854208.
PR	14-SEP-1998;	98WO-US019094.	PR	10-MAY-2001;	2001US-00854280.
PR	14-SEP-1998;	98WO-US019177.	PR	18-MAY-2001;	2001US-00860216.
PR	16-SEP-1998;	98WO-US019330.	PR	25-MAY-2001;	2001US-00866034.
PR	17-SEP-1998;	98WO-US019437.	PR	25-MAY-2001;	2001WO-US017092.
PR	07-OCT-1998;	98WO-US021141.	PR	01-JUN-2001;	2001US-00872035.
PR	29-OCT-1998;	98WO-US022931.	PR	01-JUN-2001;	2001WO-US017800.
PR	29-OCT-1998;	98WO-US022992.	PR	14-JUN-2001;	2001US-00882636.
PR	20-NOV-1998;	98WO-US024855.	PR	19-JUN-2001;	2001US-00886342.
PR	01-DEC-1998;	98WO-US025108.	PR	20-JUN-2001;	2001WO-US019692.
PR	05-JAN-1999;	99WO-US000106.	PR	21-JUN-2001;	2001US-00887879.
PR	08-JAN-1999;	99WO-US005028.	PR	22-JUN-2001;	2001WO-US020116.
PR	10-MAR-1999;	99WO-US005190.	PR	29-JUN-2001;	2001WO-US021066.
PR	20-MAR-1999;	2000WO-US006319.	PR	09-JUL-2001;	2001WO-US021735.
PR	20-APR-1999;	99WO-US008615.	PR	18-JUL-2001;	2001US-00908827.
PR	14-MAY-1999;	99WO-US010733.	PR	06-AUG-2001;	2001US-00924419.
PR	02-JUN-1999;	99WO-US012252.	PR	09-AUG-2001;	2001US-00927796.
PR	01-SEP-1999;	99WO-US020111.	PR	16-AUG-2001;	2001US-00931836.
PR	08-SEP-1999;	99WO-US020594.	PR	19-DEC-2001;	2001US-00028072.
PR	13-SEP-1999;	99WO-US020944.	XX		
PR	15-SEP-1999;	99WO-US021090.	XX		
PR	15-SEP-1999;	99WO-US021547.	PA	(GETH) GENENTECH INC.	
PR	05-OCT-1999;	99WO-US023089.	XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PR	29-NOV-1999;	99WO-US028214.	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PR	30-NOV-1999;	99WO-US028313.	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;	
PR	30-NOV-1999;	99WO-US028409.	PI		
PR	01-DEC-1999;	99WO-US028301.	XX	WPI; 2003-899790/82.	
PR	01-DEC-1999;	99WO-US028634.	XX	P-PSDB; ADE33819.	
PR	02-DEC-1999;	99WO-US028551.	DR		
PR	02-DEC-1999;	99WO-US028564.	DR		
PR	02-DEC-1999;	99WO-US028565.	XX		
PR	16-DEC-1999;	99WO-US030095.	XX	Two hundred and seventy five nucleic acids encoding PRO polypeptides,	
PR	20-DEC-1999;	99WO-US030911.	PT	useful for treating pericyte-associated tumors, diabetes and various bone	
PR	20-DEC-1999;	99WO-US030999.	PT	and/or cartilage disorders, e.g. arthritis.	
PR	20-DEC-1999;	99WO-US030720.	XX	Claim 2; SEQ ID NO 221; 636pp; English.	
PR	30-DEC-1999;	99WO-US031243.	PS		
PR	30-DEC-1999;	99WO-US031274.	XX		
PR	05-JAN-2000;	2000WO-US000219.	CC	The invention describes 305 nucleic acids encoding PRO (secreted and	
PR	06-JAN-2000;	2000WO-US000277.	CC	transmembrane) polypeptides (I). (I) is useful for stimulating the	
PR	06-JAN-2000;	2000WO-US000376.	CC	release of TNF-alpha from human blood, for modulating the uptake of	
PR	11-FEB-2000;	2000WO-US0003565.	CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
PR	18-FEB-2000;	2000WO-US0004341.	CC	stimulating the proliferation or differentiation of chondrocyte cells,	
PR	18-FEB-2000;	2000WO-US0004342.	CC	for stimulating the proliferation of or gene expression in pericyte	
PR	24-FEB-2000;	2000WO-US0004414.	CC	cells, for stimulating the release of proteoglycans from cartilage, for	
PR	24-FEB-2000;	2000WO-US0004914.	CC	stimulating the proliferation of inner ear utricular supporting cells,	
PR	24-FEB-2000;	2000WO-US0005004.	CC	for stimulating the proliferation of T-lymphocyte cells, for stimulating	
PR	01-MAR-2000;	2000WO-US0005601.	CC	the release of a cytokine from PBMC cells, for inhibiting the binding of	
PR	02-MAR-2000;	2000WO-US0005746.	CC	A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte	
PR	02-MAR-2000;	2000WO-US0005841.	CC	cells, for stimulating proliferation of endothelial cells, for detecting	
PR	15-MAR-2000;	2000WO-US0006884.	CC	the presence of tumour in a mammal. The tumour is lung, colon, breast,	
PR	21-MAR-2000;	2000WO-US0007537.	CC	prostate, rectal, cervical or liver tumour. The oligonucleotide probes	
PR	21-MAR-2000;	2000WO-US0007532.	CC	are useful for isolating genomic and cDNA nucleotide sequences or	
PR	30-MAR-2000;	20			

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred.No.55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGTGGTTGTTT 1987
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGCTGGTGGTTTATT 1083

RESULT 205
ADD79870/c
ID ADD79870 standard; cDNA; 1129 BP.
XX AC ADD79870;
XX DT 29-JAN-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; Glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

OS US2003207417-A1.

PN 06-NOV-2003.

PD 07-MAY-2002; 2002US-00140805.

XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014522.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-MAR-1999; 99WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028409.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020231.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI: 2003-875867/81.
P-PSDB; ADD79871.
DR

ADEI9327/c
ID ADEI9327 standard; cDNA; 1129 BP.
AC ADEI9327;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199025-A1.
XX
PD 23-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152385.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI; 2003-900156/82.
DR P-PSDB; ADEI9328.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
PS Claim 2; SEQ ID NO 221; 648pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGTGGTTTGT 1987
Db 1129 TTTTTCATTTTTCATTTCAGATTTCCTTCAGTTGGTGGTTTGT 1083

RESULT 209
ADE42971/c
ID ADE42971 standard; cDNA; 1129 BP.
XX AC ADE42971;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.
XX US2003199033-A1.
XX 23-OCT-2003.
XX 28-MAY-2002; 2002US-00156845.
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900162/82.
DR P-PSDB; ADB42972.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; Fig 221; 636pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGTGGTTTGT 1987
Db 1129 TTTTTCATTTTTCATTTCAGATTTCCTTCAGTTGGTGGTTTGT 1083

RESULT 210
ADD95760/c
ID ADD95760 standard; cDNA; 1129 BP.
XX AC ADD95760;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003199059-A1.

XX 23-OCT-2003.

XX 15-APR-2002; 2002US-00123322.

PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 29-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 20-NOV-1998; 98WO-US022992.
 PR 01-DEC-1998; 98WO-US024855.
 PR 05-JAN-1999; 98WO-US025108.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 20-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 22-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 08-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004514.
 PR 01-MAR-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 15-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US006884.
 PR 21-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney M, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900168/82.

P-PSDB; ADD95761.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 useful for treating pericyte-associated tumors, diabetes and various bone
 and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a

PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PA (GETH) GENENTECH INC.
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-900169/82.
 DR P-PSDB; ADE22647.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX
 PS Claim 2; Fig 221; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells and for treating
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1941 TTCTAATTTTTCATTTCCAGATTTCCTTCAGTTTCGGTTTCTTT 1987
 |||||
 DB 1129 TTTTTTTTTTTTTTTTTTCAGTCGGCACACAGCGCTGGTTTATT 1083
 |||||

RESULT 212
 ADD78764/c
 ID ADD78764 standard; cDNA; 1129 BP.
 XX
 AC ADD78764;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #111.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003203429-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 22-APR-2002; 2002US-00127900.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-875636/81.
 DR P-PSDB; ADD78765.
 XX
 PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX
 CC Claim 2; Fig 221; 637pp; English.
 CC
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells and for treating
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTGGTTT 1987
DB 1129 TTTTTCATTTTTCAGTTGGGTTGGTTT 1083

RESULT 213

AD32714/c
ID ADE32714 standard; cDNA; 1129 BP.

XX AC ADE32714;

XX DT 29-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003194766-A1.

XX PD 16-OCT-2003.

XX PF 14-MAY-2002; 2002US-00145874.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-899785/82.

XX P-PSDB; ADE32715.

XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.

XX PS Claim 2; SEQ ID NO 221; 636pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte

CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTGGTTT 1987
DB 1129 TTTTTCATTTTTCAGTTGGGTTGGTTT 1083

RESULT 214

AD32406/c

ID ADE42406 standard; cDNA; 1129 BP.

XX AC ADE42406;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199032-A1.

XX PD 23-OCT-2003.

XX PF 28-MAY-2002; 2002US-00156844.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Query Match	Score	DB	Length	Indels	Gaps
Best Local Similarity	0.9%;	21.4;	1129;		
Matches	66.0%;	Pred. No. 55;			
Conservative	0;	Mismatches	16;	Indels	0;
Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;					
1941	TTCTTAATTTTTCATTTCCGATTTCCTTCAGTTGGGTGTTGTTT	1987			
1129	TTTTTTTTTTTTTTTTTTTTCAGTCGGCACACAGCGTGGGTGTTTAT	1083			

RESULT 220	
ADD76406/C	
ID	ADD76406 standard; cDNA; 1129 BP.
XX	
XX	
AC	ADD76406;
XX	
XX	
DT	29-JAN-2004 (first entry)
XX	
DE	Human PRO polynucleotide #111.
XX	
KW	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW	liver; macrovascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW	immune system cell infiltration.
XX	

OS	Homo sapiens.	
XX	US2003100087-A1.	
XX	29-MAY-2003.	
XX	16-APR-2002;	2002US-00123912.
XX	31-MAR-1997;	97WO-US005230.
PR	12-JUN-1998;	98WO-US012456.
PR	14-JUL-1998;	98WO-US014552.
PR	28-AUG-1998;	98WO-US017888.
PR	10-SEP-1998;	98WO-US018824.
PR	14-SEP-1998;	98WO-US019093.
PR	14-SEP-1998;	98WO-US019094.
PR	14-SEP-1998;	98WO-US019177.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98WO-US019437.

PR	07-OCT-1998;	98WO-US0211141;
PR	29-OCT-1998;	98WO-US0229911;
PR	29-OCT-1998;	98WO-US0229992;
PR	20-NOV-1998;	98WO-US0248555;
PR	01-DEC-1998;	98WO-US025108;
PR	05-JAN-1999;	98WO-US000106;
PR	08-MAR-1999;	98WO-US005028;
PR	10-MAR-1999;	98WO-US005190;
PR	20-APR-1999;	98WO-US008615;
PR	14-MAY-1999;	98WO-US010733;
PR	02-JUN-1999;	98WO-US012252;
PR	01-SEP-1999;	98WO-US020111;
PR	08-SEP-1999;	98WO-US020594;
PR	13-SEP-1999;	98WO-US020944;
PR	15-SEP-1999;	98WO-US021090;
PR	15-SEP-1999;	98WO-US021547;
PR	05-OCT-1999;	98WO-US023089;
PR	29-NOV-1999;	98WO-US028214;
PR	30-NOV-1999;	98WO-US028313;
PR	01-DEC-1999;	98WO-US028409;
PR	01-DEC-1999;	98WO-US028301;
PR	01-DEC-1999;	98WO-US028634;
PR	02-DEC-1999;	98WO-US028551;
PR	02-DEC-1999;	98WO-US028564;
PR	16-DEC-1999;	98WO-US028565;
PR	20-DEC-1999;	98WO-US030095;
PR	20-DEC-1999;	98WO-US030911;
PR	20-DEC-1999;	98WO-US030999;
PR	22-DEC-1999;	98WO-US030720;
PR	30-DEC-1999;	98WO-US031243;
PR	30-DEC-1999;	98WO-US031274;
PR	05-JAN-2000;	2000WO-US000219;
PR	06-JAN-2000;	2000WO-US000277;
PR	06-JAN-2000;	2000WO-US000376;
PR	11-FEB-2000;	2000WO-US003565;
PR	18-FEB-2000;	2000WO-US004341;
PR	18-FEB-2000;	2000WO-US004342;
PR	24-FEB-2000;	2000WO-US004414;
PR	24-FEB-2000;	2000WO-US004914;
PR	24-FEB-2000;	2000WO-US005004;
PR	01-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005746;
PR	03-MAR-2000;	2000WO-US005841;
PR	10-MAR-2000;	2000WO-US006319;
PR	13-MAR-2000;	2000WO-US006984;
PR	20-MAR-2000;	2000WO-US007377;
PR	31-MAR-2000;	2000WO-US007532;
PR	31-MAR-2000;	2000WO-US008439;
PR	17-MAY-2000;	2000WO-US013705;
PR	22-MAY-2000;	2000WO-US014042;
PR	30-MAY-2000;	2000WO-US014941;
PR	02-JUN-2000;	2000WO-US015264;
PR	28-JUL-2000;	2000WO-US020710;
PR	11-AUG-2000;	2000WO-US022031;
PR	24-AUG-2000;	2000WO-US023522;
PR	24-AUG-2000;	2000WO-US023328;
PR	10-NOV-2000;	2000WO-US030952;
PR	10-NOV-2000;	2000WO-US030873;
PR	01-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000WO-US074259;
PR	28-FEB-2001;	2000WO-US034956;
PR	28-FEB-2001;	2001WO-US079649;
PR	01-MAR-2001;	2001WO-US006520;
PR	09-MAR-2001;	2001WO-US006666;
PR	09-MAR-2001;	2001US-00802706;
PR	14-MAR-2001;	2001US-00808689;
PR	22-MAR-2001;	2001US-00816744;
PR	05-APR-2001;	2001US-00828366;
PR	10-MAY-2001;	2001US-00854208;
PR	18-MAY-2001;	2001US-00854280;
PR	25-MAY-2001;	2001US-00860216;
PR	25-MAY-2001;	2001US-00866028;
PR	25-MAY-2001;	2001US-00866034;

PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-008956/01.
DR P-PSDB; ADD76407.
XX New PRO nucleic acid, useful for recombinantly producing a PRO
PT polypeptide and for manufacturing a medicament for diagnosing or treating
PT a tumor.
XX
XX Claim 2; Fig 221; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TTCTTAATTTTTCATTCACAGATTCTTCAGTTGGGTTTGT 1987

Db 1129 TTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
RESULT 221
ADD87770/c
ID ADD87770 standard; cDNA; 1129 BP.
XX
XX ADD87770;
XX
XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US20030921113-A1.
XX
XX 15-MAY-2003.
XX
XX 16-MAY-2002; 2002US-00147523.
XX
XX 09-DEC-1999; 99US-0170262P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-020237/02.
XX P-PSDB; ADD87771.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating

DR WPI: 2004-020236/02.
DR P-PSDB; ADE24394.
XX
XX New secreted and transmembrane nucleic acid useful for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome, or cancer.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format
CC the USPTO website at seqdata.uspto.gov.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TCTTAAATTTTTCATTTCCAGATTTCCTTCAGTTGGTGTGTTT 1987
Db 1129 TTTTTTTTTTTTTTTTTTTTCAGCTGCACACAGCTGGGTTTAAAT 1083
RESULT 227
ADD87218/c
ID ADD87218 standard; cDNA; 1129 BP.
XX
XX ADD87218;
XX
XX 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003203439-A1.
XX
XX 30-OCT-2003.
XX
XX 17-MAY-2002; 2002US-00147499.
XX
XX 04-AUG-1998; 98US-0095301P.
XX 02-JUN-1999; 99WO-US012252.
XX 30-MAR-2000; 2000US-00380137.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-021362/02.
XX P-PSDB; ADD87219.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 221; 648pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence encodes a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format
XX the USPTO website at seqdata.uspto.gov.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TCTTAAATTTTTCATTTCCAGATTTCCTTCAGTTGGTGTGTTT 1987
Db 1129 TTTTTTTTTTTTTTTTTTTTCAGCTGCACACAGCTGGGTTTAAAT 1083
RESULT 227
ADD87218/c
ID ADD87218 standard; cDNA; 1129 BP.
XX
XX ADD87218;
XX
XX 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

Novel isolated PRO polypeptide useful for treating diabetes, hyper- or hypoglycemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders, tumors.

Mon Aug 9 17:47:27 2004

10664775-4.rng

```
XX PS Claim 2; SEQ ID NO 221; 638pp; English.
XX CC
XX CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1987
Db 1129 TTTTITTTTTTTTTTTTCAGTGGCACACAGCGTGGTTTATT 1093

RESULT 229
ADE18223/C
ID ADE18223 standard; cDNA; 1129 BP.
XX AC
XX AC ADE18223;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003194794-A1.
XX XX
```


prothrombin; thrombin; Factor V; Factor VIII; fibrinogen; fibrin; plasma factor; bleeding episode; haemophilia A; haemophilia B; thrombus; intimal hyperplasia; restenosis; cardiogenic embolism; stroke; platelet deposition; percutaneous transluminal coronary angioplasty; PTCA; cancer; tumour; angiogenesis; ischaemia; reperfusion; thrombolysis; rheumatoid arthritis; arteriosclerosis; inflammation; septic shock; hypertension; adult respiratory distress syndrome; ARDS; myocardial infarction; vasotropic; cerebroprotective; antibacterial; immunosuppressive; cardiac; gene therapy; ds; pLM174.

Homo sapiens.
Unidentified.
Synthetic.

```

Key      Location/Qualifiers
CDS      285..1505
          /*tag= a
          /product= "Coagulation Factor VII"
          /partial
          /transl_except= (pos:300..305,aa:Xaa-Xaa)
          /transl_except= (pos:324..326,aa:Xaa)
          /transl_except= (pos:330..332,aa:Xaa)
          /transl_except= (pos:339..344,aa:Xaa-Xaa)
          /transl_except= (pos:357..362,aa:Xaa-Xaa)
          /transl_except= (pos:369..371,aa:Xaa)
          /transl_except= (pos:387..389,aa:Xaa)
          /note= "No start codon shown. Xaa = gamma carboxylated
          glutamic acid"

```

WO200277218-A1.

03-OCT-2002.

21-MAR-2002; 2002WO-DK000189.

22-MAR-2001; 2001DK-00000477.

(NOVO) NOVO NORDISK AS.

Person E;

WPI; 2003-058374/05.

P-PSDB; ABG73119.

Novel factor VII polypeptide, its derivatives useful for preparing medicament for treating bleeding episodes, or for enhancing normal hemostatic system, especially for treating hemophilia.

Disclosure; Page 82-85; 96pp; English.

The invention discloses a human factor VII polypeptide, or a variant or derivative of it, where an amino acid has been modified. This change results in a polypeptide with the same or an increased activity when compared to recombinant wild type human Factor VIIa. Blood coagulation consists of a complex interaction of various blood components that eventually give rise to a fibrin clot. Initiation of the haemostatic process is mediated by the formation of a complex between tissue factor and Factor VIIa (the active form of the Factor VII zymogen). This complex activates Factors IX and X, converting prothrombin to thrombin, which activates Factors V and VIII leading to a full thrombin burst. The thrombin converts fibrinogen to fibrin resulting in formation of a fibrin clot. The Factor VII zymogen, or its derivative, can be modified in its catalytic centre to inhibit the ability of the Factor VII polypeptide to activate plasma factor X or IX. The factor VII derivative is useful for preparing a medicament for the treatment of bleeding episodes, for the enhancement of the normal haemostatic system, especially for the treatment of haemophilia A or B and for inhibiting thrombus formation. The inactivated factor VII derivatives are useful for treating intimal hyperplasia, restenosis, cardiac emboli, platelet deposition disorders, percutaneous transluminal angioplasty (PTCA), stroke, cancer, tumour metastasis, angiogenesis, ischaemia/reperfusion, rheumatoid arthritis, thrombolysis, arteriosclerosis, acute and chronic inflammations, such as inflammation, septic shock, hypotension, adult

CC	respiratory distress syndrome (ARDS) and myocardial infarction. The
CC	sequence presented is the plasmid, pLN174, which expresses the
CC	inactivated human coagulation Factor VII polypeptide
xx	
SQ	Sequence 6098 BP; 1413 A; 1587 C; 1623 G; 1475 T; 0 U; 0 Other;
	Query Match 0.9%; Score 21.4; DB 1; Length 6098;
	Best Local Similarity 49.5%; Pred. No. 67;
	Matches 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY	1642 TTTGTAGCTTCWTGACCTTGATAGCGCATCTTCTTCAAGGTTAGGAATTTTCTTT 1701
Dd	4429 TTTTTAGGTTCTGGCCTTTGCTGCCATGTCTTCTTCTGCGTTATCC 4488
QY	1702 TTITGGTTTTCTGAAATAATTTCCTGCCTTTTGACCTGCCCTTTCCCT 1752
Dd	4489 CCTGATCTGTGGATAACCGTATTACCGCTTTGAGTGAGCTGTACCGCT 4539

RESULT 232

ABA79647

ID ABA79647 standard: DNA: 121 BP.

AC ABA79647:

24-JAN-2002 (first entry)

Factor IX mutation correcting oligonucleotide SEQ ID NO: 2493

KW	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW	retinoblastoma; BRCA1; BRCA2; CFTF; cystic fibrosis; cancer; Factor V;
KW	cyclin-dependent kinase inhibitor 2A; CKN2A; melanoma; APC; HBx1; HBx2;
KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisen-
KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW	Alzheimer's disease; cystostatic; antickling; antianaemic; haemostatic;
KW	antileptic; ss.

SO Homo sapiens.

PN WO200173002-A2.

04-OCT-2001

27-MAR-2001: 2001WO-US009761

27-MAR-2000: 2000TIS-0192176P

PR 01-JUN-2000: 2000US-0208538D
PR 27-MAR-2000; 2000US-0192179P.

30-UCT-2000; 2000US-0244989P.
FR
XX

PA (UYDE) UNIV DELAWARE.
XX

PI Kmlec EB, Gamper HB,
XX

UR
WPI; 2001-639230/73.
XX

PT Oligonucleotide for treating cervical fibro

PT modification.

PS Claim 7; Page

The present invention provides sin

oligonucleotide has at least one

sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CPTF, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBAL), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6.

sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

Query Match 0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 41;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACAGGACATATTCCTCGTGTGTTATGCTGTGTTTTG 2227
Db 83 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 24

QY 2228 CTTTGGCATATACAGCGCTGAG 2249
Db 23 AATTGGCAGTAAACTGCTTAG 2

RESULT 234
ABA79646/c
ID ABA79642 standard; DNA; 121 BP.
XX AC ABA79642;
XX AC ABA79642;
XX DT 24-JAN-2002 (first entry)
XX DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2488.
XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX OS Homo sapiens.
XX PN WO200173002-A2.
XX PD 04-OCT-2001.
XX PF 27-MAR-2001; 2001WO-US009761.
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX PA (UYDE) UNIV DELAWARE.
XX PI Kmiec EB, Gamper HB, Rice MC;
XX XX WPI; 2001-639230/73.
XX DR Oligonucleotide for targeted alterations of genetic sequences and for
XX PT treating cystic fibrosis, comprises at least one mismatch and chemical
XX PT modification.

apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

Query Match 0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 41;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACAGGACATATTCCTCGTGTGTTATGCTGTGTTTTG 2227
Db 39 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 98

QY 2228 CTTTGGCATATACAGCGCTGAG 2249
Db 99 AATTGGCAGTAAACTGCTTAG 120

RESULT 233
ABA79646/c
ID ABA79642 standard; DNA; 121 BP.
XX AC ABA79646;
XX AC ABA79646;
XX DT 24-JAN-2002 (first entry)
XX DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2492.
XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX OS Homo sapiens.
XX PN WO200173002-A2.
XX PD 04-OCT-2001.
XX PF 27-MAR-2001; 2001WO-US009761.
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX PA (UYDE) UNIV DELAWARE.
XX PI Kmiec EB, Gamper HB, Rice MC;
XX XX WPI; 2001-639230/73.
XX DR Oligonucleotide for targeted alterations of genetic sequences and for
XX PT treating cystic fibrosis, comprises at least one mismatch and chemical
XX PT modification.
XX PS Claim 7; Page 185; 294pp; English.
XX CC The present invention provides single-stranded oligonucleotides which can
XX CC be used for the targeted alteration of genomic sequences, where the
XX CC oligonucleotide has at least one mismatch compared with the genomic

XX	Oligonucleotide for targeted alterations of genetic sequences and for									
PT	treating cystic fibrosis, comprises at least one mismatch and chemical									
PT	modification.									
XX										
PS	Claim 7; Page 185; 294pp; English.									
XX										
CC	The present invention provides single-stranded oligonucleotides which can									
CC	be used for the targeted alteration of genomic sequences, where the									
CC	oligonucleotide has at least one mismatch compared with the genomic									
CC	sequence to be altered. In particular, these sequences are directed at									
CC	the following genes: adenosine deaminase, p53, beta-globin,									
CC	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A									
CC	(CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus									
CC	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,									
CC	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase									
CC	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and									
CC	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases									
CC	such as cancer, adenosine deaminase deficiency, cystic fibrosis,									
CC	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,									
CC	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and									
CC	various syndromes. The present sequence is one of the gene correcting									
CC	oligonucleotides of the invention									
XX										
SQ	Sequence 121 BP; 39 A; 24 C; 22 G; 36 T; 0 U; 0 Other;									
	Query Match	0.9%	Score 21.2;	DB 1;	Length 121;					
	Best Local Similarity	53.7%;	Pred. No. 41;							
	Matches 44;	Conservative 0;	Mismatches 38;	Indels 0;	Gaps 0;					
QY	2168 CTATTGTAATAGGTTTATAGCAGGACATATTGCTGTTGTTATGTCGTGTTTTG 2227									
Db	38 CCATTAAACATGGATTGCACTGACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 97									
QY	2228 CTTTGGCATATGACGGCTGAG 2249									
Db	98 AATTGGCAGCTAACTGCTTAG 119									
RESULT 236										
ABS68969/c										
ID	ABS68969 standard; DNA; 305 BP.									
XX	ABS68969;									
AC										
XX										
DT	21-NOV-2002 (first entry)									
XX										
DE	Novel murine polynucleotide isolated using gene trap technology #32.									
XX										
KW	Mouse; gene trapped sequence; GTS; functional genomic analysis;									
KW	phage display system; gene chip; temporal gene expression;									
KW	tissue specific gene expression; antisense inhibition; gene targeting;									
KW	development disorder; cell differentiation disorder; aging; cancer;									
KW	autoimmune disease; lupus; inflammatory disorder; skin disorder;									
KW	degenerative disorder; ds.									
OS	Mus musculus.									
XX										
US	US2002102543-A1.									
PN										
XX										
PD	01-AUG-2002.									
XX										
PF	30-NOV-2000; 2000US-00728445.									
XX										
PR	01-DEC-1999; 99US-0168358P.									
XX										
PA	(FRIE/) FRIEDRICH G.									
PA	(ZAMB/) ZAMBROWICZ B.									
PA	(SAND/) SANDS A T.									
XX										
PI	Friedrich G, Zambrowicz B, Sands AT;									
XX										
WPI	WPI: 2002-690598/74									


```

15-OCT-1998.
10-APR-1998; 98WO-US006956.
10-APR-1997; 97US-00837312.
(GEMY ) GENETICS INST INC.
Jacobs K, McCooy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;
Spaulding V, Agostino MJ;
WPI; 1999-070078/06.
New polynucleotides encoding human secreted proteins - derived from e.g.
human blood, kidney, foetal lung, placenta, testes, brain, ovary,
pituitary, retina and colon cDNA libraries.
Claim 1; Page 332; 641pp; English.
The present sequence represents an expressed sequence tag (EST), and is a
polynucleotide of the invention. The polynucleotides of the invention are
all secreted EST sequences isolated from a variety of human tissue
sources. The EST sequences and proteins encoded by them are predicted to
have useful biological activities which would make them suitable for
treating, preventing or ameliorating medical conditions in humans and
animals, although no supporting data is given. Suggested activities
include nutritional activity, immune stimulating or suppressing activity,
haematopoiesis regulating activity, tissue growth activity,
activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
and thrombolytic activity, receptor/ligand activity, anti-inflammatory
activity, cadherin/tumour invasion suppressor activity, tumour inhibition
activity. The EST sequences are also stated to be useful for gene therapy
Sequence 267 BP; 75 A; 45 C; 90 G; 57 T; 0 U; 0 Other;
Query Match 0.9%; Score 21; DB 1; Length 267;
Best Local Similarity 49.5%; Pred. No. 54;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
Qy 1649 GCTTCTGTACCTTGATAGGCATCTCTTCTCAAGGTTAGGAATTTCTTTTGGTT 1708
Db 243 GATGCATGACCTCAAAACATCTCTCAGTATCCCATTTCTGTGGATTTCTTCTCAATC 184
Qy 1709 TTCTTGAATAATTTTCCTGCTTTTGACCGCTCTCTCCCTTCCTC 1757
Db 183 TTCTTCAAAAGTCCACTTTGGCTGTCCTTTCTTTCCGCCAATGCAC 135
RESULT 239
ABX37095/c
ID ABX37095 standard; cDNA; 372 BP.
XX
AC ABX37095;
XX
DT 20-FEB-2003 (first entry)
XX
DE Bovine EST associated with lactation/muscle/fat deposition #2260.
XX
KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;
KW muscle deposition; fat deposition; genome mapping; gene identification;
KW gene analysis; cattle breeding.
XX
OS Bos Taurus.
XX
XX US2002137139-A1.
XX
PD 26-SEP-2002.
XX
PF 24-SEP-2001; 2001US-00960352.
XX
PR 12-JAN-1999; 99US-0115707P.
PR 11-JAN-2000; 2000US-00480902.
XX

```



```
QY 1780 TGCTCTGGCTTCTCGATGATGTTTATGC 1807
      ||||| ||||| ||||| ||||| |||||
Db 191 CTCTCCAGTTCAGTTGCTTTTGGCG 164

RESULT 247
ABS38969/c
ID ABS38969 standard; DNA; 263 BP.
XX
AC ABS38969;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver single exon probe, SEQ ID NO 13959.
XX
KW Human; single exon nucleic acid probe; liver; cirrhosis;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW coronary heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
WPI; 2001-488898/53.
XX
Human genome-derived single exon nucleic acid probes useful for analyzing
Gene expression in human adult liver.
XX
Claim 4; SEQ ID NO 13959; 658pp; English.
XX
The invention relates to a single exon nucleic acid probe (SEN) (I) for
measuring human gene expression in a sample derived from human adult
liver comprising one of 13109 defined nucleotide sequences given in the
specification (or complements/ fragments). The probe hybridises at high
stringency to a nucleic acid molecule expressed in the human adult liver.
(I) may be used for predicting, measuring and displaying gene expression
in samples derived from human adult liver. The genes identified may be
involved in genetic liver diseases such as cirrhosis,
hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
associated with coronary heart disease. ABS25011-ABS51005 represent human
liver single exon nucleic acid probes of the invention. Note: The
sequence information for this patent does not appear in the printed
specification but was obtained in electronic format directly from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match 0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred.No.61;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 1720 ATTTCCCTCTTGACCTGCTCTCTCCCTCTATCTCTTCTGTTTGGCATAG 1779
      ||||| ||||| ||||| ||||| |||||
Db 251 AATTCTTTCTCTCTCTCTCTCTCTCTCTAGTCCGCTGCTTTCCAGTTG 192

QY 1780 TGCTCTGGCTTCTCGATGATGTTTATGC 1807
      ||||| ||||| ||||| ||||| |||||
Db 191 CTCTCCAGTTCAGTTGCTTTTGGCG 164

RESULT 249
ABS13468/c
```

```
Db 191 CTCTCCAGTTCAGTTGCTTTTGGCG 164

RESULT 248
AAI05898/c
ID AAI05898 standard; DNA; 263 BP.
XX
AC AAI05898;
XX
DT 09-OCT-2001 (first entry)
XX
DE Probe #5889 used to measure gene expression in human breast sample.
XX
KW Probe; human; breast disease; breast cancer; development disorder; ss;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
WPI; 2001-476286/51.
XX
Novel single exon nucleic acid probe used to measuring gene expression in
a human breast.
XX
Claim 25; SEQ ID NO 5889; 322pp; English.
XX
The present invention relates to novel single exon nucleic acid probes.
The present sequence is one such probe. The probes are useful for
measuring human gene expression in a human breast sample, where the probe
hybridises at high stringency to a nucleic acid expressed in the human
breast. The probes are useful for predicting, diagnosing, grading,
staging, monitoring and prognosing diseases of the human breast,
particularly those diseases with polygenic aetiology. The diseases
include: breast cancer, disorders of development, inflammatory diseases
of the breast, fibrocystic changes, proliferative breast disease and non-
carcinoma tumours. Note: The sequence data for this patent did not form
part of the printed specification, but was obtained in electronic format
directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match 0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred.No.61;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 1720 ATTTCCCTCTTGACCTGCTCTCTCCCTCTATCTCTTCTGTTTGGCATAG 1779
      ||||| ||||| ||||| ||||| |||||
Db 251 AATTCTTTCTCTCTCTCTCTCTCTCTAGTCCGCTGCTTTCCAGTTG 192

QY 1780 TGCTCTGGCTTCTCGATGATGTTTATGC 1807
      ||||| ||||| ||||| ||||| |||||
Db 191 CTCTCCAGTTCAGTTGCTTTTGGCG 164

RESULT 249
ABS13468/c
```



```
XX SQ Sequence 280 BP; 69 A; 70 C; 74 G; 67 T; 0 U; 0 Other;
    Query Match      0.9%; Score 20.8; DB 1; Length 280;
    Best Local Similarity 51.0%; Pred. No. 62;
    Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 396 TCTAGATTTAAGCTGTGGTGCAGATAGGACATAGAGTATTATTCAATTGCTTTTAT 455
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 91 TCTGGCTCTTGACAAGATAGACCCTGGAACTAGAGAGGAGAGATTCTACTGGTCA 150
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 456 CTGTCAGACTTGTCTTTGTTTGAATATGTAATCA 491
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 151 CAGACAAGACTCTCTGTGATCTGCAATACGACTTCA 186
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Search completed: August 9, 2004, 17:19:45
Job time : 889 secs
```

